<SEC-DOCUMENT>0001558370-24-000932.txt : 20240209
<SEC-HEADER>0001558370-24-000932.hdr.sgml : 20240209
<ACCEPTANCE-DATETIME>20240209160422
ACCESSION NUMBER:		0001558370-24-000932
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240209
DATE AS OF CHANGE:		20240209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVRx, Inc.
		CENTRAL INDEX KEY:			0001235912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40545
		FILM NUMBER:		24614682

	BUSINESS ADDRESS:	
		STREET 1:		9201 WEST BROADWAY AVENUE
		STREET 2:		SUITE 650
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55445
		BUSINESS PHONE:		7634162850

	MAIL ADDRESS:	
		STREET 1:		9201 WEST BROADWAY AVENUE
		STREET 2:		SUITE 650
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55445

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVRX INC
		DATE OF NAME CHANGE:	20030527
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvrx-20231231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:cvrx="http://www.cvrx.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" xs:nil="true" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_ePKRbe4dB0aPeXYbdjXkNA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" xs:nil="true" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_OOfVHfY4c0-blkkbbWepfQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" sign="-" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_yFT6SI8hckSwZ0Z0oJRWgA">1.99</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_RJz8J98SB06oqS-Wx5ZSrA">2.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_IwFJrxEx2EaTygBMU1MB9w">20754375</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_FT04qFxYGEur9rK_xfNhLg">20532838</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_KRGdCIu5gUe_MTcgpv6-bQ">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_oldANodHgkOeQhYQiaVPUA">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_K2osPffarkeK2nJPdvZI1Q">20754375</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_PnlFT0u0ZUmD1AeGlYRhLA">20532838</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" sign="-" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_1-VKvzFxtkGYxn2bxA0KOQ">1.99</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_9k-u6oSvH0SUWtDFYknU1A">2.02</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityCentralIndexKey" id="Tc_NDyxVP6zzEewboTm__TJTQ_2_1">0001235912</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:CurrentFiscalYearEndDate" id="Tc_yjK_fswgv0acOywcWRf3xA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentFiscalYearFocus" id="Tc_wdojtOixu0SPsDJNew40jg_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentFiscalPeriodFocus" id="Tc_3vVqzWHuOUGplLU9Sp9EVA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:AmendmentFlag" id="Narr_NVJ3uWUzQ0SvNNGNMSb_xQ">false</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_YDnHhonymkmLROCgApvJbw">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_OpBAXBMwEk6NYw4JEdrq0g">20879199</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_q21DJISsyEqTNoQ9KQzmfA">20663736</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_IO8dwnoe_0GELVflzKHRYA" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Hidden_R84I04otGUuPgFKJgT8KOA">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_R1Bqa2cBBEeteyh9zoNgFw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_zQ9v7lRugkaZk4A4ENmecQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_Qx_lM9M1-U2I_9bBopvULQ" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_4ZtIQYWjMEy5zwZJd8Tmlg">P5Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvrx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b8RRVB7Uq0ilxq9okISsEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cchEQDekhUyFexTD45-WZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R8cE_HFzF0aFvnYTtQwY3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hwN6aAp_7UWY8-X1PMow3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TYjt-cOP6EmP8oe6WXLi1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_oxQlkGA_EEi6G6wAtaoTqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wy3kn6snkkWPv53PI5w4dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zbMLgVLwskWIMhYab9L2qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3dLk7Sy_E0KsftAeppu0Vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qCtrCvgNa0C-1eQGTvWtGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_z5thRTHU6UqLA7ga0nCfkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_DDdMMm9gRkiqyIWxmaA5XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:ShareBasedPaymentArrangementOtherOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PemZyTerfEyhpKp4nuNIIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_naG0zLCR-EKkwa1gEwsa0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zEoL8JtTB0KWcZl84O9JzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VXKHvG6viUyua5uD_4yltw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EBpawY17Z0eCyg95O44tGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VckApq6WlEaWJ9cemmQc9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_57PyY8_YEUuCWQnZ9zZCBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMTCyrrsukCaWB_FFt4-Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hd2dVLfWykWfyk-CsotRYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9XD2uHnOhUWYk_34nMOzkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2008_To_12_31_2008_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_PajlFFmwTkWsKigwduPhHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2008-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2001_To_6_30_2001_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_7rx5_d8IikeJHLuprsGqsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2001-06-01</xbrli:startDate><xbrli:endDate>2001-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2001_To_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_PYd31BxNC0604nl8MDpilQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2001-06-01</xbrli:startDate><xbrli:endDate>2001-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_z-s50K3S1kivNIA3YmG5FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_MEKc9Q4xt0S15FUWcDf8Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_DE_li7LfrlDcE-yU9xxp6rxsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_UW_cLJGP9UCo_5BtyGIPrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_DeT00G4a6EO7jrVDjnnWKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_Nr4zMiPicku7JB9fF5v_mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_R1Bqa2cBBEeteyh9zoNgFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_Qx_lM9M1-U2I_9bBopvULQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tmU2-D_zdkyR5NTA7xTdTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JMLg2X07bEuHweDOuklZhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_RDgZV8eKn0q48yeiBOKJrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_BAuUOTojQESzFVAzqd4DhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_MpXjFm5HkU2XNvuqY4WPsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_FSq9BY_du0er2CE9ESvvpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_amp52TUrr0uPXJ9VAkjlow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_-1zVdT_0tkOxZQEUVJnt6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_sgJuXpn0yUa8L7xiptpJRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_dqIej4ejsE2n1BDRzJlgJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2023_To_12_15_2023_srt_StatementScenarioAxis_cvrx_TrancheTwoMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_6qk8DRW53E2gnuQbDupIdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-15</xbrli:startDate><xbrli:endDate>2023-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2023_To_3_10_2023_srt_StatementScenarioAxis_cvrx_TrancheOneMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_MsUf-wRe3UOCGdw87WJNbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-10</xbrli:startDate><xbrli:endDate>2023-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XBqz8Ajq30SHLvU8-PjfiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_pdlrV4rnDEG1xPe8LI1SMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_7Lza9lQnP0GeHg-QJ6eaQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3sIcs8CI8UW6e5DtAQYNdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jWno4e5JIkauZQOY8SolYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_21_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_RM2963Hq80uyOziblZLLAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_SKjkOlcWxkeaJnFxtqthxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember__P6VIstV9ke4AlgA3xarog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_DKj1YSlDwU2ZlmMFDIgwbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_YUEJZcskw0GxQzI269v8CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_LGXJ91kYF0WAsdsON9A6IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2001-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M3MwyXey0USuIVtewS_fUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_UrSmq1MvHUGq4lKnkUhBMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eeym4sX_ZE-eYRj-nhAxtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_kyjAoWWjHEOiI5UhzjPamg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fkJEZGVxqUusT4haccsrQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__6BtJaAInUut6oE3yTHB_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GPUIUQBt3ECv70XnSLRrTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8_aaeerAjEej9OSFdIalGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TGtZmK623E2xW1C_jsdOhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LHxLWQFoVk6j4n7SU0LYMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_r0JJqTzes0K61mq122BZFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_2_2024_uYC7wagxU0yxRMgfubU3Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_dc9hk3dVYkCOZVwQkXY8cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_up0KPm3ldUy5PK6Gt_PEvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_ilFiREhHNkW7Pr6DPc2vbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_IO8dwnoe_0GELVflzKHRYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_CzzcDrZpiEu6QYTiVCHdNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_7_2023_To_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_L3R5rGyJ60OsNpQkqtgCzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-07</xbrli:startDate><xbrli:endDate>2023-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001235912</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_GqVn26Et2UKhRhM1bZ7Trg"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_rCbhtU9w5EOG859qhsdnSg"><xbrli:measure>cvrx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment__laEB6QyrUy_CRagT_GFBw"><xbrli:measure>cvrx:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_90040220_e9c6_4d32_ad35_76666d904a1e"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentType" id="Narr_guZglyooB0WmXzjYe5WtZQ"><b style="font-size:9pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">(Mark&#160;One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentAnnualReport" id="Narr_xKPCkhkV30GMy3SGBYzN3Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentPeriodEndDate" id="Narr_zLRS8ugNuEu9UGzHfjYf3A"><b style="font-size:8pt;font-weight:bold;">December 31, 2023</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">or</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentTransitionReport" id="Narr_mumhLtlDG0a5KfnQT2PRXA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityFileNumber" id="Narr_vS34CnFDW0OkHGPL79j5Jg"><b style="font-size:8pt;font-weight:bold;">001-40545</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityRegistrantName" id="Narr_81TUXIh2sEWKdBZ8kq5ntQ"><b style="font-weight:bold;">CVRx,&#160;Inc</b></ix:nonNumeric><b style="font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_819b9bde_8cd4_4de4_9076_e2d9865fa0d4"></a><a id="Tc__GiqZ8cbh02uT_gZcl4yTQ_2_0"></a><a id="Tc_mXw2ejmAyUKciZ05Ki2Y3Q_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityIncorporationStateCountryCode" id="Tc_A0GL2Tu3vUa6xyIcsMrykg_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityTaxIdentificationNumber" id="Tc_YShSGwBlN0CTOXByWkBnmw_1_1"><b style="font-size:8pt;font-weight:bold;">41-1983744</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other&#160;jurisdiction of</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityAddressAddressLine1" id="Narr_zCWXRtdvnkKW1aRRGthh1g"><b style="font-size:9pt;font-weight:bold;">9201 West Broadway Avenue</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityAddressAddressLine2" id="Narr_MA4gwwly4E64R2NAxYkmyg"><b style="font-size:9pt;font-weight:bold;">Suite&#160;650</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityAddressCityOrTown" id="Narr_VMuYyC8Z1UCPOUGf1DlC5A"><b style="font-size:9pt;font-weight:bold;">Minneapolis</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityAddressStateOrProvince" id="Narr_S1kyHNLH5Uy5oJBPXq_-HA"><b style="font-size:9pt;font-weight:bold;">MN</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityAddressPostalZipCode" id="Narr_KgBWeJeGOkqs57beFs1r6g"><b style="font-size:9pt;font-weight:bold;">55445</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices) (Zip Code)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:CityAreaCode" id="Narr_yFa7e1uWXE2FE716JeE49Q"><b style="font-size:9pt;font-weight:bold;">763</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:LocalPhoneNumber" id="Narr_TCYBL78wz0ma9nNQItDZkQ"><b style="font-size:9pt;font-weight:bold;">416-2840</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_3cc5f012_3bc5_4340_8a8f_6338e861fa29"></a><div style="margin-left:-1.5pt;"><a id="Tc_Ms_q_w6YB0u_std5CqE5gQ_1_0"></a><a id="Tc_06QkRYORHkaD9NgIUKVNsA_1_2"></a><a id="Tc_wTfdJkObZ0urs2d0BT1ndA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"/><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:31.72%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"/><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"/><td style="vertical-align:middle;white-space:nowrap;width:31.87%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:23.35pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"/><td style="vertical-align:middle;white-space:nowrap;width:31.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 0.5pt 0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">Name of each exchange</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">on which registered</p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:middle;width:31.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:Security12bTitle" id="Tc_HI3VsvyHeUi2eH7HwxRlwg_2_0"><b style="font-size:9pt;font-weight:bold;">Common stock,</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">par value $0.01 per share</b></p></td><td style="vertical-align:middle;width:2.29%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:31.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:TradingSymbol" id="Tc_2EgrLfowsE6tdbKiHw1VYg_2_2"><b style="font-size:9pt;font-weight:bold;">CVRX</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.27%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:31.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:SecurityExchangeName" id="Tc_KmIG6ea2KkO-WIhJnX0nqQ_2_4"><b style="font-size:9pt;font-weight:bold;">The Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_If_PoHo-gEaRi1NvRYVLuQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityVoluntaryFilers" id="Narr_-KJywlOB7E2MGOgmFX0q4A"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityCurrentReportingStatus" id="Narr_qkhSqLWKqEi2iBqrytOzMA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityInteractiveDataCurrent" id="Narr_pTyLZsZzXkOWJtveXZSVIA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_23356ced_cb12_41e3_af93_822ee7640bf8"></a><a id="Tc_SFuDWLaf_UuxN3pfcAhdJg_1_0"></a><a id="Tc_2LW6hxB0Z0ue3gZW6H40Jg_1_1"></a><a id="Tc_Y0LzgyPWSUy4tpRP4vP8Ag_1_2"></a><a id="Tc_5W1dxUO1jkWDeEt3ISMQNQ_1_3"></a><a id="Tc_Xa5XWJLajkyXAehXenbVoA_3_1"></a><a id="Tc_NLIuTPIjlkyDmTQL8L0KSQ_3_2"></a><a id="Tc_q_BGfGGKckasRHRUV-WSyw_3_4"></a><a id="Tc_Q4JJgKwzVk-Wt83ysogbcw_3_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:22.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:3.65pt;"><td style="vertical-align:bottom;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6.3pt;"><td style="vertical-align:middle;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4.05pt;"><td style="vertical-align:bottom;width:22.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityFilerCategory" id="Tc_8hywR7pFw0uBne07oFc8HA_3_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;</p></td><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntitySmallBusiness" id="Tc_QEdGq8NPm0uATmhsT36u5A_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:24.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:5.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityEmergingGrowthCompany" id="Narr_YXUbQcEr1Em1AK1wjjfoPg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityExTransitionPeriod" id="Narr_EnWyth76hE-n12yI-7az1w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:IcfrAuditorAttestationFlag" id="Narr_0Ad0mcgS6U2v4WXsyHLWaw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:2pt 0pt 6pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_cgcRpmqGT0KfzXmxzidYZw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:2pt 0pt 6pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:EntityShellCompany" id="Narr_n05hRLFmm0CPLbOYoYKOXw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Global Select Market on June 30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2023_r0JJqTzes0K61mq122BZFw" decimals="-5" name="dei:EntityPublicFloat" id="Narr_Hy4GF9-kKE6GpGruw38NEg">190.0</ix:nonFraction> million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">As of February 2, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_2_2024_uYC7wagxU0yxRMgfubU3Mg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_dQto2ygQbkiFWAGRkVo0LQ">20,927,729</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.01 per share outstanding.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 15pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt 0pt 15pt 0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_751f24a0_72b7_4bf0_a3c1_577eae2bf6f2"></a><a id="TOC"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:83.13%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#160;&#160;&#160;&#160;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.93%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.29%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:83.13%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#CautionaryNoteonForwardLookingStatements"><span style="font-style:normal;font-weight:normal;">Cautionary Note on Forward-Looking Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#SummaryRiskFactors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTI"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1Business"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1BUnresolvedStaffComments"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1BUnresolvedStaffComments"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">71</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Item 1C.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">71</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">2.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item2Properties"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item3LegalProceedings"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">3.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item3LegalProceedings"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">4.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item4MineSafetyDisclosures"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">72</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTII"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item5MarketforRegistrants"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">5.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item5MarketforRegistrants"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">73</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">73</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">73</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">7A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item7QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">82</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">8.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9ChangesinandDisagreementsWithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9AControlsandProcedures"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9A.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9AControlsandProcedures"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">101</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9BOtherInformation"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">9B.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9BOtherInformation"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9c"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item9c"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTIII"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">10.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item11ExecutiveCompensation"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">11.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item11ExecutiveCompensation"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">12.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">13.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">14.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#PARTIV"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item15Exhibits"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">15.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item15Exhibits"><span style="font-style:normal;font-weight:normal;">Exhibit and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">103</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Item</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">16.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="font-size:8pt;" href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">107</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;"><a style="font-size:8pt;" href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;">108</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bbd21196_1f6e_471e_b9c8_3dea58422036"></a><a id="CautionaryNoteonForwardLookingStatements"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cautionary Note&#160;on Forward-Looking Statements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements, including statements regarding our future results of operations and financial position, business strategy, financial results and financial position, clinical trial results, prospective products, product approvals, research and development costs, timing and likelihood of success and the plans and objectives of management for future operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In some cases, you can identify forward-looking statements by terms such as &#8216;&#8216;may,&#8217;&#8217; &#8216;&#8216;will,&#8217;&#8217; &#8216;&#8216;should,&#8217;&#8217; &#8216;&#8216;expect,&#8217;&#8217; &#8216;&#8216;plan,&#8217;&#8217; &#8216;&#8216;anticipate,&#8217;&#8217; &#8216;&#8216;could,&#8217;&#8217; &#8216;&#8216;intend,&#8217;&#8217; &#8216;&#8216;target,&#8217;&#8217; &#8216;&#8216;project,&#8217;&#8217; &#8216;&#8216;contemplate,&#8217;&#8217; &#8216;&#8216;believe,&#8217;&#8217; &#8216;&#8216;estimate,&#8217;&#8217; &#8216;&#8216;predict,&#8217;&#8217; &#8216;&#8216;potential&#8217;&#8217; or &#8216;&#8216;continue&#8217;&#8217; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, the important factors discussed in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K, which are summarized below. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="SummaryRiskFactors"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary Risk Factors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a history of significant losses, which we expect to continue, and we may not be able to achieve or sustain profitability;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our principal stockholders, management and directors (two of whom are affiliated with our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a limited history operating as a commercial company and are highly dependent on a single product, Barostim, and the failure to increase market acceptance in the U.S. for Barostim would negatively impact our business, liquidity and results of operations;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we have limited commercial sales experience marketing and selling Barostim, and if we are unable to continue to maintain and grow sales and marketing capabilities, we will be unable to generate sustained and increasing product revenue;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we must continue to demonstrate to physicians and patients the merits of Barostim;</span></td><td style="width:23.05pt;"/></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our industry is highly competitive; if our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the heart failure market, are better able to develop and market products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim, our business will be adversely impacted;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to receive access to hospitals, our sales may decrease;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers, price fluctuations and ongoing supply chain disruptions, which could harm our business;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide could adversely affect our business;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may face product liability claims that could be costly, divert management&#8217;s attention and harm our reputation;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may in the future become involved in lawsuits to protect or enforce our intellectual property or defend ourselves against intellectual property disputes, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products;</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel; and</span></td><td style="width:23.05pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we will continue to obtain long-term clinical data regarding the safety and effectiveness of our products, which could impact future adoption and regulatory approvals.</span></td><td style="width:23.05pt;"/></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8b292d0b_446a_421a_be33_48a00ba60fe1"></a><a id="PARTI"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART I</b></p><a id="_2b34f52e_2b20_4d25_9f4a_e6b40b72086a"></a><a id="Item1Business"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1. Business</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><span style="font-size:10pt;">CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim is the first medical technology approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that uses neuromodulation to improve the symptoms of patients with heart failure (&#8220;HF&#8221;). Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Barostim provides Baroreflex Activation Therapy (&#8220;BAT,&#8221; or &#8220;Barostim Therapy&#8221;), which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the Autonomic Nervous System (&#8220;ANS&#8221;) and thereby reduce the symptoms of HF. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in HF patients in the U.S</span><span style="font-family:'Segoe UI';">.</span><span style="font-size:10pt;"> We estimate that our annual market opportunity for HFrEF is $2.2&#160;billion in the U.S. and $1.5 billion in select European Markets (Germany, France, Italy, Spain and the United Kingdom, or &#8220;European Five&#8221;).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is one of the most prevalent and devastating cardiovascular diseases. We estimate that there are approximately 26&#160;million people globally suffering from HF, including approximately 6.2&#160;million people in the U.S. and 8.6&#160;million people in the European Five. Every year, 1.3&#160;million and 1.4&#160;million new patients are diagnosed with HF in the U.S. and the European Five, respectively. HF is characterized by the heart&#8217;s inability to effectively circulate blood throughout the body resulting in insufficient levels of oxygen and nourishment to various body parts. This impacts a patient&#8217;s ability to function and leads to a variety of symptoms such as shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention that affects the patient&#8217;s quality of life, both physically and emotionally. HF usually develops from an imbalance of the ANS, which is also the primary cause of multiple other cardiovascular diseases, such as hypertension, angina pectoris and arrhythmia. The ANS plays a vital role in the function of the heart and is strongly influenced by baroreceptors located in certain arterial walls.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are currently focused on the treatment of patients with HF with reduced Ejection Fraction (&#8220;HFrEF&#8221;), which represent approximately 40% of the patients with HF. In HFrEF, the left ventricle loses its ability to contract properly, resulting in insufficient power to pump and push the necessary quantities of blood into circulation. Approximately 75% of HFrEF patients die within five years of being admitted to the hospital for HFrEF. Patients with HFrEF are typically placed on a treatment progression plan during which they are initially given Guideline Directed Medical Therapy (&#8220;GDMT&#8221;) to help manage symptoms, and then progress to more invasive and costly treatment options involving other implantable devices with the most severe patients often requiring Left Ventricular Assist Devices (&#8220;LVADs&#8221;) or heart transplants. These other implantable devices mostly target different HFrEF patient populations, may require an invasive procedure that places hardware directly inside the heart, and are not designed to address the imbalance of the ANS that causes the disease. We believe there is a significant need and market opportunity for a safe, effective and minimally invasive device-based treatment option for HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We believe Barostim offers meaningful benefits for patients, physicians and payors that will continue to drive adoption of our therapy. The primary benefits include:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Addresses significant unmet medical need.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim addresses a life-threatening disease for patients who failed to receive adequate benefits from existing treatments and who have no alternative treatment options. Based on this, the FDA granted Barostim a Breakthrough Device designation for HFrEF in June&#160;2015.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Safe and effective treatment.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our BeAT-HF pivotal trial demonstrated compelling safety and effectiveness data regarding the clinical benefits of Barostim for HFrEF. The pre-market data demonstrated safety and effectiveness leading to FDA approval, and safety and effectiveness were confirmed by the post-market data. These results showed significant improvement in the following patient-centered outcomes:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6 Minute Hall Walk (&#8220;6MHW&#8221;) distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the Barostim group were able to improve the distance they walked in a six-minute period by 56 meters and 44 meters more than patients in the Control group at six months and at one year, respectively, following implant, meaning the improvement was sustained. A 25-meter improvement in walking distance is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by Minnesota Living with Heart Failure (&#8220;MLWHF&#8221;)):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated a 14-point, 8-point and 10-point improvement in quality of life for patients in the Barostim group relative to patients in the Control group at 6 months, 1 year and 2 years following implant, again demonstrating sustained improvement. A 5-point improvement is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by New York Heart Association (&#8220;NYHA&#8221;) classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated the following improvements in NYHA functional status versus the Control group at the specific points in time, meaning Barostim demonstrated greater and sustained improvement: at 6 months, 67% in the BAT+ group and 37% in the Control group, favoring the BAT+ group by 30 percentage points; at 1 year, 73% in the BAT+ group and 41% in the Control group, favoring the BAT+ group by 32 percentage points; and, at 2 years, 68% in the BAT+ group and 41% in the Control group, favoring the BAT+ group by 27 percentage points.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Freedom from All-Cause Death, LVAD, or Transplant. </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients</span><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in the Barostim group had a directionally favorable 34% reduction in all-cause death or the use of LVAD or heart transplant versus the Control group.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;white-space:pre-wrap;">Improvement in Hierarchical Composite Outcomes.  </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on a hierarchical composite outcomes analysis (including cardiovascular (&#8220;CV&#8221;) mortality, LVAD/transplant, HF hospitalization and quality of life), the Win Ratio (defined below) was 1.26 in favor of the Barostim group.</span><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In summary, the primary safety endpoint in the pre-market phase was previously met and subsequently confirmed in the post-market phase. In the pre-market phase, all effectiveness endpoints were previously met, demonstrating 6-month improvements in 6MHW, quality of life, NYHA Class and NT-proBNP (described below). The post-market phase effectiveness primary endpoint of CV mortality and HF hospitalization was not met. Additional post-market phase effectiveness analyses (Win Ratio, freedom from all-cause mortality) suggested a favorable effect of Barostim Therapy. The totality of the 6, 12 and 24-month data demonstrated symptomatic improvements for HF patients who are NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed therapies and who have a left ventricular ejection fraction &#8804; 35% and a NT-proBNP&lt;1600 pg/ml.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Widely accepted mechanism of action.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our platform technology is based on a widely accepted mechanism of action and is designed to address the imbalance of the ANS, which causes HFrEF and other cardiovascular diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong global clinical evidence.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were shown to be similarly robust and reproducible across all three of our HF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. Barostim Therapy&#8217;s trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Minimally invasive implant procedure.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim&#8217;s implantable pulse generator (&#8220;IPG&#8221;) and stimulation lead are implanted during a minimally invasive implant procedure typically performed in an outpatient setting that lasts approximately one hour and involves two small skin incisions. Our device does not require hardware to be implanted in the heart or vasculature, which is the case with most other device-based treatments indicated for different HFrEF patient populations. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential reduction in total healthcare costs for HFrEF patients.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;A Company-sponsored and co-authored cost-impact analysis, which was published in&#160;</span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">BMC Cardiovascular Disorders</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, a peer-reviewed manuscript, predicted BAT plus GDMT would become the lower-cost alternative treatment within three&#160;years from implantation, as compared to GDMT alone, resulting in significant cost savings to healthcare systems.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Inherent patient compliance and durability.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. Our device has a battery that does not require recharging, has an average service life of five&#160;to six years and is replaced through a short outpatient procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an IPG and a stimulation lead and is programmed by a wireless clinician-controlled programmer that communicates with the IPG. The IPG contains the electronics and battery in a hermetic enclosure and controls and delivers the imperceptible and persistent electrical pulses to the carotid baroreceptors through the stimulation lead attached to the exterior wall of the carotid artery. These electrical pulses delivered to the baroreceptors increase signals to the brain to modulate the cardiovascular function, thereby improving symptoms of HFrEF. Our wireless programmer allows physicians to verify and customize the therapy to the patient&#8217;s needs by adjusting the intensity and frequency of the electrical pulses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have developed a significant clinical data set that demonstrates the safety, effectiveness, patient adherence and durable benefits of Barostim Therapy. Our BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met the primary safety and effectiveness endpoints and demonstrated meaningful improvement in the quality of life, both physically and emotionally, for patients suffering from HFrEF. These results led to FDA Premarket Approval (&#8220;PMA&#8221;) approval of Barostim in August&#160;2019 on an accelerated basis of only four&#160;months from the submission of the clinical trial report. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The BeAT-HF pivotal trial continued enrolling patients in the post-market stage of the trial in order to gather and evaluate additional, long-term data. In December 2023, the FDA approved expanded labeling for Barostim based on the BeAT-HF trial data, resulting in simplification and clarification of the indications for use, as well as inclusion of the primary endpoint results, the 6, 12 and 24 month symptomatic data, the Win Ratio and the all-cause mortality data in the &#8220;Clinical Summary&#8221; discussion included in Barostim&#8217;s indications for use.  We currently believe our annual market opportunity in the U.S. is an estimated $2.2&#160;billion, or 76,000 patients, based on this new long-term safety and effectiveness data as well as our commercial experience and, as discussed below, the new reimbursement assignment for Barostim in 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We continue to develop and expand upon our significant body of published clinical evidence that supports the meaningful benefits of Barostim Therapy. We are continuing to collect data through the U.S. patient registry that we have established in order to evaluate and assess real world outcomes from HFrEF patients who have been implanted with Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We primarily sell Barostim to hospitals through a direct sales organization in the U.S. and Germany and through distributors in Austria, Spain, Italy, the Nordic region and other European countries. Our global sales and marketing team engages in sales efforts and promotional activities focused on electrophysiologists (&#8220;EPs&#8221;), HF specialists, interventional cardiologists, general cardiologists and vascular surgeons. We are prioritizing our sales and marketing efforts on high volume cardiology centers that are strategically located and on educating and training physicians. We support all aspects of the patient journey, which includes initial diagnosis, surgical support and patient follow-up. We also highlight our compelling clinical benefits and value </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">proposition to build awareness and adoption among physicians through targeted key opinion leader (&#8220;KOL&#8221;) development, referral network education and direct-to-consumer marketing. We utilize direct communication channels to inform and educate patients about Barostim Therapy and utilize a qualification process to aid in the identification of the appropriate patients for our therapy. In the U.S., Barostim is reimbursed by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) across all regions. We assist with reimbursement approvals, if required. We plan to continue actively expanding our direct sales force and commercial organization in the U.S., which is where we expect to focus most of our sales and marketing efforts in the near-term.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The primary focus of our research and development efforts in the near-term will be the continued technological advancement of Barostim, including tools to simplify the implant procedure for physicians. In 2022, we launched an enhanced IPG that is approximately 10% smaller in size and improves battery life by approximately 20% to an average of six&#160;years. We are also enrolling a clinical trial for a new implant toolkit called BATwire, which enables an ultrasound-guided implant procedure to implant Barostim and the use of local anesthetics, potentially expanding our annual market opportunity in the U.S. In the future, we plan to explore Barostim&#8217;s potential to expand its indications for use to other cardiovascular diseases, including different forms of HF, hypertension and arrhythmias. Expansions into these or other new indications would require additional FDA approvals and may involve additional clinical trials or modifications to Barostim to treat such indications. If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We generated revenue of $39.3&#160;million, a gross margin of 84% and a net loss of $41.2&#160;million for the year ended December 31, 2023, compared to revenue of $22.5&#160;million, a gross margin of 78% and a net loss of $41.4&#160;million for the year ended December 31, 2022. Our accumulated deficit as of December 31, 2023 and 2022, was $477.4 million and $436.2&#160;million, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our market and industry</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of HF</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">It is estimated that HF currently affects approximately 26&#160;million people globally, including approximately 6.2&#160;million people in the U.S. and approximately 8.6&#160;million people in the European Five. Every year, 1.3&#160;million and 1.4&#160;million new patients are diagnosed with HF in the U.S. and the European Five, respectively. HF is associated with a five-fold increase in sudden cardiac death. There is no known prevention for HF other than the treatment of the common risk factors associated with the disease, such as hypertension, diabetes and obesity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HF is a debilitating, progressive and potentially life-threatening condition where the heart does not pump enough blood throughout the body. Without proper blood circulation, insufficient levels of oxygen and nourishment are delivered to various body parts, impacting a person&#8217;s ability to function and leading to a variety of symptoms that affect quality of life, both physically and emotionally, such as shortness of breath, extreme fatigue, exercise intolerance, swelling and fluid retention. HF usually develops as a result of an imbalance of the ANS, which is also the primary cause of multiple other cardiovascular diseases, such as hypertension, angina pectoris and arrhythmia.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The role of the imbalance of ANS in HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#2e75b5;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The ANS, which is a part of the peripheral nervous system, plays a vital role in the function of the heart. It is a collection of receptors and neurons that acts outside of a person&#8217;s conscious awareness, regulating bodily functions such as bodily fluid production, urination and sexual responses. There are two primary components of the ANS that impact heart functionality: the sympathetic system and the parasympathetic system.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sympathetic system of the ANS is responsible for preparing the body for action through the &#8220;fight or flight&#8221; response. When the body perceives a threat in the environment, the sympathetic system reacts by increasing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168.51pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">the heart rate, widening the airways to allow for easier breathing, releasing stored energy, increasing strength in the muscles and slowing digestion and other bodily processes that are not as critical for taking action. These changes prepare the body to respond appropriately to a threat in its environment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The parasympathetic system of the ANS is responsible for restoring the body to a state of calm through the &#8220;rest and digest&#8221; counter response in order to maintain homeostasis. This is done by decreasing the heart rate, conserving energy, constricting the airways, relaxing the muscles and increasing digestion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k006.jpg" alt="Graphic" style="display:inline-block;height:168.51pt;width:204.6pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These two systems are strongly influenced by baroreceptors that are located in certain arterial walls. The baroreceptors regulate the baroreflex, which is one of the body&#8217;s homeostatic mechanisms that help to maintain blood pressure at nearly constant levels. Baroreceptors provide beat-by-beat regulation of the body&#8217;s circulatory system by sending electrical signals to the brain.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Healthy individuals have balanced sympathetic and parasympathetic activities, promoting the effective function of the heart. However, there are many factors, including a person&#8217;s diet, lifestyle and underlying conditions such as diabetes and obesity that can cause an imbalance of the ANS. This imbalance, or the elevated levels of sympathetic activity and reduced levels of parasympathetic activity, may result in additional stress on the heart, leading to HF and potentially death.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Overview of HFrEF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#2e75b5;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">When the heart pumps, oxygen-rich blood travels from the lungs, through the left atrium and into the left ventricle from where it is pumped to the rest of the body. Given that the left ventricle is responsible for the majority of the heart&#8217;s pumping power, it is larger than the other chambers and critical for proper heart functionality. In left-sided or left-ventricular HF, the left side of the heart must work much harder to pump the same amount of blood it would under healthy conditions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There are two types of left-sided HF, HFrEF, or systolic heart failure, and HF with preserved Ejection Fraction (&#8220;HFpEF&#8221;), or diastolic heart failure. In HFrEF, the left ventricle loses its ability to contract properly, resulting in insufficient power to pump and push the necessary quantities of blood into circulation. In HFpEF, the left ventricle loses its ability to relax properly (due to muscle stiffness), leading to the improper filling of blood in the heart during the resting period between heartbeats.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k007.jpg" alt="Graphic" style="display:inline-block;height:197.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:423.6pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are currently focused on the treatment of patients with HFrEF, which represents approximately 40% of the patients with HF. These patients currently have limited commercially available device-based treatment options that improve HFrEF symptoms such as shortness of breath, fatigue, weakness, swelling of the legs and feet, reduced ability to exercise, a persistent cough, an increased need to urinate and sudden weight gain. Approximately 75% of HFrEF patients die within five years of being admitted to the hospital for HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Given HFrEF is a multifactorial and heterogeneous disease, physicians use a variety of indicators in the underlying pathology, severity of symptoms and a patient&#8217;s functional limitations to classify HF patients. Below are some of the common indicators used by cardiologists to diagnose HF:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NYHA classification:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;">&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The NYHA classification guidelines are the most common measure of HF severity and allow physicians to classify patients into four groups based on observed symptoms and functional limitations. The least severe functional status is NYHA Class&#160;I (mild) with the most advanced being NYHA Class&#160;IV (critical). The majority of patients are initially identified as NYHA Class&#160;I or II and typically progress into subsequently worse states of the disease despite current treatment options. On average, patients who progress to a NYHA Class&#160;III either worsen to Class&#160;IV or die after 3.3&#160;years. HFrEF patients are typically classified as NYHA Class&#160;II (moderate) or Class&#160;III (severe).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Level of N-terminal prohormone B-type natriuretic peptide (&#8220;NT-proBNP&#8221;):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;NT-proBNP, a non-active prohormone in the heart, is released due to pressure changes inside the heart. NT-proBNP is considered to be at a normal level when it is &lt; 125pg/ml for patients 0&#8211;74&#160;years old and &lt; 450pg/ml for patients 75&#8211;99&#160;years old. Generally, patients with HF have elevated NT-proBNP levels, with those &gt; 1600pg/ml associated with an extremely poor prognosis and low responses to treatments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Left ventricular ejection fraction (&#8220;LVEF&#8221;):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;LVEF is a widely utilized indicator of systolic heart function, or the heart&#8217;s ability to pump blood throughout the body. It measures the&#160;percentage of blood that is ejected from the left ventricle with each beat. A LVEF &lt; 50% is considered dysfunctional and indicative of HFrEF.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Co-morbidities / clinical fit:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;A patient&#8217;s co-morbidities, such as severe chronic obstructive pulmonary disease (COPD), kidney disease or carotid stenosis, as well as a patient&#8217;s physical and psychological fit </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">contribute to a physician&#8217;s treatment recommendation given the use of general anesthesia in most HF-related device-based treatment options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">QRS complex:</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The QRS complex is a classification of ventricle depolarization, or the heart&#8217;s ability to open once contracted. It measures the way in which electrical signals travel through the heart and considers the mechanics and duration of the ventricle depolarization. A narrow QRS complex, or a QRS &lt; 120 milliseconds, is usually driven by a right bundle branch block, which is a blockage along the pathway that electrical pulses travel through to the right ventricle in order to generate a heartbeat. A wide QRS complex, or a QRS&#160;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">&#8805;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;150 milliseconds, is usually driven by a left bundle branch block, which is a blockage impacting the pathway to the left ventricle.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Existing treatments for HFrEF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients with HFrEF are typically placed on a treatment progression plan during which they are initially given GDMT to help manage symptoms. GDMT usually includes a progression or combination of prescribed drugs such as Diuretics, Beta-blockers, ACE Inhibitors, ARBs, ARNIs, SGLT2 Inhibitors and Sinus Node Inhibitors. After being treated with pharmaceuticals for a short period, if the symptoms persist, patients move to more invasive and costly treatment options involving other implantable devices, with the most severe patients often requiring LVADs or heart transplants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other commercially available implantable devices</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantable Cardiac Defibrillators (ICD)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">ICDs are indicated for patients with NYHA Class&#160;II or III and LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% for both wide and narrow QRS. However, these devices are generally used to prevent sudden cardiac arrest rather than reduce HFrEF symptoms as their electrical shocks focus on restoring a normal heartbeat when a heart beats too quickly or randomly. Given their purpose and mechanism of action, these devices are not a treatment for HFrEF but are used in conjunction with other treatment options that focus on reducing HF symptoms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cardiac Resynchronization Therapy (&#8220;CRT&#8221;)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CRTs, or biventricular pacing, are indicated for patients with NYHA Class&#160;II or III, LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and wide QRS. These devices are primarily used to reduce symptoms of HFrEF by generating electrical pulses to regulate the pace of a heartbeat. While CRTs can alleviate symptoms for patients with a wide QRS, they are not eligible for patients with a narrow QRS, which represents approximately 59% of patients with NYHA Class&#160;II or III and LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35%. These devices can be combined with an ICD, which are referred to as CRT-D.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Cardiac Contractility Modulation (&#8220;CCM&#8221;)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CCM is eligible for patients with NYHA Class&#160;III, LVEF 25%&#8211;45%, narrow QRS and normal sinus rhythm. CCM requires an invasive procedure whereby an IPG is implanted under the skin of the upper chest with electrical leads running through the veins and attached inside the heart&#8217;s ventricles, sending electrical pulses to the heart after it contracts. The device is rechargeable and therefore requires patients to recharge the battery on a regular basis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Left Ventricular Assist Device (LVAD)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">LVAD is an irreversible, invasive surgery generally reserved for critical HFrEF patients with NYHA Class&#160;IV. An LVAD is a mechanical pump that is implanted inside a patient&#8217;s chest and helps pump blood throughout the body. While LVADs do not replace the heart, they do require open chest surgery and often result in the destruction of a portion of the heart. Patients who do not respond to LVADs usually have no other treatment options and become candidates for heart transplants.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Despite currently available pharmaceutical and device-based treatments, HF remains underpenetrated and imposes significant direct and indirect costs on the healthcare system through patient care, morbidity, unpaid care costs, premature mortality and lost productivity. We estimate there are approximately 800,000 HF hospitalizations every year in the U.S., representing approximately $39.5&#160;billion in annual spending.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barostim&#8217;s market opportunity</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In 2021, we estimated that our annual market opportunity for HFrEF was $2.9&#160;billion, including a $1.4&#160;billion initial market opportunity (55,000 HFrEF patients) in the U.S., and a $1.5&#160;<span style="white-space:pre-wrap;">billion initial market opportunity (61,000 HFrEF patients) in the European Five. In late 2023, we revised our U.S. annual market opportunity &#8211; based on the new long-term safety and effectiveness data of BeAT-HF, our commercial experience and to account for the new reimbursement assignment for Barostim &#8211; to $2.2 billion, or 76,000 new patients.  Thus, we believe our global annual market opportunity for HFrEF is $3.7 billion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our solution</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We developed our Barostim platform technology to transform the treatment of HFrEF and other cardiovascular diseases and become the standard of care for this vulnerable and underpenetrated patient population. We believe Barostim offers meaningful benefits for patients, physicians and payors that will continue to drive adoption of our therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">&#160;</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Overview of Barostim Therapy</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our integrated platform technology, Barostim, leverages the power of the brain and nervous system to address the primary cause of HFrEF and other cardiovascular diseases. Our product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF. Barostim Therapy utilizes a widely accepted mechanism of action and works by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to decrease sympathetic activity and increase parasympathetic activity. This integrated response to rebalancing the ANS is well understood to normalize blood pressure, improve remodeling of the heart, increase vasodilation (widening of blood vessels) and improve kidney function. Based on the results of our BeAT-HF pivotal trial, Barostim has demonstrated its ability to meaningfully improve the quality of daily life, both physically and emotionally, for patients suffering from HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barostim</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim consists of two implantable components: an IPG and a stimulation lead. The image below depicts the relative location and size of Barostim under the patient&#8217;s skin:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k008.jpg" alt="Graphic" style="display:inline-block;height:168pt;width:168pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:162pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantable pulse generator</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The current IPG contains the electronics and battery in a hermetic enclosure, has an average service life of five to six&#160;years and includes a battery that does not require any recharging. The IPG provides control and delivery of electrical pulses to baroreceptors located in the wall of the carotid artery through the stimulation lead. Nominal dimensions for the current IPG are listed in the figure below:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k009.jpg" alt="Graphic" style="display:inline-block;height:162pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:144.94pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Stimulation lead</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The stimulation lead is attached via six suture points to the exterior wall of the carotid artery and is connected to the current IPG. This allows the stimulation lead to carry the electrical pulses from the IPG to the baroreceptors located in the wall of the carotid artery. The stimulation lead terminates with a two-millimeter electrode. There are two lengths of the stimulation lead available to allow for anatomical variations to be used at the physician&#8217;s discretion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k010.jpg" alt="Graphic" style="display:inline-block;height:135pt;width:435pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Ancillary surgical accessories</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to the IPG and stimulation lead, we provide physicians with single-use surgical tools, including the port plug, torque wrench, implant tool and implant adaptor, all of which were designed to facilitate the implantation of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:181.8pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Programmer</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Once implanted, Barostim is managed wirelessly by a programmer that communicates with the IPG. The programmer can be used to assist in verifying the desired location of the stimulation electrode during the implant procedure and allows physicians to input their patient&#8217;s therapy parameters and retrieve information on the status of the IPG, including the remaining battery life, without touching the IPG or the patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k011.jpg" alt="Graphic" style="display:inline-block;height:181.8pt;width:290.74pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treating patients with Barostim</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Patient selection</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is indicated for patients who are NYHA Class&#160;III or II (who had a recent history of Class&#160;III) despite treatment with guideline-directed medical therapies (medications and devices), have a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and a NT-proBNP &lt; 1600 pg/ml. Barostim delivers Baroreflex Activation Therapy to improve patients&#8217; NYHA functional status, 6MHW and quality of life.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Once a patient is diagnosed with HFrEF and recommended for an ICD and/or CRT, interventional or general cardiologists will often refer them to EPs, who often conduct a series of diagnostic tests, including an electrocardiogram, ultrasound and various blood tests, from which they will determine the patient&#8217;s eligibility for our therapy. Many of our indicated patients may have already been pre-indicated for an ICD, whether or not they chose to undergo the ICD implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Implantation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is implanted during a short, minimally invasive procedure that is typically performed on an outpatient basis by a vascular surgeon and possibly an EP. The procedure has two steps. During the first step, a small incision is made on the right side of the neck to expose the carotid sinus. The physician uses the implant tool to hold the lead electrode in contact with the outside wall of the carotid artery while the lead is temporarily connected to the IPG to verify the location of the electrode. After the electrode is sutured in place, the second step begins by making a small incision below the right clavicle where a pocket is created under the skin to hold the IPG. The main body of the stimulation lead is tunneled under the skin, but over the clavicle, from the neck to the pocket. The lead connector is inserted and secured into the IPG header. Lastly, the IPG is placed in the pocket and a few stiches are used to close each incision.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This implantation procedure, which typically lasts one hour, is usually performed under general anesthesia and may require a short hospital stay. While patients may experience mild discomfort and swelling at the incision sites for a few days, this often can be managed with over-the-counter pain medications. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Activation/Titration</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After Barostim is implanted and activated, the patient attends a few follow-up visits with their doctor, during which the device is progressively titrated from a moderate level to a higher amplitude of electrical stimulation. The primary objective of these follow-up visits is for the patient to reach the optimal level of stimulation, which is typically achieved approximately three&#160;months after implantation. The exact level of stimulation varies from patient to patient based on the response to Barostim Therapy. Barostim can be adjusted through a digital wireless programmer, allowing the clinician to monitor and customize the therapy to the patient&#8217;s needs by adjusting the intensity and frequency of the electrical pulses being sent to the carotid artery. After the titration period, it is recommended that the patient attend a clinical visit two times each year to check impedance, battery longevity and adequacy of programming.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Key benefits for patients, physicians and payors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is designed to advance patient care and provide a safe, effective and economically attractive treatment option to an underserved patient population suffering from HFrEF. We believe the following factors offer meaningful benefits for patients, physicians and payors that will continue to drive broad adoption of our therapy:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Addresses significant unmet medical need. </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Barostim addresses a life-threatening disease for patients who failed to receive adequate benefits from existing treatments and who have no alternative treatment options. Based on this, the FDA granted Barostim a Breakthrough Device designation for HFrEF in June&#160;2015.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Safe and effective treatment.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our BeAT-HF pivotal trial demonstrated compelling safety and effectiveness data regarding the clinical benefits of Barostim for HFrEF. The pre-market data demonstrated safety and effectiveness leading to FDA approval and safety and effectiveness were confirmed by the post-market data. These results showed significant improvement in the following patient-centered outcomes:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated that patients in the Barostim group were able to improve the distance they walked in a six-minute period by 56 meters and 44 meters more than patients in the Control group at six months and at one year, respectively, following implant, meaning the improvement was sustained. A 25-meter improvement in walking distance is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated a 14-point, 8-point and 10-point improvement in quality of life for patients in the Barostim group relative to patients in the Control group at 6 months, 1 year and 2 years following implant, again demonstrating sustained improvement. A 5-point improvement is considered clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Our therapy demonstrated the following improvements in NYHA functional status versus the Control group at the specific points in time, meaning Barostim demonstrated greater and sustained improvement: at 6 months, 67% in the BAT+ group and 37% in the Control group, favoring the BAT+ group by 30 percentage points; at 1 year, 73% in the BAT+ group and 41% in the Control group, favoring the BAT+ group by 32 percentage points; and, at 2 years, 68% in the BAT+ group and 41% in the Control group, favoring the BAT+ group by 27 percentage points.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Freedom from All-Cause Death, LVAD, or Transplant. </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients</span><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">in the Barostim group had a directionally favorable 34% reduction in all-cause death or the use of LVAD or heart transplant versus the Control group.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;white-space:pre-wrap;">Improvement in Hierarchical Composite Outcomes.  </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on a hierarchical composite outcomes analysis (including CV mortality, LVAD/transplant, HF hospitalization and quality of life), the Win Ratio was 1.26 in favor of the Barostim group.</span><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The significant benefits of our therapy were observed despite a four-fold uptake of ARNI medication in the control arm, as compared to the device arm.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Widely accepted mechanism of action.&#160;</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Our platform technology is based on a widely accepted mechanism of action and is designed to address the imbalance of the ANS, which causes HFrEF and other cardiovascular diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Strong global clinical evidence.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;The benefits of treatment with Barostim were shown to be similarly robust and reproducible across all three of our HF clinical studies, including BAT-in-HF (Phase&#160;I), HOPE4HF (Phase&#160;II) and BeAT-HF (Phase&#160;III pivotal trial), evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. The BeAT-HF pivotal trial, which was a multi-center, prospective, randomized, controlled trial, met its primary endpoints and the positive safety and effectiveness data exceeded the pre-specified performance criteria across multiple dimensions, measuring the improvement in the quality of patients&#8217; daily lives. Barostim Therapy&#8217;s trial results have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the Journal of the American College of Cardiology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Minimally invasive implant procedure.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim&#8217;s IPG and stimulation lead are implanted during a minimally invasive implant procedure typically performed in an outpatient setting that lasts approximately one hour and involves two small skin incisions. Our device does not require hardware to be implanted in the heart or vasculature, which is the case with most other device-based treatments indicated for different HFrEF patient populations. Patients typically recover quickly and are discharged from the hospital within 24 hours of the procedure. In addition, we are currently enrolling a clinical trial for a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics. As a result of this simplified implantation process, we believe more physicians, including EPs, would be confident and comfortable implanting Barostim, thereby expanding our addressable patient population to include those who are deemed clinically unfit for the current procedure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential reduction in total healthcare costs for HFrEF patients.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;In addition to providing improved physical and health-related benefits and quality of life for patients, we estimate Barostim has the potential to result in cost savings to healthcare systems. A Company-sponsored and co-authored cost-impact analysis, which was published in&#160;</span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">BMC Cardiovascular Disorders</i><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, a peer-reviewed manuscript, predicted BAT plus GDMT would become the lower-cost alternative treatment within three&#160;years from implantation, as compared to GDMT alone, resulting in significant cost savings to healthcare systems.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Inherent patient compliance and durability.</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;Barostim ensures patient compliance, unlike most commercially available drug treatments, as it requires no device interaction by the patient. Our device has a battery that does not require recharging, has an average service life of five to six&#160;years and is replaced through a short outpatient procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical results and studies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness of Barostim in HFrEF is supported by compelling data, which demonstrated similarly robust and reproducible results across our three clinical trials evaluating 624 patients in aggregate across the U.S., Germany, Italy, France, Canada and the United Kingdom. We designed our BeAT-HF (Phase&#160;III) pivotal trial in collaboration with the FDA under the Breakthrough Devices Program, which was implemented to accelerate the approval of novel therapies targeting unmet needs for debilitating or life-threatening conditions. The pre-market phase of our BeAT-HF pivotal trial met the primary safety and effectiveness endpoints and demonstrated meaningful improvement in the quality of life, both physically and emotionally, for patients suffering from HFrEF. These results led to the FDA approval of Barostim in August&#160;2019 on an accelerated basis of only four&#160;months from the submission of the final clinical trial report. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The post-market phase BeAT-HF pivotal trial met the primary safety endpoint, and although it did not meet the primary effectiveness endpoint, showed sustained improvements in exercise capacity, quality of life and NYHA functional status, and favored Barostim in freedom from all-cause mortality, LVAD or transplant and in the Win Ratio. This led to the FDA approval of expanded labeling with these results and a simplification and clarification of the following indications for use.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim is indicated for patients who are NYHA Class&#160;III or Class&#160;II (with a recent history of Class&#160;III) despite treatment with guideline-directed medical therapies (medications and devices), have a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and a NT-proBNP &lt; 1,600 pg/ml. Barostim delivers Baroreflex Activation Therapy to improve patients&#8217; NYHA functional status, 6MHW and quality of life.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness of Barostim Therapy have been published in more than 60 peer-reviewed publications, approximately 20 of which relate to the treatment of HF, including, among others, the publication of the pivotal trial results in the Journal of the American College of Cardiology. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have established a U.S. patient registry to evaluate and assess real world patient outcomes from patients who have been implanted with Barostim. Investment in clinical evidence continues to be one of our core strategies, and we intend to continue to develop and expand upon a significant body of published clinical evidence that supports the safety and effectiveness of Barostim Therapy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pivotal Phase&#160;III Study: BeAT-HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">BeAT-HF is a multi-center, prospective, randomized, controlled trial that began in April&#160;2016 to develop scientific evidence for the safety and effectiveness of BAT with Barostim. Between May&#160;2016 and July&#160;2020, 467 adult patients were randomized at 72 sites within the U.S. and one site in the United Kingdom.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF study was designed to encompass two stages in an integrated and seamless approach:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(1)&#160;&#160;&#160;A pre-market stage that examined three primary effectiveness endpoints (quality of life, 6MHW and NT-proBNP), as well as one safety endpoint that included the major adverse neurological or cardiovascular system or procedure-related event rate (&#8220;MANCE&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(2)&#160;&#160;&#160;A post-market stage that examined the effects of BAT on rates of HF hospitalization and cardiovascular mortality, as well as sustained safety and symptomatic improvements, which expanded the labeling for Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients were eligible for the trial if they were NYHA Class&#160;III or Class&#160;II (with a recent history of Class&#160;III); had an LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and NT-proBNP &lt; 1,600 pg/ml; were able to complete a 6MHW distance of 150 to 400 meters; were on stable optimal GDMT for&#160;<span style="letter-spacing:0.2pt;">&#8805;</span>&#160;4 weeks; had at least one carotid artery that was below the level of the mandible with no ulcerative carotid arterial plaques or stenosis&#160;<span style="letter-spacing:0.2pt;">&#8805;</span>&#160;50%; and were an acceptable surgical candidate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients who had a Class&#160;I indication for a CRT according to the American Heart Association/American College of Cardiology/European Society of Cardiology guidelines were excluded, and there were no restrictions for atrial fibrillation or atrial flutter.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In summary, the primary safety endpoint in the pre-market phase was previously met and confirmed in the post-market phase. In the pre-market phase, all effectiveness endpoints were previously met, demonstrating 6-month improvements in 6MHW, quality of life, NYHA Class and NT-proBNP. The post-market phase effectiveness primary endpoint of CV mortality and HF hospitalization was not met. Additional post-market phase effectiveness analyses (Win Ratio and freedom from all-cause mortality) suggested a favorable effect of Barostim Therapy. The totality of the 6, 12 and 24-month data demonstrated symptomatic improvements </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">for HF patients who are NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed therapies and who have a LVEF &#8804; 35% and a NT-proBNP &lt; 1600 pg/ml.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Pre-market phase results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The safety and effectiveness data in the BeAT-HF pivotal trial support the HFrEF clinical benefits of Barostim. These results demonstrated that BAT is safe in patients with HFrEF and significantly improves the patient-centered symptomatic endpoints of the quality-of-life score, 6MHW and NYHA functional status, as well as the confirmatory nature of the evidence provided by a reduction of NT-proBNP.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 14-point reduction (improvement) in quality of life for patients in the BAT+ group relative to patients in the Control group (p &lt; 0.001; 95% CI:&#160;-19&#160;to&#160;-9).&#160;MLWHF is a self-administered disease-specific questionnaire for HF, which is comprised of 21 questions rated on six-point Likert scales, representing different degrees of impact of HF on a patient&#8217;s quality of life, and is approved by the FDA as a Medical Device Development Tool. According to the medical community, a five-point reduction (improvement) is considered to be clinically meaningful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 60-meter increase in the distance patients in the BAT+ group were able to walk on a flat, hard surface in a six-minute period relative to that of patients in the Control group (p &lt; 0.001; 95% CI: 40 to 80 meters). According to the medical community, the 6MHW is an index of a patient&#8217;s ability to perform daily activities; an improvement of 25 meters or more is considered to be clinically meaningful to HFrEF patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT demonstrated that 65% of patients in the BAT+ group improved at least one NYHA class (p &lt; 0.001; 95% CI: 22% to 46%) as compared to only 31% in the Control group and 13% of patients in the BAT+ group improved two NYHA classes as compared to only 2% in the Control group.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">NT-proBNP (serum biomarker used as indicator of severity of HF):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;BAT resulted in a 25% greater reduction (improvement) in NT-proBNP for patients in the BAT+ group relative to that of patients in the Control group (p=0.004; 95% CI =&#160;-38%&#160;to&#160;-9%).&#160;According to independent research that took place in a large multicenter pharmaceutical clinical trial, a 10% change in NT-proBNP is associated with a change in the subsequent risk of cardiovascular mortality and HF hospitalization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MANCE-free rate exceeded the performance criteria of 85%, with 121 out of 125 implanted patients being event free, resulting in an event-free rate of 97% (p &lt; 0.001; 95% 1-sided CI: 93% to 100%).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to the results noted above, we observed a reduction in the rate of cardiovascular serious adverse events (non-HF related events) by 51% (events per patient-year; 0.101 BAT+ vs 0.206 Control; nominal p= 0.023; 95% CI: 0.10 to 0.73) and there were no significant differences in blood pressure or heart rate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Post-market phase results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The BeAT-HF pivotal trial continued enrolling patients in the post-market stage of the trial to determine if Barostim demonstrates a statistically significant improvement in morbidity and mortality in patients with HFrEF. Between May&#160;2019 and July&#160;2020, an additional 59 adult patients were randomized at 17 sites within the U.S. as part of the post-market phase of the trial. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The safety and effectiveness data in the BeAT-HF pivotal trial support the HFrEF clinical benefits of Barostim. These results demonstrated that BAT is safe in patients with HFrEF, showed a directional reduction in the primary endpoint of CV mortality and HF morbidity (although not reaching statistical significance), and favored patient-centered symptomatic improvements at 6 and 12 months in 6MHW and at 6,12 and 24 months in the MLWHF quality of life and NYHA Class.  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:163.52pt;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Exercise capacity (measured by the standardized 6MHW distance test): </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The</span><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">BAT+ group showed an improvement at both 6 and 12 months compared to the Control group. The difference between the arms at 6 months was 56 meters and at 12 months the difference was sustained with 44 meters. These improvements between the groups are not only statistically significant, but they are approximately twice the clinically significant value of 25 meters.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k012.jpg" alt="Graphic" style="display:inline-block;height:139.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:293.67pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Quality of life (measured by MLWHF): </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The</span><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">BAT+ group showed a decrease (improvement) in quality of life points ranging from 17 to 20 points from baseline across the follow-up visits. The differences between the groups at 6, 12 and 24 months are -14, -8 and -10, respectively, which is not only statistically significant, but is greater than a clinically meaningful difference of 5 points.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k013.jpg" alt="Graphic" style="display:inline-block;height:162.77pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:307.8pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:168.02pt;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Functional status (determined by NYHA classification):</b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Approximately two-thirds of the BAT+ group improved at least one NYHA class across the follow-up visits. Additionally, the percentage of subjects improving between the arms at 6, 12 and 24 months was higher in the BAT+ group compared to the Control group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k014.jpg" alt="Graphic" style="display:inline-block;height:167.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:295.8pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Hierarchical Win Ratio: </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The hierarchical composite analysis using the Win Ratio was evaluated using the components of the CV morbidity and HF mortality endpoints and the MLWHF quality of life (CV mortality, heart transplant or LVAD, number of hospitalizations or emergency visits for HF, number of unscheduled clinical visits with IV diuretic and change from baseline in MLWHF at 12 months). This resulted in a Win Ratio of 1.26, reflecting beneficial trend in the heart transplant/LVAD over the course of the study and MLWHF at 12 months.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k015.jpg" alt="Graphic" style="display:inline-block;height:147.11pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:256.2pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:288pt;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Freedom from All-Cause Mortality: </b><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">In addition to the results above, freedom from all-cause mortality (all-cause death, LVAD and heart transplant) demonstrated a 34% reduction between the groups. In the BAT+ group, the crude event rate was 7.0 per 100 years with 38 events during 544 patient-years at risk. In the Control group, the crude event rate was 10.4 per 100 years with 51 events during 492 patient-years at risk.  As shown below, the hazard ratio for all-cause mortality = 0.662 (95% CI 0.435, 1.007), representing a relative risk reduction of 34% in the BAT+ group compared with the Control group.  The hazard ratio for all-cause mortality using a per protocol analysis = 0.589 (95% CI 0.380, 0.923), representing a relative risk reduction of 41% in the BAT+ group compared with the Control group. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="cvrx-20231231x10k016.jpg" alt="Graphic" style="display:inline-block;height:287.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:287.4pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The system or procedure related MANCE endpoint includes all events that occurred across the duration of follow-up. The analysis includes subjects in BAT+ group who had an implant attempted (n=159), representing 6,664 total months of implant follow-up. All implant attempts were successful. As shown below, the MANCE-free rate is 96.9%, with 154 out of 159 implanted patients being event free with a lower bound one-sided 95% confidence level of 93.5% (p value &lt;0.001 compared to a performance goal of 85%).  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="cvrx-20231231x10k017.jpg" alt="Graphic" style="display:inline-block;height:62.45pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:406.5pt;"/></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;II Study: HOPE4HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HOPE4HF was a multinational, prospective, randomized, controlled trial that began in May&#160;2012 to demonstrate the safety and performance of BAT with Barostim. A total of 146 patients (72 in the U.S. and 74 in Germany, Italy, France and Canada) at 45 centers were randomized 1:1 with 76 patients in the BAT+ group and 70 patients in the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients were eligible for the study based on symptoms, historical treatment plan and anatomical criteria, including if they were NYHA Class&#160;III, received GDMT for their HF, had a LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;35% and were considered a suitable surgical candidate, among others. Patients were excluded from the study if they had recently experienced NYHA Class&#160;IV, recently received an ICD or CRT, or had known baroreflex failure, among others.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The overall MANCE-free rate was 97% (lower 95% CI bound 91%). Patients assigned to BAT+ group, compared with Control group patients, experienced improvements in MLWHF quality of life score (&#8211;17 &#177; 2.8 points BAT+ vs. 2.1 &#177; 3.1 points Control; p &lt; 0.001), 6MHW distance (60 &#177; 14 meters BAT+ vs. 1.5 &#177; 13 meters Control; p=0.004) and NT-pro BNP (-69 pg/ml BAT+ vs. 130 pg/ml Control; p =0.02). BAT+ patients also experienced at least a one-class improvement in NYHA class when compared to the Control group (55% BAT+ vs 24% Control; p=0.002) and showed a trend toward fewer days hospitalized for HF (p=0.08) as compared to the Control group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Positive safety and performance results from the 146-patient combined, randomized, controlled clinical trials were presented in the late breaking clinical trial session of the American College of Cardiology and the European Society of Cardiology HF conference in 2015. The favorable data from this trial were published in the&#160;<i style="font-style:italic;">Journal of the American College of Cardiology&#8201;&#8212;&#8201;Heart Failure</i>&#160;in 2015<i style="font-style:italic;">.</i>&#160;These results led to CE Mark approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;I Study: BAT in HF</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">BAT in HF was our first-in-human study of Barostim Therapy for the treatment of HF that was published in 2014. This study was a single-center, open-label evaluation, designed to evaluate the safety and performance of Barostim Therapy in patients with NYHA Class&#160;III receiving optimized medical therapy for their HF and had an LVEF&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;40%. Patients who had been implanted with a CRT device were excluded from this trial until six&#160;months after activation. Eleven patients met the eligibility criteria and received Barostim. After six&#160;months of Barostim Therapy, the mechanism of action was assessed with serial measurement of muscle sympathetic nerve activity (&#8220;MSNA&#8221;) and clinical measures of quality of life and functional capacity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Results</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">MSNA was reduced over six&#160;months from 45 &#177; 7.7 to 31 &#177; 8.3 bursts/minute and from 68 &#177; 13 to 45 &#177; 12 bursts/&#8203;100 heartbeats, decreases of 31% and 33%, respectively (p &lt; 0.01). Concomitant improvements occurred in baroreflex sensitivity, ejection fraction, NYHA class and quality of life as measured by the MLWHF and 6MHW distance (p&#160;<span style="letter-spacing:0.2pt;">&#8804;</span>&#160;0.05 each). On an observational basis, hospitalization and emergency department visits for worsening HF were reduced.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This study provided the first evidence that chronic stimulation of carotid baroreceptors markedly and persistently reduced the sympathetic activation characterizing HF patients. It also demonstrated that the reduction is accompanied by the improvement of a major modulator of sympathetic activity, the arterial baroreflex and baroreflex activation is accompanied by favorable therapeutic impact on cardiac function and clinical profile, as shown in the improved quality of life, increased exercise tolerance and improved NYHA functional status.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other clinical trials</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">BATwire implant toolkit</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the second half of 2020, the FDA approved a two-stage pivotal trial design to assess the safety and effectiveness of the BATwire implant toolkit. This trial is expected to enroll up to 400 subjects and follow up to 100 implanted subjects for one year. If the trial data meets the safety and effectiveness endpoints, we will submit an application for a PMA-supplement approval by FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Hypertension</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have completed two clinical trials in Europe and North America for the treatment of drug-resistant hypertension using our first-generation Barostim Therapy device called Rheos, and determined this study was successful in achieving three of the required five safety and effectiveness endpoints (&#8220;<i style="font-style:italic;">Baroreflex Activation Therapy Lowers Blood Pressure in Patients with Resistant Hypertension: Results from the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial</i>,&#8221; by John D. Bisognano, M.D. et al that was published in 2011 in the Journal of the American College of Cardiology, volume 58, No. 7, 2011). In 2014 we submitted a request for a Humanitarian Device Exemption (&#8220;HDE&#8221;) to commercialize Barostim Legacy, our second generation IPG for the subjects that were enrolled in the Rheos Pivotal trial, who are benefitting clinically from Rheos (estimated at the time to be 70&#8211;80% of the subjects enrolled) and whose IPG battery had become depleted. In December&#160;2014, after a favorable review of the long-term clinical data from the Rheos pivotal hypertension trial, the FDA granted the HDE to Barostim Legacy.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since 2011, we have completed one clinical trial in Europe and North America for the treatment of drug-resistant hypertension using Barostim (&#8220;<i style="font-style:italic;">Minimally Invasive System for Baroreflex Activation Therapy Chronically Lowers Blood Pressure with Pacemaker-like Safety Profile: Results from the Barostim Neo Trial</i>,&#8221; by Uta C. Hoppe, M.D. et al, in the Journal of the American Society of Hypertension, volume 5, no.&#160;4, 2012).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In August&#160;2011, we received CE Mark approval for Barostim for the treatment of resistant hypertension. In October&#160;2012, we received FDA approval to conduct a pivotal trial for the treatment of resistant hypertension entitled &#8220;<i style="font-style:italic;">Barostim Hypertension Pivotal Study</i>.&#8221; On April&#160;12, 2013, the study had its first enrollment. However, a redirection of our limited available financial and personnel resources to develop Barostim Therapy in HFrEF led to putting the trial on hold. In December&#160;2019, after review of the clinical data and the competitive landscape, FDA granted a Breakthrough Device designation for Barostim for the treatment of resistant hypertension.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">HFpEF</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In March&#160;2020, after review of early clinical data and the competitive landscape, the FDA granted a Breakthrough Device designation for Barostim for the treatment of HFpEF. In 2023, the FDA admitted us into the Total Life Cycle Advisory Program (&#8220;TAP&#8221;) for Barostim&#8217;s treatment of HFpEF. TAP is an initial pilot program limited only to Breakthrough Device designated indications for new products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Sales and marketing</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have established a systematic approach to market development which centers on active engagement across three key stakeholders in the HFrEF treatment paradigm&#8212;patients, physicians and hospitals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Barostim has FDA approval to improve symptoms of HFrEF in the U.S. and an Active Implantable Medical Device Directive (&#8220;AIMDD&#8221;) CE Mark for the treatment of HFrEF and resistant hypertension in Europe. Additionally, the EU approved an amendment to the MDR (as defined below) which allows qualifying AIMDD CE certificates to be accepted through December of 2027. We have already met the qualifications identified within this amendment to allow continued distribution of Barostim through this time. We market our therapy in the U.S. to hospitals and clinics where EPs, HF specialists, interventional and general cardiologists and vascular surgeons treat patients with HFrEF.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We primarily sell Barostim to hospitals through a direct sales organization in the U.S. and Germany, and through distributors in Austria, Spain, Italy, the Nordic region and other European countries. Our global sales and marketing team engages in sales efforts and promotional activities focused on EPs, HF specialists, interventional and general cardiologists and vascular surgeons. We are continuing to actively expand our direct sales force and commercial organization in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our direct sales representatives, which we refer to as Account Managers, generally have substantial and applicable medical device experience, specifically in the cardiovascular space, and market our products directly to the approximately 2,500 EPs, 800 HF specialists and 20,000 general cardiologists in the U.S. We support all aspects of the patient journey, which includes initial diagnosis, surgical support and patient follow-up. Our Account Managers are focused on prioritizing high volume cardiology centers that are strategically located and on educating and training physicians who have strong connectivity to the HFrEF patient population that may be eligible for our therapy. We also employ Field Clinical Specialists who generally have experience in medical device clinical support. Our Field Clinical Specialists work to ensure that every procedure is done correctly by educating the implanting physicians, including vascular surgeons and EPs, about the technical aspects of Barostim and the implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Similar to our direct sales team, our marketing team has a significant amount of relevant expertise and a strong track record of success in the medical device industry. Our marketing organization is focused on building physician awareness through targeted KOL development, referral network education and direct-to-consumer marketing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In terms of patient education, we utilize direct communication channels to inform patients about Barostim Therapy and to enable them to connect with sites that offer Barostim. Our primary method of patient outreach is through digital social networks. We use a qualification process to aid in the identification of the appropriate patients for our therapy. The objective of this outreach is to inform potential patients about our education webinars and website, where they can find a wealth of information on HFrEF and the purpose and benefits of Barostim Therapy, based on our approved labeling.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to driving broad awareness and increasing physician and patient education, our marketing team has developed the in-house resources necessary to obtain prior authorization approval for Barostim procedures and expand reimbursement coverage.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Third-party coverage and reimbursement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Coding and payment in the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the U.S., we sell Barostim primarily to hospitals, where the device is implanted in outpatient and inpatient settings. Our customers bill various third-party payors, such as government agencies, administrative contractors, commercial payors and integrated managed care organizations, for the cost required to treat each patient.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Third-party payors generally require physicians and hospitals to identify the service for which they are seeking reimbursement for by using CPT codes, which are created and maintained by the American Medical Association. Implantation of Barostim is described by CPT code 0266T, a Category III code approved in July&#160;2011 and effective as of January&#160;2012. Hospitals are able to use this code to submit for a system implant payment. CPT code 0268T is used to submit for an IPG replacement procedure payment, and CPT codes 0272T and 0273T are used for interrogation and programming of the IPG, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physician reimbursement under Medicare is generally based on a defined fee schedule, the Physician Fee Schedule, through which payment amounts are determined by the relative values of the professional services rendered. Medicare provides reimbursement to hospitals using Barostim under the hospital outpatient prospective system (&#8220;OPPS&#8221;), which provides bundled amounts generally intended to reimburse a hospital for all facility costs related to procedures performed in its outpatient setting. Under the OPPS in 2023, the national Medicare payment to a hospital for a new patient implant or an IPG replacement is paid using the Level&#160;5 Neurostimulator payment code APC 5465, which has a national average of $29,358. Under the 2024 OPPS final rule, Barostim was reassigned to New Technology APC 1580, which carries an average payment amount of $45,000, and took effect January 1, 2024. Payment codes such as APC 1580 are indexed to adjust for cost of living and thus vary by location. These payments generally cover the hospital&#8217;s costs for the device and the implantation procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CMS had also granted a TPT payment for the implantation of Barostim in an outpatient setting, which took effect in January&#160;2021 and expired at the end of 2023. The TPT payment was an incremental payment for new and innovative technologies that meet certain qualifications. It allowed hospitals to bill for a pass-through of the device cost, which included up to $35,000, and could be added to the procedure costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We anticipate inpatient procedures to continue to represent a small&#160;percentage of our sales. For these inpatient procedures, ICD-10-PCS codes 0JH60MZ + 03HL3M are commonly mapped into Diagnosis Related Group (&#8220;DRG&#8221;) 252, which has an established national average Medicare payment of $23,482 in 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The surgeon implanting Barostim is paid an additional physician payment under the Medicare Physician Fee Schedule, and the physician that manages the device performs multiple device interrogations and is paid using the payment code APC 5721, which has a national average of $149 per visit in 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement rates from commercial payors vary depending on a variety of factors, including the commercial payor and contract terms.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Government program and commercial payor coverage in the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Since approximately 67% of our target treatment population includes Medicare-eligible patients, we have prioritized CMS coverage while simultaneously developing processes to engage commercial payors. As of July 2020, all Medicare Administrative Contractors (&#8220;MACs&#8221;) have retired automatic coverage denial policies, thereby allowing hospitals to be paid for our procedure. CMS has committed to considering additional process improvements to increase access to innovative devices. We will continue to monitor developments in this space, including decisions made by private payors, if any.       </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We will continue to leverage our in-house market access team to obtain appropriate prior authorization approvals in advance of treatment on a case-by-case basis where positive coverage policies currently do not exist. We believe our market access team is highly effective in obtaining prior authorizations, including navigating the appeals process. We believe that we will continue to benefit from this efficient prior authorization process in the near-and-long-term by expanding on our positive coverage policies with commercial payors. In our discussions with commercial payors, we highlight our compelling and robust clinical data, including the long-term post-market BeAT-HF data, the potential economic cost-savings associated with our highly compliant treatment, increased patient demand and support from leading medical societies and KOLs. As our operations continue to grow, we intend to continue to further expand our market access team accordingly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement outside of the United States</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outside the U.S., reimbursement levels vary by country and within some countries, by region. We are currently selling Barostim in Germany, where the German Institute of Medical Documentation and Information supports various codes for reimbursement coverage. OPS code 5-059.c6 covers the implantation or replacement of a device stimulating the peripheral nervous system by activating the baroreceptors. This OPS code is combined with G-DRG ICD I50.13 to cover reimbursement of Barostim for the treatment of HFrEF. It can also be combined with G-DRG ICD I10.10 to cover reimbursement of Barostim for the treatment of hypertension. These DRG codes for both indications are combined with ZE code ZE2021-86 to cover the cost of the device. Barostim also is eligible for reimbursement in certain other European countries, where annual healthcare budgets for the hospital generally determine the number of patients to be treated and the prices to be paid for the related devices that may be purchased.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and development</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our research and development team has significant experience bringing innovative medical devices to market, including minimally invasive neuromodulation systems.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are committed to ongoing research and development efforts of Barostim with an emphasis on improving clinical outcomes, optimizing patient adoption and comfort, increasing access for a greater number of patients and enabling more physicians to perform the procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The primary focus of our research and development efforts in the near-term will be the continued technological advancement of Barostim, including tools to simplify the implant procedure for physicians. In 2022, we launched an enhanced IPG that is approximately 10% smaller in size and improves the battery life by approximately 20% to an average of six&#160;years. We are also enrolling a clinical trial for a new implant toolkit called BATwire, which enables an ultrasound-guided procedure to implant Barostim and the use of local anesthetics. This simplified procedure would also allow EPs to complete the procedure in an outpatient catheter lab center.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While we are currently focused on the treatment of patients with HFrEF, we believe our platform technology can provide meaningful benefits to a broader set of patients suffering from cardiovascular diseases with significant unmet needs. Our longer-term goal is to explore Barostim&#8217;s potential to expand the indications for use to other cardiovascular diseases, including different forms of HF, hypertension and arrhythmias. Expansions into these or other new indications would require additional FDA approvals and may involve additional clinical trials or modifications to Barostim to treat such indications. If clinical studies for additional indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For the&#160;years ended December 31, 2023 and 2022, we incurred research and development expenses of $11.6&#160;million and $10.0&#160;million, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our industry is subject to rapid change from the introduction of new products and technologies and other activities of industry participants. We consider our primary competition to be other device-based therapies designed to treat patients with HFrEF and a narrow QRS complex.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There is only one other commercially available device-based option, CCM, that targets a limited subset of the same HFrEF patient population indicated for Barostim. CCM is offered by a privately-held medical technology company and has the potential to improve a patient&#8217;s quality of life and reduce symptoms of HFrEF. However, CCM is associated with a number of drawbacks, including not being designed to address the imbalance of the ANS; less favorable clinical effectiveness results in patients with LVEF 25&#8211;35% as compared to patients with LVEF 35&#8211;45% related to exercise capacity, quality of life and NYHA functional status; implantation through an invasive procedure that includes running electrical leads through the veins and attaching them to the heart&#8217;s ventricle, which may lead to increased risks to the patient; and the requirement that patients regularly charge the battery in their implanted device.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We believe that the primary competitive factors in the HFrEF treatment market are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety, reliability and durability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality and volume of clinical data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adoption by patients, physicians and hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate reimbursement for our device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product ease of use and patient comfort;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales force expansion, experience and access;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product availability, support and service;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing and supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">technological innovation and product enhancements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">intellectual property portfolio.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Aside from device-based treatments, pharmaceutical therapies are widely used to treat HFrEF and have been in use longer and are better known to physicians and patients than Barostim. However, because Barostim is designed to be used in conjunction with pharmaceutical therapies to alleviate the symptoms of HFrEF, we do not consider existing pharmaceutical therapies to be direct competition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also compete with other medical technology companies to recruit and retain qualified sales, training and other personnel.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We rely on a combination of patent, copyright, trademark and trade secret laws and confidentiality and invention assignment agreements to protect our intellectual property rights. As of December 31, 2023, we owned 48 issued U.S. patents and had 12 pending U.S. patent applications.&#160;Outside of the U.S., we owned seven patents in multiple countries and had 14 pending applications.&#160;Our trademark portfolio focuses on nine trademarks in the U.S. and multiple other countries. Our patents cover aspects of our integrated platform technology, Barostim, including baroreflex methods, stimulus regimes, mapping methods, electrode designs, disease treatments, closed loop control, burst intervals, connection structures and baroreceptor locations, as well as future product concepts. The term of individual patents depends on the law of the countries in which they are granted. In most countries, including the U.S., the patent term is generally 20 years from the earliest claimed filing date of a nonprovisional patent application in the applicable country. There is no active patent litigation involving any of our patents, and we have not received any notices of patent infringement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#8203;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We also rely, in part, upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We protect our proprietary rights through a variety of methods, including confidentiality and assignment agreements with suppliers, employees, consultants and others who may have access to our proprietary information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pending patent applications may not result in issued patents, and we cannot guarantee that any current or subsequently issued patents will protect our intellectual property rights or provide us with any competitive advantage. While there is no active litigation involving any of our patents or other intellectual property rights and we have not received any notices of patent infringement, we may be required to enforce or defend our intellectual property rights against third parties in the future. See &#8220;Risk Factors&#8212;Risks Related to Intellectual Property&#8221; for additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing and supply</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We manage all aspects of manufacturing operations and product supply of Barostim, which include final assembly, testing and packaging of our IPG and stimulation lead, at our 31,505 square foot headquarters in Minneapolis, Minnesota. With minimal capital investment, our existing operations are capable of producing 5,000 IPGs and 5,000 stimulation leads per shift per year, and our manufacturing line was designed to be expandable and scalable in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently source certain components for Barostim from a limited number of suppliers, including the module, module board, radio-frequency module, magnet switch, battery and application-specific integrated circuits for the IPG and the electrode for the stimulation lead. Our suppliers manufacture and test the components they produce for us to meet our specifications. We maintain sufficient levels of inventory to mitigate potential supply disruption and to achieve more favorable volume-based pricing. We continue to seek to broaden and strengthen our supply chain through additional sourcing channels.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We select our suppliers to ensure that Barostim and its components are safe and effective, adhere to all applicable standards and regulations, are high quality and meet our supply needs. We employ a rigorous supplier assessment, qualification and selection process targeted to suppliers that meet the requirements of the FDA and relevant Canadian, European Economic Area (&#8220;EEA&#8221;) and Australian regulatory authorities and quality standards supported by internal policies and procedures. Our quality assurance process monitors and maintains supplier performance through qualification and periodic supplier reviews and audits. We received ISO certification for our quality management system and our most recent audits have not identified any major nonconformities. We are registered with the FDA as a medical device manufacturer and licensed by the State of Minnesota to manufacture our device.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><b style="font-weight:bold;">Seasonality</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that revenue could fluctuate from quarter to quarter as a result of timing and seasonality. We anticipate mild seasonality based on national holiday patterns specific to certain nations. These seasonal variations are difficult to predict accurately and may vary among different markets. In addition to the above factors, in the U.S. it is possible that we may experience seasonality based on patients&#8217; annual deductibility limits under their health insurance coverage. In Europe, we may be required to engage in a contract bidding process in order to sell Barostim, which processes are only open at certain periods of time, and we may not be successful in such bidding processes. In addition, it is possible that we may experience variations in demand for our product in the first fiscal quarter of each year in Europe, following publication of new coverage status and changes in hospital budgets pertaining to allocation of funds to purchase products such as Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government regulation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products and operations are subject to extensive regulation by the FDA and other federal and state authorities in the U.S., as well as comparable authorities in the EEA. Our products are subject to regulation as medical devices under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, effectiveness, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, device tracking, adverse event reporting, recalls, safety alerts, injunctions, seizures, bans, advertising, promotion, marketing and distribution and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to U.S. regulations, we are subject to a variety of regulations in the EEA governing clinical trials and the commercial sales and distribution of our products. Whether we have or are required to obtain FDA clearance or approval for a product, we will be required to obtain authorization from the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials or commercialize our products in those countries. The approval process varies from country to country and the time may be longer or shorter than that required for FDA clearance or approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">FDA pre-market clearance and approval requirements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unless an exemption applies, each medical device commercially distributed in the U.S. requires either FDA clearance of a 510(k) premarket notification, HDE, or PMA approval. Under the FDCA, medical devices are classified as Class&#160;I, Class&#160;II, Class&#160;III, or De Novo, depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation (&#8220;QSR&#8221;), facility registration and product listing, reporting of adverse medical events and truthful and non-misleading labeling, advertising and promotional materials. Class&#160;II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class&#160;I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class&#160;II devices must submit to the FDA a premarket notification under Section&#160;510(k) of the FDCA requesting permission to commercially distribute the device. De Novo is a medical device with no predicate or premarket device for comparing substantial equivalence which is subject to the 510(k) premarket notification. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221; to either a device that was legally marketed prior to May&#160;28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted, or another commercially available device that was cleared through the 510(k) process.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Devices deemed by the FDA to pose the greatest risks are placed in Class&#160;III, requiring approval of an HDE or PMA. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our currently U.S.-marketed Barostim devices are Class&#160;III devices which have received both a PMA and an HDE approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">PMA &amp; HDE approval pathway</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Class&#160;III devices require PMA or HDE approval before they can be marketed, although some pre-amendment Class&#160;III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of the device and its components, and the methods, facilities and controls used for manufacturing and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficient to permit a substantive review. If the FDA accepts the application for review, it has 180&#160;days under the FDCA to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer, and at times can take up to several&#160;years. An Advisory Committee or panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will generally conduct a preapproval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217; manufacturing facilities to ensure compliance with the QSR.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s) according to the instructions for use or labeling. The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance or study when deemed necessary to protect the public health or to provide additional safety and effectiveness data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups and make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which can affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and typically does not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA will approve the new device for commercial distribution if it determines that the data and information in the HDE constitute valid scientific evidence and that there is reasonable assurance that the device is safe and has probable benefit for its intended use(s) according to the instructions for use or labeling. The HDE approved devices are subject to the same requirement elements and changes as the above PMA devices. An additional limitation for HDE devices is they must be prescribed for a patient population that has a medical condition or disease that afflicts less than 8,000 people per year in the United States and have been designated as a Humanitarian Use Device by FDA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trials are usually required to support a PMA and are sometimes required to support an HDE, 510(k) or De Novo submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;), regulations which govern investigational device labeling, prohibit promotion of the investigational device and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must be approved prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a subject and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&#160;days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the study must be approved by, and conducted under the oversight of, an institutional review board (&#8220;IRB&#8221;), for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of subjects, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan, or the rights, safety or welfare of human subjects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During a study, the sponsor and clinical investigators are required to comply with the applicable FDA requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Post-market regulation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After a device is cleared or approved for marketing, numerous regulatory requirements continue to apply. These include:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment registration and device listing with the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and provide adequate directions for use and that all claims are substantiated and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling; FDA guidance on off-label dissemination of information and responding to unsolicited requests for information; and Federal Trade Commission guidance on endorsements and testimonials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payments Sunshine Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal False Claims Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing, an obligation to pay or transmit money to the federal government. The government may assert that a claim includes items or services resulting from a violation of the federal Anti-Kickback Statute and thus constitutes a false or fraudulent claim for purposes of the false claims statute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of a supplement for certain modifications to PMA and HDE devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal law and regulations requiring Unique Device Identifiers (UDI) on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database (GUDID);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may be subject to similar foreign laws that include post-marketing requirements such as safety surveillance. Our manufacturing processes must comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file and complaint files. As a manufacturer, our facilities, records and manufacturing processes are subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR or other applicable regulatory requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls, withdrawals, injunctions, or administrative detention or seizure of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions or partial suspension or total shutdown of production;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawing 510(k) clearances or PMA approvals that have already been granted; refusal to grant export or import approvals for our products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecution.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of medical devices in the EEA</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To be placed on the market in the EEA, medical devices require a CE Mark and a corresponding declaration of conformity. For our medical devices, the CE Mark must be issued by an organization accredited by a Member State of the EEA to conduct conformity assessments, a so-called Notified Body. Conformity assessments are conducted to demonstrate that the medical device meets the legal requirements set forth in the regulations and standards to ensure that it meets general safety and performance criteria. Clinical investigations or evidence of the safety and clinical outcomes, among other things, may be required for issuance of a CE Mark. With a CE Mark, the medical devices are generally marketable in the entire EEA. A CE Mark was first issued for Barostim for the treatment of resistant hypertension in 2011 and for the treatment of HFrEF in 2014.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">European Union (&#8220;EU&#8221;) Legislation: medical devices regulation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The regulatory framework governing medical devices in the EEA underwent a major change on April 5, 2017, when the European Parliament passed the Medical Devices Regulation (Regulation (EU) 2017/745&#8201;&#8212;&#8201;&#8220;MDR&#8221;). The MDR repealed and replaced the EU Medical Devices Directive (Council Directive 93/42/EEC&#8201;&#8212;&#8201;&#8220;MDD&#8221; or Council Directive 90/385/EEC). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Previously, medical devices regulated under the MDD and AIMDD were classified into one of four classes&#8201;&#8212; Class&#160;I, Class&#160;IIa, Class&#160;IIb or Class&#160;III&#8201;&#8212;&#8201;based on the extent of the regulatory controls necessary and sufficient to provide reasonable assurance of safety and effectiveness of the device. The AIMDD applied to implantable electrical active medical devices that were typically considered to be Class&#160;III under MDD and similar controls for the highest risk devices. The classification corresponded to the level of potential hazard inherent in the type of device concerned. Class&#160;I included devices with the lowest risk to the patient. Class&#160;IIa and Class&#160;IIb devices were higher risk devices and Class&#160;III devices were devices with a significant risk, which were subject to more regulatory oversight to ensure the safety and effectiveness of the device, such as performance standards and post-market surveillance. Barostim has been classified and regulated under the AIMDD.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MDR entered into force on May&#160;25, 2017 and is progressively replacing the MDD/AIMDD during a transition period, which was originally intended to become fully effective on May&#160;26, 2021. The MDR, among other things, is designed to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and to ensure a high level of safety and health while supporting innovation. The regulations impose strict demands on medical device manufacturers and the Notified Bodies whom they must involve in the conformity assessment procedure. Unlike directives, which must be implemented into the national laws of the EEA, the regulations are directly applicable in all EEA member states and are intended to eliminate differences in the regulation of medical devices among EEA member states.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The new regulations:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require demonstration of clinically meaningful outcomes for the performance of the medical device;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require stricter control of Class&#160;IIb and Class&#160;III medical devices during the clinical investigational phase;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Require rigorous post-market oversight by the manufacturer and increased post-market surveillance authority by the Notified Body, including unannounced audits and product sample checks and testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Provide greater transparency by establishing a central database (EUDAMED) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Strengthen rules for the assessment of certain high-risk devices, which may have to undergo an additional check by an independent expert panel before they are placed on the market.</span></td></tr></table><div style="margin-top:12pt;"><a id="_Hlk124451045"></a><a id="_Hlk124451075"></a></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To avoid market disruption and allow a smooth transition from the MDD/AIMDD to the MDR, several transitional provisions are in place, which include allowing devices lawfully placed on the market prior to expiration of their MDD/AIMDD CE Marks to remain available on the market and be put into service, both under certain prerequisites and until a certain time. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In 2022, we successfully completed the Stage 1 and 2 MDR Quality Management System (&#8220;QMS&#8221;) audits, and our Notified Body officially issued an approval document stating that the QMS has been assessed to the MDR and approved. We also received and responded to queries from all MDR sections, with the exception of Clinical Research, in 2022. We have since received confirmation that all sections of the submission have been reviewed and all queries have been responded to. The file remains under review. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Notably, the European Commission extended qualifying AIMDD CE certificates, including ours, through December 31, 2027.  This extension was driven by delays in notified body reviews and approvals across the medical device industry as well as the fact that a substantial number of CE </span>Mark certificates were continuing to expire during this unpredictable and extended transition period to MDR. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation of medical devices under MDR</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE Marking</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Manufacturers of medical devices must comply with the general safety and performance requirements of the MDR in order to obtain a CE Mark for the product and market the product in the EEA. To demonstrate compliance with the general safety and performance requirements, the manufacturer must undergo a conformity assessment procedure which requires the involvement of a Notified Body except for low-risk, self-certified medical devices of Class&#160;I. The Notified Body typically audits the quality management system of the manufacturer, which must comply with the current version of ISO 13485 requiring that manufacturers follow defined and approved design and development procedures, testing, control, documentation and other quality assurance procedures throughout the entire design and manufacturing process. The Notified Body also reviews the Technical File that includes the Biological Evaluation, Clinical Evaluation and Risk Management reports and Post Market Clinical Follow-Up (PMCF), among other items, submitted for approval of the CE Mark. If the quality management system audit and the technical file review are successful, the Notified Body issues certificates of conformity. These certificates entitle the manufacturer to draw up the EU declaration of conformity and affix the CE Mark to the labeling of its medical devices and place the medical device on the EEA market.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE marking in UK and UK Conformity Assessed marking</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Since January&#160;1, 2021, the UK (excluding Northern Ireland) has recognized medical devices with an EEA-issued CE Mark, and has since indicated it will continue to do so until December 31, 2027. Additionally, certificates issued by EU-recognized Notified Bodies will continue to be valid for the UK market until December 31, 2027. Since January&#160;1, 2021, all medical devices placed on the UK market must be registered with the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;). There are different grace periods depending on the type of medical device to allow time for compliance with the new registration process. Where a medical device is not already registered with the MHRA, a conformity assessment must be conducted by an &#8220;authorised&#8221; body (a so-called UK Approved Body, approved by the MHRA) and a separate dossier application for the UKCA marking must be submitted. However, the data to support an EEA-issued CE Mark is expected to be sufficient for a UKCA mark. Manufacturers based outside the UK who wish to place a device on the UK market need to appoint a single UK Responsible Person who will take responsibility for the product in the UK. We have registered with MHRA, have a UK Responsible Person, and are prepared to conduct a conformity assessment when necessary.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CE Marking in Switzerland</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Switzerland and the EU had a bilateral mutual recognition agreement (MRA) on conformity assessment, which entered into force in 2002, but ceased to be enforced on May 26, 2021. Currently, Switzerland unilaterally recognizes EU certificates of conformity for medical devices. Labeling and CE marking requirements for medical devices placed on the Swiss market must follow EU CE labeling requirements. To place a product on the Swiss market as an economic operator located outside of Switzerland, manufacturers, distributors, and importers must have a Swiss authorized representative (&#8220;CH-REP&#8221;). Product labeling should include the CH-REP name and address to show compliance. MDD/AIMDD devices with certificates issued by EU-recognized Notified Bodies will continue to be valid until December 31, 2027. We have engaged a CH-REP and the devices may continue to be sold in Switzerland through 2027.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical investigation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">For our medical devices, clinical investigations or evidence will be required to demonstrate safety, performance and the expected clinical outcomes. The term &#8220;performance&#8221; describes how the medical device functions. Under the MDR, performance must be linked to expected clinical metrics and outcomes. From a practical standpoint, &#8220;performance&#8221; is analogous to the term &#8220;effectiveness&#8221; when applied to our medical devices. Clinical investigations must be conducted in accord with Good Clinical Practices (ISO 14155) and are subject to audits by the Notified Bodies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Post-market surveillance</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">After a medical device is placed on the market, numerous regulatory requirements apply, which link to the manufacturer&#8217;s continuous review of risk management information. The manufacturer must establish and maintain a systematic procedure to proactively collect and review real-life experience and data gained from their devices placed on the market. Post-market surveillance is comprised of, but not limited to, reports of serious adverse events, device deficiency reports, product complaints from consumers and health care professionals, field safety corrective actions and post-marketing clinical studies/updated clinical evaluation reports. Manufacturers must guarantee that their medical device continues to provide the promised benefit to patients as well as the lack of any unacceptable risks, through a constant and systematic approach to post-market surveillance. Further, manufacturers, medical practitioners and medical institutions are obliged to report any incident involving a medical device, including any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labelling or the instructions for use which might lead to or might have led to the death of a patient or to a serious deterioration in his or her state of health. The reporting also includes any device recalls. Manufacturers must prepare a periodic safety update report for each device summarizing the results and conclusions of the analyses of the post-market surveillance data gathered.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Non-compliance</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If we fail to comply with applicable EU, UK and Swiss regulatory requirements, we may be subject to, among other things, fines, product recalls, seizure of products, operating restrictions and criminal prosecution. Failure to comply with EU, UK or Swiss regulatory requirements could prevent us from developing, manufacturing and later selling the products in the respective region.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal, state and foreign fraud and abuse and physician payment transparency laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws restrict our business practices. These laws include, without limitation, foreign, federal and state anti-kickback and false claims laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including stock, stock options and the compensation derived through ownership interests.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Recognizing that the federal Anti-Kickback Statute is broad and may prohibit many innocuous or beneficial arrangements within the healthcare industry, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) issued regulations in July&#160;1991, which HHS has referred to as &#8220;safe harbors.&#8221; These safe harbor regulations set forth certain provisions which, if met in form and substance, will assure medical device manufacturers, healthcare providers and other parties that they will not be prosecuted under the federal Anti-Kickback Statute. Additional safe harbor provisions providing similar protections have been published intermittently </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">since 1991. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Our arrangements with physicians, hospitals and other persons or entities who are in a position to refer may not fully meet the stringent criteria specified in the various safe harbors. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (described below).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $100,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines of up to $100,000 and imprisonment of up to 10&#160;years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid. Liability under the federal Anti-Kickback Statute may also arise because of the intentions or actions of the parties with whom we do business. While we are not aware of any such intentions or actions, we have only limited knowledge regarding the intentions or actions underlying those arrangements. Conduct and business arrangements that do not fully satisfy one of these safe harbor provisions may result in increased scrutiny by government enforcement authorities. The majority of states also have anti-kickback laws that establish similar prohibitions and, in some cases, may apply more broadly to items or services covered by any third-party payor, including commercial insurers and self-pay patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The federal civil False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil federal civil False Claims Act.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, private parties may initiate &#8220;qui tam&#8221; whistleblower lawsuits against any person or entity under the federal civil False Claims Act in the name of the government and share in the proceeds of the lawsuit. Penalties for federal civil False Claim Act violations include fines for each false claim, plus up to three times the amount of damages sustained by the federal government and, most critically, may provide the basis for exclusion from the federally funded healthcare program. On May&#160;20, 2009, the Fraud Enforcement Recovery Act of 2009 (&#8220;FERA&#8221;), was enacted, which modifies and clarifies certain provisions of the federal civil False Claims Act. In part, FERA amends the federal civil False Claims Act such that penalties may now apply to any person, including an organization that does not contract directly with the government, who knowingly makes, uses or causes to be made or used, a false record or statement material to a false or fraudulent claim paid in part by the federal government. The government may further prosecute conduct constituting a false claim under the federal criminal False Claims Act. The criminal False Claims Act prohibits the making or presenting of a claim to the government knowing such claim to be false, fictitious or fraudulent and, unlike the federal civil False Claims Act, requires proof of intent to submit a false claim. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties ranging from $12,537 to $25,076 for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Civil Monetary Penalty Act of 1981 imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) also created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Many foreign countries have similar laws relating to healthcare fraud and abuse. Foreign laws and regulations may vary greatly from country to country. For example, the advertising and promotion of our products is subject to EU Directives concerning misleading and comparative advertising and unfair commercial practices, as well as other EEA member state legislation governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals. Also, many U.S. states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, there has been a recent trend of increased foreign, federal and state regulation of payments and transfers of value provided to healthcare professionals or entities. The federal Physician Payments Sunshine Act imposes annual reporting requirements on certain drug, biologics, medical supplies and device manufacturers for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program for payments and other transfers of value provided by them, directly or indirectly, to physicians (including physician family members), certain other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. A manufacturer&#8217;s failure to submit timely, accurately and completely the required information for all payments, transfers of value or ownership or investment interests may result in civil monetary penalties of up to $12,646 per failure up to an aggregate of $189,692 per year (or up to an aggregate of $1.265&#160;million per year for &#8220;knowing failures&#8221;). Manufacturers must submit reports by the 90th day of each calendar year. Certain foreign countries and U.S. states also mandate implementation of commercial compliance programs, impose restrictions on device manufacturer marketing practices and require tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data privacy and security laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are also subject to various federal, state and foreign laws that protect the confidentiality of certain patient health information, including patient medical records, and restrict the use and disclosure of patient health information by healthcare providers, such as HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), in the U.S.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA established uniform standards governing the conduct of certain electronic healthcare transactions and requires certain entities, called covered entities, to comply with standards that include the privacy and security of protected health information (&#8220;PHI&#8221;). HIPAA also requires business associates, such as independent contractors or agents of covered entities that have access to PHI in connection with providing a service to or on behalf of a covered entity, of covered entities to enter into business associate agreements with the covered entity and to safeguard the covered entity&#8217;s PHI against improper use and disclosure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The HIPAA privacy regulations cover the use and disclosure of PHI by covered entities as well as business associates, which are defined to include subcontractors that create, receive, maintain, or transmit PHI on behalf of a business associate. They also set forth certain rights that an individual has with respect to his or her PHI maintained by a covered entity, including the right to access or amend certain records containing PHI, or to request restrictions on the use or disclosure of PHI. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of PHI that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify any individual whose PHI is breached according to the specifications set forth in the breach notification rule. The HIPAA privacy and security regulations establish a uniform federal &#8220;floor&#8221; and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing PHI or insofar as such state laws apply to personal information that is broader in scope than PHI as defined under HIPAA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA requires the notification of patients, and other compliance actions, in the event of a breach of unsecured PHI. If notification to patients of a breach is required, such notification must be provided without unreasonable delay and in no event later than 60 calendar days after discovery of the breach. In addition, if the PHI of 500 or more individuals is improperly used or disclosed, we would be required to report the improper use or disclosure to HHS, which would post the violation on its website, and to the media. Failure to comply with the HIPAA privacy and security standards can result in civil monetary penalties up to $63,973 per violation, not to exceed $1.92&#160;million per calendar year for non-compliance of an identical provision and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HIPAA authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit against us in civil court, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities, such as us, and their business associates for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a&#160;percentage of the civil monetary penalty paid by the violator.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, we may be subject to laws relating to our collection, control, processing and other use of personal data (i.e., data relating to an identifiable living individual). We process personal data in relation to our operations. We process data of both our employees and our customers, including health and medical information. The data privacy regime in the EU includes the EU Data Protection Directive (95/46/EC) regarding the processing of personal data and the free movement of such data, the E-Privacy Directive 2002/58/EC and national laws implementing each of them. Each EU Member State has transposed the requirements laid down by the Data Protection Directive and E-Privacy Directive into its own national data privacy regime and therefore the laws may differ by jurisdiction, sometimes significantly. We must ensure compliance with the rules in each jurisdiction where we are established or are otherwise subject to local privacy laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The requirements include that personal data may only be collected for specified, explicit and legitimate purposes based on legal grounds set out in the local laws and may only be processed in a manner consistent with those purposes. Personal data must also be adequate, relevant, not excessive in relation to the purposes for which it is collected, be secure, not be transferred outside of the EEA unless certain steps are taken to ensure an adequate level of protection and must not be kept for longer than necessary for the purposes of collection. To the extent that we process, control or otherwise use sensitive data relating to living individuals (for example, patients&#8217; health or medical information), more stringent rules apply, limiting the circumstances and the manner in which we are legally permitted to process that data and transfer that data outside of the EEA. In particular, in order to process such data, explicit consent to the processing (including any transfer) is usually required from the data subject (being the person to whom the personal data relates).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The EU-wide General Data Protection Regulation (&#8220;GDPR&#8221;) became applicable on May&#160;25, 2018, replacing the previous data protection laws issued by each EU Member State based on the Directive 95/46/EC. Unlike the Directive (which needed to be transposed at national level), the GDPR text is directly applicable in each EU member state, resulting in a more uniform application of data privacy laws across the EU. The GDPR imposes onerous accountability obligations, requiring data controllers and processors to maintain a record of their data processing and policies. It requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of information, increases requirements pertaining to pseudonymized (i.e., key-coded) data, introduces mandatory data breach notification requirements and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. Fines for non-compliance with the GDPR are significant&#8212;the greater of EUR 20&#160;million or 4% of global turnover. The GDPR provides that EU Member States may introduce further conditions, including limitations, to the processing of genetic, biometric or health data, which could limit our ability to collect, use and share personal data, or could cause our compliance costs to increase, ultimately having an adverse impact on our business. In the UK, the UK General Data Protection Regulation (the &#8220;UK GDPR&#8221;) came into effect on January 1, 2021. Similar to the GDPR, the UK GDPR sets out the key principles, rights, and obligations for most processing of personal data in the UK. The Data Protection Act of 2018, which came into effect on May 25, 2018 and was amended on January 1, 2021, works alongside and supplements the UK GDPR.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are subject to the supervision of local data protection authorities in those jurisdictions where we are established or otherwise subject to applicable law.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We depend on third parties in relation to our provision of our services, a number of which process personal data on our behalf. With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions, and that they have sufficient technical and organizational security measures in place. When we transfer personal data outside the EEA, we do so in compliance with the relevant data export requirements. We take our data protection obligations seriously, as any improper disclosure, particularly with regard to our customers&#8217; sensitive personal data, could negatively impact our business and/or our reputation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare reform</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The implementation of the Affordable Care Act in the U.S., for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The Affordable Care Act provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the Affordable Care Act has expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. There have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect additional challenges and amendments in the future. Moreover, the Biden Administration and the U.S. Congress may take further action regarding the Affordable Care Act. In 2017, the Tax Cuts and Jobs Acts was enacted, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance, effective in 2019.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, other legislative changes have been adopted since the Affordable Care Act. For example, the Budget Control Act of 2011, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and will remain in effect through 2027 unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-bribery and corruption laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our U.S. operations are subject to the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). We are required to comply with the FCPA, which generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials to obtain or retain business or other benefits. In addition, the FCPA imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of &#8220;off books&#8221; slush funds from which such improper payments can be made. We also are subject to similar anticorruption legislation implemented in Europe under the Organization for Economic Co-operation and Development&#8217;s Convention on Combating Bribery of Foreign Public Officials in International Business Transactions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">&#160;</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Environmental laws</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our facilities and operations are also subject to complex federal, state, local and foreign environmental and occupational safety laws and regulations, including those relating to discharges of substances in the air, water and land, the handling, storage and disposal of wastes and the clean-up of properties contaminated by pollutants. We do not expect that the ongoing costs of compliance with these environmental requirements will have a material impact on our consolidated earnings, capital expenditures or competitive position.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Human capital management</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023, we had approximately 200 employees worldwide, all of which were employed on a full-time basis. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our mission</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our mission is to advance health for people everywhere, giving each patient a fuller life. In seeking to accomplish our mission, we rely on our values, which are central to our human capital management policies and practices. These values are:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Commitments are Sacred&#8201;&#8212;&#8201;Honor relationships by doing what we say, when we say we&#8217;ll do it.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bold Mindset, Driven Spirit&#8201;&#8212;&#8201;Always push the boundaries, energetically seeking out impactful opportunities and inspiring others.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Pioneer with Purpose&#8230;and a Smile!&#8201;&#8212;&#8201;As individuals, team leaders and industry innovators, it&#8217;s how we pave the way forward that defines us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Collaborate with Enjoyment&#8201;&#8212;&#8201;Achieve goals and celebrate as a team.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Determination overcomes Targets&#8201;&#8212;&#8201;Determine the pathway, overcome obstacles, accelerate and successfully implement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Embrace the Challenge of Change&#8201;&#8212;&#8201;Have an eye for identifying when change is needed, and the flexibility to chart a new course.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Health and safety</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">We are acutely focused on the health and safety of our employees in the workplace. Our health and safety team monitors various metrics in an effort to ensure we are providing a safe environment to work. These results are shared with relevant regulatory agencies as required and presented to our management team.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Available&#160;Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, available free of charge at our website as soon as reasonably practicable after they have been filed with, or furnished to, the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Our website address is www.cvrx.com. Information on our website is not part of this Annual Report on Form 10-K. The SEC maintains a website that contains the materials we file with the SEC at www.sec.gov.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_16a809af_37e3_47f5_88f5_17d7dbf4af94"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors</b></p><a id="_Hlk78377047"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our reputation, business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations</i><i style="font-style:italic;">.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_Hlk78377086"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our business</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have a history of significant losses, which we expect to continue, and we may not be able to achieve or sustain profitability. If we do not achieve and sustain profitability, our financial condition could suffer.</span></p><a id="_Hlk78525051"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have experienced significant net losses since our inception and we expect to continue to incur losses for the foreseeable future. We incurred net losses of $41.2 million and $41.4 million for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, our accumulated deficit was $477.4 million and $436.2 million, respectively. We expect to continue to incur significant sales and marketing, research and development, regulatory and other expenses as we grow our U.S. commercial sales force and expand our marketing efforts to increase adoption of Barostim, add new features to Barostim, obtain regulatory clearances or approvals for our planned or future products and conduct clinical trials on our existing and planned or future products. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Until our IPO, we financed our operations primarily through convertible preferred stock financings and amounts borrowed under our previous loan and security agreement (&#8220;Horizon loan agreement&#8221;) with Horizon </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Technology Finance Corporation. We had devoted substantially all of our financial resources to research and development activities as well as general and administrative expenses associated with our operations, including clinical and regulatory initiatives to obtain marketing approval. Since our IPO, we have invested substantially in sales and marketing efforts to support commercialization of Barostim. We will need to continue to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our expected future operating losses, combined with our prior operating losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</p><a id="_Hlk78377182"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have a limited history operating as a commercial company and are highly dependent on a single product, Barostim. The failure to increase market acceptance in the U.S. for Barostim would negatively impact our business, liquidity and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We first commercialized Barostim in the EEA in 2012 and in the U.S. in 2020 and therefore do not have a long history operating as a commercial company. We expect substantially all of our revenue to continue to be derived from sales of Barostim for the foreseeable future, the majority of which will be generated in the U.S. Although increasing as our commercial sales grow, Barostim still has limited product and brand recognition. In addition, demand for Barostim may decline or may not continue to increase as quickly as we expect. If we are unable to achieve significant market acceptance in the U.S. for Barostim, our results of operations will be adversely affected. Because we do not yet have other products currently in development, if we are unsuccessful in commercializing Barostim or are unable to market Barostim as a result of a quality problem, failure to maintain regulatory approvals, unexpected or serious complications or other unforeseen negative effects related to Barostim or the other factors discussed in these risk factors, we would lose our main source of revenue, and our business, reputation, liquidity and results of operations will be materially and adversely affected.</p><a id="_Hlk78377405"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We have limited commercial sales experience marketing and selling Barostim, and if we are unable to continue to maintain and grow sales and marketing capabilities, we will be unable to generate sustained and increasing product revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to generate future revenue growth, we plan to continue to expand the size and geographic scope of our U.S. direct sales and marketing organization. In order to increase our sales and marketing efforts, we will need to continue to retain, grow and develop a substantial number of direct sales personnel, which is a significant investment. There is significant competition for sales personnel experienced in relevant medical device sales. Once hired, the training process is lengthy because it requires significant education for new sales representatives to achieve the level of clinical competency with our products expected by physicians. Upon completion of the training, our sales representatives typically require lead time in the field to grow their network of accounts and achieve the productivity levels we expect them to reach in any individual territory. Furthermore, the use of our product will often require or benefit from direct support from us. If we are unable to attract, motivate, develop and retain a sufficient number of qualified sales personnel, and if our sales representatives do not achieve the productivity levels we expect them to reach, our revenue will not grow at the rate we expect, and our financial performance will suffer. Because the competition for direct medical sales personnel is high, we cannot be certain we will be able to hire and retain additional sales personnel on favorable or commercially reasonable terms, if at all. Failure to hire or retain qualified sales representatives would prevent us from expanding our business and generating anticipated revenue. Any of these risks may adversely affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We must demonstrate to physicians and patients the merits of Barostim.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physicians play a significant role in determining the course of a patient&#8217;s treatment and, subsequently, the type of product that will be used to treat a patient. As a result, our success depends, in large part, on effectively marketing Barostim to physicians. In order for us to sell Barostim, we must successfully demonstrate to physicians and patients the merits of Barostim Therapy for use in treating patients with HFrEF. Specifically, Barostim is indicated for patients with NYHA Class III or II (with recent history of III) despite treatment with guideline-directed medical therapies (medications and devices), have a LVEF &#8804; 35% </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">and a NT-proBNP &lt; 1,600 pg/ml. Barostim delivers Baroreflex Activation Therapy to improve patients&#8217; NYHA functional status, 6MHW and quality of life. Acceptance of Barostim depends on educating physicians as to the distinctive characteristics, perceived benefits, safety, ease of use and cost-effectiveness of Barostim and communicating to physicians the proper application of Barostim Therapy for patients who meet Barostim&#8217;s eligibility criteria. If we are not successful in convincing physicians of the merits of Barostim Therapy, they may not use Barostim and we may be unable to increase our sales, sustain our growth or achieve profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, physicians typically need to perform several procedures to become comfortable using Barostim. If a physician experiences difficulties during an initial procedure or otherwise, that physician may be less likely to continue to use our product or to recommend it to other physicians. It is critical to the success of our commercialization efforts to educate physicians on the proper use of Barostim, and to provide them with adequate product support during clinical procedures. If we do not provide support to physicians or do not adequately educate physicians on the benefits and proper use of Barostim, physicians may not use or advocate for Barostim. In such circumstances, our results of operations would be materially adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patients may not choose or be able to receive Barostim if, among other potential reasons, they are reluctant to receive an implantable device as opposed to an alternative, non-implantable treatment, they are worried about potential adverse effects of Barostim, or they are unable to obtain adequate third-party coverage or reimbursement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our industry is highly competitive. If our competitors, many of which are large, well-established companies with substantially greater resources than us and have a long history of competing in the HF market, are better able to develop and market products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim, our business will be adversely impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The medical device industry is highly competitive and subject to technological change. Our success depends, in part, upon our ability to establish a competitive position in the market by securing broad market acceptance of Barostim Therapy and Barostim for the treatment of HFrEF. Any product we develop that achieves regulatory clearance or approval, including Barostim, will have to compete for market acceptance and market share. We believe that the primary competitive factors in the market are demonstrated clinical effectiveness, product safety, reliability and<span style="letter-spacing:-1.7pt;"> </span>durability, ease of use, product support and service, minimal side effects and salesforce experience. Many of our current and potential competitors that are addressing other HF indications are publicly traded, or are divisions of publicly-traded, established medical device companies that have substantially greater financial, technical, sales and marketing resources than we do, such as Medtronic plc, Boston Scientific Corporation, Abbott Laboratories and LivaNova PLC. We may also face competition from other competitors, such as Impulse Dynamics, which is a private company with a medical device indicated for a subset of our target patient population, or companies with active system development programs that may emerge in the future. Many of the companies developing or marketing competing products enjoy several advantages over us, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">more experienced sales forces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater name recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">more established sales and marketing programs and distribution networks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">earlier regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">long established relationships with physicians and hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">significant patent portfolios, including issued U.S. and foreign patents and pending patent applications, as well as the resources to enforce patents against us or any of our third-party suppliers and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to acquire and integrate our competitors and/or their technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrated ability to develop product enhancements and new product offerings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established history of product reliability, safety and durability;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer rebates or bundle multiple product offerings to offer greater discounts or incentives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater financial and human resources for product development, sales and marketing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">greater experience in and resources for conducting research and development, clinical studies, manufacturing, preparing regulatory submissions, obtaining regulatory clearance or approval for products and marketing approved products.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our competitors may develop and patent processes or products earlier than us, obtain patents that may apply to us at any time, obtain regulatory clearance or approvals for competing products more rapidly than us or develop more effective or less expensive products or technologies that render our technology or products obsolete or less competitive. We also face fierce competition, particularly in this tight labor market, in recruiting and retaining qualified sales, scientific and management personnel, establishing clinical trial sites and enrolling patients in clinical studies. If our competitors are more successful than us in these matters, our business may be harmed. In addition, we face a particular challenge overcoming the long-standing practices by some physicians of using the products of our larger, more established potential competitors. Physicians who have completed many successful implants using the products made by these competitors may be reluctant to try new products from a source with which they are less familiar. If these physicians do not try and subsequently adopt our product, then our revenue growth will slow or decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to receive access to hospitals, our sales may decrease.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the U.S., in order for physicians to use Barostim, hospitals where these physicians treat patients typically require us to enter into purchasing contracts. This process can be lengthy, time-consuming and require extensive negotiations and management time, which could include an approval by a customer&#8217;s value analysis committee. In the EEA, from time to time certain institutions require us to engage in a contract bidding process in the event that such institutions are considering making purchase commitments that exceed specified cost thresholds, which vary by jurisdiction. These processes are only open at certain periods of time, and we may not be successful in the bidding process. If we do not receive access to hospitals via these contracting processes or otherwise, or if we are unable to secure contracts or tender successful bids, our sales may decrease and our operating results may be harmed. Furthermore, we may expend significant effort in these time-consuming processes and still may not obtain a purchase contract from such hospitals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are dependent upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers, making us vulnerable to supply shortages, loss or degradation in performance of the suppliers, price fluctuations and ongoing supply chain disruptions, which could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We currently source certain components for Barostim from a limited number of suppliers. Our ability to supply Barostim commercially depends, in part, on our ability to obtain a supply of these components that has been manufactured in accordance with regulatory requirements and in sufficient quantities for commercialization and clinical testing. We have not entered into manufacturing, supply or quality agreements with some of our limited suppliers, some of which supply components critical to our products, such as modules, batteries and electrodes. We cannot guarantee that our suppliers will be able to meet our demand for their products and services, either because of the nature of our arrangements with those suppliers, our limited experience with those suppliers, or due to our relative importance as a customer to those suppliers. Further, due to our limited operating history and expected future expansion, it may be difficult for us to assess their ability to timely meet our demand in the future based on past performance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow specific protocols and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental factors, failure to properly conduct their own business affairs and infringement of third-party intellectual property rights, any of which could delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other risks that could harm our business, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not a major customer of many of our suppliers, and these suppliers may therefore give other customers&#8217; needs higher priority than ours;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third parties may threaten or enforce their intellectual property rights against our suppliers, which may cause disruptions or delays in shipment, or may force our suppliers to cease conducting business with us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to obtain an adequate supply of components in a timely manner or on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our suppliers, especially new suppliers, may make errors in manufacturing that could negatively affect the effectiveness or safety of Barostim or cause delays in shipment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we may have difficulty locating and qualifying alternative suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">switching components or suppliers may require product redesign and possibly submission to the FDA, EEA or other foreign regulatory bodies, which could significantly impede or delay our commercial activities; one or more of our limited source suppliers may be unwilling or unable to supply components of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">other customers may use fair or unfair negotiation tactics and/or pressures to impede our use of the supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">we do not conduct rigorous, formal environmental, social or governance due diligence on our supply chain and thus may not be aware if our suppliers pose such risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the occurrence of a fire, natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our suppliers may encounter financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Establishing additional or replacement suppliers for the components or processes used in Barostim, if required, could be time-consuming and expensive. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the limited sourced components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to cancel orders. Given our reliance on certain limited source suppliers, we are especially susceptible to supply shortages because we have limited alternate suppliers currently available.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><span style="color:#231f20;">Our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">business</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">strategy</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">depends</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">ability</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.6pt;"> </span><span style="color:#231f20;">manufacture</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">current</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">future</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">products</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;">sufficient quantities</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">on</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">timely</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">basis</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">so</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">meet</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">consumer</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">demand,</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">while</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">adhering</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">product</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">quality</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">standards, complying</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">with</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">regulatory</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">requirements</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">managing</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">manufacturing</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">costs.</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;letter-spacing:-0.15pt;">We</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">subject</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">numerous</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">risks relating</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">manufacturing</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">capabilities,</span><span style="color:#231f20;letter-spacing:-0.6pt;"> </span><span style="color:#231f20;">including:</span></p><div style="margin-top:5pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">quality or reliability defects in product components that we source from third-party suppliers, including manufacturing compliance with federal and state regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to secure product components in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to increase production of products to meet demand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to modify production lines to enable us to efficiently produce future products or implement changes in current products in response to regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">potential damage to or destruction of our manufacturing equipment or manufacturing facility.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">As demand for Barostim increases, we have invested, and expect to continue to invest, additional resources to purchase components, hire and train employees and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, our sales may not increase in line with our forecasts and our operating margins could fluctuate or decline. In addition, although we expect some of our product candidates in development to share product features and components with Barostim, manufacturing of these product candidates may require the modification of our production lines, the hiring of specialized employees, the identification of new suppliers for specific components, or the development of new manufacturing technologies. It may not be possible for us to manufacture these product candidates at a cost or in quantities sufficient to make these product candidates commercially viable. Any of these factors may affect our ability to manufacture our product and could reduce our gross margin and profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We operate at a facility in one location and any disruption at this facility could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our principal offices and our only manufacturing facility are located in Minneapolis, Minnesota. Substantially all of our operations are conducted at this location, including our manufacturing processes, research, development and engineering activities, customer and technical support and management and administrative functions. In addition, substantially all of our inventory of component supplies and finished goods is held at the manufacturing facility. Vandalism, terrorism or a natural or other disaster, such as a fire or flood, could damage or destroy our manufacturing equipment or our inventory of component supplies or finished goods, cause substantial delays in our operations, result in the loss of key information and cause us to incur additional expenses. Our manufacturing facility in Minneapolis, Minnesota is our only manufacturing facility, and if it is damaged or rendered inoperable or inaccessible due to political, social or economic upheaval or due to natural or other disasters, it would be difficult or impossible for us to manufacture our product for a period of time, which may lead to a loss of customers and significant impairment of our financial condition and operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We take precautions to safeguard this facility, including acquiring insurance, employing back-up generators, adopting health and safety protocols and utilizing off-site storage of computer data. Our insurance may not cover our losses in any particular case. In addition, regardless of the level of insurance coverage, damage to our facility may harm our business, financial condition and operating results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our international operations subject us to certain operating risks, which could adversely impact our results of operations and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sale and shipment of Barostim across international borders, as well as the purchase of components from international sources, subjects us to U.S. and foreign governmental trade, import and export and customs regulations and laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Compliance with these regulations and laws is costly and exposes us to penalties for non-compliance. Other laws and regulations that can significantly impact us include various anti-bribery laws, including the FCPA, as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our international operations expose us and our distributors to risks inherent in operating in foreign jurisdictions. These risks include, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors, or any of our third-party suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced or varied protection for intellectual property rights in some countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">potential pricing pressure;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">a shortage of high-quality sales representatives and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">competitive disadvantage to competition with established business and customer relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of additional U.S. and foreign governmental controls or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">economic instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in duties and tariffs, license obligations and other non-tariff barriers to trade;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of restrictions on the activities of foreign agents, representatives and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">scrutiny of U.S. and foreign tax authorities, which could result in significant fines, penalties and additional taxes being imposed on us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">laws and business practices favoring local companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">longer payment cycles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in maintaining consistency with our internal guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of costly and lengthy new export licensing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of U.S. or international sanctions against a country, company, person or entity; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the imposition of new trade restrictions.</span></td></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.33;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">If any of these risks are realized, our sales in non-U.S. jurisdictions may be adversely affected and our results of operations would suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell Barostim at prices necessary to support our current business strategies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Healthcare costs have risen significantly over the past decade, which has resulted in or led to numerous cost reform initiatives by legislators, regulators and third-party payors. Cost reform has triggered a consolidation trend in the healthcare industry to aggregate purchasing power, which may create more requests for price concessions in the future. Additionally, group purchasing organizations, independent delivery networks and large single accounts may continue to use their market power to consolidate purchasing decisions for hospitals. We expect that market demand, government regulation, third-party coverage and reimbursement policies and societal pressures will continue to change the healthcare industry worldwide, resulting in further business consolidations and alliances among our future customers, which may exert further downward pressure on the prices of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to properly manage our growth effectively, our business could suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We intend to continue to grow and may experience periods of rapid growth and expansion, which could place a significant additional strain on our limited personnel, information technology systems and other resources. In particular, the hiring of our direct sales force requires significant management, financial and other supporting resources. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To achieve our revenue goals, we must continue to successfully increase manufacturing output to meet expected customer demand. We may experience difficulties with manufacturing yields, quality control, component supply and shortages of qualified personnel, among other problems. Any of these problems could result in delays in product availability and increases in expenses. Any such delay or increased expense could adversely affect our ability to generate revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Future growth will continue to impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. In addition, rapid and significant growth will place a strain on our administrative and operational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to manage our operations and growth we will need to continue to improve our operational and management controls, reporting and information technology systems and financial internal control procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our operating results and may have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If clinical studies for future indications do not produce results necessary to support regulatory clearance or approval in the U.S. or elsewhere, we will be unable to commercialize our products for these indications.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will likely need to conduct additional clinical studies in the future to support approval for new indications. Clinical testing takes many years, is expensive and carries uncertain outcomes. The initiation and completion of studies may be prevented, delayed, or halted for numerous reasons, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, IRBs, ethics committees, EU competent authorities or other regulatory authorities do not approve a clinical study protocol, force us to modify a previously approved protocol, or place a clinical study on hold;</span></td><td style="width:20.95pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients do not enroll in, or enroll at a lower rate than we expect, or do not complete a clinical study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients or investigators do not comply with study protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients do not return for post-treatment follow-up at the expected rate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">patients experience serious or unexpected adverse side effects for a variety of reasons that may or may not be related to our products, such as the advanced stage of co-morbidities that may exist at the time of treatment, causing a clinical study to be put on hold;</span></td></tr></table><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sites participating in an ongoing clinical study withdraw, requiring us to engage new sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties or delays associated with establishing additional clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party clinical investigators decline to participate in our clinical studies, do not perform the clinical</span><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">studies on the anticipated schedule, or perform in a manner inconsistent with the investigator agreement, clinical study protocol, good clinical practices, other FDA, IRB or ethics committee requirements and EEA member state or other foreign regulations governing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party organizations do not perform data collection and analysis in a timely or accurate manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory inspections of our clinical studies or manufacturing facilities require us to undertake corrective action or suspend or terminate our clinical studies;</span></td><td style="width:9.95pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in federal, state, or foreign governmental statutes, regulations or policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">interim results are inconclusive or unfavorable as to immediate and long-term safety or effectiveness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">regional or worldwide conditions, like an infectious disease or pandemic, precluding or interfering with execution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the study design is inadequate to demonstrate safety and effectiveness; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.05pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:6.95pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the statistical endpoints are not met.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 4.95pt 0pt 3pt;">Clinical trials can fail at any stage. Our clinical studies may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional clinical or non-clinical studies in addition to those we have planned. In addition, if the FDA determines for any reason, including safety or their risk-benefit analysis, that the results of a trial are negative, the FDA may decide to modify or revoke our existing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 4.95pt 6pt 3pt;">approval or such data may impact the adoption of Barostim. Moreover, a negative perception of clinical results for one indication for use could impact the use of Barostim for other FDA approved and clinically supported indications for use.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 6.95pt 6pt 3pt;">We could also encounter delays if the FDA concludes that our financial relationships with investigators result in a perceived or actual conflict of interest that may have affected the interpretation of a study, the integrity of the data generated at the applicable clinical trial site or the utility of the clinical trial itself. Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. If these relationships and any related compensation to or ownership interest by the clinical investigator carrying out the study result in perceived or actual conflicts of interest, or if the FDA concludes that the financial relationship may have affected interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 9.95pt 6pt 3pt;">Even if our products are approved in the U.S. and the EEA, comparable regulatory authorities of additional foreign countries must also approve the manufacturing and marketing of our products in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S. or the EEA, including additional preclinical studies or clinical trials. Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may face product liability claims that could be costly, divert management&#8217;s attention and harm our reputation.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Manufacturing and marketing of Barostim and clinical testing of Barostim Therapy may expose us to product liability claims. The coverage limits of our liability insurance policies may not be adequate and one or more successful claims brought against us may have a material adverse effect on our business and results of operations. Further, interpretation of product liability laws may change in the future due to court rulings. It is possible evolving interpretations of product liability laws could further expose us to increased litigation risk in connection with our products. These product liability claims could, among other things, divert management&#8217;s attention from our primary business and negatively affect our reputation, continued product sales and our ability to obtain and maintain regulatory approval for our products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we fail to retain our key executives or recruit and hire new employees, our operations and financial results may be adversely affected while we attract other highly qualified personnel.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our future success depends, in part, on our ability to continue to retain our executive officers and other key employees and recruit and hire new employees. All of our executive officers and other employees are at-will employees, and therefore may terminate employment with us at any time with no advance notice. In particular, we are highly dependent upon our management team, especially our President and Chief Executive Officer and the rest of our senior management. The replacement of key personnel involves significant time and costs, may significantly delay or prevent the achievement of our business objectives and may harm our business. In addition, we do not carry any &#8220;key person&#8221; insurance policies that could offset potential loss of service under applicable circumstances.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, many of our employees have become vested in a substantial amount of stock or number of stock options. Our employees may be more likely to leave us if the shares they own or the shares underlying their vested options have significantly appreciated in value relative to the original purchase prices of the shares or the exercise prices of the options, or if the exercise prices of the options that they hold are significantly below the market price of our common stock. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Although non-compete agreements are becoming more disfavored and, in some cases, banned, many executive officers and employees in the medical device industry are still subject to strict non-compete or confidentiality agreements with their employers. In addition, some of our existing and future employees are subject to confidentiality agreements with previous employers. Our competitors may allege breaches of and seek to enforce such non-compete agreements or initiate litigation based on such confidentiality agreements. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Such litigation, whether or not meritorious, may impede our ability to attract or use executive officers and other key employees who have been employed by our competitors and may result in claims against us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We rely on information technology and telephone networks and systems, including the Internet, to process and transmit sensitive electronic information and to manage or support a variety of business processes and activities, including sales, billing, marketing, procurement and supply chain, manufacturing and distribution. We use enterprise information technology systems to record, process and summarize financial information and results of operations for internal reporting purposes and to comply with regulatory, financial reporting, legal and tax requirements. Our information technology systems, some of which are managed by third parties, may be susceptible to damage, disruptions or shutdowns due to computer viruses, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, hardware failures, telecommunication failures, user errors or catastrophic events. If our systems suffer severe damage, disruption or shutdown and we are unable to effectively resolve the issues in a timely manner, our business and operating results may suffer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If important assumptions about the potential market for our product are inaccurate, or if we have failed to understand what people with HF are seeking in a treatment, we may not be able to increase our revenue or achieve profitability.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our business strategy was developed based on a number of important assumptions about the HF market in general, any one or more of which may prove to be inaccurate. For example, we believe that the benefits of Barostim as compared to other common HF devices will continue to drive growth in the market for Barostim. Despite our review of studies reporting on the trends of HF incidence in the U.S., the actual incidence of HF and the actual demand for our product or competitive products could differ materially from our expectations. In addition, our strategy of focusing exclusively on patients with HFrEF who are looking for an improvement in the symptoms associated with HFrEF may limit our ability to increase sales or achieve profitability, especially if there are any significant clinical breakthroughs or product or drug introductions that significantly delay or reduce the need for heart disease therapy. Moreover, a percentage of our indicated patients may be ineligible to undergo a Barostim procedure if they have certain co-morbidities or other disqualifying factors as determined by their physicians.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our estimates of the annual total addressable market for Barostim are based on a number of internal and third-party estimates, including, without limitation, the number of patients with HFrEF and the assumed prices at which we can sell our device. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for Barostim may prove to be incorrect. If the actual number of patients who would benefit from our product, the price at which we can sell our product, or the annual total addressable market for our product is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Unfavorable economic conditions could adversely affect our business, financial condition or results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our results of operations could be adversely affected by general conditions in the economy and the financial markets. Concerns over economic and political stability, inflation levels and related efforts to mitigate inflation, a potential recession, the level of U.S. national debt, currency fluctuations and volatility, the rate of growth of Japan, China and other Asian economies, unemployment, the availability and cost of credit, trade relations, including the imposition of various sanctions and tariffs, infectious diseases or pandemics, climate-related events, energy costs and geopolitical uncertainty and conflict have contributed to increased volatility and diminished expectations for the economy and markets in general. An economic downturn could result in a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">variety of risks to our business, including weakened demand for Barostim and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our manufacturers or suppliers, resulting in supply disruption, or causing our customers to delay making payments for our services. Certain of the foregoing have harmed and could in the future harm our business, and we cannot anticipate all of the ways in which the economic climate and financial market conditions may further affect our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may enter into strategic collaborations, in-licensing arrangements or alliances with third parties that may not result in the development of commercially viable products or the generation of significant future revenue.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In the ordinary course of our business, we may enter into strategic collaborations, in-licensing arrangements or alliances to develop product candidates and to pursue new markets. Proposing, negotiating and implementing strategic collaborations, in-licensing arrangements or alliances may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or result in significant revenue and could be terminated prior to developing any products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. We have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may seek to grow our business through acquisitions of complementary products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, could impair our ability to execute our business strategies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may consider opportunities to acquire other products or technologies that may enhance our Barostim platform technology, expand the breadth of our markets or customer base, or advance our business strategies. Potential acquisitions involve numerous risks, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">problems assimilating the acquired products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issues maintaining uniform standards, procedures, controls and policies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated costs associated with acquisitions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s attention from our existing business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with entering new markets in which we have limited or no experience; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">increased legal and accounting costs relating to the acquisitions or compliance with regulatory matters.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have no current commitments with respect to any acquisition. We do not know if we will be able to identify acquisitions we deem suitable, whether we will be able to successfully complete any such acquisitions on favorable terms or at all, or whether we will be able to successfully integrate any acquired products or technologies. Our inability to integrate any acquired products or technologies effectively could impair our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">ability to execute our business strategies. In addition, any amortization or charges resulting from the costs of acquisitions could increase our expenses<span style="color:#231f20;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If third-party payors do not provide adequate coverage and reimbursement for the use of Barostim, our revenue will be negatively impacted.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Medicare reimbursement levels are important to increasing adoption of Barostim because nearly two-thirds of the target patient population for Barostim is over the age of 65. In the 2024 OPPS final rule issued in November 2023, Barostim was reassigned to New Technology APC 1580, which carries an average payment amount of $45,000. The new payment took effect January 1, 2024. Any future decline in the amount Medicare is willing to reimburse our customers for procedures using Barostim could make it difficult for new customers to adopt Barostim and could create additional pricing pressure for us, which could adversely affect our ability to invest in and grow our business. From time to time, physicians and hospitals have in the past experienced, and others may experience, delays in Medicare reimbursement, which have delayed or may delay their willingness to schedule additional Barostim procedures.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">A pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide could adversely affect our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pandemics, epidemics or outbreaks of an infectious disease may adversely affect our business. Numerous state and local jurisdictions have historically imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of infectious disease. Such orders or restrictions previously resulted, and may in the future result, in reduced operations at our headquarters, slowdowns and delays, travel restrictions and cancellation of events and restrictions on the ability of our front-line sales representatives to attend procedures in which our products are used, among other effects, thereby negatively impacting our operations. Other disruptions or potential disruptions include restrictions on the ability of our sales representatives and other personnel to travel and access customers for training and case support; the ability of hospitals and surgical centers to staff and conduct procedures; inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to manufacture and assemble products; inventory shortages or obsolescence; delays in actions of regulatory bodies; and delays in clinical trials and studies, especially if study subjects are reluctant to present themselves at medical facilities. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">While the potential economic impact brought by and the duration of any pandemic, epidemic or outbreak of an infectious disease may be difficult to assess or predict, it may result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. To the extent a pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Risks related to intellectual property</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may in the future become involved in lawsuits to protect or enforce our intellectual property or defend ourselves against intellectual property disputes, which could be expensive, time consuming and ultimately unsuccessful, and could result in the diversion of significant resources, thereby hindering our ability to effectively commercialize our existing or future products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our success depends in part on obtaining, maintaining and enforcing patents and other intellectual property rights and not infringing the patents or violating the other proprietary rights of others. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. Significant litigation regarding patent rights occurs in the medical device industry. Whether merited or not, it is possible that third parties controlling U.S. and foreign patents allege such patents cover our products, or we may decide to initiate infringement claims or litigation to protect our patents or other intellectual property rights. We may also face allegations that our employees have misappropriated the intellectual property rights of their former employers or other third parties. Our competitors in both the U.S. and abroad, many of which </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use, sell, or export our products. These competitors may have one or more patents for which they can threaten or initiate patent infringement actions against us or any of our third-party suppliers. Further, if such patents are successfully asserted against us, this may result in an adverse impact on our business, including injunctions, damages or attorneys&#8217; fees. Moreover, if we initiate an infringement proceeding, a court may decide that the patent we seek to enforce is invalid or unenforceable or that the patent in question does not cover the technology at issue. From time to time and in the ordinary course of business, we may develop noninfringement or invalidity positions with respect to third-party patents, which may or may not be ultimately adjudicated as successful by a judge or jury if such patents were asserted against us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We may receive in the future, particularly as a public company, communications from patent holders, including non-practicing entities, alleging infringement of patents or other intellectual property rights or misappropriation of trade secrets, or offering licenses to such intellectual property. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights. At any given time, we may be involved as either a plaintiff or a defendant in a number of patent infringement actions, the outcomes of which may not be known for prolonged periods of time.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The large number of patents, the rapid rate of new patent applications and issuances, the complexities of the technologies involved and the uncertainty of litigation significantly increase the risks related to any patent litigation. Any potential intellectual property litigation also could require us to do one or more of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">stop selling, making, using or exporting products that use the disputed intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain a license from the intellectual property owner to continue selling, making, exporting or using products, which license may require substantial royalty payments and may not be available on reasonable terms, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">incur significant legal expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pay substantial damages or royalties to the party whose intellectual property rights we may be found to be infringing, potentially including treble damages if the court finds that the infringement was willful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pay the attorney fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">find non-infringing substitute products, which could be costly and create significant delay due to the need for FDA regulatory clearance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">find alternative supplies for infringing products or processes, which could be costly and create significant delay due to the need for FDA regulatory clearance; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign those products or processes that infringe any third-party intellectual property, which could be costly, disruptive or infeasible.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If a court determines that we failed to secure necessary patents, competitors may be able to market competing products and make, use or sell products that are substantially the same as ours without incurring the sizeable development costs that we have incurred, which would adversely affect our ability to compete. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Finally, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">If any of the foregoing occurs, we may have to withdraw existing products from the market or may be unable to commercialize one or more of our products, all of which could have a material adverse effect on our business, results of operations and financial condition. Any litigation or claim against us, even those without merit, may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. Further, as the number of participants in our industry grows, the possibility of intellectual property infringement disputes increases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, we may indemnify our customers, suppliers and international distributors against claims relating to the infringement of the intellectual property rights of third parties relating to our products, methods and/or manufacturing processes. Third parties may assert infringement claims against our customers, suppliers or distributors. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, suppliers or distributors, regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers, suppliers or distributors or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products, or our suppliers may be forced to stop providing us with products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Similarly, interference or derivation proceedings provoked by third parties or brought by the USPTO or any foreign patent authority may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications. We may also become involved in other proceedings, such as re-examination or opposition proceedings, before the USPTO or its foreign counterparts relating to our intellectual property or the intellectual property rights of others. An unfavorable outcome in any such proceedings could require us to cease using the related technology or to attempt to license rights to it from the prevailing party, or could cause us to lose valuable intellectual property rights. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. We may also become involved in disputes with others regarding the ownership of intellectual property rights. For example, we jointly develop intellectual property with certain parties, and disagreements may therefore arise as to the ownership of the intellectual property developed pursuant to these relationships. If we are unable to resolve these disputes, we could lose valuable intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switched the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, in particular, the first-to-file provisions, became effective on March 16, 2013. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furthermore, the U.S. and foreign courts are continually interpreting various aspects of patent law. We cannot predict with any reasonable certainty how the evolution of the interpretation of these laws will affect our business. However, it is possible that changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our own, which would have a material adverse effect on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may not be able to adequately protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries may not protect our intellectual property rights to the same extent as laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories in which we have patent protection that may not be sufficient to terminate infringing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We do not have patent rights in certain foreign countries in which a market may exist. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products that are the same as or similar to our products, and our competitive position in the international market would be harmed.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-disclosure or confidentiality agreements with our competitors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information about former employers or competitors. Although we have procedures in place that seek to prevent our employees and consultants from using the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-disclosure or confidentiality agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor, resulting in litigation. Even if we are successful in defending against these claims, the litigation could be costly </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">and a distraction to management. If we are unsuccessful in defending against these claims, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential to our products would have a material adverse effect on our business, and may prevent us from selling our products or from practicing our processes. In addition, we may lose valuable intellectual property rights.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners or customers in our markets of interest. In addition, third parties have registered trademarks similar and identical to our trademarks in foreign jurisdictions, and may in the future file for registration of such trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we were not successful in challenging such third-party rights, we may not be able to use these trademarks to market our products in those countries. In any case, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to patent and trademark protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our consultants and vendors and our employees. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, however, any of these parties may breach the agreements and disclose our trade secrets and other unpatented or unregistered proprietary information, and once disclosed, we are likely to lose trade secret protection. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be sufficient. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are reluctant or unwilling to enforce trade secret protection.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further, our competitors may independently develop knowledge, methods and know-how similar, equivalent or superior to our proprietary technology. Competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. In addition, our key employees, consultants, suppliers or other individuals with access to our proprietary technology and know-how may incorporate that technology and know-how into projects and inventions developed independently or with third parties. As a result, disputes may arise regarding the ownership of the proprietary rights to such technology or know-how and any such dispute may not be resolved in our favor. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those with whom they share it, from using that technology or information to compete with us and our competitive position could be adversely affected. If our intellectual property is not adequately protected to protect our market against competitors&#8217; products and methods, our competitive position and business could be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our financial and operating results</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We may be required to obtain additional funds in the future, and these funds may not be available on acceptable terms or at all.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our operations have consumed substantial amounts of cash since inception, and we anticipate our expenses will increase as we continue to build our commercial sales force in the U.S., investigate the potential use of Barostim for the treatment of other HF conditions, continue to grow our business and operate as a public company. We believe that our growth will depend, in part, on our ability to fund our commercialization and research and development efforts. We believe that our existing cash, cash equivalents, short-term investments and revenue will be sufficient to meet our capital requirements and fund our operations for at least the next three years. However, we have based these estimates on assumptions that may prove to be incorrect, and we could spend our available financial resources much faster than we currently expect. As a result, we may need to seek additional funds in the future. If we are unable to raise funds on favorable terms, or at all, we may not be able to support our commercialization efforts or increase our research and development activities and the growth of our business may be negatively impacted. As a result, we may be unable to compete effectively. For the fiscal years ended December 31, 2023 and 2022, net cash used in operating activities was $39.0 million and $42.7 million, respectively. Our cash requirements in the future may be significantly different from our current estimates and depend on many factors, including, among others:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope and timing of our continued investment in our U.S. commercial infrastructure and sales force;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including product sales, marketing, manufacturing and distribution and hiring additional members for our direct sales and marketing team in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of market acceptance of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the research and development activities we intend to undertake in order to pursue product enhancements and expand HF indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our need to implement additional infrastructure and internal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel to support our operations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing technologies or other adverse market developments.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To finance certain of these activities, we may seek funds through borrowings or through additional rounds of financing, including private or public equity or debt offerings and collaborative arrangements with corporate partners. We may be unable to raise funds on favorable terms, or at all.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders. If we borrow additional funds or issue debt securities, these securities could have rights superior to holders of our common stock and could contain covenants that will restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. For example, our Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Fund I, LP (&#8220;Innovatus&#8221;) restricts us from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions. We might have to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to our technologies, product candidates or products that we otherwise would not relinquish. If we do not obtain additional resources, our ability to capitalize on business opportunities will be limited, we may be unable to compete effectively and the growth of our business may be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our operating results may vary significantly annually or from quarter to quarter, which may negatively impact our stock price in the future.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our revenue and results of operations may fluctuate annually or from quarter to quarter due to, among others, the following reasons:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">physician and payor acceptance of Barostim and Barostim Therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, expense and results of research and development activities, clinical trials and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our expenses associated with expanding our commercial operations and operating as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction of new products and technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the productivity of our sales representatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">supplier, manufacturing or quality problems with our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of stocking orders from our distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our pricing policies or in the pricing policies of our competitors or suppliers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in coverage amounts or government and third-party payors&#8217; reimbursement policies.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Because of these and other factors, it is possible that our operating results will not meet investor expectations or those of public market analysts.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Any unanticipated change in revenues or operating results is likely to cause our stock price to fluctuate. New information may cause investors and analysts to revalue our business, which could also cause a fluctuation in our stock price.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are required to maintain high levels of inventory, which could consume a significant amount of our resources, reduce our cash flows and lead to inventory impairment charges.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our product consists of a substantial number of individual components. In order to market and sell Barostim effectively, we often must maintain high levels of inventory. The manufacturing process requires lengthy lead times, during which components of our products may become obsolete, and we may over- or under-estimate the amount needed of a given component, in which case we may expend extra resources or be constrained in the amount of end product that we can produce. As compared to direct manufacturers, our dependence on third-party manufacturers for our component parts exposes us to greater lead times.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The seasonality of our business creates variance in our quarterly revenue, which makes it difficult to compare or forecast our financial results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that revenue could fluctuate from quarter to quarter as a result of timing and seasonality. We anticipate mild seasonality based on national holiday patterns specific to certain nations. These seasonal variations are difficult to predict accurately, may vary amongst different markets, and at times may be entirely unpredictable. In addition to the above factors, in the U.S. it is possible that we may experience seasonality based on patients&#8217; annual deductibility limits under their health insurance coverage. While historically seasonality has been minimal, we anticipate increased seasonality due to our increased focus on sales within the U.S. These seasonal variations are difficult to predict accurately, may vary among different markets and at times may be entirely unpredictable, which introduces additional risk into our business as we rely upon forecasts of customer demand to build inventory in advance of anticipated sales. In addition, we believe our limited history commercializing our products has, in part, made our seasonal patterns more difficult to discern and therefore predict.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to risks associated with currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">A portion of our current business is located outside the U.S. and, as a result, we generate revenue and incur expenses denominated in currencies other than the U.S. dollar, a majority of which is denominated in Euros. As a result, changes in the exchange rates between such foreign currencies, particularly the Euro and the U.S. dollar, could materially impact our reported results of operations and distort period to period comparisons. Fluctuations in foreign currency exchange rates also impact the reporting of our receivables and payables in non-U.S. currencies. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our business and results of operations. In addition, to the extent that fluctuations in currency exchange rates cause our results of operations to differ from our expectations or the expectations of our investors, the trading price of our common stock could be adversely affected. In the future, we may engage in exchange rate hedging activities in an effort to mitigate the impact of exchange rate fluctuations. If our hedging activities are not effective, changes in currency exchange rates may have a more significant impact on our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our ability to use our net operating losses and tax credits to offset future taxable income and taxes may be subject to certain limitations, and we may not be able to utilize a significant portion of our net operating loss and tax credit carryforwards prior to their expiration.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have generated and expect to continue to generate significant federal and state net operating loss (&#8220;NOLs&#8221;) and tax credit carryforwards. As of December 31, 2023, we had federal and state NOL carryforwards of approximately $389.9 million and $7.3 million, respectively. The federal NOLs began expiring in 2021 and state NOLs began expiring in 2020. As of December 31, 2023, we had federal and state tax credit carryforwards of approximately $9.8 million and $2.0 million, respectively. The federal and state tax credit carryforwards began expiring in 2021 and begin expiring in 2028, respectively. These NOL and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the legislation enacted on December 22, 2017 commonly referred to as the &#8220;Tax Cuts and Jobs Act,&#8221; as modified by the Coronavirus Aid, Relief, and Economic Security Act, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs incurred in taxable years beginning after December 31, 2020 is limited. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOLs and specified other tax credit carryforwards, such as research and development tax credits, to offset future taxable income and taxes. We may have previously experienced, and may in the future experience, one or more &#8220;ownership changes&#8221; for purposes of the rules under Section 382 and 383 of the Code, including in connection with our IPO. If so, or if we do not generate sufficient taxable income, we may not be able to utilize a material portion of our NOLs and tax credits, even if we achieve profitability. If we are limited in our ability to use our NOLs and tax credits in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs and tax credits. This could materially and adversely affect our results of operations by effectively increasing our future tax obligations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to complex tax rules, and any audits, investigations or tax proceedings could have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are subject to income and/or non-income taxes in the U.S., Switzerland, Italy, Germany, France and the Netherlands, as well as the tax laws and regulations related to such matters. Tax accounting and compliance often involves complex issues, and judgment and interpretation is required in determining our provision for income taxes and other tax liabilities as well as the application of tax laws and regulations. In that respect, many jurisdictions have detailed transfer pricing rules, which require that all transactions with related parties be priced using arm&#8217;s length pricing principles within the meaning of such rules. The application of such transfer pricing rules, as well as of withholding taxes, goods and services taxes, sales taxes and other taxes is not always clear, and we may be subject to tax audits relating to such rules or taxes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We believe that our tax positions are reasonable, and our tax provisions and reserves are adequate to cover any potential liability. However, various items cannot be accurately forecasted, and future events may be treated as discrete to the period in which they occur. In addition, the Internal Revenue Service or other taxing authorities may disagree with our positions. If the Internal Revenue Service or any other tax authorities were successful in challenging our positions, we may be liable for additional tax and penalties and interest related thereto or other taxes, as applicable, in excess of any reserves established therefor, which may have a significant impact on our results, operations and future cash flow.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in U.S. and non-U.S. tax laws could adversely affect our financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The rules dealing with U.S. and non-U.S. tax matters are constantly under review by persons involved in the legislative, judicial, administrative, regulatory and related governmental processes and authorities. Changes to tax laws or the interpretation and application thereof (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in U.S. and non-U.S. tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in U.S. and non-U.S. tax laws on an investment in our common stock.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Risks related to regulation of our industry</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim is subject to extensive governmental regulation, and our failure to comply with applicable requirements could cause our business to suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The medical device industry is regulated extensively by governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies and authorities, such as the EU legislative bodies and the EEA member state competent authorities. The FDA and other U.S., EEA and foreign governmental agencies and authorities regulate and oversee, among other things, with respect to medical devices:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">design, development and manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">testing, labeling, content and language of instructions for use and storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product safety;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing, sales and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">pre-market regulatory clearance and approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">conformity assessment procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">record-keeping procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising and promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">recalls and other field safety corrective actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">post-market studies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">product import and export.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The laws and regulations to which we are subject are complex and have tended to become more stringent over time. Legislative or regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our failure to comply with U.S. federal and state regulations or EEA or other foreign regulations applicable in the countries where we operate could lead to the issuance of warning letters or untitled letters, fines, injunctions, suspensions or loss of regulatory clearance or approvals, recalls or seizures of products, termination of distribution, or civil penalties. In the most extreme cases, criminal sanctions or closure of our manufacturing facilities are possible. If any of these risks materialize, our business would be adversely affected.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Barostim is also subject to extensive governmental regulation in foreign jurisdictions, such as Europe, and our failure to comply with applicable requirements could cause our business to suffer.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 5.95pt 6pt 0pt;">In the EEA, Barostim was required to comply with the Essential Requirements laid down in Annex I to the EU Active Implantable Medical Devices Directive. Compliance with these requirements was a prerequisite to affixing the CE mark to Barostim. To demonstrate compliance with the Essential Requirements and obtain the right to affix the CE Mark to Barostim, we underwent a conformity assessment procedure, which varied according to the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer could issue an EU Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements, a conformity assessment procedure required the intervention of a Notified Body, which is an organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit the Quality Management System and examine the Technical File for the manufacture, design and final inspection of our devices. The Notified Body would issue a CE Certificate of Conformity following successful completion of this conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements. This Certificate would entitle the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EU Declaration of Conformity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 4.95pt 6pt 0pt;">As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements must be based on, among other things, the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use and that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device (e.g., product labeling and instructions for use) are supported by suitable evidence. This assessment must be based on clinical data, which can be obtained from (1) clinical studies conducted on the devices being assessed, (2) scientific literature from similar devices whose equivalence with the assessed device can be demonstrated or (3) both clinical studies and scientific literature. With respect to active implantable medical devices or Class III devices, the manufacturer must conduct clinical studies to obtain the required clinical data, unless reliance on existing clinical data from equivalent devices can be justified. The conduct of clinical studies in the EEA is governed by detailed regulatory obligations. These may include the requirement of prior authorization by the competent authorities of the country in which the study takes place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process can be expensive and time-consuming.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In order to continue to sell Barostim in Europe, we must comply with the MDR and its evolving transition requirements. We have submitted our application for Barostim to comply with the general safety and performance requirements of the EU MDR (which are similar to the Essential Requirements of the AIMDD), and it is currently under review. Additionally, the EU did approve an amendment to the MDR which allows qualifying AIMDD CE certificates to be accepted through December of 2027. We have already met the qualifications identified within this amendment to allow continued distribution of Barostim through this time. Failing to continue to comply with applicable foreign regulatory requirements, including those administered by authorities of the EEA countries, could result in enforcement actions against us, including refusal, suspension or withdrawal of our CE Certificates of Conformity by our Notified Body (the National Standards Authority of Ireland, or NSAI), which could impair our ability to market products in the EEA in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our business is subject to extensive governmental regulation that could make it more expensive and time consuming for us to market Barostim in the U.S. and introduce new or improved products.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products must comply with regulatory requirements imposed by the FDA in the U.S. and similar agencies in foreign jurisdictions. These requirements involve lengthy and detailed laboratory and clinical testing procedures, sampling activities, extensive agency review processes and other costly and time-consuming procedures. It often takes several years to satisfy these requirements, depending on the complexity and novelty of the product. We also are subject to numerous additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. Some of the most important requirements we must comply with include:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDCA and the FDA&#8217;s implementing regulations (Title 21 CFR);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">EU CE mark requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Medical Device Quality Management System Requirements (ISO 13485:2003);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Occupational Safety and Health Administration requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">California Department of Health Services requirements.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current or evolving government regulation may impede our ability to conduct clinical studies and to manufacture and sell our existing and future products. Such government regulation also could delay our marketing of new products for a considerable period of time and impose costly procedures on our activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our products remain subject to strict regulatory controls on manufacturing, marketing and use. We may be forced to modify or recall a product after release in response to regulatory action or unanticipated difficulties encountered in general use. Any such action could have a material effect on the reputation of our products and on our business and financial position. Further, regulations may change, and any additional regulation could limit or restrict our ability to use any of our technologies, which could harm our business. We could also be subject to new international, federal, state or local regulations that could affect our research and development programs and harm our business in unforeseen ways. If this happens, we may have to incur significant costs to comply with such laws and regulations, which will harm our results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The misuse or off-label use of our product may harm our image in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or result in costly investigations and sanctions from the FDA and other regulatory bodies if we are deemed to have engaged in inappropriate promotion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Barostim has been indicated for the improvement of symptoms of HFrEF by the FDA and the treatment of HFrEF in the EEA. We may only promote or market Barostim for its specifically approved indications as described on the approved label. We train our marketing and sales force against promoting our products for uses outside of the approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our product off-label when, in the physician&#8217;s independent professional medical judgment, he or she deems appropriate. There may be increased risk of injury to patients if physicians attempt to use our product off-label. Furthermore, the use of our product for indications other than those approved by the applicable regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Physicians may also misuse our product or use improper techniques, potentially leading to injury and an increased risk of product liability. If our product is misused or used with improper technique, we may become subject to costly product liability claims or other litigation by our customers or their patients. In addition, if the FDA determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">they consider our business activities to constitute inappropriate promotion, including promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. Any of these events could significantly harm our business and results of operations and cause our stock price to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further, the advertising and promotion of our products is subject to EEA member state laws implementing the MDD, Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, as well as other EEA member state legislation governing the advertising and promotion of medical devices. EEA member state legislation may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national codes of conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">The discovery of serious safety issues with Barostim, or a recall of Barostim either voluntarily or at the direction of the FDA or another governmental authority, could harm our reputation, business and financial results.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The FDA, the competent authorities of the EEA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture that could affect patient safety or in the event that a product poses an unacceptable risk to health. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse health consequences or death. We may also choose to conduct a product notification or recall to inform physicians of changes to instructions for use, or if a deficiency in a device is found or suspected. A government-mandated recall or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects, packaging defects or failures to comply with applicable regulations. Product defects or other errors may occur in the future. Recalls, which include certain notifications and corrections as well as removals, of Barostim could divert managerial and financial resources and could have an adverse effect on our financial condition, harm our reputation and reduce our ability to achieve expected revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the manufacturing of our products is subject to extensive post-market regulation by the FDA and foreign regulatory authorities, and any failure by us or our contract manufacturers or suppliers to comply with regulatory requirements could result in recalls, facility closures and other penalties. We and our suppliers and contract manufacturers are subject to the FDA&#8217;s QSR, and comparable foreign regulations which govern the methods used in, and the facilities and controls used for, the design, manufacture, quality assurance, labeling, packaging, sterilization, storage, shipping and servicing of medical devices. These regulations are enforced through periodic inspections of manufacturing facilities. Any manufacturing issues at our or our suppliers&#8217; or contract manufacturers&#8217; facilities, including failure to comply with regulatory requirements, may result in warning or untitled letters, manufacturing restrictions, voluntary or mandatory recalls or corrections,<span style="letter-spacing:-1.8pt;"> </span>fines,<span style="letter-spacing:-1.75pt;"> </span>withdrawals<span style="letter-spacing:-1.8pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.75pt;"> </span>regulatory<span style="letter-spacing:-1.8pt;"> </span>clearances<span style="letter-spacing:-1.75pt;"> </span>or<span style="letter-spacing:-1.8pt;"> </span>approvals,<span style="letter-spacing:-1.75pt;"> </span>product<span style="letter-spacing:-1.8pt;"> </span>seizures,<span style="letter-spacing:-1.75pt;"> </span>injunctions<span style="letter-spacing:-1.75pt;"> </span>or<span style="letter-spacing:-1.8pt;"> </span>the imposition<span style="letter-spacing:-1.6pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.6pt;"> </span>civil<span style="letter-spacing:-1.6pt;"> </span>or<span style="letter-spacing:-1.6pt;"> </span>criminal<span style="letter-spacing:-1.6pt;"> </span>penalties,<span style="letter-spacing:-1.6pt;"> </span>which<span style="letter-spacing:-1.6pt;"> </span>would<span style="letter-spacing:-1.6pt;"> </span>adversely<span style="letter-spacing:-1.6pt;"> </span>affect<span style="letter-spacing:-1.6pt;"> </span>our<span style="letter-spacing:-1.6pt;"> </span>business<span style="letter-spacing:-1.6pt;"> </span>results<span style="letter-spacing:-1.6pt;"> </span>and<span style="letter-spacing:-1.6pt;"> </span>prospects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals for the device before we may market or distribute the corrected device. Seeking such approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement actions, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and European regulators, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Under the FDA medical device reporting regulations, medical device manufacturers are required to submit information to the FDA when they receive a report or become aware that a device has or may have caused or contributed to a death or serious injury or has or may have a malfunction that would likely cause or contribute to death or serious injury if the malfunction were to recur. All manufacturers placing medical devices on the market in the EEA are legally bound to report incidents involving devices they produce or sell to the regulatory agency, or competent authority, in whose jurisdiction the incident occurred. Under the MDD, an incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA or European regulators could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device approval, seizure of our products or delay in clearance or approval of future products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are subject to certain federal, state and foreign fraud and abuse laws, transparency and privacy and security laws and regulations, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws and regulations could cause adverse publicity and be costly to respond to, and thus could harm our business.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">There are numerous U.S. federal and state, as well as foreign, laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims and physician transparency laws. Our business practices and relationships with providers are subject to scrutiny under these laws. We are subject to privacy and security regulation related to patient, customer, employee and other third-party information by both the federal government and the states and foreign jurisdictions in which we conduct our business. In the U.S., the laws that may affect our ability to operate include, but are not limited to:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, including civil whistleblower or qui tam actions, that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their business associates that perform services for them that involve individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization, including mandatory contractual terms as well as directly applicable privacy and security standards and requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal physician payments sunshine requirements under the Affordable Care Act, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to HHS information related to payments and other transfers of value to certain healthcare providers and teaching hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.32;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:10pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">state and foreign law analogs of each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of personal and health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These laws and regulations, among other things, constrain our business, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers of our products. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continue to increase their scrutiny of interactions between healthcare companies and healthcare providers. The Office of the Inspector General of HHS also has issued compliance program guidance for pharmaceutical manufacturers which is routinely applied to medical device companies. All of this has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry, including for medical device companies. Responding to investigations can be time and resource consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;padding-bottom:12pt;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a material adverse effect on us.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. In March 2010, the Affordable Care Act was enacted in the U.S., which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other ways in which it may affect our business, the Affordable Care Act:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">established a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">implemented payment system reforms, including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:8pt;padding:0pt 0pt 12pt 0pt;">&#8226;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expanded the eligibility criteria for Medicaid programs.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">The expansion in the government&#8217;s role in the U.S. healthcare industry may result in decreased profits to us, lower reimbursement by payors for Barostim and any future products and/or reduced medical procedure volumes, all of which may have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additionally, on April 5, 2017, the European Parliament passed the MDR, which repeals and replaces the MDD and the AIMDD. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations are directly applicable (i.e., without the need for adoption of the EEA member state laws implementing them), in all EEA member states and are intended to eliminate differences in the regulation of medical devices among the EEA member states. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory<span style="letter-spacing:-1.35pt;"> </span>framework<span style="letter-spacing:-1.35pt;"> </span>across the<span style="letter-spacing:-1.5pt;"> </span>EEA<span style="letter-spacing:-1.45pt;"> </span>for<span style="letter-spacing:-1.5pt;"> </span>medical<span style="letter-spacing:-1.45pt;"> </span>devices<span style="letter-spacing:-1.5pt;"> </span>and<span style="letter-spacing:-1.45pt;"> </span>ensure<span style="letter-spacing:-1.5pt;"> </span>a<span style="letter-spacing:-1.45pt;"> </span>high<span style="letter-spacing:-1.5pt;"> </span>level<span style="letter-spacing:-1.45pt;"> </span><span style="letter-spacing:-0.15pt;">of</span><span style="letter-spacing:-1.5pt;"> </span>safety<span style="letter-spacing:-1.45pt;"> </span>and<span style="letter-spacing:-1.5pt;"> </span>health<span style="letter-spacing:-1.45pt;"> </span>while<span style="letter-spacing:-1.5pt;"> </span>supporting<span style="letter-spacing:-1.45pt;"> </span>innovation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The MDR became effective in May 2021 and, among other things is designed to:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">This regulation has not yet had a material effect on the way we conduct our business in the EEA. However, it is possible the regulation will change in the future, and we cannot be certain that future changes will not have an adverse effect on our business operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Risks related to our common stock </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We expect that the price of our common stock will fluctuate substantially, and you may not be able to resell shares of our common stock at or above the price you paid.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The market price of our common stock has been and may continue to be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control or are related in complex ways, including:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">results from, or any delays in, clinical trial programs relating to our product candidates, including the ongoing and future U.S. clinical trials for Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new products by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes or developments in laws or regulations applicable to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any adverse changes in our relationship with any manufacturers or suppliers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our efforts to acquire or develop additional products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">any intellectual property infringement actions in which we may become involved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements concerning our competitors or the medical device industry in general;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">achievement of expected product sales and profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, supply or distribution shortages;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, our executive officers and directors or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic and market conditions and overall fluctuations in the U.S. equity markets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of any of our key scientific or management personnel.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, the stock markets in general, and the markets for medical device stocks in particular, have experienced volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile or decreases significantly, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our results of operations and financial position. Any adverse determination in litigation could also subject us to significant liabilities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price and trading volume to decline.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts cover us, the trading price for our stock would be negatively impacted. If any of the analysts who cover us issues an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Because we have opted to take advantage of the JOBS Act provision which allows us to delay implementing new accounting standards, our financial statements may not be directly comparable to other public companies.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pursuant to the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Because we have elected to take advantage of this provision of the JOBS Act, our financial statements and the reported results of operations contained therein may not be directly comparable to those of other public companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">If we are unable to maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">To comply with the requirements of being a public company, we are undertaking and expect to continue to undertake various actions, including implementing and maintaining new internal controls and procedures and hiring new accounting or internal audit staff. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal control over financial reporting. We have developed and expect to continue to refine our disclosure controls and other procedures that are designed to ensure that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm, to the extent we are no longer an &#8220;emerging growth company,&#8221; as defined by the JOBS Act, and are not a non-accelerated filer. We do not expect to have our independent registered public accounting firm attest to our management report on internal control over financial reporting for so long as we are an emerging growth company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our current controls and any new controls that we develop may become inadequate and weaknesses in our internal control over financial reporting may be discovered in the future. If we fail to develop and maintain effective internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We have designed and implemented and expect to continue to refine the internal control over financial reporting required to comply with this obligation, which process will be time-consuming, costly and complicated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to assert that our internal control over financial reporting is effective, or, when required in the future, if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, or if our internal control over financial reporting is perceived as inadequate or we are unable to produce timely or accurate financial statements, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decline and we could become subject to investigations or removal by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our principal stockholders, management and directors (two of whom are affiliated with our principal stockholders) own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 52% of our outstanding voting stock. Two of our non-employee directors are also affiliated with certain of our principal stockholders. Therefore, if they act together, these stockholders will have the ability to influence us through this ownership position and matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control of the Company, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of the Company or our assets, and might affect the prevailing market price of our common stock due to investors&#8217; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law (the &#8220;DGCL&#8221;) or any action asserting a claim </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">against us that is governed by the internal affairs doctrine. The exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our amended and restated certificate of incorporation also provides that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and results of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Anti-takeover provisions included in our amended and restated certificate of incorporation and amended and restated bylaws, as well as under Delaware law, could discourage a takeover.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace or remove current members of our management team. These include the following provisions that:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">permit our Board of Directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by resolution of our Board of Directors and that a director may only be removed with cause by the affirmative vote of the holders of at least a majority of our outstanding voting stock, voting together as a single class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that our amended and restated bylaws may only be altered, amended or repealed by our stockholders upon the affirmative vote of a two-thirds majority of the voting power of all of our outstanding voting stock, voting together as a single class;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:7.9pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that special meetings of our stockholders may be called only by the Chairman of the board, the Chief Executive Officer, or a majority of the Board of Directors then in office, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition, Section 203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change in control of our company, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.31;margin:9.19pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3c2a2791_f7ac_4755_857e_7ce006e1a98a"></a><a id="Item1BUnresolvedStaffComments"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">None.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Item1CCybersecurity"></a><a id="_0faff31a_ea49_48f7_abaa_343967648148"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 1C. Cybersecurity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risk management and strategy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">We rely on our information technology to operate our business and provide our Barostim Therapy to patients. We have policies and processes designed to protect our information technology systems, some of which are managed by third parties, and resolve issues in a timely manner in the event of a cybersecurity threat or incident.  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As part of our broader risk management framework, we have identified the potential cybersecurity risks to our business. We have designed our business applications and hosting services to minimize the impact that cybersecurity incidents could have on our business and have identified back-up systems where appropriate. We seek to further mitigate cybersecurity risks through a combination of monitoring and detection activities, use of anti-malware applications, employee training, quality audits and communication and reporting structures, among other processes. We have an incident response plan in place that outlines containment, eradication and recovery plans in the event of a cybersecurity threat or incident.  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We engage a third-party consultant to assist us with designing controls and our cybersecurity risk management framework. We are also engaging with a third party to perform penetration testing. We also retain third parties to assist with the monitoring and detection of cybersecurity threats and responding to any cybersecurity threats or incidents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">With respect to third parties that manage or use our information technology or data, we obtain reports to assess the security of their systems and processes. We engage in ongoing monitoring of all third-party providers to ensure compliance with our cybersecurity standards. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have not encountered cybersecurity threats or incidents that have had a material impact on our business.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Governance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our Board of Directors recently assigned specific oversight responsibility for cybersecurity to our Audit Committee, which also oversees our general risk management. The Audit Committee reviews and discusses with management our policies, practices and risks related to information security and cybersecurity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our chief financial officer has primary responsibility for assessing, monitoring and managing cybersecurity risks. Leaders of our information technology and device engineering, together with members of our finance team, comprise our Cybersecurity Committee, which meets to assess cybersecurity risks and identify new risks and assess our risk management framework on a quarterly basis. Among the members of this committee are employees who are knowledgeable about our products and systems, have prior experience managing cybersecurity risks, and maintain an active Certified Information Systems Security Professional certification. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our chief financial officer provides an update to the Audit Committee on any risks related to cybersecurity on a quarterly basis. Our incident response plan includes notifying the Audit Committee, and then the Board of Directors, of any material threats or incidents that arise.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_edf68583_cbed_40e8_952e_d7d3db5a1b7a"></a><a id="Item2Properties"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 2. Properties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We lease <span style="background:#ffffff;">31,505 </span>square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and expires <span style="background:#ffffff;">August 31, 2028</span>. We intend to add new facilities as we grow and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_a503c080_640c_4c54_86ba_1ecee0fc7394"></a><a id="Item3LegalProceedings"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;3. Legal Proceedings</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the<span style="letter-spacing:0.25pt;"> </span>ordinary course of our business. We are not currently a party to any material legal proceedings.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_38e32fd6_1b6c_47bd_912f_9d3990dcd289"></a><a id="Item4MineSafetyDisclosures"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;4. Mine Safety Disclosures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Not applicable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2ab85076_d605_475f_a67b_a3d92ef9d90e"></a><a id="PARTII"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PART II</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a47f7654_1ab0_448d_9730_e75a8acbcc18"></a><a id="Item5MarketforRegistrants"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity</b><b style="font-size:12pt;font-weight:bold;">, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;CVRX.&#8221;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of February 2, 2024, there were approximately 68 holders of record of our common stock. This number does not include stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our capital stock. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our Board of Directors, subject to applicable laws, and will depend on then existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our Board of Directors may deem relevant. Our Loan Agreement with Innovatus restricts us from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_97bd64f4_f3b3_4a5c_b5f7_c97693f74e40"></a><a id="Item6Reserved"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 6. [Reserved]</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cc7ca1ff_188f_4a71_9f53_684f450e524c"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;7. Management&#8217;s Discussion and Analysis</b><b style="font-size:12pt;font-weight:bold;"> of Financial Condition and Results of Operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Overview</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Our proprietary platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the Autonomic Nervous System, which causes HFrEF and other cardiovascular diseases. Our second-generation product, Barostim, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with HFrEF. Barostim provides Baroreflex Activation Therapy by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is currently indicated by the FDA for patients who are NYHA Class III or II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices), have a LVEF &#8804;&#8239;35% and a NT-proBNP &lt; 1600 pg/m and is CE Marked for HFrEF and resistant hypertension.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since our inception our activities have consisted primarily of developing Barostim Therapy, conducting our BeAT-HF pre-market and post-market pivotal studies in the U.S. and filing for regulatory approvals. Our ability to generate significant revenue from product sales and become profitable will depend on our ability to continue to successfully commercialize Barostim and any product enhancements we may advance in the future. We expect to derive future revenue by continuing to both expand our own dedicated salesforce and increase awareness of Barostim among payors, physicians and patients.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our sales and marketing efforts are directed at EPs, HF specialists, interventional and general cardiologists and vascular surgeons because they are the primary users of our technology. However, we consider hospitals, where the procedures are performed primarily in an outpatient setting, to be our customers, as they are the purchasing entities of Barostim in the U.S. We intend to continue making significant investments building our U.S. commercial infrastructure by expanding and training our U.S. sales force. We have dedicated significant resources to educate physicians who treat HFrEF about the advantages of Barostim and train them on the implant procedure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The costs for the device and implantation procedure are reimbursed through various third-party payors, such as government agencies and commercial payors. In the U.S., we estimate that 67% of our target patient population is Medicare-eligible based on the age demographic of the HFrEF patient population indicated for Barostim. As a result, we have prioritized coverage by the CMS while simultaneously developing processes to engage commercial payors. All MACs have retired their official automatic coverage denial policies for our CPT codes, thereby allowing hospitals to submit payment requests for the Barostim procedure to be adjudicated on a claim-by-claim basis. Our reimbursement strategy involves continuing to broaden our current coverage and build our in-house market access team to obtain appropriate prior authorization approvals in advance of treatment on a case-by-case basis where positive coverage policies currently do not exist. Outside the U.S., reimbursement levels vary by country and within some countries by region. Barostim is eligible for reimbursement in certain countries in the EEA, such as Germany, where annual healthcare budgets for the hospital generally determine the number of patients to be treated and the prices to be paid for the related devices that may be purchased.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We manage all aspects of manufacturing operations and product supply of Barostim, which include final assembly, testing and packaging of our IPG and stimulation lead, at our headquarters in Minneapolis, Minnesota. We utilize components or various subassemblies manufactured by third-party suppliers, some of which have significant lead times. Many of these components are from a limited number of suppliers. We believe that our component manufacturers are recognized in their field for their competency to manufacture the respective portions of Barostim and have quality systems established that meet FDA requirements. We seek to maintain higher levels of inventory to protect ourselves from supply interruptions and continue to seek to broaden and strengthen our supply chain through additional sourcing channels.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From our inception until the IPO, we financed our operations primarily through preferred stock financings, and additionally, from sales of our Barostim products and amounts borrowed under our credit facilities. We then devoted substantially all of our resources to research and development activities related to Barostim Therapy, including clinical and regulatory initiatives to obtain marketing approval and sales and marketing activities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We used a portion of the IPO proceeds to continue funding the expansion of our direct sales force and commercial organization related to Barostim in the U.S. We have continued investing in research and development to improve clinical outcomes, optimize patient adoption and comfort, increase patient access, and enhance the physician and patient experience. Longer term, we plan to explore Barostim&#8217;s potential to expand its indications for use to other cardiovascular diseases. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On October 31, 2022, we entered into the Loan Agreement under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0 million in a series of Term Loans described in Note 4 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, and we borrowed $7.5 million of such total on that date to fund our commercial and investment efforts. On March 10, 2023, we borrowed the $7.5 million remaining under the first tranche of the Loan Agreement. On December 15, 2023, we borrowed $15.0 million under the second tranche of the Loan Agreement. We had $30.0 million in outstanding Term Loans under the Loan Agreement at December 31, 2023.&#160;<span style="background:#ffffff;">The Loan Agreement provides for an additional tranche of up to $20.0 million, based on the timing and other conditions set forth in the Loan Agreement</span>.&#160;As a result of these investments and our commercialization efforts, we expect to continue to incur net losses for the next several&#160;years, which may require additional funding and could include future equity and debt financing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recent developments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">In December 2023, the FDA approved expanded labeling for Barostim based on the BeAT-HF trial data, resulting in simplification and clarification of the indications for use as well as inclusion of the primary endpoint results, the 6, 12 and 24 month symptomatic data, the Win Ratio and the all-cause mortality data in the &#8220;Clinical Summary&#8221; discussion included in Barostim&#8217;s indications for use. We currently believe this would increase our annual market opportunity in the U.S. to an estimated $2.2&#8239;billion, or 76,000 patients, based on this new long-term safety and </span>effectiveness<span style="background:#ffffff;"> data as well as our commercial experience and, as discussed below, the new reimbursement assignment for Barostim in 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">In the 2024 OPPS final rule issued in November 2023, Barostim was reassigned to New Technology APC 1580, which carries an average payment amount of $45,000. The new payment took effect January 1, 2024.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Factors affecting our performance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe there are several important factors that have impacted and that we expect will continue to impact our business and results of operations. These factors include:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Growing and supporting our U.S. commercial organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Seeking expanded labeling for Barostim and promoting awareness among physicians, hospitals and patients to accelerate adoption of Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising awareness among payors to build upon reimbursement for Barostim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Investing in research and development to foster innovation and further simplify the Barostim procedure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Leveraging our manufacturing capacity to further improve our gross margins.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Components of results of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Revenue</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our U.S. sales have steadily increased since the pre-market approval of Barostim by the FDA in August&#160;2019, and the subsequent reimbursement changes. We expect to continue to drive increases in revenue through our efforts to increase awareness of Barostim among physicians, patients and payors, and by the expansion of our U.S. sales force, as well as by seeking expanded labeling for Barostim. As a result, we expect that U.S. sales will continue to account for the majority of our revenue going forward.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We derive a portion of our revenue from the sale of Barostim to hospitals in Germany and other select countries in Europe. Revenue from sales of Barostim in Europe fluctuates based on the average selling price of Barostim as determined by location of sale and channel mix, each of which may vary significantly from country to country. Our revenue from international sales can also be significantly impacted by fluctuations in foreign currency exchange rates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cost of goods sold and gross margin</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold consists primarily of acquisition costs of the components and subassemblies of Barostim, allocated manufacturing overhead and scrap and inventory obsolescence, as well as distribution-related expenses such as logistics and shipping costs. We expect cost of goods sold to increase in absolute dollars primarily as, and to the extent, our revenue grows. Gross margin may also vary based on regional differences in rebates and incentives negotiated with certain customers.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We calculate gross margin as revenue less cost of goods sold divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, but is primarily driven by the average sale price of our product, the&#160;percentage of products sold that include a full system (i.e., an IPG and a stimulation lead), as compared to individual IPG sales, and the allocated manufacturing overhead. Although we sell the majority of our devices directly to hospitals, the impact of the average selling price on gross margin is driven by the&#160;percentage of products we sold to distributors as compared to those sold directly to hospitals, as our average selling price is typically higher on products we sell directly. The full system sales typically have a lower gross margin as they include the cost of an IPG and a stimulation lead whereas individual IPG sales only include the cost of an IPG.&#160;The manufacturing overhead costs of Barostim are directly aligned to our production volume and therefore the cost per product is reduced if production levels increase. While we expect our gross margin to be positively affected over time to the extent we are successful in selling more product through our direct sales force and by increasing our production volumes, it will likely fluctuate from period to period as we continue to introduce new products and adopt new manufacturing processes and technologies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Research and development expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) expenses consist primarily of personnel costs, including salaries, bonuses, employee benefits and stock-based compensation expenses for our R&amp;D employees. R&amp;D expenses also include costs associated with product design efforts, development prototypes, testing, clinical trial programs and regulatory activities, contractors and consultants, equipment and software to support our development, facilities and information technology. We expense R&amp;D costs as they are incurred. We expect R&amp;D expenses to increase in absolute dollars as we continue to develop enhancements to Barostim. Our R&amp;D expenses may fluctuate from period to period due to the timing and extent of our product development and clinical trial expenses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Selling, general and administrative expenses</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses consist primarily of personnel costs, including base salaries, bonuses, employee benefits and stock-based compensation expense for our sales and marketing personnel, including sales commissions, and for administrative personnel that support our general operations such as executive management, financial accounting, information technology and human resources personnel. SG&amp;A expenses also include costs attributable to marketing, as well as travel, legal fees, financial audit fees, insurance, fees for other consulting services, depreciation and facilities. We expense commissions at the time of the sale.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect SG&amp;A expenses to increase in absolute dollars as we continue to expand our direct sales force and commercial organization in the U.S. In addition, we will continue to increase our international presence and to develop and assist our channel partners. However, we expect our SG&amp;A expenses to decrease as a&#160;percentage of revenue as our revenue grows.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Interest expense</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense consists of interest on our debt and amortization of associated financing costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Other income, net</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other income, net consists primarily of interest income on our interest-bearing accounts, partially offset by the effect of exchange rates on our foreign currency-denominated asset and liability balances. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Provision for income taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes consists primarily of income taxes in foreign jurisdictions in which we conduct business. We maintain a full valuation allowance for deferred tax assets including NOL carryforwards, R&amp;D credits and other tax credits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Results of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Consolidated results of operations for the year ended December 31, 2023, compared to the year ended December 31, 2022</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,256</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,999</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,257</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33,039</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,470</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 89</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 84</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,952</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,681</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 64,509</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,045</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,464</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76,142</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 59,997</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,145</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43,103)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (42,527)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (576)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,799)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (165)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,634)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">NM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,850</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,373</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (41,052)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (41,319)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 267</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (147)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (109)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (38)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (41,199)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (41,428)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 229</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NM &#8211; Not meaningful</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;"><i style="font-style:italic;">Revenue</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:35.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue by Geography</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,090</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 95</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,184</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,448</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (264)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:61.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,469</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue was $39.3 million for the year ended December 31, 2023, an increase of $16.8 million, or 75%, over the year ended December 31, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue generated in the U.S. was $35.1 million for the year ended December 31, 2023, an increase of $17.1 million, or 95%, over the year ended December 31, 2022. HF revenue in the U.S. totaled $34.6 million and $17.6 million for the years ended December 31, 2023 and 2022, respectively.&#160;The increase was primarily driven by continued growth as a result of the expansion into new sales territories and new accounts, as well as increased physician and patient awareness of Barostim. Total HF revenue units in the U.S. totaled 1,123 and 587 for the years ended December 31, 2023 and 2022, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">As of December 31, 2023, we had a total of 178 active implanting centers, as compared to 106 as of December 31, 2022. Active implanting centers are customers that have completed at least one commercial HF implant in the last 12 months. The number of sales territories in the U.S. increased by 12 to a total of 38 during the year ended December 31, 2023. A sales territory is an established regional area held by an account manager, typically after six to nine months of employment. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Revenue generated in Europe was $4.2 million for the year ended December 31, 2023, a decrease of $0.3 million, or 6%, over the year ended December 31, 2022. Total revenue units in Europe decreased to 207 for the year ended December 31, 2023, from 231 for the prior year period. The number of sales territories in Europe remained consistent at six during the year ended December 31, 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cost of goods sold and gross margin</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of goods sold increased $1.3 million, or 25%, to $6.3 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. This increase was primarily due to higher sales of Barostim.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Gross profit was $33.0 million for the year ended December 31, 2023, an increase of $15.6 million, or 89%, over the year ended December 31, 2022. Gross margin increased to 84% for the year ended December 31, 2023, compared to 78% for the year ended December 31, 2022. Gross margin for the year ended December 31, 2023 <span style="background:#ffffff;">was higher due to a decrease in the cost per unit and an increase in the average selling price. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and development expenses</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses increased $1.7 million, or 17%, to $11.6 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. This change was primarily driven by a $1.7 million increase in compensation expenses, mainly as a result of increased headcount and a $0.6 million increase in non-cash stock-based compensation expense, partially offset by a $0.8 million decrease in clinical study expenses.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Selling, general and administrative expenses</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">SG&amp;A expenses increased $14.5 million, or 29%, to $64.5 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. This change was driven by a $8.6 million increase in compensation expenses, mainly as a result of increased headcount, a $2.3 million increase in marketing and advertising expenses, primarily related to the commercialization of Barostim in the U.S., a $1.8 million increase in non-cash stock-based compensation expense, a $1.5 million increase in travel expenses and a $1.0 million increase in consulting expenses, partially offset by a $0.3 million decrease related to D&amp;O insurance costs and a $0.2 million decrease in professional fees.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest expense</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest expense increased $1.6 million, to $1.8 million for the year ended December 31, 2023, compared to the year ended December 31, 2022. <span style="background:#ffffff;">This increase was driven by the interest expense on borrowings under the Loan Agreement entered into on October 31, 2022.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other income, net</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other income, net was $3.9 million for the year ended December 31, 2023, compared to $1.4 million for the year ended December 31, 2022. <span style="background:#ffffff;">This increase was primarily driven by higher interest rates on interest-bearing accounts partially offset by a lower cash balance.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Provision for income taxes</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provision for income taxes was nominal for the years ended December 31, 2023 and 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Liquidity, capital resources and plan of operations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception, and we anticipate that we will incur significant losses for at least the next several&#160;years. As of December 31, 2023 and 2022, we had cash and cash equivalents of $90.6 million and $106.2 million, respectively. For the years ended December 31, 2023 and 2022, our net losses were $41.2 million and $41.4 million, respectively. Our net cash used in operating activities for the years ended December 31, 2023 and 2022, was $39.0 million and $42.7 million, respectively. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On October 31, 2022, we entered into the Loan Agreement under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0 million in a series of Term Loans described in Note 4 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, and we borrowed $7.5 million of such total on that date to fund our commercial and investment efforts. On March 10, 2023, we borrowed the $7.5 million remaining under the first tranche of the Loan Agreement. On December 15, 2023, we borrowed $15.0 million under the second tranche of the Loan Agreement. We had $30.0 million in outstanding Term Loans under the Loan Agreement at December 31, 2023.&#160;The Loan Agreement provides for an additional tranche of up to $20.0 million, based on the timing and other conditions set forth in the Loan Agreement.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On November 4, 2022, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Co., as agent, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0 million in an &#8220;at-the-market&#8221; or ATM offering, to or through the agent. As of December 31, 2023, no shares have been sold. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future liquidity and capital funding requirements will depend on numerous factors, including:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our investment in our U.S. commercial infrastructure and sales forces;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of market acceptance of Barostim and the ability for our customers to obtain appropriate levels of reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including product sales, marketing, manufacturing and distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our R&amp;D activities for product enhancements and to expand our indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our need to implement additional infrastructure and internal systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire additional personnel to support our operations as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing technologies or other adverse market developments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that our existing cash resources and Loan Agreement for Term Loans together with revenue will be sufficient to meet our forecasted requirements for operating liquidity, capital expenditures and debt services for at least the next three years. If these sources are insufficient to satisfy our liquidity requirements, or provide funding to execute or accelerate our growth strategies, however, we may seek to sell additional equity or enter into an additional loan agreement. If we raise additional funds by issuing equity securities, our stockholders would experience dilution. Additional debt financing, if available, may involve covenants further restricting our operations or our ability to incur additional debt. Any such debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additional financing may not be available at all or may only be available in amounts or on terms that we do not deem to be favorable. If we are unable to obtain additional financing when needed to satisfy our liquidity requirements, we may be required to delay the commercialization and marketing of Barostim.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Cash flows</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the primary sources and uses of cash for each of the periods presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39,021)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,677)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (591)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (685)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,984</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,493</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effect of exchange rate changes on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,625)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35,878)</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash used in operating activities</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2023 was $39.0 million and consisted primarily of a net loss of $41.2 million and a decrease in net operating assets of $4.8 million, partially offset by $6.3 million from non-cash stock-based compensation expense, $0.5 million from the depreciation of property and equipment and $0.2 million from amortization of deferred financing costs and loan discount. <span style="background:#ffffff;">Net operating assets consisted primarily of inventory, accounts receivable, prepaid expenses and other current assets, accrued expenses to support the growth of our operations and accounts payable.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the year ended December 31, 2022 was $42.7 million and consisted primarily of a net loss of $41.4 million and a decrease in net operating assets of $5.6 million, partially offset by $3.9 million from non-cash stock-based compensation expense and $0.4 million from the depreciation of property and equipment. <span style="background:#ffffff;">Net operating assets consisted primarily of inventory, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses to support the growth of our operations.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities was $0.6 million and $0.7 million for the years ended December 31, 2023 and 2022, respectively, and consisted of purchases of property and equipment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2023 was $24.0 million <span style="background:#ffffff;">and consisted of $22.5 million related to proceeds from debt financing, $0.9 million related to proceeds from the </span>Employee Stock Purchase Plan <span style="background:#ffffff;">and $0.7 million related to proceeds from the exercise of common stock options, </span>partially offset by debt financing costs of $0.2 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities for the year ended December 31, 2022 was $7.5 million <span style="background:#ffffff;">and consisted of $7.5 million related to proceeds from debt financing, $0.6 million related to proceeds from the </span>Employee Stock Purchase Plan <span style="background:#ffffff;">and $0.2 million related to proceeds from the exercise of common stock options, </span>partially offset by debt financing costs of $0.8 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Indebtedness</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">On October 31, 2022, we entered into the Loan Agreement with Innovatus, as the collateral agent and a lender, under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0&#160;million in a series of term loans. On the closing date, we borrowed the minimum amount of $7.5&#160;million under the Loan Agreement. </span>On March 10, 2023, we borrowed the $7.5 million remaining under the first tranche of the Loan Agreement. On December 15, 2023, we borrowed $15.0 million under the second tranche of the Loan Agreement. <span style="background:#ffffff;">The term loans advanced pursuant to the Loan Agreement (collectively, the &#8220;Term </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Loans&#8221;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii)&#160;5.50% plus (b)&#160;2.65%. The Term Loans mature on January 31, 2028 and require interest-only payments until November&#160;1, 2027. The Term Loans are secured by substantially all of our personal property. We have the option to draw down&#160;up to $20.0 million between September&#160;1, 2024 and December&#160;15, 2024 if we achieve trailing three months revenue of $9.0 million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding requiring that we achieve 50% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period.</span><span style="font-family:'Times New Roman','Times','serif';background:#ffffff;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Critical accounting policies and estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and judgments that affect the amounts reported in our consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable and supportable under the circumstances. The results of this evaluation then form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and such differences may be material to our consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following discussion addresses our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require our most difficult, subjective and complex judgments.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Stock-based compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain an equity incentive plan that was adopted in 2001 to provide long-term incentives for employees, consultants and members of the Board of Directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. In connection with the IPO, we adopted the 2021 Equity Incentive Plan under which we may grant equity incentive awards to eligible employees (including our named executive officers), non-employee directors and consultants in order to enable us to obtain and retain services of these individuals, which we deem as essential to our long-term success.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We use an estimate of the value of our common stock, with the assistance of an independent appraiser, to determine the fair value of options.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i)&#160;the fair value of common stock, (ii)&#160;the expected share price volatility, (iii)&#160;the expected term of the award, (iv)&#160;the risk-free interest rate and (v)&#160;the expected dividend yield.</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Fair value of common stock&#160;&#8212; For valuations after the completion of the IPO, our Board of Directors determines the fair value of each share of common stock based on the closing price of our common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in our assumptions or market conditions.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected share price volatility&#160;&#8212; Due to the lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar (guideline) companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of guideline companies have characteristics similar to us, including stage of product development and focus </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">on the life science industry.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected term of an award&#160;&#8212; Determined based on our analysis of historical exercise behavior while taking into consideration various participant demographics and option characteristics. We utilize the simplified method to develop the estimate of the expected term.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Risk-free interest rate&#160;&#8212; Based on a treasury instrument whose term is consistent with the expected term of the stock options.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expected dividend yield&#160;&#8212; We assume an expected dividend yield of zero, as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;) permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A discussion of recent accounting pronouncements is included in Note&#160;2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</p><a id="_fbb2cac9_426a_473d_b5f6_13d29c5afda6"></a><a id="Item7QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Interest rate risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The risk associated with fluctuating interest rates is primarily limited to our cash equivalents and debt under the Loan Agreement, which are carried at quoted market prices and the prime rate, respectively. We do not currently use or plan to use financial derivatives in our investment portfolio.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Foreign currency exchange rate risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Portions of our revenue and operating expenses that are incurred outside the U.S. are denominated in foreign currencies and subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the Euro. Additionally, fluctuations in foreign currency exchange rates may cause us to recognize transaction gains and losses in our statements of operations and comprehensive loss. To date, foreign currency transaction realized gains and losses have not been material to our consolidated financial statements, and we have not engaged in any foreign currency hedging transactions. As our international operations grow, we will continue to reassess our approach to managing the risks relating to fluctuations in currency rates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Inflation risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflationary factors, such as increases in our cost of goods sold and operating expenses, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain and increase our gross margin and selling and marketing and operating expenses as a&#160;percentage of our revenue if the selling prices of our products do not increase as much as or more than these increased costs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Credit risk</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023 and 2022, our cash and cash equivalents were maintained with financial institutions which we believe have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us; however, our cash balances were in excess of insured limits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;8. Financial Statements and Supplementary Data</b></p><a id="_882117f2_10d3_46fb_8e08_d6c10e482c3f"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Board of Directors and Stockholders</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">CVRx, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the financial statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">We have audited the accompanying consolidated balance sheets of CVRx, Inc. (a Delaware corporation) and subsidiary (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company<span style="color:#0000ff;"> </span>as of December 31, 2023 and 2022, and the results of its<span style="color:#0000ff;"> </span>operations and its<span style="color:#0000ff;"> </span>cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:8pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:AuditorName" id="Narr_jdYvAK8oS0W6GFiLKqpq7w">GRANT THORNTON LLP</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2016.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:AuditorLocation" id="Narr_Jkven45CVEiQMEj9UWgBcQ">Minneapolis, Minnesota</ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">February 9, 2024</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d6b74642_5475_4ab9_9823_fc635b2dc2b2"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedBalanceSheets_40430"></a><a id="ConsolidatedBalanceSheets"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_a954118e_803a_45fd_8f19_da53077d6187"></a><a id="Tc_Y5syf_TMqkCWCBo5dziUwA_1_2"></a><a id="Tc_J1vdaLk790G233UCfLXp5g_1_5"></a><a id="Tc_yc9hvBCSoEuZo2sZDnHuww_2_2"></a><a id="Tc_mBtBLcHHPEyEwu8He_Y1Yw_2_5"></a><a id="Tc_Yp5wkPKMykm5URV_5H8HOQ_3_0"></a><a id="Tc_35rZ_6rRiEiCRu6dwm4tAw_4_0"></a><a id="Tc__S1Nr1NPZE2bzJmoZ31OfQ_5_0"></a><a id="Tc_-lKSi1JyiUu8TsjL4zdHhQ_5_2"></a><a id="Tc_-_clX4ur90uVhZJC_fJQKA_5_5"></a><a id="Tc_F2VgFJRm7kaquZmHE6Ufjw_6_0"></a><a id="Tc_xS7dJomcrE-fprM84reL_g_7_0"></a><a id="Tc_hYPdaYK7Ck-TgraRmV9NBA_8_0"></a><a id="Tc_UvU76Sfg8kueGAj8IFt7vA_9_0"></a><a id="Tc_J21eDtyepkuqhBw-zbKuVA_10_0"></a><a id="Tc_j3YhlR_0ukOR8_O94pswBg_11_0"></a><a id="Tc_ktveM6GRjkis0b1GhCsAMA_12_0"></a><a id="Tc_2NUcma64LkeZyhbPbWJMlw_13_0"></a><a id="Tc_NKT2LkIyUkC8wqy8FrjZGQ_13_2"></a><a id="Tc_ButVF51hckuKMeMv1AnaZg_13_5"></a><a id="Tc_gMDlPW6boUe9dEW7oxpUIA_14_0"></a><a id="Tc_SF3Z2g-ffkSO4_m7jIyUCg_15_0"></a><a id="Tc_S6277CGd1UGqHAmoSjXWDA_16_0"></a><a id="Tc_YggyVV3h9kK__S6QBu-kUw_16_2"></a><a id="Tc_48T9w67240CDI52Iq-t3QQ_16_5"></a><a id="Tc_ywJzoWcB0ES06vu3kzuSUw_17_0"></a><a id="Tc_8-jO0NxdJk2jc7vav2YYAg_18_0"></a><a id="Tc__Kz7_5c1Vk2ThIVby9SfnA_19_0"></a><a id="Tc_kx44PlAwfEa-MdHBFYyZhQ_20_0"></a><a id="Tc_4Fv9Y4cVAEy8k-WQkWRnFA_21_0"></a><a id="Tc_dOjiR7o2tEarrVM5R875Kw_22_0"></a><a id="Tc_fuxEqqiGk0OlMHd7h0_p_A_23_0"></a><a id="Tc_AMJjHJnYSUyuqhDkhJThvg_24_0"></a><a id="Tc_eg8QPCKncEyV3MTo7A2Lsg_25_0"></a><a id="Tc_XF8Siw6ptU-j9jVGfFGB5Q_26_0"></a><a id="Tc_xmXfZEF9fEm2LdL154mugg_27_0"></a><a id="Tc_S9BJds4whkKerKE-DN7I_A_28_0"></a><a id="Tc_95hKh7Ej1UmfdbGj4392SQ_29_0"></a><a id="Tc_vNu-JajkkECHqMM2N2ktLA_30_0"></a><a id="Tc_7mmQqMnxJ0-kSBxpglvSVw_30_2"></a><a id="Tc_yQyaFBNIokykv3kYjMvDkg_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LzNvCaLZHkK_71AbctLdwg_5_3">90,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_y8-LQuKdSU2Wjtnw-Vab9Q_5_6">106,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_6zjtccf1QkCvr5XQDMgErA">508</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="Narr_PHPryfE8I0agf3rPgJrEmw">679</ix:nonFraction>, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_SfcDMXCGzUu-mVKMS0nARQ_6_3">7,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_M1ScxOsAk0W9VVnytzWzpQ_6_6">5,504</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_p7kqH38ZFE-HTPFruPaHxA_7_3">10,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_OcGLenrbNUScmu79B_N1tA_7_6">6,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_fiLcsXhE60Og1xdqSeNvww_8_3">2,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_3IsdG-FM3kyENSdxD2NPHQ_8_6">4,223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_JJAqpTqgQE-84wQRIFaP6Q_9_3">112,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_rE4BNfIVtECdaz9ZMTaDeQ_9_6">122,878</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_wDJjkDVjdUKA6md7ZSnnbA_10_3">1,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ajSyAF8clkiGL-5KD6mg5g_10_6">1,698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_sNUZeLp580SjHsNQEoVaQA_11_3">1,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_pEs2atZs9ka7UCUMInNG5A_11_6">334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_vFE2VnGVh0at2t6d9EQ-Pw_12_3">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_3CC3HuU4nE2zyou0osUO2A_12_6">27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_xXWprTAd_k-Pzf3fO081kA_13_3">115,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_1meMNhWAJEKxDPoaygTF0w_13_6">124,937</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Uf0O5tIBVk67i-NrBbCiZA_16_3">1,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_41rTQJ4zA06GoXx7PYg25A_16_6">1,719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_5F52MHYx1Uix1LogfdCmxg_17_3">5,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_TSQzI7TtREeZ8HaEZ-DmqA_17_6">6,369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_w2GRfU84AUOGdd4OyV9hYQ_18_3">7,864</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_SiziKAKlbkWjBFYvp4PGpA_18_6">8,088</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_0_PHEjJcPk6hvLSazPaCcw_19_3">29,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_EofeAGeBZ0e34-EqfmFv4Q_19_6">6,747</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ZIDQkJpH6U2OWU2iMdfS6g_20_3">1,160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ldPR3t1WMEy14r0mE6kXdQ_20_6">117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_F8i9bBltEk6WQ9jaQVOZ9A_21_3">1,036</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_uwaz2O4HeUGC81ynuhaODQ_21_6">805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Hbg7oBuPf0GLRMwS5V-Nfw_22_3">39,282</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_7TkXTJj5iEao-hgRMXsVKA_22_6">15,757</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_0OjycGWTKUqai0GtyK5leA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_hJfdqvljQEKWrKfV-mRwug">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_JaxzQX74g0OME_vRoXqITg"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_fvAAWWgeAEmvi5e2n_4AoQ">200,000,000</ix:nonFraction></ix:nonFraction> authorized as of December&#160;31,&#160;2023 and 2022; <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_eQgGNiZirEWj5ZujRN_sfQ">20,879,199</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr__c9B3EO8PES2nAk_JhV4Sw">20,663,736</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_OpBAXBMwEk6NYw4JEdrq0g;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_q21DJISsyEqTNoQ9KQzmfA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December&#160;31,&#160;2023 and 2022, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_WxLsmixnpE-v8pjxLMsw7g_25_3">209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_PMdPTAtmd0yrGt5RxxkP4A_25_6">207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_FyDhBr_NM0aedgqZAlvVbw_26_3">553,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_SYdVKlVeW0OzpiP9pR5ykA_26_6">545,362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_iilMjx0L502KaH6gIgzHPQ_27_3">477,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_-pbLq2CObUKuZqKtzjC5sg_27_6">436,182</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_JYZdptL3kkSlBZpmPEGj2g_28_3">207</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_ktQbUY62NEmeS5NUEkgo1A_28_6">207</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jF5N8QsbVEqF8BuDGxxPJQ_29_3">75,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YGWDMRi0XkC-mQtjj1yx2A_29_6">109,180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_brMZsG3rjU2mZIy-5vYv3g_30_3">115,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_K9ncy6C2v0C8djGOrDpCAg_30_6">124,937</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_12c4a711_ce28_4338_90bd_dacd1b9fe33a"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofOperati"></a><a id="ConsolidatedStatementofOperations"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b><b style="font-weight:bold;"> and Comprehensive Loss</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share data)</b></p><a id="_579d41a3_9f33_4f4c_acf4_58e7bb942d61"></a><a id="Tc_Bnquh7KRV06SAaR-deonuQ_1_2"></a><a id="Tc_ojrvavxO3EShadULEGVY_w_2_2"></a><a id="Tc_aBvVyBpkD0mFZjrgearrqQ_3_2"></a><a id="Tc_zdzvQ_AsA0eSY8dool0phg_3_5"></a><a id="Tc_O7qwZ6UC7USXfnmA1eJXCw_4_0"></a><a id="Tc_1Y1YCHKEkkOMhADzSb2K8Q_4_2"></a><a id="Tc_T5gvhiSxjU6dSLyhMk5pwg_4_5"></a><a id="Tc_YotctbANREKzDpJioug1Hw_5_0"></a><a id="Tc_zd3C4G12Akeacd8nHe9vGg_6_0"></a><a id="Tc_M1QC58ag_0mbUCw4U10Mbg_7_0"></a><a id="Tc_enunMvCD9kO8xfQpqJSqCw_8_0"></a><a id="Tc_N93qGgrS90SvpqYTpkrkSg_9_0"></a><a id="Tc_aLopFNv_jEWMW3920vYjdg_10_0"></a><a id="Tc_diU649R5CUq8aFFUF0unfA_11_0"></a><a id="Tc_JTedodQJlky3QNyEnJwGcw_12_0"></a><a id="Tc_SeVNd2PfGEab_6JMfHf__w_13_0"></a><a id="Tc_i0DgFsRQ4Uqd9BzZiBzYSw_14_0"></a><a id="Tc_aVoalGZdiUW4KFTVCoWBrA_15_0"></a><a id="Tc_844WAJAMVEKFtmsukLunGg_16_0"></a><a id="Tc_vOv5EzlzsEeHo7VoU_jneg_17_0"></a><a id="Tc_Cf1s7cQyWUCQgLn6VRQ69Q_17_3"></a><a id="Tc_roFX7UJjXESzhIUOJacm4w_18_0"></a><a id="Tc_fo3_ZFmSRUavW-OK8Uf1FA_18_2"></a><a id="Tc_8oYpraqZkkWUTF2zx8sw4g_18_5"></a><a id="Tc_NojbgKwB_0uoWuylY3rfMg_19_0"></a><a id="Tc_-vxMeXeIxUuS-hFBCnPdfg_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.08757782%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_yFv_QR1-dUiJA6FhnZxxFA_4_3">39,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_99t4lMrK0kq4x4BNTRAeWg_4_6">22,469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_cs8SrOhS80GJJ2ZCe6Nmdw_5_3">6,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_MqkyAV_t1Emt9iq3PjrYCg_5_6">4,999</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_vXX5WOyaG0GT0N6bRSQNMA_6_3">33,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="Tc_IGp2q3uhQkijpxeFug6Eog_6_6">17,470</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Ju0sHZLp0UKKixxUXGL64w_8_3">11,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_-UAxBaOfpkOJwf1Yx4zFhw_8_6">9,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_9LOFJq3CD0O1S1RVQMiy8Q_9_3">64,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_V2gTLcCUcUGI-AXeR3iNlw_9_6">50,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Jq4jc1fVkUeym8S1bln_UA_10_3">76,142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_O5zQaBLjvESSFE2ky-YRjw_10_6">59,997</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_S74QEmYkBU-W-9vuA3w7FQ_11_3">43,103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_4DszrbNF-EmiVe7jG45W0g_11_6">42,527</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_iOZehtDDGEyYOKnj9rW-uQ_12_3">1,799</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_h9iFFzrHqUCMyoH2TFj2XQ_12_6">165</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_gcQRMT5luUe31TNfRTO01Q_13_3">3,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_voSYtGsxoEezBcQpiYPtHg_13_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_q1XEVG2cUUagqMkGHD38EA_14_3">41,052</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_HqT2oY414U6BsOeNK8GAaA_14_6">41,319</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_6mTa21kqAkiuKuf7PUkGwQ_15_3">147</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_MrLcMFqoh0W6jJDuGHpttg_15_6">109</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nW0RPcdM6Ea9rWBITEPykg_16_3">41,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0pIEMAMSsECLyrlqfms94A_16_6">41,428</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_TAKYC--ftEKSN4zbPFuPSA_17_6">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_dzDrdnhol0yUUIx51b_nlQ_18_3">41,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_wi8-g5Tmh0--UheY1f0SJQ_18_6">41,437</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yFT6SI8hckSwZ0Z0oJRWgA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_0mK8p8c0KUacFJ5OeSy2Qw_19_3">1.99</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_RJz8J98SB06oqS-Wx5ZSrA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_yaXitwVM-UehuJJEzJN2eA_19_6">2.02</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:56.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average common shares used to compute net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_7XWY7J1LgkG6WC-ktMhGnw_20_3">20,754,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_3te3EkcuHEGdpCAf6gVY9A_20_6">20,532,838</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_431c3652_2e4a_4e9b_a9db_455ae600d1ba"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofConvert"></a><a id="ConsolidatedStatementsofConvertiblePrefe"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; </b><b style="font-weight:bold;">Equity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share data)</b></p><a id="_45a2d059_abac_469f_bf01_48c87d7d582a"></a><a id="Tc_WVL-0m3jjUallG-QSRrIqQ_1_13"></a><a id="Tc_JhY52ehBiECqmK_tyxTWRQ_2_7"></a><a id="Tc_nhg_5feTvU6rHaPFiCeKXw_2_13"></a><a id="Tc_BhelRyZo4kuq9STz2F-b6g_2_16"></a><a id="Tc_h2EiUoxc1EiccJIgP5Htrg_3_2"></a><a id="Tc_ImTDOElWQUO2QTK0XC0ZiQ_3_7"></a><a id="Tc_34GzSYI2bUun67CTBuZGKQ_3_10"></a><a id="Tc_uv936TpnUUWv8M6Kh1pvsQ_3_13"></a><a id="Tc_ml7KFpT7JkO3OzUx26uh3A_3_16"></a><a id="Tc_QVMSjLGWG0Sc4vXMDqduzg_4_2"></a><a id="Tc_Xyfn2BZtn0Co7huq0DVHlA_4_5"></a><a id="Tc_A6t-gxmGyE-KSoq8VORDWg_4_7"></a><a id="Tc_1xV4c1c2kUOKOM2tBQWuIw_4_10"></a><a id="Tc_k3-7XRRdAUK5YS6VVmgXGQ_4_13"></a><a id="Tc_zV1NDhcodkWWq-4d74FqyQ_4_16"></a><a id="Tc_JdwQ9goFb0SluIYSlrf2fQ_5_0"></a><a id="Tc_6wnxNpm1z0SRFQfth3YUhg_5_4"></a><a id="Tc_Fy9dgDkitUiPcIDqzR3ugg_5_7"></a><a id="Tc_-6BtK2ea50G5GjM8-S65gQ_5_10"></a><a id="Tc_b0eVB5mq5kO_-ob4YQg8oA_5_13"></a><a id="Tc_OZZyGUid9UKTstsasWJ5Ug_5_16"></a><a id="Tc_08UEL7XxZ0uZOgbSb3pJ1g_6_0"></a><a id="Tc_bSkaIXijTEOlevbVcl2ocw_6_11"></a><a id="Tc_sxads_KV2EGL67ojGZPsRQ_6_14"></a><a id="Tc_tGigadvTPE2hNiFVuOo2IA_7_0"></a><a id="Tc_NZPhSqXucUqTUTai7SSgWg_7_11"></a><a id="Tc_bOyuthGlCEm3raImLFyVOw_7_14"></a><a id="Tc_obljVKXW0U-R4YqoGXotFw_8_0"></a><a id="Tc_8Ti4xd7OGEaVvYj7R74sHA_8_2"></a><a id="Tc_6GjHTY1Mg0WE5jOgDDjBuQ_8_5"></a><a id="Tc_19lJvlfb0EOVjfmQEMUaIw_8_11"></a><a id="Tc_cOCackYTpkqeD9EuZeHZvQ_8_14"></a><a id="Tc_irR8UMPggkyE3uqwI3kxXw_9_0"></a><a id="Tc_9P2zXUCjbkyXpx-qNYFkLA_9_2"></a><a id="Tc_q-3n0eXB2UWgEcWtisxM9Q_9_5"></a><a id="Tc_iewFCEeVKEOzptFtsMxNpw_9_8"></a><a id="Tc_TFP9tCaxTUuKRkG8tIlX8g_9_14"></a><a id="Tc_fj-d7bvmhUKNi-qkU0ssjQ_10_0"></a><a id="Tc_5XrsDZVXYEKrW_lprDhxWQ_10_2"></a><a id="Tc_xXBEZmy1X0qtz98CNlgzLg_10_5"></a><a id="Tc_qa5Zxbc9FEKbcxuiSOGGwA_10_8"></a><a id="Tc_CtTpJlhZl0OOjdvBN5bTqA_10_11"></a><a id="Tc_pBN4voBAJkOYPKo_OpmD7g_11_0"></a><a id="Tc_lrUjpMT7ZkyliwIG4n0J7w_11_4"></a><a id="Tc_fSeaZwAoskWSSRjUorcm9Q_11_7"></a><a id="Tc_6_weKDFH3ECevKl_4rTuzQ_11_10"></a><a id="Tc_FgYY1nqePkahUDSGlaLjhg_11_13"></a><a id="Tc_XGnDlwG_gU66ADhMIeQRYg_11_16"></a><a id="Tc_iNkYp3oaE064fB7f__FRsA_12_0"></a><a id="Tc_UurH3lPU8ECmCGmfHthrJw_12_11"></a><a id="Tc_ElKxtHFizUCL9vjT4Slh3Q_12_14"></a><a id="Tc_z9rMPJOJP06qlaq_tSRAhA_13_0"></a><a id="Tc_n4atGB9idE2qJofh950rOQ_13_11"></a><a id="Tc_sFBQ5C1kj0OW_SbC3oAnug_13_14"></a><a id="Tc_avZI1okCQESdU-a2UJDHqA_14_0"></a><a id="Tc_udp7xGodB0qZ0ULiRKc4wQ_14_2"></a><a id="Tc_R5scvikO9EykBcqgwNKD2w_14_5"></a><a id="Tc_XztnS4Ywk0--Q7QSo5WR6g_14_11"></a><a id="Tc_nm9hSds8ZEmN98mb59n5tw_14_14"></a><a id="Tc_6BB2Q_hw7UKTfBVg8RqHsg_15_0"></a><a id="Tc_4jndySL_cEuV9vD9wciFrw_15_2"></a><a id="Tc_lIZ5oFiAL02k-iP8U4-kmA_15_5"></a><a id="Tc_l4yCxcUbLUGZqRrsGm7UUg_15_8"></a><a id="Tc_tsgiaYmi40eklkA2w5bwSA_15_14"></a><a id="Tc_m_MP0Ttgm02CviLkQFStGQ_16_0"></a><a id="Tc_qQ86rt07tkC_y0nEirtwnw_16_4"></a><a id="Tc_zNsGOuF2sUaa-4Ukr0i3HA_16_7"></a><a id="Tc_iIecnDkry0aUL54kDg2qSg_16_10"></a><a id="Tc_1cELoNqRYEKS9Ii9qCeX6w_16_13"></a><a id="Tc_kxImTxoFSEeQ-0uOuT7p9w_16_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gN_P46pkKUe8iGRdgH7_IA_5_2">20,399,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Fh1G7dO-SU61kuKdKvxoOg_5_5">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zbMLgVLwskWIMhYab9L2qw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-GQ_SDzPL0uesk1Ajo7Bmg_5_8">540,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wy3kn6snkkWPv53PI5w4dA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ukzDojS7cUKgjwQSuj6frw_5_11">394,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3dLk7Sy_E0KsftAeppu0Vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KcFOpEwJqkigCyUCSiJ6vw_5_14">198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__hIElquNMEiHhnFOL0IGLw_5_17">145,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ZxFCNbq9FEmCP1GRZQYfyQ_6_2">150,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_kdbLx_Iq7U6MGyMwA7LRxg_6_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fz5NzSugzU63DWN5hvLYbQ_6_8">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_6tlxkH7mrEGlE8qgLzLAlw_6_17">184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_ZSwEUiDRQU6VjeSv8Ms4lA_7_2">113,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_zFTZL7rInkG33wo3JuZsSg_7_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_vG03xDeTlE2SgZ09nP5hHA_7_8">586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_3SYUS26JXkisgZiLthuXXg_7_17">587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_yv0ZFrs5SUSVmWCUoE743A_8_8">3,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MmLU8Bk7HkKXrQx-2FwU6g_8_17">3,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the year ended December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jWno4e5JIkauZQOY8SolYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Z-I40aTwZE6Qjvp_suHXQg_9_11">41,428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fG-uwixYrkybGV-CreiWNQ_9_17">41,428</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Cumulative translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XBqz8Ajq30SHLvU8-PjfiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_adiWEsHOl0eKoJAKDwyfXg_10_14">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="3" id="Tc_SNxFUmNZ6EetVWANoiaQqg_10_17">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:34.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_z5thRTHU6UqLA7ga0nCfkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_UTfS6T2rX0i0mFX0HVTpxQ_11_2">20,663,736</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_z5thRTHU6UqLA7ga0nCfkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EAb75GRUG0SYVzsVEs4EVw_11_5">207</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TYjt-cOP6EmP8oe6WXLi1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OsCPPokjJEKqXtB4msJpwA_11_8">545,362</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hwN6aAp_7UWY8-X1PMow3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LmfvW1MM9Ua27chhVIDXUg_11_11">436,182</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_oxQlkGA_EEi6G6wAtaoTqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_l98bLgEX4k6FJRVJjKHjeA_11_14">207</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_CSBHrpnZxUaqydoHiMzKmQ_11_17">109,180</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_c_iCpf_h0UuRM2xHXLXnSQ_12_2">144,187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_60oVhXlHPkyrQ_UGDlwm3g_12_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Qt-BRuB8F0u4edAmAZEoKw_12_8">727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_thU03FM6KUud5QeswWnd4A_12_17">728</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_aSkhPMx4CU28h-yQwwQbZg_13_2">71,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_-PDF4DR0tU6tIpgK1Ua0og_13_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_-7RYMc7OsE2NkIgkDLbvfg_13_8">934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc__NivF5NMukGFKf8REi6tbg_13_17">935</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Vrjgdykd7kufUtaf8kdUkg_14_8">6,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc__Qxzr8nbDEWB8-BBV1EMzg_14_17">6,303</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the year ended December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3sIcs8CI8UW6e5DtAQYNdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fAxcI_Z1BkSaeY7PqzpD4w_15_11">41,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zP_3M6nhzECPCntOVVfn9Q_15_17">41,199</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qCtrCvgNa0C-1eQGTvWtGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_HDqaZlhtuUuGVDAoFkiobQ_16_2">20,879,199</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qCtrCvgNa0C-1eQGTvWtGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8E7wrmFHA0umC2b89DkpnA_16_5">209</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cchEQDekhUyFexTD45-WZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_W29SY9n_cEiWmlyH3fjycg_16_8">553,326</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b8RRVB7Uq0ilxq9okISsEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DV6Tf3om4UGbpJDePFKodQ_16_11">477,381</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R8cE_HFzF0aFvnYTtQwY3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_8jwWuUsy8UyUL6TXQBnfAA_16_14">207</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.4pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_En8H4ZIWNEGV_J9xN4JpBg_16_17">75,947</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:middle;width:34.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_86de53dd_539d_4248_8397_bb777a4ea388"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="CondensedConsolidatedStatementsofCashFlo"></a><a id="ConsolidatedStatementofCashFlows"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><a id="_aec9e398_f1cb_49a4_9d16_6e2ec4dbf0c1"></a><a id="Tc_imIvYLu40UiZPmlDNgKvsg_1_2"></a><a id="Tc__mm-UGdMdUK-TEAZr6NItg_2_2"></a><a id="Tc_Hsn_kONDbEmmKnaA8Zh96A_3_2"></a><a id="Tc_DJKxPM-iHk-kzcekqT_cXQ_3_5"></a><a id="Tc_CfClgl95v0WgE9MalDnsrg_4_0"></a><a id="Tc_7d6yQ4gzdk-5vYut1K4l5g_5_0"></a><a id="Tc_ue2TqMWymky3f_LAso492w_5_2"></a><a id="Tc_NCAsk2pciECMArlaKBp3IQ_5_5"></a><a id="Tc_BjZPTnFlEEuQjkIw4HBw3A_6_0"></a><a id="Tc_5WgA8423QEyG-QyEmCb3BA_7_0"></a><a id="Tc_4QH1TzLvXU6-HjTGw2XSPw_8_0"></a><a id="Tc_CoMAAEFi3k-wCtoIdTpBww_9_0"></a><a id="Tc_6mjQksYgvE-Elfueoy7vfg_10_0"></a><a id="Tc_l1vwmt25n060B0Ix4WG8lg_11_0"></a><a id="Tc_cRw-kM59iEulMryLjeOFZg_12_0"></a><a id="Tc_H83Uh9ORiUqslIXlOxPAYQ_13_0"></a><a id="Tc_csWhtlgqd0yOzBMUbzG7ZA_14_0"></a><a id="Tc_t2HsTTlX10ugIdKgbV6Fmg_15_0"></a><a id="Tc_x4dbCYA2PUWeY8wayVKUYw_16_0"></a><a id="Tc_pHdECOnAzUmBD9lANRuNKA_17_0"></a><a id="Tc_QiPHho5I9EyvH9GK1XHG7w_18_0"></a><a id="Tc_pRB6uGloekqtf2zyfjMxLg_19_0"></a><a id="Tc_rDU8iOzQukygx9Sdv12yzw_20_0"></a><a id="Tc_KdhEIXbDp0-ELf7ypEiEBg_21_0"></a><a id="Tc_VFqcyaNyW06ixfAH_JEdwQ_22_0"></a><a id="Tc_A5V9fiFz2ESa4PKWiUfwUQ_23_0"></a><a id="Tc_O--kkuuYJUOAyyjesQm7fA_24_0"></a><a id="Tc_99iz7jkU0UK-zKgoYn0xOg_25_0"></a><a id="Tc_Jzs3Y9n7mkKQNijg_Rt6Uw_26_0"></a><a id="Tc_G4bKeBFgHUKxTj4415Mf0w_27_0"></a><a id="Tc_ewwZnwr1GUKDKG2Ch18Rcg_28_0"></a><a id="Tc_lfabSe-3E0mn1ey2HtTOeg_29_0"></a><a id="Tc_C0UCJOT_2kep2HbkLN-fAA_30_0"></a><a id="Tc_zDroDQ1Y-EaG1775A7jJwQ_30_2"></a><a id="Tc_jPDv5Zxw40WTbksE1PNBrQ_30_5"></a><a id="Tc_Te2FwWq5C0Gmctr31g7ogA_31_0"></a><a id="Tc_XgIlUGwCxEKU_SrhFR2biA_32_0"></a><a id="Tc_mQY2I4OkdkWxwQo9cSAn8Q_32_2"></a><a id="Tc_XzC_1sVVnkyomYUFV8MzVg_32_5"></a><a id="Tc_Rj_ySfc9WEqgc06vOIRSpw_33_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_elifCtOvr0-Hc-xw3UO6Mw_5_3">41,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_mTuP9X4dBkSxAVk_wC3_0Q_5_6">41,428</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_y35BgnHAc0SpC3LwQpDWPQ_7_3">6,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_H_meNd7MnkyuegPr1oE0mQ_7_6">3,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_6n8iyP57PkC1NQyWRGKkzA_8_3">522</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_UZITZISu3UqsGl-mYxNy5Q_8_6">412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_WS4F4UT5yUWZfcdQni_uCQ_9_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_0Ad76IS93ESjI7jBRqN3tQ_9_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of deferred financing costs and loan discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_dEbrylCahE61ACsastyj9w_10_3">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_cNgh41iyL0qDkel8JqJvCw_10_6">25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_OB5JM1UvJ0asGKMaYSxKGg_12_3">2,047</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_lz2DwLLLpE6WGQkW3pKIPw_12_6">2,944</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_ZUgzbFqStUSQqCne5lEx7Q_13_3">4,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_9QyFFcOoR0Kro_j5oYNSTw_13_6">3,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_xEN8sOcM4EuPw4FSUMfSNg_14_3">1,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_O02AuJfwZkqMDRLB-2rAQA_14_6">1,634</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_yVT3rcux10ehWYCPPFC5xA_15_3">165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_QUSBJv-0NEudpylUr8gExA_15_6">1,209</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_AnyjpyP6iEWkZ0IZxCJtZg_16_3">170</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_Kcp55-pZsUanEfygTlsHZg_16_6">873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_avg6R68ncU-9Epl7g2A1BA_17_3">39,021</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_8P2hv2WnrEOy2-QMKdE0Kw_17_6">42,677</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_l5AWIMfQNE60zmECEk52zQ_19_3">591</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_y9IdeHZqjUqhcU3a6cgO8Q_19_6">685</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_U0Yc4trGJUaW7-fC8mgFBw_20_3">591</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_OFUvS-4ccU6CrKXGdo5hgA_20_6">685</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from the exercise of common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_tSaSTzXvAU64aq99FrQeog_22_3">728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_DCl9wc2Ya0eoF8v1AA5WyQ_22_6">184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_4afF07bNYkm8yYWp4w1bhw_23_3">935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_J5IyCY-3rU6HDM-SyLnb7A_23_6">587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Proceeds from debt financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_A5penc1PoE258Q7hJlYneg_24_3">22,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="Tc_qrlp0BUMJEGKIFhnXET9Ug_24_6">7,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Debt financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_X1gDG82ESkSOo9lCAAjeQA_25_3">179</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_RQ8bJeVxgEaNQAr8AyVDAQ_25_6">778</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_akUlqrVU3kKr8NVO89Bm6A_26_3">23,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_IhkUjefWkkO0ITfva9w4wQ_26_6">7,493</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Effect of currency exchange on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_wgi4iDwMlECbNG1dIQLQVA_27_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_TLF6qfeiek-AARQHajA3Hg_27_6">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net change in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_dj6-D8I7HE--EdwdcECHPA_28_3">15,625</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_B8EZVPbNXUW-2TcJvkeWYw_28_6">35,878</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_BFET9EOVX0GnHk0oEul0WA_29_3">106,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FU-lsmrzNkOdOFsiTgTAgg_29_6">142,072</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Ma3c2K5jTEW9btt_a4gZPg_30_3">90,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gjijIbn2XUm-5JarJLgABA_30_6">106,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:73.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_pcnF8f1bqU-6EY-ZLmlBgA_32_3">1,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_E4jGLD-QwkOiKZDYxAkoRA_32_6">59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash paid for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc_XGgqiIiIL0uVYqi2cN23sw_33_3">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="Tc__W3Ab23yFUWObW7kcNawUg_33_6">5</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CVRx,&#160;INC.</p><a id="NotestoCondensedConsolidatedFinancialSta"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_HEvfjK1xAU-asHxkhJMpow" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Business organization</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRx,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. We have developed and is marketing a medical device, Barostim, for heart failure (&#8220;HF&#8221;) and resistant hypertension. We are focused on the sale of our product in the U.S. and Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that we will generate sufficient product sales to produce positive earnings or cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_HrVqg9vxq0eQwUdl3qyZGA" continuedAt="Tb_HrVqg9vxq0eQwUdl3qyZGA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Summary of significant accounting policies</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" id="Tb_Bb6DPZRoIEuaAfn9pl6HlQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy, which was closed during 2023. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="cvrx:JobsActAccountingElectionPolicyTextBlock" id="Tb_lpZqqhVcYEyQnpwatNcMpg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:UseOfEstimates" id="Tb_rQSGBqDOnEmnlFp0yr87Pw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_0-QlA8a6nEajwRNHriu14g" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2023 and 2022, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value. Additionally, as of December 31, 2023 and 2022, a majority of our cash and cash equivalents were maintained with two financial institutions in the U.S., and our current deposits are likely in excess of insured limits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_nyo9K7ILRkWNxoc3sKip5g" continuedAt="Tb_nyo9K7ILRkWNxoc3sKip5g_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. <span style="background:#ffffff;">We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HrVqg9vxq0eQwUdl3qyZGA_cont1" continuedAt="Tb_HrVqg9vxq0eQwUdl3qyZGA_cont2"><ix:continuation id="Tb_nyo9K7ILRkWNxoc3sKip5g_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023. We have determined that the adoption of ASU 2016-13 did not have a material impact on our results of operations, cash flows, or financial position as we do not have a history of credit losses.</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:InventoryPolicyTextBlock" id="Tb_TfxT24rZkUSMBRF3McfUYQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We regularly review inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_RlMf-rofSEa6GTOoQAT_RA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) asset, accrued expenses and operating lease liability &#8211; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_W5q3XjvPBkGXe4oN6YHKKg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sell our products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. Our revenue consists primarily of the sale of our Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services it transfers to the customer. We recognize net revenue on product sales, adjusted for any applicable estimates of variable consideration, when the customer obtains control of our product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract. All our contracts have a single performance obligation and our payment terms with customers are generally between 30 and 90 days. Variable consideration related to certain customer rebates is estimated based on the amounts expected to be paid based on the agreement with the customer.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_UiYUQQjmG0-Bj0lBFmr79g" continuedAt="Tb_UiYUQQjmG0-Bj0lBFmr79g_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HrVqg9vxq0eQwUdl3qyZGA_cont2"><ix:continuation id="Tb_UiYUQQjmG0-Bj0lBFmr79g_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_pZtIw4MqmUy0GL8KqZEOcw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;), which requires public companies to disclose for each reportable segment the significant expense categories and amounts for such expenses. ASU 2023-07 is effective for annual periods beginning December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU will be effective for our annual period ended December 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which requires public business entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2023. This ASU will be effective for our annual period ended December 31, 2024.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_32f539bb_67c4_4ac3_982a_bd76d3c40eed"></a><a id="Tc_tCOvR50QT0OFtEKClC5W4Q_1_2"></a><a id="Tc_90IB4DnNjk-rlzsAOnAYVw_1_5"></a><a id="Tc_Q8Emk7mz_U2WTNOk1X6VFQ_2_0"></a><a id="Tc_xeJtryQQg0uKCSW_hMzSTw_2_2"></a><a id="Tc_32cnrcAyoUKjR4yPzdyyCA_2_5"></a><a id="Tc_nb5nFreJQUmv5hkDv8MXGg_3_0"></a><a id="Tc_rrMd58Q5uESlREcGi6zXtw_3_2"></a><a id="Tc_PCojCYJD2EWh8otcS6YjDw_3_5"></a><a id="Tc_whWgEpn1PUikqJHyFkpT4w_4_0"></a><a id="Tc_4W9_fGoqbUayx0WSSe-atA_5_0"></a><a id="Tc_t3QRBiN2Nk6mq1_jF0sNWQ_6_2"></a><a id="Tc_8bJ58ytw7Ua-dzoDMrrBfw_6_5"></a><a id="_e1d0bd89_c340_4f30_93c0_b016a1488585"></a><a id="Tc__Tr1am7bGEGwNHaKOj3nsg_1_2"></a><a id="Tc_SbnF5C3WDUWeENZ0ROrRXg_1_5"></a><a id="Tc_eMuygnv8Fk-10ldlr_m06w_2_0"></a><a id="Tc_dKts7uHkMU2prb61ZZpBSQ_2_2"></a><a id="Tc_iEugr_K-FU-owkOz37aAlw_2_5"></a><a id="Tc_xhov6k6kbkSZmvaoMrmmnQ_3_0"></a><a id="Tc_cyA5StRO0EyEgUDyc8IqnA_3_2"></a><a id="Tc_oJh5IdtZJ0CGc5kGPQEyiw_3_5"></a><a id="Tc_1CziFLzoeU-96P4MTqUFJQ_4_0"></a><a id="Tc_KoMBc3YNlkutf0v_ZoAGjw_5_0"></a><a id="Tc_P3TFW74cJUe80Rwoeg4Upw_6_0"></a><a id="Tc_m65zh5cSw0qmqvuRF3cHkw_7_0"></a><a id="Tc_9m5oavcIek-DJzVbpZZCrQ_9_0"></a><a id="Tc_jQVHfdV1AkWKPkK3hdRqLg_10_2"></a><a id="Tc_6jn9MIv1IEudBSZEZXXTUw_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_o5DdFHTu4kykK96UwCkjlw" continuedAt="Tb_o5DdFHTu4kykK96UwCkjlw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected balance sheet information</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_7DEnhg82NkecqaQtCtYUSw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_MXn7JApc9kGjQ8eLFtOmYw_3_3">4,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_d7q8ywcM4kSLC6BXzjR1_Q_3_6">2,390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_kY8nDSzQfUaa4MWZajE70A_4_3">654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_X4eLdYqT2UyY3urIonE25g_4_6">1,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_VDAKXeKx0EG7vH-RS-jUMg_5_3">5,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="Tc_OtCOB57DW0Ga0O57EBqt5A_5_6">3,534</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_7b2pWnAkgk2zSonlBNo9Kg_6_3">10,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_shYepnAFmkW5pwo1w5cb8w_6_6">6,957</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_ILnY_osKA0m5Tu3wIFpUyg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tmU2-D_zdkyR5NTA7xTdTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nLboCbPAXkqVokiZfLTOOQ_3_3">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_FSq9BY_du0er2CE9ESvvpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-rlwu_bMkUqGLVhZx1UI-A_3_6">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_BAuUOTojQESzFVAzqd4DhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_FjiqDHd2E0GxJGGHkNqasQ_4_3">2,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_sgJuXpn0yUa8L7xiptpJRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8X3Md1jSAkqXJwhnlMM2Yg_4_6">2,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_MpXjFm5HkU2XNvuqY4WPsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Z31YjbkCskWpDPi5jwRtOA_5_3">776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_dqIej4ejsE2n1BDRzJlgJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_F62kkk1p2E6eVv0HIVJ1gg_5_6">618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JMLg2X07bEuHweDOuklZhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_KUNQy1Po9UydM7Max9xnzA_6_3">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_amp52TUrr0uPXJ9VAkjlow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JW2Bjnno_UWz9ojh5CCZTQ_6_6">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_RDgZV8eKn0q48yeiBOKJrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cHU_qUDPgEC1g8sQOas_qw_7_3">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_-1zVdT_0tkOxZQEUVJnt6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_R8RYiGxC60mQ_R6EhfojRw_7_6">231</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_6ERV1aoGg0WbHqMsRXx3zQ_8_3">4,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8FqEuese5kGpjqSmWbLxcg_8_6">3,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_NOtd_d6CrUiyplGTcPwKhg_9_3">2,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_tQL8D7XKz0uTnXjWjrM8Zg_9_6">2,280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Tejrgy6fkUi3JCD_n3ck2A_10_3">1,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_r5TXwNxkk0yPgfIVZfgqfA_10_6">1,698</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/>Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally&#160;<span style="-sec-ix-hidden:Hidden_zQ9v7lRugkaZk4A4ENmecQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to&#160;<span style="-sec-ix-hidden:Hidden_4ZtIQYWjMEy5zwZJd8Tmlg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></span>. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_2090__YHZ0qnqdpcmWYdaQ">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_qhnfL4fkv0CvsSnvtGsKqw">0.4</ix:nonFraction> million for the&#160;years ended December 31, 2023 and 2022, respectively. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fdc13b0f_c9f8_417a_a27c_315374830de9"></a><a id="Tc_TkgAbFN_LUmUdOuJ7KDa2Q_1_2"></a><a id="Tc_5R1km3SVeEKg4cXUgpe-TA_1_5"></a><a id="Tc_cd5gf-9aNUOyX7d0l74UFg_2_0"></a><a id="Tc_moTOQARaxkmLSXE-HNS1uA_2_2"></a><a id="Tc_zSSUtbIa-Ua7dIQJdLXZeQ_2_5"></a><a id="Tc_1-vyMOwa-UGUpFizkQ6dBg_3_0"></a><a id="Tc_xGE2Bh2uOkmQRYk5-S8yAw_3_2"></a><a id="Tc_C1_uNWUhMEu2BxxPZubqNQ_3_5"></a><a id="Tc_Ub6D61pbFUONEhriAXUbCQ_4_0"></a><a id="Tc_1OPOTzWgYk6fdRBvW6S8Cg_5_0"></a><a id="Tc_znJDBD_1akuJv2bWEzXuVg_6_0"></a><a id="Tc_Y7j4Q653k0uYA70Sz0ePzA_8_0"></a><a id="Tc_YXLyeaYAukyvpUbhDaJ1Qg_9_0"></a><a id="Tc_iVNDyYCwv0qzo2OGREhw_Q_10_2"></a><a id="Tc_Q14mk5p8fUe_wBk5r0djzA_10_5"></a><ix:continuation id="Tb_o5DdFHTu4kykK96UwCkjlw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_OFlPDXFWkEWktxGP7vhGdA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ClinicalTrialAndOtherProfessionalFees" scale="3" id="Tc_snset307002iwjafRYI_hw_3_3">277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:ClinicalTrialAndOtherProfessionalFees" scale="3" id="Tc_T52sNKEo8EKfZnZMTttpTQ_3_6">1,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_n_4gcXMTzkCLvmz-uADGHA_4_3">3,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_u1nMyTzSYUeluY1VxTwBpg_4_6">2,303</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedPaidTimeOff" scale="3" id="Tc_KRaSufnFE0GO5kV_aP7YJA_5_3">770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedPaidTimeOff" scale="3" id="Tc_9cLWhZI6sUeh2SGFIwK-6g_5_6">960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedLiabilitiesCustomerRebateCurrent" scale="3" id="Tc_5uek8hf_Ik2DeIxjRdIPiw_6_3">411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:AccruedLiabilitiesCustomerRebateCurrent" scale="3" id="Tc_Bc22SGMreU684tLK-eg1CA_6_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KRGdCIu5gUe_MTcgpv6-bQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Operating lease liability, current portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_qzWYVOCpG02lijmRXH6bAA_7_3">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_wrv7cHuIokmvykgzZCORyw_7_6">222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_-gJkaPzESUGeTj7c_1hlFQ_8_3">125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_DMaNRVKa1E-gAxoSGukbCg_8_6">120</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_rWfb5bR8y0OF17OTROubHw_9_3">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Hsy1mgkzP02qPU4WpgsG3Q_9_6">775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_O0CCh4pyVUuvLXXeXouoew_10_3">5,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_QGDP8m_Pe0GaLPimdrEReQ_10_6">6,369</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk116894649"></a><a id="_5ecdc6c5_17c8_4823_ae0e_5a8c2a563958"></a><a id="Tc_wn_wZVPG3ECSH7f1vaKhLg_1_2"></a><a id="Tc_l2ZS_ET3CUOe-C_OVEUJqg_2_0"></a><a id="Tc_hD6MSfAxykCYcR4HJuoI7Q_2_2"></a><a id="Tc_F789dD2ClEyH267MVYTEDg_3_0"></a><a id="Tc_-fz3oHhhNUaomWttm_2Zcw_3_2"></a><a id="Tc_kI2hhKZ0wkuLbUuigmUI6Q_3_3"></a><a id="Tc_UFkeKVw24UCMldGXhMRdQA_4_0"></a><a id="Tc_bq-vwF5fckCtX8rgjFgVbQ_4_3"></a><a id="Tc_EsnYM07pOUuUbin2ZsKn4w_5_0"></a><a id="Tc_Kam6aVQKjkmvYW_WHtbCnw_5_3"></a><a id="Tc_FndkTHNKsUywtZ5CLnPi6Q_6_0"></a><a id="Tc_nHn_PAaB8EadaJg-B-H0ow_6_3"></a><a id="Tc_FOVx05NeM0C3ccUOZXpvlA_7_0"></a><a id="Tc_Vxb9NAX4T024ZzCk4ut7yg_8_0"></a><a id="Tc_OEIA0YD3gEqdsznVGPb0YQ_10_0"></a><a id="Tc_PfHVL8IYfkq4ecLBuTpYBQ_11_0"></a><a id="Tc_4TzbNioGqUGp3PoSbdWuFg_11_2"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_56PbfSrp9kyK4bSI-uXLaA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">4. Debt</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovatus Loan Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On October 31, 2022, we entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, under which we may borrow, subject to our achievement of certain milestones, up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_1ojXi2B_EEmTAewOK1a2tQ">50.0</ix:nonFraction> million in a series of term loans. On the closing date, we borrowed the minimum amount of $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_ui9LLsbTL0CzBRCKzCsebQ">7.5</ix:nonFraction> million under the Loan Agreement. On March 10, 2023, we borrowed the $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_3_10_2023_To_3_10_2023_srt_StatementScenarioAxis_cvrx_TrancheOneMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_MsUf-wRe3UOCGdw87WJNbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_pbJyA63-8EiHsRQ48RXy9g">7.5</ix:nonFraction> million remaining under the first tranche of the Loan Agreement. On December 15, 2023, we borrowed an additional $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_12_15_2023_To_12_15_2023_srt_StatementScenarioAxis_cvrx_TrancheTwoMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_6qk8DRW53E2gnuQbDupIdw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_f8o-hJAftUicBqvP1xFfMw">15.0</ix:nonFraction> million under the second tranche of the Loan Agreement. The Loan Agreement initially requires interest only payments through November 2027, followed by <ix:nonFraction unitRef="Unit_Standard_item_rCbhtU9w5EOG859qhsdnSg" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A" decimals="INF" format="ixt-sec:numwordsen" name="cvrx:NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" scale="0" id="Narr_XOkdDZdXKE-4417aniVg6A">three</ix:nonFraction> monthly principal and interest payments. A final payment of $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="6" id="Narr_DEzbRMrn-k6BzTOebR2FfQ">1.4</ix:nonFraction> million, equal to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA" decimals="3" format="ixt:numdotdecimal" name="cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" scale="-2" id="Narr_m8kvzW2Rv0SkE2-_2IGTzA">4.5</ix:nonFraction>% of the original borrowed principal, is due in January 2028. The term loans advanced pursuant to the Loan Agreement (collectively, the &#8220;Term Loans&#8221;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_X5E_nBjGO0GtwGqhO6ilig">5.50</ix:nonFraction>% plus (b)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="Narr_44fIG9nxU0G90Uw_aploRw">2.65</ix:nonFraction>%. The Term Loans are secured by substantially all of our personal property. We have the option to draw down&#160;up to $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_ilFiREhHNkW7Pr6DPc2vbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="Narr_MUBXn6Iw8UeqEFO4hGMwpg">20.0</ix:nonFraction> million between September&#160;1, 2024 and December&#160;15, 2024 if we achieve trailing three months revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_ilFiREhHNkW7Pr6DPc2vbQ" decimals="-5" format="ixt:numdotdecimal" name="cvrx:RevenueTreeMonthsTrailing" scale="6" id="Narr_K7qSJMjVP0K6Hy5g70GXLg">9.0</ix:nonFraction> million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding, requiring that we achieve <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A" decimals="2" format="ixt:numdotdecimal" name="cvrx:PercentOfRevenueTarget" scale="-2" id="Narr_PAXOCj6SUkSDSoJTJp5aMQ">50</ix:nonFraction>% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period. The Loan Agreement requires the payment of certain penalties if the Term Loans are paid off prior to maturity for any reason, including pursuant to an acceleration clause, and includes various restrictive covenants, including a restriction on the payment of dividends or making other distributions or payments on our capital stock, subject to limited exceptions. We were in compliance with these covenants as of December 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In connection with the Loan Agreement, we recorded $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_-ikuADde6U2WzNZk0Lh4aA">1.0</ix:nonFraction> million of debt issuance costs and discounts as a reduction of long-term debt. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_8B9ns1w950acCUrE_RSyIw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual principal maturities of debt under the Loan Agreement are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="Tc_WY4D4kMtKkuODxfCsAtcCQ_7_3">20,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="3" id="Tc_GbMw96EWAEa4nmbg3vXTdQ_8_3">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="Tc_QYhhvKwKFEOGmR8S0GrdhA_9_3">30,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized debt costs and discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_iTESwVeVQEGnxqnKzsB87g_10_3">778</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_YnkCaZUc1U2ot5lYxFGh2A_11_3">29,222</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5690a0ff_01a9_4645_abc5_93304d0096b6"></a><a id="Tc_ZtdUh_MbO0iQ-xY0Mp7tMg_1_2"></a><a id="Tc_roCA7iV2lky_Yxmji4Vs5g_2_0"></a><a id="Tc_VJGvcIZjBkqpcUIFtsifMw_2_2"></a><a id="Tc_DLPo41fFVkKLNCi-rJG_NA_3_0"></a><a id="Tc_wjgsj0CDp0C7TwAv60iWTA_4_0"></a><a id="Tc_NCa8aKMAS0yAQziSrzZZog_4_2"></a><a id="Tc_01D8SYffUU2CgBifMuE0ew_5_0"></a><a id="Tc_MTPgCNooBk-ssADXV4KECg_7_0"></a><a id="Tc_bqKtgnbpjU25BlH8M0pqYQ_8_0"></a><a id="Tc_eUjearxFakaB4RCq6qapRA_8_2"></a><a id="_d7fa4fe4_3124_4928_899a_69885bfea346"></a><a id="Tc_TiqHBkJPU0Ga58AXJdKNQg_1_2"></a><a id="Tc_LnSt9El4gkGhDbY3qCc57Q_2_0"></a><a id="Tc_isc6IFs040S9QsLihDM_TA_2_2"></a><a id="Tc_n3byAYQ410CrO3lhihuIcw_3_0"></a><a id="Tc_LdafF-itm02WjDAXjZD8jw_4_0"></a><a id="Tc_H-qrvnJkS0qToCbnh2wPQg_5_0"></a><a id="Tc_YUHV1Sx-cE28ae5AP27s2A_6_0"></a><a id="Tc_7l7vIYq9EkyK4DOfQrJgEg_7_0"></a><a id="Tc_Ioe8XhbHAUWzy74-0ZB4pg_8_0"></a><a id="Tc_nyyjlTTtIUOosm8C2kA6ow_9_0"></a><a id="Tc_hTFnPa06jkyj-LCeCsFKYg_10_0"></a><a id="Tc_Q5ki5V65lkCcpqQv-pEg0g_10_2"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_OjSgZy1i-E6BL4J2JBzCfg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">5. Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">We lease </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_sqft_GqVn26Et2UKhRhM1bZ7Trg" contextRef="As_Of_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_IO8dwnoe_0GELVflzKHRYA" decimals="INF" format="ixt:numdotdecimal" name="cvrx:LesseeOperatingLeaseAreaOfLandLeased" scale="0" id="Narr_xCL9nzInPU6c0pBeck6a-Q">31,505</ix:nonFraction></span><span style="background:#ffffff;"> square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and was scheduled to expire August 31, 2024. On April 21, 2023, we extended the operating lease for our office space in Minneapolis, Minnesota for an additional&#160;</span><ix:nonNumeric contextRef="As_Of_4_21_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_RM2963Hq80uyOziblZLLAA" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_hlAh4Oe1TEm-xMH9geVtQA"><span style="background:#ffffff;">49</span></ix:nonNumeric><span style="background:#ffffff;">&#160;consecutive months through August 31, 2028. On November 7, 2023, we expanded our existing office space with the addition of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_sqft_GqVn26Et2UKhRhM1bZ7Trg" contextRef="As_Of_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_CzzcDrZpiEu6QYTiVCHdNQ" decimals="INF" format="ixt:numdotdecimal" name="cvrx:LesseeOperatingLeaseAreaOfAdditionalLandLeased" scale="0" id="Narr_vY2_iLwWQE6c_aH-C4chlA">7,615</ix:nonFraction></span><span style="background:#ffffff;"> square feet of property adjacent to our principal executive offices and our manufacturing facility. The term on this expanded property is for </span><ix:nonNumeric contextRef="Duration_11_7_2023_To_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_L3R5rGyJ60OsNpQkqtgCzA" format="ixt-sec:duryear" name="cvrx:LesseeOperatingLeaseAdditionalRenewalTerm" id="Narr_vLRBcL084UCSCzKYRLAPEA"><span style="background:#ffffff;">57</span></ix:nonNumeric><span style="background:#ffffff;"> consecutive months that will run concurrently with the term on the existing lease. We intend to add new facilities as we grow, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. Our operating lease agreement includes an option to </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_SKjkOlcWxkeaJnFxtqthxg" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_UzBV2LndVECYJ3iqDpwDYQ"><span style="background:#ffffff;">renew</span></ix:nonNumeric><span style="background:#ffffff;"> for one additional period of </span><span style="-sec-ix-hidden:Hidden_R84I04otGUuPgFKJgT8KOA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">three</span></span><span style="background:#ffffff;"> years. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability, as it is not reasonably certain of exercise.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to base rent, we also pay our proportionate share of operating expenses, as defined in the lease. These payments are made monthly and are adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" id="Tb_A8ctzUjLeUO0qiAqRSikdg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the lease balances within the consolidated balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_PvS55w4pZU2ZB9CKUQPJ-Q_4_3">1,349</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_YDnHhonymkmLROCgApvJbw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_BdCxKe8PiUqmEuPQjb8QUw_6_3">231</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_zntDlKTxakiepwkZduE_Pw_7_3">1,160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_hjyEmy9nP0ymI6Nn-py0rA_8_3">1,391</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_lzn8BNphVUi-0bdRSh2lFw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Maturities of our lease liability for our operating lease are as follows as of December 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_khaLLIhEYUaC9aq6E9nf-Q_3_3">315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_yqFpsBlBbkyPFNx17gYlug_4_3">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_kTkeOlNM_k60-QnjYum8tg_5_3">362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc__cVlGKCPYka54sB2oAMW-Q_6_3">374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_w3sJil-3rUG5wcocsMUm4g_7_3">223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_aqV_mmlzZ0e2p-r3CKiQ2g_8_3">1,624</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_0Utq9yA9h02y_gkSigY7Ww_9_3">233</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_Gvdc0vg9o0SGAEijSgxpVg_10_3">1,391</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the remaining lease term was <ix:nonNumeric contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr_PufI4pmeREmXn0NDiBfNSQ">4.7</ix:nonNumeric> years, and the weighted average discount rate was <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_5ykjKLjXOkOtzPqruaDyGw">6.7</ix:nonFraction>%. The operating cash outflows from our operating lease were $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_Lv-BjIU-t0C7Li0ZY7_uNQ"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_rhh-9FVceE21Qu1Y7pjw0g">0.4</ix:nonFraction></ix:nonFraction> million for each of the years ended December 31, 2023 and 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_DyyFiJ58d0u6g3L9MVAXBw" continuedAt="Tb_DyyFiJ58d0u6g3L9MVAXBw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have common stock warrants exercisable for <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA" decimals="INF" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" scale="0" id="Narr_YA4379anT0KAvjUb1iNbZQ">716,131</ix:nonFraction> shares of common stock upon conversion at a weighted average exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA" decimals="2" format="ixt:numdotdecimal" name="cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" scale="0" id="Narr_zZ8T0Akh7EyP3gJ7xm1DIA">2.39</ix:nonFraction> per share. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_DyyFiJ58d0u6g3L9MVAXBw_cont1"></ix:continuation><a id="_9eb82ce5_df0f_475e_99de_a10da6b0e7aa"></a><a id="Tc_JDQ5cIr7JEaKdfo3-I8Y1A_1_4"></a><a id="Tc_S0Tup5ZYUUSMDVp_w4NNtg_2_2"></a><a id="Tc_IBZiJWDDQEKpXGnfSPDCyw_2_4"></a><a id="Tc_pdXyxAxxj02qBzKp0pVnbw_2_7"></a><a id="Tc_5NY0wdA6P0SGtgg2dmrHHg_3_2"></a><a id="Tc_BGhUB1L830qHtjvXcziJlA_3_4"></a><a id="Tc_mqEtobunlEKurD3we17g2A_3_7"></a><a id="Tc_vif4BOSvH0iEDqCKj_zT2A_4_2"></a><a id="Tc_U-QMIRSMFkKWd0uZO28jaw_4_4"></a><a id="Tc_4rv3lxIO1ES2ldahpwTVsg_4_7"></a><a id="Tc_FHOQGQ4Ugkep8fnDW3NJZA_5_7"></a><a id="Tc_DHXQCQVGdkCCT7qtYKmrMQ_6_0"></a><a id="Tc_fe9Jhu9cV0enaBIvdYaWKg_6_4"></a><a id="Tc__A2nADjfJESbCV1HwzZYgQ_6_8"></a><a id="Tc_Dk6nQI_tWk64KfTNz_SqLg_7_0"></a><a id="Tc_jTWRlpjnXkqPeg9tsiOagA_7_4"></a><a id="Tc_ijZznNcIa0uiqz9pOsF1EA_8_0"></a><a id="Tc_0Ke3JngjHk-_s9Pcx7Dy3w_8_4"></a><a id="Tc_hb9fHBpt7USmFNhCFaF1MQ_9_0"></a><a id="Tc_EsuGPNHuH02hG6LPVOfZIg_9_4"></a><a id="Tc_nSr8RDdVEkuTziyUU4DEjQ_10_0"></a><a id="Tc_JSkTprkUZEOk9h6-2xjHvA_10_4"></a><a id="Tc_RTfL4Z97NUmIgeoQPtZnzA_10_8"></a><a id="Tc_GNq9HO22oEi55uEz3KJNkA_11_0"></a><a id="Tc__TRgF0stHUKTITr5WZz1hg_11_4"></a><a id="Tc_cg8iHJiWuEa44u_E8cojyg_12_0"></a><a id="Tc_YvTORr18pES5lA5MYE89pg_12_4"></a><a id="Tc_O9Q_vRWamkqL1D0szUSi1Q_13_0"></a><a id="Tc_B6_6j2A9mkmEjbQEw5mhkA_13_4"></a><a id="Tc_uitYBBIHj06ABv9dOKu1AA_14_0"></a><a id="Tc_LgfXA55HPkqILIORxU6f1A_14_4"></a><a id="Tc_Ri6cbIKysEuRKf90n5f4JA_14_8"></a><a id="Tc_JDtnzP8GfU-RL6tvOm1Lng_15_0"></a><a id="Tc_vS-5xUKSiEaJRbZcKT41mQ_15_4"></a><a id="Tc_QMgm-LTDk0uqRhCG1mSt-w_15_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_UaBBzSh0I0K6s8bobm7gaw" continuedAt="Tb_UaBBzSh0I0K6s8bobm7gaw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stock-based compensation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of plans and activity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2001, our Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#8220;2001 Plan&#8221;). Under the 2001 Plan, as amended, <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_LGXJ91kYF0WAsdsON9A6IA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_OTMBJYY5Fk2c9Oc7jc_D7g">2,674,749</ix:nonFraction> shares of common stock had been reserved for the issuance of incentive stock options granted to employees, non-employee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the date of grant to <ix:nonNumeric contextRef="Duration_6_1_2001_To_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_PYd31BxNC0604nl8MDpilQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_kJ3fPAyI4EukuE1_RhQeEA">four&#160;years</ix:nonNumeric> and expire within a maximum term of <ix:nonNumeric contextRef="Duration_6_1_2001_To_6_30_2001_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_7rx5_d8IikeJHLuprsGqsw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_b_GIxLdRZUmO9VwwS0ufZw">10 years</ix:nonNumeric> from the grant date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2021, our Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_dc9hk3dVYkCOZVwQkXY8cQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_HPTMPvNKzUqq5o2lUR6z9w">1,854,490</ix:nonFraction> newly reserved shares in addition to the <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_naG0zLCR-EKkwa1gEwsa0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_NOZ_wGz7ZEeQmYY0l3C_1A">600,737</ix:nonFraction> shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_dc9hk3dVYkCOZVwQkXY8cQ" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" scale="-2" id="Narr_CFdWv0wPCUOrb9dc6f0nQg">5</ix:nonFraction>% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_DKj1YSlDwU2ZlmMFDIgwbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_SLV8nDKihEmW_8fuvr3z2g">1,033,186</ix:nonFraction> shares being reserved for issuance under the 2021 Plan as of January 1, 2023. The 2021 Plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_up0KPm3ldUy5PK6Gt_PEvg" format="ixt-sec:durwordsen" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" id="Narr_7AlqTaOy20mhWa4j1y0MiA">10 years</ix:nonNumeric> from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2023, there were <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember__P6VIstV9ke4AlgA3xarog" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_w5XJawD_3UOaMS7O5BuRZQ">1,671,202</ix:nonFraction> shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of our common stock on the date of grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years 2008 through the IPO, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain non-employee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as our standard form of option agreement for non-employee directors as they have an exercise price not less than the fair market value on the grant date and vest over <ix:nonNumeric contextRef="Duration_1_1_2008_To_12_31_2008_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_PajlFFmwTkWsKigwduPhHg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_IzHbOGg45kmvyTDuUBDmjw">48&#160;months</ix:nonNumeric> from the date of grant.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_qfVzhM8FZ06gl2vFflJEyQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_EK8EYGz-qUCA3y9ueCTfOA_6_2">2,749,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_irspkEBjGEGC__0PHev8_Q_6_5">7.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_-O0myfJdI0qHnp8Vzzf-eA_6_9">16,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Nsl3SRDa70q9FR99je9cqg_7_2">1,486,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_gZrHJup3Okq2Py6W3_epmw_7_5">8.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_huHMtXS2okKyt68DbEOdLQ_8_2">328,902</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_81VhxnfkDUWDhiE59ZaEbg_8_5">7.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_57Cr3CkN70iJ0sHLbBtNKw_9_2">150,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9eYrzjw8RU2Sey4qBbtPMQ_9_5">1.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_kM1TTHWyZU6CCRB3v_t2oA_10_2">3,756,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_BYpceHyUNka4aBypsMorgQ_10_5">8.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_bsIhE1Z5N0-IkwCtI66hfw_10_9">36,616</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_0aVkmQwaPUS680210Tx52g_11_2">1,161,926</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_rMhq3ai4HkiAOEPmKsYdmQ_11_5">14.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_9J7-0vcWWEWzld_G0c54AQ_12_2">285,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_-BCUIlR7kUqAqFSaoMnZqg_12_5">10.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc__NFQNaqg7EmZKiJxWDYTJA_13_2">144,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_SL2-kzfoEE2AHGbsuPqlAg_13_5">5.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_C4YCf0PI4U-gnzFRV-rymQ_14_2">4,488,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_TsazrhR1IUGU4WtyGC0qZQ_14_5">9.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_tX7-A9G5tUGXcqNv14Z8og_14_9">97,266</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_g55N46jzpk2qDxIACZyKzQ_15_2">2,450,327</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_ITLwl8htqUO2qudfd2Jz9Q_15_5">7.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_WJusDfmxXEaRdZOjbhPwmA_15_9">59,295</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023, stock options outstanding included <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_DDdMMm9gRkiqyIWxmaA5XQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_KKYxQyC5ZkGDHIV1zqPTcw">8,559</ix:nonFraction> options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2023, the weighted average </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ddbe76a4_b4e0_46c0_930a_8556a4231823"></a><a id="Tc_gD7-WdS9bk-Q6mAfyou4tw_1_3"></a><a id="Tc_SordFzZLk0yjMIo4PjIj2w_2_3"></a><a id="Tc_tBzy5k3uzEyS1VsKODX2Hg_2_6"></a><a id="Tc_f1nmGU49e0Os59ACGfX8ew_3_0"></a><a id="Tc_vzyisjhWHU-7k6GSYPr1Xw_3_2"></a><a id="Tc_mYXdY_iQs0SSve8iTNbplA_3_6"></a><a id="Tc_X13472x2dkGtMwjWq4IDnA_4_0"></a><a id="Tc_bm2Cio5jvUGScnnCdBSLpg_4_3"></a><a id="Tc_xMQHM2H3A06oqQ7TqWAqNA_4_7"></a><a id="Tc_CsYLmpoZHkCFU5boi-iDZw_5_0"></a><a id="Tc_6pxEEb06xUuv9MqfSHlQEg_5_3"></a><a id="Tc_XkzMFfIYLUuFA2mb783iHQ_5_7"></a><a id="Tc_r0jyTQ7tZ0Kz6ZHDDIxUcw_6_0"></a><a id="Tc_CnKTifQe5EikXy6xvSW0_A_6_3"></a><a id="Tc_o3UCPEhERUS5DXRjiDE_Qg_6_4"></a><a id="Tc_fER86Yc9R02YihRoJMbEiA_6_7"></a><a id="Tc_7A4AuE8gKEOWnV15Q5S3Rw_6_8"></a><a id="Tc_JhIneD7CikeYYg5RJQnO8w_7_0"></a><a id="Tc_9NAwNHtMoUSp7kOq_aZPWg_7_4"></a><a id="Tc_VE97UtfmKUKhjEo8uCu-hQ_7_8"></a><a id="Tc_2_fREU71v0u-hD8AGUMhug_8_0"></a><a id="Tc_STgLCidxRkW0QG4ov1FkZQ_8_3"></a><a id="Tc_IDpXZYdcIEyneP2atMJH1w_8_4"></a><a id="Tc_3MTkceyvwk6SkmtQzioSmA_8_7"></a><a id="Tc_AvH3X6Mbi0uMgUB3XSFqNA_8_8"></a><ix:continuation id="Tb_UaBBzSh0I0K6s8bobm7gaw_cont1" continuedAt="Tb_UaBBzSh0I0K6s8bobm7gaw_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_ANcL7QrjhUOTkkpkRoJKkA">7.3</ix:nonNumeric>&#160;years. For options exercisable as of December 31, 2023, the weighted average remaining contractual life was <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_r2Qi-WURfES_ZEis9ILdMg">6.3</ix:nonNumeric> years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of common stock initially reserved for issuance under the ESPP was <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_EDngguvYp0KbciIlorf-_w">278,170</ix:nonFraction>. The shares available for issuance under the ESPP automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" scale="-2" id="Narr_LbLmq9i4eU2n-0c9XyAY7Q">1</ix:nonFraction>% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_YUEJZcskw0GxQzI269v8CA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_qJg37c_GeEyGttm6jcMfZA">206,637</ix:nonFraction> shares being reserved for issuance under the ESPP as of January 1, 2023. The ESPP permits certain of our U.S. employees to purchase shares of our common stock at a price per share not less than <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA" decimals="2" format="ixt:numdotdecimal" name="cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" scale="-2" id="Narr_y7DG8HcS_kedjHABl9rFHA">85</ix:nonFraction>% of the l<span style="letter-spacing:0.25pt;">ower of (i)&#160;the closing market price per share of our common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of our common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase date under the ESPP was June 30, 2022. </span><span style="background:#ffffff;">For the year ended December 31, 2023,&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_lKnqzJJVv0eSxXML82FxRA">71,276</ix:nonFraction></span><span style="background:#ffffff;">&#160;shares of common stock were purchased under the ESPP for&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="Narr_BemTuqbPQEyYgRDMyO_vuA">0.9</ix:nonFraction></span><span style="background:#ffffff;">&#160;million of employee contributions. </span><span style="letter-spacing:0.25pt;">As of December 31, 2023, there were </span><span style="letter-spacing:0.25pt;"><ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PemZyTerfEyhpKp4nuNIIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_s9JD_M3dAkiTL_fz0U_hTA">503,634</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> shares available for issuance under the ESPP.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We use the Black-Scholes option pricing model to determine the fair value of stock options and ESPP purchase rights on the grant date. We measure stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period for stock options and the offering period for ESPP purchase rights. The amount of stock-based compensation expense recognized for stock option awards during a period is based on the portion of the awards that are ultimately expected to vest. The amount of stock-based compensation expense recognized for ESPP purchase rights during a period is based on the estimated purchase rights as of the grant date. We account for forfeitures as they occur.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_NJU5tpJiYUyDaZufA5IECQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_l5f4qMq4vEmPxbfN45BsTw_3_3">10.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_6orxADIeeEuTw1N2vxPjlw_3_7">4.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VXKHvG6viUyua5uD_4yltw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_BN6pSpec2UOZj0Z6ZM-Bcg">5.5</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VckApq6WlEaWJ9cemmQc9A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_sLFwIa8ZZUapXMofL4yQ4w">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMTCyrrsukCaWB_FFt4-Jg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_h_rxyKtCUU-6B1ZMpjAg1Q">5.3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9XD2uHnOhUWYk_34nMOzkg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_8p8YuHgOnUW3AEimIop1Wg">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zEoL8JtTB0KWcZl84O9JzA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr__Ix7a4iUj0yAXcigPjUYNA">2.5</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EBpawY17Z0eCyg95O44tGg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_B_SNFFRNt0eFiKEwRlNWCw">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_57PyY8_YEUuCWQnZ9zZCBg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_I4TVMw6uSEW0KNs51qsYJg">3.2</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hd2dVLfWykWfyk-CsotRYA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_tA37H4kUUUq-7P86F68t5g">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_hG4ToHrgyUCsjRmVle_TFA">77.2</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_YdflUVXhrkmNUNGqQRcZaA">79.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_G8LCugGpIk6sHEOimOOjiw">56.3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_dhmx_79RR0mhw_7uYah1Ow">60.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_httBTbdRPEyFu7QIc8cksw_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="4" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_joMfFfFtb0qPG3BABGnF-Q_7_7">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_SCf5JyDUnUqknutjW1XvRw">3.40</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_c5Jrfn3xiUy8gx47xdfL6w">4.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_qrUE0FQ2B0inl0JRKMhREQ">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_IC6SjC4nQ0qXyL-8Gn0w-w">4.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9ddfc1b2_3a23_47b1_a176_509846dfb541"></a><a id="Tc_BwEfYnQQ3UuSNoTVL-E6oA_1_2"></a><a id="Tc_TgaKYtaYtE6HCY9NecRuTg_2_3"></a><a id="Tc_FoWUArwnhUalUaHklgXHgw_2_7"></a><a id="Tc_1mv5tdzK3UGbivDhrGGRow_3_0"></a><a id="Tc_LphWojW0MUOQTwSaulm_jQ_3_2"></a><a id="Tc_qdGHtjXAqkmd7_dCx9Xe4g_3_6"></a><a id="Tc_ogG0bDKxLUiWL8pAiX3BEQ_4_0"></a><a id="Tc_SYRYP6qL1kmR1hQIPBtrxA_5_0"></a><a id="Tc_mctA1XjcmEuPSBS1ej3psg_5_3"></a><a id="Tc_Potedud880yEW4dJoJJiVg_5_4"></a><a id="Tc_vxqMUHIeqEGRQoedspE_HA_5_7"></a><a id="Tc_OIloms3AGU-mKE9CHxuyOQ_5_8"></a><a id="Tc_fCkTjDlO5EGL4TSapU0Fzw_6_0"></a><a id="Tc_Xb9Qicze602PgN9h8DEBcg_6_3"></a><a id="Tc_lkP_lVQgQk2MUh2M29Zwxg_6_4"></a><a id="Tc_HOLMdjr_QEONdAtiy3pD7w_6_7"></a><a id="Tc_q4xKSKseK0CQxvbzPh0fWA_6_8"></a><a id="Tc_vc08D_QWjEGPuVtbM-9x1w_7_0"></a><a id="Tc_l_UDLTD8jEmN4RETa_zLcw_7_3"></a><a id="Tc_7xiyeLmKGka9rJfr0emRXg_7_4"></a><a id="Tc_IEjxr9qmFU2buH4mA46zJQ_7_7"></a><a id="Tc_QcstqAemfUCfQAkPj763kQ_7_8"></a><a id="_271d42ff_8f1d_482b_8bd2_ccb11f67ee86"></a><a id="Tc_RNU21c5DlUmlNHWeV2x7ZQ_1_2"></a><a id="Tc_P8wABu-bfEmqpLhxS73hBQ_2_2"></a><a id="Tc_SFEXRwJuA0y6suzHL8Y5FA_3_0"></a><a id="Tc_3f1uFnPkqE2TgC9W2xVhEA_3_2"></a><a id="Tc_iSorAqwVqk6N8zxWlL1W2w_3_5"></a><a id="Tc_HMbnaE-hAE2b205yWb-C9w_4_0"></a><a id="Tc_bjGCwgwrDESmtovVYoI7rw_4_2"></a><a id="Tc_Euo1cKop90mZm_KzaWpZ4Q_4_5"></a><a id="Tc_7j5Z0WNi7EWD7NElQ_Zy_w_5_0"></a><a id="Tc_Cxbl_ioX6UG6v5Y2bR5dRQ_6_0"></a><a id="Tc_QpUyEw9Mf0eRWFAltaLxqA_8_0"></a><a id="Tc_cqyO5-_a7EeO6310F0qTUg_8_2"></a><a id="Tc_n-_epMRTaU-wZB5f39hpFA_8_5"></a><a id="Tc_OvgdlEi-skSyKdh92T0pDw_9_0"></a><a id="Tc_q9gjUg7uKk6sWuT9Xm_43g_10_0"></a><a id="Tc_T9efK92Q_E-YY7ybtbNRmA_11_2"></a><a id="Tc_xpkN_m6GTkeT2F2nBqi9jQ_11_5"></a><ix:continuation id="Tb_UaBBzSh0I0K6s8bobm7gaw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_-3tod4s2nE6bZCq4F6jdLQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:31.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per ESPP purchase right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_FxcmODofWkmEJZsFB3sBWQ_3_3">5.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc__dFZTijdzEacQvm-0s8rLQ_3_7">1.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)&#8201;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_okv8Y4ytQUqgTRIkYyFQHA_4_3">0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_oJdn65-2SE-LuaB92KTG8w_4_7">0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_6CMeAQUPwUKxE7pf4vkJZQ">76.2</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_Gu5M6W-AWkW-lc30E5lsiA">84.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_R6ANK4f5EUy6oQaER8pKkA">51.3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_KtvoPtnx-UGMMTOoJZIfOg">62.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_0gIPzdw5M02FCzWVJ9KpQA">4.77</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_I--XO-NmRkW-wFVvZyjsig">5.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_E2UzAs6Nw0ydZu8U5_IzXA">0.22</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_JSGxuImZWEGaJVeuGC9B8g">2.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We review these assumptions on a periodic basis and adjust them, as necessary. We utilize the simplified method to develop the estimate of the expected term for stock option awards and ESPP purchase rights. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_HpFFC8JyhkK0EwZTkPuRjA">zero</ix:nonFraction>, as we have never paid dividends and have no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_-HON-094-UKJZlGPvFVOVA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components and classification of stock-based compensation expense for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DMx2Q-pIhEONVzCgF2k4wA_4_3">5,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nkD-u4WiQ0mrjniXFapG0w_4_6">3,664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hLGfoJfI2EyE0jj5VWT_Og_5_3">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NZ6ualOdQUG6CqFYITkLmg_5_6">223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_3_nrVofSwUaJkkVv2eEKog_6_3">6,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HocpfTsmDk2Sl1PdfrOFcg_6_6">3,887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fkJEZGVxqUusT4haccsrQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ng3JO9uzsEWzy_q7b5i1JA_8_3">5,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8_aaeerAjEej9OSFdIalGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cx2EMHKyo0C7T-jjNVKPjg_8_6">3,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__6BtJaAInUut6oE3yTHB_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_X3sPPXVQ5kmYH2dxh1SUDA_9_3">1,152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TGtZmK623E2xW1C_jsdOhg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Lr3yl4WjkEeke1_ppg_4Iw_9_6">519</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GPUIUQBt3ECv70XnSLRrTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IJ79Wulcpkq3dlArUZvjKQ_10_3">78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LHxLWQFoVk6j4n7SU0LYMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_5qdgiXubm0iEASJz44TUJw_10_6">64</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_pdKQSMw23UGH2sfAqxsPkw_11_3">6,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_m9qZ1NE-f0ClLZSUgJEusA_11_6">3,887</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, unrecognized compensation expense related to unvested stock-based compensation arrangements was $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_ty-PpDV-e0S5qeObcNYdfw">13.4</ix:nonFraction> million. As of December 31, 2023, the related weighted average period over which the expense is expected to be recognized is approximately <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_eJ7hXHjl4EOiEmS6FMj_RA">2.4</ix:nonNumeric>&#160;years.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_0Tv-MvIzDUi9XUgMtesNUA" continuedAt="Tb_0Tv-MvIzDUi9XUgMtesNUA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Income taxes</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, a valuation allowance was recorded against all deferred tax assets due to our cumulative net loss position. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bbcd1f9a_28cc_4d64_a9ea_21f124c4b3f9"></a><a id="Tc_WrbHsTUCWUqJe_QPtNck6A_1_3"></a><a id="Tc_czlhR8-ThUeZ83Nr-k9WKA_2_3"></a><a id="Tc_hmmINF5J0UyLtm-lGxtf9w_3_0"></a><a id="Tc_Mr5gpN_yLkydm7l9CT7n_g_3_3"></a><a id="Tc__u-m6yD3aUm50_HxQ7UIPQ_3_6"></a><a id="Tc_7dxJwP2TiEWLXzXAjvqlzg_4_0"></a><a id="Tc__82O7Wx22EC1g1i3U0bpmw_5_0"></a><a id="Tc_aLrk7KpHwU-qqCMPdJNdaA_5_2"></a><a id="Tc_RoE-t3Lqf0WmtF3FVTUDdA_5_5"></a><a id="Tc_rJFk6QySok26nbA5ZV2U8Q_6_0"></a><a id="Tc_lUtJOuj0zk2qBQqaLISNFQ_7_0"></a><a id="Tc__auVBUXhd0ikRXy2MfopEw_7_2"></a><a id="Tc_rr6mfX7DxEiSdE0W-Dd7Vw_7_5"></a><a id="Tc_nQRm6dTu-kmhdqebxsH3Xg_1_3"></a><a id="Tc_EnjnelV4r0mrK8-wWUKmqQ_2_3"></a><a id="Tc_LRsdzBzCgk-dd7gBx2laeA_3_3"></a><a id="Tc_yA6G63ULMEOmdLwk4En-6Q_3_6"></a><a id="Tc_qvPFzDD4UUyLxDwz8mxbBg_4_0"></a><a id="Tc_SqFiJsZa6UaTyFECkerSSQ_4_4"></a><a id="Tc_WcKp1n_gu0SeuJdi-zMJzQ_4_7"></a><a id="Tc_Z8M38MhB10u7Hnw2jhhRSw_5_0"></a><a id="Tc_j2FnZdawekm_9j0tkKtPWw_6_0"></a><a id="Tc_jNcvCF-E_EKQBDsc8vPEWg_7_0"></a><a id="Tc_bNgJncAMd0i5BM9bmS9Deg_8_0"></a><a id="Tc_SjpB6cqtCkKPBeYrxwuf7g_9_0"></a><a id="Tc_W5qS3Z5yl0CZSAWSLLV7_w_10_0"></a><a id="Tc_ZUdL5Ek99kGLOb5cIyrkJw_11_0"></a><a id="Tc_wNYhg7kVMkOtHuuXGZOYSw_11_4"></a><a id="Tc_qHfUeqZVEEWUI2HjBpXDJw_11_7"></a><a id="Tc_j1Hs83y3ME2kYvnMAusjqg_1_3"></a><a id="Tc_Ip2jgk5sgkKL-WvQR6iefg_2_3"></a><a id="Tc_LK5SjhgJxUitnyO2gmjb7w_3_0"></a><a id="Tc_P_hcjkpTz0y6oJ251_ZaQQ_3_3"></a><a id="Tc_TxzKFqzJfUuoO4OxUp0jGw_3_6"></a><a id="Tc_YvMO3PZbBEOghin3wlXWDw_4_0"></a><a id="Tc__xLj96lUsECjczpBn7OHcg_5_0"></a><a id="Tc_cWE7PDAwZEi9iox1lgXH8Q_5_2"></a><a id="Tc_6tDmoAiRZk2LrK9flkcQ-Q_5_5"></a><a id="Tc_uICmWIyI8EOQpMFnX5JMtA_6_0"></a><a id="Tc_LTDrn_7OGkeBZPVqIPxV5w_7_0"></a><a id="Tc_2nwJRI_q5Uu55CqaxSGnaw_8_0"></a><a id="Tc_zUbdwT6hqU6RewTGIWKftg_9_0"></a><a id="Tc_Kqd-QaV05kSV-P4LIPzqyA_10_0"></a><a id="Tc_3mc-6361iUuNuO516DqNUA_11_0"></a><a id="Tc_-dYQCOf6ikmjyBF71mzf1g_12_0"></a><a id="Tc_HC6Cgkzb7E-TKU1Mg9Tsvg_13_0"></a><a id="Tc_eZmjypFAd0GXHs80F_n6oQ_14_0"></a><a id="Tc_-Y_d78qO_UmXeICh8I3Ilg_15_0"></a><a id="Tc_t6EOx1i79EGe5rPPhh9tkw_15_2"></a><a id="Tc_Qv6GYfW4KEOeA5UIWf7A0g_15_5"></a><a id="_Hlk62564010"></a><ix:continuation id="Tb_0Tv-MvIzDUi9XUgMtesNUA_cont1" continuedAt="Tb_0Tv-MvIzDUi9XUgMtesNUA_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_1giAcaiuDU6R3D4D4NaNYQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_Z5nVHSRV8UytDOymJEGKxg_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_85E4tKMQ1ESB8G-CAkzgXg_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_YvvKVC4XaUaSm1aBh0oaxQ_6_3">147</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="Tc_3rADFbiBTUmZUNqhDcdBvg_6_6">109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_hGjnzcCHFkGTnyfkPWsQ0A_7_3">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_GRdBu-wn6kSEJKq7tmPRAg_7_6">109</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows for the periods indicated:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_mbHavD_77E2H_HKyAntgFQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_bwLWz7Rc0ki-BCsdx9jaBA_4_3">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc__R3Tr3O6NEOaHOCirrPIFA_4_6">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_YO9H-xHQek6pGFdcUwuUZQ_5_3">4.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_xYl33uTA9kiVVnRknmq7QQ_5_6">2.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_GGvuyQAKT0-PW5dtsxShdw_6_3">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" sign="-" scale="-2" id="Tc_15_s-Je-rUyZ6ZvnRX3ocg_6_6">0.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" sign="-" scale="-2" id="Tc_hAfgSUty3kWopqHZXEoNsg_7_3">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" sign="-" scale="-2" id="Tc_u9v3KmOVMEetT8U6o72a9g_7_6">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_wONjMgmV1UK5jkfQSKRZWQ_8_3">2.6</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-2" id="Tc_EssoK77eZUOHOtpejDTUmQ_8_6">0.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_bmO3SfkEX0uRO5tD7RtdPQ_9_3">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_iJ8N9cpZgEulyvBQY6Retw_9_6">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_8XGMYvn5SEuIAlDerjhL8A_10_3">21.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_IwlR2W0nWEGb7r2S6izzPw_10_6">19.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_1LAZIn8rtEuwKGYL8K0bsg_11_3">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Tc_jDjH_uPpCEmuTZnYYEL4Vg_11_6">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows for the periods indicated:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_mT7QbQmt_0ykTAnyanp2aQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_qZghomTcVkmd0Ots9UjWUw_5_3">89,173</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_I1UYr2gXwEi4wt860GWyZA_5_6">82,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_bABffPOhMECQ5cBbV4Q3AQ_6_3">9,664</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_PQV9e4eGZEWdqbzYGiukBA_6_6">9,072</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" id="Tc_eZQSnEuqpEO88VpSJr3Ymg_7_3">8,963</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" id="Tc_1DUgIGadKkeHJ9Z1aUS-bA_7_6">8,412</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_p1hLjxrrWket62o_vY5qvQ_8_3">1,473</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_VY-7gszDK06bH_FU3cXdww_8_6">752</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_dtcXex9lb06veswx62YR8g_9_3">680</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="cvrx:DeferredTaxAssetsStartUpCosts" scale="3" id="Tc_48zord1AkkmBn6TeVlBDJA_9_6">894</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_uLMWVjQShEGnAOHqQIycjA_10_3">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" scale="3" id="Tc_HJ6MX-uAJ0uD1jBMJ3GO8g_10_6">212</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_TjygEyDegUCs52nRAmjMag_11_3">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="Tc_3lyLw3pe80OdfPxRTcpBHA_11_6">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_ptGKXLGnRkuY1dT6VrDFtA_12_3">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_lamefEVQN0Sw6TQXhU3Pkw_12_6">300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_GxA26gAquEST9rO37Lvj3Q_13_3">110,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_LH0uiF9qKEq42JCB4BPE8w_13_6">101,836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc__6sBaYs-xkGpznaIroE0wQ_14_3">110,552</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_YrW_ktuuIUqaeOjiuuItEg_14_6">101,836</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_8729aqw9hEGFcc1MpLDYTg_15_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_fknw6Nd5GkmPosVAZw9a-A_15_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023, we had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_7Lza9lQnP0GeHg-QJ6eaQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_BrnnSg4n1kCXef9WkS5lhg">389.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_pdlrV4rnDEG1xPe8LI1SMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_hJHjznAnfUeAZ4UiCt0HPg">7.3</ix:nonFraction> million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2023, we had federal and state tax credit carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_7Lza9lQnP0GeHg-QJ6eaQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_ZapPGW8oBUaeu1I2tz_UWw">9.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_pdlrV4rnDEG1xPe8LI1SMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_keD6PwIUAEWnvtqwlgMvCA">2.0</ix:nonFraction> million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits will begin expiring in 2028. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9e1cc25a_fa66_4c85_8dad_80518de99313"></a><a id="Tc_4HfGb69E50ix8f5jQLCugg_1_3"></a><a id="Tc_0LY2crz1bUOI6g4wWRjfIA_2_3"></a><a id="Tc_pYvbV-5d_UioLdavV7gcLQ_3_0"></a><a id="Tc_Btd71qYgvk6Md7MK1TSxmQ_3_3"></a><a id="Tc_nJFmx0M9uEWeb42AM2OL5A_3_6"></a><a id="Tc_RjDZ_Rz7EEumAemKcqfLzg_4_0"></a><a id="Tc_3p0W1qC8dEGehADXefwJ_g_4_2"></a><a id="Tc_IsZtCiHbMkSBdESf00OXJQ_4_5"></a><a id="Tc_EnqBLzt72UmfcE33jmBldQ_5_0"></a><a id="Tc_EXFW98YmAEWJJVx9sRFxaQ_6_0"></a><a id="Tc_5FcD_ZOjeEel_A-fGw9ORg_7_0"></a><a id="Tc_72sNu6yMv0COrT3AkcKh_g_8_0"></a><a id="Tc_WxHhXK2iXkKTkrowoyGEcA_9_0"></a><a id="Tc__ihHnLF1mkKs2wHnhYoraw_10_0"></a><a id="Tc_A-R5qPj41UOp3VUsPG6pLQ_10_2"></a><a id="Tc_NyS2X7-hyk6W83kfqelfFg_10_5"></a><ix:continuation id="Tb_0Tv-MvIzDUi9XUgMtesNUA_cont2"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit our utilization of the NOLs and could be triggered by subsequent sales of securities by us or our stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_Fuyla09NXk220WEykXE6kQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_Kf8ZWcGzVUOz6RdGfe9OEQ_4_3">2,046</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_z9DPw28jv0Kt0soc1yre_A_4_6">1,939</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_wQHXUvKjoUq7s7l20jcRCQ_6_3">12</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="Tc_lrd2DJg57U-Jow-fNnzBxw_6_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_ByZWT1eGoUWkuh632SsaVQ_7_3">185</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_Ypg7YPqk302h9YAkArpEDg_7_6">113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_PCNbdBTMxkOam3Ht6tjcNg_9_3">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_ASx4WhAdgEOI0U40m1v1hA_9_6">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_JUlHS_Y6oE25_9IvNVpUng_10_3">2,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_hILw-fDEBUSc6h21VB_CdA_10_6">2,046</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The amount of unrecognized tax benefits subjected to the valuation allowance was $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-5" format="ixt:numdotdecimal" name="cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance" scale="6" id="Narr__2CvsZuts0K92CsciyVlZw">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-5" format="ixt:numdotdecimal" name="cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance" scale="6" id="Narr_1hMIEoAQ20K0i-EMxa2Cig">1.6</ix:nonFraction> million for the&#160;years ended December 31, 2023 and 2022, respectively. We recognized approximately $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="6" id="Narr_rreyNCr1gEucl7jSLGGsCQ">0.1</ix:nonFraction> million of interest or penalties for each of the&#160;years ended December 31, 2023 and 2022. As of December 31, 2023 and 2022, total accrued interest and penalties were $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_Pr3GW3TeeUOEYrH40VicEw">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_mR2dCCIA7kS-YISjbXcoVw">0.4</ix:nonFraction>&#160;million, respectively. We recognize accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. We do not expect a significant change in the amount of unrecognized tax benefits in the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2004 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. We do not have any tax audits or other proceedings pending.</p></ix:continuation><a id="_ce914ebb_f4ca_4882_93b3_e23dfc67a5b1"></a><a id="Tc_sqlnxpe8wESge7eeGVww6A_1_3"></a><a id="Tc_G2Y5sZ2tb0yakae0pccXyA_2_3"></a><a id="Tc_Y2UAekE_vEKobtJLXH-k7g_3_3"></a><a id="Tc_eyzMRw4rWEKUKclb4DIxsQ_3_6"></a><a id="Tc_hEkdZBfN50mveuOkkflWCg_4_0"></a><a id="Tc_JaQVnsCMiUSG0fFJZz8dRw_5_0"></a><a id="Tc_IFMIL9BipUais_QI_-Dbew_5_3"></a><a id="Tc_6tFUtl7w1EKPe1DMf5CJjA_5_6"></a><a id="Tc_a0ciePc15EmgVeobZBPEhg_6_0"></a><a id="Tc_J_V28T83mUmxJ_-3o1imhg_7_0"></a><a id="Tc_n47csiJFWUa6aP-wjOBsKQ_8_0"></a><a id="_Hlk78985748"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_2j4a6zQV2Um89PNXHaX70w" continuedAt="Tb_2j4a6zQV2Um89PNXHaX70w_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">9. Loss Per Share</b></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_6Ojm5wg51kOSAIJ8W-ZzQg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Bl8JKkCmKk2s6i0NgZ7JhQ_5_4">41,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_pPbFGW5y4US8ZboCT-jqMQ_5_7">41,428</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_nP2TRmoKckGCfT3oxiR1Nw_7_4">20,754,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_phj-TtmCZ0CSh72iwUzJzw_7_7">20,532,838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1-VKvzFxtkGYxn2bxA0KOQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_aQobqL87lUCxdrVnX_LnOw_8_4">1.99</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9k-u6oSvH0SUWtDFYknU1A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hVvVwDwgxEil6uvxYHg92A_8_7">2.02</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our potentially dilutive securities, which include stock options and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. We excluded the following potential common shares, presented based on amounts outstanding at each period end, from the </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_nsPN4k1ykUOb3arYJO9X6g_1_2"></a><a id="Tc_juzciwGwLU24Kwo1B2rfbA_2_2"></a><a id="Tc_UxT2IO00bUSVEA-cJT_xKA_3_2"></a><a id="Tc_3qel2LpEI0ejnUz-OhbpyA_3_4"></a><a id="Tc_yQmB17GcE0ySYjspc3qjig_4_0"></a><a id="Tc_UKjcdmEEGk2fs9oGeblgkg_5_0"></a><ix:continuation id="Tb_2j4a6zQV2Um89PNXHaX70w_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_9Z824_9G0E6A8V_UMSGVwg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M3MwyXey0USuIVtewS_fUw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_OL3i2SBZokWuwmazBnD7PQ_4_2">4,488,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eeym4sX_ZE-eYRj-nhAxtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_e22pD9YxYEeCidF_x7Nc1Q_4_4">3,756,835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_UrSmq1MvHUGq4lKnkUhBMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wOas_bpCNUiMOb36_bKlzw_5_2">716,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_kyjAoWWjHEOiI5UhzjPamg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KgN_zTfg1EiT-iOyQrVCxg_5_4">716,131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vXXfTj_KAEGQXNFywuUqsg_6_2">5,204,976</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6AyAjprz-Eykgwv3WVpmIw_6_4">4,472,966</ix:nonFraction></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_v6P-OBMMdUC-XIr6GgJlTQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commitments and contingencies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have certain contingent liabilities that arise in the ordinary course of business. We accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_7TbO-0EF4k2BYmcZp4TaPQ"><ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_Xi85bmxgbUO0tIP2PwHASg">no</ix:nonFraction></ix:nonFraction> contingent liabilities requiring accrual or disclosure as of December 31, 2023 or December 31, 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_29BCHxQQ40m55Vf0RbOONQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Employee benefit plans</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sponsor a voluntary defined-contribution employee retirement plan (the &#8220;401(k)&#160;plan&#8221;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. We do not provide matching contributions to employees.</p></ix:nonNumeric><a id="_6966e109_9db4_4f0b_977c_c69d781d356e"></a><a id="Tc_6icVX5ZnjEqz1MBIIcZQ2g_1_2"></a><a id="Tc_0RhBGFvSekK-1DcAkT3K6Q_2_2"></a><a id="Tc_Ec-BhgUabkqwpy8Nx5nWEA_3_0"></a><a id="Tc_HhaZQxa7Y0Sr4gMwFmny6A_3_2"></a><a id="Tc_jVJr1qApb0qyLJOuFLcCPQ_3_5"></a><a id="Tc_vhnGzJS2qEWapTEpOI_9Yg_4_0"></a><a id="Tc_GNsvPbu6hEywxsEMQ4sUag_4_2"></a><a id="Tc_8hKE5dQfkU2-oHrQPj-NfQ_4_5"></a><a id="Tc_I5neQA_oWEK6endJ_dMLmQ_5_0"></a><a id="Tc_fJtrrYdsmEq0MahEzBKn4g_6_0"></a><a id="Tc_m7VmU70ccEmoOVkoo05rxQ_7_2"></a><a id="Tc_dERfmsyAY06nSlR9-MBepg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_R_uCxYkfHUiAPTdWRnQcvw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Segment, geographic information and revenue disaggregation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our chief operating decision maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. We have <ix:nonFraction unitRef="Unit_Standard_segment__laEB6QyrUy_CRagT_GFBw" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_PqU_t4U_L06RlRcyZEXO3g">one</ix:nonFraction> business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, we have determined that we have a single reportable and operating segment structure. We and our Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_L4JIyeT_pUmxDvSEk4rJNg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We derive all our revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_MEKc9Q4xt0S15FUWcDf8Vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_GsBZOSo0-EOqY5EveItrzA_4_3">35,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_DeT00G4a6EO7jrVDjnnWKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_HUOMvmrFa0unkXuO5jWCgQ_4_6">18,021</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_DE_li7LfrlDcE-yU9xxp6rxsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_0o0k7TSIHkq-sgleHQLilQ_5_3">3,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_Nr4zMiPicku7JB9fF5v_mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_CLVvS8-fF06_OBeISuAUzQ_5_6">3,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_z-s50K3S1kivNIA3YmG5FQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_XyBs8AKQ6kub4IeNOUm4KQ_6_3">494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_UW_cLJGP9UCo_5BtyGIPrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_uoPhoOJgiken4ZLQ8oBRMg_6_6">971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_9aqEqdaq3EKczEK19souPw_7_3">39,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg" contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_FSAWmRqzEU6FpVA3LtUYiw_7_6">22,469</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023 and 2022, long-lived assets were located primarily in the U.S.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_x8WfqCeT_EysrCwE3wkDDg" continuedAt="Tb_x8WfqCeT_EysrCwE3wkDDg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">13. Subsequent events</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On January&#160;31, 2024, we announced that our Board of Directors appointed Kevin Hykes as President and Chief Executive Officer, effective February&#160;12, 2024 to succeed Nadim Yared, who previously announced his plans to retire upon the appointment of his successor. In connection with a transition and consulting agreement we entered into with Mr. Yared, we also modified certain terms and conditions of Mr. Yared&#8217;s stock options granted under the 2001 Plan and 2021 Plan, however, the impact of this modification on the amount of stock-based compensation expense cannot yet be quantified.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_x8WfqCeT_EysrCwE3wkDDg_cont1"></ix:continuation><a id="_e4fc74d0_ecd8_41c3_bccf_0e12c1375d2d"></a><a id="Item9ChangesinandDisagreementsWithAccoun"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item 9. Changes in and Disagreements</b><b style="font-size:12pt;font-weight:bold;"> with Accountants on Accounting and Financial Disclosure</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">None.</p><a id="_a1a82092_8928_4218_b2e4_1dcaa94402f5"></a><a id="Item9AControlsandProcedures"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9A. Controls and Procedures</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and other procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this Annual Report on Form 10-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in internal control over financial reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Management Report on Internal Control over Financial Reporting</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Management assessed our internal control over financial reporting as of December 31, 2023 based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies and our overall control environment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Based on this assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external reporting purposes in accordance with U.S. GAAP. We reviewed the results of management&#8217;s assessment with the audit committee of our board of directors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_76860196_7592_4f15_84ae_43e11eea5046"></a><a id="Item9BOtherInformation"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9B. Other Information</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the three months ended <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr__4Sc6R5W7kecb84uvMh4yQ">December 31, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_ndVbYL8T0UC9xQw-5q7QaA">none</ix:nonNumeric> of our directors or officers adopted, modified or terminated a &#8220;Rule <ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_3fv9CQ7noEeqhsFn56qUzQ">10</ix:nonNumeric>b<ix:nonNumeric contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_bb0oUhvipEOz-KRQO1YqkQ">5</ix:nonNumeric>-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4cc2b18e_ed4e_4fe0_9e10_8105b82dddcf"></a><a id="Item9c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">None.</p><a id="_2754c4bd_0c27_4f74_9aba_f62e1652100c"></a><a id="PARTIII"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART III</b></p><a id="_bd767f4a_1e52_4d79_904f_8a933e49ba52"></a><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023.</span></p><a id="_4ca1234c_978f_4fc8_b8a6_d43e56a914e9"></a><a id="Item11ExecutiveCompensation"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item 11. Executive Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023.</span></p><a id="_24cf4838_63a9_4543_bb82_773804dffdcc"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item 12. Security Ownership of Certain Beneficial Owners</b><b style="font-size:12pt;font-weight:bold;background:#ffffff;"> and Management and Related Stockholder Matters</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">T<span style="background:#ffffff;">he information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023.</span></p><a id="_14c5d699_7c3c_4288_b279_757b994c17ce"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023.</span></p><a id="_e07097e4_2727_4ef6_a2b2_f4398b5102f8"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;14. Principal Accountant Fees and Services</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The information required by this Item is incorporated by reference to our definitive proxy statement for our 2023 annual meeting of stockholders to be filed with the SEC within 120 days of the fiscal year ended December 31, 2023.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:12pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5160072e_3e51_496a_8566_c47f899aa667"></a><a id="PARTIV"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PART IV</b></p><a id="_30a3676c_3dd4_406b_8c26_28c46de382f4"></a><a id="_950575"></a><a id="Item15Exhibits"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Item&#160;15. Exhibit</b><b style="font-size:12pt;font-weight:bold;"> and Financial Statement Schedules</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(a) 1. Financial Statements:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The following consolidated financial statements of the Company are set forth in Part II, Item 8:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span>Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA" name="dei:AuditorFirmId" id="Narr_zcq4-MoB8EGkg4B-EkVM9Q">248</ix:nonNumeric>)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">Consolidated Balance Sheets as of December 31, 2023 and 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 72pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:36pt;"></span>Notes to Consolidated Financial Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">     2. Financial Statement Schedules:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">All financial statement schedules are omitted as the required information is inapplicable or the information is presented in the consolidated financial statements or related notes.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">     3. Exhibits:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>See the response to Item 15(b) below.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;background:#ffffff;margin:0pt;">(b) Exhibits:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:88.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921089779/tm2121505d1_ex3-1.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of CVRx, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921089779/tm2121505d1_ex3-2.htm"><span style="font-style:normal;font-weight:normal;">Amended and Restated By-Laws of CVRx, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on July 7, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex4-2.htm"><span style="font-style:normal;font-weight:normal;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.2*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-3.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of September 12, 2014, issued by the Company to Life Science Loans, LLC (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-4.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of September 12, 2014, issued by the Company to Silicon Valley Bank (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.4*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-5.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of July 21, 2015, issued by the Company to Life Science Loans, LLC (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.5*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-6.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of July&#160;21, 2015, issued by the Company to Silicon Valley Bank (incorporated by reference to Exhibit 4.6 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.6*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-7.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.7 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.7*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-8.htm"><span style="font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.8 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.8*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-9.htm"><span style="font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.9 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.9*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-10.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Stock, dated as of May 31, 2016, issued by the Company to Oxford Finance LLC (incorporated by reference to Exhibit 4.10 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.10</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-12.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Series G Convertible Preferred Stock, dated as of September 28, 2018, issued by the Company to Biosense Webster, Inc. (incorporated by reference to Exhibit 4.12 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.11</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-13.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan A), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Credit II LLC on February 6, 2020 (incorporated by reference to Exhibit 4.13 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.12</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-14.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan B), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Credit II LLC on February 6, 2020 (incorporated by reference to Exhibit 4.14 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.13</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-15.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan C), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation, as assigned to Horizon Funding Trust 2019-1 on February 18, 2020 (incorporated by reference to Exhibit 4.15 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.14</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex4-16.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Warrant to Purchase Shares of Series G Preferred Stock (Loan D), dated as of September 30, 2019, issued by the Company to Horizon Technology Finance Corporation as assigned to Horizon Funding Trust 2019-1 on February 18, 2020 (incorporated by reference to Exhibit 4.16 to the Company&#8217;s Registration Statement on Form S-1 filed on June 4, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">4.15</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837022001539/tmb-20211231xex4d16.htm"><span style="font-style:normal;font-weight:normal;">Description of the Company&#8217;s Common Stock (incorporated by reference to Exhibit 4.16 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Lease, dated October 13, 2008, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">First Lease Amendment, dated November 30, 2010, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.3*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Second Lease Amendment, dated October 22, 2012, by and between the Company and Duke Realty Limited Partnership (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.4*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-4.htm"><span style="font-style:normal;font-weight:normal;">Lease Amending Agreement No. 3, dated April 21, 2016, by and between the Company and AX CROSSTOWN VI L.P. (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Lease Amending Agreement No. 4, dated May 18, 2020, by and between the Company and AX CROSSTOWN VI L.P. (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837023009381/cvrx-20230331xex10d1.htm"><span style="font-style:normal;font-weight:normal;">Fifth Amendment to Lease, dated April 21, 2023, by and between the Company and TCI TT, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 11, 2023)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.7<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex10d7.htm"><span style="font-style:normal;font-weight:normal;">Sixth Amendment to Lease, dated November 7, 2023 by and between the Company and TCI TT, LLC </span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">Eighth Amended and Restated Investors&#8217; Rights Agreement, dated July 1, 2020, by and among the Company and the holders listed therein (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.9#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921077026/tm2112357d6_ex10-8.htm"><span style="font-style:normal;font-weight:normal;">2001 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.10#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Employees/Officers) pursuant to 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.11#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-3.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2001 Stock Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.12#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-9.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.13#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-5.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Employees/Officers) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.14#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-6.htm"><span style="font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Non-Employee Directors) pursuant to 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.15#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921088336/tm2120909d1_ex10-7.htm"><span style="font-style:normal;font-weight:normal;">Form of Non-Plan Stock Option Agreement (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-8 filed on July 1, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837022001539/tmb-20211231xex10d14.htm"><span style="font-style:normal;font-weight:normal;">Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.17#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-12.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Form of Executive Officer Employment Agreement (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465921084344/tm2112357d10_ex10-13.htm"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Form of Indemnification Agreement between the Company and its directors and officers (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1/A filed on June 23, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.19*</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465922113505/tm2229314d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Loan and Security Agreement, dated as of October 31, 2022, among the Company, Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 1, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.20</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465922114951/tm2229612d2_ex1-2.htm"><span style="font-style:normal;font-weight:normal;">Equity Distribution Agreement, dated as of November&#160;4, 2022, by and between the Company and Piper Sandler &amp; Co. (incorporated by reference to Exhibit 1.2 to the Company&#8217;s Registration Statement on Form S-3 filed on November 4, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.21#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465924008555/tm244504d1_ex10-1.htm"><span style="font-style:normal;font-weight:normal;">Employment Agreement between the Company and Kevin Hykes dated January 26, 2024 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 31, 2024)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10.22#</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000110465924008555/tm244504d1_ex10-2.htm"><span style="font-style:normal;font-weight:normal;">Transition and Consulting Agreement between the Company and Nadim Yared dated January 30, 2024 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 31, 2024)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1235912/000155837022001539/tmb-20211231xex21d1.htm"><span style="font-style:normal;font-weight:normal;">List of Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K filed on February 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">23.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex23d1.htm"><span style="font-style:normal;font-weight:normal;">Consent of Grant Thornton LLP, independent registered public accounting firm</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex31d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">31.2<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex31d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex32d1.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350, as adopted pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">32.2<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex32d2.htm"><span style="font-style:normal;font-weight:normal;">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">1350, as adopted pursuant to Section</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#160;</span><span style="font-style:normal;font-weight:normal;">906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">97.1<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="cvrx-20231231xex97d1.htm"><span style="font-style:normal;font-weight:normal;">CVRx, Inc. Mandatory Compensation Recovery Policy</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.INS<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Instance Document<span style="font-family:'Times New Roman','Times','serif';">&#160;&#8211;</span> the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.SCH<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.CAL<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.DEF<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.LAB<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">101.PRE<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">104<span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 0.65pt;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit<span style="font-family:'Times New Roman','Times','serif';">&#160;</span>101)</p></td></tr></table><div style="font-family:'Arial','Helvetica','sans-serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Times New Roman','Times','serif';">&#8224;</span></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;background:#ffffff;padding:0.75pt;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:96.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:3.87%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">*</p></td><td style="vertical-align:middle;width:96.12%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K under the Securities Act. The Company agrees to furnish supplementally any omitted exhibits and schedules to the SEC upon request.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_54b35627_bccc_4383_95f3_1cce6b4039dd"></a><a id="Item16Form10KSummary"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;background:#ffffff;">Item&#160;16. Form 10-K Summary</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">None.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="font-family:'Times New Roman','Times','serif';" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_99da139e_9395_48b5_a6cf_615acb6b434d"></a><a id="SIGNATURES"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: February 9, 2024</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CVRX,</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">INC.</b></p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ Nadim Yared</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Nadim Yared</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:12pt;"><td colspan="2" style="vertical-align:middle;width:43.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="3" style="vertical-align:middle;width:88.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: February 9, 2024</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signature</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title</b></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Nadim Yared</p></td><td style="vertical-align:bottom;width:56.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">President and Chief Executive Officer (Principal Executive Officer)</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nadim Yared</b></p></td><td style="vertical-align:bottom;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Jared Oasheim</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jared Oasheim</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Ali Behbahani</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ali Behbahani</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Kevin Hykes</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kevin Hykes</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Joseph Slattery</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Joseph Slattery</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Mudit Jain</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Mudit Jain</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Kirk Nielsen</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kirk Nielsen</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">/s/ Martha Shadan</p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;">February 9, 2024</p></td></tr><tr><td style="vertical-align:top;width:25.06%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Martha Shadan</b></p></td><td style="vertical-align:top;width:56.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.31%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>cvrx-20231231xex10d7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:14:46 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Courier';font-size:12pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.7</b></p><p style="font-family:'Courier';font-size:12pt;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SIXTH AMENDMENT TO LEASE</b></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This SIXTH AMENDMENT TO LEASE (&#8220;Amendment&#8221;) is dated this 7th day of November, 2023, by and between TCI TT, LLC, a Delaware limited liability company (&#8220;Landlord&#8221;), and CVRx, Inc., a Delaware corporation (&#8220;Tenant&#8221;). </font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">A.</font><font style="font-family:'Times New Roman','Times','serif';">Landlord, as successor in interest to Duke Realty Limited Partnership, and Tenant are the current parties to that certain Lease dated October 13, 2008 (&#8220;Original Lease&#8221;), as amended by that certain First Lease Amendment dated November 30, 2010 (&#8220;First Amendment&#8221;), as further amended by that certain Second Lease Amendment dated October 22, 2012 (&#8220;Second Amendment&#8221;), as further amended by that certain Lease Amending Agreement No. 3 dated May 20, 2016 (&#8220;Third Amendment&#8221;), as further amended by that certain Lease Amending Agreement No. 4 dated May 18, 2020 (&#8220;Fourth Amendment&#8221;), and as further amended by that certain Fifth Amendment to Lease dated April 21, 2023 (&#8220;Fifth Amendment&#8221;) (the Original Lease, First Amendment, Second Amendment, Third Amendment, Fourth Amendment and Fifth Amendment are hereinafter collectively referred to as the &#8220;Lease&#8221;), for the lease by Tenant of that certain space located at 9201 West Broadway, Suite 615, Brooklyn Park, Minnesota 55445, consisting of approximately 23,890 rentable square feet, as more particularly described in the Lease (&#8220;Current Premises&#8221;).</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">B.</font><font style="font-family:'Times New Roman','Times','serif';">Landlord and Tenant desire to amend the Lease to provide for an expansion of the Current Premises, and to make certain other specific modifications to the Lease, upon the terms and conditions hereinafter set forth.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">NOW, THEREFORE, in consideration of the foregoing and the mutual covenants hereinafter contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">1.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capitalized Terms</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;All capitalized terms in this Amendment have the same meaning defined in the Lease, except where expressly defined to the contrary in this Amendment.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">2.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confirmation</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Tenant acknowledges and agrees that: (a) Tenant is in sole possession of the Current Premises demised under the Lease; (b) all work, improvements and furnishings required by Landlord under the Lease for the Current Premises have been completed and accepted by Tenant; (c) Tenant has no offset, claim, recoupment, or defense against the payment of rent or other sums and the performance of all obligations of Tenant under the Lease; (d) the Lease is binding on Tenant and is in full force and effect, and Tenant has no defenses to the enforcement of the Lease; (e) Tenant has not assigned the Lease, or sublet the Current Premises; and (f) Tenant is not in default of the Lease and Tenant acknowledges that Landlord is not in default of the Lease.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">3.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion of Premises</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Commencing on December 1, 2023 (&#8220;Expansion Date&#8221;), Landlord leases to Tenant and Tenant takes from Landlord the addition of Suite 660 consisting of approximately 7,615 rentable square feet of space, which is depicted in gray on </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b><font style="font-family:'Times New Roman','Times','serif';"> attached hereto (&#8220;Expansion Premises&#8221;). &#160;From and after the Expansion Date, the total leased space shall consist of both the Current Premises and the Expansion Premises as depicted on </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b><font style="font-family:'Times New Roman','Times','serif';"> attached hereto, which totals approximately 31,505 rentable square feet. &#160;Commencing as of the </font></div></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">1</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Expansion Date, the Current Premises and the Expansion Premises shall be referred to as the &#8220;Premises&#8221; for all purposes under the Lease and this Amendment, subject to the terms hereof.</font></div><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">4.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;The current term of the Lease for the Current Premises is set to expire on August 31, 2028. &#160;It is agreed and understood that the Term of the Lease for the Expansion Premises shall be fifty-seven (57) consecutive months commencing on the Expansion Date, such that it will run concurrently with the Term for the Current Premises as extended herein, and expire on August 31, 2028 (the &#8220;Extension Term&#8221;). For clarity, the Option contained in Section 10 of the Fifth Amendment extends to and includes the Expansion Premises.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> &#160;</font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">5.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent</u><font style="font-family:'Times New Roman','Times','serif';">. Tenant shall continue to pay the Monthly Rental Installments for the Current Premises in accordance with the Lease. The Monthly Rental Installments for the Expansion Premises after the Expansion Date shall be paid in accordance with the Lease in the following amounts: </font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="padding-left:31.5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:96.83%;"><tr><td colspan="3" style="vertical-align:top;width:36.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time Period</b></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rate (PSF)</b></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Monthly Rental Installments</b></p></td></tr><tr><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">12/1/2023</font></p></td><td style="vertical-align:top;width:3.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8211;</font></p></td><td style="vertical-align:top;width:18.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">11/30/2024</font></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $12.00 </font></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $7,615.00 </font></p></td></tr><tr><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">12/1/2024</font></p></td><td style="vertical-align:top;width:3.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8211;</font></p></td><td style="vertical-align:top;width:18.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">11/30/2025</font></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $12.48 </font></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $7,919.60 </font></p></td></tr><tr><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">12/1/2025</font></p></td><td style="vertical-align:top;width:3.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8211;</font></p></td><td style="vertical-align:top;width:18.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">11/30/2026</font></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $12.98 </font></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $8,236.89 </font></p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">12/1/2026</font></p></td><td style="vertical-align:top;width:3.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8211;</font></p></td><td style="vertical-align:top;width:18.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">11/30/2027</font></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $13.50 </font></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $8,566.88 </font></p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">12/1/2027</font></p></td><td style="vertical-align:top;width:3.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8211;</font></p></td><td style="vertical-align:top;width:18.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">8/31/2028</font></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $14.04 </font></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> $8,909.55 </font></p></td></tr><tr style="height:4pt;"><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:18.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:24.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:38.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></td></tr></table></div><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">6.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Condition of Premises</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Tenant shall accept the Current Premises in its as-is condition as of the date of this Amendment and as of the date of the commencement of the Extension Term, and Landlord shall have no obligation to make or pay for any alterations, additions, improvement or renovations in or to the Current Premises to prepare the same for Tenant&#8217;s occupancy during the Extension Term. &#160;Tenant shall accept the Expansion Premises in its as-is condition as of the Expansion Date, and Landlord shall have no obligation to make or pay for any alterations, additions, improvement or renovations in or to the Expansion Premises to prepare the same for Tenant&#8217;s occupancy, except to pay the Allowance provided for in </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">7.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvements by Tenant</u><font style="font-family:'Times New Roman','Times','serif';">. All alterations or improvements by Tenant in the Leased Premises (&#8220;Alterations&#8221;) shall be subject to Section 7.02 of the Original Lease and </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</b><font style="font-family:'Times New Roman','Times','serif';"> attached hereto. &#160;</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">8.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Pro Rata Share</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;During such period that the definition of Premises includes both the Current Premises and Expansion Premises, Tenant&#8217;s Pro Rata Share set forth in the Lease shall be adjusted to 43.21% (31,505/72,919).</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">9.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Prior to Tenant taking possession of the Expansion Premises, Tenant shall provide to Landlord evidence reasonably satisfactory to Landlord that Tenant&#8217;s insurance, as required in the Lease, shall be in effect and include the Expansion Premises as of the time of possession.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">10.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Real Estate Brokers</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Notwithstanding anything to the contrary contained in the Lease, Landlord and Tenant each represents and warrants to the other party that it has not authorized or employed, or acted by implication to authorize or employ, any real estate broker or salesperson to act for it in connection with this Amendment, except for John Ryden of CBRE, on behalf of Landlord, and Tim Olsen of Carlson Commercial, on behalf of Tenant, each of whom shall be paid </font></div></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">2</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">a commission by Landlord pursuant to a separate written agreement. &#160;Landlord and Tenant each shall indemnify, defend, and hold the other party harmless from and against any and all claims by any other</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';">real estate broker or salesperson whom the indemnifying party authorized or employed, or acted by implication to authorize or employ, to act for the indemnifying party in connection with this Amendment.</font></div><p style="font-family:'Courier';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">11.</font><a name="_Hlk136523868"></a><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rent Payments</u><font style="font-family:'Times New Roman','Times','serif';">. All rent shall be paid to Landlord without notice, demand, abatement, deduction or offset, in lawful money of the United States via ACH.</font><font style="font-family:'Times New Roman','Times','serif';"> Landlord will not accept any other forms of payment, except upon the prior written approval of Landlord.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">12.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Landlord and Tenant each agree to execute any and all documents and agreements reasonably requested by the other party to further evidence or effectuate this Amendment.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">13.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;This Amendment is binding upon and inures to the benefit of the parties and their successors and assigns.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">14.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reaffirmation</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;Except as modified herein, all other terms and conditions of the Lease remain in full force and effect, and nothing herein may be construed to relieve either Landlord or Tenant of any obligations as set forth therein.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">15.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conflicts</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;In case of any conflict between any term or provision of this Amendment and the Lease, the term or provision of this Amendment will govern.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">16.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;This Amendment may be executed in one or more counterparts, each of which is deemed an original, but all of which when taken together will constitute one agreement.</font></div><p style="font-family:'Courier';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">17.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PDF Signatures</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;In order to expedite this transaction, signatures sent by PDF via e-mail or by any electronic means by which electronic signature technology identifies and authenticates the signer and the signer&#8217;s intent to sign (e.g. DocuSign) may be used in place of original signatures on this Amendment or any other document or agreement in this transaction, other than those to be recorded in the public records. &#160;Landlord and Tenant intend to be bound by the signatures on each PDF document, are aware that the other party will rely on the PDF signatures, and hereby waive any defenses to the enforcement of the terms of this Amendment or any related document based on the form of signature. &#160;In the event PDF signatures are used in any instance, ink-signed originals of those documents must also be promptly exchanged by the parties, but the failure to subsequently deliver those originals will not affect the enforceability of the PDF signatures.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">18.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;This Amendment shall be construed under the laws of the State in which the Premises is located. &#160;Whenever possible, each provision of this Amendment shall be interpreted in a manner that would render it effective and valid under applicable law. &#160;If any provision of this Amendment is determined to be invalid or unenforceable, that provision will be ineffective only to the extent of the prohibition or invalidity without invalidating or otherwise affecting the remaining provisions of this Amendment.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">19.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Authority</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;The undersigned officers and representatives signing this Amendment on behalf of Landlord and Tenant represent and warrant that they have the authority </font></div></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">3</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">to execute this Amendment on behalf of the business entity and that the same will be binding upon the business entity.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">20.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;The Lease, this Amendment, and any exhibits attached hereto, constitute the entire understanding of the parties with respect to this transaction, and supersede all prior agreements and understandings between the parties with respect to the subject matter. &#160;No representations, warranties, undertakings or promises, whether oral, implied, written, or otherwise, have been made by any party to any other party unless expressly stated in the above-referenced documents, or unless mutually agreed to in writing between the parties after the date hereof, and neither party has relied upon any verbal representations, agreements, or understandings not expressly set forth herein.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">21.</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effectiveness</u><font style="font-family:'Times New Roman','Times','serif';">. &#160;The parties agree that the submission of a draft or copy of this Amendment for review or signature by a party is not intended, nor will it constitute or be deemed, by either party to be an offer to enter into a legally binding agreement with respect to the subject matter hereof and may not be relied on for any legal or equitable rights or obligations. &#160;Any draft or document submitted by Landlord or its agents to Tenant will not constitute a reservation of or option or offer in favor of Tenant. &#160;The parties will be legally bound with respect to the subject matter hereof pursuant to the terms of this Amendment only if, as and when all the parties have executed and delivered this Amendment to each other. &#160;Before the complete execution and delivery of this Amendment by all parties, each party will be free to negotiate the form and terms of this Amendment in a manner acceptable to that party in its sole and absolute discretion. &#160;The parties acknowledge and agree that the execution and delivery by one party before the execution and delivery of this Amendment by the other party will be of no force and effect and will in no way prejudice the party that executed this Amendment or the party that has not executed this Amendment.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">[Signature Page Follows]</i></p></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> &#160; IN AGREEMENT, the parties have executed this Amendment as of the day and year first written above.</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">LANDLORD:</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TCI TT, LLC,</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">a Delaware limited liability company</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ H. Herbert Myers</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:60.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">H. Herbert Myers</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:60.04pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">President</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:106.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">TENANT:</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">CVRx, Inc., </font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">a Delaware corporation</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">By: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Jared Oasheim</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:74.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Name: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jared Oasheim</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:74.04pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Title: </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CFO</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:127.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:8pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">4196580</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">5</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Depiction of Premises</font></p><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><img src="cvrx-20231231xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:419.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:441.75pt;"></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">6</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Courier';font-size:12pt;line-height:1.07;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Exhibit B</b></p><p style="font-family:'Courier';font-size:12pt;line-height:1.07;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Tenant Improvements</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">1.</font><a name="_Hlk149227080"></a><font style="font-family:'Times New Roman','Times','serif';">Landlord will provide Tenant a cash allowance not to exceed $114,225.00 ($15.00 per rentable square foot in the Expansion Premises) (&#8220;Allowance&#8221;) for the construction of standard tenant improvements to be mutually agreed upon by Landlord and Tenant (&#8220;Tenant Improvements&#8221;). The Allowance may be used by Tenant for all &#8220;hard&#8221; and &#8220;soft&#8221; costs of designing, developing, constructing, and completing the Tenant Improvements.</font> </div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">2.</font><font style="font-family:'Times New Roman','Times','serif';">Tenant may use its own contractor and subcontractors (together, &#8220;Contractors&#8221;) to perform all Tenant Improvements. The names of all Contractors, together with proof they are licensed, are bonded and have worker&#8217;s compensation insurance must be provided to Landlord as hired.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">3.</font><font style="font-family:'Times New Roman','Times','serif';">Before commencement of the Tenant Improvements, Tenant must provide the following to Landlord, all of which must be to Landlord&#8217;s reasonable satisfaction and subject to Landlord&#8217;s prior written approval:</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt -3.6pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';">Plans and specifications for the Tenant Improvements.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt -3.6pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt -3.6pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';">An estimated budget and cost breakdown for the Tenant Improvements.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt -3.6pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt -3.6pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">An estimated completion schedule for the Tenant Improvements.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt -3.6pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt -3.6pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';">The names and contact information for all Contractors and proof of worker&#8217;s compensation insurance, licensing, and bonding.</font></div><p style="font-family:'Courier';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt -3.6pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';">Copies of all contracts with Contractors.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt -3.6pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt -3.6pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(f)</font><font style="font-family:'Times New Roman','Times','serif';">Copies of all required permits for the Tenant Improvements, including a building permit issued by the applicable local municipality.</font></div><p style="font-family:'Courier';font-size:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt;margin:0pt 36pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">4.</font><font style="font-family:'Times New Roman','Times','serif';">Tenant shall be solely responsible for the construction and completion of the Tenant Improvements to the reasonable satisfaction of Landlord and for the payment of all amounts due and payable in connection therewith, without cost or expense to Landlord except for Landlord&#8217;s obligation to pay the Allowance. Tenant shall diligently proceed with the construction and completion of the Tenant Improvements in accordance with the plans, specifications, and completion schedule approved by Landlord. Tenant shall secure all licenses and permits necessary for performance of the Tenant Improvements and for occupancy of the Premises. No material changes may be made to the plans, specifications, or completion schedule approved by Landlord, without Landlord&#8217;s prior written consent.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">5.</font><font style="font-family:'Times New Roman','Times','serif';">No materials, equipment, or fixtures may be delivered to or installed upon the Premises pursuant to any agreement by which another party has a security interest or rights to remove or repossess the items, without Landlord&#8217;s prior written consent.</font></div><p style="font-family:'Courier';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">6.</font><font style="font-family:'Times New Roman','Times','serif';">At all times, Landlord has the right to inspect the Tenant Improvements and Tenant will immediately cease work upon written notice from Landlord; provided, however, Landlord shall only require Tenant to cease work as a result of Tenant&#8217;s breach of the Lease, Tenant&#8217;s failure to comply with the plans and specifications approved by Landlord, safety concerns, or any other </font></div></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">7</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">reasonable concern by Landlord.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">7.</font><font style="font-family:'Times New Roman','Times','serif';">Tenant must pay and discharge promptly and fully all claims for labor done and materials and services furnished in connection with the Tenant Improvements. Tenant shall obtain from each Contractor and provide to Landlord a mechanic&#8217;s lien waiver in form suitable for recording.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">8.</font><font style="font-family:'Times New Roman','Times','serif';">Tenant shall indemnify, defend, and hold Landlord harmless against any and all claims, demands, lawsuits, expenses, damages, and causes of action asserted by any person arising out of, caused by or relating to the Tenant Improvements, the Allowance, and/or Tenant&#8217;s use or operation of the Premises. The foregoing indemnity shall include all expenses in connection with any claim. The provisions of this paragraph will survive the expiration or earlier termination of the Lease.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">9.</font><font style="font-family:'Times New Roman','Times','serif';">Tenant must maintain during the performance of the Tenant Improvements, at its sole cost and expense, insurance of the types and in the amounts specified in the Lease, together with builders&#8217; risk insurance for the amount of completed value of the Tenant Improvements on an all-risk non-reporting form covering all Tenant Improvements under construction, including building materials, and other insurance, in amounts and against risks as Landlord reasonably requires in connection with the Tenant Improvements.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">10.</font><font style="font-family:'Times New Roman','Times','serif';">Landlord reserves the right to establish reasonable rules and regulations for the use of the Building during the course of the Tenant Improvements, including, but not limited to, construction parking, storage of materials, hours of work, use of elevators, and clean-up of construction related debris.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">11.</font><font style="font-family:'Times New Roman','Times','serif';">Upon completion of the Tenant Improvements, Tenant may request funding by Landlord of the amount due for the Allowance. Landlord may, but has no obligation to make any advances with respect to the Allowance until Landlord has received the following, all of which will be to Landlord&#8217;s reasonable satisfaction:</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0.9pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';">Any certificates required for occupancy, including a permanent and complete Certificate of Occupancy issued by the applicable local municipality.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0.9pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0.9pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';">A Certificate of Completion signed by the architect who prepared the plans and specifications approved by Landlord.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0.9pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0.9pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">An estoppel certificate signed by Tenant, in form satisfactory to Landlord, and stating that Tenant has taken occupancy of the Premises and that there are no defaults under the Lease, and any other matters that Landlord may reasonably require.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0.9pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0.9pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';">A cost breakdown itemizing all expenses for the Tenant Improvements for which the Tenant seeks Allowance reimbursement, together with invoices and receipts for the same.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt 0.9pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0.9pt 0pt 36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';">Mechanic&#8217;s lien waivers for all Tenant Improvements.</font></div><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Within thirty (30) days of the receipt of the foregoing, Landlord will fund to Tenant the lower of (i) Tenant&#39;s actual costs for the Tenant Improvements, or (ii) the Allowance, less any amounts paid in monthly installments as progress payments or directly to Tenant&#8217;s Contractors.</font> <font style="font-family:'Times New Roman','Times','serif';">Landlord shall </font></p></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">8</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Courier';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">only be obligated to pay the Allowance with respect to those costs submitted to Landlord by December 31, 2025, and Landlord shall have no obligation to pay any invoices received after such date or at any time during which Tenant is in default, beyond any applicable notice and cure period.</font></p><p style="font-family:'Courier';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="font-family:'Courier';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:36pt;white-space:nowrap;">12.</font><font style="font-family:'Times New Roman','Times','serif';">All Tenant Improvements, whether installed by Landlord or Tenant, will become a part of the Premises, will be the property of Landlord and, subject to the provisions of the Lease, must be surrendered by Tenant with the Premises, without any compensation to Tenant, at the expiration or termination of the Lease in accordance with the provisions of the Lease.</font></div></div><div style="clear:both;display:table;margin-bottom:18pt;min-height:18pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Courier';font-size:12pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">9</font></p><p style="font-family:'Courier';font-size:12pt;margin:0pt 18pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cvrx-20231231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:14:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">We have issued our report dated February 9, 2024, with respect to the consolidated financial statements included in the Annual Report of CVRx, Inc. on Form 10-K for the year ended December 31, 2023. We consent to the incorporation by reference of said report in the Registration Statements of CVRx, Inc. on Forms S-8 (File No. 333-257616, File No. 333-262901, and </font><font style="font-size:12pt;"><a name="_Hlk158196345"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';">File No. 333-269696</font><font style="font-family:'Arial','Helvetica','sans-serif';">) and on Form S-3 (File No. 333-268183).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ GRANT THORNTON LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Minneapolis, Minnesota</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">February 9, 2024</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cvrx-20231231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:14:46 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Nadim Yared, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of CVRx, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 9, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;"> /s/ Nadim Yared</font></p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nadim Yared </p></td></tr><tr><td style="vertical-align:top;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cvrx-20231231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:14:45 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">I, Jared Oasheim, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">I have reviewed this annual report on Form 10-K of CVRx, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 9, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J.</font></p></div></div></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:48.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:42.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:51.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cvrx-20231231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:15:04 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Certification of CEO Pursuant to 18 U.S.C. Section&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">As Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the annual report of CVRx, Inc (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2023 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 9, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Nadim Yared</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nadim Yared</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>cvrx-20231231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:15:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Certification of CFO Pursuant to 18 U.S.C. Section&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">As Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">In connection with the annual report of CVRx, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December 31, 2023 (the &#8220;Report&#8221;), as filed with the Securities and Exchange Commission on the date hereof, I, the undersigned, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The Report fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 9, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">J. </font></p></div></div></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jared Oasheim</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>cvrx-20231231xex97d1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.5.122.0--><!--Created on: 2/8/2024 08:15:06 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.59%;padding-right:10.59%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-size:10pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 97.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CVRx, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">MANDATORY COMPENSATION RECOVERY POLICY</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;"><a name="a154254"></a></font><b style="font-weight:bold;">Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">The Board of Directors (the &#8220;Board&#8221;) of CVRx, Inc. (the &#8220;Company&#8221;) has adopted this Mandatory Compensation Recovery Policy (this &#8220;Policy&#8221;) pursuant to Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), the Securities and Exchange Commission (&#8220;SEC&#8221;) regulations promulgated thereunder, and applicable Nasdaq Stock Market (&#8220;Nasdaq&#8221;) listing standards. Subject to and in accordance with the terms of this Policy, upon a Recoupment Event, each Covered Executive shall be obligated to return to the Company, reasonably promptly, the amount of Erroneously Awarded Compensation that was received by such Covered Executive during the Lookback Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a229070"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Administration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">This Policy will be administered by the Compensation Committee of the Board (the &#8220;Committee&#8221;). Any determinations made by the Committee will be final and binding on all affected individuals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a353154"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Definitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Accounting Restatement</font>&#8221; means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that (a) is material to the previously issued financial statements (commonly referred to as a &#8220;Big R&#8221; restatement), or (b) would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as a &#8220;little r&#8221; restatement). </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Covered Executive</font>&#8221; means each of the Company&#8217;s current and former Section 16 Officers.<sup style="font-size:8.25pt;vertical-align:top;"> </sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Erroneously Awarded Compensation</font>&#8221; means, with respect to each Covered Executive in connection with an Accounting Restatement, the excess of the amount of Incentive-Based Compensation received by the Covered Executive during the Lookback Period over the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts, computed without regard to any taxes paid. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (a) the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received; and (b) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Financial Reporting Measures</font>&#8221; are any measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Incentive-Based Compensation</font>&#8221; is any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Lookback Period</font>&#8221; means the three completed fiscal years immediately preceding the Required Restatement Date and any transition period (that results from a change in the Company&#8217;s fiscal year) of less than nine months within or immediately following those three completed fiscal years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">A &#8220;<font style="font-style:italic;font-weight:bold;">Recoupment Event</font>&#8221; occurs when the Company is required to prepare an Accounting Restatement. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.59%;margin-right:10.59%;margin-top:30pt;page-break-after:always;width:78.82%;border-width:0;"><div style="max-width:100%;padding-left:10.59%;padding-right:10.59%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Required Restatement Date</font>&#8221; means the earlier to occur of: (a) the date the Company&#8217;s Board, a committee of the Board, or the officer(s) of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Section 16 Officer</font>&#8221; is defined as an &#8220;officer&#8221; of the Company within the meaning of Rule 16a-1(f) of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">&#8220;<font style="font-style:italic;font-weight:bold;">Section 409A</font>&#8221; means Section 409A of the Internal Revenue Code and the regulations and guidance promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Amount Subject to Recovery</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">The Incentive-Based Compensation that is subject to recovery under this Policy includes such compensation that is received by a Covered Executive (i) on or after October 2, 2023 (even if such Incentive-Based Compensation was approved, awarded or granted prior to this date), (ii) after the individual began service as a Covered Executive, (iii) if the individual served as a Section 16 Officer at any time during the performance period for such Incentive-Based Compensation, and (iv) while the Company has a class of securities listed on a national securities exchange or national securities association. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">The amount of Incentive-Based Compensation subject to recovery from a Covered Executive upon a Recoupment Event is the Erroneously Awarded Compensation, which amount shall be determined by the Committee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">For purposes of this Policy, Incentive-Based Compensation is deemed &#8220;received&#8221; in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a79987"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Recovery</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;"> of Erroneously Awarded Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Promptly following a Recoupment Event, the Committee will determine the amount of Erroneously Awarded Compensation for each Covered Executive, and the Company will provide each such Covered Executive with a written notice of such amount and a demand for repayment or return. Upon receipt of such notice, each affected Covered Executive shall promptly repay or return such Erroneously Awarded Compensation to the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><font style="white-space:pre-wrap;">If such repayment or return is not made within a reasonable time, the Company shall recover Erroneously Awarded Compensation in a reasonable and prompt manner using any lawful method determined by the Committee; provided that recovery of any Erroneously Awarded Compensation must be made in compliance with Section 409A.  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Limited Exceptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Erroneously Awarded Compensation will be recovered in accordance with this Policy unless the Committee determines that recovery would be impracticable and one of the following conditions is met:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered, provided the Company has first made a reasonable effort to recover the Erroneously Awarded Compensation; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the recovery would likely cause a U.S. tax-qualified retirement plan to fail to meet the requirements of Internal Revenue Code Sections 401(a)(13) and 411(a) and the regulations thereunder.</font></td></tr></table><div style="margin-top:6pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.59%;margin-right:10.59%;margin-top:30pt;page-break-after:always;width:78.82%;border-width:0;"><div style="max-width:100%;padding-left:10.59%;padding-right:10.59%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Reliance on any of the above exemptions will further comply with applicable listing standards, including without limitation, documenting the reason for the impracticability and providing required documentation to Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">No Insurance or Indemnification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Neither the Company nor any of its affiliates or subsidiaries may indemnify any Covered Executive against the loss of any Erroneously Awarded Compensation (or related expenses incurred by the Covered Executive) pursuant to a recovery of Erroneously Awarded Compensation under this Policy, nor will the Company nor any of its affiliates or subsidiaries pay or reimburse a Covered Executive for any insurance premiums on any insurance policy obtained by the Covered Executive to protect against the forfeiture or recovery of any compensation pursuant to this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a79985"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Interpretation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. This Policy shall be applied and interpreted in a manner that is consistent with the requirements of Rule 10D-1 and any applicable regulations, rules or standards adopted by the SEC or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed. <font style="font-size:12pt;"><a name="_DV_M13"></a><a name="_DV_M14"></a></font>In the event that this Policy does not meet the requirements of Rule 10D-1, the SEC regulations promulgated thereunder, or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed, this Policy shall be deemed to be amended to meet such requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a808908"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Amendment</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">; Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">The Board or the Committee may amend this Policy in its discretion and shall amend this Policy as it deems necessary to comply with the regulations adopted by the SEC under Rule 10D-1 and the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed. The Board or the Committee may terminate this Policy at any time. Notwithstanding anything herein to the contrary, no amendment or termination of this Policy shall be effective if that amendment or termination would cause the Company to violate any federal securities laws, SEC rules or the rules of any national securities exchange or national securities association on which the Company&#8217;s securities are listed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a79984"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Other Recoupment Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar provision in any employment agreement or other compensation plan or agreement and any other legal remedies available to the Company. This Policy is in addition to any other clawback or compensation recovery, recoupment or forfeiture policy in effect or that may be adopted by the Company from time to time, or any laws, rules or listing standards applicable to the Company, including without limitation, the Company&#8217;s right to recoup compensation subject to Section 304 of the Sarbanes-Oxley Act of 2002. To the extent that application of this Policy would provide for recovery of Erroneously Awarded Compensation that the Company recovers pursuant to another policy or provision, the amount that is recovered will be credited to the required recovery under this Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><a name="a799871"></a></b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Successors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:28.8pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.59%;margin-right:10.59%;margin-top:30pt;page-break-after:avoid;width:78.82%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvrx-20231231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %2 9H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&'CA,?+98'K@9'7G#^JU;VL'M(]S[6SS2U\3>!/VBOB;KO[97CO2HHK*_\
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MBK2A1O*]"<<XJ6L<3B*F)J.=1^BZ)=DNB.RG!0BHH*YWXB113> _$*S &/\
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M$H.12UC17$NCRB&X)DMS]V3TK85@ZAE.0>010,6BBB@ HHHH **** "BBB@
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MZCK:;K/=_=8&L91<'RR*O=71'JT(ABAD10I1AR/2M-3N4$=^:I7@^TZ66[E
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M\0<5]>:/H]CX?TNUTW3+.#3]/M8UA@M;:,1QQ(!@*JC@ >@J4X4?A=Y?@O\
M-AK/?1%+P=X/T;P!X8TWP[X?T^'2]&TZ%;>UM+=<)&@[>Y/))/)))/)K9HHK
ME;OJS0****0!1110 5%=+OMI1ZJ>E2UP_P ;/BOI/P1^%WB'QIK0:2RTNV,@
M@C.'N)"0L<2_[3N54?6FDY.R#8Q?B]\,O!'Q8^%UYH7CU;6/1R2Z7T\RP/92
MCE)HI3CRW4\@@^QR*^?_ ((?M4I\)?'EI\(/B7XTTCQ3:3'RO#/CVROHIH[V
M,$!;>]*L?*G' W'AN.><U#X>^ ,'C_1+/XE_M(O>>*M4U)S+I?@>!I#IFCAU
M+I D*D"2<HN"SG!;Y>3BG']E'X'?%WQ=>:-:^!]"M] F%PEM=Z';BUE58[>U
M/F)*F#D27!ZYY7!':N^$8*+A-MK\O3^M3%N3U1]J@AAD'(I:^1O@KK7C/]GO
MXNV/P/\ &6NR^)M$U2TEN_!?B2\($\L<(S+8W']Z2-<%6[@>X ^IOM5^G#6R
MO[BN.<.1VW1HG<TZ*S/MM\WW;4#/J:0VE[=\33"-#U5:S&2WFI",^5 /-F;@
M!>U1)9FSLYY'.^=U.3_2KEK8Q68^1?F[L>IHOCBTEP,_+VH CTE<6$1'?)_6
MKE4]).;"+Z'^=7*!A1110 4444 %%%% !1110 4444 %(>E+2&@#+T0['NHO
M[KUJUE6/RZO=KZ\UJT"04444#"BBB@ I"< FEHH ^(DO/&O[4/[5WQ4\&O\
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MHZ5?:3XC%S:1I);JICDC)^=$8/N^96/&!ZT?$+]MWQQ\!]:\:>&?B)HF@?\
M"40^'+/5?#$>D+/Y&I7<K"&2W)=\N%F;^':=B,>N*]^TO]EKX?Z1+X(FBL=0
MGN?!][<ZCI=S=ZI<3RBXGQYLDKNY,I; ^]D#'&*Y7XX?LNM\;?V@/A7XQU)]
M,'AKP89KJ:V97-Y=W!96A3.-OE*Z(Q!.3\PQS4QG0<K..FOYW7^0VIVW/:O
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M(4"(H51V%.50B@ 8 X %+0 4444 %(>AI:0]#0 #H*6D'04M !1110 4444
M%)WI:3O0 M%%% !1110 4444 %%%% ",H92",@]0:RY[633I#/;<Q]7CK5HH
M AM;I+N(.A^H[BIJR;J%M-N/M,(S&?OH*TH)EN(ED0Y5J )**** "HYW\N%W
M_NJ34E4=9E\JP<=WPHH BT%,69<]78FM.J]A%Y-I$G<+S5B@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH RM7!M[BVN5_A;:WTK4!! (Z&J^HV_VFSD3
MOC(^M1:/<>?9(#]]/E- %ZBBH+VY%K;/)W'0>IH I:A,UW.MG$>O,A]!6A!"
MMO$L:#"J,54TJU,41EDYEDY)/I5^@04444#"BBB@ I#T-+2'H:  =!2T@Z"E
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&4,I!&0>H-94).E
M7AB8DP2G*D]C6M5;4+07=N5_B'*GT- %FBJ6EW1N(-K_ .L3AJNT %9.IYNK
MZVMAR,[FK58@ D\ 5E:6#=WMQ='IG:N:!&J*6BB@84444 %%%% !1110 444
M4 %%%% !1110 4444 %9$/\ Q+]6>,\13\K]:UZH:Q:F>WWI_K(SN% %^LJZ
MS?:BD'_+./YFJS:WRSV/GGJH^8>A%0Z-&3')._+2-^E C1 P*6BB@84444 %
M%%% !2'H:6B@!H88'-+N'K2T4 )N'K1N'K2T4 )N'K2TF:X/XO\ CC4_!WAV
MW?0H+:YU6\O8K&(W9/E0L^?F?!SCCI[U<(.<E%=3JPN&J8RM&A2WD[:Z+YG>
MT5\Z>(_%.K_%;0_!VB7EY-H#7E[<C6SI4QC;R[<98*W55;K_ (U;^'7C7Q=I
M7P]T32--L+KQ-KETTSV]UJCL(H+42%4::3^(C'3.?TKK>&@J::FN:]K>7>_R
M/;JY'5HT>>4USWLX]$KR5^;;[+^5GU/H"BN"^%/C;6?%*ZWI_B"SM+76-'NA
M;3-8.6@DRN05SR.^17>UR3@X2<6?/U:<J,W"6Z"BBBH,@HHHH **** "BBB@
M HHHH RIO] U-9!Q%-PWUK5JGJL'GV;8'S+\PI]A/]HM(W)YQ@_6@1!K%SY-
MML7[\AV@58L+86EJD?<#)^M9\'_$SU1I3S##PON:V* "BBB@84444 %%%% !
M1110 4444 %%%% !1110 4444 %(1FEHH YZ^BDT^:2-#^XGY ]/:MRVC\J"
M-/10*CO[-;VW:,\-U4^AJMI%ZTBFWFXGBXP>XH$:5%%% PHHHH **** "BBB
M@ HHHH *X/XY+KS_  LU\>&S(-4\@;?(SYNS</,V8_BV;L?IS7>5'<2-%!(Z
MH96520B]6('2M:4_9U(SM>SN=>$K_5L13KJ*ERR3L]G9WL_)GSMX(T@Z+HMK
MXH^&&LWFLV2HHU3P[J%P9'8X^8@'E)!S]>V>AY+PIX=N_%UUJ%GI-VS:C-(9
M[@7DI!N%WAE8Y^[(AX/J,X][?A+QC;7GC^#Q3J-_8>%[H2N+K2],LI_.D 8C
M9,,;23CEOQZU[;KVNZ-8:&/$7A^WM9M5U8BUM;F.(!Y'8XY[Y&#G/I6^+J3E
M-W?^?_!]3]3Q^,Q&65)*4'*52UI-;--VC.5DII:M26MO16Y_Q5X9TFTU633]
M#M$?Q7JT9BN9(V)CMD8 2R$=%)&??DUT'CB[N/!GA#2-"T-A;WEY)%IEM.>!
M%D8+_7&?Q-=%X/\ "%OX5L2 ?/U";Y[J[?EY7[\^GH*K?$K2=,U3PG='5+IM
M/@MB+A+U 2T#J?E< <GD]/>N6DKR5S\QQN.E**3ES*&MV][>NR71="SX)\%V
M'@;1A8V(9V=C+<7$AS)/(>KL?4UT%>4Q?$/Q!X$2U/BVUCU#0Y=H3Q!IX.U0
M<;6ECZC/J/UKU"TNX;ZVBN+>5)X)5#I)&<JRGH0:VJTJD+3EJGU_K\CQ*.-I
MXJ<HI^^MT]]>OH^C6A-1117.=84444 %%%% !1110 4444 (1D8/2N>^TR6L
M<UH@)D=]JGVK=N;A+:%I'.%45G:7;M<SO>RC!8_(/3WH$7;"T%G;+&.3U8^I
MJS110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=4LW
MW+=0?ZZ/D@?Q"M*B@"M8WJ7T =>#_$I[&K-8][;2:;.;NW&5/^L3MBM*VN8[
MN(21G(/;TH FK-U.^>TN(0IX/++ZUI5@Z]_Q\IZ[:!,W58.H(Z$9I:@LCNM(
MCG/RCFIZ!A1110 4444 %%%% &+XEB@L="U:\2"(3):ROOV#)(0]37C6G:K#
MIL7PELG8+%,S7#9[LQP#^;5[EK5B=3T>^M!P;B!XN?\ :4C^M?+-SI>K>+]'
M\+0:?;S#4M!MKN&8(A(CGA?<J,>Q88QZFO1PF'5=N[M;_)E5\>\+A9):N][?
M)K]3ZR'2L3QOH)\3^$M6TM&VR7-NZ(?1L97]0*9X%\6VOC?PO8ZO:MQ.F)$/
M6.0<.I]P?Z5O5QM3H5+-6E%_BCC_ '6,H:.\)K\&CY]^'/Q5U)[*ST7QC9V]
MSI%Q*=(-R$PT$ZC:(9UZ?,.A_P #CJ_AVL_P]\?:EX&>22?2)H#J6DESDPIN
MP\6?0')'_P!>N \/:E<:+\4M8\0SK'/X<U/7WTJXAD4$1RK@Q2X/&0V>>HY]
M:]*U?$O[0.@@8W0Z-.[?0O@5]7BJ<(RG",;1E!R=MN9:_)K9]T_,_)<IQ5:I
M3I5JE1RJ4JT8)O=PF^5W?VHR7O*^JDFKNR/3:***^//V0**** "BBD)P#0!F
M07\DVJF,']UR /IWK4KG-,?_ (F2$_Q$]*Z(4"0M(S!023@#O03BLBZN'U2<
MVL!Q$/\ 62"@8UBVM7>!D6D1Y/\ >-;*J%  & .@%1V]NEK$L:#"C]:EH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",C
M!Y%9%Q:RZ9,UQ:C=$>7B]*V*3K0!#:7D=Y%OC.?4=Q63K,?FWP&<?N\C]:L7
M6G26\OVBS.U_XHQT:JAN/[0NB678PC8%3ZXH$:VF-NL(3[5:JEI#[K&/VR*N
MT#"BBB@ HHHH **** "O*;^V/@;XU:9<VF8]/\4QR0W<(/R_:(QN60#U(X_/
MUKU:O-?BTZ:=X@\$ZO<[H]/L=0<W$X4L(]R8!..V17H8)WJ.F]I)K\&U^-K'
MFY@^6BJE[<KB[_-7^5KW+NF?#FY\,>.I-7T&^CL]'U!B^I:7(A*-)CB2+'W3
MGK^-=Y7B>C)XJU_Q;XC\4^%M0633VF2&&TOE80W:JH!VY^[@]#QUKKK#XN6=
MK.+/Q-97'AF_QTNE+0O[K(."/K71B</6J-.ZFTE>WQ+3JMW;:^OF>)@<QP6&
M4HRBZ492;3?P/6UXRVC>U^5VU=U>]SF?B]X-T_PK\,]?>Q:42W>IQZ@!(^=L
MS2+G;Z#KQ6II*&_^/5_/)RUGH447T9W!/\ZVO$_BSP+K&F+'J^LZ;<6B2),$
M^T@_,IRIPIR?I6)\+[AO%7CCQ7XL@BD32;L0VMG+(A7SA&/F< ]LXKIC5J?5
M9^U3NE+5_P![D5E\DSPZF$P_]JT?JDHN+</=B[V4%5DY-+97G%+S/4J***^>
M/TD**** "F2G;$YZ8!I]0WAVVDQQD;3TH PM-39>0L?XB171$A1DG %<\DBP
M"R=SA02Q(^M629]:;"YAM/7NU D+<W4NJ2FWM3B(</+6C:6D=G"(XQ]3W)IU
MO;QVT82-0JBI:!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 52OM+BO 6'[N7^^/ZU=HH Q;6YDT@^3<QGRR
M>)%Z5KQ3),@9&#+Z@TLD:RH5=0RGJ"*S)-)DMW,EG*8SU*$\&@1JT5EQZPT+
M".[B,3?W@.*T8IHYUW1N''J#0,?1110 4444 %,EA2>-HY$61&X*L,@_A3Z*
M W&11)!&J1HL:+P%48 _"H[RQMM0A,5U;Q7,1ZI*@9?R-3T4[M.Y+C&2Y6M#
MGH?A[X8MY_.C\/Z:DN<AA:ID?I6^D:Q(J(H15& JC  IU%5*<I_$[F5*A2H:
M4H*/HDOR"BBBH-PHI"0!DG JC<ZQ! =JDRO_ '4H O=*R]3U&-XVMXLRRMQA
M.<4WR;W4^93]FA_NCJ:OVEA#9KB->>['J:!&?9Z.TFQ[MBP4?+'G@#WK750H
M  P!V%+10,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** &21),NUU#KZ$5GRZ(BMOMY&@;
MV/%:=% &3Y^HV?WXQ<(.Z]:DCUV G;(KQ-WW"M*HY((Y1AT5A[B@0V*\@F^Y
M*A_&I0015&31+60DA"A]5-0G1&0?NKJ1*!FK165]@OT&%O,CWI/(U3IYZ8]?
M\B@1K4F:RS!J@Z3H?J!0+347^]=*N>P__50!J4UYHXQEG5?J:S1I$[G]Y>N?
MI3DT& '+L\A]S0,EFUFUAR-^\^B#-5SJES<G%M;'']]ZO16%O#]R)0?7&:GQ
M0(RAIES='-U<';_<2KUM806N/+C /]X\FK%% PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvrx-20231231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &+ U # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]#?$WQCA\
M-_&GP=\/6TMYYO$=M<W"WXF"K (8W<@ICYL[,=1UJOX@^-T.@_&FW^'K:3)-
M--H3ZY]O$X"A5:1?+V;>O[KKGOTKQ?\ :2\(R^._VL/A+H<.MZGX<DNM-O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5UJ%OI]K!?W0 N+J.%5EF &!O<#+8  Y/:KU% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!A:IXF_L^Z>!;?>5Q\Q; Y%9S
M^,;D_=AC7ZY-7O%.F&X@6ZC&7B&&'JO_ -:N1KNIPA*-['/.4DS=/B^](^Y"
M/HI_QH_X3"]_YYP?]\G_ !K"HK;V<.Q'-+N="GC&X!^:",_0D5J:3XB74KCR
M6A,3D9'.0:XJM#0IO(U:V;IEMOY\5G.E#E=D5&;N=]1117GG2%%%% !1110
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MK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQA?5NY_&K-%<DJDI[FZBHA1116904444 %%%% !1110 4444 %%%% !1110
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MVB?&GXIZ+\#K/QSJNLZ=J$^OW-MI.EVYM\+;2/(X,\Q&,\#H.!Q71^(_B/\
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MPK%I>J+>6\\JLIRBJ<$?B*[+3?"^H:H0RQ&.,_\ +27@?_7KO=.\-:?IF#'
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MU=:1:ZI:7&J6HW3V<4RM+$/]I1R*\'_8=BGF_9_:(3B*Y;4+Y1,BY"N96^8
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M_E7]:GTF#QN7X&HZ&&C9[<[W?SZ'IUAH=EIH'D0*&_OMRWYU>KEO^%G^&O\
MH)Q_D:/^%G^&O^@G'^1KRUAZJV@_N/5EC*,G=U%]Z.J5BI!!((Z$5ZO\./B@
MRO%I>L2Y4X6&Y;J/9C_6OG[_ (6?X:_Z"<?Y&@?$_P - _\ (3C_ "-=%%8B
MA+FC%_<<>)>$Q4.2I-?>M#[>!! (Y!I:^?OAU^T_X2@TTV.LZW'&T( BF8$[
ME]#[BNO_ .&F_AM_T,MO_P!\M_A7U-.7M(J5K'P-:G[*;A>]NJ/4J*\M_P"&
MF_AM_P!#+;_]\M_A7?\ ASQ'I_BS1[?5=*N%N[&X&8YEZ,.E:&)IUC^)_"&B
M>--.:PUW2K75;1O^6=U$' ]P>H/N.:V*\-\3?%?4/#'[1BZ->ZB+?PI!X?EU
M&XB*# 9/XLXS^% 'HOA?X7Z#X1T";1K&&:33G+[(KR8SF%6'*(SY(4=AGBN:
M?]F_P6WP^7P>+>ZCTV.Z-[#<13[;F&8MNWI(!P0?:N:\-_M<Z%XCU2QLU\.:
M[9KJB2/I%Q<PJJ:D5!.V/YL@G' ;%> Z=^U-\3+/P5XE\4R6FK7>_6196XFL
MX?L5B@DP8\A@Q<CY><C-,#[ ^&OPDT/X5Z??0:0]Y<W-_+YUWJ&H3^?<SOC
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M[?E&.#CO7GNB_M?>&-8UW3K;^R-8M=%U*].GV6OSPJMI/-G:%'.X9/ )%/\
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M(8I58)]<'B@#Y:T_]FCQ'J7AOQB9O#6@>&-1U+3/[/M(;:]GNY6;<I9GE=R
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M>?F., 5Q?Q"_9?UKQ[K_ ,6YVNK6U@\316#:;(S$[9+?=D2 <@'./QKZ=HH
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MR/@\MO\ \+8^'5_I<5I:I<6ES'=PZ=:S)Y3&-CY<\CG]X^?85^A]M86MGO\
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MJ'21#D,#W%3U]8G<_-6FG9A1113$%%%% !1110 4444 %%%% !1110 4444
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M"BJFEZI:ZU8PWME.ES:S+N21#D$5;KZU--71^9-.+L]PHHHIB"BBB@ HHHH
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M/>OJ\#CZ=:*IRTDOQ/SC.<EK86<J]/WH-W\UZ_YGHU%%%>T?)!1110 4444
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MN;:*[A:*9!(C#D&I**[#Y5-K8X37?!\MF6FM 9H>NS^):YU'>"171FCD4Y#
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M(13JXJIUO%?*S/B..YRCAL#23TM-_.Z"M[PUX)U3Q2^;6'; #AIY.%'^-3>
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M?K&*Z.:O-<LJ:L_[W_ .;DP\&I0JNZ_N_P#!'WJK,!<Q\!_OKZ-52G&5CNZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7&^+FSJ:CTC'\S795P_B:02:O*!_" O^?SKHH?&95-C)JCJ6C6^IK^\7;)V
M=>M7J*]%-IW1S-)Z,XB_\-7=D247SX_5.OY5DLI!*L,'N#7IM0SV5O<_ZV%)
M/]Y0:W5;I)'.Z.MXL\UBT@ZC<QP6XQ-(VU1V)-0:QH&H:#,8K^TDMVS@%A\K
M?0]#7K?AS0;)=;M72W171MP([8KT.[LH+^%HKB%)XVX*R*"#7S&8X&C5FI4E
MRL^JRW-:^&CR5GSK\5\SY0HKW37O@SI&H[I+%WTZ4]E^9/R/]#7E'CSPE=?#
MV&&XU%T>TE?RUGBR0#CN.U?+UL)5HIRDM.Y]GA<PH8MJ$'[SZ/<PJ*BM[V"\
M7=#,DH_V6S4M<9Z336C"BBB@04444 %%%% '%M_R59/^O$_SKM*XMO\ DJR?
M]>)_G7:5TUOL^B./#?\ +S_$_P! HHHKF.P**6M?1_">K:\RBRL9I5/_ "T*
M[4_[Z/%5&+D[15R)3C!<TW9&0*T-%T"^\0WBVUC;M-(>I'W5'J3VKTOP[\$0
MI676;D/CG[/;GC\6_P *]-TO2+/1;9;>RMTMXA_"@QGZ^M>I1R^<]:FB_$\'
M%9S2IKEH^\_P.>\"> +;PA;^:Y$^H2#$DO8>R^U==117T-.G&G%1BM#XZK5G
M7FZE1W;"BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** &2R"*)W8X"@DFO.)I3/-)(>KL6/XUV7B>\^S::R X>4[1].]<37=A
MXV39SU'=V"BBBNHR"BBB@#<\)#.I,?1#795QOA)L:DP]4-=E7GU_C.FG\(5X
MW^U'IRW?P_AN2N7MKI&!QZ_+_6O9*Y#XK;/^$'OPZA@=HP?7->9BXJ="<7V/
M6RVJZ.,I371H^&XIY('#1R,C#NIP:UK7Q;J5K@>?YJ^D@S^O6NTN_#6G7A)>
MV56/\4?RG]*R+GP# _,%R\?LX#?X5\+[.<=C]A^M4*GQHK6_C^0?Z^T5O>-B
M/YYK0B\=6+_?CFC/L ?ZUC3^!+Z/_5RQ2#ZD&J<GA+58_P#EVWCU5U_QHYJB
M%[/"SV=OF=MIWB*RU6[AM;9W>XF8(D>PY8^E=9)X-UV+.[2+SCKB%C_*N1^"
M7A:[D^)FCM<VKK'"YE);ID"OLJO;P.%^LTW.;MJ?(YQCEE]:-.BN:ZO_ %8^
M7?\ A%M:_P"@1?\ _@,_^%2IX.UR0 C2+S'O P_I7T[17H?V9#^9GA?V[4_D
M1\V1?#SQ%-PFE3_\"PO\S7*_&+X=Z[I/P_O;R\M5@A1XP<R*3RWL37U[7E'[
M3_\ R1[5?^ND7_H8K:GE].$E*[T.:KG->K!PY4D_7_,P?#GP1U&[TJQDGO[>
M!'A1OD4N<%1]*ZS3_@?I<.&O+NXNCW5<(I_K^M=QX=_Y%_3/^O6+_P! %:-;
M1P5".O+<YIYIBYJW/;T,'2O VAZ+@VNG0AUZ.XWM^9R:W H48  ]A3J*ZXPC
M!6BK'G3J3J.\VV_,****LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2?\ )U4/_8";^8KV>O&)/^3JH?\ L!-_,5[/0 44SS4$@CWKO(R%SSCUQ3Z
M"BH9;VWAGB@DGBCFESY<;. SXZX'>IJ "BBB@ HHILDB1+N=U1<@98X&3TH
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M6FBZ=;6%C;QVMG;1B*&")<*B@8  ]*M4 %%%% !1110 4444 %%%% !1110
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8* "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvrx-20231231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %0 5 # 2(  A$! Q$!_\0
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MS'@9)"GMDQ-QO:OO/2(]EDO&"22<U=6G[.6FJ>QK%W+M%%%8EA1110 4444
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MF[*RZGTC^RM\*_\ A2_[/G@;PB\:QWECIL;WFU=N;F3][-]?G=ASZ"O5Z0#
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MJ^L6.@:?+?:E>06%G",R7%S($11[D\5!I?B;2=;THZGI^I6EYIZ@DW4$RO&
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MF@8V_O5LH2QY8\*OJ:JZ79,7-W/S,_(!["H[*U>_G^UW(^7^!#TK7H$%%%%
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M]6Z4"*TAN-:8!4\JW!^\W>M&ST^*R7"#+=V/4U9 "C &!Z4M !1110,****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvrx-20231231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %& 20# 2(  A$! Q$!_\0
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M[*78Q?"NAW5[J;)R%9>O:NUTSPJ^GWZ,9  WRG)]:^:A^T%#X6\2W-K>1ZE
M(YY(F#0[>C%<CZ5UTOQPL)22LE_<$#)\I2V*RK5XN6C+C!VU/7-266WUZ:U:
MX;9+'A0&/##_ ":2.[_X1?P6FJ:E;0ZCIRW$J7!F195C4#*<$'[V"..Y%>*3
M_&+3_$/DW-N+P7T%R48-VX#!B?3K47C?XJ"X^&>L>'WU$^;=X"PVQ!,H#;\,
M#V&W.1SU'>CVJ<;IBY=;'1?"W]I?Q'H7CVSL;?1/)\)WLC1?V:Q?-LV?E*NQ
M*J6;("C"\#/7(^W='U>VUW38;ZT<O!*.,C#*0<%6'8@@@@]"#7Y _88-'NM(
MUB>;R%O+?SEAA53$&^=&<\X)W))@C!&Y?2OT._9Q\3WJ0Z1IM_=B^_M72%O$
MNL\3S0B-'D^KQR0EO]I&/>M<)B/>]G)W)J0TYD>^T445[!S!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6;XEO9--\.:I>0D"6WM994)Z
M;E0D?J*T'D6-2S,% ZDG%<CXV\9>&K?0=2LK_6K2#[1;R0E5F!?YE(X YSS2
M>S&CXZ^%OQ4@CT&!?&5YIKVQD2UL].LF,MW.21F208_=(222[9R3P/2O^T1K
MGA'Q7X6MH;*X2*YMK^&(VL)PI96,"!AZ(N\*.Q=CU-:&@:+\/+.STRR:TLX-
M0T^Z:>/4;H%LQ?+E6+$;_N_+G[O) S7B&L^#M)UNWDO9M::75/M,5Q;P^68U
MC=)]S-(Q)W$@'&.!FODZBJP]VI9['H+ED[H^@;'XBIXVTS3-,^RVZ66F6L<3
M0S$>7'@8Z'Z5T'A2+X876KDZG;:=+>*NV+[, "7/;Y>/SKYKTVWM(XO$<]S"
MFH31FUM[:-;MHE#R2,NYL?>' X/7VJO;>+)-$NXFOH(V6-%*PV2F.,8)&"1U
MZ=:U2C93(UV/I+Q=KL5UX%\2Z2EI#;:CI+O/9B#.41DR.00<E,]_X2.]?&6H
MRW&G:G&]A?"4SLK>6DS* _=,$\,>.O7.03FO;?#'C[R]9GO;#3I98[J 1R0.
M6=&8-D'YN1PS _6K?@R)O!UY?75GX>\/SFY+&(ZQ8BXDMLYP(V!S@9.,\CIG
MBLN24NI=[' 6_B;5]-M+1%EALM4N0]D5!8RN6^4+(&Z$<,>X KM/#/A&\N+6
MW@NM1%S,%P94CZCL3DUSVH:%/J6M7&M:A*FHZO*P#7.T(L29'RQH.%';U->G
M^"I(K6<_: S!8!M4=2<@ #\ZV>'ARIM"YV=KX+^'T^G6UW!+;--;R1K(LDL@
M14E&""A..2.H'8CO7I=G\6-.\/V\-C>Z/#I-W! I+SR!TD4?+O5T&#DCH2#[
M5SNJ:E.M\J/*V(1M"L26XZY]2>OO4?B#PD/'^CQ6RO- #/$DTL,>XK&XQ("/
M0$(<]B!45<)1C#FDMB5.4G8\2^*+^'O&'BB&ZBT^WFD,[S2RE,[F9LG'M77?
M"OX>Z;K]W+(-/MTMX5,LLK+@*!T'U)-:?BG]E[4?#E\MSH^I1ZK%G*VTQ$4_
M'7 Z-^!J?X?^'M0T6_6"^;[,L<DD(C\P M*ZC"LN[/;C@C)[5</8M*,&-\W4
MZ*?X>>#]1CFM$T2W"-()3( 58R 8##' /U!Z\]37EEU^R%<ZGXLWV4DYTR%H
M[F2\GF"B1"<LB(HSG&5QGW!KU^*X<7&0RHZG))&T*!ZYX KI/!WQ7T66QU&:
MX6:WCM9OL-HI >74"@R9(HQ\VW<Q )X/6JQ'+&-XK4F%[ZGRQXW_ &=I[WP]
M!9Z5I=[?VUE+,OE%6#VZN0Q1)%^^H?+ D X?!'<^C_ N[.A?&+X?^#(;H3OH
MMA?&^19-XMY)HDV6^X 9*+$&/H7 [5L?&*UUN_\  /CC5+*6ZTG6M3MD$%A8
M3LIA$>=A8J?FE()R1[+SBO!/V!(+I/CQ:FZN?M+_ &:Z9NORMY>#G/.<DYS7
M-A]*D.K;1I/6+/TSHHHKZX\X**** "BBB@ HHHH **** "BBB@ HHHH **0D
M 9/ KF/$'CNSTG=%!BYN/13P/J: .GW#.,\UF:KXFTW18R]W=QQD?P Y8_@*
M\HUSQ-KNJ6UP]K<>3<XW(J?*IQ_"3Z$=ZRM(\%7&NW:?VG>2RN_S&&WSC\3U
M/Z4 :_B/]IG2;&4V^E6<E].>%WYR?HBY8_I7-R^.OBOXPS_9ND2:9;O]V295
MMQCZOEOTKU[PSX TCPU $TS2+>R/\4FP*S'N3C+'\371IIX7K(P]HP$'Z<_K
M2 ^=V^#'C_Q(#)KGBB.V1OO*ADE(_%BJTY_V9-'CLYI+S7+Z_F5"WROL48&>
M1&I_G7O.H:GHNBG-W/;Q/UQ(=S_ER:YS6?BCHBV-S#&)Y@T;)E8\+R,=ZB32
MW92NS\\M4U;2+[5X=)T66UN+R6[%L'+,^YBVU4W'(&3QR>IQ7 S^)XV:_@AN
M(II;29XI3DHRD/M;&X8X.?K5_5_"$WPX\9V>M1QCR;"]6[,>6;SL3!S@YP1C
M/'6O+M=\*>(=/GUS6(HQ(+V5YE\J-^-\N_D8YX/6OF9<]6[9Z"2B>_?"_2+C
MQ/IGB*2VURT417VG&9'C?,2><278+G*G/45Z5K/[+GBBZ+7C>+M'@T\PF0R1
MI(_RY)R.@_6OG;X#:I/91^(?[2EN[<R3Z4GF65N0S;IB,, .1ZU['J_Q0ME6
MXTMO$/C.6)82BVUC:LR;=S#!&S&./6N:K&<8^Z4FKG,> HK*\UR[L3?WNHVU
ML2LE[$8XPA4X+;222F<]\XYQ7V5X,^'/PZ30=.U26WA(N8$F!U"\+$9'3&0#
M^5?F1H\?C2UUIY;6R>VM7E)7=;I"6!;^(G!Y'7GUKZ4TS7O+T^P_T:VANK>!
M5N4MI?/)8G[S,2>W8&K5)R:2EN)L^R+C7OAMHML]K(^C)&PPT*0K(2/< $UQ
MEP_PT8RG3=#U:ZD<$(UC:S!8R1P5W8 QU]*\J\$_$BXTHHUSIJ>;+'M5%*C;
MQG!)[CV]:ZF3XN:I(?W=O#"ONY;^0IRH3A*R_,FZ9HZC/J]QMN?^$=UB61L!
MA# I+MC[V-WRYZX/3/6N> \3:CID'BF2.#3]/M)D%G8>?ND!$RAGDP,,2R@$
M>@XJ:Y^)6I7*J X5O]DDY/\ WU6:YUG6-+BM[2QO)HAC9%:0-_>SG(4\YYSF
MM;U)Z28K);'3_$:TUGQ;XDL8=9U>Q0);N8Y;,%!"2Z@D$G.[T/7%.\'^%;*[
MTC58-2OHIXK>_D#ZA<LQD8@K@[@V[/ QQ7-'X4^-]:NTD'AB]E&,B:_N"/\
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M6SX,\'?:PE]>K^YZQQ'^/W/M5+P9X:.LW?VFX7_18SR#_&?3Z>M>H*H10JC
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MGUI,4X"E"\_XU(QFWVHVT_% 6@!F*,=:?MHVT ,Q1CO3\4;: &8I"*DQ28H
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M]M&,T 1[:3%28I-M $9%(14A7%)MH BQ[4TBI2#TI"* ()1\C?2O5OV8H_\
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MK=A=R23I]N^V!;/:QN=R*-B%E554@!BQ4#()%$?PLU#4O FVZUO4TUZ;.K)
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M+2)(XD5(U&%51@ >@%;QAU9FY=$/AA2WB2*)%CC0!551@ #L*?116QF%%%%
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M!"P\-.ER4-]J1&&NY@/E]D'11]*]PTS28]/B!QEZ &V]D(H4A'5NI]JU
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MV>](T^6.:[1]6NP<A[CE0?9>@KVW1/!4=K&@:-8T'10, ?A756UE!:*%BC5
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M'X5( !T%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #617&",UF7NE1M\ZX!HHH @@M4<;6&:<^FB,Y5L444 1,&3C(-
M59IRG49HHH K277L135O&''4>AHHH NV=RH8$1(I]0H%:T$S-Z444 6!<[1T
MIT=P7.,444 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvrx-20231231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $. V8# 2(  A$! Q$!_\0
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI#64NOVLFJ2Z>LRM=1
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M'#[CG.:FJO:.'A5QC:P##TP:GI#%HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH J:G;?;;&> MM$B%21VR,5P=
MS\(-+OK72;:\D-W#8HRJLJ@[L]S7HQ%&* /-+WX):1JMK8VFH2O=Z?9JPB@(
MP!GZ>E5(O@78KI%_837\S+/&L<,F!NA"GY<?AQ7JNTD]<#TI I&!G/UIW%8\
MFN_@PU\+:TEU=I;"! @4P@R# QPU= /AI;_V?I=N;I\:?D(VW[V1CFNW,>3G
MBB.(KW_ 47 \Z_X50=.MX)-,U.2UOX@R"X*YRI.2I%5C\$]/DAOX9+J5WO8
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M**?]61Z^]?0CZ!:W<DDS0QL\RA)'=>64=CZBLFX^%GAJXO1=MI%L+C(8R+&
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M)_T%3_WY?_"C_AI#P)_T%3_WZ?\ PHL,]2HKRW_AI#P)_P!!4_\ ?I_\*/\
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M!TIE@N(E9CESG/'6LSQS>BP\-7<I; *[<CWXI#/F#QQK7_"3_M!Z/8Z@%:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HI*,T +129H)H ,48HS2T )BC%%+0 E&*6B@!*,4M% "44M%
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M6!4>6IYKB?VG-0"Z%';!B"[@8]:]-^'=B=/\):9$W!\E/Y4^@NIU#XQR<"O
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MEUAG8#:,@85_<G@9KZ3TC4HM3LX[E&&'&2!V/H:&)&AWI:0,&Z'-+2&%%%%
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M,.?$#_H(:-_WTW^%)_PP[\0!_P Q#1_^^V_PH ^>,'KQCWH.1T)QZ9KZ"?\
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MC%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>YR63;RPYQ5BFLH<8
M(R* /%?C_P#!Y/B'I$M_9V\ UJUC/E2L,LR]2OUKY:M(M0DU308/^$1A6ZB5
MHOL\J!?M9'4N#WK]"Y8T"'*Y%>(_&C]GNT\>$ZKHS?V9K<?/F(VT2CTXZ&J3
M$T?+7D7O_"+:DY\-0^2M]B2_P-\+9_U0[XK2O]/U(^,+A/\ A#K2"X.G>8-/
M4+LC3:/WW7&[O6!KFA?\(M%<6.MR:E8:QY^([=XAY+IW?=NY:DN?[$&N/Y>M
MZN; VO\ Q\O //:7'^K*[_N9[YJR2MK-I<1>!]/GDTA+>)IG"ZDI&^<_W"/2
MN/7&T\[0.N!GR_<5T&HQVDN@V_D7MU)?;V#VDL7[A!_>!SU_"L-[>YXPL9*=
M,@C=_A0!T7P[BGE\6V:VNF1ZS<,#LL9@-DW'WFSQ6M):W?\ PBVJN=$A6V74
M LE^<;X7S_J5_P!GM7-^%XX8]8C_ +2GGTZR.?-FM$WS*?\ 9&1D?C6E(-.7
M2KK;J-W]J$^(K4Q9BDCS]]FSPWMC\: .A?3;W_A(+B)O#$&X:>6^Q!AM1,?Z
MX<]:KV\5Y'H.@R/X?M9+7[2?*NWPOVHY^XY]/K6=_P 2M]5V)JNIO"\.(W2W
M#3O+C_5[=_W??/X5[3\&?V<;W7VL=6\3>?::=$WF)IDIYE;L3_='MS2 N_ W
MX17'B?Q-=>)-;T*'2]*CD$EI:A1PX[K_ +/\Z^L;5=D07& .!Q4=E8P6ME%;
MPQ+' BA50= *L)&J !1@#@"H;N6.I:**0!1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWD5!%(&P6<8KK-6T*^F\0^'YY];O1-/;L\JV\@$;$+D<8->R0^&]/MS-LLH
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< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvrx-20231231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %O DL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **0D $G@"L.Z\;Z'9NROJ,3,IP1&"_\
MA0!NT5R,WQ/T6(X4W$OND7'ZD4Z'XFZ+*N2\\7L\7^&:=F*Z.LHKE)?B7HL>
M,//)G^Y%T_/%5W^*>DA3MBNF/8% ,_K19A='9T5PO_"UK/'_ !Y7'_?2T?\
M"U[/_GPG_P"^EHLPNCNJ*X7_ (6O:'_EPG_[Z6E_X6K:?\^,_P#WTM%F%T=S
M17#_ /"U+/\ Y\KC_OI:LK\3M*(&8[H'O\@/]:+,+HZ^BN1;XG:2.D=T?^V8
M_P :K?\ "T[3/%C.?^!+19A=';T5QT/Q.TU@?-@N8SV 4-_6M33_ !KI6HNJ
M).8G;H)5*_KTHLPNC=HI <C(I:0PHHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7?$171;/3@X5KK68U*C^)(8"?_0F6OS7'2OMO_@J!X@74/&?AJSC)\MIK^^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKCM;_P""=EM<JTGAOQR''4)?VH8>PW1M_2NOZY1FN61A["I%W1F_"WQU\/\
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M^&%_VJ_,7X[?MF>-_C%JDGGZC<6]NQ(CAB;]X%]% ^6,?3GU)H ^_P#]H?\
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M?%GPP/&OP[US257=/);F6#VE3YT_48_&@#\F:*T_$=C_ &?K-S%M*JS;U![
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ML3]:M_!KX.:U\6?%UAX4\,6F^>4[I9G!\NWC!^:61NP'YDX Y(K]@_@=\$]
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M]DO]E33_ (!>'1J.II%>^-+^(?:[H?,MJIY\B(^@_B;^(CT KZ&HHH ****
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvrx-20231231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $9 DT# 2(  A$! Q$!_\0
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MT1_X?/\ C[_HG_A[_P "9Z/^'S_C[_HG_A[_ ,"9Z_.ZIH;.>XBFEB@DECA
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M)VM6N1#(;97$;3!#L#$9"D],X!X]JBH^H8?^7\6'MJG<_1'_ (?/^/O^B?\
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M*** "BBB@ HHHH **** (YSB)JDJ.X_U+?A_.I*A?&_1?J5T"BBBK)"BBB@
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M'/ G@_5H;\NM[X(\42ZG<9"9&]65=@!Y##O65+$\]E;?_@E2IVN?-OCSX/\
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M^(](^!_CW7? FJ>-+/PIJ3^$]-B\ZYUF2'RK95W!<J[X#G) PF35KX4_L_\
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M4B+_ , 3_C7ZDT4?7,1_.'L8=C\MO^'+5S_T4B+_ , 3_C1_PY:N?^BD1?\
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M5S_T4B+_ , 3_C7VM\5/C5XP\&Z#X,US3M L1I.KWFG6MX][,WG0M<RJA54
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M3[-L3?EP3D ]!4/QS^+=K\&OAU<>))5CGD>>"SM(Y"=CS3.$3.T$X&2QP"<
MXH^N8C^</8P['Y\_\.6KG_HI$7_@"?\ &C_ARU<_]%(B_P# $_XU]D7G[3MI
MX<^"%_XNN]4TS6]5M[^/3#':V\]K''<2NJQ))%(/-7&\$_+DCD"O0?@M\0U^
M(OA1[R35]/U74()C%<_V?;36RPM@$(T<P#J<>H&:/KF(_G#V,.Q^>W_#EJY_
MZ*1%_P" )_QH_P"'+5S_ -%(B_\  $_XU]E>+OC3XT\)>,K:*]L='MM-NM7C
MTZTT9Y-VI74+'!N%VM@+U.,=!S7OPZ4?7,1_.'L8=C\M_P#ARU<_]%(B_P#
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M5C=ER VT]LC(H^N8C^</8P['YH_\.6KG_HI$7_@"?\:/^'+5S_T4B+_P!/\
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M(O\ P!/^-'_#EJY_Z*1%_P" )_QK]2:*/KF(_G#V,.Q^6W_#EJY_Z*1%_P"
M)_QH_P"'+5S_ -%(B_\  $_XU^I-%'US$?SA[&'8_+;_ (<M7/\ T4B+_P
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M-Y4GS?A6M\(/"T_@_P %VFFW.@Z;X>GA 1K;3+CSXWP  Y;RX\L0.?EKMJ*
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MZE30!['_ ,* \'^FO_\ A3ZG_P#)%'_"@/!_IK__ (4^I_\ R17HU% 'G/\
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M\",]Z]]K@?&'_)6/A[_NZC_Z)6@"O_PH#P?Z:_\ ^%/J?_R11_PH#P?Z:_\
M^%/J?_R17HU% 'G/_"@/!_IK_P#X4^I__)%'_"@/!_IK_P#X4^I__)%>C44
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M&]+O;(N;.XMHY83(<ML*@C)]<4 <;_PH#P?Z:_\ ^%/J?_R11_PH#P?Z:_\
M^%/J?_R17HU% 'G/_"@/!_IK_P#X4^I__)%'_"@/!_IK_P#X4^I__)%>C44
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M* .LHKD_^%K^#_\ H8]/_P"_PH_X6OX/_P"ACT__ +_"@#K**Y/_ (6OX/\
M^ACT_P#[_"C_ (6OX/\ ^ACT_P#[_"@#K**Y/_A:_@__ *&/3_\ O\*/^%K^
M#_\ H8]/_P"_PH ZRBN3_P"%K^#_ /H8]/\ ^_PH_P"%K^#_ /H8]/\ ^_PH
M ZRBN3_X6OX/_P"ACT__ +_"C_A:_@__ *&/3_\ O\* .LHKD_\ A:_@_P#Z
M&/3_ /O\*/\ A:_@_P#Z&/3_ /O\* .:_:;_ .2)>(/]^T_]*X:]1KP?]I'X
MF^%+WX,Z]#!K]C+*SVF$64$G%U"3^@KTS_A:_@__ *&/3_\ O\* .LHKD_\
MA:_@_P#Z&/3_ /O\*/\ A:_@_P#Z&/3_ /O\* .LK@OCIX,N_'GPOUG2]/YU
M$".ZM5SC=+%(LBK^.W'XUH_\+7\'_P#0QZ?_ -_A1_PM?P?_ -#'I_\ W^%
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M%\.Z1X=GM;'3M.:.*XCN(#(9;=4(VH0PVL3M.XYZ'CFH?^%K^#_^ACT__O\
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MG_\ ?X4?\+7\'_\ 0QZ?_P!_A0!UE><? ;_D3M9_[&KQ#_Z>+NMO_A:_@_\
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MV_Q%^-OA;X>7MNT_@M;O1C%#-/J@2")(TE(VE$;YI,9!.WI5[6O@%J&IZ/\
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MB1OY;9Q@K&O!!P<U[NJA5  P!P * ,S_ (1?1O\ H$6'_@,G^%'_  B^C?\
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M+,< D<5E^-OVKK71K_PAI5C_ &-I6HZWI,>MW4WB6_-M!96[X"IA06DD8EL
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M"BO)O!]]X_\ &?A^UU>WUFVL(+D;DAU#2##-CL2NXXSU%;7]B?$7_H9M(_\
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M#OZ*X#^Q/B+_ -#-I'_@O/\ \51_8GQ%_P"AFTC_ ,%Y_P#BJ ._KSCX#?\
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M(A1454/\('% 'P?XM\&>+=/_ .$8M?$FL36ECJ6EW6M2W%W#=S1QZM<S^:R
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M#\2Z+=V2V\-YY$$4@D%RT?F9=ER%R>@/I7Z)B"-=V(T&[[V%'/UH%O$%*B)
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M'/0^M7+WQSX?TW6K?2+K6;*WU2X ,5I),HD?/3 ]^U &Y17+'XI>$!%J$O\
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M8H7V@GJ< G\#572_B?X2UN^M;*P\1:==W5TN^"*&X5FD'MSS0!T]%<_9>/\
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M'F@#7HKRRX_:&\+Z%KFGZ1X@O[73;_5M:GTC2XX9Q.)S&C.'<K_J\A&&&Z'
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M&4>T[5P\7P?\=>*-7\1O<^$+RTTN]T71[-;:ZMX(4D>#4#)*ACC.,+&QP3U
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MB@#S'_A)?C!_T3[P?_X6=S_\K*/^$E^,'_1/O!__ (6=S_\ *RO3J* /,?\
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M=S_\K*/^$E^,'_1/O!__ (6=S_\ *RO3J* /,?\ A)?C!_T3[P?_ .%G<_\
MRLH_X27XP?\ 1/O!_P#X6=S_ /*RO3J* /,?^$E^,'_1/O!__A9W/_RLH_X2
M7XP?]$^\'_\ A9W/_P K*].HH \Q_P"$E^,'_1/O!_\ X6=S_P#*RM;X.>&=
M9\*>#);;Q!#96VK76K:GJ<T&GW+7$,7VJ^GN%19&CC+[5E )*+R#Q7<44 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cvrx-20231231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %! E\# 2(  A$! Q$!_\0
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MXL?MIVW/U#_X?:G_ *(P/_"J_P#N*C_A]J?^B,#_ ,*K_P"XJ_+^BJ^H8?\
ME_%B]O4[GZ@?\/M3_P!$8'_A5?\ W%1_P^U/_1&!_P"%5_\ <5?'/P4_8Q\:
M_'7X?77C31]8\,:-H-MJ!TQY]?U/['^^"(V 2A'(<8YR>>*XWXU?L]^-?@'X
MYM_"OBO3HX]0NXDGLIK.4307D;G"M$XZ\Y&#@@]N1G)83".7(EKZLKVM5*Y]
M\?\ #[4_]$8'_A5?_<5'_#[4_P#1&!_X57_W%7Q!\<?V5?'/[/6M>%],\7I8
M6\WB&$36DMO<%XT!8*5D8J-K*6&1SBO5D_X)H?$:71)-93QG\.'TB.40/J"^
M) ;=9" 0AD\O:&P1QG/-2\-@DDWL_-C]I5;L?1/_  ^U/_1&!_X57_W%1_P^
MU/\ T1@?^%5_]Q5^:7BC0)?"OB/4]&GN;6\GL+F2V>XL91+!(R,5+1N/O*<<
M'N*H3V\MLP6:)XF(W .I!(]>:V^H89_9_%D^VJ=S]//^'VI_Z(P/_"J_^XJ/
M^'VI_P"B,#_PJO\ [BK\Q;>SGN]WD023;1D^6A;'UQ3_ .R[PLR_9)]RXR/+
M;(STSQWI_4,/_+^+%[>IW/TW_P"'VI_Z(P/_  JO_N*C_A]J?^B,#_PJO_N*
MOS'CTZ[F:01VLSF,X<+&3M^OI48MI3$91$_E!MA?:=N[TSZT?4,/_+^+#V]3
MN?IY_P /M3_T1@?^%5_]Q4?\/M3_ -$8'_A5?_<5?F3_ &7>[RGV.?<H!*^4
MV0#T/2M/PWX)UKQ5KEMI-A83O<S2Q1$M$VR'S)%C5I" =J[F49/K2^HX9?9_
M%C]M4[GZ1_\ #[4_]$8'_A5?_<5'_#[4_P#1&!_X57_W%7YS?$3X<ZY\+_%&
MHZ%KMJ8;FRNIK0SHK>1,\3;7,;D#> >XKF*%@<,U=1_%A[:HNI^H'_#[4_\
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M()"^6V2!U/2D&FW;3>2+68S8W>6(SNQZXQ5?4,-_+^+%[:IW/TX_X?:G_HC
M_P#"J_\ N*C_ (?:G_HC _\ "J_^XJ_,465P3*!!*3$,R#8?D'OZ4]--NY A
M6UG8.-RD1D[AZCCD4?4,-_+^+#VU3N?IO_P^U/\ T1@?^%5_]Q4?\/M3_P!$
M8'_A5?\ W%7YFV^A:E>7D-I!I]W/=3Y\J".!F>3 R=J@9/ )XKK?BC\%?$_P
MBN--CUVV0QW^G6NI1W%KO>)8[A"\:.Q4 284Y7V[U/U'#)VM^+'[:IO<_07_
M (?:G_HC _\ "J_^XJ/^'VI_Z(P/_"J_^XJ_+^BJ^H8?^7\6+V]3N?I^G_!;
M@N@;_A2X&?\ J:O_ +BI?^'VI_Z(P/\ PJO_ +BK\NX/]2OTJ2IC@,.XIN/X
ML;K3ON?J!_P^U/\ T1@?^%5_]Q4?\/M3_P!$8'_A5?\ W%7Y?T57U##_ ,OX
ML7MZG<_4#_A]J?\ HC _\*K_ .XJ/^'VI_Z(P/\ PJO_ +BK\OZ*/J&'_E_%
MA[>IW/U _P"'VI_Z(P/_  JO_N*C_A]J?^B,#_PJO_N*OR_HH^H8?^7\6'MZ
MG<_4#_A]J?\ HC _\*K_ .XJ/^'VI_Z(P/\ PJO_ +BK\OZ*/J&'_E_%A[>I
MW/U _P"'VI_Z(P/_  JO_N*C_A]J?^B,#_PJO_N*OR_HH^H8?^7\6'MZG<_4
M#_A]J?\ HC _\*K_ .XJ/^'VI_Z(P/\ PJO_ +BK\OZ*/J&'_E_%A[>IW/U
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MZ?YBGTP_Z]?]T_S%*6R&A]%%%62?=OAWP7K_ ,<O^":OAWPU\.[277=<\/\
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MHD^;:^"P"]2<G.:RG6JPB_5_=;YE*$6_D?#/P0_9"TSXH>!M.\3>)?BKX=\
MQ:OJ(TO2;"\C:ZNKN8G S&C QJ3D G/3MQGR'XQ_"O5_@E\3?$'@?7GMY=5T
M:X\B66U<M%("H='4D X964\@$9P1FON/]FCP5IFA^/M>^(/PF\1?#?6=!O\
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M.PKV[QA^R1;^$5UK19/B#I<WQ T;2$UF\\-O93PQM$8TE:.&[8".614D!P
M<$ D@U#J1C:[W&HMGSQ17TAKO[(-C8WZ^'--^(=GJ'CZ30X-=@\.3:9+ +F.
M2V6Y,45QN9#((R3AMN2N!7S@RE6((P1P0:<)QG\(--;B44459(4444 1V_\
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M\;>-?"GQ(^"G[3_C>P^(.J^+O"NMZ1#)9Z5J^EW%K;:3=8VPQ1-,H5WW[/\
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M ,?KW?\ 9M_:O\2_&B6SDO-9\+MJ-SIMQJ4?@Z#0+_3]0F50WEQPW=U/Y$S
M[ Y0,%R<[>H[OPK\4_B=I7Q-\ ^&O'5CX923Q=87=W)I>BK-]KT1H(ED(ED,
MKI.FYA$9%6,;V7&0:/K=?^=A[*'8^3?^'*6C?]%7O_\ P2)_\?H_X<I:-_T5
M>_\ _!(G_P ?K[X^(TGC"Q@;4= \0^&]!TJSMWFO9-=TF>\("Y8N&CNH0JA0
M<@@_6LS]G[QMXE\?_"'1?%7B^*PL[[5(WOH5L[62U06;,6MW>.220H[1;'8%
MS@MCM1];K_SL/90['PU_PY2T;_HJ]_\ ^"1/_C]'_#E+1O\ HJ]__P""1/\
MX_7WSX/^*VC^,_%GBG0;22);C0KN*U+_ &A&%R7@2;<@!S@!\'W!KG?BEXD^
M)>EZEJDOAJ'PUH?AG2=+-]-K?B97G2ZE^<M"B131M$J*@+2/D?.-H.#@^MU_
MYV'LH=CXH_X<I:-_T5>__P#!(G_Q^C_AREHW_15[_P#\$B?_ !^OJV3XR_$'
MQ'X#\%>*K"Q\-> M#U3P[%K>JZQXPE9X+6XD166S2)9HG!P68R-P  ,$D@=_
M\'O'VM?%GX(>&O%LFFQ^&M=UO2DNQ9WD;RQV\K+P2N59D/# 94E2.11];K_S
ML/90['PG_P .4M&_Z*O?_P#@D3_X_1_PY2T;_HJ]_P#^"1/_ (_7UWI/C7XH
M6OQYT/P1J&I^$];TPZ9/JVM2Z;H=U:2V<((CME5WO)5WRR%L*5^[$Y]*]SH^
MMU_YV'LH=C\T?^'*6C?]%7O_ /P2)_\ 'Z/^'*6C?]%7O_\ P2)_\?K]+J*/
MK=?^=A[*'8_-'_AREHW_ $5>_P#_  2)_P#'ZY34O^"06D67Q3\/>%1\3;UX
M]3T;4]3-U_8Z QFVGL(PFWSN=WVPG.>-@ZYX_5FO,_$'_)RO@/\ [%'Q%_Z6
M:+0\77?VV'LH=CX=_P"'*6C?]%7O_P#P2)_\?H_X<I:-_P!%7O\ _P $B?\
MQ^OTNHH^MU_YV'LH=C\T?^'*6C?]%7O_ /P2)_\ 'Z/^'*6C?]%7O_\ P2)_
M\?K]+J*/K=?^=A[*'8_-'_AREHW_ $5>_P#_  2)_P#'Z/\ AREHW_15[_\
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MW_X;W7__ )"H_P"&B_"G_0)\=_\ AO=?_P#D*@#T^BO,/^&B_"G_ $"?'?\
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ML89=)GL_LD-Q;M T/V20 1R*5QL(QC:1QTZ5YW_PT7X4_P"@3X[_ /#>Z_\
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ME)IN@331^+V\1?\ "?O<M_:K6YNC/Y/EB/.[RS]GQYFS9GCH*]@_X:+\*?\
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M ,-[K_\ \A4?\-%^%/\ H$^._P#PWNO_ /R%0!Z?7G_AO_DMWCK_ +!&C_\
MH=]5#_AHOPI_T"?'?_AO=?\ _D*J7PK\96'CCXM>/-0TZWU6V@73=)A*:QI%
MWIDVX->DD1744;E?F'S!=IY .0< &Y\.O^1\^*G_ &';;_TU6-:.F?%OPGK?
MCN]\':?JZW_B&R0O=6UM!+)';XQE))@IC1\,#L+!L'.*SOAU_P CY\5/^P[;
M?^FJQKY-^ M_J/@?2/AH='\=ZCJOC;6_$NH67B+PG?W*-$C$W#W!>W5=T1B=
M8V,O4AL$G<H !]E>,/B;X9\ :GX;T_Q!JL>FWGB.^&F:7')&["YN2I81@JI"
MDA3RQ [9R11XS^)OACX?7WAVR\0:M%IMWXAOUTO2X61W:ZN64L$ 4''"GYCA
M1QD\BOF;]J7P3XO^)S?##P]XA.C:3XDNM:OCI-YHT\LL=K<1Z?));3DR(I#+
M,@) &,#WKSO4/&6H?M$>,_A[\2]3LY=,MO#OB/1_#%OILR$>3JC2^9JKX/\
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M5))"VR8.) 56)N&!( !]/>&?$VE>,_#^GZ[H6H0:KH^H0K<6MY:N'CEC89#
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M.C?V8O$^BK^SGX L8HFT>ZF\/FXM]'>Y62\FAC^5YXE.&=6+*X8+C$J=,@4
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MBS1?9M0TX:/KUA*=OFQQNTEK<1G^_&SS(5/WEG)R"@#._P"%9^(_^BM>,?\
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M.D0Z9K=NUU9PWEM?HBR-&1-!*LT394@\.BG'0XP>*YW_ (5GXC_Z*UXQ_P#
M31O_ )7T?\*S\1_]%:\8_P#@)HW_ ,KZ )OB'\$_"GQ/U&RU'6K6ZCU.T@DM
M([[3KZ:SG,$A!>%GB92T;$ E3D9&:T=&^&7AWP]-I_\ 9MD]G:6&D_V);Z=%
M.XLTM,J0OD9V%OE WD;L9&<$UD?\*S\1_P#16O&/_@)HW_ROH_X5GXC_ .BM
M>,?_  $T;_Y7T 9'A_\ 9Z\)_#*X77/">B/<ZWIEE+:Z-;:EJ<\EM8HX&8H
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M /0:*\^_X5GXC_Z*UXQ_\!-&_P#E?1_PK/Q'_P!%:\8_^ FC?_*^@!/V=_\
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MEW'BKP;\1]-N_"9^(FGZ'=:#J]C.+E-*NH9Y89MT+C=*A22!" P.X,P)7@T
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M4 %%%% !7E?[*7_)KGP=_P"Q-T;_ -(8:]4KRO\ 92_Y-<^#O_8FZ-_Z0PT
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MWAVVDO#=2ZF$U'5["61$$;P&=@IB8*Z.HY^92.,BJ/[._A?Q1\,_AG9>%Y]
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M8E,H -N6&X5V.D>+9O%GP[L?$WAVQ2[FU+38]0L+*_F-LLADC#QI(X1S']X
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MB?X2^&L-I)XI\1Z;H(NY5AMEOKA8WG<D +&I.6.2.@- &/\ \+U\)?WM<_\
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M<W\$[K/[%UOI-I<*FKWVA:O<Z79&0">6V,TYA>-"=Q39)#@@8 9?45] >+_
M7AGX@V$5CXI\.Z3XELH91-';:O8Q74:2#HX612 P]1S5U?#^EKJ-IJ"Z;9B_
MM(&M;>Z$">;#"Q4M&C8RJ$HN5'!VCT% 'RUX UG1M<\3?LJP:!=VMY/9>'+Q
M[F.QD5C!:C3HXB) OW5$WEK@_P 0QU%?6M<]X>^'GA7PCJNI:GH7AG1]%U+4
MW\R^O-/L(H)KMLYW2NB@N<D\L370T %%17-U#96\D]Q*D$$:EGEE8*JCU)/
M%2=: %HHHH *\_\ #?\ R6[QU_V"-'_]#OJ] KS_ ,-_\EN\=?\ 8(T?_P!#
MOJ #X=?\CY\5/^P[;?\ IJL:] KS_P"'7_(^?%3_ +#MM_Z:K&O0* "BBB@
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M\.^';IFW:=8%$5!L)/E"1E>41#A!*%XP0-KQ)^SMX:\2?"_PGX!>]UBP\/\
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M^"?#MO>Z99PQ>=(MU=/.LLT:=Y?+A$:D<@2.!]XUR?[5MO!\1_V<?$OB=O\
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MX.\320E-+\0V-K?:9/K&CW5S8JRZQ:PA6=[9(W>3=MD1@DB(S!@0",X .O\
M[*^*G_0T>#__  F[K_Y/H_LKXJ?]#1X/_P#";NO_ )/KE;G]JC0])TO7;C6O
M"GBK0M1T@6#S:+>VD#7LL5Y,88)8UCG=6!=6!7<'&W!7. >Q^&WQ8L_B1>:_
M8#1-8\-ZQH<\<-[IFMQ1),@D3?%(#%)(C(RYP0V>"" 10!!_97Q4_P"AH\'_
M /A-W7_R?1_97Q4_Z&CP?_X3=U_\GUYUX=_:HTR.RT+3K/0O&?CC5]5LM4U6
M!+.PLQ/]GM+[[-*''GH@VLZA>?F4#)WG:;.E_MF^#]4TJQU=="\3VVA:IHMY
MKFD:K<V,20:I%;0&>:.$>;O601JQ E6,-M.&(YH [S^ROBI_T-'@_P#\)NZ_
M^3Z/[*^*G_0T>#__  F[K_Y/KB)_VPO"NFZ9?WNK^'?%.AK%HC^(K*+4+*)9
M-5L4,8>2V"S'+*9HLI)L<;P=N*U[S]I&UMKBVL(? ?C._P!<>T;4+C1K:RMS
M=65H'*)/,&G"J'*L40,9&"GY,@B@#H/[*^*G_0T>#_\ PF[K_P"3Z/[*^*G_
M $-'@_\ \)NZ_P#D^N<T[]JKP3K/AC5M>TT:CJ%C96^G74 AA0/J$=]@6Q@5
MG&=S[D(?80R,#TS4T'[3?A>Y\9C0DT_6#8MJS:$OB'R8O[/.H*2K6X/F^;D.
MK)O\O9N&-V: -W^ROBI_T-'@_P#\)NZ_^3Z/[*^*G_0T>#__  F[K_Y/KSGP
MU^VGH/BRQ\*W5AX!\=-'XKM7N= WV%J/[2*+ODB0_:<(ZKN8F4HA"DJS=]7_
M (:Y\*W-CI7]F:%XCUC7+U;MY?#UI:PK?6*VLWD7)G$DR1KLE&S D8L?N!L&
M@#L?[*^*G_0T>#__  F[K_Y/H_LKXJ?]#1X/_P#";NO_ )/KA+S]LOP>-.N-
M4TC0?$_B71;71[37KK5-)LHF@M[*X#E97\R5&RHC<L@4N,'"G!QT'P^^-VI>
M-_C+XR\'OX2U&QTC1;>UGM=;E:W,-P)0Q!.V=GPX&Y/D' ;?M. 0#;_LKXJ?
M]#1X/_\ ";NO_D^C^ROBI_T-'@__ ,)NZ_\ D^J/B7X]:=X5\5-I5[X:\1_V
M9'>V^G3^(UM(QIT-Q,56-"6E$K LZ*62-E!."PP<87AW]JWP[X@UW3[-_#?B
M;2M,O]7O-"M]?U"TA6P>]MGE5XMRS,XW>1(58IM(7!(/% '5_P!E?%3_ *&C
MP?\ ^$W=?_)]']E?%3_H:/!__A-W7_R?7D%U^T[>^.OBK\&+;PMI^OZ3X1\2
M:E?*VI:A90I:ZU:QV4KQM"=[2*N]5<;EC+#D9%:_QC^,/BK0_%OC>QT37=$\
M.0^$/#\.N"#5X YU9G\XE Y=?+C'E!-R@G=(.F " >D?V5\5/^AH\'_^$W=?
M_)]<_>_#GXEWWC[1O%;>+_"BW>F:9?:7' /#=SY;I=2VDCL?]/SD&S0#_>;/
M:O,/''[1>NS^(+"\MO$LO@3PE<^'=-UB.^E\+3ZI&7N1([^;,N$A6-1%DL<?
M,<XQ6WXF_:(\0^"?B%J5O?+#=Z69)[6SL7M&MTR(X&M9OM9.PK*SS%ASM6-C
M_ V0#U3^ROBI_P!#1X/_ /";NO\ Y/H_LKXJ?]#1X/\ _";NO_D^MC7_ (C:
M'X7\!3^+[Z_AGT:"W$YN+!OM"RY( $6W[Y9B%&.I(KBY/VD=+L-&O[K6/"?B
MK0=1MY[6V@T6_L8OM=_)<%A MN8Y7B<L5;(,@*[27VCF@#<_LKXJ?]#1X/\
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M\/76M,GAOQ1K&BZ+]C;4->TNSAELX([J&.:&3F82.I65,[(V([C') -;P-X
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MQ83VEKJ&KZ?:1R6EE+<HDD(D'F"8@K+&2ZQ,B[N6&#@ V/[*^*G_ $-'@_\
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M #.2*[[X8?&I?BI\5Y/[$U%[CPA<>%X-1M[66!8Y(KG[7/#,'R-X=3$492<
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MVEU#XJ\/)J-J8I+Z>ZB>)68-'(GVAT)!PXQD<"O?/[2\=?\ 0N>'O_!_/_\
M(5']I>.O^A<\/?\ @_G_ /D*@#SFU_9NN--\,_$+2=+U^'0#XGTJQTZVFT2R
M%DNGFWMO)+1QQL JL<D*FW:#@'O7&:#^QS?Z;K.KZB^I^'-+_M$Z(6M=!T5K
M6(-I]\UTS-F5B[2!MNYCD8'4"O>?[2\=?]"YX>_\'\__ ,A4?VEXZ_Z%SP]_
MX/Y__D*@#R'Q=^S?XKU2Q@TW2O$^D+HTOBJ]\3:CIVI:?))'?>8ZR6\#[)%.
MR-\LPZ.53H 08_&G[+5]XS\73>++]?!&KZ[J>F0Z=J<>O^&5U&V0PM)Y<MJL
MC[HSME(922K;5)Z5[%_:7CK_ *%SP]_X/Y__ )"H_M+QU_T+GA[_ ,'\_P#\
MA4 >*>./V4==U3PMXR\(>&/$VD:#X1\4&VEGLFT@EK22*.&,K;A)%1(F6"/"
M;?EY XZ>A?'GX&VOQEA\-7#)I,VH^'[YKRV@UW3EO[&8/$T<D<L+$9!# A@<
MJ5!%=3_:7CK_ *%SP]_X/Y__ )"H_M+QU_T+GA[_ ,'\_P#\A4 >/ZY^R[J%
M]X6T[2+,>!;:S1;HW6CCPE#%IXFE92MS;B-EEBF0+MW"3YLY(R 13U[]DS7K
M_P .:IHL'CC[='J_@6#P?J%_K%JT]W-) )O*NMX<9),S;@V2<#G.37MG]I>.
MO^A<\/?^#^?_ .0J/[2\=?\ 0N>'O_!_/_\ (5 '#^*O@%<>(]"^*.GKK,4#
M>,M1MKZ.0VY86HBCMT*D;OFS]G)SQ][VJE\4/V=]1\=Z_P",=4LO$,5@=>@T
M6'[)-;N\+K8RW3O%.$D4O%*+D*5!'W.<@XKT7^TO'7_0N>'O_!_/_P#(5']I
M>.O^A<\/?^#^?_Y"H \:\/?LKZOX;T*XCL-7T#3=2'BVV\4VL.FZ.;>PA,4"
MPM#Y*R9P0&.X$')&>]=1HG[/EQI/Q T7Q&VM12)I_B36=>-N+<@NM] 8A%G=
MP4SDG'/H*[W^TO'7_0N>'O\ P?S_ /R%1_:7CK_H7/#W_@_G_P#D*@#YP\6_
M#CQ7\!_'<?BWPHFK:QJ&K-K:WDFGZ"=2M_*N=1-[;PM$DRR)*K32!9<>41NW
ME<K75?"W]FZ]N_V)/"7PH\6A--U>'1[=+E2B7*6]RL@F"NO*2!7PK+DJP!&<
M&O9?[2\=?]"YX>_\'\__ ,A4?VEXZ_Z%SP]_X/Y__D*@#R&T_9:N+32A<V">
M"O"WB>SU.RU2PO/#'AE+& R6XE7;<*K[IE99Y!C<-NXD<DUS'A3X)_$#7/%G
MCC4]0O[/2_$5AX[M?$6FW\VF2"PO572%M654\S<4Q-(NX/G<GX5]"_VEXZ_Z
M%SP]_P"#^?\ ^0J/[2\=?]"YX>_\'\__ ,A4 >'7O[*'B74(+*6_\6:1K,ZZ
M]JFM7VF:EI+OI5ZUYY6W?;B4;FA\MMA8L/WC9&3FI_!O[)FK>";#P)%9>)M/
M:7P_I>N:-=#^S3'%/;:C<K<9B19/W31F- !R,9X'%>U?VEXZ_P"A<\/?^#^?
M_P"0J/[2\=?]"YX>_P#!_/\ _(5 'D'AC]FGQ9\//"^G:7X3\96%G-+X4TSP
MSJT][IK3;VL[8P)=6X$@V,59OE;<.%]#FQ;_ +)UOHWPX\=>#-'UG[/INO>&
M;#PW9//"9'M4M;5H!)(0PWEMP8XQWKU?^TO'7_0N>'O_  ?S_P#R%1_:7CK_
M *%SP]_X/Y__ )"H K?$+X>R>-[CP7+'>K:?\(]KL.L.&C+>>(X9H_+'(VD^
M:#GGITYKR^W_ &4+'3_B5JNOPZ?X,U#3]3UPZ]+-K/AF*[U."9F#NL5RQX&\
M;E)!*9XZ"O6?[2\=?]"YX>_\'\__ ,A4?VEXZ_Z%SP]_X/Y__D*@#YU^$7[/
M7B[QA\./#&C>-K^+2_"NF:YJNJ?V$-/>&_D=[N\$(DE+X\O;,9!A 3E.<==3
MPC^QDWA3PU)HEI<^$],DM-&GTC3?$FC^&(K36TWQB)9I+I6#;]@(<IM+[B3B
MO=O[2\=?]"YX>_\ !_/_ /(5']I>.O\ H7/#W_@_G_\ D*@#P?2_V.K^WL/'
M43:GX<TF7Q+H-MI*KH.BM;1Q2PS/*)Y,RLTI8OSDYXZUK>)_V4I/$WC"^\27
MMOX'UJ_UJUM8M5_X2'PNFHB.6)-C/:F1\HK+CY'+#(!]:]B_M+QU_P!"YX>_
M\'\__P A4?VEXZ_Z%SP]_P"#^?\ ^0J /'_%/[,/B'4;;6] T7Q3IVF^#M5\
M1V_B5[*;36DN(9DN(9Y(HW$@41N\61\N5W$#BO4?$WPUE\0?%_P-XU6_2&+P
MW8ZI9O9F(EIS=_9L,&S\NW[.>,'.[MBK_P#:7CK_ *%SP]_X/Y__ )"H_M+Q
MU_T+GA[_ ,'\_P#\A4 >5']E47GPP\%^#+_6TGM=#\1:CK-U+' 5-S#=KJ*F
M%?F^1@-0'S<_ZL\<\8/AC]CB7P[X7N]&M[CPCI-S'HLNCV'B+0O"\5EJX+*B
MB:6X1@VXHA#A-N_>3QQ7N?\ :7CK_H7/#W_@_G_^0J/[2\=?]"YX>_\ !_/_
M /(5 'BGA+]E/6O"_P#PF5Q::GX3TNYU^PTZS-IIWAM/L3?999G;SXI7?SA*
MLQ5B2&&,ANE2:;^RQKVA6NE7VD^(]*TS6=*\2'7[&P@TZ0:1:AK.2UD@B@\W
M<BLLK/\ *P ?H,5[/_:7CK_H7/#W_@_G_P#D*C^TO'7_ $+GA[_P?S__ "%0
M!Y?\*_V;M7\#?$2Q\6ZOXFMM8O(Y-=FN$@L3 LCZC<6TWRC>VT)]G(QSG<.F
M.<3X<_L<VOPUN[6VTQ/"$>GZ=)<RZ=JY\*V[ZY"9!)Y6;I\AFC,@P^W+! &S
MDY]K_M+QU_T+GA[_ ,'\_P#\A4?VEXZ_Z%SP]_X/Y_\ Y"H \^^#?P#U3X<>
M.[WQ)?:IHZ?:-,&GRV'AS2_[.M;R7S%?[7/$'*&?"E04"\.W7C%C5_@#<:GH
MOC>Q&LQ1GQ%XHM/$*.;<GR%A>U8Q$;OF)^S'YN,;NG%=S_:7CK_H7/#W_@_G
M_P#D*C^TO'7_ $+GA[_P?S__ "%0!YUXV_9UO?$/Q O?&NF:_#I^O0ZG8ZKI
M1FM3+%#)!:S6TB2J&&])(YW'!4@X(/%94O[-'B%O$=KX[7Q99CXD0ZR^JF[-
M@W]G-$]G]C:U\CS-VSRPIW;]V\9]J]:_M+QU_P!"YX>_\'\__P A4?VEXZ_Z
M%SP]_P"#^?\ ^0J /GR+]B>Y.H-K^HZIX;\2^))-;U75)8M=\/K=:;)'?&%W
MC\AW)5T>!2L@;."0<Y->J?"KX%)\-/%2ZQ ^CVL)T./2VT[0]*33[591<RSO
M)'$AVJ"9<8ZD@DDDFNO_ +2\=?\ 0N>'O_!_/_\ (5']I>.O^A<\/?\ @_G_
M /D*@#S+QI^RW%XM\?>//$ZZXUK+X@T9+&QB$&?[.O,QE[M3GEF^S6G''^IZ
M\TFG?LM0Z9HNGZ3#K6+2W\"7'@Z60P9EFEF>-Y+LG=C+,CL5[ESS7IW]I>.O
M^A<\/?\ @_G_ /D*C^TO'7_0N>'O_!_/_P#(5 '"^&O@?K5G-=7FLZ[8W5_<
M^$4\+N;.T>*,%'E*S ,['[KJ"N>H)SS@7-9^!T^H_"+P+X7M]82UUSP<=-N=
M/U0P%HC<VD8C#/%N!*.N\%=V0&ZY%==_:7CK_H7/#W_@_G_^0J/[2\=?]"YX
M>_\ !_/_ /(5 'GNK_!KQWK>K>'_ !9=>-M/?QIH=Y<R6(&E8TV.UGA6*6U,
M8?S&!*))O:0L&7 PORUSWB;]D1_%O@*>QU#Q.?\ A+KWQ))XCN]<@M0J;IHS
M;7%O''N)6)K1GA +$_=8Y(KV/^TO'7_0N>'O_!_/_P#(5']I>.O^A<\/?^#^
M?_Y"H \7^,O[)M]\3-;UN:VU;1!IVH:=;V-I'K6E->RZ1Y2XS9GS L6_ )(7
M=GOVKJ-3_9YN=0\)?$71AK<2/XKUJVU9)OLY(MA$MHI0C=\Q/V4\\??'ISZ!
M_:7CK_H7/#W_ (/Y_P#Y"H_M+QU_T+GA[_P?S_\ R%0!XGXH_9+U7Q)\0;OQ
M!-K^CWBOXEM?$$%[J.E-<:G;QPRQO]BCN#)B.$!"H"*.#SGG,.M?L;RZMYK3
MZIHFJ_8O%^J>*]*M=:T87=J1J#2M<6UU$SXD ,Q*.NTJ44\\Y]R_M+QU_P!"
MYX>_\'\__P A4?VEXZ_Z%SP]_P"#^?\ ^0J ,SX<_"^/P+\/+SP]':Z#ILUX
M]Q+,/#FD)IUH'ER 1"AY(7:"Q.6V\UQFE_ 7Q'X,T[X?W/A7Q+86_B'PUX6A
M\*W,NI6#S6M[ BQ?.$6161@\6X?,>&(.>#7HW]I>.O\ H7/#W_@_G_\ D*C^
MTO'7_0N>'O\ P?S_ /R%0!P?P4_9S3X.:^FHQ:TVJ&33)K:[:6';)/=S7TUY
M//D' 5I)V 3'  Y-3>/OA'XOU;X@:QXF\*^)]-T<ZKH<6B7$&H:<UR45))7\
MU")%^8>:0 01ZUVW]I>.O^A<\/?^#^?_ .0J/[2\=?\ 0N>'O_!_/_\ (5 '
M@/C?]BNZU[3#H^GZ[I$^D)X>LM!LCX@TMKZXTQ;>(1B2U)D"QL^U69@N[/(/
M2NH\2_LTZUXF\?V.MS^(=*BAM=2MKZ+4K?2%M]9BAB"[K(743*)('VLI$JN=
MKD') (]6_M+QU_T+GA[_ ,'\_P#\A4?VEXZ_Z%SP]_X/Y_\ Y"H \-\'?L8V
MG@Z(Z;!!X+FTZVBO8['57\*P_P!M+YT<J)YEV#DLGF\NH#,%P3R2=N]_9<NK
MO1Y;(>(85+Z;X8L-_P!E/!TF]6Y9L;O^6H7:!_#UYZ5ZO_:7CK_H7/#W_@_G
M_P#D*C^TO'7_ $+GA[_P?S__ "%0!Y1\5?V4+?XG>*-;UZYOM/FNIM5TW5]/
MM-3TY;RT62UM9;9X[B)CB5)$F?I@J0I!R*]%^$7PP@^''AN]T]]-\-64M[<M
M//#X9T6/3;0Y55 ,:D[SA>68DG..@%:7]I>.O^A<\/?^#^?_ .0J/[2\=?\
M0N>'O_!_/_\ (5 'C6F?LD7FB_"WQ=X6L_%SB^U;4K>6TO7@8)!IMM*AMM.D
M5'5GB$:M&^&&X2-]*K^$_P!D6\T#Q)8:LVJZ%8);^++'Q,=/T/1_L=LH@TZ>
MS:%$#G!8S!]YR<@Y!SD>V_VEXZ_Z%SP]_P"#^?\ ^0J/[2\=?]"YX>_\'\__
M ,A4 >%6G[(FOW,/@K0-8\7V%WX+\+2ZJ+>TM]-:.\N(;RSN[8"24R%0R"ZS
MD* =O3GCL_@=^SM'\)=6@NY=.\%"2SL/[/@O]"\,16%_,N5R\TZDDY"#<JX!
M//85Z%_:7CK_ *%SP]_X/Y__ )"H_M+QU_T+GA[_ ,'\_P#\A4 =97G_ (;_
M .2W>.O^P1H__H=]6I_:7CK_ *%SP]_X/Y__ )"JKX/\.ZY;^-O$GB+6H-/L
MSJ5I96D5M87;W.T0&X)9F:*/KYXP #]WKS0!VU%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cvrx-20231231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 E,# 2(  A$! Q$!_\0
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M/@Q^TKXE\)^$O$L.G:%9Q6S0V[6$,I4O"C-\S*2>2:\"_P"'GG[1'_0YV_\
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ME6BCZI0_D0>UGW/JK_AYY^T1_P!#G;_^"NV_^(H_X>>?M$?]#G;_ /@KMO\
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M?_$4?\///VB/^ASM_P#P5VW_ ,17RK15_5*'\B)]K/N?57_#SS]HC_H<[?\
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MOYK;0K.XUEI?MVP<K;2."THX.&;&:F'U.7V;>HW[5=1G_#SS]HC_ *'.W_\
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MOL4**O\ ]@:G_P! V\_[\/\ X4?V!J?_ $#;S_OP_P#A1[2'\R#E?8H45?\
M[ U/_H&WG_?A_P#"C^P-3_Z!MY_WX?\ PH]I#^9!ROL?:G_!/KXP> ;+PUX@
M\#_%#5[;2M$LM0M?$FF37A&W[3 V2BY'4X!J'X?_ +1FD>,-,_:6\1>(->M]
M$U;Q5=6=QIL,Y#2%$G<JJ+_'Y:;..^/>OC'^P-3_ .@;>?\ ?A_\*/[ U/\
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MOL4**O\ ]@:G_P! V\_[\/\ X4?V!J?_ $#;S_OP_P#A1[2'\R#E?8H45?\
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M8;==L<99B=J DX49P!GI5&K_ /8&I_\ 0-O/^_#_ .%']@:G_P! V\_[\/\
MX5W^TA_,C'E?8H5&G^MD_"M/^P-3_P"@;>?]^'_PJ&/1-1:>91I]T67&0(&R
M/TJ)5(77O+^D-1>NA6K8\':VOAKQ9H^K.GFI8W<5PR?W@K X_2JW]@:G_P!
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M]74M2^P0?:+Q(S&)Y-@W/M(!&3S@@8S0!O4444 %%%% !1110 4444 %%%%
M!1110 4444 %<#\;?^1-T[_L9?#_ /Z>+.N^K@?C;_R)NG?]C+X?_P#3Q9T
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MVJ'_ )[1_P#?0H^U0_\ /:/_ +Z%<;_PI7P5_P! *+_O])_\51_PI7P5_P!
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MX?\ _3Q9T ._X4IX8_N:A_X,9_\ XJC_ (4IX8_N:A_X,9__ (JN\HH X/\
MX4IX8_N:A_X,9_\ XJC_ (4IX8_N:A_X,9__ (JN\K(\7>*M.\#^%]5\0:O-
M]GTS3+:2[N)<9VHBDG [GB@#F?\ A2WA?.-M_GT_M&?_ .*H/P7\+*P!%^">
M@.HS<_\ C]?-/[,GQJL_B'^U%K]_<>,[#4)_$'AJ&[M]#M-22>*P(N&VVX"L
M5,JQ!2Y'<GMBI/VF=3U3PGK?Q/UO4[/Q3_:=O96MSX/U/34F;3[<)'\ZNR?N
MT;SMVX2<LK+MSTH ^DO^%+>%RVW;?[O3^T9L_P#H5+_PI3PQ_<U#_P &,_\
M\57S_P#$:[\6?#/Q!%XEGU9+:ZUE'D\U'EEEMXI4BC8?9_NGRG;Y /O2.@.
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M4:5)I7BZRT_56TN^FDCO+:YMVN4Q*[&12QR&4G/''!% 'T./@SX5)  OB6Y
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MR,7D;\236?\ \*@L?^AC\6_^%#=?_%T?\*@L?^AC\6_^%#=?_%T =Y17!_\
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M .\HK@_^%06/_0Q^+?\ PH;K_P"+H_X5!8_]#'XM_P#"ANO_ (N@#O**X/\
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M*,$1QK@#"J"<=_4FLCX;_#6Z\%Z9XL\*3L)O"]Y?7=YILB-B2&*[=I9H"/\
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M^U?_ ,FM?&/_ +$W6?\ TAFKU2@ HHHH **** "BBB@ HHHH **** "BBB@
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M//)(QG-)K7[3/A#2(](DAM]:U>+4=/752^FZ<\OV6T) \V9>&09X(P6X/'%
M&[]M^)O_ $!O"?\ X-[G_P"1:/MOQ-_Z WA/_P &]S_\BU2^,GQ0N_ 'A+0=
M8T>&UO/[2UG3]/S=*Q417$RHS  @[@&R,]^HKB;K]H;7M+^%_C&]O-+L!XYT
M76_[ MM.19/L]S<2S)':-C=N*LLB,<'H&QTH ]#^V_$W_H#>$_\ P;W/_P B
MT?;?B;_T!O"?_@WN?_D6NXMO-^SQ>>5,^T>84&%W8YP"3QGWJ2@#@_MOQ-_Z
M WA/_P &]S_\BT?;?B;_ - ;PG_X-[G_ .1:[RB@#@_MOQ-_Z WA/_P;W/\
M\BT?;?B;_P! ;PG_ .#>Y_\ D6N\HH X/[;\3?\ H#>$_P#P;W/_ ,BT?;?B
M;_T!O"?_ (-[G_Y%KO** .#^V_$W_H#>$_\ P;W/_P BT?;?B;_T!O"?_@WN
M?_D6N\HH X/[;\3?^@-X3_\ !O<__(M'VWXF_P#0&\)_^#>Y_P#D6N\HH X/
M[;\3?^@-X3_\&]S_ /(M</\ &2\^(Q\(Z?\ :-(\+I'_ ,)%H6#%JMRQW_VM
M:;!@VPX+;03V&3@]*]TK@?C;_P B;IW_ &,OA_\ ]/%G0 [[;\3?^@-X3_\
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M.X[<8%=!8_'6ZUOX1>#?$EC86\/B#Q/>6VG6NGSL7C$[.?.Z$$JD<<S]1PE
M'3_;?B;_ - ;PG_X-[G_ .1:/MOQ-_Z WA/_ ,&]S_\ (M<YI_Q8\4G]HD>
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M)O\ T!O"?_@WN?\ Y%KO** .#^V_$W_H#>$__!O<_P#R+1]M^)O_ $!O"?\
MX-[G_P"1:[RO,OBY\1=;\,Z_X1\+^&(=/.O^)+B:.*YU5)'MK:.*/>[,B,K,
M3P  PZT :/VWXF_] ;PG_P"#>Y_^1:/MOQ-_Z WA/_P;W/\ \BUG>!?BS=ZK
M\*=9\2^(+&"UU/09=0M=1@L69H7EM)'1C$6YVML!&>1NP>E>=:?^T%X_L='@
MU/5= T?4DUSPO?>(M#LM'$PG62WC1Q:S;F;S"XE7#H%Y!&WH: /5OMOQ-_Z
MWA/_ ,&]S_\ (M'VWXF_] ;PG_X-[G_Y%KEO@M\=;GXC73:9=06M[=Q-*SZG
MIBM%:20@+L=4D9F&YBZXR>8R:Z;XG>.=0T'5?"_AS0DB;7?$%X88Y9UW);P1
MJ9)I2O?"C 'J10 _[;\3?^@-X3_\&]S_ /(M'VWXF_\ 0&\)_P#@WN?_ )%K
MR_P]^T+XNUF32?$_]FZ,W@#4?$\GAE(5$HU*/;.]LMRS[O+(,L?,84$*P.XX
MKT>[\?>(;[Q?XITOP[I-EJD.BVD"JEQ.8#->2$L4,F"%14VD_*3DT 6?MOQ-
M_P"@-X3_ /!O<_\ R+1]M^)O_0&\)_\ @WN?_D6O.(OVG+W0O@-JOCCQ-ING
MV^L6>M76AK96DS_9FGCNFMU.\@MMRNXD+G'1<\46/[1&I:QX!T%]'O= UKQA
MJVN#0G,=I=VUI83,#)^^@E*SY6/:<':6R", T >C_;?B;_T!O"?_ (-[G_Y%
MH^V_$W_H#>$__!O<_P#R+7FD?[0'B70]'EU7Q'9Z?Y/A_P 3)X:\1C3D<1[9
MY(HX+R'<Q8*K31%T8GY6;GY>?H>@#@_MOQ-_Z WA/_P;W/\ \BT?;?B;_P!
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MA.L__!JO_P 31_PDGCW_ *$ZS_\ !JO_ ,30!WE%<'_PDGCW_H3K/_P:K_\
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MZ_XUF^'VLI=^%+2WMFB422KJ2N47>N2!CF@#V&P_X\;?_KFO\J*+#_CQM_\
MKFO\J* .$\%7\&E:O\3[VY<16UMK/G2N>BHNGVI)_(&L+X&?M V?QLN-1DM?
M[(MK2-%FM;>#5!<7IC+$;YH@H$61M( 9NN#BM'1-$'B8?%W1VD\E=0U)[0R
M9V^9IMLN?PS7GG@+X#:]<ZQX5A\3Z-I6C:3X:T.?1S+I-R?,U(R&/#?*JF-0
M(MV"2=S>W(!VTWQ\BLOVD(/A7=Z6((KO2?M]GJYGR)IP6+6^S;P?+5G!W<A6
MXXK/\+_M-Z5K_P 3?B)X?N+6/3M \'0))-K\MQ\DSC_6J%V\!#@9R<G(QQ7&
M_%#]FK7]6U_6]8\)26]CJ.FV&G3^%[FYN&9HK^UED8K(3D['CD:-CD_+(?2J
M5I^REK5EHFNZ;!<6JO?Z#:Q-=/(3]HU%+@W,S2#&=CR$Y/H: /6;;]I?X>7&
M@:MK+ZU):6>E")KQ;RSF@EC20XC?RW0,48]& P?6L+Q5^UWX&\/^!+WQ19#4
M];M[/4X-*N+2TT^<7$,LI7:71D!5=K;@Q&&X ))%<IXI^"_C?XE^(]0\3:MI
MNG:)>?V99Z1;Z;%>^>DJQW:7$LKOM XV848Z$^M6?B/\"/%7B-_BM/IRV3R:
M[=Z->:9'+.5$AM"C2*YP=F2N >: -C2_VL/#5GXZ\0Z#XFO8]*CM]0M+33W^
MQ3J0L\:%#<L01$2[;1NV>G6O>*^:/B+\"O%WC7X>_%>R@M;&UU?Q7J.F7MI$
MUSE4$,ENT@9]O;RGQQSQZU]+T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7 _&W_D3=._[&7P__P"GBSKOJX'XV_\ (FZ=_P!C+X?_ /3Q9T =]111
M0 4444 %%%% !7C/@?\ :0TOQ]\4M5\+Z>VE0V5A--:"6XU-1>W,T1PYCM@I
MS&#D;BP/RG Q7LIY%?,.F?L]>*8=;T71'L-'M- TCQ1<>(4\0VTF+RXCD:5_
M):/;PV92I;<054<4 =O\(_VE-+^,'C74],TPZ7!I<!FCM#)J:MJ%VT4FQI/L
MP7Y(B5<ABV2 #M -3_&_]HG3_A'K^A>'D33YM;U6&6[#:MJ L;2VMXV5&DDE
M*L<EG5555)/)X )KSWP+\ /%_A^]\ Z3/I>B6FF>!]1N[^#6K*;;<:HKK*L<
M;)M_=EO-'F$DY*Y'6NH\=_#SQAJOCO1?'EIX9T/5]2D\.SZ#?Z-?W0"VK/*L
MBRQ3%#N&=RL,#((QTH ]RTV^BU/3[:[AEBFBGC619('WHP(SE6[CWJS7$?!/
MP'=?#'X4>&/"U[<I>7>F6:PRRQ@A-V2Q"Y_A&=H]@*[>@ HHHH **** "O._
M!7_)7_B3]-,_]$/7HE>=^"O^2O\ Q)^FF?\ HAZ /1**** "BBB@ HHHH YC
MXC>*=3\(>&)+[1M N/$NJ/-%;P6$#; 6=PN^1\'9&H)9FP< 'BO)IOVK8/#G
MA7QG>^*-)M;#5/#6HVVEM'8Z@)[.[GN(T>(1SLB8X<!LK\N#UKU/XGV?BF\\
M+$>$)+(:JEQ$[VVH+^ZNX W[V M@["RY 8#@XKY_/[-7B2\T37[NWTG1]$,O
MB&PU[3O"HG\ZT#6Z@2"23;@-*>>!@8'6@#WWX4>/!\1_!=KK1ETF2:1W21=%
MO_MMNA#$ "7:N3C&1M&"<<]:\U\)_M,7OB;QMI6GMX;M[;0M5U>[T6VN!J.Z
M_2:!7)>6VV#;&?+;Y@QQE<CFM?X7^#_%WA&_\0ZS<Z+IEG<>*-=CN;G2[2[_
M '6FVRVRQ&16V 22,T:L0  =_7CGS_P)^SUXHT#XA:)J5WI>EI>:?KEWJ5YX
MMCNRUUJ%M*) (#%M^7.Z,')Q^[&* /J.BBB@ HHHH **** /*_VK_P#DUKXQ
M_P#8FZS_ .D,U>J5Y7^U?_R:U\8_^Q-UG_TAFKU2@ HHHH **** (;VX-G9S
MSB)YC$C.(XEW,^!G '<FO$K7]H77M$NR_C/P8OAZQFT2\UVW6"^,]U'#;*'=
M)XC&OEN5(P 6&<C->WW#2)!(T*"24*2B$X#'' SVKP;X7>"/&-YXAUO4/B'X
M3M)[W7HY;6[O5U19XK>T((6VCBV#Y,'D]R230!T7PS^,VM^*/$FGZ+XF\-6W
MA^YU72AK&G&TU#[6'ARN4D_=IM<!ER!N'7FLSXI_M"ZAX#\8:OH^G>'[34+?
M1-.M]3U">^U+[*\D<TCHJVZ>6WF,/+8G)49(&:Q/A?\  S6O WC'4?%":=Y9
MT[37TO1-*N]9DNRR;@1NE9<1+A5 4 X[DUG_ !@^!?B;QQXYUS6!H.E:ZNK:
M5:6=C<7EZ8GT26-F,A0!3O!8A\C!RM 'TE87:W]C;W*JR+-&L@5NH!&<'\ZG
MJGH]K-8Z396UQ+Y]Q# D<DO]]@H!/XFKE !1110 5Q?QE_Y)CX@_ZX#_ -#6
MNTKB_C+_ ,DQ\0?]<!_Z&M '6V'_ !XV_P#US7^5%%A_QXV__7-?Y44 <9\.
MO^1G^(O_ &'D_P#2&TKNJX7X=?\ (S_$7_L/)_Z0VE=U0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<#\;?^1-T[_L9?#_ /Z>
M+.N^K@?C;_R)NG?]C+X?_P#3Q9T =]1110 4444 <AXX\=GPOJOAW1[2W6]U
M;6[LP00L^T+&J[I9#[*H_,BN \)_M%2^+O'NJZ);:?I*66FWMU:S,VL1?;=D
M!*O(+;[^W(J_\2;232?CE\-?$LR@Z6L=[I4LA_Y8RS(IC8^@)0K^-<CJOPX\
M3^*_&_AZ&[\$:1HQTOQ')JEQXFTTQQI<VGS_ "!,F0O(K!7!XZG/2@#KO 7Q
MZG\6^(M#L[[P])I.F^(HKB;1KUKA9/M AY8.HY0E?F'L#6K\2OBEK7@_4I[3
M1O"D^N)9V#ZE>74DOV>".-<_(KL,,Y )VUYKX!^ 6J>'_C%9:RG]N1^%O#27
MG]DV.K:G#/&'G&W;;I&@*1@;N969N0 0!BMOXR_\)]XX@\.:-%X/O_\ A&+R
M(7/B"&QOK=;A\=++<SJ A/WV7.0,#J: /8_"OB&'Q;X7TK7+6-XX-1M([N*.
M3A@KJ& /OS7FNL?%[Q7X;\=>$_#VI>$[4'Q%J#V=NUMJ >5(DC:22<IM^XBJ
M,^[J.]==X*\67&J:M=:&WAJZT*#3;&TDW3%#&KR!\P+M)!**JDD$CYQ6-HO@
MK5-1^,GB/Q?J\*P);6":-H)+!S'"Q$EQ* #P7D$8.><1+0!4N_C[8Q_'G3?A
MI:Z=-=2W%I-//J:L!%!(@5O)QU+;6!/IFK/Q&^+M[X5\56OAG0= ;Q%K<FGS
M:K+!]H$*QV\;!2<GJS%L 5Y-X;_9R^(G@[XQ>!=7;Q=I_B#2+%]1N-2OFT7[
M/<.\^PD,?M+;BV, @ *%'!KJ?%&B>-T\?Z3\0]-\(O>7MWX=GT>[T1KZ%9+2
M5I0\;%R=K+P0<'/3% '7^#/C5!XJ\0Z!9O9&UL?$>E'4])N"W+F/;Y\+CLZ[
MU(QU&?2O3J^<?#7@R[T;QQ\$_"S2K-J/A/3;V_U5H#E(A)!Y"(3_ +3NQ'J(
MR:^CJ "BBB@ KSOP5_R5_P")/TTS_P!$/7HE>=^"O^2O_$GZ:9_Z(>@#T2BB
MB@ HHHH \FU7XV7ZZAXC31/#<^NVNE7\6BQ-;D[I[YMI<' (2*,.H9SWR.U9
M*?M&7GV&>Q?PM)_PF":^OAV/24NE,4EP8/M&\2XQL$66)QG@BL/PYJOBSP=X
M5^*6A^%=%35/&MMXEN[JWM99%C5H+MQ+%<_,RAE =AC/)C(J.S^$\^J_"&?3
M+OPUXETSQ)IEXFL6VJVVI6L>I7.HG(>XCDW/&IPS K("NT[<$4 >M_"[XC+\
M1=+U%YK%M+U72KZ33K^Q9P_E3( >&'52&!!]ZRO!_P 8+CQ/\3M8\'W7AJ^T
M1[&R6^BN+QTS<1F1HPP52< E21GG%<]\ _AWKWPFT*2/4;6ZU75/$>L3:AJ=
MS<WJ2R6BF,!#(V%$C?( =@ !;@ "M:]\/:IH?QMU_P :O9F;1D\,);(T; O)
M-'+)(4"]>A'/O0!Z9J.H6^DV%Q>W<RV]K;QM++*YPJ*!DD_A7E_PB_:#TOXH
M>%/%'B2YLY/#FD:'>S0//J#A=T$:A_//]U2IW8/:KGCKPOK'QO\ A):65M?/
MX*N]2%O=7,=W:?:RJ!@[6\B"1,AL;6PPXSZUY)X=_9N^(FHZ-XVTC6_%^EV-
MOJ/B6+5(FBT+=!>01J/DDB%SD1LRI\FX8V8.0U 'KWP(^,T7QP\+7^N0:1=:
M+%;ZA+9I;WHQ*R+@J[+_  EE8':>1G!K/\'?'NS^('CK6=!T5-/>WT]Y[9)I
MM2B%Q//$2K[;<'?Y8<,N\C^$UA_ CP5\0/AF?%*^(VM=?_MCQ)-<QO8VRV@B
MA=1FX(,KY!('R=1[UQ_A'X+>(/#VN>'-*?PM8Z9:Z!XENM<E\60S1@W=N[RR
M;=H._>PD"MNX^7//% 'O7PV\=1?$#PX;\0_9+NWN9;*\M2V3#/$Y5U_,9'L1
M75UX]^SAI4Z6GCG7V+"S\1>);O4;-&[0_+&K#V;86_&O8: "BBB@#RO]J_\
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M,?$'_7 ?^AK7:5Q?QE_Y)CX@_P"N _\ 0UH ZVP_X\;?_KFO\J*+#_CQM_\
MKFO\J* /(M \9ZGH'CCXAVUGX)U_Q#$=:C<W>F26*Q FQM?E_?W,;9&/[N.1
MS71_\+/UW_HE?C#_ +_:5_\ )U/\!S&WU[XE2K&TS)K881I]YR+"U.![FN;\
M%?'^[\46_P 23=^#]1TZ_P#!EPD#Z9&PN;FY+VR3J%6//S$2*,#- '0_\+/U
MW_HE?C#_ +_:5_\ )U'_  L_7?\ HE?C#_O]I7_R=53X=_%+6O$?BZ[\-^(_
M#BZ!J2:=%JD0BNA,IA=BNU^ 5<%>15:U^/%H_P"T+>?"VYT][:X32TU&UU!G
M^2X8D[X@.S*,'W!H U/^%GZ[_P!$K\8?]_M*_P#DZC_A9^N_]$K\8?\ ?[2O
M_DZN8\&?M.:#XI\;?%+2[A$TO0O LD$,NMSRCRKEF\Q9=HZX22)D[Y(.*Z&T
M_:*^'5YX2O/$R^)H8=&L[F*SNI[F":![>61@L:R1N@=-Q88+* 0<YQS0!-_P
ML_7?^B5^,/\ O]I7_P G4?\ "S]=_P"B5^,/^_VE?_)U<GXG_; ^'7A_P_I6
ML6]_>ZQ9WVLQ:(PLM-NFEMYG8 ^9'Y6]< @@$98?=!H\)?M3>%-0\:>(/"^O
M:I:Z1JMMK[:1I\!CE_?IY$,D;2-MVQLQE< ,5SMXYS0!UG_"S]=_Z)7XP_[_
M &E?_)U'_"S]=_Z)7XP_[_:5_P#)U>@T4 >??\+/UW_HE?C#_O\ :5_\G4?\
M+/UW_HE?C#_O]I7_ ,G5Z#10!Y]_PL_7?^B5^,/^_P!I7_R=1_PL_7?^B5^,
M/^_VE?\ R=7H-% 'GW_"S]=_Z)7XP_[_ &E?_)U'_"S]=_Z)7XP_[_:5_P#)
MU>@T4 >??\+/UW_HE?C#_O\ :5_\G4?\+/UW_HE?C#_O]I7_ ,G5Z#10!Y]_
MPL_7?^B5^,/^_P!I7_R=1_PL_7?^B5^,/^_VE?\ R=7H-% 'GW_"S]=_Z)7X
MP_[_ &E?_)U'_"S]=_Z)7XP_[_:5_P#)U>@T4 >??\+/UW_HE?C#_O\ :5_\
MG5P_QC^)&MW/A&P1_AGXLM@/$6A/OEETS!*ZM:,%^6])RQ 4<8RPR0,D>\UP
M/QM_Y$W3O^QE\/\ _IXLZ &?\+/UW_HE?C#_ +_:5_\ )U'_  L_7?\ HE?C
M#_O]I7_R=7H-% 'GW_"S]=_Z)7XP_P"_VE?_ "=1_P +/UW_ *)7XP_[_:5_
M\G5Z#10!YQ=_$+5K^(1W/PE\6SQA@P62322 0<@_\?W45-_PL_7?^B5^,/\
MO]I7_P G5Z#10!Y]_P +/UW_ *)7XP_[_:5_\G4?\+/UW_HE?C#_ +_:5_\
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M4G[=TR2?QJ?_ (6?KO\ T2OQA_W^TK_Y.KT&B@#S[_A9^N_]$K\8?]_M*_\
MDZC_ (6?KO\ T2OQA_W^TK_Y.KN=1U"VTFPN;V\F2VM+:-IIII#A411EF)[
M 5\]>%OVP(O%GA'6-6M_#%S!>Q^)U\-:787$P1[MI(XY(I7./W8*2!B.2* /
M3/\ A9^N_P#1*_&'_?[2O_DZC_A9^N_]$K\8?]_M*_\ DZK'PN^(EUXY37[/
M5=*_L77="O\ [!?6BR^:F3&DJ.CX&59)%/2N&\*_M)3>)?%NE6O_  CPM_#^
MK:O=:)9WIN@;G[1 LA8O!C*H?*?G/'&>HH ['_A9^N_]$K\8?]_M*_\ DZFR
M_$K6YHWC?X4^+W1P593+I6"#U'_']7H=% 'G5M\1M8LX(X(/A/XNAAC 5(TD
MTD*H] /MU2?\+/UW_HE?C#_O]I7_ ,G5Z#10!Y]_PL_7?^B5^,/^_P!I7_R=
M1_PL_7?^B5^,/^_VE?\ R=7H-% 'SE^T]\1=:OOV:OBS;2_#;Q58Q3>$=6C>
MZN)=,,<(-G*"[[+QFVCJ=JDX' )XKTS_ (6?KO\ T2OQA_W^TK_Y.K,_:O\
M^36OC'_V)NL_^D,U>J4 >??\+/UW_HE?C#_O]I7_ ,G4?\+/UW_HE?C#_O\
M:5_\G5Z#10!YQ<_$'5;QX6G^$OBV5H7\R-GDTDE&QC(_T[@\FIO^%GZ[_P!$
MK\8?]_M*_P#DZO0:* //O^%GZ[_T2OQA_P!_M*_^3J/^%GZ[_P!$K\8?]_M*
M_P#DZN\NI_LMK--L>3RT+[(QEFP,X [FO(?!OQTU?6?%&GZ1K?A&?19-6T^?
M4M/A\[?<>7$5RDT9 ,3D,N >^1VH Z+_ (6?KO\ T2OQA_W^TK_Y.H_X6?KO
M_1*_&'_?[2O_ ).JG\'OC%<_%#6?&>F7OAVX\-WOAN]ALYK:YF25V,D*S*24
MR!\KKP":RO'WQXOO"OB?Q#8Z;X<_M;3/#%M;7.M7C7(B:(3995C4CYR$7<>0
M.0* .A_X6?KO_1*_&'_?[2O_ ).H_P"%GZ[_ -$K\8?]_M*_^3J[FPO8M2L;
M>[@;=#/&LJ-ZJPR/T-6* /-[7X@ZK9&8V_PE\6PF:0RR%)-)&]SU8_Z=R>!4
M_P#PL_7?^B5^,/\ O]I7_P G5Z#10!Y]_P +/UW_ *)7XP_[_:5_\G5RGQ4^
M(NM7WP_UFWE^&WBJPCDC56N;B73#'$"Z_,VR\9L#V4GVKVRN+^,O_),?$'_7
M ?\ H:T =;8?\>-O_P!<U_E118?\>-O_ -<U_E10!QGPZ_Y&?XB_]AY/_2&T
MKD_!/@SQ/X&\:_&[Q''IL5ZVO:C;7VC6XG5?M/EV$,1#'^#]XC#GZUUGPZ_Y
M&?XB_P#8>3_TAM*[J@#P#X4?#S6]9M]<7Q]X?U6RUO7"MSJ.M6^LF)B48&.W
MA:"021QH.  0#SG.37+_ !,_9^\7OXJ\0>)/!B(NM:9#I\GANXO[QI6>2)9(
MYDE=R6(9).2Q)) YKZGHH ^2M/\ V5]<\+Z?XET[28XIX3IF@FWDGF .HWEK
M+<371E]#))+N)/4N:V-4^#_C#QQXLU[Q;?Z-#H\FIZAX<1=':Y23]Q87;333
M2,/E+%9" /1/>OIVB@#Y=\;?!/QE<^(/&&LZ=IT-X9/&NB^(K*V-RJ&Y@M40
M2KD\*V0<9]*F\4_!#Q7K'A3QC;P:? E_JOQ"L_$,*F9039QBTW$MZCRI./;W
MKZ<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!^-O_(FZ=_V,OA_
M_P!/%G7?5P/QM_Y$W3O^QE\/_P#IXLZ .^HHHH **** "BN3\;>.U\*7^@:9
M;VOV_5=:N_LUM;;]@"@;I)"<'A5!/Y"L'P=\;+/QUXWU/1=*T\OIFGR36TFK
M2W<2^9/&<.D<.?,90<C?@#(.,T >E5YOH_A/6;[XQ:]XKU>V2*RLK---T2(2
M!BZGYYI3_=+-M4 ]E]ZR_AI\=KSXE^*+BQM/"ZVND0S3P_VD^KP/(?+8KN^S
MCYP"1BM;XF?&>S^'NMZ1H<.GOJ^N:D&DCM1<Q6R1PJ0&D>20A0,D #DD]!0!
MPG@&S\?7GQ,U#Q9XR\$.=2<R66E^5?PM;Z999. HW9,DN SOCT4<+SUGQ.\/
M^)?B;X5\+Z"VEIIUEJE_#)XC1KA6-O:1YE:($??,CHD9QQM9J]1BE,MND@ R
MRA@ P(Z>M>2ZQ\:_$7AGQCX9T/6/ AMDU_46L;:>#6(IG"K&\CS&,*#L5$))
MSQE1U(H ]=50BA0, #  [4M>/>#_ -HNW\5^(M)M7\-W^G:%K=Q<VNCZW--&
MT=Y) 6#@Q@[HP=C%2>N.U=/\1_'7B#P1!/>V'A6/6=)M;9KFYO9-5CM1$%!+
M#:RG/ SF@#NJ*\R\"?&63Q3K.A:?JFA2Z!)K^DC5M,\V82&0+M\Z)\ ;73>C
M=P5;/8BO3: "BBB@ KSOP5_R5_XD_33/_1#UZ)7G?@K_ )*_\2?IIG_HAZ /
M1**** "BBB@ HKRG6_CH;"^\2+IOAZ[UNUT>[ATE&M7 >[U"3:3"@/"HBNFZ
M1C@$D8^4U0M?VBVO-(N8X?"&HS^*X-:&@MH,,\3_ .D^4)B3/G8(Q'\Q<].F
M,\4 =5\9_AO>_%?P6WA^TUYM 26XBEN)!:BX6XC1@QA=-RY1B & (R,CH37S
MQI7[-WQ)TJ7Q5JE[?V&M7<7CJ#Q-IUI% MHMY''!%&QSO81DA2H0]-F<\\?1
MWPQ^)4?Q&TC4[B73)]$O]+OI=/OK&X=9/*E0 G#KPRD,""*Y'P;^T;;>*]>T
M2";PY?Z3H7B&:>#0]9N9HRE\T6[.8P=T>X(Q7=U [9H D^&^D>+]$U3Q)X@U
M/08X+WQ7KT4LUC'=(QT^T2U2%9&;H[?N5)5?[_M7E_@#X ^)="^)NBZU=^'K
M6'7K37+N^U+QDMV"^H6<HD @\KJ,YB'(&/+X-?5%Y>0:?:375S*L-O"ADDD<
MX55 R237A^A?M9Z-XC\!ZUXGL= U-HK/7$T&RM)=L<E]-(ZI$X+$!$8N#EN@
MYH ]VHKBOAG\2#\0(=9BN=(FT/5='O#8WME+,DP5]H<%9$X92K ]CZBN9U'X
MP^*M%\7:%H6H> /L[:U<R6UK/'K$4N B,YD9 @(4 <^F10!ZW17,?#OQS;_$
M'PXNI10M:3QSRVEU:NVYH)XV*.A/?!'6NGH **** /*_VK_^36OC'_V)NL_^
MD,U>J5Y7^U?_ ,FM?&/_ +$W6?\ TAFKU2@ HHHH **X3QG\5+?PIXFM-%CL
MI+Z86<VJ7\B'Y;.TC!RY !+,S<*HZ\US'A3]H:;5];L-.UKP5K'AU]5TF76=
M+$C1W$MS!&%+*T<9+1RX=#L.>N,Y&* /7+T3M9SBU9$N2C>4T@RH?'&1D9&:
M\!^''PZ\6'XPV'B_5O#.G^&+U-.FM=<O+"X#IJ\K,IC94R2JKAC\W/S8YKT7
MX1?%R#XMVWB&6+0]2T"31M3;3)K7545)BPBCDW%5)VY$HX)SQS7,?$']HX>
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M\:/^$JT7_H,6'_@2G^- &I167_PE6B_]!BP_\"4_QH_X2K1?^@Q8?^!*?XT
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MX2K1?^@Q8?\ @2G^- '.Z#XOO/B#8>+;.RL+SP]<Z?<R:;!>WB!EDE\I6,B
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M_P  (O\ XFC_ (5;X-_Z%71O_ "+_P")KJ** .7_ .%6^#?^A5T;_P  (O\
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MM9T$D4T5E$RNI&000O((J?\ X5;X-_Z%71O_   B_P#B:Y;]E^RNM/\ V?/
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M%2&  KN_'GB7PW+\>M.US6[ZPG\(WG@N\CLKRX96MI)/.3S%1CP6*XX') H
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M:O9:]IL%_I]S'=V<Z[XYHCE6%7*\:_9MN+A8_B'IH4C2M-\5WT&G'J/*)5V
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M< ]"<=Z=?> OA_ILBQW'AS0(YVBDF2 V,1DD1,;V5-N6"[ES@'&X>HH Z/\
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M&9A;_8X?,* @%MN,XR0,],F@#>_X271_^@K8_P#@0G^-'_"2Z/\ ]!6Q_P#
MA/\ &LC_ (57X,_Z%/1?_ "+_P")K%\.^&_AMXJN-7@TSP[HMS+I-VUC>+_9
MB+Y<P56*\H,\,O(R.: .Q_X271_^@K8_^!"?XT?\)+H__05L?_ A/\:R/^%5
M^#/^A3T7_P  (O\ XFC_ (57X,_Z%/1?_ "+_P")H U_^$ET?_H*V/\ X$)_
MC1_PDNC_ /05L?\ P(3_ !K(_P"%5^#/^A3T7_P B_\ B:/^%5^#/^A3T7_P
M B_^)H U_P#A)='_ .@K8_\ @0G^-<%\:_$6E2>#M.":G9L?^$DT X%PAX&L
M69)Z^E;&C>!? .OV7VNS\*Z0T/F/%F32TC.Y&*MPR ]0>>_45<?X4>"G&&\(
MZ(PR#@Z?$>0<@_=]: -G_A)='_Z"MC_X$)_C1_PDNC_]!6Q_\"$_QK(_X57X
M,_Z%/1?_   B_P#B:/\ A5?@S_H4]%_\ (O_ (F@#7_X271_^@K8_P#@0G^-
M'_"2Z/\ ]!6Q_P# A/\ &LC_ (57X,_Z%/1?_ "+_P")H_X57X,_Z%/1?_ "
M+_XF@"IXNT[PYXMFTBYEUJUM;[2KM;NTNH;B/<C8PR\GE64D$>]:44WA2#4W
MU&.72$U!QAKI7B$C?5NM0?\ "J_!G_0IZ+_X 1?_ !-'_"J_!G_0IZ+_ . $
M7_Q- $UJ_A.RNY[JWDT>"YG!$LT;Q*[@]<D<FF72>#[ZVMK>X.BSP6P ABD:
M)EC Z;0>GX55F^''@.WG@@E\-Z!%-.2L,;V<(:0@9(4$<X'/%3_\*K\&?]"G
MHO\ X 1?_$T +81>$],U_4M:MKK3X]3U".&&XN/M*DND0(C0<\*-S<#NQ/>M
M"#6= M9)I(;_ $Z)YFWR,DT8+MC&3SR:SO\ A5?@S_H4]%_\ (O_ (FL'7M#
M^&7AG7O#VC:CX>T6WU'7[B2UTZ'^RT;SI(XFE<9"$+A$8Y8CICK0!TT,WA6W
MU*34(I=(COY!A[E7B$C?5NM0W$7@Z[LK>SF_L66UM_\ 4P.8BD?^Z.@_"N5U
MF/X/^'O$EIX?U*T\*V6M7958+&:VA61RQPHQMX)/ SU[53NM3^"EEXR/A.>'
MPK'XC#B(Z<;2+S0Q7< 1MX.T@_0T =)!I'AQ?'C>*I]<MKF[BL_L%C;M/&L5
ME"2&DV 'EG95RQ[*H&,'/3_\)+H__05L?_ A/\:XOPSHGPL\903S:)I?AK4X
MH)OL\C6]I"VV3 ;:?EZX((]1S6[_ ,*K\&?]"GHO_@!%_P#$T :__"2Z/_T%
M;'_P(3_&C_A)='_Z"MC_ .!"?XUD?\*K\&?]"GHO_@!%_P#$T?\ "J_!G_0I
MZ+_X 1?_ !- &O\ \)+H_P#T%;'_ ,"$_P :\]\%^(M*7XN_$=CJ=F%8:;M)
MN$P?W#=.:@\)S_";QQ>+;Z-X>TV[WRW$,<QT(I#(T.T2[9&C"L 7 R#@G(&<
M'&G!X>^&,OC6Z\+1^'-$_M^&S2^EMQI:#$+,55M^S:>01C.: .V_X271_P#H
M*V/_ ($)_C1_PDNC_P#05L?_  (3_&LC_A5?@S_H4]%_\ (O_B:/^%5^#/\
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M>>."1Q5*\L_!E\][)*VD>?>1M#/.DD:RNK## N#GD>]._P"%5^#/^A3T7_P
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M/$D\^G:;)-!&9$5T^<#'W6!KMQXBT1;::X_M*P2"+B60SH%3G&&.>.01SZ4
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M.H6>+G!A!F3][D\;>?FR?2@#YXNI_B!I?[*-RVGZ[/K&O"Y*1:G''.)TL3<
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MN[:.ZG^:&!Y%#R>ZJ3D_A534?%6A:='?27FJ6,0L(C-<AYTW0(!DEAG('UH
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MK>E6_P!F%S?V<?VDCR/-F0>:>VS)^;\* /DSQ5JVOG4-4FFUCQBGB6"#3?\
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MY;@;W.X289NHQR<5]7B) " B@'K@4H15QA0,=,#I0 ZN+^,O_),?$'_7 ?\
MH:UVE<7\9?\ DF/B#_K@/_0UH ZVP_X\;?\ ZYK_ "HHL/\ CQM_^N:_RHH
MX3P78Q:GJ_Q.LYL^5/K0B;'7!L+45SB_LE?#D>$8O#!T@MHL-^^I16Q;A)V4
M#<#C/#9<>C,36SX;U^W\+>+/'<>I6VHQ?:M82X@>+3;B9)(_L=LFY62-@?F1
MAUZ@UTG_  LC1?[NJ_\ @FO/_C5 'F/@GX2:Q:_%SQ]K,FHZQH^F2WUF]G!;
MR(L%ZD=M&I+#!)Y4J>G2O,M ^".H^%O!'@6_U#P5<:M;6^MZK>>(M#MD5[FY
M\RXG^S3,A8"4*I4[<]&!QQ7TW_PLC1?[NJ_^":\_^-4?\+(T7^[JO_@FO/\
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MRO)O&UD5) 44').0#UKZO_X61HO]W5?_  37G_QJC_A9&B_W=5_\$UY_\:H
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MO]W5?_!->?\ QJ@#J*XOXR_\DQ\0?]<!_P"AK5S_ (61HO\ =U7_ ,$UY_\
M&JYCXF^,;#7_  )J^GV%OJUQ>7$02*(:/=C<=R]S$ /QH ](L/\ CQM_^N:_
MRHI;)2EG K @B-00>W%% $U%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cvrx-20231231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $' <H# 2(  A$! Q$!_\0
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M];;_ /1'Y?\ PI!_\BT?\/K;?_HC\O\ X4@_^1:_+RBCZA0[?B'MI]S]0_\
MA];;_P#1'Y?_  I!_P#(M'_#ZVW_ .B/R_\ A2#_ .1:_+RBCZA0[?B'MI]S
M]0_^'UMO_P!$?E_\*0?_ "+1_P /K;?_ *(_+_X4@_\ D6OR\HH^H4.WXA[:
M?<_4/_A];;_]$?E_\*0?_(M'_#ZVW_Z(_+_X4@_^1:_+RBCZA0[?B'MI]S]0
M_P#A];;_ /1'Y?\ PI!_\BT?\/K;?_HC\O\ X4@_^1:_+RBCZA0[?B'MI]S]
M0_\ A];;_P#1'Y?_  I!_P#(M'_#ZVW_ .B/R_\ A2#_ .1:_+RBCZA0[?B'
MMI]S]0_^'UMO_P!$?E_\*0?_ "+1_P /K;?_ *(_+_X4@_\ D6OR\HH^H4.W
MXA[:?<_4/_A];;_]$?E_\*0?_(M-'_!;"W,C)_PIZ7( .?\ A)!WS_TZ^U?E
M]42_\?4G^XO\VJ7@*":T_$:K3[GZD?\ #ZVW_P"B/R_^%(/_ )%H_P"'UMO_
M -$?E_\ "D'_ ,BU\C?\$^]#T[Q'^UEX'T_5M/M=4L)I)A):WL*S1/B%R,JP
M(//J*^O_ (^>"(M7_9[^/-]XM\)> 0V@ZFL?A>X\$P6[7MHGGNN;S[.3Y?R;
M!AL'._(X%<U3#X>G44.7MU[NQ<9SDKW(?^'UMO\ ]$?E_P#"D'_R+1_P^MM_
M^B/R_P#A2#_Y%JC^S;^S_P"$KC]E?1O NN^'X)_'?Q5L=3U32M4GLPS67DQI
M]F!E()C5\*1@C=ENM>3_ /!.WQU</\:-"^$'B'P=X8O]*DN+PW;:MHD,U\DJ
M(Q*&5P2 &7&.W-3[##VDU'X?,?/.Z3>Y[-_P^MM_^B/R_P#A2#_Y%H_X?6V_
M_1'Y?_"D'_R+7@6O^#?&/[:?[0M]X.T?PGH.G:/X0UBYM[N3PY8V^G2I8M=K
M$TCD#$CJL?RY!P<\<UQ/[9'['.N?LP^+;RX@MKJ7P#<7JVFCZI?7$4D]P?)#
MMO"!<'(?^$< 5K'#85M0:M)]+DNI4M=;'UG_ ,/K;?\ Z(_+_P"%(/\ Y%H_
MX?6V_P#T1^7_ ,*0?_(M>#?!S]D3X6:G\.OAAJWQ(\8>(=.\0_$F_EM]"L=!
M@B:*.**58W:8NC')8@9!&-PX.#7<:O\ L+_!7P+X9^)?B7QEXO\ %VF:'X3\
M3'1(Y+3R)I)HS''LW*(/OEY.2,# Z=ZAT<(G:S_'T&IU7K<]!_X?6V__ $1^
M7_PI!_\ (M'_  ^MM_\ HC\O_A2#_P"1:\8^'W[%?PKO]*^&?ASQAXYU_3OB
M9\1M'36-'BTVUC?3K6.92UNL^Y=[,1UVLO.1Z$XNJ?L3Z'X:T'X/#5]2U6/7
MO%'BZ\\,ZY%#-$8;?[/<-"S09CR#E3RQ8>U/V&$O:S_'S_R#GJGT#_P^MM_^
MB/R_^%(/_D6C_A];;_\ 1'Y?_"D'_P BUYIJ_P"Q#\&O FG_ !AUSQAXH\86
MGA[P+XDMM'B?3_L\L\T4L%NPW*8L%]\^,C  '0U\\_M>_L]Z=^SM\2K+2]"U
M>?7/#6KZ9!J^EW=VJB<P2#@2;0 3D'D <$<4X8?"5'RQ3_$3G4BKL^SS_P %
ML+<2*G_"GI<D$Y_X20=L?].OO3O^'UMO_P!$?E_\*0?_ "+7Y;M_Q]Q_[C?S
M6OL?]DG0?#7@/]F[XN_&S4_#FG>*_$'AV>UTW2;+6(!<6L,DS(IE:(XW<RKU
M[+QWJIX2A!-\M]4M^]@56;ZGT#_P^MM_^B/R_P#A2#_Y%H_X?6V__1'Y?_"D
M'_R+7SW!J7A#]NKQ/\+_  ;I_A>U\!_$^[OYK?6-3T6PBM]+GL5CDEWK$K[O
M.54'& "2>>@K<O/V,_A3X_\ #UQK_P */%_B35].\/>)+30_$<.LPQ)(\4\Z
M0_:+5DC P&8'#@_*221MPT/#X:.DXM/Y_P!:CYZCV9[1_P /K;?_ *(_+_X4
M@_\ D6C_ (?6V_\ T1^7_P *0?\ R+7F_P 0?V&?@UI5M\8M-\,^,?%]UXH^
M&MK'JFHP7T-O]G>V*B5HT8(I:3RPX#9 #8^4BNS^(O[)WP.\>?%S]GWP-X?T
M_P 0>&%\7Z)/?7%U:&W1IK>.REG224E7_P!(+QH&PNS:6Q@X-1[/"?RO\>UQ
M\U3N:O\ P^MM_P#HC\O_ (4@_P#D6G)_P6IBE.$^#DSG&<+XC!_]M*\.M_V5
M/@3/>^/O%">/O%,WPP\"6EM:ZO<1VL8U"XU2:YDB$4(,841 +'R5;)8\@"O8
MOV;/V>-'^"'[1MCK/A/7+GQ!X(\9?#O4M6T>YOXA'=(G[G='*%PI(W(=P ^]
MC'&2Y4<*DVHN_P P4JC>Y=_X?6V__1'Y?_"D'_R+1_P^MM_^B/R_^%(/_D6O
MBC]D7]GF#]I'XK?\(_J6JRZ+H-C93:GJ=[ H:58(P,A >-Q) R00.3@]*^D-
M _8A^"OQ$T+X<>(O!GBGQE=Z!XK\4OH;MJ/V:&:&)(I"Q $.-^Z/ACQAL;<C
M-:3P^$IOEDG^)*G4DKH]'_X?6V__ $1^7_PI!_\ (M'_  ^MM_\ HC\O_A2#
M_P"1:\CO?V+?@W<_%+Q7HVE^._$W_",_#[3+S4?&5W<6T9N(S&P$45J!& 21
MORQ##Y> ,UK>"O\ @GU\._B1XV^&FJ>&O%7B.\^%WC2VO0LMRL$.IVES;H6V
M,WEE&5L-T08VGV-9^RP:5VG^)7-5/1O^'UMO_P!$?E_\*0?_ "+1_P /K;?_
M *(_+_X4@_\ D6O"/V>_V+?!WQ;^"'@WQGJNKZY:ZEK7BY/#\\-G+"L*0$D%
MT#1,0_'4DCVK2^,?[%WPJT7P3\7)_ 'B_P 27OBKX9SPG5[/7(H1;RPRLP41
M%$4E@%.6S@E?NC(JO8812Y;/\?07/4M<^NOV8?\ @IQ#^TC\9M&\ +\.7\/-
MJ,=Q(-0.M"Y$?E0O+CR_LZ9SLQ]X8S7W'7X8_P#!+W_D]#P7_P!>VH?^D4U?
MN=7F8RE&C5Y8;'12DY1NS\K?^"U7_(S_  E_Z\]3_P#0[:OS6K](O^"TUPS>
M-OA9 0-B:=?N#WRTD /_ *"*_-VO=P'^[KYG'6^-A1117HF 445]+_!+]EWP
M9XY_9\UKXK>-?'>I>%=+TW7!HI@T_1OM[,QCB=6XD4\F0CIQBLYSC35Y#2;V
M/FBBO?)?V4]2^).KZE)\#1JGQ*\.:6EM'?ZA=6L6FS07$SLJIY,DNXJ %)<<
M %BVT*36%-^R-\7H/BI%\.'\$7H\8RVOVY-/$T)0V_/[[S@_E!,@C=OQGC.>
M*2JP?4?*^QY!17V/\4/^"?6M^%O /PAL]"TS5[OXK^+Y;Z&_T&[O[06\;6Z/
M*?)?"J!Y<9;)E8'MU%>(?$[]E3XK_!O2--U3Q?X,O-*L-1G%K;S)+#<!ICTC
M81.Y1CV5L$]LU,:U.>S&X270\GHKU_XA_LC_ !=^$_@Z/Q5XL\$7VDZ Q027
M9EAE,&_&WS4C=GBSD#]X%Y('4UWWQ#_8F\57/CBVT/X9>%?$.JB+PQ9:_?P:
MU=V N%$S2+OC$4NUHR4^5>7ZY'0E^VI_S(7*^Q\Q45]-> _^">?Q?\4?%FQ\
M"ZYHL?A&>XLGU!M0OKF":!( K893%(WF$NJH53)7>"P"\UX[XF^#GB7PK\7I
M/AM>6B'Q0NHQ:8EO%-'(LDLK*(L,K%?FWH>O&<'!!IJK3D[*5^H.+6Z.'HK[
M1F_8+\$2^+]6^&]C\9;>?XMZ99-<3Z)+I,D5B95C61H5NBV"P##MZ^A \3\#
M_L<_&7XD>&;OQ#X<\"7VHZ/;RRP_:?.AB\YHB1)Y*R.K38((S&&&01U!%2J]
M-J][>NGYC<)+H>-45[/\.OV./C'\6/#\>N>%O!4^I:8]Y+8><]Y;6Y2>/[Z.
MLLJLA!X^8 9X'-/\4_L8?&KP5X.UCQ3K7P_U&PT32&=;V=I86>$*^UI/*5S(
M8P03Y@4I@;L[>:KVM.]N97]1<LM['BM%>]']A+X[?\(^VMI\/KN?31IZZHLL
M%[:RM);LI8,B+*6=L*244%QD94;AG#^&G[(_Q>^,'A:7Q)X2\#WNJZ*CNBW;
M2PVXF9?O")975I<<C]V&Y!'48H]K3M?F7WARR['D-%>O_#7]D?XN?%[1KG5?
M"?@RXU.QMM2DTBXDDNK>V:"[1%=XY%ED1DPKIRP R<9SQ570OV6/BMXD^)FK
M_#_3_!E[-XMTA=^H6#R11K;+@$,\K.(PI#*0=V&!&,T>TAJN9:!ROL>545[-
M9?L<?&74/&FN^$H/ MZWB'1+1+^]L6G@5A QPLD;&0+,I/ \LMR#Z&NO\%?\
M$^OB]XA^+>E^ ]<T-/"=U>VCWYO[VY@F@2W7(WJ8Y#YAW;5*H2PW@D <TG6I
MK>2#ED^A\U45UGQ5^&FL_![X@ZUX/\01QQ:KI<WE2>5*DBLI 9&#(S#YE96Q
MG(S@X((KDZU335T3L%%%%, J)?\ CZD_W%_FU2U$O_'U)_N+_-JB6Z_KHQKJ
M>J_LT?&6'X ?&CP_XZN-+DUJ+2VD9K*.80M)N1EX8J<=<]*]U\1?MK^ +7PO
M\1]-\$?"V\\/:A\0IMVOZC>:V;IGC:1WD$2>6%0GS),'MN[X%?'5%9SHPG+F
MD-2:5D?:OB3_ (*@^/8OB)X?NO!$1\)_#O2([2V3PB$MYQ)!$ '3SC%N7<HV
MC;C;Q7 ^&?VL="\(_MCW?QLTWP=/!IUU<SWCZ"+U0PEFC*R$2B/'+LS_ '>Y
MKYHHJ5AZ25DNEAN<GNSM;GXE2K\9)_'MG:>6[:\VMQV4DA(S]H\X1LPQD=B:
ML?'3XNW_ ,=?BKX@\<:C9PZ;=:Q,DSV=L[-%$5C5,*6YZ)G\:^B/#'_!/Z/Q
MAX]^#NE:9XPDFT'Q[X?FUN75#8C?8F%09(PF_#@,\0R2/O'CCG%L_P!B-+#0
M_&^J:[X@ND/A_P <6O@RTL+*V3S=2EDEC#E6=PL;".564'(SP2!S4*K1333U
M_P"#;\Q\LK'T-^QM<6OQ ^$WPHE\7>'_  QJMEX&U:YDT[7)/%*6-SHT)<2.
M;BV(S(&905 .>!D 9)\<_:>_;%\/^,?#OQB^'>@Z9)J5AXA\7_VQ:>(4N L3
M1QF,<1[<D-Y1(;<.&'%<-XM_8>^(&K_$OQKH_P -_".L:KHGAW4(K"7^U[ZP
M2[@>2-759=DNP\'.Y,J!U(KQ;XG_  I\6?!CQ;/X9\::+-H6MPQI*UM,R.&1
MAE75T+*ZGGE21D$=0:RITJ4JG-S7ZV[=>Y3E)*UCZ6\!?MT^&M!TCX?ZCXC^
M&$?B'X@> M*72-"UQ=2:&!88U*P&6#:=[(#U!'>I/ W[>^DQ^$?#]E\0O #^
M,==\/^([CQ)IVIVVI&S"3S2M+)O0(=WS.QZXZ<<5\<T5N\-2?3\63SR/TNTK
M]HCP-\2_V;?V@?'GB[PJ=1T;7/&%A<-X5_M80W+*([2,%954$[63=D+CC!KX
MR_:D_:%E_:/^(D&O1Z/'X>T?3["'3-,TJ.3S/L]O&. 6P,G)/8=J\>HHIX>%
M-\R_X;;_ ""4W)6(F_X^X_\ <;^:U[W^SC^TS#\&O#_B[P?XE\,Q^-/ /BJ)
M$U+1VN3;R!T^[)'( 2K=.W\(Z8KP1QB>(]\,O\C_ $J6M'!3YHR[_P"1-VK-
M'UM>_MX1^%=8^&=O\-/ \'A#PCX'OI=0@TFYO&NY;R:5'CE:68@'E)90,#C?
M[ "UJG[<'A30=!ET3X=?#)O!^FZOXAM=>\0+)J9N'NS!,LRPP_(!$F]%[' &
M*^/Z*CZO3[#YY'UEJ'[<%C?>+_VA-:'A*X1?BGI TR&'[<I.G$0&+>QV?O.N
M<#;72:!_P4#\/6'BCX,>*;_X=W5QXE^'MA)ICW,&K!(KRW:SEM\*AC.P[I%?
M))^Z1WKXIKT_]FGX1Z=\=_C1X>\":EK4OA^+6'DBCOH;<3E9%C9U!4LO!VD=
M>XJ9T*48MM:+U[6_(:G)NR.V^$/[4&D>"H/B5X>\6>#1XM\"^.;A;N]TI+TV
MT\4L<QEB9)@IP5)].<#W%>DZ?_P4*M=,^*NE:W:>!18^#M!\)W'A;1?#]O??
M/;QR[,RO*4.X_NU& HX ]ZY2Y_8;U.Q_9V^(WQ-NM7EAF\)Z]<:3'IAM.+N&
M&6.)Y]^[*_.Y&,'[AYK<\9?L1:5\/_\ A-K"\U#7O$&K>'O MMXGN&TM+2"#
M3[N7S"8;@2R;GB544YC&\[NG !Q?U>3;?IU\O^ 4N='&?L$^.-7\%?M!6(TK
M^Q98]3L;FQN[37[\65M<PLA)C\T@[78J O!Y//&2/L#XN?&#P1^R?\-?A#I^
MG>'K+3]3T?Q1-KI\&Z;KZZC)% 4E4M)<@$ L7&.#Z<X)KXKM_P!A;XZWGA\:
MW;?#Z\N=,;3H]6CF@N[:0RVSH75HT$I9VVC.Q07&1E1D9\'JY4J=>?,I7[V^
M8E)P5K'TQX2_;$@\/_&SXG^*;[PF-7\(?$*&XM-7\.RW91S!+DX695X9<GYL
M=S7;Z7_P4.@\$^,?AH/!?@1=#\ ^"EN1%H,U^9Y[IIU*R.TY488 G'R]SG/;
MXPHK5X>G+=?UL2IR1^B/P+_;$\":]X@^'OPM\)_#Z7P-H8\80ZPMS=:Q]H2+
M[Q8-N1<<GCD  #BL#]KW]J7PKX9USXW> ?!?@M+/6O%NHQP:[XG;4C<QWD47
M*^5'C"9W'HQ')]L?!M%0L+!3YOZ[E>T=K'U;_P $O?\ D]#P7_U[:A_Z135^
MYU?AY_P2OLTNOVR/#DC%@;?3]0E3'<_9V3GVPY_2OW#KPLP_COT1UT/@/RA_
MX+2?\C_\+_\ L&7O_HV*OSBK]KOVT?V0H/VM_BYX8T^?Q:?"::'H-Q=&<6 N
MA*'N$4@@RQ[<;<YR:^:M%_X)7?#SQ*FJ/I'[2>B:JFE*SZ@UE8V\PLU7.XR[
M;T^6!@Y+8QBNO"XRE1I*$MS.I2E*3:/SFHK]+M0_X)!^%])\.KK]]\>K.RT%
MEC<:I<:/%':E9"JQD2F[VX8LH4YY+ #J*77_ /@D#X8\*#3SK?QYM-'&H726
M5F=0T:*#[3</]R&/?=C>[=E&2>PKK_M"AW?W&7L)GYH5^A'[&7CX:5^QIXI\
M.^'_ (G>"/ 'CB?Q9]JM_P#A+KVR13;""W#L(;D,"#M(#;>H.#Q73^(O^"0'
MAGP?;VMQKWQXM=$@NKE+.WEU'1HK=9IWX2)"]V SM@X4<GL*UO\ ARG:_P#1
M7YO_  G!_P#)58U<9AZL>5M_<7&E.+N>9>*_%C^#?@+^TA;:]\5O!OB;QUXD
M&@75O<^$M4M5%V%NTCDCAC@V LD4>75%X4Y;J37O5Y\>_AQJ6I:%X>_X63H.
MEZEXA^%<N@Q^(4U.)XM-OBORK/*K_NG!8L-Y'*XZD5R+?\$5;1%+-\8)54#)
M)\.# _\ )JA?^"*MHZAE^,$K*>01X<&#_P"35<[K8>6\G]WDE^A:C-=#M_@[
MKOARW\:?LD^#=-\?^'_'&N>'Y]?@U"71=32[*G^S[O#$9W!>RL1A@ 1D$&O,
M-1^(O@[]G'P#=Z;XA^(^C?$#4-4^*%AXB2PT2]^VR:?9VUY%-,95))C<K$R;
M#@DGOS70>"O^"<D'[//Q8TG5M"^/[Z'XTL-.O-6M'?P@MQLM43R;B3#SM&<+
M/C!Y^;('&157_@C]8>-7_MY/C6]Z=6']H"=?#2KYHD._>%^TC .[/05"JT.;
M63MZ>;?ZCY9VV,3XA^/?!?P[\-_M(>*;GXMZ!X^M?B99RVOA_P /:7J'VJZA
M>;=LDFASF'R@P^\!]S'7 KI?'7QK\$&X^*,^G^//#YFN?@G9:79R6VL0;I;Y
M?M.;>,A_FF&Y?D7YAN''-0?\.4[7_HK\W_A.#_Y*H_X<IVO_ $5^;_PG!_\
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M^,?A*[^'G[5<>B>.-%FO]9\1:7-I:V&K0M+?1*D(=H CYD48.2N0,'-?/_\
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MTBU[_@CW;:1XM\+Z0/BM+*-7DN4,W_"/@>5Y<)DZ?:><XQU&*Z/_ (<IVO\
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MWPKIEMI.KC&H6OD!ENQMVXDW9+@#@9Z=JBT[X'^ M)\+:OX;M/"NG0Z)J_\
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MNY<C (QM'7.>,4 >Z?\ "K_$O_17O&?_ (":)_\ *ZC_ (5?XE_Z*]XS_P#
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M2<MD=^HS0!ZA_P *O\2_]%>\9_\ @)HG_P KJ/\ A5_B7_HKWC/_ ,!-$_\
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M\(=/\0:_KESH[VWB.6">UU.6W;5+6WOHTLI9FC(,@,6Q@<_-PV<,00#W/7=
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M5_B7_HKWC/\ \!-$_P#E=1_PJ_Q+_P!%>\9_^ FB?_*ZO1** /._^%7^)?\
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M-2<$D ]30!ZMX%T^3XEZ NM>&OCCXOU33C*\#2)9:.C1RH</&Z/IH9'4]58
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M-!!*[QR-L!88R WR$  ]@_X5?XE_Z*]XS_\  31/_E=1_P *O\2_]%>\9_\
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MR/7Y$\M]52SC%TRXQM,NW<1CMFJ\'PX\)6NLR:O#X7T6'5I)Q=/?QZ?"L[3
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M9B0 37")X]\+WGB/7=&TR^^+NMSZ'J3Z3?W&F?:9[>&Y549D\P<'"R(?HPH
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M0K@I@=,8QVJI\:?"VE?#K7OBWX6\-V4>C^'8]7\"W\>F6Q(@CN)-342R*I.
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MK"/> W.'R<$X'T!10!XW^QO_ ,FK?"S_ +%^U_\ 0!7G'AJ'QGJ/[//B73?
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MFW6N:ND4$UW<,&:.WBW&."/@;8U9Y&QW9V))KI: //\ Q[_R4GX9?]A"]_\
M2">O0*\_\>_\E)^&7_80O?\ T@GKT"@#YT_:$U?PWX2\=3^*/%,6MW&F:3X<
M3,6A:C/9SL9M0BA'^JFBW &13AFX ..>N[XB\+> O#/CSPSX4O#XL^VZ_#=S
MV]POBK4O(B6W0/)YA-V",AN, ]\XKC_VM_!^K>.X/%6CZ':/?ZH_A:&XBM8_
MORB'5()F51W8K&P [G J37->;XU?%[PKK7A[1=<BTSP[HFL?;[C5-*GL@LL\
M"1Q0H)54NY.X_*" %Z]* .ZT3P9\+?$NIRZ;I'BN]U748H5N)+2R\=:A-*D3
M %7*+=DA3D8.,'(J30_ ?PS\3ZA?V&C^)M0U:^L&V7EK8^.-0FEMFZ8D5;LE
M#['%>(^"/A1%X/F_9EFTGP=+ILL>B:I%K3Z?8>3.#)INXI.^!M9YN1YA&7]Z
MP_AWX/U&"YG\/^"='OVDC\(:I86>J:SX;;2=1T.9U7RK>6X0B*[+R<D@$@IO
MW')) /:?$]C\,M)\(^,M7T;7-0\2WWABPN+V[TRQ\>:@TJ-%&S^7)MN6,9.W
M&2O'H:UO!7A#X;>/+3.DZ_J5]?0Q1R7ME9>.-1GDLV=0=D@6ZRI[?,!TKR7^
MS?"6L?!?4M&T#X:ZS8>+=.\ 7^F2W0T62U%NS6^U[5F.WSGDD&X!!)D@MD9R
M3Q1\(]1T;Q'86/P_\/+X=O+OX3ZIIL5UI]G]GC2]_P!'%LDCJH&\,SE0QS][
MWH ]FT+P%\-/%-Q?P:-XEU#5Y]/?R[R*P\<:C.UL_P#=D"W9*'@\''2N%74_
MAA>_%/3?"6E:O?:O93Z5J&I7FL6?Q U"2.P:U>!6BD5;D@$B?<2S+MV=#GCR
MOPG\)QJW@/6E\)7OBZ#QA;^ KW1(=/O?#L6EV\3O&H$#2K!'OD$BG8P9L;F;
M//*Q^'-'\7^.],B\"?#_ %'03#\,=;T6YDE\/R:<@N6%J(K9G9%#-D/CDCJ0
M3S0![[XU\'^ O"/A?4]42_UF_N[;2;G5[:P7QMJ2/>0PQ[RR?Z225Y4%P"!O
M'J*JZ3HOPU?P?X6US7M<U'PPWB"V@FM;74?'>HQEY)$5A$C/<KYC#<!P,GTK
MQ74M9NOB)J>@II7AOQ)$=*^%>N:7=F^T:XMU2[:.T58 70!G)1L!<YQQFLS5
M_AQ=OXATN7QH_B*RT#4? &F:18+IOAR/4PC!7^U6KJ\$IAD9F1LX7<, GY.
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M6DQO\E73< 0*Y#XM>)/$7C+]C[XJ6&KI/>SS30:/X=NIM--A/J$DRVHB"VY
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MR6A8B.<HP94D7^--P!*G@X&<BMNB@ HHHH \_P#'O_)2?AE_V$+W_P!()Z]
MKS_Q[_R4GX9?]A"]_P#2">O0* /&O'>M76E?&V&&#P;JGC.&[\,2Q3VFFO9
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M_P"DK5Z#0!YQ_P +3\3?]$=\:_\ @9H?_P LJ/\ A:?B;_HCOC7_ ,#-#_\
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MZ'JT-A#!(+JV7S=NUI48QL//D&Y?7U&:T/#OP(M?"_BSP7KUCKEZDWA[0?\
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M#T+!@0 "]_PSC:Z?IFB#1?$FH:-KNC:EJ6H6>L1112.%OKB2>>!XW4J\9,@
M[_(ISFK7A/\ 9WTCPI=^';Z/5+V\U/3-8O=>N[VX">9J5Y=0/#+)+@ #Y6
M4  (HZ"N?O\ ]L'PS8ZYIUJ/"_BVYT;4?$-OX7LO$D.GQ?V;<7LMR+;"NTP?
M8DFX,Y0 [&V[C@'O_BA\6]/^%T6DQ2Z3J_B+6-7G:WT_1="@2:[N65"[E0[H
MBJJ@DLSJ!]30!Q5_^RYIT]CJ"V7B/4=.U*;QG)XVMK^.*)VM;MU"F,(RE6CV
MY'(SSUXJUXG_ &9])\4_#[QOX3N-9OH[;Q7X@B\0W-RB)YD,J36TH1!C&TFU
M4<\_,?:N/^#/[1FK:OX0\=ZYK6C^(]?NH?'-_HND:#9Z;$-0BA1(VC@9<I&N
MS+Y>1P/5SQ3_ !U^V$VE>'?!^J>&/ ^N:W)JGBR/PMJFGS+;Q7.FW <K);NK
M7"KYYX*89HR,DN 1D ZKQQ^S</'VL78U+QKKTWA>\U2VUB?P].R31K-!)'(J
M0S.#+!$7A1C&C  [L8W&O9Z\B\9?M+:'X$UM[75_#GB>#1K:YM;*_P#$GV!/
M[-L+BX:-8HY',@=OFEC4M$CHI;!88./7: "O-]!_Y.-\<_\ 8J>'_P#TLUFO
M2*\WT'_DXWQS_P!BIX?_ /2S6: -'XD?#-O'=SH>I6.N7GAO7M$G>:RU&S1)
M,!T*21O&X*NC*>AZ$ @@BN4D_9ITBY^%DW@>ZUG4+NRU+5QK&NW<H3SM7<SB
M::.7  5)"JH0H'R#;ZU[%10!P_Q*^%\?C]M!O+35KKP[KF@W376FZG9QI(8B
MT;1NC1N"KHR,001Z$8(%/^&WPOM/ASX6O]*CO[G5+S4[NXU#4=3NPHFNKF8_
M/(0H"C@*  , *!7:T4 <I\*OA]:_"GX<>'/!UE=37MIHEE'8Q7%P ))%08#,
M!QGZ5Y=I?P/?4] \<?#/7[>\B\.3:LWB#0->L)0KV[2W'VD*IZI/!<AF&1M9
M&CQGYU'OE% 'A\_[+.GZU;>(+OQ!XIUC6?%NK26$J^),107%D;*0RVGD(BA%
M"2,[D8.XN<]L:^A_ J\T>Y\6:VWC;5+GQOX@L[>P;Q(UK;A[2"$N8DBAV>7@
M&20G<#DM["O6:* /'OB!^SO_ ,)EKWB#4=.\8ZSX87Q-I\6F:];Z>L3+?11J
MZ*REU)ADV2,A=,'&.Z@UU&N?!CPQK_AO3]"N+61--T_2I]'LX8Y#B"&6#R&9
M<_QB/*ACR S>IKN:* /G3QK^S_J"_#77O ^GW]YK-[X[N+>PUG7)HHXEL]/C
M@CAD(1<#=Y$11< EGDR< <?0UK;165K#;PH(X84$:(.BJ!@#\JEHH \^\;_\
ME3^&W_7?4/\ TE:O0:\^\;_\E3^&W_7?4/\ TE:O0: /$]0_9ALM1O9[.7Q1
MJI\%W&M)K\OA<I$86NA,)R!*5\P1&50Y0'KGG!Q2_P##/NN6GQ,\2>-].^(=
MY;:MK6R$M<:7;W!M;5/N6T+,/DB!+,0/O,Q+9.,>UT4 >&>*OV6++Q0?%6G'
MQ7JUEX1\67@O]>\/P1P[+R8K&LNV8KYD:R") RJ?7&,FKWQ>_9)^&/Q@L+\:
MAX0T"RUB^O(+RYUR#1K4WLK1RHY#RLFYMX38V3RI(KV6B@#SCXQ?"IO&OPEN
M/#/AHV>A:A8FVO-#*Q>7;6MU:RI-; J@^6,/$JD*.%)P*YO4/@W>>/[^?QG8
M:YKOPXUSQ)H\&G:]IT*03%UC\S8#O5E61/-E42)U##KQ7M=% 'C5]^S1IVG3
M>';KP7XAU+P/J6C:&OAM;RP2*=KC3U.Y(Y%E5@61]S*^,@N_4'%=3X6^$ECX
M.T'1?#>FW]ROA'3=(DTEM$F5'2Z#;?WTDA&_?@.#@@'S&)&<8[RB@#Q[P%^S
MLG@_7O#5]J'B[5_$MGX6M9+/0+"_6)4LD=1&69D4-*XC4(&<\#/<DU9\;_L]
M:7XIMW_L_5;S0;R>:^DNKR)$GDN!>1B*<-Y@(SL5%4_PA% &!BO6** /(/#G
MP\OKOXT6>N3V3Z=X9\&Z(WA_0(IVW2W,DQB:YN.^(PD%O&N>6*R' &TGU^BB
M@#S_ ,>_\E)^&7_80O?_ $@GKT"O/_'O_)2?AE_V$+W_ -()Z] H \5^*O@E
M/B1XV\0^&&9(SJO@J>UCDDSMCD:X&Q^.?E;:W'I7">%OV1=9TK7/A#?ZAK%A
M<C00]]XK1"Y_M740\US%+'E.0MW<229;:<!?H.B^-NN?\(O\6]+U27Q!X@\/
M6?\ 9=M82W&@064K W6I0V\;RBZBD C5Y%+%!N ).&Z5E7OQ,LK.?QU"/BK\
M0+B;PAJ=CI%Y'#8:'FYN+MHHX1;YLAO'FR^42VW#QN.0 2 4KW]F#QE#H=T]
MA?:%)K%O\5YOB#8PW,\RV\ULSMB"5Q$623;(Q.U7&0!D@Y&EXN_9N\4^(OA9
M\9O#D5[I$>H^-?%46NV+O-+Y,,*KIX*RGR\A\VDN H8<ISR<==IUN]]I=G?3
M?&GQ5I:73%8H=2AT2WE)#LGW&L,\E3CUK%^*NI:W\+9?#=J/&GQ,\5ZIX@O)
M+&PTW0;/P\9G=())W)-Q;0H (XG/WL\=* .N^/GPNU7XIV'@:#2;BSMWT+QC
MI/B"Y-X[J'M[6?S)%3:K9<C[H. 3U(K@;O\ 9O\ $L_PN\!^&UOM*%]H/Q%7
MQ=<R&:7RGM!K%Q>[$/EY,OES*,$!=P(W8PQUO!FLIXR\,C66^,/C'0 E[+IM
MS8ZY;Z';7%K>1MMDMY!]A*[P?[K,""""00:-0UVRLM6U_28OC;XNU'6-"BMY
M]0TZQLM(EFA29RB' T_!Y!R 25 Y R,@'GW[3?P]UWPWI_CCQ)!<:>Q\3>-/
M!LFEH[.WEO!=V<)\\;1@%US\I/R^AXKH/&_[/'CWXJ6GCG6-?OO#ND>*=3@T
MBVT>TTZ6>XLH(].OQ?QF>5XT=C)+E6VI\JXQN/7TAO!5W>ZF^DM\9?$<^HQ!
M9FL3%HC3(!@JQ3[!D=B#BII?!FI0/(DGQF\3QO%+' ZO'H@*2/C8A_T#AFW+
M@=3D8ZT >3^)?V=_B-\2T^+%WXFNO"^E:CXN\.V.DV,.E7-Q<0V\MO)+)^]=
MX4)5BZ_,JY )&WY<M#\9OV;?'?Q:NVN+^T\&:PM[X9CT@V6M7EW);Z)>@2^9
M<VB+#B8L9$&YQ&^(UYQ\M=GXSUNS^'T5]<>(/C=XMT_3[&UDNKF^-GH[PQ!&
M"M&2NGDF3)'R %O:L_P3XDF\9^/?&/A>/XN^)[2?0;VUM+>5VT0G41/8P78>
M)/[/!P%G"X&?NY[XH L:1\"_%FB>*/"FH0W&C36MOX(/A354DN)5>.15+1RP
M8BQ(IDPI#["%Y&3\M97@KX$?$'X46_@[4O#4OAK4]>LO!MGX3U6WU2[N(;8F
MV9WCG@D2%V8!Y9,JR+N!'*XK9\?:W'X N;W3+KXT>*9?$D6CW>M0:,(-'66X
MAMT+O@_V<0OX\XR0"%.-?P?977C'PO;:U:_&?Q((FM8KFYC3^PY/LF^,.5D(
ML/E(!YSCI0!G?"S]GK4?AKJW@R0:C:7MIHWA[4=.NY/G626[N[M+EG1<$"/<
M).K9&5&#VZKX+_#35/AS\$=,\':E/:3ZG:P7,3RVKLT),DLKK@LJG&'&?EZY
MZUSWC>#4_"7PO\2>-[3XL^*];L-'TJZU0+:)HI6X6&)I"JR#3R!G81GG%$7G
MSZ/IFHV_Q@\7ZA'>W=O8E=.M]%N?(FF("K)ML/E )&2>E &#X?\ @'XQ\$>"
M?@]-HUSH=YXQ\":8^F7%M>W$T=A>Q2PJDH698BZ$%%96,9S@@@9I? _[.7B+
M0O&NB>+M4U#2Y=9N/&%_XJUR&U>3R8Q-I4EA%!;;DR^P>22S[,_.?1:[7_A'
M;CS;V+_A>'B'S+''VM/^)'FWST\P?8/E_'%(/#MP9K*$?'#Q"9;X9M8_^)'N
MN!ZQC[!\WX9H TOC+\/-1^(EOX-CTV>U@.C>*-.UNX^U.R[H+>0LZIM4Y<@\
M X'J17!:O^S]XBO[G]I:2.\TQ5^)=C%;:/NEDS RZ0MD3<?N_E'F GY-_P O
M/7BNIFT*6WAN9I?CEK\<5KCSY'.AA8<DJ-Y^P?+R".>X/I7,#5YT^*-QX-G^
M,'B6VVZ-9:O;ZA*VAJEU]HGN(5BC!T_DC[-G()SO'''(!FW/[.WBI=7^*U["
MWA34H/%=OH,-OIVN0275K.EE 8[B*X38-@?/R.N\KPQ7(P<[P[^S?XVTGX?>
M+=$N(_"5[I^JZI:W=EX*U>XN]5T>SMHXU66&.XF02QEW'F*5CVQ,!M7K7JT?
M@K5)?)V?&7Q0_G2-#'MBT4[Y%SN1?] Y8;6R!R-I]*9/X0U"VU2'39OC3XEB
MU&9"\5FZ:()G4=2J&PR1P>0* /*O"?[,OC;2[3PM'?:OIJ6FD^.(_$D&C+J-
MW>0:78K:F(VMM/.GF29D+2 ,$4;V P!SN7'[/'B*;X>_#G01>Z7]K\.>.U\3
MW;F63RY+47ES/LC/EY,FV=!@@#(/S8P2[X8ZKK7Q/UOQ1!8_$_Q+%I6CZC+I
M<-VL^A2S74T3,DI,*Z=^[3<C;26)8*3@"M36KFYT/XA:#X,F^*/Q"DU;6-_D
MRQ:/I1M8]L4DN'G.G! Q6)L*"6Z9 !S0!\]>(K?6(-1^'7PLT;7O"FOZ5I/Q
M+L=1ABL;B=M92"'4&NYEN+?R]D:Q+O!EWD, O W5]2_%SX?>)-;\4^#_ !AX
M.?2I/$'AU[E!9:W++#:W4$\8213)&CLC JC [&Z$=\U@>!_#][XONM==/B1X
MMTW7=&OI-.U*WEL]$,T+A5="7&G_ #))$\<BG^ZXS@@@<;!\49KC4$2/QI\5
M3I%VT\.E:Z=,T 66K3Q)(Y@MR;7S-["*0(9$C1R.&.1D SH?V9?B++X0U:'4
MKCPOJ=]J7CF]\4WV@-?7<6E:C;3PA%MYY%B\SY' ?:4=&**#D'BMX:_9,\:>
M%_AH=,L?^$2LM9L_B3'XYT_3K.:XCTT0*(_]&+>3OC(PX!",.%/<A?0+'6Y-
M5@\ R6/Q3\>78\:*9-/6.QT3,48@,SO-FR&U5 "G&X[F48.<US'BCXH77A/Q
MUXD\/W/B[XL7-AX:2VDUKQ'9:7X?FT^P2:/S%=P+;SRH7EBD+!0"3P,T <M\
M;?V0/'GQ2U7QA,3X0U>;5M5LM3TW7-;N[LWNDPPM;,UC @B9(XR89/G4@MYI
MW(3R/LRO+H_"UY->V]FGQK\2->7,0GAM@FB>9+'C.]5^P9*X[CBL/Q5?:?X*
M\.ZUKNL?'SQ!:Z7HJ%]0F2/1I6M\ DAD33RV[@X4 DXX!H ]MKS?0?\ DXWQ
MS_V*GA__ -+-9K@/!7B:7QGX\\7>&8OB]XFMI=$NK2VMIW;1#_:0GLH;H-$G
M]G@\"8+@9Z9XSBM7QEX$G^')U/QI+\1/'U_JUY#9Z4T.F6.DSW-YLFE^S0)&
M;$(#YEW+\QV@;R78*N5 /<J*^:_#7C>]\17=C;S>/OB+H4TFKOH%_;:M9Z"D
MVFZAY*3103>79NA\V-U*O&[*2RC.3@=C?Z=J>G>/M'\(R?%/QRVI:I876H0R
MK9Z+Y*QP/"CAC]AR&)G3  (X;)'&0#V.BO#O#5V?$FCZAJ;?&+Q?I%G9:I<Z
M0\FJ0Z% &G@E,;;3]B(()4XYR1V%=%-X3OK?4;?3Y?C5XEBO[E=\%JZ:()95
M]57[!EA[@4 >GT5X?J^IZ9H6M:/I%[\?]>BU+5[LV-E;*FBNTDX1GV';IYV\
M*>6P,X'4@&>_DM=*\9+X4O/CMXDMO$!L9-2-E+!HZE;:,KOD9O[/VJ!N!P2#
MC)Q@$@ ]IHKREM!E06A;XY>( +QS';9_L/\ ?N#@JG^@?,0>,"I$\,7<NIC3
MD^-OB-]0.[%HJZ(93M.&^3[!G@CGCB@#U*BO*8] FF%R8_CCX@<6TBPS[?[#
M/E.QPJM_H'RDDX /)-8^HIJ-OJ_A6TL?BUXJU:WU^[FM8[RT71'CB,<+R$Y&
MGD-]S&,C&: /;J*\IM] FNX)YH/CCX@FA@E$,LD?]ALL<AZ(Q%APWL>:R+V]
ML-/U;P]ILOQ[\0&]\0S/!I<<4>C2"Z=%+,%9=/('"D9) )X'/% '6>-_^2I_
M#;_KOJ'_ *2M7H->0Z_\,3#K6B7NK_&'Q-;:C;R2+IS7(T:)B[KL<(IL0')4
MXQ@]:T8?!NI7&H26,7QG\3R7T8)>V2/1#(H&,Y7[!D?>7\QZT >FT5\]S^([
MN/X4^(O'\/Q$^(UYI>A?;OM-G;Z?H37;BTD>.8QH;,*W^K9AE@2!TSQ6O(UR
M?%'AC0K;XL^-K^Y\0V,^I6LUM::(8DMHA&3+(38@A6,L87 .2W:@#VVBOEY_
MBO:2?"3Q!\0K'XE_$?5-+T;4O[*FL;73]"%W+.;B.!/+5[-4*N9HG5F=<HX/
M'2NH^'-_J?Q"O=3TN3X@_$;POXCTQ(I;S0=>L-"CNX8I-WE2@Q6<D;HQ1P&1
MV&48'!&* />:*^<?BEXSN?A/>W,6H>/OB=JEKI]A_:VKZAI>DZ));Z3998>?
M.SV2%A^[D.R$22 (3LQ@GIO"-CJWBO5_$&DK\4_&5IJ>BSI'/;O;Z*V^&1-\
M%PA&G\QR+NP?[R.O530![117R]:?%O3+_P %>*_$EM\5_'\T/AC6AH6IV"V.
MA_:HIS=);HP0V>#&S.&#;N5!XR"M>J2>#=2B17?XS^)T1G:,,T>B %E!+*/]
M Z@*<CM@^E 'IM%>1?V?'L9_^%]:UL6186;S-"P';E5/^@]3V'4UA^#[V]\5
M^)O%6A2?%OQ3IVH:'K#:1'!-_8ADO,6MO<&1$_L\'&+C;CG[A.>> #WFBO*_
M^$<N/-OHO^%W^(?-L1NNTQH>ZW'K(/L'R_CBKMEX!UG4K9;BT^,'BNZMWSME
MA@T5U.#@X(L,=: )_'O_ "4GX9?]A"]_]()Z] KQG5/"6J>'_BK\-YK[QKKO
MB:-[R]1;?5(;!(XS]AF.\&WMHFSQCEB.3QG!'LU 'AWQD\'R^/O%7B7P_;H)
M+R^\$SQVH+!<3BY#0L"> 1($()Z$5Y]X>_9R\71^(/@]>:C:P"(2OK'C<B:-
MC]O22>^A YS)B\N#@KG C'08KUSQ9XKTGP1\7KC6]<O8]/TRT\+EI9Y 3C-X
MJJ H!+,6(4*H))( !)KE_B-^T[IZZ=X4B\%74\U]K7B)-#N7N?#NH3RZ=_HT
MMPWFV@C657*QIM5PI*N7&54F@#AM(_9SU^[L-8CUOPK:W<K>"KO2[+[3);RE
M+U[ZZE54.X["4DB;?P!D<Y!QZ)\4?A3XF\<7_P %TL;S4=%_L*]FGU75M,GM
MQ<V*G2[F$,OFAU?=*Z1G"/PY/'WAH?$7X^6OPK^*VCZ'XAF,.@7.@7.I33VF
MFW-W,)8IHDW;85<K&%=BQ*X'!+"NAU7X_P#@'1M9M=,NM?47%PEO()8K6>6V
MA6?'D&:=$,4/F9&WS&7=D8ZT ?-VK_!'XD:?X4M]!@\)7&K3)+K,5]K5O<:5
M-=:I<W#J\=](]\)!'#*I*R*B"163:B[ I.O-\#_&T6G^)+=/"IEN=:\(:#:?
M:UN[4%+RTF)N(9"9,EB&#!QE#M/S9P#[E)^T;\/(GUW?KSK%HEO=W5Y<G3[K
M[/Y=J2+DQ2^5LF,95@RQ,Y!!&*I/^T;X2U&&!M%U$33#5++3[BVU&QO;28+<
MN5C>.)H-[[\'8VWRV(/SB@#S;0/@[XIM/'>@VC>$HK"XTKQ9=^(;SX@)=P,=
M2M96N&%OM#_:#(4FCA9741JL7RL<*!=^./[/_B#XB?$^:[TQ$@\/7>E"_GF6
M=48:W9K*NG.5SDX-P'ST!M8L]!77>"OVI_"7BGP#%XIO+76M(AEU&^T]+-]$
MOIKAS:SR1/(L:0;V3;&&9@N(R2C$,K )J'Q[2W\?I9VMQIMSX;N[/0IK*Z<3
M;I6O[F[B.THC[B5@CVJ549)W, > #R?6_P!G;QEK?PRN[*XT*UD\0ZIX.U;[
M<C7$)3^V;R[6Z:(,6Y^8NH?[H"CY@,47OP \2ZY??$/Q%_PA$6G:YJ?B[PAJ
MVD-+/:?:H+6T32EO,2)(0GEK!=J5#?-M.T-N7/MVG_M+?#_4;_6;)=1U2UN]
M'M5O;R*_\/ZC:%(FD\M&7S8%\PL_RJJ;BQZ UEW/[4WA&3Q)X+TG2X=6U8^(
M]7N-%=XM(O4?3KB*V:<I<1-!OC; 3*N%(1_,/R*S  QOC]\-O$'B7QQ:ZKH?
MAL:TEQX4UK0I+F*:WB>UFGB0PLWFNI*L49,IN(+C("Y(\_\ 'W[-'B:[\-6=
MIX6T6'1_+T'05OK73YK6W^WSV=Z)I[8[@\3.4! ,J-$Q(5B5)KVE?VB_"&E:
M'I=YKFJ+!<7ZSRK'IEG>7B1Q13-$TLFV#=%&"N#)(JJ#GD@9J>/]I3X<3>+?
M^$;C\1%]4_M"'2CML;DVZW4T4<L,1N/+\H&1)H]F7PY;:N6!  //-)^#>L0_
MLT?%O0;31-8M-<\6V>IM;Z/KEYIS2F>:Q$"+BS5+6 .R#*H2N279LNV,[Q-\
M M;MO&-C-X9\.V^G:46\*3W'V.2"!!/9WMRUU(4##+)$T'('S# 7<00/:_!_
MQF\(>/==N=(T/4Y;R]@5VR]C<0PS*C[':&:2-8Y@K<$QLP!ZUYUX8_:2M[CQ
MI\3Y/$-V=&\+^%-9AT*UADT2]$]U,]O;2!ED*XED9[AD6"-"Y54?E74D \.O
M_P!F'QQ>_#KQ-HDOA[7+OQ%#I%SI\-Y<7^CK8:HTL\;DQF*-+F3(3<3=LI4Y
M&7SFNR^/OP;\>:]XWFA\+>$(Y- B;19=-GTC^R[:.)+6[66>.=IU^T!@ QB6
MW*)R=S D@^XVW[1?P_O9M%@M]:GN+O6+B2TM+2+3+MKCS8V19$EB$6^$H9$+
M>:%VJVXX7)I-?^-6E>%/B^O@_6[W3='L9-"&K1WU]=K"7D^T&(Q@,0" !GUH
M \DTGX(:UX7\'^&M0G\!VWB'4+#Q3K>JZKH,4MHL^HPW%S>BUEWR.L,CI'/$
MP65QM4D<,H%96L_LWZKK=CX[E/@#3K&:]^'8TS1+-;J*?[)J?VO4[A88Y)'S
M&RFXMVW B,$X5MJ<>I>$_P!J+PK>^ -'\1>(;L:?)J<M]Y4&FVUQ?@06]U+
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M3T?3]2U(:7+J]P^J7;6\8B60((T(4_.S$\G"C'/6@#C[/]G_ ,3^&;-5\/\
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M^%)J/_Q^BB@ _P"%9:/_ ,_GB'_PI-1_^/T?\*RT?_G\\0_^%)J/_P ?HHH
M/^%9:/\ \_GB'_PI-1_^/T?\*RT?_G\\0_\ A2:C_P#'Z** #_A66C_\_GB'
M_P *34?_ (_1_P *RT?_ )_/$/\ X4FH_P#Q^BB@ _X5EH__ #^>(?\ PI-1
M_P#C]'_"LM'_ .?SQ#_X4FH__'Z** #_ (5EH_\ S^>(?_"DU'_X_1_PK+1_
M^?SQ#_X4FH__ !^BB@ _X5EH_P#S^>(?_"DU'_X_1_PK+1_^?SQ#_P"%)J/_
M ,?HHH /^%9:/_S^>(?_  I-1_\ C]'_  K+1_\ G\\0_P#A2:C_ /'Z** #
M_A66C_\ /YXA_P#"DU'_ ./T?\*RT?\ Y_/$/_A2:C_\?HHH /\ A66C_P#/
MYXA_\*34?_C]5[[X1>'=3A6&\?6[N)7241S^(=0=0ZL&5L&?J& (/8@&BB@"
MQ_PK+1_^?SQ#_P"%)J/_ ,?H_P"%9:/_ ,_GB'_PI-1_^/T44 '_  K+1_\
MG\\0_P#A2:C_ /'Z/^%9:/\ \_GB'_PI-1_^/T44 '_"LM'_ .?SQ#_X4FH_
M_'Z/^%9:/_S^>(?_  I-1_\ C]%% !_PK+1_^?SQ#_X4FH__ !^C_A66C_\
M/YXA_P#"DU'_ ./T44 '_"LM'_Y_/$/_ (4FH_\ Q^C_ (5EH_\ S^>(?_"D
MU'_X_110 ?\ "LM'_P"?SQ#_ .%)J/\ \?H_X5EH_P#S^>(?_"DU'_X_110
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15)964$JQ&<9P374444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cvrx-20231231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (_ C\# 2(  A$! Q$!_\0
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MX=)?2M7TJ^^S&Z6/4;3RA)&'5"5(8@X++D>]=5N/O^1H,FG'<?FC(J,L??\
M*DWX(!S^5!-R:BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MII?M"2CRXO+"'#=_FW\8]#0L/4?P1OZ:FJJSBK*3^\U7^"?@51G_ (1FP'_
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MJ/E=3WS75[A_D4&<ERNS%HIGFJ!UQ2[QB@0ZBF[A2YH 6BBB@ HHHH ****
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M"3*LV2V0<_<-K)#<01S0,DD3H&1XV#*RD9!!'48Q0!-1110 4444 ><>'/\
MDO7CC_L!:)_Z-U*O1Z\X\.?\EZ\<?]@+1/\ T;J5>CT %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 ><>'/\ DO7CC_L!:)_Z-U*O1Z\X\.?\EZ\<?]@+1/\ T;J5>CT
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MT[4I=&U-_P"S+J>UDFD0.ENTJB7!#8= #N!^5\,N/ND@\5\Z:?\  S6?V?\
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M./#G_)>O''_8"T3_ -&ZE7H]><>'/^2]>./^P%HG_HW4J]'H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (YXUE4!@",YY&<
M5P?QF^%5K\7OAKK_ (4N+B6T74K26 /&[(A=D8+Y@4@N@8ABF1G:*[\C-&T5
M=.I.C4C5INS6J\F@W5F?,'[*NI6_@_Q=XP^'E]K^HZK?V%ZKZ>;I9EAFM_(C
M>5H491@),TJLY/S%@ 3@5]/+U-> _%;P+XR3XP>&_&>@ZI8Z=I=C:WXOIIK9
M<QYMU$*2@S+]H#.&V]-AY.>"/7_ &OR^*/!VB:K.\37%Y8V]Q*(3\BN\2NP'
M)P,MTSZ5W8Z4*\HXF+5Y)7_Q;/HM[7^9$=+HZ&BBBO.+"BBB@ HHHH ****
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M^C=2KT>O./#G_)>O''_8"T3_ -&ZE7H] !1110 4444 %%%% !1110 4444
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M);_QEXBU*\:"T>ZBDFEM99?LP3= N2Y8*L\3!6SD?HJOW1]* %HHHH ****
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M3_T;J5>CUYQX<_Y+UXX_[ 6B?^C=2KT>@ HHHH **** "BBB@ HHHH ****
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M*^.-P!&0.AS0!R'AS_DO7CC_ + 6B?\ HW4J]'KSCPWG_A?/C<D$9T+1.O\
MUUU*O1Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI:>#DM+N:_NTO!]D;4Q\L\,9ANU"H@ ,*KNR@Q^AJ\*,=* %IIC4G)&33J*
M&&%&ZJ#]:7RU&..E.HH \X\.?\EZ\<?]@+1/_1NI5Z/7G'AS_DO7CC_L!:)_
MZ-U*O1Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ?\ QZC_ (0GXE?]%)M?_";B_P#CU 'IF:"P49) 'O7F?_"$_$K_ **3:_\
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M8?B!97DVDZ9<WR6\GAN/;*T43.%.)LX)7''/-= O@GXD\X^)%H![>&HO_CU
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M6P^$G@BR\-:;-<W<$,UQ=2W-VRF6>>>=YYI&P  6DE=L  #.!P*[&@ HHHH
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M<5)3(U*J03DY)I] !1110 4444 %%%% !1110 5Y'_PNB[L/CWIWP^U/PU%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<;CZ"F"^0D#S8B2=O##KW'7K0!;HJ"*Y$Q^1E8 E25.>?2IZ "BBB@ HHHH
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MS43'8",\5R.M?%OPEX<UJ]TC4=:@@U.QTV75[FVPSO#:Q[0TC!0<?>7 ZG/
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MNF7365V\#92.=5#%-W1B PR1D5TPZ4TU)7B[D3A.E+DJ1L^S%HHHID!1110
M4444 %%%,DZ#ZT .HR/6N>\:>.M!^'6A3ZSXCU*#2-,BP&GG)Y8]%4#)9CZ
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M0 4444 %%%,E.T _RH =FEKSB[_:"^'ME:W=S)XGLS;VM^=,EEB#.@N @D9
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M,;@]!GG+#]GJVT^P\,Z3%K]T- T2[@U(:=]EB!FNXIGF$ID W*&DD)*#(PH
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M1LRQAHR"&,29#[QC(& 37=^#/"NG>!_"VFZ#I,1@TW3X1!!&S%B%'J3U/?\
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M-40;44  #L*='VVOM;?U_2*S%Y:XP_L]23UOS._2.WSYOE8?11172>(%%%%
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M5XUMO!C>(M2U'5-1\.11QF]$_EM>LIB9FEP.K20HQ*[3U&0"0>1K$6=K=/\
M@GT=LF]K&5Y*%YW779\C\^B9T?PT^*ND?%6PO;S1H[G[';3&%;B94"7&/XTV
ML3C@\,%8=Q@C/:#J:\]^%GP8\._"*35SH*7"?VE*DDHGEW[%0$(BX PJAFQG
M).>2<"O0EK:ES\B]IOY'CXWZLL1-8-OV?2^]O,6BBBM3C"BBB@ HHHH :_2N
M)^(GQ5TCX;2Z+#J,5Q<W6K3M!:V]HJF1RJ[G/S,HX&.,Y.< $\5V[#(KS_XK
M?!?P]\7X=-BUY+D_8)'>%K67RVVN )$)P>& &<8(P,$5G4<U']WN=>#6&]NO
MK;?)K>V][:?C:_D2:#\3]*\1_$+Q#X4LENFO-%@AN+B=H\0/YK.H6-L_,5,3
MAN, C&20<<WXL_:-T/P1KNM:5J^D:Q#<:8ELY>-898YOM$QB@"LLORLY#$!]
MN%4DXXRMI^S_ */H7Q&B\6^'KN\T.YE>-;ZUMYR8+J%//9HV0YX>28,W/5%Q
MCG.KK/P4TC7)O%LLMY?Q2^))+62[>.2,E! @14C#(P"$ EE8-DLW2L'[=QZ7
M_3H>K%95"LI/F<.6/D^:ZYNZVYK?)'8^$_$UCXR\-Z9KVES>?IFI6T=U;2%<
M%HW4$$CL<&MJLCPQX<L?"7A[3=%TV$P:=I]NEK;Q$EML: *H)/7@5KUTQYK+
MFW/"J>S4Y>R^&[M?>W2X44451 4444 %%%% $3L%R>2/:O/_ /A=6@2>+_$'
MAT+<M<:%%YM[=!%,,;;$?R_O;]Q$B8^7:2<9R,5Z Z!D8'H>M>6ZC^SOX.U/
MQUJWBF^L9KN]U*,I/;O.1"6(A!<!<,&(MX>=V!LR "2:QJ.IHJ9Z&#6#_>?7
M.9*VEN]UW:Z7^=C=\$_$FU^('P]L_%VC6%_-;WL#S064@2.X;:[)M(9PJG*G
MJP'O7'^&?VJ/"7B/5_#&FBVU.QN?$"YM/M42!<&66*,EE<Y$C0R;2N> -VW(
MSI?#SX'VWPZT#6/#]CK6J2^'[JV6WMK2>?>UJ2)?.=&QPSM+D\8^1>.N9K#X
M!>&K:\\&S%[R9?"=M%;Z?#)(FS,:D)*_R;B_S$G!"D\E3@8R_?-1:LNYZ"_L
MJ,ZRES.+;Y&M+*SLGW=[7]&>FP\@GU]ZEIJ# Q3JZSY\**** $;D&F!"!GO4
ME% K$>W&:\K^)OQ\T#X5?$+P+X2UJWOOM/BY[E+2\A5&M[;R%1F,Q+!@"74
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M<S/*JRG]^R[(PW+?.PP@'!^MG!SD8KRWQQ^T'X,^'?Q TWPCKNH36>J7UO\
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M[=0"BBBF 4444 %%%% "$9IK1!CD]:?12L!"+5-P/<'.??I0MNJEN^?:IJ*
M&A=HP*=113 **** "BBB@ HHHH :5R"/6F& 'GH<=0*EHI6 K_8UP0#M!_NC
:%2"$* !P!TXJ2BBR>X"*NT>M+110E;0#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cvrx-20231231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !R N8# 2(  A$! Q$!_\0
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M,9SCJ_-]S@JU9QFTF?J#_P /M?\ JC/_ )=/_P!QT?\ #[7_ *HS_P"73_\
M<=?E]177]0P_\OXO_,R]M4[GZ@_\/M?^J,_^73_]QT?\/M?^J,_^73_]QU^7
MU%'U##_R_B_\P]M4[GZ@_P##[7_JC/\ Y=/_ -QT?\/M?^J,_P#ET_\ W'7Y
M?44?4,/_ "_B_P#,/;5.Y^H/_#[7_JC/_ET__<='_#[7_JC/_ET__<=?E]11
M]0P_\OXO_,/;5.Y^H/\ P^U_ZHS_ .73_P#<='_#[7_JC/\ Y=/_ -QU^7U%
M'U##_P OXO\ S#VU3N?J#_P^U_ZHS_Y=/_W'1_P^U_ZHS_Y=/_W'7Y?44?4,
M/_+^+_S#VU3N?J#_ ,/M?^J,_P#ET_\ W'1_P^U_ZHS_ .73_P#<=?E]11]0
MP_\ +^+_ ,P]M4[GZ@_\/M?^J,_^73_]QT?\/M?^J,_^73_]QU^7U%'U##_R
M_B_\P]M4[GZ@_P##[7_JC/\ Y=/_ -QT?\/M?^J,_P#ET_\ W'7Y?44?4,/_
M "_B_P#,/;5.Y^H/_#[7_JC/_ET__<=(G_!;?>BM_P *8QD9Q_PE/_W'7Y?T
MR#_41_[H_E4_4</S)<OXO_,?MJEMS]1/^'VO_5&?_+I_^XZ/^'VO_5&?_+I_
M^XZ_+ZBJ^H8?^7\7_F+VU3N?J#_P^U_ZHS_Y=/\ ]QT?\/M?^J,_^73_ /<=
M?E]11]0P_P#+^+_S#VU3N?J#_P /M?\ JC/_ )=/_P!QT?\ #[7_ *HS_P"7
M3_\ <=?E]11]0P_\OXO_ ##VU3N?J#_P^U_ZHS_Y=/\ ]QT?\/M?^J,_^73_
M /<=?E]11]0P_P#+^+_S#VU3N?J#_P /M?\ JC/_ )=/_P!QT?\ #[7_ *HS
M_P"73_\ <=?E]11]0P_\OXO_ ##VU3N?J#_P^U_ZHS_Y=/\ ]QT?\/M?^J,_
M^73_ /<=?E]11]0P_P#+^+_S#VU3N?J#_P /M?\ JC/_ )=/_P!QT?\ #[7_
M *HS_P"73_\ <=?E]11]0P_\OXO_ ##VU3N?J G_  6WWKG_ (4QCDC_ )&G
M_P"XZ7_A]K_U1G_RZ?\ [CK\NX?]7^)_G3ZF.!P[BFX_B_\ ,;K5+[GZ@_\
M#[7_ *HS_P"73_\ <='_  ^U_P"J,_\ ET__ ''7PM^S=^S7XG_:C\;W?A;P
MI?:38:C;63WS2:Q-+%$45E4@&.-SNRX[8Z\U=^&/[*/C;XH>./''A*V;3M$U
MOP=I]SJ.IP:Q+)& D#JCHACC?<^6&,X!'.:AX7"1;36WF_\ ,:JU7U/MS_A]
MK_U1G_RZ?_N.C_A]K_U1G_RZ?_N.OR^HK7ZAA_Y?Q?\ F3[:IW/U!_X?:_\
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M_P#W'1_P^U_ZHS_Y=/\ ]QU^7U%'U##_ ,OXO_,/;5.Y^H/_  ^U_P"J,_\
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M-_\ @'ZMCXFO_P -?_#_ , )X8\,IX?\<>$(];UX#28C->7#12#YGQRH$:@
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M]CCF007P&Z/_ &L $]ZZ+]HW7/AOJ>B_%KX?^-]7L9--L+=3HFF:;X%OK=M
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M7H_[1OC'Q-%XAU#4+70_#>D2:O<VNC1B6_O IP(H$(.6//8\[1CFOG>OH_\
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M^-'Q(\"KXP\.> K[4O#[H\D5P)X(Y)U7J8H7D$DHX_@4Y[9K]1?B)XYL]/\
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MKA@1("Y((''!KXGT']E?XG_#;Q9X%\0^,O ][I7ANYU[3H3=7@C:)_,G3:I
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M_K^K#5.5SX.EADMY&CE1HY%.&1Q@@^XIE?<O[6W[,\/B(_M#_&@^(7@F\/\
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M ,:H]O2_G7WH.278\UHKTK_AF7XQ_P#1)/'G_A,7W_QJC_AF7XQ_]$D\>?\
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MC<K!6'4-@X(Z5)_PS+\8_P#HDGCS_P )B^_^-4?\,R_&/_HDGCS_ ,)B^_\
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M=^W-X&^$?P8\7Z9X*T*R\5^+/%WBZ]UC4[7Q1ICO8&TDE=H@P612S!5C^7.
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M]1110 4444 %>?\ PB_UGCC_ +&:\_\ 08Z] KS_ .$7^L\<?]C->?\ H,=
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MCDA7Y<B(L[R8SG<QYP<5VG]I>.O^A<\/?^#^?_Y"H_M+QU_T+GA[_P '\_\
M\A4 <KJ'[-_A2\_:"TWXP0B>R\46VGR:=<);E1!?(PVJ\RXR71<J&!!P<'(
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M (/Y_P#Y"H ZRBN3_M+QU_T+GA[_ ,'\_P#\A4?VEXZ_Z%SP]_X/Y_\ Y"H
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MJZ?IURE[8>'7>..PM[A%PLA5$#2%3EAO8@$Y X%;?]I>.O\ H7/#W_@_G_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
LB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cvrx-20231231xex10d7001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvrx-20231231xex10d7001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (O DT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLP9@0H5,<CD=ZIRHVZ7:;]';;[Q)2/I"BBBO+.@**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N6\4?%'PGX*U6RTS7=>LM,OKS!@@N)-K,"=H)]!GC)P,UU-?+7[
M4WAC4#JFOQ^'V>[UCQ=HT>E&Q?2I+D$I(=C1S+\L1^<YWG P&[5K2BIRLR9.
MR/>KGXJ>$;/Q=%X7FU^QC\02E52P,H\PLPW*OIN(Y ZFFZ=\6/!^K^(;[0K+
MQ#8W.KV0<SVD<F779]_'KM[XSBO!M0O='E^+&@>$K[0KW3K32;FSU#4M2BTV
M5QJNJ+$J0@2JI'EQ\%G)&2 .F:R_AWX?U2?Q7\+_  ^-$OK75_"6IZG<ZW=3
M6ICA$<GF!2LQ&)-Y=3@$^_2MO8QM?R_K^O,CF9],>"_B!X>^(=E=7?AW4X=4
MMK6=K6:2'.$E !*'('(!'YU53XK^$)#8 >(;#-_J+Z1:@S &:\0D/ OJXP>*
MYCX+:7=:;XB^*+7%I+:Q7/B>2:W,B;1+']F@&Y?49!&?8U\[>/O@IXDG^)_Q
M$N+72IY=.\-M_P )EX:>-#B74Y-C.B>I_<,,?]-/>IC3A*33=AN3M<^RM$\1
M:;XCCNI-,O(KV.UN'M)FB;(25#AT/N#UK1KX*\2^%?B+:^&/ YGGNO#^E:II
M-S?W+)9W4[VVL7$YDRR6[!@ZHP"E\KD$5W<ECX@LOCII27;^(_$<UQ+9PRB2
M.XM%AC\@+++%(I,+0$Y9HW ;<3STJG0727<7/Y'U3I_B/2]5TR;4;*^@NK&)
MI%DN(G#(I0D."1_=((/TKG_!7QA\%_$6[:U\.>(;+5;A8O.\J%CN:/.-Z@@;
ME]Q7EG[.'@X>#O@WXRT%=,O+'48=3U598+@/\Y9W,90M]Y2C)RO7/K7B/@:S
M\0-X?\._V4_B+6=4T[P9?:?=P7VE?8_['8VXV^1(J*7<NH0 ECQG-"HQ;DK[
M YO30^\J6OCGQAX;U3PU9Z);ZA;^*)M$D\)JVF+I<UQ),NNM@LTQ4[@_W<%_
ME'S5B_$/4/B,/&.A^;8ZM;^(-.&C++<QBZG%R"8_M+Q>61#&H)<.&#$\GCBA
M4+[,?/;H?8VN^+M+\.:CHUC?W'DW.KW)M+-=I/F2!2V,CIPI/-;5?&MEX>U/
M6OBKX>CUNPU^;Q9#XHOSJ=VRS&SBLGBE6W:-O]6%V% -O(.<UBZ%I7Q>OM4T
M>WU!=:73M2OXO"=R"[ P6UG(LAO2>WG;77?W#"G[!?S"Y_(^XZ*^+M(B\7>*
M/CZL$MGK.D:7J%]J>G:G&YNW=(#$PA=IF(B"$A601C*\<UZ1^RI_PE.OZAXC
MUGQ-<7##2!'X7M$DF+),;4LLMQC."78K\W7BHE1Y5>XU.[M8^BJ***YC0***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]!<O_!?_ -N?1/VB+_GJG_?0H,\1ZR)_WT*^=?\ AAOP?_T,7BG_ ,&CT?\
M##?@\_\ ,Q>*O_!J]'/7_D7W_P# )^JY5_T%2_\ !?\ ]N?17GQ#_EHG_?0H
M^T1?\]$_[Z%?.G_##7@__H8O%7_@U>D_X88\'?\ 0Q^*O_!J]/GK?R+[_P#@
M"^JY7_T%2_\ !?\ ]L?1GVB+_GHG_?0H^T1?\]$_[Z%?.1_87\''_F8_%?\
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M ,32'_@G=\.3_P S%XY_\'[_ /Q-.[["]C@_^?S_ / ?_MCZ>^TP_P#/5/\
MOH4?:H?^>T?_ 'T*^8/^'=GPY_Z&/QS_ .% _P#\32'_ ()U_#D_\S'XZ_\
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M1_P[@^&W_0R^//\ PH7_ /B*>@O9X;_GX_\ P'_@GU-]IA_YZI_WT*/M,/\
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M;\#Z_P#M4'_/:/\ [Z%'VN#_ )[1_P#?0KX__P"'8GP]_P"AO\<_^#R2@_\
M!,/X>G_F;_'/_@\DI\L/YOP%RP_F_ ^O_M<'_/:/_OL4?:X/^>T?_?8KX_\
M^'87P\_Z&_QS_P"#R2C_ (=@_#S_ *&_QS_X/)*.6'\WX"M'N?8'VN#_ )[1
M_P#?8H^UP?\ /:/_ +[%?'__  [!^'G_ $-_CG_P>24A_P""7_P\/_,W^.?_
M  >24^6G_-^ K1[GV#]K@_Y[1_\ ?8I1=0GI-&?^!"OCS_AU]\//^AO\<_\
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MDD5V=(YLA05PO')ZT[XC_$W4_#7Q!T3P]'=6&@6%];F:/5M5C9H+F<.!]F#
M@(VWG)//:NF\5?#F/QAK.EW%_JETVF6%S'>KI:JHCDGC^XY;&[ /.T'!(J+X
MD?#0?$G3IM,N]7N;72;J+R;NRCBC=95SG(+*2C?[0YH Y#X=_%75?&'Q/\3:
M+=ZC96]OI6HS6<>G164ADD1$4AS-G:#ENGM7LM<QX(\ V7@3^V!93S3+J=\U
M\ZS'.QBJKM7VPHZUT] !1110 4444 %%%% !1110 445YO\ '+5])TOPY:)J
M+:K<7ES.8M/TO1KAH;B^G*G" J1P.6))  &30!Z12!LD\$8KYQ\7P>)O"_@_
MP'?ZKK,TVKV,UC#J=_::D=Z;YE4J(!\L^X,%9CZ$@4O[0_B359?%0MM#U*54
MTS0[C4IDBOS:I RR +,I'^N9=KCRCQZ]: /HW-&>>E?(/B[Q;X_\':]::U:7
M5QJMSJM_+/9SK>!H9-.-FTBQ&SZH\9 8MCKWYQ7=_ C6K\>.=.LUUN\UNRU3
MPE;ZQ?&YG,RQ7K2X++G[FX%OD''R=* /H,<TM?)OB[Q+K7@6T\=:?X@U*_D\
M1W^G:G=Z-KMAJ!:TGB12RQ&(']Q)$N.<<XSGM7N_P:TF[TOP;;&]M&M)YTCE
M._4I+TOE%^;=)R,^@XH [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN:^'OQ!T?XG^&
M8]>T*2673GGGMU::,QMOBE:)^#_M(?K72T %%%% !1110 4444 %%%% !111
M0 5Y9\3?&/P_;Q'9:#XILO[1NK4QS&4VYDCL/.;RXV=Q]S><J*]3KYV^,7P?
M\3>*OB+=ZS8V<5SYL=D--U(7/EKIODR;Y?.A_P"6^>J]>>..M ';ZPG@3P_K
MRV,?AMM0U?1;)+N*&QM3-)#&SL$QSC=D,1GT)K#M]6^$C^%?!;/917]AJMVT
M&E&YMWED,TLK%PY/(S('SN.,BHO#GAG6]3\">)=<UCP[<ZCK/BB],UQI:7GV
M.>*U3]W!&'R-I"*&(R.7:F?\*C\21_#;X=Z(RVTUWHGB&VU&=%<!8+5'E(C#
M8&]D5U7/\1!- ':>(-5\(>#?&'F-HIN?$MS9//\ Z#:>;,T*LJ8XZ;B0!TS@
M^E8&B_$WX?\ @_2&OM&T::QN;VXG2YTZSL<7<;P<S&1!R @.3V^88ZUEBT\=
M7=KX\\7Z/I/E^)=0NX]+TJWN]J-#80OM,H#'!8[I) #@'Y<UDZ;\-/$?AU-)
MUC1O#EU-?QVNH:?>6VK7\+7%Q)=,CF\>1?E/SIRHP<'@<4 =9=:S\-[77(O,
M\.AH->1(#K'V'=:3>>NY8S)T&\=<#&>#71^ _B[X9\;:DVD:*9T,4!EMC+ 8
MXKB!'\LR0D_>4,-M>7:;\-_&.GZSX=T34]*N=4\.>'(+>+2I+2ZB2V-R(\-=
M7$;$.^QB=J#@ 9Y)JU\#/@]XD\#>-([^_LXK&.'3Y;34;K[2)AJ=PTOF"6%/
M^6"9+$KQ][&.,T ?0=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX:\/6/[=OBFZM-.L8-2_X0FS8R0HJR FZD5C@=RJH"?0"@1](T444#"BBB@
MHHHH **** "BFNZQJ68A5')). *4$$ @Y!H 6BBB@!JR([,JL&9>& /(^M.K
MQ+X&NS?&+XY LS :Y9@ DD#_ $*/IZ5[;0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%<9J?P\O-1U"XND\9>(K))7+BW
MMIXA''[*#&3C\: .SHK@_P#A5]]_T/?BC_P(A_\ C54O#EGJ7AKXIC1IO$6J
M:U87&C/=^7J31OLD6=$!4JBD<,>* /2:*** / _@LQ;]I?X]Y).+G20,]O\
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MQ_$3XA*#R<^(9#_,5[E10!XE_P ,N6O_ $4;X@_^#]_\*KW7[*D<Q7ROB?\
M$.WQUVZZQS^:U[K10!\N_$G]A^;QUX.OM$A^+WCR!KDI\U[J9N(6 8$J\8VE
M@?J*L>%OV1O&?@[PWI^E:7\?_&T*6D"PJLJ6\\8P.P="V/0%CCUKZ:HH ^=8
M?A5^T'X<*G3/C-I'B"-&R(/$'AQ5+#T:2%P?R%33>.?VB/!VXZG\.O"_C>V1
MAF7PYK#V<S#VBG4C_P >%?0E% 'Q=\%_VE-/\*_$[XMW7C?PKXC\'2W^K6TL
MBS6#7<5H5M8UV2RP!E!(&X=L$&OIOP9\:_ 7Q"8)X<\7:1JTQ_Y8072^:/JA
M(8?E7#? T!OC%\= 1D'7+3@_]>4==-\1/V<?AM\5 '\1^$=/NKM3N2^@3[/=
M(?431E7!_&@#TFBO 6_9^\<?#VTW?#/XHZI!'$,QZ)XO U2R;'1!(<31CMPQ
MQZ5EI^TSXU^%B;/C-\.+O1[)3@^)O"A;4]-/NZ*/-B'U4XH ^DJ*YSP-\1O#
M'Q,T6+5O"VNV.NZ?( 1-93!]N>S#JI]B :Z.@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KA9O\ DN-I_P!BY-_Z4Q5W5<+-_P E
MQM/^Q<F_]*8J .ZHHHH \-^"?_)?/CU_V%-,_P#2".O<J\+^"$@?X^_'P#^'
M5=,!_P# ".N@O?%?CS7?'?B71_#2^'K>PT4V\;2:H)VEE:2+S"1LX &<4"/5
M**^?3\2OBN/A$?'GE>$/LXT[^T/L>VZW8QG;NSU]ZTM6\8_%G2M5\+61_P"$
M/D;7I'C1PET!%MB,G///3% 'N%%>-Z5X@^+6J>)];T</X.C?2Q 6E,=T0_F(
M6X&>,8K%3XB_%=_AX_BSR_" A5BOV;;=;CB;R^N?QH"Y/^Q3_P D%M/^POJW
M_I?/7N]?&G[,OB/XCZ%\)?#%KI?_  C#VFJZ_J=JANDN/,C?[5<.S':<$94X
M]B*]@L?%/Q9O?'&J>&P?!RRV%G!=M/LNL.)6<!<9[;/UH&>UT5\]Q?$[XKR^
M =:\4>3X0$6F7%S UOBZRYBE,9(.>,XS6OXD\6_%GPX?#H?_ (0^?^V=0BL$
MVI=#RBZ,VX\\XV]/>@5SVVBO-_!GBOQ=_P +"OO"_BF/1I&32X]2@N-)$H&#
M*T95A)_NYR*H+XF^(GB3Q+XFM] _X1JVTS2KW[''_:*SM,Y$:.6.PX'+?I0!
MZO17SY:?$SXKW?PQM/&0B\(+!<&,"U*W.Y=\XA^]GL3FM[4?$/Q:T_Q5H^B%
M_!SR:C%<2K*([H!/*V9!&><[_P!* N>RT5XII'BKXLZO?^);53X/B.B7 @=B
MET?-S$LF1SQ]['X5DW/Q)^*]M\*(?'!B\(&"2SBN_L>VZW .5&W=GMNH"Y]
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M&3]6B)'?%?1U)UH YOP%\2?"_P 4-#35_"NN66N:>QP9;24,4;^ZZ]4;_98
MUTM>(^._V8-*N]?N?&'P_P!1F^'7CQQN;4=*4?9;YAR%N[;[DJD]3@,.QK/\
M&_M&:GX3U[3_  9\9]*@\(>)[K,=GK=LQ;1=4/;RIF_U4A_YY/@^A- 'OU%(
M&# $$$'D$4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH *BN;J&S@>:XE2"%!EI)&"JOU)Z5+7F&O>'M/\
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MWIGC.#5O&6L^'X()"^E0PR3W.1LWR9(C'N ,GZB@#S+X&?\ )8_CG_V'+/\
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M5K&P'(.WR\@\@DU'X5_;<^$WC?QSI'@RQU:]77M88QVEG>:;-#YQ )/+*!C
M->@>+?@AX.\8N)KK2([2^619DOM/)MYED4Y5]R8R0<$;@>E:)J2NC:+4E>+N
MCP'X97NH?#_QC\2?"GAXQ#Q!J.OZ?IMI-*F](BMA&UQ<,.^U0[8[L5'>O<;G
MPQX[\*R"]T;Q'_PE2$@SZ9KBI'O]3#+&HV'V8$>]>6_LZ^!9;/X__&+4M1UB
MXUJ;3[^VM+9[M%#C?:Q,[DJ "Q"HN<=%]Z]NT;XM>"_$/BV]\+:7XITG4/$E
MEN^TZ5;W:/<0[3AMR Y&,C/UIE">$_B5IOB:_FTF>&?1/$,"[IM(U$!)@O\
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M)!7) 7KCO\M=_P!?K4ZD7*5THW:TWL>N\VQ-&M"4Y<T5&[5UJ[/_ (!^I_\
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M/]LT ?0E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->I_9E_YXC_OBOG5O!>HW^@?#6%M>;1HM/\ MD=WJT$ZQMRV %.?XC6S\-/
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M]K>)$HTVUC=( RYS(2!G<01V[5WN>0,CFBAXBHURMZ?\&X/%U91Y&]/\W?\
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M1T;/_/JF*V*UE4BFTH+3U_S.F=6$9.*IJR_Q?YG%?\)!XZ'_ #)^GG_N+_\
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MDF>20B/"JD:LQ/![=J] '[2?@%[F2U74=0-RB"1H1HM[O522 Q'D]"0>?8T
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MR0RC!!ZY'%>F_#B]^'<_B=$\-:/>66J>4Y$LUG<Q+LXW#=(-M0!2_L7X^?\
M0R^!/_!7=?\ QVJ&N>&OVAK[3I(;3QOX'TF=B-MW'HT\A3G^Z\F#FO=JY[QX
MWA]?#=P?$YC&CY7S3,6"YS\OW>>M SP/_A77[3W_ $6?P?\ ^$S_ /;*K?#3
MPY\>K'Q'XSMY/&G@W5=02[@-S>SZ/-&')A7:%5),  <5V?F? W_GIIW_ 'W-
M_C6M\"F\.MKGCL^%C"=(^WP;# 6*[O(7=][F@"K_ &+\?/\ H9? G_@KNO\
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M  )S@>F*]0KQ[Q<OPH?Q-?MK$/EZOOQ=&&"Z7>^!RQC7:QQCGF@#<\CXK?\
M/YX3_P# >Y_^*KY6_;2M?&5CX_\ @9?>);_1K^Q?Q$]M'I]G:2($E:!OWV]G
M)) X Q7LK7/@*T\?^ U\(S7$-_-JK1RKBZ421?9Y25/F#:1P#BN#_P""@_\
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M]5KWCP'X7^(<O[1%UXAU[PM;:7H;1LK7]O<1'S76/8&VJV[#$9&1D9YZ5]%
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M!\7:-DC_ *^E->\4""BBB@84444 %%%% !1110 4444 %%%% !1110 4444
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M*%9L#.3V&: .7\<>%-,C\%Z\R^/=6E86$Y"-JL9#?NSQC%>C?#[CP%X=[_\
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MBB@9\^_M?3/'#\)E4X$GCS2U;W&7KZ"KYZ_;!_U?PC_['W2_YO7T+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5P,Z1M\=[)B 9%\.38SV_TF+I7?5R_C#X>Z)XVFM)M32=
M+JUW"&YL[F2WE56QN7>A!*G R#QQ0!T^!Z?I0WW3]*\<^(7PCT/1/ ?B+4+*
M]UN*\M=/GGAD&LW)*NL9*GE^Q KTOPA<277@_19YG:6:2P@=W8Y+,8U))_&@
M#QS]B:!8?@M<E<YD\1:P[9]?MLH_I7>^*/ VJW/BR77-%\8-X;FN;2.UGA:R
MBN%D$;.58;SD'YR.*X7]BO\ Y(K+_P!A_5__ $NEIWCX^!9OC!J4?C95F5-(
MM#:)+YQ5<R3;R G SA>OI0!>\9WGC+X;^'[CQ%)X^MM?%EA_[(GTR&'[;R!Y
M2,AW!SG"XSSCBO9+68W%M%*R&,N@8HW5<C.#7AVCWGP0T/5;;4+*VLHKV!MT
M,SV\\AC;U&X$ ^]>YPS)<0I+&VZ-U#*P[@]* '5Y;J?AS1I]1NI)/B?K%G(T
MC%K>/6H46(Y^Z%*\ >E>I&O'-9F\$)K%ZD_PNO;^=9F\RZCT%'65L\L&/WLG
MO0!S/C'PWX9A\7>"L_$/5)5-W-OE;7UR/W)YX/&:ZW_A'O")'_)2=3_\*$?X
MUP?BB\\&VWB[P;-!\+=0MD%Y*K@:!&#(3"V .>?6NXCU;PK*NY/A9J6W_:T2
M('^= CTSPO!9VVAVL=AJ#ZI:J"$NY+CSVDYZE^]:;C*,,[>.H[5D^$Y;:;0;
M9K/2Y-&MR#MLI81$T?/=1P*UI,;&R-PQR/6@9Y#+X4TQI7)^,>O(2Q.P:O:
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M,AMD>)T!@QNRR@5W?AK]M76/C/\ $WP%HMOX#C@G&I27$2Q:J"TFVWDX^9%
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M_A,;CX7>)=*:T\:V5S&MU):DW+*DN(DVRGYCDXS@<'FO;C\=?%W_ $1?Q?\
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M=^)DE8M\1KB'<20K6Q&!GI_K:XF]\"^(!\7=*A_X6%*93HMRPF\CD#SHN/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%M"""(D!'<**'NX8_*W3(OFG$>6'SG&<#UXI?M$0G$/F)YQ7>(]PW%>F<>E
M$E%0?;K;RYG\^+9"2)6WC"$<G<>V/>AKVW1(7:>(+,0L1+C$A(R OKGVH GH
MJ)[J%+A(&E19W!98RPW,!U('4XR*(KF*<R".5)&C;:X5@2I]#Z&@"6BH(;VW
MN)98HIXI98CB1$<%D/H0.GXU/0 4F*6D) &3P* %HJ&VO+>]B,EO/'/&"07B
M<,,CJ,BF'4;06HN3=0BV)QYWF#9G..O3KQ0!9HJ-KF)9TA:1!,X++&6&Y@,9
M('?&1^8I%NH7N'@65&G0!GB# LH/0D=0#@_E0!+14+WEO' 9WGC6$<&0N HY
MQUZ=:<]Q%'+'&\B+))G8A8 MCK@=\4 245&+B)IV@$B&95#&,,-P!Z''I2&Y
MA6=8#*@F8;A&6&XCUQ0!+144MS#!)$DDJ1O*VV-68 N<9P/4XIPE0N4##>.2
MN>10 ^BF"5"I;<NT=3G@4ID4;?F'S=.>M #J*:'4MMR-W7'>CS%()# @'!.>
ME #J2FF5 %)=0&Z'/7Z4N]=^W<-W7&>: '5A>-=/TG5/#]Q;ZW>MI^G,5WSK
M=&V*G/'[P$8Y]ZVO-3#G>N$^\<]/K7G=_P#%7P[X@CGMK?0=6\5Z<&VM/9:4
MUS:NP/0,?E;!'49% &!_P@OPS_Z&V;_PI7_^.5=^".G:1I7B#QY;Z)>MJ%@+
MZW*SM=FZ)8P+D;R3GZ9XI/[=\*_]$NUC_P )I:T/A%8^7K'C"_@T"Y\/:=>W
MD+6UO=6@MF8+"JLPC'09'7O0(]*HHHH&?/\ ^U/;&Z\5_ ]0=NWQM;O^4$U>
M_P!>!?M/7*Q^-_@;"02TOC*(@]N+>6O?10 M%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<KK^
MA^++[4GETGQ/9Z79%0%MYM*^T,#W._S5Z^F*ZJO)H=&E^)GQ#\60ZMJ&H0:7
MH4T%G9V-A=O;HY:%97EDV$%FRV "< #WH H_%CPYXWB^&OB1[KQE87%NMC(9
M(DT,(77'(#><<?7!KTRV_P"1*B_[!X_]%US-Y\#/#&H6TEM=-JMQ;R#;)%)J
MMPRN/0C?R*['5(DMM NXHQL2.V=5 [ (<4 >$_L"_P#)K/A+_KI>?^E4M?0U
M>"?L+1K'^RWX*VJ%W)<,<=R;B3)KWN@#S?XW:?!I?A:3QC;1"'6O#I%[#=1@
M!S&&'G1-_>5DW @]\'J*A^+<XNQ\.IQPLGB6S<?0QRFNF^*'AF[\9?#OQ%H=
M@\4=[?V4D$+3DA Y7C=CG&:\U\2Z+\4_$5OX:C_X1[PY!_8VH07X_P")K*WF
M>6C+M_U7&=W7VH$=K:C_ (OKJA_ZENT_]*KFN3MO^20_$_\ [".L_P#HQZ?%
M:_%2+QS=>(O^$<\.'S]-AT_R/[6DXV2R2;L^5W\S&/:LJ/PO\4H_"/B;1/[!
M\.'^VKB\N/._M27$7GL3C'E<[<_C0(ZWQ(,R_"W_ *_H_P#TE>M&Y_Y+A8?]
M@";_ -'I7':EI7Q2U!_"[?\ "/>'$_L2=9O^0K*?-Q$T>/\ 5<?>S^%6)+7X
MIR>-K?Q"?#GAP&+3WL?(_M:7G=(K[L^5_LXQ0,2,?\4'\8/^OR__ /1"TNOC
M_BE?@W_V%M/_ /2:2LM?#/Q2&@^+]-_L'PY_Q4$UQ+YG]JR_N?-C"8QY7.,9
MHO\ PS\4[[2O!UG_ &#X<3_A'KNWNM_]J2GSO*B9,?ZKC.[/X4 =CXC'_%^?
M!I_ZA.H?^A0U8^%__(Q?$'_L.G_T1%7*:CIGQ3O_ !WH_B0^'O#B?V=:7%K]
MG_M64[_-*'.?*XQL_6I/#%C\4_#FH>(+H>'?#DQU:^-[M_M:4>7^[1-O^JY^
M[G/O0!R/AO0;7PYH&I>.M.1[;6[/Q;=17,T<A'VRV>^\IXI >& 5\KGE2HQ7
MTJ*\/O\ PMJWA3X'ZO!K8M4U*[UI;^2*SD+QQ^=J$;A0Q )P"!G%>XT#"O/?
MBLD^N7OAGPJDTUM9ZW=R+?26\AC=K>*)I'C##D;L ''.,UZ%7"^,?^2F?#[_
M *Z7_P#Z3&@#*^'/AS3?"7CSQWI6CVB:?IJ0Z?,MK"2(U=HY0S =B0BY]<5P
M]TH_X98M!_T^1_\ IQKM=4D\4^%OB)XCU#3?"<NOZ?JEM9K'/#>Q0E&B$@8%
M7.?XQ7GLVE?$23X.P^$!\/Y?MJ3+*9_[5M_+XNO.QUS]WCZT"/5/$7_);?!7
M_8)U7_T.TJIX<'_&0'C7_L#:;_Z'<5S^J:QX[OOB!H&OI\.;E;?3K*\MI(CJ
MMON8S- 5(YZ#RFS]14&E:CX]L/B7K_B1_AU<-:ZC86EI'$NJV^]6B:4L3SC!
M\P8^AH&58&+_ +,ET68L?M)Y)R?^/X5W_B[_ )*=\/\ Z7__ *)2O+8;#XAI
M\(YO"9^'TOVQY3()AJMOY?\ Q\B7'7/3CZUTVMZSX[U3Q;X:U9/AS<I#I?VG
MS(VU6WW/YB*HQSV(YH ZS3/^2VZY_P!@.T_]'35Y9X@\/P:AX#\0>.V>2/Q=
M!K,C6VJ*S;[=([D1I$HSC9L&"O0Y.:Z>TUKQW;_$#4=?;X<W)M[G3X+-8AJM
MON#(\C$GGIAQ4A\#^)M0^!^IZ5_9T-IKU[>2W:V$UP"JAKGS AD7(SM[CO0(
MV?B23)XR^%S-RQU:0G'K]EEJ]I#EOC7XA 8E5TFTR,\ EY*XWQ4_Q$UK7O"%
MXO@6$)HMZ]S+LU:,[U,+H N0.<L*L:;?_$&R\=ZUKC> E:"^M;>!(QJT6Y3&
M7R3Q_M4 5],GE_X4I\47,KETO-;VL6.5P7Q@]L5NZQ-(-*^$V)'&^^M0WS'Y
MO]$DZ^M<7::9\1K;X?\ C+0#X&C,^M3ZC+#(-5BVH+C=MSQVSS6E??\ "PKJ
MT\$PCP(@.AW,,TQ_M6+YPD#QD+QZM0!W6E.Q^-'B%"[%!HUD0N> ?-GYQ67X
M?D<^'?B>3(Y*:K?A3N/R_P"CQ]/2L>RU#X@VWC[5->/@)3!=:?;VBQC5HMP:
M-Y&)/'3YQ^54],?XAV.E^,+5O :,VLWMS<PD:M%A5DB5%!XZY4T 6M:FD_X0
M;X.'S'R]_I>\[CEOW&>?6NAL)7/[0NKQEV,8\.VS!,\ _:).<5P>H6WQ#G\/
M> ]._P"$ 9I/#]S9SS.FJP8D6&/8P7/<GI6E;:CX]A^*%[XG/PZN#:W&E16
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M(3_\12_\,J+_ -%6^)?_ (4)_P#B* /=:*\);]E,%2!\6/B6I(X/_"0$X_\
M'*@_X9-F_P"BQ?$W_P 'H_\ C= CWVBO O\ ADV;_HL7Q-_\'H_^-U)'^RK<
MQKM'Q@^)1'OK2D_^BZ />:*\(_X99N?^BP?$G_P<K_\ &Z4?LLW((/\ PM_X
MD<?]1E?_ (W0![M17@#?LJZN6)'QM^(X!/ _M*+C_P ATG_#*FK_ /1;?B/_
M .#&+_XW0&I] 45X%'^R[KL"D1?&[XA@DYR]["_\XJ=_PS)XD_Z+E\0/_ BW
M_P#C5 SWNBO!/^&9/$G_ $7+X@?^!%O_ /&J1_V:?%Y;]W\>/'D:=ES:G]3%
M0![Y17@/_#-/C'_HO?CS\K3_ .-5)!^S?XSMY-Z?'KQPS8QB1+-A^1AH 7]H
MBU2[^+'P'5\X3Q--(,>HM)"*]YKY:\6?L?>+?$WCSP3XAOOC#KVMIX<O3=QV
M^I0PH$8X!=/)5/FV@K\V1AJ^I ,"@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZIIEIK6G
MW%C?6\=W9W"&.6"5=RNIZ@BK5% 'F%II7B_X7H\.F(WC/PTAS#:3S[=1M%_Y
MYH[?+,@[!B&'3)JS%\;],C8)J&A>(M+D.1MGTN1AD=1E 17HU% ' ?\ "[?#
MG_/+5_\ P57'_P 11_PNWPY_SRU?_P %5Q_\17?T4 <!_P +M\.?\\M7_P#!
M5<?_ !%4]0_:!\+Z;L\RVUU]^<>5HUR_YX2O2Z* //4^.?AEX5E,6L(A&?FT
MFX!'U&RD_P"%[^%/[VJ?^"JY_P#B*]#I,4 >>_\ "]_"G][5/_!5<_\ Q%'_
M  O?PI_>U3_P57/_ ,17H6*,4 >>_P#"]_"G][5/_!5<_P#Q%'_"]_"G][5/
M_!3<_P#Q%>A8HQ0!P8^.'A$@'[9=#/8V$^?_ $"J<WQUT>[#PZ!I>L^([X-L
M%O:6$D8S[O(%4#WS7I&T>@H  Z#'TH X3PAX1U6\\23>+?%2VZZPT7V>QL+=
MS)'IT!Y8!SC=(YQN8 #@ <5WE%% !6?K^A67B;1KS2M2@6YL;N,Q2Q-T93_(
M^AK0HH \ML-=\3?"RVATW7K"]\5Z/%\EOKFG1>9<+'V%Q".2P&!O3(.,D UI
MQ_'+PDX.ZYO8F!P5DTZX4C\-E=_2;03T% '"?\+O\(_\_MU_X 3_ /Q%'_"[
M_"/_ #^W7_@!/_\ $5W>T>@HVCT% '"?\+O\(_\ /[=?^ $__P 11_PN_P (
M_P#/[<_^ $__ ,17=[1Z"C:/0?E0!Q(^-'@X@'^U\>QMY<_^@TO_  N?P=_T
M%Q_WXE_^)KL_)C_N+^5'DQ_\\U_*@#C/^%S^#O\ H+C_ +\2_P#Q-'_"Y_!W
M_07'_?B7_P")KL_)C_YYK^5'DQ_\\U_*@#BC\:O!H<)_; W$9 \B7_XFG?\
M"Y_!W_07'_?B7_XFNR\B/_GFO_?(I?)C_P">:_E0!QR_&3P8PR=?MT/HZNI'
MX$4O_"X_!?\ T,-K_P"/?X5UQMH2<F)"?]T4?98/^>,?_?(H Y'_ (7'X+_Z
M&&U_\>_PH_X7'X+_ .AAM?\ Q[_"NN^RP?\ /&/_ +Y%'V6#_GC'_P!\B@#D
M?^%Q^"_^AAM?_'O\*/\ A<?@O_H8;7_Q[_"NN^RP?\\8_P#OD4?98/\ GC'_
M -\B@#C_ /A='@@$@^)K!2.H:0@_RH_X71X'_P"AGT[_ +^UUQLK<GF"(_\
M !1]AMO^?>+_ +X% '(_\+H\#_\ 0SZ=_P!_:/\ A='@?_H9]._[^UUWV&V_
MY]XO^^!1]AMO^?>+_O@4 <C_ ,+H\#_]#/IW_?VG)\9?!$CJB^)M/9F(  EZ
MG\JZS[#;?\^\7_? H^PVP_Y=XO\ O@4 3*0P!'(/(I:** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **Y3X=?%+PQ\6-*N]2\*ZG_ &K96EPM
MK-+]GEAVR-#%.%Q(JD_NYXFR!CYL=00.KHW2ET:37FFKIKR:::?5.X!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>cvrx-20231231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/8/2024 8:15:01 PM-->
<!--Modified on: 2/8/2024 8:15:01 PM-->
<xsd:schema targetNamespace="http://www.cvrx.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cvrx="http://www.cvrx.com/20231231" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails">
        <link:definition>40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails">
        <link:definition>40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" id="DisclosureDebtMaturitiesOfDebtDetails">
        <link:definition>40402 - Disclosure - Debt (Maturities of debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesDetail" id="DisclosureLeasesDetail">
        <link:definition>40501 - Disclosure - Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" id="DisclosureLeasesMaturitiesOfLeaseLiabilityDetails">
        <link:definition>40502 - Disclosure - Leases (Maturities of lease liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" id="DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2">
        <link:definition>40502 - Disclosure - Leases (Maturities of lease liability) (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" id="DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails">
        <link:definition>40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureBusinessOrganization" id="DisclosureBusinessOrganization">
        <link:definition>10101 - Disclosure - Business Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" id="DisclosureSelectedBalanceSheetInformation">
        <link:definition>10301 - Disclosure - Selected Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10401 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10701 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShare" id="DisclosureLossPerShare">
        <link:definition>10901 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11101 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregation">
        <link:definition>11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" id="DisclosureSelectedBalanceSheetInformationTables">
        <link:definition>30303 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>30403 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShareTables" id="DisclosureLossPerShareTables">
        <link:definition>30903 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables">
        <link:definition>31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" id="DisclosureSelectedBalanceSheetInformationNarrativeDetails">
        <link:definition>40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" id="DisclosureDebtNarrativeDetails">
        <link:definition>40401 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40501 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>40601 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" id="DisclosureStockBasedCompensationNarrativeDetails">
        <link:definition>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" id="DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails">
        <link:definition>40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails">
        <link:definition>40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>40801 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>40901 - Disclosure - Loss Per Share (Basic and Diluted Net Loss per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>40902 - Disclosure - Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" id="DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails">
        <link:definition>41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10501 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30503 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvrx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element name="BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" id="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="JobsActAccountingElectionPolicyTextBlock" id="cvrx_JobsActAccountingElectionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LabEquipmentMember" id="cvrx_LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ComputerEquipmentAndSoftwareMember" id="cvrx_ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClinicalTrialAndOtherProfessionalFees" id="cvrx_ClinicalTrialAndOtherProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedPaidTimeOff" id="cvrx_AccruedPaidTimeOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoanAndSecurityAgreementMember" id="cvrx_LoanAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" id="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OtherCountriesMember" id="cvrx_OtherCountriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandOneStockIncentiveAwardPlanMember" id="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonOfficerEmployeesMember" id="cvrx_NonOfficerEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficerEmployeesMember" id="cvrx_OfficerEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlanMember" id="cvrx_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TwoThousandTwentyOneEquityPlanMember" id="cvrx_TwoThousandTwentyOneEquityPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsToPurchaseCommonStockMember" id="cvrx_WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" id="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" id="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" id="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DeferredTaxAssetsStartUpCosts" id="cvrx_DeferredTaxAssetsStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" id="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" id="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedLiabilitiesCustomerRebateCurrent" id="cvrx_AccruedLiabilitiesCustomerRebateCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" id="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfficeSpaceInMinneapolisMinnesotaMember" id="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseAreaOfLandLeased" id="cvrx_LesseeOperatingLeaseAreaOfLandLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OperatingLeaseRightOfUseAssetAbstract" id="cvrx_OperatingLeaseRightOfUseAssetAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementOtherOptionsMember" id="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnrecognizedTaxBenefitsSubjectedToValuationAllowance" id="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LineOfCreditDrawDownPeriodThreeMember" id="cvrx_LineOfCreditDrawDownPeriodThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentOfRevenueTarget" id="cvrx_PercentOfRevenueTarget" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueTreeMonthsTrailing" id="cvrx_RevenueTreeMonthsTrailing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" id="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TrancheOneMember" id="cvrx_TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TrancheTwoMember" id="cvrx_TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseAreaOfAdditionalLandLeased" id="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LesseeOperatingLeaseAdditionalRenewalTerm" id="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmployersOfCertainNonEmployeeDirectorsMember" id="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" id="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>cvrx-20231231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/8/2024 8:15:01 PM-->
<!--Modified on: 2/8/2024 8:15:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureDebtMaturitiesOfDebtDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesDetail" roleURI="http://www.cvrx.com/role/DisclosureLeasesDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638430201003819582" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638430201003819582" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638430201003819582" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638430201003819582" xlink:to="us-gaap_AccountsReceivableNetCurrent_638430201003819582" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638430201003819582" xlink:to="us-gaap_InventoryNet_638430201003819582" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638430201003819582" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638430201003819582" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638430201003819582" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638430201003819582" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638430201003819582" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638430201003829561" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638430201003829561" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638430201003829561" xlink:to="us-gaap_LiabilitiesCurrent_638430201003829561" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638430201003829561" xlink:to="us-gaap_AccountsPayableCurrent_638430201003829561" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638430201003829561" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638430201003829561" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638430201003829561" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201003829561" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638430201003829561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638430201003829561" xlink:to="us-gaap_LongTermDebtNoncurrent_638430201003829561" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638430201003829561" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638430201003839552" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638430201003839552" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638430201003839552" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638430201003839552" xlink:to="us-gaap_CommonStockValue_638430201003839552" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638430201003839552" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638430201003839552" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638430201003839552" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638430201003839552" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638430201003839552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638430201003839552" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638430201003839552" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638430201003849549" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638430201003849549" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638430201003849549" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638430201003849549" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201003849549" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201003849549" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638430201003849549" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201003849549" xlink:to="us-gaap_OperatingIncomeLoss_638430201003849549" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638430201003849549" xlink:to="us-gaap_GrossProfit_638430201003849549" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638430201003849549" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638430201003849549" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638430201003849549" xlink:to="us-gaap_CostOfRevenue_638430201003849549" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638430201003849549" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638430201003849549" xlink:to="us-gaap_OperatingExpenses_638430201003849549" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638430201003849549" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638430201003859555" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638430201003849549" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638430201003859555" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201003849549" xlink:to="us-gaap_InterestExpense_638430201003859555" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638430201003859555" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201003859555" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201003859555" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638430201003859555" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638430201003859555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201003859555" xlink:to="us-gaap_ProceedsFromStockPlans_638430201003859555" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201003859555" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638430201003869555" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201003859555" xlink:to="us-gaap_PaymentsOfFinancingCosts_638430201003869555" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638430201003869555" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638430201003869555" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638430201003869555" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_ShareBasedCompensation_638430201003869555" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_Depreciation_638430201003869555" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638430201003869555" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638430201003869555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638430201003869555" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638430201003879551" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_IncreaseDecreaseInInventories_638430201003879551" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638430201003879551" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638430201003879551" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_ProfitLoss_638430201003879551" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201003869555" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638430201003879551" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201003879551" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201003879551" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryRawMaterials_638430201003889550" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryWorkInProcess_638430201003889550" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet_1" xlink:to="us-gaap_InventoryFinishedGoods_638430201003889550" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638430201003889550" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638430201003889550" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedBonusesCurrent_638430201003889550" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff_638430201003889550" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_AccruedPaidTimeOff_638430201003889550" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638430201003899555" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_638430201003899555" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638430201003899555" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638430201003899555" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638430201003899555" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Debt (Maturities of debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_1" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638430201003899555" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_1" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638430201003899555" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638430201003899555" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_638430201003899555" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638430201003899555" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount_638430201003899555" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638430201003909557" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesDetail" xlink:type="extended" xlink:title="40501 - Disclosure - Leases (Detail)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201003909557" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638430201003909557" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Leases (Maturities of lease liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638430201003909557" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638430201003909557" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638430201003909557" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638430201003909557" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638430201003909557" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638430201003909557" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2" xlink:type="extended" xlink:title="40502 - Disclosure - Leases (Maturities of lease liability) (Details) Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638430201003919556" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638430201003919556" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638430201003919556" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638430201003919556" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638430201003919556" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638430201003919556" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638430201003919556" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638430201003919556" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638430201003919556" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_638430201003919556" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638430201003919556" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_638430201003919556" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638430201003929554" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638430201003929554" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638430201003929554" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638430201003929554" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638430201003929554" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638430201003929554" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638430201003929554" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638430201003929554" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638430201003929554" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638430201003929554" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="us-gaap_DeferredTaxAssetsOther_638430201003939552" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638430201003939552" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638430201003939552" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638430201003939552" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638430201003939552" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_638430201003939552" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638430201003939552" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638430201003939552" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638430201003929554" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638430201003939552" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>cvrx-20231231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/8/2024 8:15:01 PM-->
<!--Modified on: 2/8/2024 8:15:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="cvrx-20231231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentInLeaseNoncurrent" xlink:label="us-gaap_NetInvestmentInLeaseNoncurrent" xlink:title="us-gaap_NetInvestmentInLeaseNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_NetInvestmentInLeaseNoncurrent" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_AssetsAbstract To us-gaap_NetInvestmentInLeaseNoncurrent" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2" xlink:title="us-gaap_AccruedLiabilitiesCurrent_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To us-gaap_AccruedLiabilitiesCurrent_2" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis_1" xlink:title="dei_DocumentInformationDocumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_1" xlink:title="dei_DocumentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_DocumentInformationDocumentAxis_1" xlink:to="dei_DocumentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_DocumentInformationDocumentAxis_1 To dei_DocumentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" xlink:title="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_1 To srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cvrx_LabEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetUnderConstructionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="cvrx_LoanAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TrancheOneMember" xlink:label="cvrx_TrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_TrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TrancheTwoMember" xlink:label="cvrx_TrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_TrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="cvrx_LineOfCreditDrawDownPeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_RevenueTreeMonthsTrailing" xlink:label="cvrx_RevenueTreeMonthsTrailing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_RevenueTreeMonthsTrailing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PercentOfRevenueTarget" xlink:label="cvrx_PercentOfRevenueTarget" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_PercentOfRevenueTarget" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" xlink:label="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cvrx_LesseeOperatingLeaseAreaOfLandLeased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" xlink:label="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cvrx_OperatingLeaseRightOfUseAssetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvrx_NonOfficerEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvrx_OfficerEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="cvrx_EmployeeStockPurchasePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="cvrx_OtherCountriesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>cvrx-20231231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/8/2024 8:15:01 PM-->
<!--Modified on: 2/8/2024 8:15:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net of allowances of $508 and $679, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability, non-current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 10)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2023 and 2022; 20,879,199 and 20,663,736 shares issued and outstanding as of December 31, 2023 and 2022, respectively, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Comprehensive Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares used to compute net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares used to compute net loss per share, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated and other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Ending (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances, Beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued/purchased under ESPP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Employee Stock Purchase Plan (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs and loan discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Long-Term Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from debt financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of currency exchange on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Organization [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business organization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected Balance Sheet Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selected balance sheet information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plans [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, Geographic Information and Revenue Disaggregation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment, geographic information and revenue disaggregation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:to="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation And Consolidation Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement presentation and basis of consolidation</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:to="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy pertaining to JOBS Act accounting election.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JOBS Act Accounting Election [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">JOBS Act accounting election</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Annual Principal Maturities of Debt</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xlink:to="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of lease balances within the balance sheets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Lease Balances within Balance Sheets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of lease balances within the balance sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturities of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EmployeeStockPurchasePlanMember" xlink:to="cvrx_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESSP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Provision for Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of Taxes at the Federal Statutory Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Net Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes to Gross Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work-in-process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office furniture and equipment</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LabEquipmentMember" xlink:to="cvrx_LabEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LabEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab equipment</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ComputerEquipmentAndSoftwareMember" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to computer equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital equipment in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial and Other Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial and other professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonuses</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_AccruedPaidTimeOff" xlink:to="cvrx_AccruedPaidTimeOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of paid time off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Paid Time Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_AccruedPaidTimeOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid time off</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liability relating customer rebate classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Customer Rebate Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability, current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LoanAndSecurityAgreementMember" xlink:to="cvrx_LoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to loan and security agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan and Security Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TrancheOneMember" xlink:label="cvrx_TrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TrancheOneMember" xlink:to="cvrx_TrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Tranche 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche One</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TrancheTwoMember" xlink:label="cvrx_TrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TrancheTwoMember" xlink:to="cvrx_TrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Tranche 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:to="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the third draw down period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line Of Credit Draw Down Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Draw down from September 1, 2024 to December 15, 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate ( as a percent)</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_RevenueTreeMonthsTrailing" xlink:label="cvrx_RevenueTreeMonthsTrailing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_RevenueTreeMonthsTrailing" xlink:to="cvrx_RevenueTreeMonthsTrailing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_RevenueTreeMonthsTrailing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of three months of trailing revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_RevenueTreeMonthsTrailing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Tree Months Trailing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_RevenueTreeMonthsTrailing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three months of trailing revenue</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PercentOfRevenueTarget" xlink:label="cvrx_PercentOfRevenueTarget" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PercentOfRevenueTarget" xlink:to="cvrx_PercentOfRevenueTarget_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PercentOfRevenueTarget_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of a revenue target needed to achieved a goal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PercentOfRevenueTarget_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent Of Revenue Target</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PercentOfRevenueTarget_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of trailing twelve months revenue goal</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" xlink:label="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" xlink:to="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of debt payments to be made under the loan agreement that consist of principal plus interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Debt Payments Consisting Of Principal And Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of monthly payments of principal plus interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of final payment on original principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Percentage of Final Payment on Original Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of final payment on original principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs and discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2029</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Unamortized debt costs and discounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of Property [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of Property [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:to="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to office space in Minneapolis, Minnesota.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office space in Minneapolis, Minnesota</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:to="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The area of land leased on operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Area of Land Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of land leased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" xlink:to="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The area of additional land leased on operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Area of Additional Land Leased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional area of land leased</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" xlink:label="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" xlink:to="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Additional Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional renewal term option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:to="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right Of Use Asset [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash outflows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_WarrantsToPurchaseCommonStockMember" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants to purchase common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Warrants Converted To Common Stock Warrants At Initial Public Offering Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xlink:to="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to employers of certain non-employee directors to whom the BOD authorized the grant of stock options for the purchase of shares of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employers of Certain Non Employee Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employers of certain non-employee directors</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Stock incentive plan 2001.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2001 Plan</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to two thousand twenty one equity plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for grant</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based payment award, term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of automatic annual  increase in shares reserved for issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Issuance Automatic Incremental Annual Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual incremental percentage</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Share Price Permitted To be Purchased, Minimum Percentage Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:to="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Other Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options not granted under the 2001 or 2021 Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of End of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of Beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled / Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of June 30, 2023 (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of End of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding as of Beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled / Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of June 30, 2023 (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable as of June 30, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term, outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life, exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_NonOfficerEmployeesMember" xlink:to="cvrx_NonOfficerEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_NonOfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to non officer employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_NonOfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non officer employees</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OfficerEmployeesMember" xlink:to="cvrx_OfficerEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to officer employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OfficerEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officer employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general &amp; administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research &amp; development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:to="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of  unrecognized tax benfits that are subjet to a valuation allowance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Subjected To Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits that are subjected to a valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, income tax penalties and interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits, Income tax penalties and interest accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, federal and state</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Foreign Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes, total current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax at federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development ("R&amp;D") tax credit</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rate change</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D tax credits</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized R&amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-qualified stock options</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_DeferredTaxAssetsStartUpCosts" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Start Up Costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Start-up costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued vacation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrecognized tax benefits at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross unrecognized tax benefits at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross increases: Prior year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross increases: Current year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross decreases: Prior year tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Excluded potential common shares from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities accrual amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvrx_OtherCountriesMember" xlink:to="cvrx_OtherCountriesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvrx_OtherCountriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to other countries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvrx_OtherCountriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other countries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>cvrx-20231231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.5.0.8 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/8/2024 8:15:01 PM-->
<!--Modified on: 2/8/2024 8:15:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureBusinessOrganization" roleURI="http://www.cvrx.com/role/DisclosureBusinessOrganization" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformation" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureDebt" roleURI="http://www.cvrx.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeases" roleURI="http://www.cvrx.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockholdersEquity" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLossPerShare" roleURI="http://www.cvrx.com/role/DisclosureLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregation" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSubsequentEvents" roleURI="http://www.cvrx.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationTables" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureDebtTables" roleURI="http://www.cvrx.com/role/DisclosureDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesTables" roleURI="http://www.cvrx.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLossPerShareTables" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureDebtNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureDebtMaturitiesOfDebtDetails" roleURI="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" roleURI="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" roleURI="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvrx-20231231.xsd#DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" roleURI="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.cvrx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638430201004409574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638430201004409574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638430201004409574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638430201004409574" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638430201004409574" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638430201004409574" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638430201004409574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638430201004409574" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638430201004419572" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638430201004419572" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638430201004419572" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638430201004419572" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638430201004419572" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638430201004419572" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638430201004419572" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638430201004419572" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638430201004419572" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638430201004419572" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638430201004419572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638430201004419572" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638430201004429554" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638430201004429554" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638430201004429554" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638430201004429554" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638430201004429554" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638430201004429554" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638430201004429554" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638430201004429554" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638430201004429554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638430201004429554" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638430201004439550" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638430201004439550" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638430201004439550" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638430201004439550" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638430201004439550" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638430201004439550" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638430201004439550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638430201004439550" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638430201004449549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638430201004449549" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638430201004449549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638430201004449549" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638430201004449549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638430201004449549" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638430201004449549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638430201004449549" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638430201004449549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638430201004449549" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638430201004459554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638430201004459554" xlink:to="us-gaap_AssetsCurrentAbstract_638430201004459554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638430201004459554" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638430201004459554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638430201004459554" xlink:to="us-gaap_AccountsReceivableNetCurrent_638430201004459554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638430201004459554" xlink:to="us-gaap_InventoryNet_638430201004459554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638430201004459554" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638430201004459554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638430201004459554" xlink:to="us-gaap_AssetsCurrent_638430201004459554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638430201004459554" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638430201004459554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638430201004459554" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638430201004459554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638430201004459554" xlink:to="us-gaap_OtherAssetsNoncurrent_638430201004459554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638430201004459554" xlink:to="us-gaap_Assets_638430201004459554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638430201004459554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract_638430201004459554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638430201004459554" xlink:to="us-gaap_LiabilitiesAbstract_638430201004459554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638430201004459554" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638430201004469551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638430201004469551" xlink:to="us-gaap_AccountsPayableCurrent_638430201004469551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638430201004469551" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638430201004469551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638430201004469551" xlink:to="us-gaap_LiabilitiesCurrent_638430201004469551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638430201004459554" xlink:to="us-gaap_LongTermDebtNoncurrent_638430201004469551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638430201004459554" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201004469551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638430201004459554" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638430201004469551" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract_638430201004459554" xlink:to="us-gaap_Liabilities_638430201004469551" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638430201004469551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638430201004459554" xlink:to="us-gaap_CommitmentsAndContingencies_638430201004469551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638430201004459554" xlink:to="us-gaap_StockholdersEquityAbstract_638430201004479550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638430201004479550" xlink:to="us-gaap_CommonStockValue_638430201004479550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638430201004479550" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638430201004479550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638430201004479550" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638430201004479550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638430201004479550" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638430201004479550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638430201004479550" xlink:to="us-gaap_StockholdersEquity_638430201004479550" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638430201004479550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638430201004459554" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638430201004479550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_638430201004489554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638430201004489554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_638430201004489554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_638430201004489554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_638430201004489554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638430201004489554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_CostOfRevenue_638430201004489554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GrossProfit_638430201004489554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638430201004489554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638430201004489554" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638430201004489554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638430201004489554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638430201004489554" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638430201004489554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638430201004489554" xlink:to="us-gaap_OperatingExpenses_638430201004499550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638430201004499550" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestExpense_638430201004499550" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638430201004499550" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638430201004499550" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638430201004499550" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638430201004499550" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638430201004499550" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638430201004499550" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638430201004499550" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638430201004499550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638430201004499550" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638430201004509551" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638430201004509551" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638430201004509551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638430201004509551" xlink:to="us-gaap_StatementEquityComponentsAxis_638430201004509551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638430201004509551" xlink:to="us-gaap_CommonStockMember_638430201004509551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638430201004509551" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638430201004509551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638430201004509551" xlink:to="us-gaap_RetainedEarningsMember_638430201004509551" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638430201004509551" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638430201004509551" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638430201004509551" xlink:to="us-gaap_EquityComponentDomain_638430201004509551" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638430201004509551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638430201004509551" xlink:to="us-gaap_StatementLineItems_638430201004509551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638430201004509551" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_StockholdersEquity_638430201004519552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_SharesOutstanding_638430201004519552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638430201004519552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638430201004519552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638430201004519552" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638430201004519552" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638430201004519552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638430201004519552" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_NetIncomeLoss_638430201004519552" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638430201004519552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638430201004519552" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6384302010045195521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_StockholdersEquity_6384302010045195521" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638430201004519552" xlink:to="us-gaap_SharesOutstanding_638430201004529550" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_ProfitLoss_638430201004529550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_ShareBasedCompensation_638430201004529550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_Depreciation_638430201004529550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638430201004529550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638430201004529550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638430201004529550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638430201004539558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" xlink:to="us-gaap_IncreaseDecreaseInInventories_638430201004539558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638430201004539558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638430201004539558" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_638430201004539558" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638430201004539558" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638430201004529550" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638430201004539558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638430201004539558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638430201004539558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638430201004539558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638430201004549553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_ProceedsFromStockPlans_638430201004549553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638430201004549553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_PaymentsOfFinancingCosts_638430201004549553" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638430201004539558" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638430201004549553" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201004549553" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638430201004549553" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201004549553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201004549553" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201004559555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638430201004559555" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638430201004559555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638430201004559555" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638430201004559555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638430201004559555" xlink:to="us-gaap_InterestPaidNet_638430201004559555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_638430201004559555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638430201004559555" xlink:to="us-gaap_IncomeTaxesPaid_638430201004559555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureBusinessOrganization" xlink:type="extended" xlink:title="10101 - Disclosure - Business Organization" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638430201004559555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638430201004559555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638430201004569559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638430201004569559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation" xlink:type="extended" xlink:title="10301 - Disclosure - Selected Balance Sheet Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638430201004569559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_638430201004569559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10401 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638430201004569559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638430201004569559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10501 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638430201004569559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638430201004569559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638430201004569559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638430201004569559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638430201004579557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638430201004579557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638430201004579557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638430201004579557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShare" xlink:type="extended" xlink:title="10901 - Disclosure - Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638430201004579557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638430201004579557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638430201004579557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638430201004579557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11101 - Disclosure - Employee Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638430201004579557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638430201004579557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation" xlink:type="extended" xlink:title="11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638430201004589557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11301 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638430201004589557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock" xlink:label="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock_638430201004589557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_JobsActAccountingElectionPolicyTextBlock" xlink:label="cvrx_JobsActAccountingElectionPolicyTextBlock_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="cvrx_JobsActAccountingElectionPolicyTextBlock_638430201004589557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_UseOfEstimates_638430201004589557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638430201004589557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638430201004589557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638430201004589557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_InventoryPolicyTextBlock_638430201004599554" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638430201004599554" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638430201004599554" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638430201004599554" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638430201004599554" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables" xlink:type="extended" xlink:title="30303 - Disclosure - Selected Balance Sheet Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638430201004599554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638430201004599554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638430201004599554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638430201004599554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="30403 - Disclosure - Debt (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_3" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638430201004609556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock" xlink:label="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock_638430201004609556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638430201004609556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_StatementTable_638430201004609556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638430201004609556" xlink:to="us-gaap_AwardTypeAxis_638430201004609556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638430201004609556" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004609556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004609556" xlink:to="us-gaap_EmployeeStockOptionMember_638430201004609556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638430201004609556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638430201004609556" xlink:to="us-gaap_PlanNameAxis_638430201004609556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638430201004619560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638430201004609556" xlink:to="us-gaap_PlanNameDomain_638430201004619560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638430201004739560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638430201004619560" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638430201004739560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638430201004739560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638430201004609556" xlink:to="us-gaap_StatementLineItems_638430201004739560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638430201004739560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638430201004739560" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638430201004739560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638430201004739560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638430201004739560" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638430201004739560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638430201004739560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638430201004739560" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638430201004739560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638430201004739560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638430201004739560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638430201004749568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638430201004749568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638430201004749568" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareTables" xlink:type="extended" xlink:title="30903 - Disclosure - Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638430201004749568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638430201004749568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638430201004749568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryRawMaterials_638430201004749568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638430201004749568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryWorkInProcess_638430201004749568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryFinishedGoods_638430201004759557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_2" xlink:to="us-gaap_InventoryNet_638430201004759557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638430201004759557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638430201004759557" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638430201004759557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638430201004759557" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" xlink:to="us-gaap_OfficeEquipmentMember_638430201004759557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LabEquipmentMember" xlink:label="cvrx_LabEquipmentMember_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" xlink:to="cvrx_LabEquipmentMember_638430201004759557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ComputerEquipmentAndSoftwareMember" xlink:label="cvrx_ComputerEquipmentAndSoftwareMember_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" xlink:to="cvrx_ComputerEquipmentAndSoftwareMember_638430201004759557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" xlink:to="us-gaap_LeaseholdImprovementsMember_638430201004759557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="us-gaap_AssetUnderConstructionMember_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638430201004759557" xlink:to="us-gaap_AssetUnderConstructionMember_638430201004759557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638430201004759557" xlink:to="srt_RangeAxis_638430201004759557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638430201004759557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638430201004759557" xlink:to="srt_RangeMember_638430201004759557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638430201004759557" xlink:to="srt_MaximumMember_638430201004769558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638430201004759557" xlink:to="srt_MinimumMember_638430201004769558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638430201004759557" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638430201004769558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638430201004769558" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638430201004769558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638430201004769558" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638430201004769558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638430201004769558" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638430201004769558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638430201004769558" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638430201004769558" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638430201004769558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_5" xlink:to="us-gaap_Depreciation_638430201004769558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ClinicalTrialAndOtherProfessionalFees" xlink:label="cvrx_ClinicalTrialAndOtherProfessionalFees_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_ClinicalTrialAndOtherProfessionalFees_638430201004779555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedBonusesCurrent_638430201004779555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_AccruedPaidTimeOff" xlink:label="cvrx_AccruedPaidTimeOff_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_AccruedPaidTimeOff_638430201004779555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_AccruedLiabilitiesCustomerRebateCurrent" xlink:label="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="cvrx_AccruedLiabilitiesCustomerRebateCurrent_638430201004779555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638430201004779555" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638430201004779555" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638430201004779555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638430201004779555" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638430201004779555" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract_4" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638430201004779555" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Debt (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638430201004779555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638430201004779555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638430201004779555" xlink:to="us-gaap_DebtInstrumentAxis_638430201004789554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638430201004789554" xlink:to="us-gaap_DebtInstrumentNameDomain_638430201004789554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LoanAndSecurityAgreementMember" xlink:label="cvrx_LoanAndSecurityAgreementMember_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638430201004789554" xlink:to="cvrx_LoanAndSecurityAgreementMember_638430201004789554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638430201004779555" xlink:to="srt_StatementScenarioAxis_638430201004789554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638430201004789554" xlink:to="srt_ScenarioUnspecifiedDomain_638430201004789554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TrancheOneMember" xlink:label="cvrx_TrancheOneMember_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638430201004789554" xlink:to="cvrx_TrancheOneMember_638430201004789554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TrancheTwoMember" xlink:label="cvrx_TrancheTwoMember_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638430201004789554" xlink:to="cvrx_TrancheTwoMember_638430201004789554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LineOfCreditDrawDownPeriodThreeMember" xlink:label="cvrx_LineOfCreditDrawDownPeriodThreeMember_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638430201004789554" xlink:to="cvrx_LineOfCreditDrawDownPeriodThreeMember_638430201004789554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638430201004779555" xlink:to="us-gaap_DebtInstrumentLineItems_638430201004789554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638430201004789554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_638430201004789554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638430201004789554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_638430201004789554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_638430201004789554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_RevenueTreeMonthsTrailing" xlink:label="cvrx_RevenueTreeMonthsTrailing_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="cvrx_RevenueTreeMonthsTrailing_638430201004799551" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PercentOfRevenueTarget" xlink:label="cvrx_PercentOfRevenueTarget_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="cvrx_PercentOfRevenueTarget_638430201004799551" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest" xlink:label="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest_638430201004799551" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_638430201004799551" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal" xlink:label="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal_638430201004799551" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638430201004789554" xlink:to="us-gaap_DeferredFinanceCostsGross_638430201004799551" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Debt (Maturities of debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_4" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638430201004799551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_638430201004799551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_638430201004809556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638430201004809556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_638430201004809556" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract_638430201004799551" xlink:to="us-gaap_LongTermDebtNoncurrent_638430201004809556" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638430201004809556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638430201004809556" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638430201004809556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_638430201004809556" xlink:to="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638430201004809556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OfficeSpaceInMinneapolisMinnesotaMember" xlink:label="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_638430201004809556" xlink:to="cvrx_OfficeSpaceInMinneapolisMinnesotaMember_638430201004809556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638430201004809556" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAreaOfLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfLandLeased_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="cvrx_LesseeOperatingLeaseAreaOfLandLeased_638430201004809556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638430201004809556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638430201004809556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased" xlink:label="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased_638430201004819552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_LesseeOperatingLeaseAdditionalRenewalTerm" xlink:label="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="cvrx_LesseeOperatingLeaseAdditionalRenewalTerm_638430201004819552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638430201004819552" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OperatingLeaseRightOfUseAssetAbstract" xlink:label="cvrx_OperatingLeaseRightOfUseAssetAbstract_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="cvrx_OperatingLeaseRightOfUseAssetAbstract_638430201004819552" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvrx_OperatingLeaseRightOfUseAssetAbstract_638430201004819552" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638430201004819552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638430201004819552" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638430201004819552" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638430201004819552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent_638430201004819552" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638430201004819552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638430201004819552" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638430201004819552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638430201004819552" xlink:to="us-gaap_OperatingLeaseLiability_638430201004819552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638430201004819552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638430201004819552" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638430201004829552" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638430201004809556" xlink:to="us-gaap_OperatingLeasePayments_638430201004829552" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Leases (Maturities of lease liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638430201004829552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638430201004829552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638430201004829552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638430201004829552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638430201004829552" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638430201004829552" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638430201004829552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638430201004829552" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638430201004829552" xlink:to="us-gaap_OperatingLeaseLiability_638430201004839559" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638430201004839559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638430201004839559" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638430201004839559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638430201004839559" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638430201004839559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638430201004839559" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_638430201004839559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638430201004839559" xlink:to="us-gaap_TemporaryEquityLineItems_638430201004839559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638430201004839559" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering_638430201004839559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice" xlink:label="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_638430201004839559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638430201004839559" xlink:to="cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice_638430201004839559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" xlink:to="us-gaap_AwardTypeAxis_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638430201004849558" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004849558" xlink:to="us-gaap_EmployeeStockOptionMember_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" xlink:to="us-gaap_GranteeStatusAxis_638430201004849558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638430201004849558" xlink:to="us-gaap_GranteeStatusDomain_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638430201004849558" xlink:to="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" xlink:to="us-gaap_PlanNameAxis_638430201004849558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638430201004849558" xlink:to="us-gaap_PlanNameDomain_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TwoThousandOneStockIncentiveAwardPlanMember" xlink:label="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638430201004849558" xlink:to="cvrx_TwoThousandOneStockIncentiveAwardPlanMember_638430201004849558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638430201004849558" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638430201004849558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_TwoThousandTwentyOneEquityPlanMember" xlink:label="cvrx_TwoThousandTwentyOneEquityPlanMember_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638430201004849558" xlink:to="cvrx_TwoThousandTwentyOneEquityPlanMember_638430201004849558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638430201004849558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" xlink:to="srt_RangeAxis_638430201004849558" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638430201004849558" xlink:to="srt_RangeMember_638430201004859552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638430201004859552" xlink:to="srt_MaximumMember_638430201004859552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004849558" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638430201004859552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638430201004859552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm_638430201004859552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638430201004859552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638430201004859552" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_638430201004859552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage_638430201004859552" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage" xlink:label="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage_638430201004869555" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638430201004869555" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004859552" xlink:to="us-gaap_ProceedsFromStockPlans_638430201004869555" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004869555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004869555" xlink:to="us-gaap_AwardTypeAxis_638430201004869555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638430201004869555" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004869555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004869555" xlink:to="us-gaap_EmployeeStockOptionMember_638430201004869555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_ShareBasedPaymentArrangementOtherOptionsMember" xlink:label="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004869555" xlink:to="cvrx_ShareBasedPaymentArrangementOtherOptionsMember_638430201004869555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638430201004869555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004869555" xlink:to="us-gaap_GranteeStatusAxis_638430201004869555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638430201004869555" xlink:to="us-gaap_GranteeStatusDomain_638430201004879559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployersOfCertainNonEmployeeDirectorsMember" xlink:label="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638430201004879559" xlink:to="cvrx_EmployersOfCertainNonEmployeeDirectorsMember_638430201004879559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004869555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004879559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638430201004879559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638430201004879559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638430201004879559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638430201004879559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384302010048795591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6384302010048795591" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638430201004879559" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638430201004889556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638430201004889556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638430201004889556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638430201004889556" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384302010048895561" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6384302010048895561" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638430201004889556" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004879559" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638430201004889556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638430201004889556" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638430201004889556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638430201004889556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638430201004889556" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638430201004889556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638430201004889556" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638430201004899552" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638430201004889556" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638430201004899552" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" xlink:to="srt_TitleOfIndividualAxis_638430201004899552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638430201004899552" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638430201004899552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_NonOfficerEmployeesMember" xlink:label="cvrx_NonOfficerEmployeesMember_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638430201004899552" xlink:to="cvrx_NonOfficerEmployeesMember_638430201004899552" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OfficerEmployeesMember" xlink:label="cvrx_OfficerEmployeesMember_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638430201004899552" xlink:to="cvrx_OfficerEmployeesMember_638430201004899552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638430201004899552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" xlink:to="us-gaap_PlanNameAxis_638430201004899552" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638430201004899552" xlink:to="us-gaap_PlanNameDomain_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638430201004909555" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" xlink:to="us-gaap_AwardTypeAxis_638430201004909555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004909555" xlink:to="us-gaap_EmployeeStockOptionMember_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" xlink:to="srt_RangeAxis_638430201004909555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638430201004909555" xlink:to="srt_RangeMember_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638430201004909555" xlink:to="srt_MinimumMember_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638430201004909555" xlink:to="srt_MaximumMember_638430201004909555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638430201004899552" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638430201004909555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638430201004909555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638430201004919553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638430201004919553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638430201004919553" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638430201004919553" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638430201004919553" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638430201004909555" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638430201004919553" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638430201004919553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638430201004919553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638430201004919553" xlink:to="us-gaap_IncomeStatementLocationAxis_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638430201004929558" xlink:to="us-gaap_IncomeStatementLocationDomain_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638430201004929558" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638430201004929558" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638430201004929558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638430201004929558" xlink:to="us-gaap_CostOfSalesMember_638430201004929558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638430201004919553" xlink:to="us-gaap_PlanNameAxis_638430201004929558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638430201004929558" xlink:to="us-gaap_PlanNameDomain_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EmployeeStockPurchasePlanMember" xlink:label="cvrx_EmployeeStockPurchasePlanMember_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638430201004929558" xlink:to="cvrx_EmployeeStockPurchasePlanMember_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638430201004919553" xlink:to="us-gaap_AwardTypeAxis_638430201004929558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638430201004929558" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638430201004929558" xlink:to="us-gaap_EmployeeStockOptionMember_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638430201004919553" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638430201004929558" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638430201004929558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638430201004929558" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638430201004929558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638430201004929558" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638430201004939557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638430201004929558" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638430201004939557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638430201004939557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638430201004939557" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638430201004939557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638430201004939557" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638430201004939557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638430201004939557" xlink:to="us-gaap_DomesticCountryMember_638430201004939557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638430201004939557" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638430201004939557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638430201004939557" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638430201004939557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" xlink:to="us-gaap_OperatingLossCarryforwards_638430201004939557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638430201004949555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638430201004949555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance" xlink:label="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" xlink:to="cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance_638430201004949555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638430201004949555" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638430201004939557" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638430201004949555" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_638430201004949555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_638430201004949555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638430201004949555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638430201004949555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638430201004949555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638430201004959559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638430201004959559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638430201004959559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent" xlink:label="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent_638430201004959559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638430201004959559" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638430201004959559" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638430201004959559" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638430201004959559" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638430201004959559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638430201004959559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638430201004959559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_638430201004959559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638430201004969554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_DeferredTaxAssetsStartUpCosts" xlink:label="cvrx_DeferredTaxAssetsStartUpCosts_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="cvrx_DeferredTaxAssetsStartUpCosts_638430201004969554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_638430201004969554" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_638430201004969554" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsOther_638430201004969554" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsGross_638430201004969554" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638430201004969554" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_DeferredTaxAssetsNet_638430201004969554" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefits_638430201004969554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638430201004969554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_638430201004969554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638430201004979554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_638430201004979554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_6" xlink:to="us-gaap_UnrecognizedTaxBenefits_638430201004979554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Loss Per Share (Basic and Diluted Net Loss per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638430201004979554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638430201004979554" xlink:to="us-gaap_NetIncomeLoss_638430201004979554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638430201004979554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638430201004979554" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638430201004979554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638430201004979554" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638430201004979554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638430201004979554" xlink:to="us-gaap_EarningsPerShareBasic_638430201004979554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638430201004979554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638430201004979554" xlink:to="us-gaap_EarningsPerShareDiluted_638430201004979554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638430201004989555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638430201004989555" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638430201004989555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638430201004989555" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638430201004989555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638430201004989555" xlink:to="us-gaap_EmployeeStockOptionMember_638430201004989555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_WarrantsToPurchaseCommonStockMember" xlink:label="cvrx_WarrantsToPurchaseCommonStockMember_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638430201004989555" xlink:to="cvrx_WarrantsToPurchaseCommonStockMember_638430201004989555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638430201004989555" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638430201004989555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638430201004989555" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638430201004989555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638430201004989555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_ContractualObligation_638430201004989555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638430201004999559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638430201004999559" xlink:to="srt_StatementGeographicalAxis_638430201004999559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638430201004999559" xlink:to="srt_SegmentGeographicalDomain_638430201004999559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638430201004999559" xlink:to="country_US_638430201004999559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE" xlink:label="country_DE_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638430201004999559" xlink:to="country_DE_638430201004999559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvrx-20231231.xsd#cvrx_OtherCountriesMember" xlink:label="cvrx_OtherCountriesMember_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638430201004999559" xlink:to="cvrx_OtherCountriesMember_638430201004999559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638430201004999559" xlink:to="us-gaap_SegmentReportingInformationLineItems_638430201004999559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638430201004999559" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638430201004999559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638430201004999559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638430201004999559" xlink:to="us-gaap_NumberOfOperatingSegments_638430201004999559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900039248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 02, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CVRx,&#160;Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1983744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9201 West Broadway Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-2840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,927,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Minneapolis, Minnesota<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001235912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901844944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,569<span></span>
</td>
<td class="nump">$ 106,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $508 and $679, respectively</a></td>
<td class="nump">7,551<span></span>
</td>
<td class="nump">5,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">10,983<span></span>
</td>
<td class="nump">6,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,987<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">112,090<span></span>
</td>
<td class="nump">122,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">115,229<span></span>
</td>
<td class="nump">124,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,980<span></span>
</td>
<td class="nump">6,369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,864<span></span>
</td>
<td class="nump">8,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">29,222<span></span>
</td>
<td class="nump">6,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current portion</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,282<span></span>
</td>
<td class="nump">15,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2023 and 2022; 20,879,199 and 20,663,736 shares issued and outstanding as of December 31, 2023 and 2022, respectively, respectively</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">553,326<span></span>
</td>
<td class="nump">545,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(477,381)<span></span>
</td>
<td class="num">(436,182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(207)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">75,947<span></span>
</td>
<td class="nump">109,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 115,229<span></span>
</td>
<td class="nump">$ 124,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899926608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for accounts receivable, net</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">20,879,199<span></span>
</td>
<td class="nump">20,663,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">20,879,199<span></span>
</td>
<td class="nump">20,663,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901806352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 39,295<span></span>
</td>
<td class="nump">$ 22,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of goods sold</a></td>
<td class="nump">6,256<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">33,039<span></span>
</td>
<td class="nump">17,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">11,633<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">64,509<span></span>
</td>
<td class="nump">50,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">76,142<span></span>
</td>
<td class="nump">59,997<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,103)<span></span>
</td>
<td class="num">(42,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,799)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">3,850<span></span>
</td>
<td class="nump">1,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(41,052)<span></span>
</td>
<td class="num">(41,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,199)<span></span>
</td>
<td class="num">(41,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (41,199)<span></span>
</td>
<td class="num">$ (41,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute net loss per share, basic</a></td>
<td class="nump">20,754,375<span></span>
</td>
<td class="nump">20,532,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute net loss per share, diluted</a></td>
<td class="nump">20,754,375<span></span>
</td>
<td class="nump">20,532,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901842080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated and other comprehensive loss</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 540,707<span></span>
</td>
<td class="num">$ (394,754)<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
<td class="nump">$ 145,959<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Beginning (in shares) at Dec. 31, 2021</a></td>
<td class="nump">20,399,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">150,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from Employee Stock Purchase Plan (shares)</a></td>
<td class="nump">113,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2022</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">545,362<span></span>
</td>
<td class="num">(436,182)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="nump">109,180<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">20,663,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">144,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Proceeds from Employee Stock Purchase Plan (shares)</a></td>
<td class="nump">71,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances, Ending at Dec. 31, 2023</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 553,326<span></span>
</td>
<td class="num">$ (477,381)<span></span>
</td>
<td class="num">$ (207)<span></span>
</td>
<td class="nump">$ 75,947<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, Ending (in shares) at Dec. 31, 2023</a></td>
<td class="nump">20,879,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901611232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (41,199)<span></span>
</td>
<td class="num">$ (41,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,303<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and loan discount</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,047)<span></span>
</td>
<td class="num">(2,944)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,026)<span></span>
</td>
<td class="num">(3,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="num">(1,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(170)<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,021)<span></span>
</td>
<td class="num">(42,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(591)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(591)<span></span>
</td>
<td class="num">(685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of common stock options</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt financing costs</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,984<span></span>
</td>
<td class="nump">7,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of currency exchange on cash and cash equivalents</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(15,625)<span></span>
</td>
<td class="num">(35,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">106,194<span></span>
</td>
<td class="nump">142,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">90,569<span></span>
</td>
<td class="nump">106,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904474000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business organization</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Business organization</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CVRx,&#160;Inc. (the &#8220;Company&#8221;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. We have developed and is marketing a medical device, Barostim, for heart failure (&#8220;HF&#8221;) and resistant hypertension. We are focused on the sale of our product in the U.S. and Europe.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that we will generate sufficient product sales to produce positive earnings or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904812096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Summary of significant accounting policies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy, which was closed during 2023. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2023 and 2022, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value. Additionally, as of December 31, 2023 and 2022, a majority of our cash and cash equivalents were maintained with two financial institutions in the U.S., and our current deposits are likely in excess of insured limits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. <span style="background:#ffffff;">We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023. We have determined that the adoption of ASU 2016-13 did not have a material impact on our results of operations, cash flows, or financial position as we do not have a history of credit losses.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We regularly review inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) asset, accrued expenses and operating lease liability &#8211; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sell our products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. Our revenue consists primarily of the sale of our Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services it transfers to the customer. We recognize net revenue on product sales, adjusted for any applicable estimates of variable consideration, when the customer obtains control of our product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract. All our contracts have a single performance obligation and our payment terms with customers are generally between 30 and 90 days. Variable consideration related to certain customer rebates is estimated based on the amounts expected to be paid based on the agreement with the customer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;), which requires public companies to disclose for each reportable segment the significant expense categories and amounts for such expenses. ASU 2023-07 is effective for annual periods beginning December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU will be effective for our annual period ended December 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which requires public business entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2023. This ASU will be effective for our annual period ended December 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904198960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected balance sheet information</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Selected balance sheet information</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,390</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,033</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,534</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,957</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,684</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 618</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 231</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,978</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,280</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,698</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br/>Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally&#160;<span style="-sec-ix-hidden:Hidden_zQ9v7lRugkaZk4A4ENmecQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to&#160;<span style="-sec-ix-hidden:Hidden_4ZtIQYWjMEy5zwZJd8Tmlg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></span>. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $0.5 million and $0.4 million for the&#160;years ended December 31, 2023 and 2022, respectively. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,303</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 960</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KRGdCIu5gUe_MTcgpv6-bQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Operating lease liability, current portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 120</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 775</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,369</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882992795872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">4. Debt</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovatus Loan Agreement</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On October 31, 2022, we entered into a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0 million in a series of term loans. On the closing date, we borrowed the minimum amount of $7.5 million under the Loan Agreement. On March 10, 2023, we borrowed the $7.5 million remaining under the first tranche of the Loan Agreement. On December 15, 2023, we borrowed an additional $15.0 million under the second tranche of the Loan Agreement. The Loan Agreement initially requires interest only payments through November 2027, followed by three monthly principal and interest payments. A final payment of $1.4 million, equal to 4.5% of the original borrowed principal, is due in January 2028. The term loans advanced pursuant to the Loan Agreement (collectively, the &#8220;Term Loans&#8221;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii) 5.50% plus (b)&#160;2.65%. The Term Loans are secured by substantially all of our personal property. We have the option to draw down&#160;up to $20.0 million between September&#160;1, 2024 and December&#160;15, 2024 if we achieve trailing three months revenue of $9.0 million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding, requiring that we achieve 50% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period. The Loan Agreement requires the payment of certain penalties if the Term Loans are paid off prior to maturity for any reason, including pursuant to an acceleration clause, and includes various restrictive covenants, including a restriction on the payment of dividends or making other distributions or payments on our capital stock, subject to limited exceptions. We were in compliance with these covenants as of December 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In connection with the Loan Agreement, we recorded $1.0 million of debt issuance costs and discounts as a reduction of long-term debt. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual principal maturities of debt under the Loan Agreement are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized debt costs and discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (778)</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,222</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904752992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">5. Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">We lease </span><span style="background:#ffffff;">31,505</span><span style="background:#ffffff;"> square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and was scheduled to expire August 31, 2024. On April 21, 2023, we extended the operating lease for our office space in Minneapolis, Minnesota for an additional&#160;</span><span style="background:#ffffff;">49</span><span style="background:#ffffff;">&#160;consecutive months through August 31, 2028. On November 7, 2023, we expanded our existing office space with the addition of </span><span style="background:#ffffff;">7,615</span><span style="background:#ffffff;"> square feet of property adjacent to our principal executive offices and our manufacturing facility. The term on this expanded property is for </span><span style="background:#ffffff;">57</span><span style="background:#ffffff;"> consecutive months that will run concurrently with the term on the existing lease. We intend to add new facilities as we grow, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. Our operating lease agreement includes an option to </span><span style="background:#ffffff;">renew</span><span style="background:#ffffff;"> for one additional period of </span><span style="-sec-ix-hidden:Hidden_R84I04otGUuPgFKJgT8KOA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">three</span></span><span style="background:#ffffff;"> years. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability, as it is not reasonably certain of exercise.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to base rent, we also pay our proportionate share of operating expenses, as defined in the lease. These payments are made monthly and are adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the lease balances within the consolidated balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,349</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_YDnHhonymkmLROCgApvJbw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 231</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,391</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Maturities of our lease liability for our operating lease are as follows as of December 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 362</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 374</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,624</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (233)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,391</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the remaining lease term was 4.7 years, and the weighted average discount rate was 6.7%. The operating cash outflows from our operating lease were $0.4 million for each of the years ended December 31, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882992766496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have common stock warrants exercisable for 716,131 shares of common stock upon conversion at a weighted average exercise price of $2.39 per share. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882992877216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Stock-based compensation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Summary of plans and activity</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2001, our Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#8220;2001 Plan&#8221;). Under the 2001 Plan, as amended, 2,674,749 shares of common stock had been reserved for the issuance of incentive stock options granted to employees, non-employee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the date of grant to four&#160;years and expire within a maximum term of 10 years from the grant date. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2021, our Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#8220;2021 Plan&#8221;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was 1,854,490 newly reserved shares in addition to the 600,737 shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 1,033,186 shares being reserved for issuance under the 2021 Plan as of January 1, 2023. The 2021 Plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of 10 years from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2023, there were 1,671,202 shares available for future issuance under the 2021 Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of our common stock on the date of grant. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years 2008 through the IPO, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain non-employee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as our standard form of option agreement for non-employee directors as they have an exercise price not less than the fair market value on the grant date and vest over 48&#160;months from the date of grant.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 16,262</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,486,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (328,902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (150,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,756,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 36,616</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,161,926 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">14.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(285,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">10.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(144,187)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">5.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 4,488,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">9.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 97,266</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2,450,327 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 59,295</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023, stock options outstanding included 8,559 options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2023, the weighted average </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">remaining contractual life was 7.3&#160;years. For options exercisable as of December 31, 2023, the weighted average remaining contractual life was 6.3 years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of common stock initially reserved for issuance under the ESPP was 278,170. The shares available for issuance under the ESPP automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 1% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 206,637 shares being reserved for issuance under the ESPP as of January 1, 2023. The ESPP permits certain of our U.S. employees to purchase shares of our common stock at a price per share not less than 85% of the l<span style="letter-spacing:0.25pt;">ower of (i)&#160;the closing market price per share of our common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of our common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase date under the ESPP was June 30, 2022. </span><span style="background:#ffffff;">For the year ended December 31, 2023,&#160;</span><span style="background:#ffffff;">71,276</span><span style="background:#ffffff;">&#160;shares of common stock were purchased under the ESPP for&#160;</span><span style="background:#ffffff;">$0.9</span><span style="background:#ffffff;">&#160;million of employee contributions. </span><span style="letter-spacing:0.25pt;">As of December 31, 2023, there were </span><span style="letter-spacing:0.25pt;">503,634</span><span style="letter-spacing:0.25pt;"> shares available for issuance under the ESPP.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We use the Black-Scholes option pricing model to determine the fair value of stock options and ESPP purchase rights on the grant date. We measure stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period for stock options and the offering period for ESPP purchase rights. The amount of stock-based compensation expense recognized for stock option awards during a period is based on the portion of the awards that are ultimately expected to vest. The amount of stock-based compensation expense recognized for ESPP purchase rights during a period is based on the estimated purchase rights as of the grant date. We account for forfeitures as they occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">10.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.5 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.3 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.5 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.2 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">77.2% to 79.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.3% to 60.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.40% to 4.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.75% to 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:31.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per ESPP purchase right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)&#8201;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">76.2% to 84.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">51.3% to 62.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">4.77% to 5.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.22% to 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We review these assumptions on a periodic basis and adjust them, as necessary. We utilize the simplified method to develop the estimate of the expected term for stock option awards and ESPP purchase rights. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be zero, as we have never paid dividends and have no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components and classification of stock-based compensation expense for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,664</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,304</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 519</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, unrecognized compensation expense related to unvested stock-based compensation arrangements was $13.4 million. As of December 31, 2023, the related weighted average period over which the expense is expected to be recognized is approximately 2.4&#160;years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882992795872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Income taxes</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023 and 2022, a valuation allowance was recorded against all deferred tax assets due to our cumulative net loss position. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 147</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows for the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.2)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.4)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Significant components of net deferred tax assets were as follows for the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">89,173</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">82,050</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">9,664</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">9,072</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,963</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,412</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1,473</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">752</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">680</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">894</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">212</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">144</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">300</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 110,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 101,836</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,552)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101,836)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023, we had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $389.9 million and $7.3 million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2023, we had federal and state tax credit carryforwards of approximately $9.8 million and $2.0 million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits will begin expiring in 2028. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit our utilization of the NOLs and could be triggered by subsequent sales of securities by us or our stockholders.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 185</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 113</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,046</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The amount of unrecognized tax benefits subjected to the valuation allowance was $1.7 million and $1.6 million for the&#160;years ended December 31, 2023 and 2022, respectively. We recognized approximately $0.1 million of interest or penalties for each of the&#160;years ended December 31, 2023 and 2022. As of December 31, 2023 and 2022, total accrued interest and penalties were $0.5 million and $0.4&#160;million, respectively. We recognize accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. We do not expect a significant change in the amount of unrecognized tax benefits in the next year.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2004 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. We do not have any tax audits or other proceedings pending.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904514000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">9. Loss Per Share</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41,428)</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,754,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,532,838</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1-VKvzFxtkGYxn2bxA0KOQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1.99)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9k-u6oSvH0SUWtDFYknU1A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our potentially dilutive securities, which include stock options and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. We excluded the following potential common shares, presented based on amounts outstanding at each period end, from the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,488,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,756,835</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,204,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,472,966</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904584592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Commitments and contingencies</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have certain contingent liabilities that arise in the ordinary course of business. We accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure as of December 31, 2023 or December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139883003119728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee benefit plans</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Employee benefit plans</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sponsor a voluntary defined-contribution employee retirement plan (the &#8220;401(k)&#160;plan&#8221;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. We do not provide matching contributions to employees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904387216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment, Geographic Information and Revenue Disaggregation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, geographic information and revenue disaggregation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">Segment, geographic information and revenue disaggregation</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our chief operating decision maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. We have one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, we have determined that we have a single reportable and operating segment structure. We and our Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We derive all our revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,021</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,477</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 971</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,469</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of December 31, 2023 and 2022, long-lived assets were located primarily in the U.S.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904577392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">13. Subsequent events</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On January&#160;31, 2024, we announced that our Board of Directors appointed Kevin Hykes as President and Chief Executive Officer, effective February&#160;12, 2024 to succeed Nadim Yared, who previously announced his plans to retire upon the appointment of his successor. In connection with a transition and consulting agreement we entered into with Mr. Yared, we also modified certain terms and conditions of Mr. Yared&#8217;s stock options granted under the 2001 Plan and 2021 Plan, however, the impact of this modification on the amount of stock-based compensation expense cannot yet be quantified.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899995472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock', window );">Statement presentation and basis of consolidation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statement presentation and basis of consolidation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy, which was closed during 2023. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_JobsActAccountingElectionPolicyTextBlock', window );">JOBS Act accounting election</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">JOBS Act accounting election</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As a result, we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2023 and 2022, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value. Additionally, as of December 31, 2023 and 2022, a majority of our cash and cash equivalents were maintained with two financial institutions in the U.S., and our current deposits are likely in excess of insured limits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounts Receivable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. <span style="background:#ffffff;">We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023. We have determined that the adoption of ASU 2016-13 did not have a material impact on our results of operations, cash flows, or financial position as we do not have a history of credit losses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Inventory</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We regularly review inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) asset, accrued expenses and operating lease liability &#8211; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue recognition</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We sell our products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. Our revenue consists primarily of the sale of our Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services it transfers to the customer. We recognize net revenue on product sales, adjusted for any applicable estimates of variable consideration, when the customer obtains control of our product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract. All our contracts have a single performance obligation and our payment terms with customers are generally between 30 and 90 days. Variable consideration related to certain customer rebates is estimated based on the amounts expected to be paid based on the agreement with the customer.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;), which requires public companies to disclose for each reportable segment the significant expense categories and amounts for such expenses. ASU 2023-07 is effective for annual periods beginning December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU will be effective for our annual period ended December 31, 2024.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In December 2023, the FASB issued ASU 2023-09, <i style="font-style:italic;">Improvements to Income Tax Disclosures </i>(&#8220;ASU 2023-09&#8221;), which requires public business entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2023. This ASU will be effective for our annual period ended December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_JobsActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to JOBS Act accounting election.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_JobsActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901800976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Inventory consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw material</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,390</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work-in-process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,033</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,615</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,534</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,957</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net consists of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,684</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 618</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital equipment in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 231</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,978</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,280</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,698</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued expenses consist of the following at:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Clinical trial and other professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,733</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,303</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paid time off</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 960</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KRGdCIu5gUe_MTcgpv6-bQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Operating lease liability, current portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 222</p></td></tr><tr><td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 120</p></td></tr><tr><td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 831</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 775</p></td></tr><tr><td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,369</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882906212432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Annual Principal Maturities of Debt</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The annual principal maturities of debt under the Loan Agreement are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized debt costs and discounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (778)</p></td></tr><tr><td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,222</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904448864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock', window );">Schedule of lease balances within the balance sheets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the lease balances within the consolidated balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,349</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="-sec-ix-hidden:Hidden_YDnHhonymkmLROCgApvJbw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 231</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability, non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,160</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,391</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of lease liability</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Maturities of our lease liability for our operating lease are as follows as of December 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 315</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 350</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 362</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 374</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,624</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (233)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,391</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lease balances within the balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899027456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of stock option activity:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 2,749,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 16,262</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,486,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (328,902)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (150,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 3,756,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">8.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 36,616</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">1,161,926 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">14.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cancelled / Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(285,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">10.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(144,187)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">5.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Balance as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 4,488,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">9.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 97,266</p></td></tr><tr><td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Options exercisable as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">2,450,327 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;">7.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 59,295</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Recognized Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the components and classification of stock-based compensation expense for the periods indicated: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,664</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee Stock Purchase Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 223</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general &amp; administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,304</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research &amp; development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 519</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 64</p></td></tr><tr><td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,887</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:31.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average fair value per ESPP purchase right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)&#8201;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">76.2% to 84.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">51.3% to 62.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">4.77% to 5.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.22% to 2.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted average fair value of options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">10.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;non-officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.5 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5.3 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected term (in years)&#8201;&#8212;&#8201;officer employees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2.5 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.2 to 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">77.2% to 79.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">56.3% to 60.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3.40% to 4.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1.75% to 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882905222528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Provision for Income Taxes</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The components of our provision for income taxes are as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 147</p></td><td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 109</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Taxes at the Federal Statutory Rate</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax at federal statutory rate</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Permanent differences</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development ("R&amp;D") tax credit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1.4</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Uncertain tax position</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">State, net of federal benefit</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.6</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred rate change</p></td><td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21.2)</p></td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.4)</p></td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">89,173</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">82,050</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">R&amp;D tax credits</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">9,664</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">9,072</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,963</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">8,412</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-qualified stock options</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">1,473</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">752</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Start-up costs</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">680</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">894</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">212</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">144</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">300</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 110,552</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 101,836</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (110,552)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (101,836)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Changes to Gross Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The changes to our gross unrecognized tax benefits were as follows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at beginning of year</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,046</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,939</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross increases:</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 185</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 113</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross decreases:</p></td><td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prior year tax positions</p></td><td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross unrecognized tax benefits at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,046</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904761840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41,199)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (41,428)</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted average common shares outstanding&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,754,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,532,838</p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#8201;&#8212;&#8201;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_1-VKvzFxtkGYxn2bxA0KOQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1.99)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9k-u6oSvH0SUWtDFYknU1A;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,488,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,756,835</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 716,131</p></td></tr><tr><td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,204,976</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,472,966</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882904623776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic Information and Revenue Disaggregation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment, Geographic Information and Revenue Disaggregation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We derive all our revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,021</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,477</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 971</p></td></tr><tr><td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,469</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901165456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">$ 4,714<span></span>
</td>
<td class="nump">$ 2,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,615<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 10,983<span></span>
</td>
<td class="nump">$ 6,957<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901908160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,551<span></span>
</td>
<td class="nump">$ 3,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">2,788<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 1,763<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,721<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">776<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Capital equipment in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cvrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899915184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901716368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Selected Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ClinicalTrialAndOtherProfessionalFees', window );">Clinical trial and other professional fees</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 1,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonuses</a></td>
<td class="nump">3,335<span></span>
</td>
<td class="nump">2,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_AccruedPaidTimeOff', window );">Paid time off</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_AccruedLiabilitiesCustomerRebateCurrent', window );">Customer rebates</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total accrued expenses<span></span>
</td>
<td class="text">Total accrued expenses<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Taxes</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,980<span></span>
</td>
<td class="nump">$ 6,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_AccruedLiabilitiesCustomerRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liability relating customer rebate classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_AccruedLiabilitiesCustomerRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_AccruedPaidTimeOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of paid time off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_AccruedPaidTimeOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ClinicalTrialAndOtherProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ClinicalTrialAndOtherProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900750320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate ( as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PercentOfRevenueTarget', window );">Percentage of trailing twelve months revenue goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest', window );">Number of monthly payments of principal plus interest | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal', window );">Percentage of final payment on original principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember', window );">Loan and Security Agreement | Draw down from September 1, 2024 to December 15, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_RevenueTreeMonthsTrailing', window );">Three months of trailing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of final payment on original principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of debt payments to be made under the loan agreement that consist of principal plus interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PercentOfRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a revenue target needed to achieved a goal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PercentOfRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_RevenueTreeMonthsTrailing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of three months of trailing revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_RevenueTreeMonthsTrailing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cvrx_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cvrx_LineOfCreditDrawDownPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900639584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Maturities of debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2029</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt costs and discounts</a></td>
<td class="num">(778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 29,222<span></span>
</td>
<td class="nump">$ 6,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899397168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 07, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of-use assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,349<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued expenses<span></span>
</td>
<td class="text">Accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash outflows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=cvrx_OfficeSpaceInMinneapolisMinnesotaMember', window );">Office space in Minneapolis, Minnesota</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_LesseeOperatingLeaseAreaOfLandLeased', window );">Area of land leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">49 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased', window );">Additional area of land leased | ft&#178;</a></td>
<td class="nump">7,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_LesseeOperatingLeaseAdditionalRenewalTerm', window );">Additional renewal term option</a></td>
<td class="text">57 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LesseeOperatingLeaseAdditionalRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LesseeOperatingLeaseAdditionalRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The area of additional land leased on operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_LesseeOperatingLeaseAreaOfLandLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The area of land leased on operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_LesseeOperatingLeaseAreaOfLandLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=cvrx_OfficeSpaceInMinneapolisMinnesotaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=cvrx_OfficeSpaceInMinneapolisMinnesotaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900816016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Maturities of lease liability) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 1,391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899829616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details) - Warrants to purchase common stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering', window );">Preferred stock warrants converted to common stock warrants at IPO | shares</a></td>
<td class="nump">716,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice', window );">Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882894819040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2001</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2008</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember', window );">2001 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="nump">2,674,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember', window );">2001 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,637<span></span>
</td>
<td class="nump">278,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued/purchased under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage', window );">Annual incremental percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage', window );">Minimum Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,671,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage', window );">Annual incremental percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember', window );">2021 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm', window );">Share based payment award, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Employers of certain non-employee directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of automatic annual  increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_TwoThousandOneStockIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_TwoThousandTwentyOneEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=cvrx_EmployersOfCertainNonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=cvrx_EmployersOfCertainNonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900796352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, exercisable (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Employers of certain non-employee directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of Beginning of period (in shares)</a></td>
<td class="nump">3,756,835<span></span>
</td>
<td class="nump">2,749,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,161,926<span></span>
</td>
<td class="nump">1,486,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled / Forfeited (in shares)</a></td>
<td class="num">(285,729)<span></span>
</td>
<td class="num">(328,902)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(144,187)<span></span>
</td>
<td class="num">(150,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of End of period (in shares)</a></td>
<td class="nump">4,488,845<span></span>
</td>
<td class="nump">3,756,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable as of June 30, 2023 (in shares)</a></td>
<td class="nump">2,450,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of Beginning of period (in dollars per share)</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.20<span></span>
</td>
<td class="nump">8.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled / Forfeited (in dollars per share)</a></td>
<td class="nump">10.52<span></span>
</td>
<td class="nump">7.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">5.05<span></span>
</td>
<td class="nump">1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance as of End of period (in dollars per share)</a></td>
<td class="nump">9.77<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable as of June 30, 2023 (in dollars per share)</a></td>
<td class="nump">$ 7.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 97,266<span></span>
</td>
<td class="nump">$ 36,616<span></span>
</td>
<td class="nump">$ 16,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable as of June 30, 2023</a></td>
<td class="nump">$ 59,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvrx_ShareBasedPaymentArrangementOtherOptionsMember', window );">Options not granted under the 2001 or 2021 Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance as of End of period (in shares)</a></td>
<td class="nump">8,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=cvrx_EmployersOfCertainNonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=cvrx_EmployersOfCertainNonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvrx_ShareBasedPaymentArrangementOtherOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvrx_ShareBasedPaymentArrangementOtherOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899146416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 10.65<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">77.20%<span></span>
</td>
<td class="nump">56.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">60.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.18%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">76.20%<span></span>
</td>
<td class="nump">51.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">84.60%<span></span>
</td>
<td class="nump">62.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">4.77%<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">5.53%<span></span>
</td>
<td class="nump">2.52%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees | Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember', window );">Non officer employees | Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember', window );">Officer employees | Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember', window );">Officer employees | Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvrx_NonOfficerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvrx_OfficerEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882898986480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,303<span></span>
</td>
<td class="nump">$ 3,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,901<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general &amp; administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,073<span></span>
</td>
<td class="nump">3,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research &amp; development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900842992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance', window );">Unrecognized tax benefits that are subjected to a valuation allowance</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, income tax penalties and interest expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, Income tax penalties and interest accrued</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">389,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of  unrecognized tax benfits that are subjet to a valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882905261280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Components of Provision for Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Provision for income taxes, federal and state</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Provision for income taxes, foreign</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882900906368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development ("R&amp;D") tax credit</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent', window );">Uncertain tax position</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Deferred rate change</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(21.20%)<span></span>
</td>
<td class="num">(19.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901754800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Net Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 89,173<span></span>
</td>
<td class="nump">$ 82,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">9,664<span></span>
</td>
<td class="nump">9,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">8,963<span></span>
</td>
<td class="nump">8,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Non-qualified stock options</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvrx_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Accrued vacation</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">110,552<span></span>
</td>
<td class="nump">101,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(110,552)<span></span>
</td>
<td class="num">(101,836)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized R&amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvrx_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Start Up Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvrx_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882905228448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at beginning of year</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 1,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases: Prior year tax positions</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases: Current year tax positions</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Gross decreases: Prior year tax positions</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at end of year</a></td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">$ 2,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882899381552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Basic and Diluted Net Loss per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (41,199)<span></span>
</td>
<td class="num">$ (41,428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">20,754,375<span></span>
</td>
<td class="nump">20,532,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">20,754,375<span></span>
</td>
<td class="nump">20,532,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders - basic</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders - diluted</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882905286096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">5,204,976<span></span>
</td>
<td class="nump">4,472,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">4,488,845<span></span>
</td>
<td class="nump">3,756,835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded potential common shares from the computation of diluted net loss per share</a></td>
<td class="nump">716,131<span></span>
</td>
<td class="nump">716,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvrx_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901768672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent liabilities accrual amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901193328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic information and revenue disaggregation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 39,295<span></span>
</td>
<td class="nump">$ 22,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 35,111<span></span>
</td>
<td class="nump">18,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,690<span></span>
</td>
<td class="nump">3,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cvrx_OtherCountriesMember', window );">Other countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 494<span></span>
</td>
<td class="nump">$ 971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cvrx_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cvrx_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901796416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (41,199)<span></span>
</td>
<td class="num">$ (41,428)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139882901614976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "'@$E8(4L_D=('  ""-   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;87.B.!S&OTK&V[G9FZD5 MJZUW;&:MWUMK5>[>[>WLZ]B) J4TB\$&K[
M[2^ &MD) 6[BFU:0_P/\#.%Y0KC84/8<KS#FX#4*27S96G&^_M#IQ-X*1R@^
MI6M,Q#=/E$6(BT6V[,1KAI&?%45A!UI6KQ.A@+2N+K)U,W9U01,>!@3/&(B3
M*$+L[1J'='/9LEN[%0_!<L73%9VKBS5:XCGF7]8S)I8Z>Q4_B#") TH PT^7
MK8']8>3"M"#;XFN -_'!9Y">RH+2YW1AXE^VK/2(<(@]GDH@\>\%#W$8IDKB
M./[=BK;V^TP+#S_OU,?9R8N36: 8#VGX+?#YZK)UW@(^?D))R!_HYA/>GE W
MU?-H&&=_P2;?MMMK 2^).8VVQ>((HH#D_]'K%L1! 2PK@-L"^%.![984.-L"
MIVZ!NRUP,S+YJ60<1HBCJPM&-X"E6PNU]$,&,ZL6IQ^0]'>?<R:^#40=OQI1
M+Q$_(P>(^."&\("_@0G)VU/ZN[3!E_D(O'_W&W@' @+N@C 4J^.+#A<[3R4Z
MWG9'U_F.8,F.; CN*.&K6.S%QWY1H"..>G_H<'?HUU"K.,+>*7#L$P MZ"@.
M:*@O'^/%*;!@5NXJRD?Z\C\2(O9NJ?9>.!MG_T,XF9[S/W^('X-%S)FX3/Y1
ML<^U7;5VVG=\B-?(PY<MT3G$F+W@UM6OO]@]ZW<5-Y-B(T-B!:;NGJFK4Y=,
M']_66(5-7VY;[<\J/MJJIGP,B17X=/=\NO7X# A)4 @>\)HRK@*EU^$L4>$=
M:JN:@C(D5@#5VX/JU0,UPRR@Z?7I ]'=*MM4A=*NTRKMM;3U3:$9$BM .]M#
M.ZMY]3$D?$+6BY6W,+W6$PIC91/3EC6E94BL0.M\3^M<>X;;+G\<A!A,DVB!
MF8J27L.R[+9K==VNBI2VM"DI0V(%4OT]J7X=4@]X&:1W1-' IBA27HIZG>'7
MA]>3_*@FQ%,AT]8W169(K(#,MJ3-L^I $R=*F;@$,T]Q N9<=&* ,C"D">'L
M3?SWE20KU$<W*GSZHJ;\3*D5 1[X9+L.P$?T"B:^Z-6"I\#+G5GYU5HAZ=IM
MNW_NG+DJ^SG4%S>F9TBM2 ]*>K .O8'O"_7X9/<!W(KMP#U1MSF]9!]:-OB&
M8PZN&47^!@GY%TS43D2OU1BF(;4B3)D4;*UIUL-\W% E3+WD/ DXS@^QU[64
M!(VF E-J18(R%]AZ9_\SP6&Z)+K!1[HA2GIZN;N $(S6- Q4P7BHKVZ,[AB)
MP9:1P=9[_9_1[6\A,T9? N*I+V6]YMU4B<UH?#"E5L0F X2M]_T_8YO1F(O$
M]7>P+K_GZA6[75=M]/1UC;D=(T+8,D/8>N.?79D#AE$Y)KW 64^9LO15C2$=
M(SG8,CK8>M]_2SW1EF8K2G39H4+$M7MM>.ZJ.W^CX<&46I&6C ^VWO<_!EQD
M+/H$;/A^\1N88R]AHI4ID54D"!I%P@#&G'K/)TIN1A.$*;7B:*N,$%!O\D6,
M]P.R!/.W:$%#%:X* 1&X_E*.TQK-":;4BI1D3H!Z4[]K3N#FU5LALL2EZ;1"
M:#J8CP9_*GD930:FU(J\9#* M9+!,&$L'2O*!XBR9B:,1:)\T%"A^!TK79B^
MJC&U8T0 *", K!4!)H1CEC\Z2\<CT0ZCDII>L8R:4=MO2JU(3=I^6,OV?\-A
MV'XFPNN+SA_%XJ[I@TD<)^K;9H7F5!6WAOJBQMB.8?FAM/RPEN7_2L.$<,3R
M04JFOC3U2B6PC!I]4VI%6-+HPUI&/T,$AB(;+2E3>HL*G2DE;>1Y6,@($3\7
M5-(S:O=-J17I2;L/]6Y]2V\>H3 $UTDLOH[5#4VO4_9$2E_6&-8Q;#^4MA_6
M>F1P$V&V3.^8'X4"7XF@%*T14;<YO6 I-:/VWY1:D9JT_[#6XX.;U\/G4OES
M/24RO5KI@RE]76-FQ[#^CK3^CMZY3X;C!S!(_(!3!@:<XYCG8]_C$"V5\Q'T
M>J74]'6-YQX<(PHX,@HX>@>_?P Z#@@B7B R>C9:EJV[82Q[[B+\6CX#ZD?*
M4CVY0[^;<IA&<X(IM2),F1.<6CEAOA+F3=?%5<B4PS(:#TRI%6$=S"6J%0]F
MR2(,/'&14J2,!'J5QM.&S,X;RM6ZF5HZ>_'ERNY;%YT7%1B9 )Q:"6 [<#//
M!FY$FT+B@,!]PD6W1M(Q#B4LDY9^N%7K'9P>M/KP[ SV]^>X!7$,\^](\^_H
M+?NNUR\;Q:@H__@PF#Z"QT_W#]/'^RFXO9TI:1A- *;4BL1D G#TSGU';!RP
M"$Q&2FAZ!>B>*RD9=?JFU(J4I--W] Y]1RD=NT[O?TI,>HF#QVXG(%N(*4=*
M<D9MORFU(CEI^YU:MG\H7 03EF)"?/P*/F/UW;!JPI!E0Z?;MZ&2FE';;TJM
M2$W:?J=BK'X[P#@.XO1AR7>,F'8:7X5<NVW#MF,KL1EU_J;4BA-HI?-W*V;V
M2 \KN8W%2F4JKQ KF_*H+VL\H_88KM^5KM^M[?HS8MLIH^7,]'+C[TIB1JV]
M*;4B,6GM7;TG'PA<?HZL)$Y6")2:>GU=8TQ&37WGX*6-= 0G>_DE!EXZ$R]_
M?V._=O^"S2![K:0C-\_?SKE#Z0!0#$+\)$JMTS-A@%C^PDN^P.DZ>P5D03FG
M4?9QA9&/6;J!^/Z)4KY;2'>P?^WHZC]02P,$%     @ AX!)6-/L7U&C!0
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MTU9M.PAI6APK?IN\^;U$L%D-H:^U#8^+VZD()]4<G\L$BW YKM^%VK<*'6\
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M=#IZNM'B4!PP;H36(BTN]XP";&, _^\$:%EY8\XLJS/JU;]02P,$%     @
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M<]0T$R,KUZU7TF#O=\,"3V=0-@"?KZ4TCQ-[ +3G??H+4$L#!!0    ( (>
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M 94-0-%"4+0("JU+ZU$ZP*#:P3C:Y%/&L/QV+</JYQJH? "*%ET:0?=!Z5%
M, $$A'&,J5R HJU-;2F/@UY9&8*V&EUNM<O'44 PQP6$2X6JI>4':PK5_@,&
MC9'C6);95Z@U=M>VYUD^[D=48S@L5#56GA/89Y0O\^01_\2*?J1.U0=M6$&;
MAN\%@ZFS&N_)Y D+B1:"HD50:#6G\Y-W==2[6[^1\B&5!^&,;B2\\=J3DZ*L
M7X>J;P3;5:_O?&)"L+RZW%(BRU-E(/_?,":>;M0;0>U+:<M_ 5!+ P04
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M:P'U_RUC\OE&OZ [SEK]#U!+ P04    " "'@$E8N>];J30#  #3!@  &
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M*4:S\]?0HP-E"K8M6_142@!7I+%'2X!&8@>UF,'W#JTG.R1<*V,(6];*38;
ML<<4OA+4^$!R:Q[$#5I)'A'$#^[)*[,%A(9*5: .2:J@":S1LO.JF8!84.AE
M/52H="<$7HVL/[S?$PZ(\C64\V@\U$\M":_H(;%_H%VQ7"QI+E,(RAUJ JZ
M.PNMY;(K?! 1MCZG=VE$?-=9X9O"-1JQ*C$E#_38BK,XR4,/LBGC"0(T.T<N
M%AG:8O <*-#54(G_.:@L-[ML-@X*[G0IOT:*.]KU%:5RH @WPJSJO$A-X=]:
MQAN&91C0N<ZB*6CHWI.XAM:P)1. 15)75:I0@>9.45 I9'E<(&C9J<A.)FJ$
M>3@?!TS3Y\YP=F T#=EMM-,HPOC!<_:K>\>^&(SJ5_I@]]=HMTH&H*F2TFGZ
MSYL$[&"A0^"YC;:U82\F&%_#02,;$F2_8O:[(#38_X^M?@)02P,$%     @
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MG4S7ZA8]20$K6ZJ2D"8$:;E$U XH498]AXQ:>RE%JQVMV(_CQ($[#F*X9;P
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MV(89$!<0NY9*)P6/O:A(W),YL]46$@K2W$(?-11#X=N41#HEFB$*2/EVO*<
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M8Y8<"V!]:6W8#'B#[GE\_@]02P,$%     @ AX!)6')_8UY@ @  404  !D
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M\.ZR>6!ZS:6!"E>4&HTNS@/0G8&[B56U-\U26;*@'Y9TYZ%V ;2_4LKN)J[
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M;$V;O/XD[O[&+#]3Q)>*7.G_R9TY&\\F)&U4+0H+#!04O#1_Z;V50P=@$8P
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M$CEMY0T(P+E9YL1AC02.A%X0QUZXF+E[5@SY.]TNJ1967TVQH6)WJ)+BEF>
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M)WW)/-N3R6A[W92=;F2D6S%U 'AU4V*_XU[A#^F-2OVE4*$]!X<.ST(H;MP
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MYO"T*&NN2H3.0U>C 4D@/33.%J)0V%=:M]0Z!'SD857)L.=@J104@7+%W(/
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M+=[R_DRJ>"8E_D;*=*3R?RSQV[&2=,+^?3QVTQB6E0)V#*>.09DJ\(AEPH^
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MV>3D*&(FW'K"B].UOVELM<,>]LL2+XI@R #U.ZU=_T(!AJOGYB]02P,$%
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M/]QTTR1B%6TZV,'5$$'.-CXU?E\+*W3#:[1]-'J%/# '3>GD%AV^U3')MCK
M-'8)OA1"<$"#>#)WCG%HCZE)^D92Y+F%YY,B4AFM9^0X=%DCBD96=5M!"JMM
MN1WEMDUNW%+)^]2/HB;0,:F_3.\'7[M\4W4^>./(IIPNC/ZRD62\#4UN23',
M%9"<TE4G6M3HRAE'&?"5=G:EOK:;4ZSV*D]E.XMC$=)F9ATBD\>EK8.TB5>F
M\?92YIHN)%92%[$9B.JBI68%DB&-R]K,WZUNIUJC<KPV:+:UF4U@[-%UUU3R
MJ<[3IYV6;%GPK;/W)N[&E>1H;_Y=HQ2:6FUZ96<6_[ 4 M$KE%AR#-@&)1QP
M@W/0=1,^:.QMO4#KB]KF:.J*]R P/U-QAK)X1^V^(DH+/,:U>^"(V8;SXU[X
MM1G --(+"9]S4**0.3VK07\ [P/7R:ANF@DVU4J0D\ &U7/I+ UDS8C0[J*U
M:,=1@PL:^0DI&ODP6T"-E\3+=0'08A.(TV.?($A6NL8B6-%WW/!EQ<;UYS0U
MD!BL;,[7HV'S$FLR;2^QQ$=;H:,Z'A[W18,"9_H%1B:Z-TWS5=/3^GU1,^ZB
M9OS(Q:3-;@_..6HO8#*H]<$KSI\4%>MLXAR>B\+]0<R3;'-9(G;F3VI?<\8E
MKN?YR-7I4L4*!:3LO4I5@#B^^V:+M19.-FS637LQ-F@^3^?LN"9]V_96.]$\
MMS05-#"^G4S/6QP?1S\B_7QTTM]R%)>L\2OVXQXPMI'N;NI'>^_0SVC<,F'[
M^M<:?(XDM+OD_\2U_&/GT.#R+Q0+'JRIC^XS4.1"M'^>2OQ.#]Y4C&*7.5V'
M0%(.AL_[XK*D!DJU87+-=SZ<SU.U8()^HSU=P];$X,V4 (W:4?\!C;B#IU->
M?'O*I4$<8XB5=UO2=Z%VN/&;$]WO\2]K?'UD0OSYJ?VV_?5N$G^SZI;'G_[^
ME'0]Z$$\<VP=#IX_Z\7>I'D(MN)?L&8V@##XXQ(DI1PMP/NYM:%YH /:WS3/
M_@M02P,$%     @ AX!)6% 0NQ\G!   [ L  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&ULU59M;]LV$/XKA!H4+:!&;]:+4]M [*9H@78QDF[],.P#
M+9ULHA*IDE2<[-?O*-DRO;A&L7W9OE@\\N[AO3P\WV0KY#>U =#DL:ZXFCH;
MK9LKSU/Y!FJJ+D4#'$]*(6NJ491K3S42:-$9U947^G[BU91Q9S;I]I9R-A&M
MKAB'I22JK6LJG^90B>W4"9S]QAU;;[39\&:3AJ[A'O2OS5*BY TH!:N!*R8X
MD5!.G>O@:IX8_4[A-P9;9:V)B60EQ#<C?"RFCF\<@@IR;1 H?AY@ 55E@-"-
M[SM,9[C2&-KK/?K[+G:,9445+$3UE15Z,W4RAQ10TK;2=V+[ 7;QQ 8O%Y7J
M?LFVUQTE#LE;I46],T8/:L;[+WW<Y<$RR/P?&(0[@[#SN[^H\_(=U70VD6)+
MI-%&-+/H0NVLT3G&35'NM<13AG9Z=M_E!PHRIQ7E.9#[C@H?>5]OD[A77^BJ
M O5ZXFF\T)AY^0Y\WH.'/P /0O)9<+U1Y(874!P#>.CIX&ZX=W<>GD5\!_DE
MB0*7A'X8G<&+AO"C#B_ZY^'_?KU26B)[_CB5@!Y^=!K>O*@KU= <I@X^&07R
M 9S9RQ=!XK\]X_QH<'YT#GUVCR^T:"L@HD2/'X!K(9]..7D>9C EN<#'IK0R
M@'H#I!05/EK&UX3J*_+R11;ZT=M__<4:0KT"V=7Q2'C%.-XK6D5YH5X/!J;6
MMA"2.[K%1Z!!,EH-)Q=DY*;!R))#-QK[Y"NVA3>,OVFDR$&IX3R)#[J!ZT<1
M><\XPZ=4D+40Q4$Q=I,@'J3(C:/1LZ N2."[XRRR-A)W'*=GRAP/98Y_NLQ+
MB>U8ZB>"&2(WWUO68(/4+OD%]*G"GP<^ H,#&,<7\+^APFU9,GRW92LYTZV$
MXV!L<OBA)46Q3S[1U0G-T$W#P)*2;$06HFY:I)NE;JY1HM1;BG?NM=,T.= K
MR,@GP#^,C:@*PFJDWP,8TP.QQMEA&9,%;9A&/A_NP!S\G;2Q1=HP"IYE=.3&
M<6!Q=9P:+Y2Z(M=YWM9M14VW*P#;4<[Z!F<BH;60FOW9;UB9R#)+"C/_%._=
M-(F.Y&2<G:%],M ^^6G:H^^R1;]O'G$84:!.<?T\VAX!=@A[@O_G^;W 2%B.
MM-!=LS/%$NBP-,PHL;!8,-PN 915@S!-CRN$S6TN>*LLK<B-HMBJ;N1'9$E9
M030.79B6TF+UH>[CQ">+;BQ!%R2LD$[J.0F#Y\0,XX3<8KM!BF&2*_,P2,7H
MBE5,/[DXZDAI*-\8'EH</,?U$-/SA3Z><" (XQ-[/KGM,K??R2S,-'UN<8&=
M?VQQWK3T*!F?XK9G36"8F74W9QJ2M5SWP]BP.XRRU_T$=U#OY^#/5*X95YBB
M$DW]RQ2;N.QGRU[0HNGFN9706(9NN<%Q'*11P/-2"+T7S 7#@#_["U!+ P04
M    " "'@$E814#(WK("  !!!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6R-55M/VS 4_BM60 @D1E*WT%+:2 4V;1)(%9?M8=J#FYPV%KYDMD/9
M?OV.[38KHU1[B7TNW^?O^'(R6FKS9"L 1UZD4':<5,[5PS2U1062V1-=@\+(
M7!O)')IFD=K: "L#2(J49ME9*AE723X*OJG)1[IQ@BN8&F(;*9GY=0E"+\=)
M)UD[[OBB<MZ1YJ.:+> >W&,]-6BE+4O))2C+M2(&YN-DTAE>]GQ^2/C*86DW
MYL17,M/ZR1M?RG&2>4$@H'">@>'P#%<@A"="&3]7G$F[I =NSM?LGT+M6,N,
M6;C2XALO735.!@DI8<X:X>[T\C.LZCGU?(46-GS),N;V,+EHK--R!48%DJLX
MLI?5/FP !MD[ +H"T* [+A147C/'\I'12V)\-K+Y22@UH%$<5_Y0[IW!*$><
MRZ]AYLCA YL)L$>CU"&E#Z3%"GX9X?0=>(>26ZU<9<E'54+YFB!%+:T@NA9T
M27<R7D-Q0KJ=8T(SVMW!UVT+[ :^[JX"OT]FUAF\ 3^VE1@)>ML)_*L8VIH5
M,$[PVELPSY#D!WN=L^QBA[Q>*Z^WBSV_QU=6-@*(GI.)4@T39&JX*GB-LUOF
M&L,=!^O#OI)M\G<O\% !89&X;HGE*^+2;U&#YV>(P^P;S129+ P /CY'F$$"
M2^9:X .V0W*P-Z!9]^*_1SQ0D#/D]H=ZR!6NH1O+5&F/VAQ_UO[3(_O!UZ'!
M=_J*;.4\V^;L;W,.WFBAV7&693YV_B;6B;%_W=WHO@&+M3\J)K5Q_#>4<=<*
M;9W%_463VT(W"JTU\K#?'QSA;JK%!P=&1L ZN$_H^3&E=.W8=I72C6<MP2Q"
M\[(D+!-?>.MM^^,DMH6_Z;&YWC*SX,H2 7.$9B?]TX28V+"BX70=FL1,.VPY
M85IACP?C$S ^U]JM#;] ^]?(_P!02P,$%     @ AX!)6$)!8]4Y P  XP@
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MYTKQW#PN*$FIT =@?\:YJA=:0?-5]>)/4$L#!!0    ( (> 25@0T?=[-P4
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M!B@6:68!SJ^$T/N.V:!Z&5K\!5!+ P04    " "'@$E85.UZ67<#  !,"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6RU5E%OXS8,_BN";SBT@!';
MLIVX;1*@:3MLP*Y77+<5P[ 'Q69BH;;D27+3_?NCY-C-]1KOMF$OEB61'S]2
MI*CY3JI'70(8\EQ70B^\TICF/ AT7D+-]$0V('!G(U7-#$[5-M"- E8XI;H*
M:!A.@YIQX2WG;NU.+>>R-147<*>(;NN:J;]64,G=PHN\?N$3WY;&+@3+><.V
M< _FE^9.X2P84 I>@]!<"J)@L_ NH_-5:N6=P*\<=OK@GUA/UE(^VLF/Q<(+
M+2&H(#<6@>'P!%=0518(:?RYQ_0&DU;Q\+]'_][YCKZLF88K63WPPI0++_-(
M 1O65N:3W/T >W\<P5Q6VGW)KI.=48_DK3:RWBLC@YJ+;F3/^S@<*&3A$06Z
M5Z".=V?(L;QFABWG2NZ(LM*(9G^<JTX;R7%A#^7>*-SEJ&>6/TFMR1TH<E\R
M!>3D9[:N0)_. X/@5B3(]T"K#H@> 8HH^2"%*36Y$0447P($R&J@1GMJ*SJ*
M> WYA,213VA(XQ&\>' U=GCQM[GZ^^5:&X59\<=;SG90R=M0ME+.=<-R6'A8
M"AK4$WC+]^^B:7@Q0C09B"9CZ,L5TSPG3!3DFE>M@8+<8G4Z^DU/_RW.WXI:
M[%$%HE8]JG9!8<8HOFZ-S0)B),EE76/M8!KFCZ6L"E":[)@F.:ORMF(6!2\&
M8DJP(%P6FG!1\-SMG'"!.[+5:%3[!)YS:$QO"'F\F"TP=4_/R?MW&0WCB_\\
M_@9,=6EX5 23"^HU$K )=DS()M[AA)+;M@;%C%1_3_:VC^[KC>_(21+YT=G9
MZ:NEA&:G2$Q(K/-Q&P_NLD'WV!/2V<)P3C::FN#EJPU&F(NMTX@N[!#1B_UL
M_54J?.VY/TL3/YZEATMI3/TLSEY<^T>)\R^I8&RBR:M@T4E(AX61BDN'BDM'
M:^-2&.[L8X<@]Y"WBAN.@;QYSJO6IM%&R9I<R;I!#UTWD1MRPY3 "!_<*6\5
MY;CA_R'#1S/;9;3+Y(^-]4/;LVI:E9?8V;XX-)+X29;Y69*2&'-AB@>?D@>F
M%!-F1*LW-(NF?A1'1^>I3\/$/YM-K9T9]<^FT['S# XZ'%;@UO5QO(9D*TS7
M[(;5X:EPV77(%_'NG?&!J2U'QRO8H&HXF>$)J:YW=Q,C&]<OU])@]W6_)3YW
M0%D!W-](:?J)-3 \H):? 5!+ P04    " "'@$E8F3B;/0L#  #Z!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RM56U/VS 0_BNGL"&0JN:EA5)H
M*_&VC0]HB,+0-.V#FUP3"\?.;(?"O]_92;-.0+]L7Q+[7IZ[YWP^3U9*/YH"
MT<)S*:29!H6UU7$8FK3 DIF^JE"29JETR2QM=1Z:2B/+O%,IPB2*#L.2<1G,
M)EYVHV<355O!)=YH,'59,OURAD*MID$<K 6W/"^L$X2S2<5RG*.]KVXT[<(.
M)>,E2L.5!(W+:7 :'Y\-G;TW^,9Q93;6X)@LE'ITFZML&D0N(1286H? Z/>$
MYRB$ Z(T?K6801?2.6ZNU^B?/'?BLF &SY5XX)DMIL%1 !DN62WLK5I]P9;/
M@<-+E3#^"ZO&=A0%D-;&JK)UI@Q*+IL_>V[KL.%P])Y#TCHD/N\FD,_R@EDV
MFVBU NVL"<TM/%7O3<EQZ0YE;C5I.?G9V1QS*K'MP6=4N695P5.XDLUA^ZK)
M#&[Q"66-<,$-RW.->:/:NV,+@69_$EI*Q,&%:1OTK F:O!,T3N!:25L8N)09
M9G\#A,2@HY&L:9PE6Q$O,.W#(.Y!$B6#+7B#KBP#CS?X_V7Y<;HP5E.W_7RK
M,$W8X=MAW0T\-A5+<1K0%3.HGS"8[>[$A]')%E+#CM1P&_IL3C<ZJP6"6D)+
MD$A42ELN\[>2W0[W@-3^FNX4,"% U9HNJ:^(@:56)1A&W0%6M6V,V@"7<%EK
MFBB^@+9 N._/^W!'BZ42-" H$;"NK:#2ZHEG!-""PN(%4E5+JU_(5@.RM "A
MTO8\4J]S[DY9*HT$SR3$T4='UX6RRC+1P3DS)ZV(@LI<:ADG,,R.87?G*(D&
M)__\_XZ,\G0=_DI%_8KE K7OV3TJBRU4;:@H9K^S<:WL/DE3I+7X PP.>G$<
M;PCBHUZ4Q-2KU)[RI5,,>H?C:&,W'(W@*W'6;2$Y57>M'8Z'W7H\BE\E3%''
MO61\L"%(DM[P</Q67X8;\XC./?=3US11F]'42;O!?MK,LS_FS:MPS73.I0&!
M2W*-^J.# '0S:9N-596?;@MEJ<G\LJ#'";4S(/U2*;O>N #=<S?[#5!+ P04
M    " "'@$E89"O@FI8"    !P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6RM55U/VS 4_2M6AB:0!OD.M$LC02L$#Y,0A?$P[<%-;AL+Q\YLMX%_
M/]L)46E#A::]Q%_W')][<^]UVG#Q+$L A5XJRN3$*96JQZXK\Q(J+,]X#4R?
M++FHL-)+L7)E+0 7%E11-_"\Q*TP84Z6VKT[D:5\K2AA<">07%<5%J]70'DS
M<7SG;>.>K$IE-MPLK?$*YJ >ZSNA5V[/4I *F"2<(0'+B7/ICZ>)L;<&/PDT
M<FN.C"<+SI_-XK:8.)X1!!1R91BP'C8P!4H-D9;QI^-T^BL-<'O^QGYM?=>^
M++"$*:=/I%#EQ+EP4 %+O*;JGC<WT/D3&[Z<4VF_J.EL/0?E:ZEXU8&U@HJP
M=L0O71RV '[T 2#H ,%G 6$'"*VCK3+KU@PKG*6"-T@8:\UF)C8V%JV](<S\
MQ;D2^I1HG,KF-J!0H"M,,<L!S6WNW+(V04RDC^<Z=8HU!<27^F #3''Q>H*.
M9Z PH?($G:+'^0P='YV@(T08>BCY6F)6R-156J*YR,T[.5>MG. #.3/(SU#H
M?T.!%X0#\.GGX<%[N*L#TT<GZ*,36+[PWZ/SZW(AE=#9^'O(VY8^&J8W%3J6
M-<YAXN@2E" VX&1?O_B)]WW(]_]$]BX281^)\!![=H\;G78*!,%TR-$6'5NT
MZ1R;+#KWH]3=;#NP;Q2$(Z\W>B<LZH5%!X4]Z2YQ2MAI+7@.<C#E6H)DZ]HD
MWI6V;^-[83@L+>ZEQ0>E71-&=&46:,7Y<#'$>[?&B1_O2-LW"N,P&I:6]-*2
M@](>N,)4UVI7S$/:DKV?Y7NCBW!'W+Y5,HK/=\2Y6_W)O T_L%@1)A&%I89Y
M9^<:+]I^VRX4KVW+6G"E&Z"=EOJ) F$,]/F2<_6V,%VP?_2ROU!+ P04
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MUP7J]80Q^7JB=_#K?VP6_P-02P,$%     @ AX!)6$#KPTM5 @  Q 4  !D
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MU93>Z)U6)-J9T0:*5[;M-ESI)K;+0H]9$"9!GV\Y5X? ?* ?W.EO4$L#!!0
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M59O42E4?FZ9I'TQR(583F]DWT.[7SW;2B(Z056A\('[<<^XYE_B::"WDD\H
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M.JHF*):VH\\$ZOO!#C-]@X,T 7I_+@2^3LPET?PGB/\ 4$L#!!0    ( (>
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M?15%; ,Q@A>Y99$K2)L,1H2N,HP/:M0?>(TZ;AGC^XTZMI14C;1)1=KDG?U
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M4:VS67W(TW6Y:N-=FN=I7&ZN. NX* K([Q=IFC]]*"K8KG8Z_0=02P,$%
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MPD"<7U+*=SO% ,V'(;/_ 5!+ P04    " "'@$E8AEA=T8 %  #&(0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6S%6EUOXC@4_2M6=K7J2%,2.Q]
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MN-24+']I(+\1=)&=NS]2(6B27<X)#@E3#>3W4TK%RXT:H'QU8_0_4$L#!!0
M   ( (> 25CD;1Q75 0  !P6   9    >&PO=V]R:W-H965T<R]S:&5E=#0P
M+GAM;,58;6^C.!#^*Q:W6K526["!O'232&W:U:UTJXV:[>Z'TWUP89*@ N9L
M)VGNUY\-!$)"T'9+E2^)@9G',X_'PX,':\:?Q0) HI<HC,706$B97)NF\!80
M47'%$HC5DQGC$97JDL]-D7"@?NH4A2:QK(X9T2 V1H/TWH2/!FPIPR"&"4=B
M&464;VXA9.NA@8WMC8=@OI#ZACD:)'0.4Y"/R82K*[- \8,(8A&P&'&8#8T;
M?#TFJ4-J\2. M=@9(YW*$V//^N*+/S0L'1&$X$D-0=7?"L80AAI)Q?%O#FH4
M<VK'W?$6_7.:O$KFB0H8L_!GX,O%T.@9R(<978;R@:W_A#PA5^-Y+!3I+UKG
MMI:!O*60+,J=5011$&?_]"4G8L>!N$<<2.Y ]ARP<\3!SAWL--$LLC2M.RKI
M:,#9&G%MK=#T(.4F]5;9!+%>QJGDZFF@_.1H*IGW?'FKB/#1F$6J.@1-^3U[
M (_-X^ _]>"HT?V+'L,Y.KL#28-0G*-+]#B]0V<?SM$'%,3H^X(M!8U],3"E
M"E=/:GIY:+=9:.1(:)B@KRR6"X'N8Q_\*H"I\BR2)=MD;TDCXAUX5\C&%XA8
MQ*X):/SK[J0A'+O@WD[Q[&/<+RB'RZ>4U@G=J,TAT0WG-)Z#'E]LZ?61(A"-
M:1)(&NH%N4 W$5LJZ[__4I#HBX1(_%-'<#:_4S^_[A#7(J$># W5 @3P%1BC
MCW_@CO6ICIR6P"I4.0553A/ZZ#M3J2.1UF%&F+=;AY 154=!ANNFN+JGK48=
MVU*+O]I-[=#([O6ZA5$E9+<(V6T,^3'FY0[ZU6C=@T"P[5C67KB-$__F2G2*
MM#J-:?U,&Z.NR15PU>A1 CQ@?ETRS4 $;8!R@1P49;N<.,BGF[I&,6Y$^LV$
MNT7"W<8X[Z,D9!N K NB;XE>P[IT&V%>N]E: JMDW"LR[IVX+_7:I*HEL I5
M_8*J_COUI?[!3G?[%M[;Z)E19[<O=3I.?5_"5OG*MYHK>CJ9U+Z.&]U>NRQM
MH563W-$U^,1%G ?0%ETMH57I(B5=Y)T*.0?>+5+'(GN%7&-$B'VDD$O]A!LU
MQVBJU'\0SR_0'&+U,@K11QHEGQ#UE5 .A.14?R+4QMRJ,&H+K<I"*8VP<^I*
M;Q1GKZ:K);0J7:4LP\VZ[ V5[AX4L6MU][5DC95M6\>:=BF[<+-<>E!44.XM
M\AKW8:4^P1.]P+6AMJ28\I3>0W_A4H#A[JD+O%7MUA9:E:Y2O>%&Q?.6 N\=
ME"[&[D$O/[1R<?](?9=""C<KJ3$3$K$9FC/F"R186/M)T0SRZH5J":UZ&%'J
M,&*=N*Y)JXJN+;0J7:6B(XT2Z UUG0/OBNUN;Z^J:VP.E+:Y<\X6 9^GQX]"
MA:'6(CN%*NX61YPWZ<'>WOU;?#W.#BI+F.S<]"OE\R 6*(29@K2NNBH@GAU%
M9A>2)>EIWA.3DD7I< '4!ZX-U/,98W)[H2<H#H1'_P-02P,$%     @ AX!)
M6'"A+=NN P  <@\  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULM9=M
M;]LV$,>_"J$50P)TT9-MV9EMH'%6+$#;!4VSO1CV@I;.EE:)=$GZH?OT/5*V
M+$<R5QON&UND>'_>[TB>>,,U%Y]E"J#(ILB9'#FI4HM;UY5Q"@65-WP!#-_,
MN"BHPJ:8NW(A@";&J,C=P/-Z;D$SYHR'IN]1C(=\J?*,P:,@<ED45'R]@YRO
M1X[O[#H^9O-4Z0YW/%S0.3R!>EX\"FRYE4J2%<!DQAD1,!LY;_S;B=_5!F;$
MGQFL9>V9:)0IYY]UXR$9.9[V"'*(E9:@^+>"">2Y5D(_OFQ%G6I.;5A_WJF_
M-? (,Z42)CS_*TM4.G+Z#DE@1I>Y^LC7O\,6R#@8\UR:7[(NQT:>0^*E5+S8
M&J,'1<;*?[K9!J)FX/>.& 1;@^"E0>>(0;@U" UHZ9G!NJ>*CH>"KXG0HU%-
M/YC8&&NDR9A>QB<E\&V&=FK\P&)> /E$-R#)U0<J!-5QO297]Z!HELMK\@MY
M?KHG5Z^NR2N2,?(IY4M)62*'KD('M(P;;R>[*R<+CDSF!^0]9RJ5Y#>60'(H
MX*+GE?O!SOV[P*IX#_$-"?W7)/""L,6AR?>;!Q9WPBJ:H=$+C^C]L0 =/S8G
M[[B49(+A_(I';4U%(LG?[W T>5!0R'_:8E=*=]JE]7&^E0L:P\C!\RI!K, 9
M__R3W_-^;>.^D-A!%#I5%#HV]=V>4G1#8(/Y1D(;;JG1-1HZV:S&?B<:NJLZ
M1<L8;U"-.7"N6SG7M3KWS 3$?,ZR_R Q+DZ!P2Q3DJB4*D(%8$J;_HM91K_G
MA)(5S9>TS#DY9CW*XE:><MI>W=?(\UX M0SJU08=$/4JHMYY1*_QN%8K@>M
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MTKN)$$"4!5[94'QA:J0I5UAQF<<4BV(0>@"^GW&N=@T]055FC[\!4$L#!!0
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MDS5&;L<R9J)F0TN&09M,C]"&,OZIK9WV:--1M&MI+K1^)IB4"3S6O,(2K&V
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M >;]7!A+FXZ=H/WDR/X"4$L#!!0    ( (> 25B:3.%!*P(  "H%   9
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MFF6AQBAPG:#.-XS)_487Z =S^AM02P,$%     @ AX!)6&0ZHFM# @  B@8
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MYTKW+CLL]<\"A G0SW/.U7%B-AA^/\D;4$L#!!0    ( (> 25BF=]M.( ,
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ AX!)6*]C>4MV!   ["$
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MX;7^3O&KK\KVKAWB!C$TIP)/F*NR 8\'.<%C+46)WUZR<RZY*H UP;4!8$H
MID<#9"<S'D!F!&3VAI!S#^$_8)E>LML-F  R)R#SHT'.G2X"R"$!.3P:Y(3;
M=0 Y(B!'<2'/:RL46,MNS8HK\;P[GS\0:!_BHLWKJN+FJ1E4L5("/\8Q!9T5
MA:XQ!060'PG(CY$A0:)9=N?SK^080'XB(#_%A9S"(B1)!E22'L1EN09N(4S(
M":F,R,[PV>)^K64)QO[!+G[4:+:0C;)%$ED7#=N?YQBNDDUTA3W95[:E1)%$
M-L65*G0%[([_[(XGY84DLABN-::R&1B<AMQ 2$6)((EN@JH2KLW^?@6%9G"X
ME -5B&[H*!$DD4UP46VD?@)@YZ!@*1R;84+KT%$N2&++ %;^BO?L$O3*\,U:
M%(=6H)0-DM@ZJ!<6?M1^J7SQX,<[!*,,D$16 "G3[VFX0*;LD$:V ZG3+B:E
MC32R-KQ0V0D6:A+LNQ"*K"XB^Z(UZUXL2A-I9$T<TM@+:(A)F2.-;([09GMC
M2 DDC2R0KM;VXE'J2".K@TS.W5E+.22-[A JN60A)N60])@EQ?<\Q*2,DL8V
M"HDY#'<S**-D1S7**,2DC)*]B5%NN#'<[P&^8R=3<%S(SB3/*+UDD?72$O[+
M76V$PW6K7TJ4V/:"&F*2VU>1=;.UX+[P47[)8E<F+US= $K?RJ3HA(\R31;9
M-/L*XN!W&6)2QLEB&^?@HJ)!#3$IXV2QC7,0LUF/AYB4<;+8QCF(>69M7868
ME'&RV,8YB/D5"KT*MZ8IX^21C=-=2;Y*Z2$F99P\LG&ZF#Z>6FWWIV=&AYB4
M=O+(VNEB^H%6A<"$V0R\7H:8E';R-]P,VXWF#82[KSGYO\F;5CF3-5<K?.,T
MNS2^Q @Q*0OE;USOX)S'DL)OG4V%K#O1I"R41[;0+N:9<J+T@#C=V3R494Y9
M*(]L(7+[D9V$F)2%\NAUS^LJ4ORJ(L/R+*<LE$>VT(P_L8=FV)N/^Y)B*FPA
MM:T[.\Y#RD'#Z ZR I=P[,[P$H>:G:&$<,2KG2W)(26@8?N@P?;I@A*60D%Y
M@_U;;"^X+&:&^9?VGY)\Z#<XE[64$VR[5=>:E]N'%;8/6GSY#U!+ P04
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M&^IM!'H;ZFT$>AOJ;01ZVV"SA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U
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M_CG:W--*%_4QG[5_H*>?4$L! A0#%     @ AX!)6 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "'
M@$E8#,2\7>\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " "'@$E8F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (> 25@A2S^1
MT@<  ((T   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " "'@$E8T^Q?4:,%  "O%@  &
M@($6$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ AX!)
M6+)?4EK% @  ^P<  !@              ("![Q4  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( (> 25@"E60*SP0  (X2   8
M      " @>H8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M" "'@$E8[<PYT=P%  "@)@  &               @('O'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ AX!)6#8>D"@V!@  VAH  !@
M             ("! 20  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( (> 25BY[UNI- ,  -,&   8              " @6TJ  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "'@$E8E[>6<_8)   B
M&   &               @('7+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ AX!)6%*XL5\.!   5 L  !@              ("! S@
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( (> 25BC71@!
M5 8  +T.   9              " @4<\  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ AX!)6)R81]3[!0  *@\  !D
M ("!TD(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "'
M@$E8<G]C7F "  !1!0  &0              @($$20  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (> 25@4B:AL70P  $,K   9
M          " @9M+  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ AX!)6"?K_"4)"   [AD  !D              ("!+U@  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "'@$E8O$RX2R $  "-
M"P  &0              @(%O8   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( (> 25B@9:MEOP(  $P&   9              " @<9D
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ AX!)6.$@
MRU#; @  9 8  !D              ("!O&<  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    " "'@$E8.!Y3>V8$  "&"@  &0
M    @('.:@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M (> 25C"&8I?0@,  /(&   9              " @6MO  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ AX!)6"+D%GN6"@  WQP  !D
M             ("!Y'(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    " "'@$E84!"['R<$  #L"P  &0              @(&Q?0  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (> 25A%0,C>L@(
M $$&   9              " @0^"  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ AX!)6$)!8]4Y P  XP@  !D              ("!
M^(0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "'@$E8
M9><:_0@&  !A%0  &0              @(%HB   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( (> 25@0T?=[-P4  "42   9
M      " @:>.  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ AX!)6%3M>EEW P  3 D  !D              ("!%90  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "'@$E8F3B;/0L#  #Z!@
M&0              @('#EP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( (> 25AD*^":E@(    '   9              " @06;  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ AX!)6("L<2UT
M!   O1D  !D              ("!TIT  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    " "'@$E80.O#2U4"  #$!0  &0
M@(%]H@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( (>
M25C@42< ;0,  ,D*   9              " @0FE  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ AX!)6/0<^M/C!0  42\  !D
M         ("!K:@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    " "'@$E8 ]-0F:T"   ?"   &0              @(''K@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (> 25CD[:S 304  "@>
M   9              " @:NQ  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ AX!)6!<YM4&\ @  >0<  !D              ("!+[<
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "'@$E8-81@
M@I "  #D!0  &0              @($BN@  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( (> 25A65-]BY@<  /E4   9
M  " @>F\  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
MAX!)6#(;Z/0'!@  )"(  !D              ("!!L4  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    " "'@$E8AEA=T8 %  #&(0  &0
M            @(%$RP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( (> 25CD;1Q75 0  !P6   9              " @?O0  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ AX!)6'"A+=NN P
M<@\  !D              ("!AM4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    " "'@$E8!0 (E)L"   M!P  &0              @(%K
MV0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( (> 25BL
M56X2:P,   H+   9              " @3W<  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ AX!)6+Z\:I.+ P  >@L  !D
M     ("!W]\  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (> 25B 6GQW7 ,  %L.   9              "
M@>SO  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ AX!)
M6)+6:5E) @  I 4  !D              ("!?_,  'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    " "'@$E89#JB:T,"  "*!@  &0
M        @('_]0  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( (> 25BF=]M.( ,  .P1   -              "  7GX  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ AX!)6)>*NQS     $P(   L
M ( !Q/L  %]R96QS+RYR96QS4$L! A0#%     @ AX!)6*]C>4MV!   ["$
M  \              ( !K?P  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M (> 25BAE^J4R0$  * >   :              "  5 ! 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( (> 25@HM&@3PP$  (D>   3
M              "  5$# 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     [
- #L %!   $4% 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>98</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Business Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureBusinessOrganization</Role>
      <ShortName>Business Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables</Role>
      <ShortName>Segment, Geographic Information and Revenue Disaggregation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails</Role>
      <ShortName>Selected Balance Sheet Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebtTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Debt (Maturities of debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails</Role>
      <ShortName>Debt (Maturities of debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureDebtTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Leases (Maturities of lease liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails</Role>
      <ShortName>Leases (Maturities of lease liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLeasesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Components of Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes (Components of Net Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Loss Per Share (Basic and Diluted Net Loss per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Loss Per Share (Basic and Diluted Net Loss per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossPerShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails</Role>
      <ShortName>Segment, Geographic information and revenue disaggregation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cvrx-20231231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvrx-20231231.xsd</File>
    <File>cvrx-20231231_cal.xml</File>
    <File>cvrx-20231231_def.xml</File>
    <File>cvrx-20231231_lab.xml</File>
    <File>cvrx-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cvrx-20231231x10k.htm">cvrx-20231231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvrx-20231231x10k006.jpg</File>
    <File>cvrx-20231231x10k007.jpg</File>
    <File>cvrx-20231231x10k008.jpg</File>
    <File>cvrx-20231231x10k009.jpg</File>
    <File>cvrx-20231231x10k010.jpg</File>
    <File>cvrx-20231231x10k011.jpg</File>
    <File>cvrx-20231231x10k012.jpg</File>
    <File>cvrx-20231231x10k013.jpg</File>
    <File>cvrx-20231231x10k014.jpg</File>
    <File>cvrx-20231231x10k015.jpg</File>
    <File>cvrx-20231231x10k016.jpg</File>
    <File>cvrx-20231231x10k017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="463">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvrx-20231231x10k.htm": {
   "nsprefix": "cvrx",
   "nsuri": "http://www.cvrx.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "cvrx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvrx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvrx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvrx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvrx-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvrx-20231231x10k.htm"
     ]
    }
   },
   "keyStandard": 242,
   "keyCustom": 23,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 17,
   "memberCustom": 16,
   "hidden": {
    "total": 23,
    "http://fasb.org/us-gaap/2023": 18,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 98,
   "entityCount": 1,
   "segmentCount": 35,
   "elementCount": 475,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 463,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "00300 - Statement - Consolidated Statements of Stockholders Equity",
     "shortName": "Consolidated Statements of Stockholders Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cvrx.com/role/DisclosureBusinessOrganization",
     "longName": "10101 - Disclosure - Business Organization",
     "shortName": "Business Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation",
     "longName": "10301 - Disclosure - Selected Balance Sheet Information",
     "shortName": "Selected Balance Sheet Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cvrx.com/role/DisclosureDebt",
     "longName": "10401 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cvrx.com/role/DisclosureLeases",
     "longName": "10501 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquity",
     "longName": "10601 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensation",
     "longName": "10701 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxes",
     "longName": "10801 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cvrx.com/role/DisclosureLossPerShare",
     "longName": "10901 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "11001 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans",
     "longName": "11101 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation",
     "longName": "11201 - Disclosure - Segment, Geographic Information and Revenue Disaggregation",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cvrx.com/role/DisclosureSubsequentEvents",
     "longName": "11301 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables",
     "longName": "30303 - Disclosure - Selected Balance Sheet Information (Tables)",
     "shortName": "Selected Balance Sheet Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cvrx.com/role/DisclosureDebtTables",
     "longName": "30403 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cvrx.com/role/DisclosureLeasesTables",
     "longName": "30503 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
     "longName": "30703 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesTables",
     "longName": "30803 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cvrx.com/role/DisclosureLossPerShareTables",
     "longName": "30903 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables",
     "longName": "31203 - Disclosure - Segment, Geographic Information and Revenue Disaggregation (Tables)",
     "shortName": "Segment, Geographic Information and Revenue Disaggregation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails",
     "longName": "40301 - Disclosure - Selected Balance Sheet Information (Schedule of Inventory) (Details)",
     "shortName": "Selected Balance Sheet Information (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
     "longName": "40302 - Disclosure - Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)",
     "shortName": "Selected Balance Sheet Information (Schedule of Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails",
     "longName": "40303 - Disclosure - Selected Balance Sheet Information (Narrative) (Details)",
     "shortName": "Selected Balance Sheet Information (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
     "longName": "40304 - Disclosure - Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)",
     "shortName": "Selected Balance Sheet Information (Schedule of Accrued Expenses) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "cvrx:ClinicalTrialAndOtherProfessionalFees",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "cvrx:ClinicalTrialAndOtherProfessionalFees",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
     "longName": "40401 - Disclosure - Debt (Narrative) (Details)",
     "shortName": "Debt (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ProceedsFromLongTermLinesOfCredit",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
     "longName": "40402 - Disclosure - Debt (Maturities of debt) (Details)",
     "shortName": "Debt (Maturities of debt) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cvrx.com/role/DisclosureLeasesDetails",
     "longName": "40501 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails",
     "longName": "40502 - Disclosure - Leases (Maturities of lease liability) (Details)",
     "shortName": "Leases (Maturities of lease liability) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "longName": "40601 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA",
      "name": "cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering",
      "unitRef": "Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA",
      "name": "cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering",
      "unitRef": "Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
     "longName": "40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)",
     "shortName": "Stock-Based Compensation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_LGXJ91kYF0WAsdsON9A6IA",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "40702 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)",
     "shortName": "Stock-Based Compensation (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
     "longName": "40703 - Disclosure - Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)",
     "shortName": "Stock-Based Compensation (Assumptions Used in Determine the Grant Date Fair Value of Stock Options) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
     "longName": "40704 - Disclosure - Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)",
     "shortName": "Stock-Based Compensation (Recognized Stock-Based Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "40801 - Disclosure - Income Taxes (Narrative) (Details)",
     "shortName": "Income Taxes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
     "longName": "40802 - Disclosure - Income Taxes (Components of Provision for Income Taxes) (Details)",
     "shortName": "Income Taxes (Components of Provision for Income Taxes) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails",
     "longName": "40803 - Disclosure - Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)",
     "shortName": "Income Taxes (Reconciliation of Taxes at the Federal Statutory Rate) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "longName": "40804 - Disclosure - Income Taxes (Components of Net Deferred Tax Assets) (Details)",
     "shortName": "Income Taxes (Components of Net Deferred Tax Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails",
     "longName": "40805 - Disclosure - Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)",
     "shortName": "Income Taxes (Changes to Gross Unrecognized Tax Benefits) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "longName": "40901 - Disclosure - Loss Per Share (Basic and Diluted Net Loss per Share) (Details)",
     "shortName": "Loss Per Share (Basic and Diluted Net Loss per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "40902 - Disclosure - Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "shortName": "Loss Per Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "41001 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ContractualObligation",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ContractualObligation",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails",
     "longName": "41201 - Disclosure - Segment, Geographic information and revenue disaggregation (Details)",
     "shortName": "Segment, Geographic information and revenue disaggregation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment__laEB6QyrUy_CRagT_GFBw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Uncategorized",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R51": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvrx-20231231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r562"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowances of $508 and $679, respectively",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Taxes",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r117"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "cvrx_AccruedLiabilitiesCustomerRebateCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "AccruedLiabilitiesCustomerRebateCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liability relating customer rebate classified as current.",
        "label": "Accrued Liabilities, Customer Rebate Current",
        "terseLabel": "Customer rebates"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_AccruedPaidTimeOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "AccruedPaidTimeOff",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of paid time off.",
        "label": "Accrued Paid Time Off",
        "terseLabel": "Paid time off"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r141",
      "r436"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r83",
      "r145",
      "r433",
      "r449",
      "r450"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated and other comprehensive loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r32",
      "r389",
      "r392",
      "r419",
      "r445",
      "r446",
      "r664",
      "r665",
      "r666",
      "r672",
      "r673",
      "r674"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r457",
      "r672",
      "r673",
      "r674",
      "r719",
      "r737"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee stock compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r312"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r599",
      "r609",
      "r635"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r600",
      "r610",
      "r627",
      "r636",
      "r640",
      "r648"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r356"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for accounts receivable, net",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r229",
      "r234"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred financing costs and loan discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r407",
      "r552",
      "r553",
      "r667"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Excluded potential common shares from the computation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital equipment in process",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r143",
      "r169",
      "r203",
      "r211",
      "r216",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r382",
      "r386",
      "r398",
      "r430",
      "r484",
      "r562",
      "r574",
      "r682",
      "r683",
      "r725"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r149",
      "r169",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r382",
      "r386",
      "r398",
      "r562",
      "r682",
      "r683",
      "r725"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r592"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r592"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r592"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Selected Balance Sheet Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_BasisOfPresentationAndConsolidationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "BasisOfPresentationAndConsolidationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to basis of presentation and basis of consolidation.",
        "label": "Basis of Presentation And Consolidation Policy [Policy Text Block]",
        "terseLabel": "Statement presentation and basis of consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r139",
      "r542"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r91",
      "r165"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r91"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_ClinicalTrialAndOtherProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ClinicalTrialAndOtherProfessionalFees",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables relating to clinical trial and other professional fees.",
        "label": "Clinical Trial and Other Professional Fees",
        "terseLabel": "Clinical trial and other professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r67",
      "r431",
      "r471"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r240",
      "r241",
      "r527",
      "r681"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r565",
      "r566",
      "r568",
      "r569",
      "r570",
      "r571",
      "r672",
      "r673",
      "r719",
      "r735",
      "r737"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r472"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r74",
      "r472",
      "r490",
      "r737",
      "r738"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2023 and 2022; 20,879,199 and 20,663,736 shares issued and outstanding as of December 31, 2023 and 2022, respectively, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r432",
      "r562"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee benefit plans",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r151",
      "r153",
      "r158",
      "r426",
      "r441"
     ]
    },
    "cvrx_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to computer equipment and software.",
        "label": "Computer equipment and software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Contingent liabilities accrual amount",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of goods sold",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r169",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r398",
      "r682"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of goods sold",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes, federal and state",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes, foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r670"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes, total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r371",
      "r376",
      "r670"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r167",
      "r255",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r271",
      "r278",
      "r279",
      "r281"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r71",
      "r72",
      "r116",
      "r118",
      "r171",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r408",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r668"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate (as a percent)",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r118",
      "r282"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate ( as a percent)",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r64",
      "r274"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r408",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r668"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r171",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r408",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r668"
     ]
    },
    "cvrx_DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of final payment on original principal.",
        "label": "Debt Instrument, Percentage of Final Payment on Original Principal",
        "terseLabel": "Percentage of final payment on original principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Final payment",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r51",
      "r52",
      "r63",
      "r64",
      "r66",
      "r68",
      "r100",
      "r101",
      "r171",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r408",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r668"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized debt costs and discounts",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r267",
      "r283",
      "r550",
      "r551"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs and discounts",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "cvrx_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized R&amp;D expenses.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Expenses",
        "terseLabel": "Capitalized R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r717"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r717"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property and equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_DeferredTaxAssetsStartUpCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "DeferredTaxAssetsStartUpCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Start Up Costs.",
        "label": "Deferred Tax Assets Start Up Costs",
        "terseLabel": "Start-up costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r717"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Compensated Absences",
        "terseLabel": "Accrued vacation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r717"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Non-qualified stock options",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r717"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r314",
      "r345",
      "r346",
      "r348",
      "r557"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r592"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r592",
      "r628"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r187",
      "r189",
      "r191",
      "r192",
      "r193",
      "r197",
      "r396",
      "r397",
      "r427",
      "r442",
      "r545"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "verboseLabel": "Net loss per share attributable to common stockholders - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r189",
      "r191",
      "r192",
      "r193",
      "r197",
      "r396",
      "r397",
      "r427",
      "r442",
      "r545"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r194",
      "r195",
      "r196"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of currency exchange on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r361",
      "r377"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r718"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Deferred rate change",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r714"
     ]
    },
    "cvrx_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r718"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development (\"R&amp;D\") tax credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r718"
     ]
    },
    "cvrx_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesReconciliationOfTaxesAtFederalStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Percent",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to employee stock purchase plan.",
        "label": "ESSP",
        "terseLabel": "ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_EmployersOfCertainNonEmployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "EmployersOfCertainNonEmployeeDirectorsMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employers of certain non-employee directors to whom the BOD authorized the grant of stock options for the purchase of shares of common stock.",
        "label": "Employers of Certain Non Employee Directors [Member]",
        "terseLabel": "Employers of certain non-employee directors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r134",
      "r154",
      "r155",
      "r156",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r198",
      "r232",
      "r233",
      "r296",
      "r349",
      "r350",
      "r351",
      "r372",
      "r373",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r419",
      "r445",
      "r446",
      "r447",
      "r457",
      "r511"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r596",
      "r606",
      "r632"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r593",
      "r603",
      "r629"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r600",
      "r610",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r600",
      "r610",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r600",
      "r610",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r600",
      "r610",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r600",
      "r610",
      "r636"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r169",
      "r203",
      "r210",
      "r215",
      "r218",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r398",
      "r547",
      "r682"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r592"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r84",
      "r120",
      "r203",
      "r210",
      "r215",
      "r218",
      "r428",
      "r438",
      "r547"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r495"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r495"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r358",
      "r362",
      "r367",
      "r370",
      "r374",
      "r378",
      "r379",
      "r380",
      "r455"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r132",
      "r183",
      "r184",
      "r207",
      "r360",
      "r375",
      "r443"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r600",
      "r610",
      "r627",
      "r636",
      "r640",
      "r648"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r652"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r652"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r652"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r122",
      "r157",
      "r206",
      "r406",
      "r496",
      "r572",
      "r736"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r163",
      "r164"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r543",
      "r562"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r138",
      "r147",
      "r235",
      "r236",
      "r237",
      "r424",
      "r544"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw material",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "cvrx_JobsActAccountingElectionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "JobsActAccountingElectionPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to JOBS Act accounting election.",
        "label": "JOBS Act Accounting Election [Policy Text Block]",
        "terseLabel": "JOBS Act accounting election"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to lab equipment.",
        "label": "Lab equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "cvrx_LesseeOperatingLeaseAdditionalRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "LesseeOperatingLeaseAdditionalRenewalTerm",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Lessee, Operating Lease, Additional Renewal Term",
        "terseLabel": "Additional renewal term option"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_LesseeOperatingLeaseAreaOfAdditionalLandLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "LesseeOperatingLeaseAreaOfAdditionalLandLeased",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The area of additional land leased on operating lease.",
        "label": "Lessee, Operating Lease, Area of Additional Land Leased",
        "terseLabel": "Additional area of land leased"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_LesseeOperatingLeaseAreaOfLandLeased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "LesseeOperatingLeaseAreaOfLandLeased",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The area of land leased on operating lease.",
        "label": "Lessee, Operating Lease, Area of Land Leased",
        "terseLabel": "Area of land leased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Maturities of lease liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r169",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r383",
      "r386",
      "r387",
      "r398",
      "r470",
      "r546",
      "r574",
      "r682",
      "r725",
      "r726"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r119",
      "r435",
      "r562",
      "r669",
      "r679",
      "r720"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r137",
      "r169",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r383",
      "r386",
      "r387",
      "r398",
      "r562",
      "r682",
      "r725",
      "r726"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_LineOfCreditDrawDownPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "LineOfCreditDrawDownPeriodThreeMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the third draw down period.",
        "label": "Line Of Credit Draw Down Period Three [Member]",
        "terseLabel": "Draw down from September 1, 2024 to December 15, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "cvrx_LoanAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "LoanAndSecurityAgreementMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to loan and security agreement.",
        "label": "Loan and Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r171",
      "r685"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2028",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r171",
      "r273"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtMaturitiesOfDebtDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r308",
      "r423",
      "r444",
      "r462",
      "r463",
      "r516",
      "r518",
      "r520",
      "r521",
      "r523",
      "r538",
      "r539",
      "r548",
      "r554",
      "r556",
      "r563",
      "r684",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r308",
      "r423",
      "r444",
      "r462",
      "r463",
      "r516",
      "r518",
      "r520",
      "r521",
      "r523",
      "r538",
      "r539",
      "r548",
      "r554",
      "r556",
      "r563",
      "r684",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r93",
      "r121",
      "r135",
      "r150",
      "r152",
      "r156",
      "r169",
      "r175",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r190",
      "r203",
      "r210",
      "r215",
      "r218",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r397",
      "r398",
      "r440",
      "r492",
      "r509",
      "r510",
      "r547",
      "r572",
      "r682"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r600",
      "r610",
      "r627",
      "r636"
     ]
    },
    "cvrx_NonOfficerEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "NonOfficerEmployeesMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to non officer employees.",
        "label": "Non officer employees"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "cvrx_NumberOfDebtPaymentsConsistingOfPrincipalAndInterest": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "NumberOfDebtPaymentsConsistingOfPrincipalAndInterest",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of debt payments to be made under the loan agreement that consist of principal plus interest.",
        "label": "Number of Debt Payments Consisting Of Principal And Interest",
        "terseLabel": "Number of monthly payments of principal plus interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office furniture and equipment",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_OfficeSpaceInMinneapolisMinnesotaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "OfficeSpaceInMinneapolisMinnesotaMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to office space in Minneapolis, Minnesota.",
        "label": "Office space in Minneapolis, Minnesota"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_OfficerEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "OfficerEmployeesMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to officer employees.",
        "label": "Officer employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r210",
      "r215",
      "r218",
      "r547"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cvrx.com/role/DisclosureLeasesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability, current portion",
        "verboseLabel": "Accrued expenses",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureLeasesDetail": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash outflows",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r417"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "cvrx_OperatingLeaseRightOfUseAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease, Right Of Use Asset [Abstract]",
        "terseLabel": "Right-of-use assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Organization [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureBusinessOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business organization",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r113",
      "r451",
      "r452"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Cumulative translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r11",
      "r114"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Cumulative translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvrx_OtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "OtherCountriesMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to other countries.",
        "label": "Other countries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r598",
      "r608",
      "r634"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r601",
      "r611",
      "r637"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r601",
      "r611",
      "r637"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt financing costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "cvrx_PercentOfRevenueTarget": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "PercentOfRevenueTarget",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of a revenue target needed to achieved a goal.",
        "label": "Percent Of Revenue Target",
        "terseLabel": "Percentage of trailing twelve months revenue goal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712"
     ]
    },
    "cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants converted to common stock warrants at IPO.",
        "label": "Preferred stock warrants converted to common stock warrants at Initial Public Offering",
        "terseLabel": "Preferred stock warrants converted to common stock warrants at IPO"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants converted to common stock warrants at IPO, weighted average exercise price.",
        "label": "Preferred Stock Warrants Converted To Common Stock Warrants At Initial Public Offering Weighted Average Exercise Price",
        "terseLabel": "Preferred stock warrants converted to common stock warrants at IPO, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from debt financing",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of common stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r150",
      "r152",
      "r161",
      "r169",
      "r175",
      "r183",
      "r184",
      "r203",
      "r210",
      "r215",
      "r218",
      "r231",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r381",
      "r384",
      "r385",
      "r397",
      "r398",
      "r428",
      "r439",
      "r456",
      "r492",
      "r509",
      "r510",
      "r547",
      "r559",
      "r560",
      "r573",
      "r666",
      "r682"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r140",
      "r437"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r429",
      "r437",
      "r562"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r307",
      "r308",
      "r340",
      "r341",
      "r342",
      "r422",
      "r423",
      "r444",
      "r462",
      "r463",
      "r516",
      "r518",
      "r520",
      "r521",
      "r523",
      "r538",
      "r539",
      "r548",
      "r554",
      "r556",
      "r563",
      "r566",
      "r680",
      "r684",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r307",
      "r308",
      "r340",
      "r341",
      "r342",
      "r422",
      "r423",
      "r444",
      "r462",
      "r463",
      "r516",
      "r518",
      "r520",
      "r521",
      "r523",
      "r538",
      "r539",
      "r548",
      "r554",
      "r556",
      "r563",
      "r566",
      "r680",
      "r684",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r593",
      "r603",
      "r629"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r357",
      "r733"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research &amp; development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r594",
      "r604",
      "r630"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r595",
      "r605",
      "r631"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r602",
      "r612",
      "r638"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r102",
      "r434",
      "r448",
      "r450",
      "r454",
      "r473",
      "r562"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r232",
      "r233",
      "r349",
      "r350",
      "r351",
      "r372",
      "r373",
      "r388",
      "r390",
      "r391",
      "r393",
      "r395",
      "r445",
      "r447",
      "r457",
      "r737"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r209",
      "r213",
      "r214",
      "r220",
      "r222",
      "r224",
      "r305",
      "r306",
      "r425"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r540"
     ]
    },
    "cvrx_RevenueTreeMonthsTrailing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "RevenueTreeMonthsTrailing",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of three months of trailing revenue.",
        "label": "Revenue, Tree Months Trailing",
        "terseLabel": "Three months of trailing revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r309",
      "r656",
      "r675"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Provision for Income Taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Taxes at the Federal Statutory Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Recognized Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r80",
      "r81",
      "r82"
     ]
    },
    "cvrx_ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lease balances within the balance sheets.",
        "label": "Schedule of Lease Balances within Balance Sheets [Table Text Block]",
        "terseLabel": "Schedule of lease balances within the balance sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Annual Principal Maturities of Debt",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Grant-Date Fair Value of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Changes to Gross Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r715"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r459",
      "r460",
      "r461",
      "r517",
      "r519",
      "r522",
      "r524",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r541",
      "r555",
      "r566",
      "r686",
      "r734"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment, Geographic Information and Revenue Disaggregation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, geographic information and revenue disaggregation",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r208",
      "r212",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general &amp; administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of award  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Term",
        "terseLabel": "Share based payment award, term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of automatic annual  increase in shares reserved for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Reserved For Issuance Automatic Incremental Annual Percentage",
        "terseLabel": "Annual incremental percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable as of June 30, 2023 (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable as of June 30, 2023 (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled / Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r333"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance as of End of period (in shares)",
        "periodStartLabel": "Outstanding as of Beginning of period (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance as of End of period (in dollars per share)",
        "periodStartLabel": "Outstanding as of Beginning of period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage at which the shares are permitted to be purchased under the shares based arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Price Permitted To be Purchased, Minimum Percentage Percentage",
        "terseLabel": "Minimum Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationRecognizedStockBasedCompensationExpenseDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled / Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r318",
      "r337",
      "r338",
      "r339",
      "r340",
      "r343",
      "r352",
      "r353",
      "r354",
      "r355"
     ]
    },
    "cvrx_ShareBasedPaymentArrangementOtherOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "ShareBasedPaymentArrangementOtherOptionsMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Other Options [Member]",
        "terseLabel": "Options not granted under the 2001 or 2021 Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable as of June 30, 2023",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, exercisable (in years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances, Ending (in shares)",
        "periodStartLabel": "Balances, Beginning (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r166"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r134",
      "r154",
      "r155",
      "r156",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r184",
      "r198",
      "r232",
      "r233",
      "r296",
      "r349",
      "r350",
      "r351",
      "r372",
      "r373",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r419",
      "r445",
      "r446",
      "r447",
      "r457",
      "r511"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r459",
      "r460",
      "r461",
      "r517",
      "r519",
      "r522",
      "r524",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r541",
      "r555",
      "r566",
      "r686",
      "r734"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r425",
      "r453",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r493",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r567"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r309",
      "r656",
      "r657",
      "r675"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationTables",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r198",
      "r425",
      "r453",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r493",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r567"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r597",
      "r607",
      "r633"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued/purchased under ESPP",
        "verboseLabel": "Proceeds from Employee Stock Purchase Plan (shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r74",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r74",
      "r102",
      "r324"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r74",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r30",
      "r102"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances, Ending",
        "periodStartLabel": "Balances, Beginning",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r95",
      "r474",
      "r490",
      "r512",
      "r513",
      "r562",
      "r574",
      "r669",
      "r679",
      "r720",
      "r737"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r168",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r394",
      "r514",
      "r515",
      "r525"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSelectedBalanceSheetInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Selected balance sheet information",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityByClassOfStockTable",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, by Class of Stock [Table]",
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r50"
     ]
    },
    "us-gaap_TemporaryEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityLineItems",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r724"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationAssumptionsUsedInDetermineGrantDateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r227",
      "r228",
      "r230"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cvrx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Tranche 1.",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureDebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Tranche 2.",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "cvrx_TwoThousandOneStockIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "TwoThousandOneStockIncentiveAwardPlanMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Stock incentive plan 2001.",
        "label": "2001 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cvrx_TwoThousandTwentyOneEquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "TwoThousandTwentyOneEquityPlanMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureStockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to two thousand twenty one equity plan.",
        "label": "2021",
        "terseLabel": "2021"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSegmentGeographicInformationAndRevenueDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Gross unrecognized tax benefits at end of year",
        "periodStartLabel": "Gross unrecognized tax benefits at beginning of year",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r364"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Gross decreases: Prior year tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, Income tax penalties and interest accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Gross increases: Current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesChangesToGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Gross increases: Prior year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "cvrx_UnrecognizedTaxBenefitsSubjectedToValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "UnrecognizedTaxBenefitsSubjectedToValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of  unrecognized tax benfits that are subjet to a valuation allowance.",
        "label": "Unrecognized Tax Benefits, Subjected To Valuation Allowance",
        "terseLabel": "Unrecognized tax benefits that are subjected to a valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r128",
      "r129",
      "r130",
      "r131"
     ]
    },
    "cvrx_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cvrx.com/20231231",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.cvrx.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants to purchase common stock.",
        "label": "Warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares used to compute net loss per share, diluted",
        "verboseLabel": "Weighted average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r193"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://www.cvrx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used to compute net loss per share, basic",
        "verboseLabel": "Weighted average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r193"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.cvrx.com/role/DisclosureLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001558370-24-000932-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-000932-xbrl.zip
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MFV]5\JG#.6 _?8BG3IA#TN'47%.:@/ B(7R#1U0BB(=OQ+>I0(Q>OK!%.Z1
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M!G%@<[>[KFQ#N(MZ4\Q(::Y7$3M'479Q['26Y8'_9*P0>>%S3&-JKD*]C^?
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M@VYXP:6+\'T=.^-!,B9RP)-LR,$ZW@D<36D!JI@DT@2Q-(%?6>4[WUPSV>%
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MB1:T5?69,G4W=68FU-8O4R=??HQ32MY]^Y6;4I8=<P=GG"W8+3]PCAF!(^8
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M"U=W&RI[)+#!$?DLI)5G,!YC.T/\2*QP!_V8]M7NGUKB@Q>(1M6V_P730B@
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M:IKW"';;;2BKS'LAR L/S-U$JYAOU%.-+<\5&O?&#=@=K5!YPL"L*UX0[JI
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MLK>R.LY4^U"<"U+VME8]%G8F-P>TZZ^4C;G/GKNZ@P+\B1 @CS;R92;#5_A
M;'K+5:UUQ^,7E@ TK6)>LIWKG-WKU0H*\;[0PBCW8N8*$!OY+&0233N"5"^2
M<T&I_O;23-DZTYL#3@W0R@90%>S+( 42D*H(^&#*@>$.3"+,)V&)>*E<SKZG
M >5>2.!9@QU<.92&= M:5W1%.:>!$%2LQZE\5;S_A:2NU.8"5;VL5(]2G4C-
M :#Z*60#FW+.$I,4;[D41'VI:5IS56=.'VE:9S2W"/1SQ(M5J) IFT$F]W$8
MOH\Y[%%V!*$>!.>"0WUM50]%7:G- 8UZZV0#D,K,97SE[ GP)YD ^#!I<J-=
M/L,N7@([_C_Q.$GTEG.\I/,XO+N3W%&>[]4Q7P#V%0MW*>T*3%VIS065>EE)
MLX;K0FH.>-1/(2LKMXPS$:S5:>:"2.YRCI3QQX=%TQKLV" P1[H%2-KF9G-<
M)")*60"RB97L _6SBP;7KWZX"VB@RGENMKLT.S X-%^'8A+V&,T%N&S;5E.<
MPA*7.<"==5WM7,G>"T7V4I%<K+Q^;R%8/7SBPTHTUK9D8<<)<G0-Y\KW=!MS
M2!R_V2>37[QE7W;(A.M(;2Z8V<M*FMRV+J3F@'[]%+*2K::(DX(U*?%>D*>W
MH@4Z$$-D-*=/_]Q[GS]XPF[,"W67-G5M<6-'HX:U+_Z4&^*-^V9Q+;SU(^B2
M@O!"[92X?>7'JJ:@WB:CYC3R?HGYKS?1'8]]FK2&WF'CF<1>K8ZUP5=I.8/H
MJY?70O@!8<(BDI%&$8!VE05J9RPZVRIZ3H/P/8M8(L;FG^(X: W"P\8S"<):
M'6N#L-)R!D%8+Z^%(,P)$TD910S:U;50< WDW*Z ]85Y8<W0.I-O[8X[3+O:
MH7Y1V]P7;RAWUF#,$M5NRIGH]+YX>Q1LFXKI&/7$[?T=M#>JQ[[OAM?GNPC?
MNXP6E$B]92_R7#M:,]A\D6DW+@OW:"-<,&VNYF/4<Z:>?JR]V<L#1;<9>GJ-
M\"-X>O^*08-]?;E:,9\6^M96%&IKB]N?&S4L>W!M0[P^VRQN7R]55,EJQR.6
M0M59F'_0G(F]FE9B*='L=/I6.-VM1:NB6-5Q$^3UJ1H$MER2"B!8X&!6E$K(
ML'>\::M0C:#R;5D;>V&DSHPI+\05@]=#O$H_>YSJP\JH%^(P,]>Z"+OV+LC#
ML(,"HX:EG\FQ]V8Y1"29*-,&Z@1&N6S6UTV!;"'9<QP&-YLMCU_4,XV-,[?F
M'C@CO8.VU<+6VN9XYW(F0O<O5)W1)JQ$W(7?RM7.SU% ^64<)2G?^8 OC8[;
MT@6WYYKH6W;=IO9X?==(ZM[HJ\J6E,"71<3V>5S"TY+[BG_M75?\X^_W<!FC
M9GOS\#N<SEBK 7A=Y0M\[E4O7N^\)IA8)2GSX<4A 8AB9:OVT^UN,IIX4BW>
M'7^+W)N.4>S@*\0>90F;M#YE>SNOQ:L^>*]LL]MH_>KP>[R>5:M)[EN5+W%Z
M5[V(_=_-D-0F<R.QQ&MTHX/O$;M1G2:%&Y6_1.I&M2+V=B-%#=5!VBV+Z$U*
M-YU/C,L=<3I@=]V-3M&*7OA<MH?L(R5' ",B.>$Z-Y9965VMEG>:J9M7=#9R
M<=ECANY=E7L4UW:9V#>1WM6#Q@59UR@\S2Z5[^\VN]!+:7 %&^*^*E<E_@ZI
MK#\:!><;N!#S3_FYUCRZ[1)[Y'$C@VT[5G;*+-'&BS;6->Q]=W4O""E+LB"%
M+#)TR](LR &:+:IPY@3'T%@4WF#\D93M&I3DD9;R2H*@FLG\G-#5+KQE*UVZ
MLUE/W,C507NCB<V^&UZ\Z2+\2%,<Q8D *UP3'8LFN$Y2MI$QOU/:ANRE5V%>
M73Z(: (;DH]P:U#HL$R?*1>*K03F""SQPO>4'JY$.G7$&;G===\GAICTPIX;
MTDF'_F=QG+]!%LB+?&?$DS43CYX,)P%4OQ7?Q$\A6WOJ_1*(]*WW!G<7DLK+
M@WXF.4E!=-DN!N'AC*^0GJR$^!,GEDQCT5S[QT)[R8B4.1%@-?V;A1-;H/7W
M=[04Y#L:7,210.OD<L=YX[JNMBU.P#32\&#%==P0[W2F6=P!:R&@2C*R"Y(1
M=K6>&4'%C)R]&4DFYIW'@D>VH<O5J@YM:EOA#)T6K8J)Q7$3Y+.(!H$GFC)L
M!6LB)LCPC]6T _X(RN=H 30)$"6"ZO0#^0B:W95_)^M042KW?;E+TGA#^3U]
M$BY2/P!W[(H?5$SU/T2:MG[S@!]C+7J'I7K\3,"-EP5HF+%\VR]-_(RU^ 1X
MBW6*)R:C*P:OJ27B6RF*$X0:WSZ954J,8**3V4/Q<C+QF=0*EU4'<++\6&XI
ME^XH4[ASE=^:UR&MG7 "8#>=*]<V&WO@7:(8RMW[(F=.GDCZBR*>W]PN6R93
M.P3Z>VQ?Y*A-9#7#HW,5*]J_4/X4.]4_1V^J'IQ#B%N0-BL399>K]RP2JP#F
MA7=QPN WN7Y-A=1P-?Z6)?T0KA/Y.6-A=SN:HZ8Y[;GB:P\-1T3B!2GD@8EI
M(1')12*?]D*1ZTC,I+F<2+NI3ON;-.V4.\[%FWR&N\ZU[7&#6ZNF-;O/QXWQ
MPD^[R$.'^/+3KBBVHD?0U=F[M?*XJVZQV;CV:NN$.R3-=*[,(AI[X U.0[E[
M#TOR"%.SD>)PZ36!UBYB]8H^I3?RZG%;,<[ZEKBCLD&[<BC6-,,;?TW"VGBZ
M0-9:$_&P(<")[%DE+BMH5K5N*)A9VW!.7JHKAWG<:BX^:N46^H$S.BQQ657N
MH[=IKFO9T'Q.;GFLI]XY]VWGXJ(U$EMRU 4!VD,NMNNJ ,8>Y-UG3V*]G:\Y
MI2T5 =MZX/3'#MKN*P4V-D=^FFLH_+@5!(4,JEA7)@7Q<C$FKB<XKC%N<SUS
M!J3@,%7Q@&*/[<&GD<=9K*F7HVN',VI;-<N+"M0VPC=NM(O:?_*MB$U<4"=G
M^W.4;*DO\S-JYS%M;1&[7YN&A0OJ&B)UPU9QA[NB]>G*(_<BL<I<1@VU56O:
MX/2N1HV*2<AA ^33#JVX%B8:D+>JGVQDG,F[::<6UA7.]1 4R2=%<]I#QM'5
MLHX'CY_C5CPHM\&/!T<:'>)!T6 >>' L[F1X\)T3/+"G<*Z'H.@>#T91R^)V
M!HOH<G7):<#2*^Y]OHH_1W=4S$6"1]&O8=)@VA$Q<G32?;_'8=(+.<9TTZ&O
MP]YHD09P*'UF/""!X$X"P1Y:"/X3[W),8@?@0I8KHO@08$2 $U&LB.3E$*FF
ML<)5\4M#")('$9F2,'FW( *7_@W\XHKZV6>_5Q^Z/VBX;:G[IV^-$_D,M=2?
M,MSB+^O7)K"UP[!;M]7[RH'[WO-E%F%6@O4BYCS^+.#VTMN*;](WC:DZDL#M
MTWWL47F(H4-_O-[?2PMKQVX9)U*P(CDO)PE$DQHCU_VIT-VOU]W!.';A)2QY
M$"M!+UA&?_4X@YR2>R^E[XQ M+$[;E3H:@?]T*?OBQ<-.FM@#0DD+Z*8$;$$
MR-D1X.<$#":S1:$JBX10-$D)ARNH7WH)\6"AXPOV7[G'A)M,.E#Z:L<%8*EI
MOY'Y&CK/"0_:;*!' UW/N6!!J_S6D"#G)".?*%[9XA<!#HQFAYMJ\).AT:_9
MPKNG+S3:T4=8JL=1^IP\<D_,<Z)UW5J_J3'.L#73L=B>T[9$OB77+G?O?>-G
M"M59LPH2J=QLVD@6\M\9&\*5 --NP(VG=49Y08 V4<1)3GWZ/;8Q?][F']0>
MT-PIZ%JN<F4\OJ:UM6VT+1%#3+-V!;[4-T,.+BU"#T&6;#SSUO(6@Y=['4DE
M"Q)1&M  ]G8]_YE1>$K>(^O8"Z?%F9$,D)&%S?V,,%&4IP>8<37,?MX"6]+/
M-'PI4"?_S>%WM0<W'W=P%+!<P6SMSGN3=V'@O49XP"Q:+U=W8JKFLZTL]9E/
MM>HLTY,.8J@:8ID"R/H000YS@U3J&R&**41' .N>;<87(.])1(@74+*#IT;E
MH:?*[\Y3G<5'7DI\):&L)I@+2+;A+BEV#Z;%2L=6E*O'G"_9,P:0+5@3P;M8
M5DX/MHY-)&$W?-O[FMYUW&\RJ<4T\S,[/5*^22Z\,(SC*/\HOJ!0G]%HM=Z)
M'$X,MV4G_=:4.:VY;%;UT,C:]E7..T<E(KG#!K?D7WRL$!]D0+"K-:'!H$!-
MF(.1O?G?D3[91%35Z DS+9;1DK.U_"!'P#K$'D(,)XK8L5$Q'>Q-"?F<<+A>
M]E;'JW*@P)%8G#'=C][33O7<&:<.9$N64I!RM[=4+L%^"CC]K,^=M>ZZNI&;
M:=^*<DX#5:^,7L9)FC0](]K4'B?D&FM:G9EI&F.>>K6)/"SLDV0G2^E+PBX?
M"AU9498KZ@-A>=\Y8(D/1S%.*H1!C1F8"()P%V\?O%3=[7X2D.;YN@IAK9UP
MQZJ9SI4LP,8>>*/64.[^5_:C]=EC7J!H(8;H!%Y!^AOU.,F9D4\Y.S?YL"4+
M9"(QFMS3?)^DM#%S$X'@[]F+KNY67UKSB8;.%M(%B3&A><1.=W5LA50>1@L5
M5<##3=*L$VN(</XC<M0X7PG;V0..0W(G@QVU=NH)'Q5:)X$@]1K9!Q$/^,P'
M2NR:183Y#^X//_+7Q-0+/D8;MT==<*."B;[Z@XIJ>[S1;23UH A.]Q$\WGHX
M3KW0_ C!LIJ/P-U]2/X<94_5T^ J6XS?<;IAN\UY%,BFV:I=[@9\/$IPLT=U
M3H'=VVKZV.],<B[PT%\Q:[OI)1%(+@/Y,I/B*[D35;L5]]%RZMH/RG817<,+
M\N;0,[T);VF2_%BQFTSGP;)S)Z2C5+X8<D43G[,MG'<UU0UO[H$;>@RTK2PF
M],WQ0H:)T$-\F<+3,NJ%F1)]Z[7$6ZH=WE,OO$Z@?J.(VW/?WVUV(2#!%=0D
M\ID\M2V)!ZN!&$J%O&F*<0ZEA]/OK5DJKZPXB!B^F+&G4N_<.T^^'$QRHA,7
M#351'D3<:ZVM*3J U+R#I\D^7>*FCLY\0Z91&WO18KVNZ7*U8CY]V'H^O8D^
ML"BBWC8.62+_3,1*4U^YS+PK3H?OHW^1YF78#WE25U<M1JW9'DMA2 +2B&:D
M),^"%!)-F]@UE8&61KKC63'=ME3S:N^%$Q,Z:MV^>KK%7^7+5/ Q5E&W@PI_
MZ6IQ2H;5ETK/.?66JULO"N0_#^](=.F'TW,[:[XOQ&G0"?DXUDF%0??_!5&8
MD86PDR6?&9<E>>+JT^,3%]^<0OD\B(^>W3W/+ *\U&?3WMJ8S@3GQ[^]NP&Y
MJNL]C>AG+X0#XD:0;^J%$]8Z:GT\(&N[8!^0VP6W'LL9$WDORTV6 T+-1YF(
MG >!?($<CI'[34DT%'!&\0!K&$Q3ZKK/=L+2J(R-J8M7,)C)+&84B[3.9_9<
ML4YM1K%+2>V:N>[(T%CPUL]G.G>>&R VV: 9"^MZSA$&&_7HC8"0%@;H]]GC
M 8$MMM_=17^+/D17C]%_B/\\_(ZH?<D%_)?05V^S#04<_.[NW=]^_^'=]U>_
M(WR_B2G^C'DJ4'/E^;+@2!Q1\D8]+GJSHI[/0N8[P/L,*:41";RWY&MR$_GA
M+H#WX)]V<+.)1'%*0K9AJ2SOM"!^O'EBD=H@A1H5'O^5"JF$C:2 D&0B!$PH
M?V'R1E2DS(4 K4?YX?1 O4<J9_/6B6U14IEG*LMTQUCNIF%9C%Z_LB2EPD^7
MJZ5*QHBO7\4'NKHD76G@1/1!%FE;MFH)S&L1VZZ&=90H6 *6*J9PUJ38DD\I
MWU$!XF%RE,KC;L$[)RL-.7FNKO+9^CE=KGX6T"ED3#5W:3MUQ(D3W77?GSF;
M]$(^X^NF0^_$B9@$=,4B.5H2[\5C(:3K37QV/(FJQUM9P B*O E61/+2WR:>
M8'8TC14DW;-X=;832GM .OG1Q7RHJNTM\Y[D2RDMI0':>^'$LHY:EV<Y+5WP
MSFM,!;<6SP4+5V$\O>9RLTDLBA4'1E'%<C?KS#5V.\3L[&)UQ!AU<MMP+#7O
MU'87>?'"G5P95./2R6-<]2>$&Y5%*/_5^1"\IC/ND.UF@_8C\<.>> .ZH_PC
M'!-GO-0'V [*K1MBKZ\*_;3?\?@H49_?9X3GACI8Z:#;_"*]3N^V&"_WF5=T
MUTIN/:Z+J[W.GM0;7?="17ZLHH/I=%[MW6A*4VJ,.UZ;==3/I?.6>&.S15YK
M,^F<,H(5[@A*^E[R3.)=N@KCST[NO]<O%<0*.U?V:D=[;59I2<PI8,WLT;XD
MKN\_E^ VU,+Z(%PL7 L4$ .S6'@ZKH59,S 7DI;L\Y&^IH_R-2?U+EV'<=Z0
M'.Y(&FJGMBFL"2V\$398HS&C;?_>1E8P<QF-,@E^H?PI[CX-GL1.(N[_#3.\
MP._R^#D>:+8]E=, DP.K],&0C,3\H>-0D4D10S!&CABVS",B^/?H@0*>LK5A
MKXS."8%%V3*]X0*(G A@5%29%C* ]1Q PXJ)1#S_ 3MLO!>FMF"PC,SI@$;9
M+GTQ VB<!F14-)D4,8 SFLWY4<TCPOC?T:-%0^G^[F1.""UTI?H[TC@1M+!2
MFK\76C@KU3^U>9P]^&&HZ$ [G0PZ#$&%^:/!Q"C@)!-O,EO(-P#(+LJ+:=/L
MAG;QE#DZ//BY).OUJR^:-K[ET9?6C)&BS4+&L*$C-%,,:55G3$ I,R>*.U'L
M'=7W=V>J'PG;;'=@!R;H"_7ZO%$^&&0>Z68;<X^_7?]C)S2^>+L,O219KA[2
MV/^UJ9"_44?<\&&N>QDKVGOA!88.LO>O#)&Q((K'@CR]$<D&4MXE(^O5_COX
M>Z;P+Q[G7I0NN;SI5E/5WZ0];N]NU;3LU-K&>'VY7>2^+EQX:T8;"H2H:Z"6
MR^L/]=O::OIF/6;HN\>U\0V:S\Q_+56Z;_!@ZR7O,Q;)8WPGS/,L^%_&FTT<
M2:C7E[LWZX;33;OJ790<,.B#O.! %PU&+6__.1,$_MYFHD"Q)R$+24"8::L3
M3&&77]I41K" N&VI9-_0'&>LF^K9L$2XQ5^TOE5B6\N!D6K4WXDO*><TD/&6
M!\IE'+U0*"SW&)>B,?_V/+V!BB9>>+=["IF_7 D* ESJHMLN>9R./I8=B\'/
M(FWD@^08F@ZX=:YD44/$?MST<W%@."F/(OLF7DIN[I;3#J2G9#LE%%%2D5RL
MZ8L&G9)-[Y8H1XU?*"RO:' NNGIK>OU*N<\2>L>9?[B#.C'KW\9H8V+_,4:B
M)KZ_G5'*R KN$&-!/F<"$D])2&@F(MF"C+,=XB8RO-JV+]:?A:CD,29*V,,F
MY]KAC^0RDTQHDDM-I-BS'A[1!T(WXT^R@_#@/]-@%]+EZN'9X_1"Z!H(BV]I
ME$CL.@<5UE3F85R\[=MD"2#G4(*\Z:32)GV<@^EHEBQO:E@CCG<7Q+Z*?4,]
MET2>F0*?,_@\(&5I2%D<.&4M-\Q$(E(FEP>N/P'^4/H@YB&[I.&@M:X=[FC3
M:E:.FJ-&>+U?+VI?+\XH$D72X>EI1;7&4]/ZEC-R1/TI:4VSF3BCI5/10W>T
M?A1ZO=F&\9N8:RY7E^JPZF,<91_2*\:I+R@E^C/1COUQ>F5O2Q3+\RZ=D:^Q
M>ZDRZKDIS26"J86OOB)1')UE7U 2Y&+)8];G>$/29THNEE?$VZ7/,6?_A(6&
M^&BM4@M6V5I#/9N2R =_X.OBB!):P-1$L71V1#OI;W%=-G/&C@A^)&=("H[D
MD^+IH)J\.Y,T>YX]2'[\'#\^Q[O$BX)E1.42_D9 5Y2R%RKGQG="&STB=^N.
M&)![V*' XPY]D<-Q'TU&16.U:\9R&<A6,"."T+MIH7%*NX!V!.B-$N2/GX74
M;T()E6Y@'-U-_>81UJV:U\6SMM-\ KE=!<L1S&FHKK>(^$T_B_]E@HA_@"3R
M\4*JDET@G)U%\GB&$1'X;OK)BBO5IMD$;]MPU.TWWK8DW%DAC!,![=NNLM\]
MF"K>W16+NO7>X3;8U6[9U+X=E$DX_$K&_E3PTMNRU NEK,D]A==D:? ^YN]W
MZ8[3FR39P4.SFA^C#QW< =G;,I5+'5V)X VW_JKTO@!2.I1?D(RIBJ6$Y&SE
M3HUB3'+.CBJ(36^ABA%6R@BLW@BX)P ?=S#QR8XLD_/\<49A,;G?;7L$:&>'
M&YO&MK.5*40++[Q(-[K&SJ8;"Z)$+$[D$U)(*3%$RNFD0A):H^\MENW_>Q6+
MK6LL-F 7J+<95-[&\3MG]JCBA$3+5BOVEX:31+[[9%'!_O>J^ 8"RY-+(<(B
M\KN[Z&_1A^CJ,?H/\9^'WQ&U8[60H49?O<TVI O1ZMW??O_AW?=7OR-\O[TE
M_HQE_N#*\^6)'NQAO5&/B]ZP+;V15>$71.YR/3/1E$8D\-Z2K\E-Y(>[@(HO
MGW:IF$&1*$Y)R#9,I2,NX,#OB44*; 7EC<=_I4*J+>520/E*.B<P&6,^7&>,
M OG,]+3;9@A^40LCE%H73_Z*'BH+$F69K'"7BH^%LY?VAEGEKS2!C>8[RED<
MO+,]^M>SP#E4C6E/*S/V&OHG.$MOTM(Y[F5R$278O&;B8QBVT1XNYMG5Y49I
M:R??U#G?I3$<LOEB4L$E*2\\CZ*=%PH=X#C:6]=>IG,N$4[0Q&$;2VL#*^*<
MZKK"KG%ZWT\J2,F52<Y2K!J $2Q2!&]("!2KE6Q#@)=W8?/MUYE,_7$874UZ
M+YJ'SXML^,S:5<_1LEV:Y>KH?$#H4AP,D$(;4E*'*'W(7J$9K3QP_("9!5G)
MJ%N=-5V,VO)3>3E0*"V6]?)&Y 7-RQP%'UC$-KO-WB(CC=7#Y#C%$=K"+S-\
M7!X@Q*F.QC9,TA=-,MHE"(&KOY^?F?\LD_+SC7@Q%FQSX;(R[WF^?@"%T"DO
M-U>K+F^O^DR&:)>_A(5UK1JSI?RD4 #NW$-1_ER'!<E_\]+\:Y;C,8:XT1H.
M]W;A>X_QOWKACIZ+J<M&7<2Y?MU27]CPBKVP@$;!O9=JK\A/P!?G"#RYY:WL
M-IHR/<$MR,ZJ.\1OD)5(84E)V@7)Y26YP 0DGM>.Y62_0V&L(#?6&Z/A*/N9
MN7Y[[9=B$L272CO]/9+.%'!BX0!KU*PC3+K/9@7021D;B%.<7Y; 1N;+P(X^
MAQH^"Y+LGOY+A 9,WU^RO7XXH(]!,MA92\54*D.<<L5@>=H>AOLKF$=9.BG9
M<AI0.#1E$0@C9Z"P19>(6&0K!I_)4P7HE;*-LRV[R7^7 N'W'!=$\B094X?7
M>2>V2ZXP9'Q(WZPL'>4]/^$R<*-&WO=S\HA6[_$M4VZY2Y-41)4(KOLX#-_'
M'+ZT/9BV,<,Y7DQC8RL3YD9.)SA+-M/7X=1XF<^%2R*23R DR:2<%C^16WR?
M29OQF3F6*GW&_PT*/K\9!*U:=B3P5$Q^$[AYH"HRR,QO)8R!E6J&?QTUOI^(
MS](77BC/JSU99^8ZDFN4;+7R99%Y\-5X%GM(/9[.RV;E05C9[8*N622KE)A8
M;Q;#C[S3DMQ$*A_N)QXGUN_,-W(Z[2&HP;HV!Z$:-J<[##4IBV$@4O)!.I>2
M$#X1,LYRXCZ&K7_*-D5F#IQB$;.B#&Y(%_89Z4>HYW3:P-E@79O 6</F=(&S
M25D,P%F2;X^>CEY QVCK2YC!AZ&PX#>YK>8/H]E+"W#]>=3MCSH^IPVA6LO:
M!- C)J<+GWI5,8!G2;HQMS]&GW':MW)^($?WE+/E_'_N(DJ^_W8!IW'?SQU(
M2[L53>_MP/[[:JKS.G-!3AN*^_\V(VU5&TIQNF ^P!88T+ZRV=WR>A7Y=/Z4
MI-SST]D?'D[U4V%\#VP:*[K]#?_O0'#\-N?$K'_SD#];G#^%T\Y1?YBV,]!
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MTF]3#_*UMIL?R-^SY-?WG,+]#"I^Z'3B>7PS^]\0P!O\#J/!>P/OWPBXFU@
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MKM6&O4%.2_E$8*Y=OPF!+G]699Y0-YXIC\ N-Q1JN+NB(\)==^*SA+N>-C2
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MV0LCPO;7O_Q+_DG6_R__/U!+ P04    " "(@$E846*TE/H[  "%500 %0
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M!OWU\.CQ@=ZYU<AJMX@QLI(:>"XK ZPRV8WN_>OJ,?!K!%7Z;HR4Q*/.162
M426'W,6+E[@V,>R==<6,$9CTX'.Y&6,Z.8LQY4IZ24(Q21T40^;VL+YXF15'
M)Y\^:6WB5" BEZ<Q1I0K% %*.75^<B,W(Y5CN:XK;I@\%8C(K]N-L:;\ 7S_
M/U'PC.Z!&Y(MV.PJ#&..L9I1WC")JE"1B]08^\KO@1\3;N/DRA.S=>U..<-$
M*#/Z7'3&F%(26L[<""P"_,J]@]^4,DQLXK'G0C/ :I*2=+]R?3]/'LD46JF4
M84(3CST7F@&FE)2DBQ7 "[(W^X:#YVA)W=M=Q)YQM:4-$Z(\#;DP#;"U9*2]
M;-VQ4L<ZMB0K14T3HQP!N0P-L,%<>7,\B6>0M#.)(A"FW+[TW46-%-F%C9&C
M(@FY) TPU>3.D9<0W4>KZ +C )\%9(0>1Z+B2F6V?"1L.=!3L@U)R25LC%'G
M?DG.3Z(ULUC(& E*#CV7F#%FF]OXT8?>I1^X;%M-H8QA\A*-/'>E-\8J0V,/
MJ7=DX/V91%B&TSBB3Y90JS[;=LJI9)A E4G))6R D29;^AG7&(6OQLA,-.9<
M. :883)2+B%>7=4=(DK?31,09]2YB PPNF3$Y,]4L864ES!-3-QQYX(RQM!R
M1KB!7?\*S<#+?P+V=G&G7)GXXY-/QR=Z"DU^]+GH##"K9%=<ES#T7/^_@8O9
MX9BLHL8(4(F 7(8&F%6VA]&<L$OR2YV!FE'2& FJC#\7H%'6%$I6:NN3$V&A
MK*%"%%&0B]$ D\F$4#5+**NW?Y6^&R,N\:AS$75I(_G;A]WL*2U2JDB]3UE@
M,3.A"J':>>]LFB-_+K;H9$TZRF]>-@;EW T?D_;B\/W"===93AP_"O-?MA#-
M?OBY&?YT?@D1&3 DLS!([QD8:5?4JC:?8TW(23._"09>+E1&\:?1+A":2(1.
M2P6J=$GFTERRV:Y-2L [9763LX2\6$*6H:PC64< A^ Z%?B:+,[4735I=5CI
MTU=&:3HV\A^:=_K)]0%-T!:=N1B_0K1($N<RT"!55T]TR BZ"I+F!-L%FNRU
M+)H[%1 N//K@!D3UKJLR56R"B#*='264T@09FS=D"-4,)!2+V"1Y(5T=):#2
M1-*W&*Q=F+]Q0K3B-%J2XTV1@0P 2-2T"1=-R>THV94F<)$!AK40D!9V6U-V
M%$2N/[ZP\X>RZ(.P4?&U+/:JP*NB)Q24U8 B@79M#*:$>)<&;R6/^-S!Q9(<
MPW\0?4AYR< $MXX5H%"GL*--Q!/ CX$6N-@NAC<!\KCK0VU9.W @39F-NP+N
M=L *^7)(L6OESU]G@X F^:^^:B:P+\I6UPT434W+K>C5)15U6YS(0T)3Z;>2
M(A\4^V.(+E M=Q?!KE#FUF?"K4-M\-$8"C(TVH6(W)1ZZ[Y2.ZJ<?;E<6&,D
MR,B3;5Z6(-,Z,- GE:L,9..AOKR-D%"@U"ZK@C0<]@ ':@!H?0NAR7DC0(L'
M@%?)&^4B^T%]88V!H+I;D*?/+C50-J-M7@@7&Y1$]>S!1C-2[;JR3*QL!1;*
M&1QK*U@$##4:[;(_%N@6;QSLD;F(*+MLDIR'1UF.;>P:.H.@ ]N3*N5V[2.4
M[=6R_/XR6I!D3SA1)-RN?40AFI[K'KM33#=(*,JP7ED(";3,##6;P92 6Q?.
MKM"9NX9DD2MP@F6/$E:T#AX-2;9K2;FC[W8C,,O?>)]X7KR*?1K(= [FT(.L
MI45<T3K -"39KL6E0'1R-*-IDS!8 A3")T ?^UN!ZR ,;T TG3^X+VSSMTHK
MUD&I"_KM.NI662J]I[4.'9(DVG4,%IT &KKDZ :.'ITQI,GO2G-P@3-P[/9M
MPODEB*#G;EYV$09R?Y(/Y'9^*77QK^_V,[#[Y_ [#M\/GJD@+@-\'L2/T3SV
MJV%L@NMVE3;*<^;KZ/Y;LF*IV6:T)KN'X_%HQA R?Z<X8>8LL0?< IQD&Q3;
M1U@U[4%*4V)[. V/AH\T]>0DCI9D*?MKNUZP<;%;PTH\2!'9PR%W9!PD3\1(
M8R M;;'\.03V<! =6?;L]+LR52Q&@8C*KHZDNU#H_S"Q^3&<SC-G%/(UN60L
MF&:H44;R<''$SQ*U[<\)YLZV1X=PURGUZ62=ZG[:2,U6NQS+?I4^>,BU,K21
M_ F@&%R2646OG.D0_H#1\BP.(S(J?/'B^3&=$C2,BOPS8]L]&[2DL391D7C9
MD-X-%RPXG(2$C1D[F"M-H8R%8!#39_P9XQLF&OP6!W/F;5JAA(4B%E'7@\_W
M2 Z^61854= @L[R%PE>CU?BSQ!V1$>$OS<-V3G2:'R1)-#+:F;L"3AW=(*$F
MS[K%7Y58NUQT[H'OTV?Y ")\] D7)K,51)#RD+XXS$>*7&7;(-.":KN\=2J,
ME%U?RKPY&?T6M"TBY BT*Y9L0_/6/T0D_FU)W0#0Y<9"0&4/;A)#)ZTDZ@>$
M@DW$3BD+!2Y#82;LQN]UG*3"1F!!K73C'":H0]A-@((ROOG2YU>R$ P-",ZP
MT?8ID/'.%EM%EYO.((H)Z5OK\2F8!SCCWH/[ L*+%\)!0CA$+GZ](DQ/ NBH
MT2U(]E3YG&(JE=YZM!"30W,K W3;1U'&7-DR1F33]I3L\-E&,D9I:X$D1VD&
M@L;/KFBPXMV 2+BG+96Q4.1B^G(S2-M7;4<TDS)<W2^)3H0+E/JA>:_)@_=N
M\H8VX6/R-S^5YNQ_XC#*DM(FCO&W 4X^1!&&CW%$O=D>@M1/D[=1&FH,%N)T
M?/[E\\#D:[\*^P3Q,IP:%F),E=H<$:VM?*-IQCRD+/>U/'5#Z#&P4%O60A3(
MTYG+WUSOPUU:SZ$?1TSO0T;I/<  C](<!>;>'?X!:(9U,)L\D?/B MS$JT>
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MP**H!!59U-&)X G@QT ',&X]P,.'@'$%DS"*.G4D+CL A0DP[@#1"R&,P#W
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MS"E*&XKCZH:"MJ']EJ&#1"H_/XXWA;^[48P3#$[G^9M-&]G)3V2Y9DK _GQ
M@/U9P^0K5!R\Z=N"5L/\7+(4&"K3^%-U&J>M:#^1&Z1IZ<H/98NMI/ULE0FI
M20RBXIK#7U];M:7;W*QR>L?MH%-"[4JP79?))M]MO&;JZU5*PS=HR20@=4UF
M1WO[)X ?@Y$R E6,JDKJ_TN-68B1=$3[!4'#[",C&(_RS,Z)L%C[P%(AW11
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M(;5YD&_.#J#UPH6N?+7ZU%$5@JD"=A<@]6+V,S*G:(KA(ODAGVQUBJIQ8W:
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M7--U*:,:M* +C-3$*H!# Y+U2S%U$Z#I? X]@/,D29Q\4LS"6LNW@9RVDF]
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M6'2+ W+ZB%YI!MV(<.3BGS%,]@:RB&,V8!^<U$@UWN!7/:=&2W:2DMK"]F&
M35971CM]Y/T-!Z'TRI,4MD_>;+(R>9\8ZV7<_/Y(^0[$!B1(TIA;YP[&<[_I
M'ADW0'H_0(K:)WL64;FP6]MB1[BI2>XSPX<@T7",6$[5ZYI/@NN:M$\G"IRD
M5Z?8;7)CDW>\=W<VGS4)DF8,G5':I)G^N6ZFJ]#5T;W+.LE8G-@_1E'N[+!M
M#,@DHA<(L4]OHRX):V]I '6:8[G@0*B($J6F;854>R:,?7DS+/*RN+]^L,=L
MO,SX+Y:C3XT-QE\(,3<Y/>)/L7%;\=<%&]I>\VAPL.IATV4/1GA";WL-E&ZZ
M+M!L@$,6]>(AD,XO,:%'+]VA'Q/0D7-D\:O:\>JD^H0#;<PAK3E)<\XO27>.
MBV9.UF'B$Y>46N>E##A:7;@8$16QX9/@7,4J_O-HZ/E-N)W.!LKRR1-A,LUH
M^Q"<!:L5#9,(O#^7@4\0':; X-/5L#7=] -//%7ET"71QGO*E9@A@Q+=9-^E
M- 58&0H!(R:V^P/ Q9+>43\!["[ 34R3H4_GR:P*IW$41D3UDZF6*?^"W8^F
M=1-HFVX:UPV :LJG1QX8?WJ7Y4TRD5MB+&E#-RCU"([F2&1SRK:G-AD<R;A=
M88P: EFMO&&P):]ZR<HVY@N6.^L)3]O5EMUK1,ES1+/$ZIWC)F.G)'*RTF_8
MD>1)1Q[A(O0,8$":H C.**7P"=P#+R8#@""\>/'\> 9FB1$U6*WC*,L>5V&2
MHH6IDFEXU\)4'(^S'9"3C\BA"'$*8Z*!F?FHM@WMD1%J\"3$]]X2S&(?3.<M
MP<-[C;3;3LJ3^.OHN2IYPJQJI@%X8?);ARV9<OI:WP#GM=0>>]0-J0-@KPKX
MH?EK'_IOW!7@/O<JJJ8;#H>&A"PH!1PS&5D7J[4?O *06-&GR<BY3X@RRYN!
M)8$D:PX,2O2.B 1&_.@?+L8NBL*'X#;&WM)-HM?R6Y-:2<M6LTS@K<@V^3W0
MEDKW6O"V;%?-ZP8W$_=,?&;N,8BYCYMVTK9N\.T529T#E\/#02[G>[+1T<4%
M1C3XESYOEF9V6P#D)>L6INF<GM2,;X0Q%?>N0B>)4U>I&^>734<&6-,X_)*.
MGU%JX^?@)GXZ(-IS[/K31Q\N$FPQ2:DIJYNB4>9W57G(T]F7KU9/\_\>+"AC
MOH%@@=WU$GI7:![@59Y8X@X\ 10#4MY=+#!(Z5;3!T=5?9!U^F_.MEL';OM-
M= 1.>W9FI:[U5Q 9;7=@'6"*,X$N8!4?WN=SNYO<'5,!$J>OV4<YF[IT2^6I
M=#)ZQC*>6'B&\W8$:V?%"7%4@ [YVQ8VY"\_DWSI9?7A^C7V;&Y9[43?D3"W
M,%$GWS@@[*XBKE]K%>:6U04(ZN+:$;42@;J(.@3>KXO@Z8-'CSGX-95V]I>M
ML+,??OZXWS79;3YH)48E410L<7QJS)39^05#9N<7-LF,0<V(IB6&73Q)P726
MC)J<1-B&\+IR5@A,B;B.'.E&,0UR-A(BV[5,55W T-\.JC4W3#8L9V?PU$*9
MFB'^@-'R+ ZC8 5P:L&D9Y0P!.0?&HK* %.#EK3#5E,$5,'4%3=L"U#(W5\W
MZ?PSGC,#]UCE+<:.&LT]Q$QU>D%0VDP";Y9V=X5"2,;]@-UD%M!KZ04H 8%K
M^2.T'Q_7)-)*&G6R5IV=9F5->I3DOWU(T9C]]H__#U!+ P04    " "(@$E8
M% @C/Q 1 P#*-1P %0   &-V<G@M,C R,S$R,S%X,3!K+FAT;>R]>5?JRK8W
M_/_]%!F>L^]9>[S""CVX]EG/0 3%#A40]1G/8!1) 9&08!H:/_T[9U4EA$9%
MEPU@SKU[;X&DVEF_V<_ZY_^,^[HTI):MF<9__Q.+RO^1J*&8JF9T_ON??+50
M+O_G__S^GW^Z#CP&CQKVGFM'.H0,_KO3=9S!WL^?;6*WHJ;5^2E^^!F7XXD=
M\;"N&3W_R=%H%!VW+)T]'9?EQ$_\N45LZCVNF*[A6!/_#?:T395HQQS^%#_.
MM#^VM9GF1PFO\=C/F[/3JM*E?1+1#-LAAN)W@\VJSFPOXK743_ZC]Z@V=B(P
M@)E.O %I!HR?WNQ?G?YT+&+8;=/J$P<6$AJ*I2)R-I*(^3,;6N.91O"+J&+V
MV71B\>F3MN4LKBU\.3-O;?S4JL82@7%YCUNT_>0NI'_"K]Z#KF,]^6#N)_P:
M7$+MF9V=7W*5:LMW%7Z8G9EM)N.QS'--\R?$"\NV/Y;+Y7Z.D6:]5JFB+N\>
M?I@EJ 6*G6D3?YW2WAM(#^AI^=1>(J9X))Z>H5]M*?VF.?UJ.[__Z5*B_OZG
M3QTB*:;A4 -Z=NC8^<D7!E^.T =7&_YW1_P><28#NO/S]S^.YNCT]S\_O?_R
MIEJF.OG]CZH-)=N9Z/2_.WUB=30CXIB#O80\<'Y!IS_AYYEG5,T>Z&2R9Y@&
MQ0>T\1ZV1BW^IZ:JU&!_P@,EBR@X9<DU-.<*:;8.?S2KL((JL=1FO7K0M&ZS
MR49YOSLH:LKP_ORAHSYV*AU8&7O/T'28H>7"8K,)C7D;>;M9:3=C\68BUL2M
M;K8FFESN3!)JKT!&=S<Y4B^?'EWN2 ;IPX %C.T5S'Y?<_JP+';>4 O0(& B
M8*-&[1U) W(Z8F-OTHN3JQ9-JOLRN: WMRWU_J9WGL>EF)W4ITXRWCQ.'YT_
MZ+FK=$\[NDH4FFU3/RZ/WCK)2J5]?=2^32IRI*7W>JU6@P[:EZ^>Y($VU%3*
MIFAWB47MIGV7+13V([?QNG:;U"H#FG^,G<$P;:UC_'<G,CO) ]=B1Z(9:XJM
MK)G!C;TMZ9F3?3.1ZY']_MCI*">9@9[?D52J:'VBPWF-SR] D5@&3-F^H%85
M1W2@Z:Y#U9G)3TJU=+6<[2J]ZNA.OI/-XZM&!W8X%LWEOG8!XC,+$&_J9\5B
MO/%P<R<?RL63?N2P<#1*_?D"7!T_9H]SV>J^G#8?JI'&.'57M6 !XE$Y_E8R
M%]-OQHX.2X<EU:Y7XX?W1XGB0<VX[KSWMLOSLVY0K=.%:>9!]"$=>N[V6]2J
MM,7DV4+8%==![$91:&8URJ/2L34NCN-%4IMT]L_JL;/]W A60\ZDDHE,Z@M6
MY/5T\*XK4JK)R8?2^/:PZ%HYZZ0Y;I]W3SNX(JE$/)O(/K4BT FU-.4]@ P.
M#BZ)T3FE($^>:J2EZ9HS*;B6!> &:^Q01+E*NZ09P(\UHE^8MH:#*8Z!]=E:
M2X>W;&=F7B=7AVJA[*8Z==H\JRF=P3 =:0'J/2?Y_BNO*(#.JC<$0%(Q"&\5
MQ*Q?L0BKLJP/60135_/GIGK4Z57H9??V4B/7%_7\.R_"]J+%2=RT+]IM8O7H
M2=PXOE"'=^78Y7=&BPM#!\!PY;MZ_R"6IX?Z[57W-/\R6FR53!&+7)\,'TMC
MIW=X.S;BK7%>/JE<?B.9(M>+N&FS.CR2J_6&<U"Z[1GUV LRQ3*H?.O^\1&#
M]KE7!*$70!+ R2)ZV5#I^(1.^%AK2O/\8#*^OD@_/A;IJ&76^LUF[;AVV8PW
M8SN_9=#UXHE4+A9_!;;_^8 %E)8T6R'Z+256T5 / -O],4_N3YIM>]09RD2I
M3$9*XZJ=&.>;"1QS)!*+1Q*Q3QWP@:FX_9D1E^ ;VQ_O2#7OG8HV=N7JA7UP
M?$Y'2?F^TTSB>+&++QPLD+!FJK/#30RO'QX;1VZE?CC03^NYZB!7O,XW4SC<
MTNVG#C8/(U79:'4B4/:<6%;S_/HXX3;JCY=R=7A^?GA^5FTUQP O;3BP=$,%
MD=L#XZAK&I-^KW]Z52ET\H/A<6NTOH+(RFLW1=+R>6F9AFX:5<<$[9/U7;9M
M=PY+*X/]_,W^V:C82Y_?CI+'1=5ZD)G\G<WD8J]F*.\PV:?%]C^>[$,\=G!<
MKMJ3XD/MW+S,G5P^]MM,?$BG$YE$^@^4C433MISF%25ZT48:S1LJT(_;=W7X
MH![0@06#9R?V@-J*I0WPSTK[PC*!WIU)?JS93;3K0J-M3:'5 5%HV3C3#(.2
M@:EK-OO3-AUR1E%@:I8K675DF+0I'Q9/K]OZX\G1U6U^?E5.J6U3.GNFKJA!
M1T2O4:L_JZIGDV4Y:3J'=?>B4SHY[M2R)Q58G8O$:X!I^;H0HT/9'/$33$7K
MNWTQD:O8_@.)*_O[1>K023?W:)YW2@M*FK=0%SHQ'%C<XH.K#1 (ZC9MN_JI
MUJ8SDWF\S TS^I7;Z9&[7C*?+)[WJ7+Y$9,AX\!D+L<@].3.8I%ZO-S,M?;-
MP;!^NH!QKYU,\LXI7]XV[L^*D]3CZ.Y8S=;Z.AS2B]3B9'[.FD8MVJ: 60JU
M?_^#%N@]FQF78782LTCOH=WVOSNVUA_H:&EFWW69T1_),>*Y&*)C6T7S[L^Y
M-ME'VW0M]HF9]O?$"K(9O,2GQ)(T?6#'M0"X-_L#TV"V15QH[ZG (?<6/.L4
MJK'J64KNV^Z1W+N]TLK'@.QB*)0):-XGD'7A<UNCEL26@2[US13*)[/RV?S+
M7G,V[>"(^4<5.AL/=$W1'#XT2=7ZR(],8[KQS\YRY_<2+.-M_?-S:1>_O;'Y
M(_FY;-H#)HCXHW:(Y:#,Q^2CB!R#__?;\7_SUT^=/BJDO]E?O,]>)S]G:& 5
MDIC7&OZ4).[O1E92/2@UBI&[R,E#Y"0R:.CYD"16)(GXZB01?R^26,#9U]'
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M.[%@#0O/O^M&OG>F]^GAS7$NUKLMR8V\K=J5\UP^7=ZD7?WRNO/SR=OO>+5
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M%YV/)+J7PQ66\^]/KZVUN='E[6=B$+":PXK1N1C3Q"*9@$-CF*YC2J[-XQ>
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M8'S;)'EB7U3R!NA/]Z-S+&?'.#NH"DB50XV.WFTPN559./^U<'TUQH"-8#8
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M42DOQ5,1-K1Y",(9"HU#5$2T_=+0B.0"DO5)P-;PC,P>8LUWQ)K+69_6+-(
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MHY?GX&4HO";<UJ\UP@-N1:@W%L!Z+O5BC>3_\"!]9N0'RWT1:6S3D B*&;!
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MTF];>FMF""^K''/#S .G\N6'=5]>_(,;Q-BZ,>)?T8C_BJ(+=L)O6R)$#L+
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MX7@]68HMDJ6ON)1M>JZJ!;E2_=%OD$U8FZ,5#-#UY!"^0)4YX!AL:\9>KYG
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ML,E-T4]?NTA#;X4:*)+9]2I;UMO)$Q\B")(1OX=F0XW!P@#DS)S%00\D?HN
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MH_5S3HXU+/XOXA#[>4Z>>C6:<8K_%#R@0-LFKS3-O9U\HX)C;3+BLW" (S=
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MW4G&0X8^+GMK#45CC/MW@Z9ERC<O:7%P6AUUTXQ"6_:H&,D3N529V$>KLOK
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M<*0F08;4SJ9\1E9]ARB7 M%*P+:PC.&  ,U(ZCVNE-TD2W@]I1!KD> .&DM
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MVTZK,D*+PPH.2U;](/=6Q?]WC.W6R3;"1V>UGA??/OCQY>MD*U_K(\2'[2]
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M7..V8P]?1);!/GZ']"PD7/J82D0DM13QCR_WZ+)XDI_W:4),DTER'5.0!?3
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MW=)2QZ-PX2(S7QFD2%CST8P]JR8YXH0)P#[YZXJFLZY^'W*#^S'(D;FJ^OP
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M8Y/D:SKHG"G_'W#;G/17GRW^JN->\Q[+G-&\C&T]G-RA56NE.!*YB3.;QIN
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M%5=!MK-TF\=02QMO(Y.2K*65"Q4/&$HF*6&;EPS()'=9Y!TSTF?AVM9C1P+
MNQ'_ZL+@643=V<(UX'*O#T!MRG$0U@(.]ET\@M[NYQ:PY7GDR[WNU_2L+B<X
M<H:JNFR.MG:7QD*#PHQ@RR*R&V(+75*5'=ZDW,IMC38Q#$IIZYM_A7C6MX(
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MH?$NF&R$%4%9O<F;6)/8"FV]!;KV3]&>O2\NX^]U>?61*\$7DX*[1"AS^[#
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M_J&K?]H09PW-T;*$?8D]2FJ<?:M![ 83Q9+I:"!-O)(N.\T-Q,H:IV2 0U*
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MRC]8<Z^G\$BP*_^!%,'#39YV_A%3HU+B F7U+ANN^0]6HKF- _[=D*XK ;4
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M](4!7JY,/&OHCPATFL:*/BC XTO [^X:?<9WFX@2B(/W4@$R#2M5*O,& XE
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MY\W@"S%5Z6YZ#)E#].UL<)F04I?Q<K8NVU-0_"MR+_C-Y% $SW#MCM_1/X;
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M-BF*)L$:/>"D7;@$<7N')1=GBEQK0ILYNQ^:/6TR]XN37A+9Z%Q;32S1:)Q
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MA#?G=F0@=$4 ?76!;?V(9L&117(C3@&ZLUQPB@81SWT6$';H6#7@RTW23)*
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M&5$P$D-O#"U'M 1#!*RF0C%C@_9%[%JTS5*3P2TL9@4W<%G[/<WE,B&KR8I
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MW_MCJK%%FURYL%A4M!J5/WK^\T_C.XQ2/CBAO,W82O7G)-:ZV0^%4I_-J5*
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M.Y&,[/C4T%16N^J9!L:_B!BX.2-9T2?%<<=E]UGY^XFGG]N/L/1#M;/Q0!\
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MIS9I;6H^^>>ZX/2@%(-HF;/!SB(P8X&["?"8*@08T-_"+GNI)> PWS_QEE!
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M^%?% Y>^$'::(KEE\?",))-!NH(49DM2X3UWQB%YZ'Q2?+;&,GL!R;X3ADX
M)*<E6/<"DO>,U6\(DO.EDE U^UZT<32JV>%>+&U9=;M",AJTD$F-'H&+O&'T
M?GLU;DXZL2^33OS C7ZW3#K9KJ1WT(FX 4[MCCHLE6P$R\:$T[]4G;&[AH/G
M5JR_YWFGWXDXMG9)\5^5-*F+9/+0)+1%0<.SO' B8N9=YMFN!SJDD#F%\-]
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MH=P*@3P1>!T4I84 "8/\E+2)-+,\TPPK)EY$X^=<KQ;(W8YI*_XGX_L9H!$
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M23$[94@V9XF&D<!,VB[5;3-_[68IR&R2O>XRG[WAAKC]6AL1FVW-@>Q4V_6
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M)B3HL(@MO$5_'JS61T\VTF;$SSFK6P &HP)?6>2&D:U<8&-2[OH'+S**IM*
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MFW:>"9Z@@ONM$E+GHB3MGU*/0N__XSPU>4: /'W?2P;W/4W>=$M6.KI*7]/
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MD:H0%A,X,EL33[FN,A@BE<&V5V3FW%DK3-T_,O%^[@07)JSO7TI[1SLR_=X
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M(O0'.#+Q-P#:?^V>M/8 WXIC6[!1+,[7 AC5.H6R^J*:N<=>_,7IW9=%JTT
M'$DETQ$N'7SG2R!T#FSW'FQ$.7TIY"JI:J[.ZYF^>-M]B-4G!#:)A!!)KHG1
M,_3 S))NA6]$.:I.HU2Q^GE-_B-6AI>9I\O2)-=/E)\GL=N<8H[8SJI>]CM7
M+OT5YL%[Q$#2Z"=NP67WHQ__J9;E(&6NY9'_4!R_?X@1SUW=WM2M66[4*!NU
M=+'V.FAG#G (8X'+U9-\F.,C#$;=$&%,CI$V"UTVH7/Q2)V+)Q^D](EBHBNN
M"7D\3N^L@3K5A[GH.#7L3>]*UB39$?DX>1#&AFTN0A?KR;A83SXZ^0%^K9:4
M:B-C#Q1V9A;L^/UTVJ_&,L"OT%&+/>''71D\/^Q8TK#=J2I156=D::C:DA:Z
M_4(_\WE)CNV7FYLS3Q7SSHV>I9SC$RCKDJ-G5]U+4RR76 DIG=%+1AL_M"8B
M3XK8QN-"1.!WF!Y][LP8^N!/A!FW7P#N*\Q8?U8>BMH#>F0KKT.UFA[>QV?]
M## COMCCL7A$2&S*&3R]Y*.,+#L#1P-'-@9T6Y75L)9,Z LX5E\ B*&_3DPI
MN$>VI.I(R4FFCD%E^3CNBC(<ED/XL'C:-0))5;52;\K>Q5F^*%TG.C>=U^MJ
M3>1)5=I8,AD14L$84I@K&+H'CM4]L <6WKHJ\7LL'!VV[D9\MM)J%IV74=%^
M[67C5@=8&.L4,2$1X=:\0_C[=#P&/@W"((^Y96,P-%$7Z98Z1HQF6.%CJ*\_
MACJ;=YK!MU#']"CS%#4+'^>1)YE9/]_=Z)@-T1UFOC*R*^V&--TDHVZ?7Y2A
M?2?T^W7M\F4XJ.8*/1[+J!0-0 0=FMM3,<Z=I8,/I<Z&I8/OI+X92^^B:OVV
M6+IOUUK-YP1?S@U0/5YNYOH=@\L 2[\1H_@]E>,H.O0L/<:VWLR99T+[**PL
M$U:6.4ZMQO_4)4?8=8UPZ^7CY53-:CWD1OG4I7-5F$ZKMS61)Q5TD_%(>F.!
MS9#IPY(R84F98])[/L3TSX7'J]*]RC[UL]%!S>[UN-F4SP#3P\-P-AWA-O;H
M.F8_RKOE9$C>YML:36B-G6JUF>UU'#[TL8Y(/NVRT$Q&5SXDK5IFZ<4J"&:O
MR0]>;F;1^/AY+'1$@1;>Y>(1GM]A7N>Y\_'1E9_97O_B0Q_KB/AXEY5G/LK'
MQ;0NSQ)9?LQF4TJO4#&OAMD,X6/0.OA8)"V\F^_YCPWME(^%][9-)3+""#17
MM1F.GU-)HXL828:PD*3/H'& ;MB@TICX8YU1\;<[)DDX-6UXOF)WD86 +(AZ
M30)+;567=%DE7AW\ 2F6<[&]P_R^.%/4\7__XG^\[\D:DDQ@^*X[^9R?81%7
MBK'LG[O@VF5\>'CP<6TJ[MLT^??_^?>^,'VBLJ$9YD]/\/@.U:5/DG@B@SHH
MVC*1U(]*;;SP3TF;2#/+TZ33%W.9]G,NNP1"(>R%$/^3\?T,T B <B!-HSZ
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MOV9K'-^SIL4N-5'AT#,R,.^,J$JRI4G:<.UUS*S88XQ,!PT]F>O3-L_'[<'
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M)#VQW(Q+S(\=/27&>64<CX;%(Z!_-U12=PWT/7<.O[]!:&+OQ0P[N;Z<$8M
MT%Y!_VLI@+BRUC]S H3&EGQHS4#CYLC8P;JP\?]]J@^Y"5UHC[MFA74%1C:R
M"YTNZYT3";\R2+Z>BA;:9!"(]LO$>#E!R_?[OQZL^++&\2\$/-X,9OC[Y00
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MCP.G= +P#@?062<A"1L(1$?R?)BP*N/_^28M0&"!D,/?5W5D60J^X(<H<(X
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M&+"1K0*AW48' F=-%6Z!]\*]1;$_3T!/B9'IM\R6RAR=6(&=M=;%Z<]81WI
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MB9@#9VI*!"JXBO\*; <*BX._ 617)W1U!79-#"Q@+X"(ZJX2 CH<M1\(!1C
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M>@^$[4YF0'0(.&O3M0A!G*K [[*'NJ6(T+\45 .U+P.V8QK A@];$'B)CNG
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M2U3XF8SMEMK-LEM&L'F)K+<'K=FD(H.1H6<:/2O;+8@#1G7[.V7+LND"L^C
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M-%4B'+8T$E;--9J>9$T9@CD%P#SS@)%W?6EGOR,)*=!I/!22S_-U[]>QC0Z
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M*G^V/+]4'%X+KHMU]WL% *#HPMOAE?U^G?55F8(AR^YZO$1J4T&I )=HEN2
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M)/ 6EG^"YI^.I3#"-\9,+T"4OY5_ GO>ARS-M"%G AM.E9P0)YP%PC/J%7[
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M,NPNS,:L."LZ4V35+N$Y.E<RBDG8GCGSK6 W^H<M7<56DX"QI80""W5(MI,
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M(OF (U>Y%Q\'^&*$BA$J8@CU_I9RGX-095-8SOJV7E"QGH:VQ9G5*@H0H?Q
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MAK,,C?A//:4_5]94$B/(-((>IGOFE[_N&!\<WG>XQ_!=/Z^#<OZQA7!K]A@
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MVJ>-+6\L,3[N.?V9/:=))(51<9.]UYC@,WI.HW&CP]O1X&6]C>,Q62)'%F"
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M#$T!^28L0T05@0[!ZK: 7]46<'PF7XASV93/;,4&BPY]MAY!12-QHK%>"9T
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M)R90FOC%1XK15X9.&.)+F=$JT-$(0F 4&([-"-G_82)_PVC,#"40E$4&;(*
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M#[@PEC@]RW2P6BG,FV7@2 %@1\-M,Y%&#J61TXU@T%#8=AN_TD8 PJ3YS$^
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M'7.445H7253V'13L4VNH!P-/_8\8B#5B\ZR41R*.+R"L0,V<K/ -7FZ*@E3
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MVD/UZ89YK#!7F=ME^3Q \BG>4;P[2 MRR'A'<\ 2)JS[@[N5CSQ] G=B"'?
MZ1@F+F\9[-8X9$3!CH)=@NW'(8-=C@IKLH1UZ_G/ LM*0H'[K;[9 TB %EB!
M)$!SK+9&PMFIWG3;X[5,4C,[FH,6C>L /3Z!NH=2A7EX^$J-[8^RS>X\Q7:1
M;0SGI$O?C:&-@''00HILU%C$WU@<,K+E9\W4\IE,9"1XD<I],N5^.9 <(5QP
MQ <CW,KU1G_\6],''R+<*%DE[R/(5R".@@U5NM@KW2&#38$*:[*$=7]KAFM
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MQ'NBF&4W$>[-W71;!$Z7Z$TWF?-A!T=P 4>Y8OHI7#F"%.*. J[PM4'L*5*
MH@8AA@;AH "*\OG$7A[W!E!K1%P/-NX=20<C$%2R3,<SW,E*O(OPZD;1]"[S
MK-@8-2;Q2F"_BE<+ RN*5Q2OOHE]..0]-9[+<%1 8RZ@^SIMPW/KE-2]TAV7
ML!UX#4?7=,76T;))'2"5](P-19[OKM@'C3P"1IX9LT)+X'Y765^MYBTOK -!
M$#:1[9XF<V8#@<Y#V[)-%R/$%:1@Z*:&>I!2@;^QR481@IBIYS4,76445<6Z
M1V*NIFYW*8)0K8J?5ATR@@@<19!#D?65T^>G 458*Z8IP7B,TMOAW&=;1_-.
M==U&*-MJ2(7;PV%>76*7;*2?>K'P=9\_0&!YZ!M$7S7%;B@F<M+5@8&&3%$E
M8(KC17[W>/B;:N;ZFOD[F8:>IX8^EN(4:T._QO[+ D-_JIN*J>*N44-/#?T6
MXZEO:\EYZK)32_Y52\[OW&7G"DP]4\N4,LFSZ7 VRB\OKED]ERQG)1BA)#9'
M$8HBU$X1BL8:%*&^C%"[CC4H0L6D-S%%J 1!";5]\;!]F^IMXN1:RM.H]%#D
M?G60E_)KA:&/]P,@AE SS+5B:HIKV4.2VX9,QP?^>Z1:>)B&S*UEZ.J00@95
MG7BI#H6,Z-$?+E.YJ5'4.%31KYB&;B+FS_']%;;JCJM "O.)I7IP-&=-L8"(
MA.0[<^'@D/!"#U^C!:_!?^"'F9;+*+T>4FQ\![FQ D3F&-)@=?-$<14<2AJ(
M:2!5\1Q$*/=(LUVEA6,P&S' >H#G1&/ZNML>/6/<O_!]='$M.2J0Q+4W,*JU
MTCDUJK&4J!T;U0=E8)E6=\B4!R[VD0E_B]I&765L9:DY2HSP)-4<E8I7U!S%
M4J+V;XY*BJ%ZAA^\7^EFIP&EI*AQ2IXH)=4XG91/J7&*I43MWSB=H*9NZM0V
M)5V2DFJ;KHK'U#;%4J+V;YNNE 8RJ%E*LA EU2S=WI>I68JE1.W?+-W:"$Z+
M[S>@HYNP5*II:5YXY-=*\^9H:5Y:FG=WI7DCXTKFQN\LK=:[*4]-I%[:H>)9
M";+@F%ML@A<D,OQL@HZ[D#FNFQ.)"L!^"CJDX"ODRX!0;@/Y&,%8XACBUP+$
MC%B2%8=&RHS')D37R!4PZ^RD3><RG(2Z<^S3I.XO@X3A$WN#.8\CK\[D\*O\
M!_/9##N"0-,RT6A&&;!.#,NP8^#S_[N<;1RAZJ<6"[R#C]6VL%7A#2<(O)'I
M&9J'6!LU7_OJUBEA6(0J8Y JE%F@"8<UU7,)P/?5F(JIP4$B+&%8MK ))6EB
M8!+!C#*6C?\.4HXA_[AG*.9ZD_BY+Q.Q1'-JQX[&R?=-B2B$+QU9)/_Z2M@M
M9 KYC] L8ADCKP,$:AI6/T34\',:GGSD!P9]/"2?.N2C[Y6&8QF>&UC2&><L
M:B@_1NHN;I$1VG<IE^'XV'4OB_OD G\YX/01^0M*'/YD4VG\U:_/NK[F\HH_
MXW-$;;<N31BDXN<O4[)TWK3&J0]P1A%[54QP2,(OU>RH;:1Y!C8V;>4-$DR1
MR5A=W9T^TU=Q49?)L=Q/Y=?/["^(R>Y1*\R<J*4O&0_*6OI'Z/SRFT 57%3=
M#/,0Y;8'YGL''MCT;%-WVHSC]7H&L7&*80#Y_7#T_@4-#4B%:^42X_7PVVWT
MZB''760$-S*JD^%](5S:T GQY%&:7%F\7A=YV'P,6#( 4!A=^]\?<E9L"-D<
MGY<;JJK*HE 09"G;%&1.55&N(;*"I&D__"#9_P5,'I<#DF6.O:QY7=R"87##
MEF7N/XTY8P ]CL;[#<O0YA<EAX;[OCN7RT18HH,^_.=WPQ^8;?<B.IES&WJ#
M_>?,A+.7L+6W/%U[HVMONUM[^S$R9I*D*9P@(5D2I*PL%AI96<FI33G'916U
M@<V9($X:LUKE[*;X4+\OUS9IPF;LT4+U6<O*_?AWW/Q=6:\HY0  )^"E;A/(
M)>4^@^/Z#"= <,%E?VJ_1J?AQU!>'JAMQ6RA\$@\)PEB*GB>7Y\3OZ&M. P&
MZ2%#CJE V6O=P=\3FG_\]@8.1O" ^@3_ .P-U%:,)M00@ <1%\*_(>77P?9,
M_"OR0,5SVY:->ZME=C%F)]C9/1K7()#\XC?DS9L*JE98_5T85>'7@G+^[P_^
MQS+.J8@=[(2''%O>89WTV)9=GUTM LQE<AR=C;C,ABAELO%;;OB&TQ%=(_C<
M?HUW-SXS7O'*O?A*S[*Y#+?KM)))SV7252D]WO])$2^EL9H7.N>9X4[,S$,G
M;ZO<E#(C_R@J+M.JQV\+ ^,E1AN D<1UZ%-+'*,>'88Q^ZPWNQ?!X^'1EUH8
MR%3@MH=+<+T!@[%6UYAP66.77?CM_(Z6^Z0RM6^9NE&Z:!FI\J5G?\:*"DV,
MA.9!=XU$2 UD2.ND7!8I2CR?2)G*T[[E:?.]V;?@_;RU=5/5>XHQ*V_3^5C4
MSZ=^?BQ[M$ Z1\*Y1'<Y+I.G"TR[6>\;V0IA*5M1*&3XI.?B)&)J-I^@L;9Z
M[WD3;LG=MO%V&FRUD6R=8$>M@;#$A3MI3<O GZ#L:0_9CF4ZL.$6;+8%+XOL
MVH$C&%#&J4I/4?TFP%7+OZJ1;$0]R$O\-CMP0::6E"E(GVVP?>8@0C)U;I'E
M8+(9,>@@^2M&28N)L!9+C'\6>T4++3<=_ZV//U?(" N]4CK^F]LIV[@A6G<$
MI-X'J6:?;C*17VI(M6R223J573;]+9P2.B)9(O#7S-=^4A-9R85$&]P<Q?5L
M-+F/M UC\FW'D*QJ?7G\OFP,ONWX@1,S=QLSGKK\<=[HA_9M- 6K#=6&U^MV
MKL'?9N1VKKO)&+D5U':U/<88#O&. N@EC/C"K=+E%KT#J[!H8LC*2@\_V'1W
MC%U?WZ!AEEQ-3X+&DWS7F$OCG#;.79I8TUA D+)/2[&>(S6U);V4USA/07<L
MBAN6O,/6NV_OY,Y(_>8W9ZD:'*P:Q,=I7-(=NP!;SU05IXWT;KQCM!E/:U&-
MUHAO-?X2G+&BJEJ>Z<*^2C)<+>K%K.+%3,ETW%</J?6.B_4^<">&Z@#5@>1Y
M,$5#9XY1NZ&T%5./MY3/># GNHU4U[+C+:_4"UG%"YF22^J%Q$BB8VV!J1="
M=>#0=2!Q7L@E>M--YGS804Z\99SZ( ?D@TQ()?5 8B3/L;:^U .A.G#H.I X
M#^3"<E"OS=0,H.4';LTXRSGU0@[("YF13.J)Q$BF8VV%J2="=>#0=2!QGLBU
MI^DN<Z'H9KQ%G#HA!^2$1(62^A\Q$N=8VU[J?U =.'0=2)S_<:G;'>9&1X:#
MJ >2/ ]D(I?^>SDADY))W9 8R72<3/ \#:">"%6# U.#Y'LBUXKMMA6FUE8T
MA;HBR7-%ONUBR*1<4D<D1A*]8PO\K5D<%X_5>H4\M]S,V#8L4:U(6@G/PB9+
M> 8=C);4#"Y-5-0,K@&>";YMFZ[\^6;IVOS"GS]&C6U8VA#_TW:[QK__'U!+
M P04    " "(@$E82/'82 5"  "G1@  &    &-V<G@M,C R,S$R,S%X,3!K
M,# V+FIP9\R[=UA3W[8V&J1),]*D2F@*@H#T3D2EBS0!Z2J]=P@U D( *0("
M2I5> X*$7J0$4*3WWJ032*@!$KC\]CG[G+/W.7??<[^_OIGU/L]ZLE;6FN]8
M<X[QCCE6KJ:NE@"WU975E $$-P  @NL/X&H6\!1 >./&7]MU([K>B&\2$Q,1
M$9.3DI+<I"2GI*0@IZ"@ND5SF^H6]2T*BMMW;E/3TM'3TU,"&1COT#'2T-'3
M_741 L+KWQ 1DQ$3D]%145#1_?]N5S\ U#<)= G2" DX 3>H"0BI":ZZ *#K
M?A(3_*T!_KT1W+CN(PGI33)RBNL3$+<!-P@("6\0$?[5Z^NC0=?' 434Q#0<
MPHHDM#IO2#G=Z41"$G)N<CVI:J?7'49SB[[U""4CO\/ R,1\[SX/[P,^,7$)
M22EIF:?/E)155-74]5[J&QB^,C*VM+*VL;6S=_#T\O;QA?CYA[T/CX!%1D4G
M)GU*3DG]_"4M-R^_H+"HN*2T^GL-HK:NOJ&QH[,+V=W3^_/7R.C8^,3DU/3,
M\LKJG[7UC<VM;<S!X='QR2GV[/PO7@0 0H*_M_^1%_4UKQM$1(1$I'_Q(KCA
M^]<)U$3$',(D-(HZI&_<:3E%0F[2/4G(J6HGXQ+51=._]1@FO\,MMGP/\Q>U
MOS'[WQ$+_3]B]A_$_I/7#("2D.#ZX1%2 \  O%YN-"_@_SZ$!O0ZP_:Y*5 +
M[WARJ].-[-.=X4V]05KJ6ERZC1<'Y>0!0L: ,5MR$57"L;208WZK'9%@4G$=
M+^ZWE*-J#\Y7BC0YATG/OR[NLPYQP.$SP#,[K6%-9>\+IZ.DG>C&6C<>5;W+
M,[HKP - -[)G).3+AD7MD><1W=JDLY9NW[%Q,Z?B,,-!(:)9<T),^ECG\>W[
M97;X^SK'*^4J[JQM[N.M$3E!(N/G'6WOD(9!)-,-9ICL$\T;8R.YU=#O+JBS
MT,T$_&0>ZK2V;0=U6GF:^$Z\N-3@O 7138*/W<3I__!\C/Q7]/-[C[\>5?YR
MC5FLX4'">7J@K"Y'%DS8\RF(7E?'[ MFEW3Z@7!KYW6JE8,GX1^)?P((/TI7
M1(N9V8SX<.IIS^&-<UNEL5L7+HZ@FUZH.Z<:\>UL]ZKKT?A61*.9OZJ0.%6O
M43^B^LF:=DBR'WE8AH\XU A?%ZA4XMAV2VR0 ">:BJQKE4 G01(G?FD:R*JQ
MNV?/-TE-U[Q>"_FY^P!OGJ<VJ^C98[GCS[\*OA,\;RXT,MLC,Q"+GIC50T,[
M9S\$@.C,-,O]#-\NUT9-3 B$F[U]J&P4L6OUMM'9]J058P['A H1!\IAG0+M
MJ09A7E< ZLZ@^\4IYOJ(OICF#^R;I3^6U;@SW*3SMH]E@_G/MQ4@V7HZ%E1"
M.+K&F<,>G7LPF),@CG/F"G!R9WSLGLRH(#[BR.3F\V!5UV41EYX"?RT8U '$
MAM/&PE8TKO>I4.)MQ!!+L\L?8\=!*D9W4D4'XH@[33J_A5:5D9Q]=F'L)OO!
MQI;O:T"38=XS^LFPTZ -K;OCK+5"#&^!1>RZX.Y)1H*_D?2=O:BJ"QZLQ6<\
M78OTA0*_-+$E!W0OUA7%RCU:I#W6 $<8&&>_OV3#)EV #,9(ZM8&T%^(WJR^
M[^FS#MD)29C, )>.MY2SC<@/(K[W"P1J+FG-\*^X-%U80_;5H_GYKP 1)\9*
M<<4"&ZT'EYUON-78&V.?!609&OR,_$CBCS%F(\,W>^-=3G^P<4Q<@MKS \4P
M>]4S;%&ER-*SR>'?IOE:[B0_2BOT6W=H /(!\4 =9[R%]DF"PL_<5B7T/JID
MU>*V.>YQ$P+[U+L8:]@NTUI6M.V/C"AA:3!1[>-$NCSV31B8>R=1_-K#K[MG
M-_G"?#N[)J52S%?&-]P)3A75<MM>@=TQ\TE_73&UZ:R<ZH^EC$9K1<8]/G.V
M?+TD8R$Q<:D68'%Q;O3&0][<: !O;EZ:5UU,<PR]BN=C&GV3%G4*89A3G;6Y
MIHYC7Z9FM'%)-%N$W@3<:.O1#*[++]%[8>PF?-UB&^P6E$8[=RPNQ_R0.G/$
MQO;8TYA.6[@T^ATQP>/=!V,&0<<7#T,7YEPSCJ\ -N\>SIEW.HARO8,VRHP+
MH5C2DR[C77RN 'X[61AH;+,0>@#IVJQ9INAPX!'%(<0-&[YM5;=F'A"$\>R"
MWF%>5,%"\[;]-5LZ5U:[C),K4^F$?85#_2S/SOWCMJ7XQE-E#&"'\@R+E\J?
MEK;5)ZOW_(^[ZFZOHB2'9@GQ&Q1*+57-3/&ZM 17 +ELWP/QCBWP][J(G/M!
M-LY/N]+"#N]-Y'B=66[?2#A?+\9N+!_#.N'LV/2.X;["!?N!:@WFYWM)2A^9
M7@DK(-QS8!G)4B^=6VJJVQ:A/XZXGI))E'27K4/G1ZX 6/I+'WE!$R;G[M5@
MR[LB&S?203,:;RFFBA1"0L0W@LEK8"O'"WDK=XULDC2-FC^PB'+HZP-H7@#-
M57;,O!8IO&Z(NA)-Z,8ES@ZTP]95RTMUPID"I'\>"AS-8H1+E&.%/'0#Y[V&
M_<RO #F(DYT^U^.)BS$HC7Z9F3)+!7UMVZE)F.G;'>:>D#WS1=V(?>.1R-^2
MWU1:GUT!K'N.X<[\73(,'PYJ#=4%4Y-HJ1(KQ[4L.JJ3F90\!0P]^Y*-W;.Y
M4HJTU(Q23A.G?]>>FH:=WCN&J_^8@KL7F<P#LX2S]X5(2E@HFCB-)\RVKNVX
M@"C^2CD;9$UQYGOS=1*^(J)&/PR@2,2VDEN/B-Z2^!4"*]GF%X<+UG083\<,
MG<8V:7.]C2ZQ+E'R?Z2@1OK2!>$2$DZG\YCXGW#3K_*+G.8%(406:7X?DU+@
MN7(%8)FQ7Q!J=<0[*HX>A[B^\?^SX9C;4U]\-#_2FI%;$ZZF-R'855_B$KBU
MDCWE^N-\O<XSJ,#AD@L=CMB'I7:<S@2'^2<H^KY..'/OODCX[&P*_!0[M2$M
MO=E,?_$ HO&CE0]-TO8FH/2GWU(;L TF=I1E]>!>DZT ^TT17)8R*2) D_X%
M0KE\RJ.B9T!! 1\A1[\Z2(>-UY'9B*K19$%*"IMAXSO]]<^11=N'RHJ&R>IW
M=%6):T7V*I70&S_ E%B]E?G%+BI1E,3,IW/Z-I@!DDDI7^+;-[N.^W.ACTA-
M7WM5JN4FE4G\[0:#*=E5J; CT&US4ZQM=[ X.BX$6GQ7][236;"<<W0]XYL-
M.YT0<Q6A1QY Y2Y?5W;5!NSA)?MV%@_Z"A#=;+;,*YZI)&YF^6187)$J(L>C
MG"4@YTE???QG+L'E]I46BE6&]X&*JT#29C:&R:(A\5FCQ+V)5[/4O[=ZH[5.
M@(?=BDST'] :JS(XY=JFX>,RO5S(K*J"05'^+XF/RJ1I6<505MNAT"#5Y;+Q
M#CFS!X<>36K>T9N+7B=M*GF(X=Z=)_3)3&46ML.G&OT^TE2R)^)#<I(KLF5M
ME-C![BSZ(2%OKC)SB(7JN(&\C&/H\A2*UXP^DB6!]8;4EKG1,G3JR4:W@B3V
MNR>&UF!"(%!@18A!X;MKCMUY*3RKR#7SYTEQAPN1A!0ED.W'Y$R-84;9F.'8
MMML'.5<]?"I.VA.3)10EXP.'V\EDI+C;GZ=D%IER3FW[#,=6(>6<WJ, ! <)
M'XD]S('X]\U42U< .HC_F7@VC8,Y"#U^L9T&#'?=3]&4?-YH,V<5^X3429+O
M;B11VKER@Q9;H#[:MP,/1K4*8I23EON<K"UTFU4U+G@M4Q1^,*O#5?8*6:OF
M5INY+L0AONT*#)A+6('##"H_6'1\#U$V.R7TS-!@DA8UY_Q'GQC =W-;I<4V
M\!X^60Z,;EJAVH_;\YYW15X^:JB^[&>NK>.67:V=8WG]RC)6C9NRZ4;/1'V+
MYR6Y'II0-3D7@7E_?K1Z:;1YKM_?'?R>W6+BV]LK0&A>(,BOMJ\0,C$#.L.F
M=H[XV2Y&\!S!6[(XBO+&TG^<7T:?=7:"T#K Z2L DI9;&/>T9E20$76 "+#?
MC51XW_L..-!RV'EY?T3.J%"I>#.M(*6JZ)?HW?GP#BW:>!M=Q0I[O0P%[N%<
M^]U^&=YR_%.] Y:?[_U2J7[HS'QG$CC)NYNXA#L -8:5E+K9CUJHWF_A 77>
M1NF]L@_6\!NM2W?S^XDR%KOIP-F=\Y)89XC<FT[[T;5NNM%RW%M3:R][1#@V
M28'AZ:'&/<#ZE6 37P6/^]/=:Z:Z @C<\WRO%S<MK?!CTJSD"I!O;F)RPN-)
M?@"<J; >;Q;_BC7X=;]A\MCYQ9VJ$.&0M8SO=1?LK,$*XYO61Y:12+TB\;VZ
MRMSQ2]+L^ KTE/VX24%1V7"P[)U+&ARUZ@*8$;L4?QLR@2-;T,AIE657Z6.U
M@Q K=@=XL5T.7*<.CT@=XJ94:S%1T34YR@<M9#U2)8ZL+S@+[^=EJFPVWIL6
MC-PM(KY9_+7"=X5;1W,)?+O\!^,5X/L&CT*O*E[)2W\ ]RRDHIEXA3=IOS9;
M"F0A4/KH"M -*\7U>?PQG8^S./$ENP*0%ZE974HDI^\T3Q88?@[NKZJ!WA33
M7>RV?G-TR-RBT.A)[&2MC]\X2WA161=:AIO!+YM6?L 1VJZH:G:17H -/ZR'
MG@.3QV&:4]O\I?D5O"]>KO4SE&1Q 37H-4=**[*/#X)M@4M"U%JK5'<.^O1B
M5.#V22R.7V48[C(&N4'YMH_2"[-H6:X Y3$H\0T0T*6M.O@!=E1]C X)#>!;
MF 4MI1!\E+B(.3Q22-X$8U#EF([?;7#OMUNEWD'C>6KX[?/ 02 ,HX=\;8A(
MWB![<>OBHMK>HC\__;BA1(G.D/HH1(E.FY@%)2B;UP),?K2Y>CYV9^93RL%-
M(9()%(^E,8)J/-\W@2[!0Y9M)80F+$'CU;"I1MXOCOK[&IZG5D?P\-?;3"\4
M_U#_:_U=R8Z=1;_=0*9*9 FAPW]M7@%NBX4TCJ#<2GS"+E]I;M_L)3H: )*T
M!$>CVE?Y7SOR'9F7K:<%%#86?5>FWWQ*3?HB=Q2CU;@[O)Y-K"!JC-,;J1"H
M%(B+7>D7:,XT5$Y?2R0C)?[$IDX[=+(9=!3\".>$=OT!O:FUHL7LJ+W%[.5'
M718X:JH@%<?;(]@SY+7M)EUY&_\=$7\+Q^),N**453$#BD\[X*>@,%%]7NUH
M\IF0\%ES/>!@X?-=]=4H_)=6X%0@!!L+#]3%-I7SQ 1Z%RRT7"M9P==VY3CY
MVZY)SDW'GO'-'@2L:PUL"_P$3Q @U$-.A]29N#T:U ;#B?6!_WZ["K5NQF69
MQ>KFN1HT;;O5\<F8@@@^]PK@F"H"40!B=4"4Z\Y5.\;E"C9-00P@.1VO2.HA
MS&YWDRO@"M N<WD;:X[RUJ*9L@A4Q]"^*1AO?N,U68Z:Y!0](-A5/)\<G4(*
M0&XUP^T"ROIPI_(*2DUCAU1"R$4*'!?FQ>ARW)<[2?F01F>Q;;<M'W__SG1O
M637*8@8YVCKI'_=+'4$UMY+R+X=G0.VSL7R;V\:ML8*5)+GJ01F1TR$?7'7=
MRCU'6@.P%>!O;4LE;:3[JEW^J>$5*,_M'Z8QT$VQ-@0L?1DT6W1BC='-%F39
MJCA2 Q4^Q81= :"')GS"SCP3 KAK=<EAWGM>AVPCQ5&M]DG# Y66\$"3T#<P
M$Y3" S*<^A^0F^,&E!;:+ALHG&OQLP+'BKG.&GR[WJ7&;$ZZ"KR/C2.JW9LK
MV2/HJ:J$]Z@;KX4;=2Y;2Q4U8$RA""TD>#KW1(#V!(:>,_2G^UUEC%-!=PG<
M2U'K.7_YV$9T]"-I==KY;'MC7/+*79I1DQ%Q%N>WW>?"8@P3B5%ODX'>;]KI
M<^";_M HL?06(?WJNK&:G?K?AG=2=:(XDX'ZUG+4QY61@99+('IHNT*SBO=J
M-NS1/!:V%#2WX!H9R&AE?V\X3++?VT[M(DPNKC.BMU/PYY/6*&.+:Q/P8&G+
M?:<NJJ/7+]D"GZ%/D1:D6ZV\Z-:B6_#<;6JRUPWO-[;+9<H(V_5ZN4@:U=?L
MBVSLZ'24V,EY<]^)3&Y,,F9)\#!5\K81ZN#+CKH:.@OB80LFWCN(Z5[+73=-
M_RY31Q'"L2+Z-7- K J* 4-5"7!<_&X2]"6].,QACW!6UG&R#S\UF6T'1A:<
M9TNG]YU^5K?HUX?^*=7%^7D=RE]/SDKV\T?E4$:)17)'[J,[>M#-6GAT!V9X
M=@D>U/)0$'CYU&$F#L&U'6?ZLN'1\;UI<.\:U#:""AW068]BO2;(*>XO[U>T
MN]'30773GTSE\IG#4>/V;^@B/S3:(EUN+JX,GOS&0:'F.I@?O+PFYK=1[P?J
MBE**[XZ'T3Z9Y:D/B.1&-4@<X37]E4L.S(QZ9?:0?JXH9I%+D@M>+D.9(\[Q
MU'W@?C#(5WS;O^Y\UN)TAW$B63VQB"?8)%AFZLP)'B#7 ])T6B.#+FE'UU4V
M^6['RCP@%G *4M51H@-<@X 5?:_+FM5%STB[[WZ\&\>GE%K7^C]>\+3H]6G!
M'+L_3'KGVD3O0@E(V4\+RC]0P*KJ+^ZV]UX!4EQW4,9'@'^_RG^#@4443J,0
M*]G9F-)4OJ#RIL!^8M_;VUNX \G\P,822SY6^1'L*F!^L:)<AYX]@0Z[!O=Y
MKLZK#$Q8??C",0(?.+M%^ACY @A]&&\\\4D^?PQ:1LMC[2EZ8H)VR;EX$:C=
MB,\/]+7K*RK[:;LD?VO-(T7"H2OHV[7!!5@W2,>J0)WQK['#Z#"#,(L/*RJ=
MU;7!$E461^F*7<8UA"RY'WV=;@&#9=\Y3AW=O=77*7,O(J%PMJ BTY+(9P+-
MWM'#S*NO<P307QUIH12T-"&-/!FK1628E_24&V]G6[1YIM4R,T8')AVWO;RH
M%!U08,;YHB>[@#?F('&.]5Y"NVO\9;,.(I%QF9SX90ZG-_[+<:+'O96*5:VU
M8[M+3=_KH[<GO&B4Y&[=Y7XBPO3*3?'NS<I!,VA7([1GGPWW?+@<QQDHC@&J
M^NTBK@"$%H.-8%K[ -C^QV)0"Z%C8/-!#)G<I"B:\"1T#&K9AP*K3NR[RBFA
M@8:-$N?!93+[36CDSY^.)LEWZ6A'\PA:P%$J\+A?)0.IDVZ2?P*0VTN+TZZE
MET9!!?@_PWTPI*;6-C8^UNE<S=>B=&LS (0R(SVQ0/5<"#D2AKE[0XNJCHGN
MDUXJV%\!T+I=S&Q):,=NQADO$*O1=S7\6-(^=)/PH!CL0F4SX!J=75T7=711
M[+*;C=SD: KI[.'VB*RM_K84*CNI= 4@5D7CTB9W@U8TBE,%\A>F'9CNOGS8
M3H;+K^1,/RU>[ \6P@TJHKAV]#DB%'OEMQQ3L2;P*T"'!GJTP[\!^FAQ2R+U
M'LP#G0<:F]0QMS3P$2>_-B/+K+WS'J?:4K*Z&ETTDYEJ.Q';3:Z8ES6ZA =7
M@)7G"P+7TM(V>.AD)CNL?$^\+2Q8HD%$$L8@*[ G(ME)=DGV>%T4IW&0@>K%
MW\;J8&P[0<S-])8KV63;:L5;AD]!\REDI O1+[<3'RR5X)6I/$ (:#NO@@*.
M"@,*1QOJ'P1/Y\]Q=+8'W#&_HS?[4"+;1OS XD=D\YO20)&15OE [CH:;*_+
M* ZZ=!\_QKS6WS#]L+>%LXF+Q@KXN6&5.^+(0I S+6E$0^,4!3U\9/@>/H2G
MS6T^78+U"%'@@M"FYISH_E&1LL]"7A<)U=L=2T%8GOA2*7#(ME3EDPHR)>3T
MGE/FL:(2W4_K5URVG@@5/5U1N>!]$]>3T;:1YK(5$YZ02Q&L*-*J_([Q.V>V
M<[T.W%SW*[S6I:QYVN2P5DD[IQ6PT5,_F -+JX5-6.9'D>K.?9L3^BD&#68B
MY=O9 V[T[IM'D#3S&KPH:N<>/7)8C+@"<"'[T=["]8;,M\8Y5WD7SW)'-89W
M<>DRBAH68!P?M@2.I45NH7M6GD>F?;7 )NZT^=Q]0=U1PI/_SGU0>NDP= $W
M0*_&#9#F/BG'O#):YO-0FY?7,Q&?AQH[#?QF$V3\%;AE!&<.0!YKG8\[P Q
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M6YY3'BBYL@H8(Y*9J3T\IN_Y_%XSH%O:T)D6V//V4*WBDOWV3"?QMQO@6/R
MIP<Z$W M&-!)^ _+2MB)A\[T[&,NKT>#A^D,@?=[QVWD[G:%C#)MOH!LTW9>
M@O%%5D:X)R[-A.CE="__9P+?M<>2BD7JT ^.\$#CTW@R".@)6B+,-<_.W[HU
ML[ S]EM7INJ&)VV?A-_/]=8\RF_25$IRIOK^+6_RW@<<J@\<',1%[9VS*5F4
MVPB[Y\Y+026:!X?MK==/46-G5X"3(JQP1>!S?(R<TM>=.LT*2,?(#X<MSZJ7
M'WJA_@:/OA*\NTLB$[9OUG:M3=XHB 7W7Y)B1-6K%UI"C<V7#@0Y\&-?3N_Y
M0G^43:U'W8]:];X5<].:BSULS+ +^BUF8^FT^PH0NWBCXD//K2^EF5!EPR7Q
M_*D!TF]V6AL6DGSQU&0_\S//:@R,]ZV'G7-VNODR<UM(+Q>1." F_<05&WN;
M+\TV&OS=Q=3]HN&$E793WZJRMD?]C.N2/"I7#7KQ8%NFF2P]'KA=*U/N1,IG
M8/;^"O!'_=QV^0H0]1:3'1(H7_G#\U9)D<E"S@ D41RZ8_3RM+C#K*+-8@R!
M$0V.YFO!XVM3K=W]_.0,:E,P-=^U1-^K#BL;?8D' ,BX)SEL/UY.@EGRL&1H
M_BX%KLB:M+EK!VV[>8*A_"E^-*T:&H?E;CC1T[GLL2"VPE)=JQC;3L-2:)U5
MS#9S4U6?_)^>P/1XCP:R[!/^CF"VZT%<!T;=)>TR*6;$,6$#/+G96")>MXO'
MJE(W'KH^B0JIV\QK(K\(;BP-WB//-EO<C%G=5WACEQN])O:76)<K6KT"[![F
MX"!#<(,5OR,PG;UN4-$SC&"6C[E]'>''WL[$_) &()$_*_5Z&WDKV#%E@?_#
ML@H2RS&LP&-<(L'\_JES?)1 M[N[TQP!#TC,3'& ],TQL5\\BAC-WVG!AJ,0
MC*WLY):4&!#TFC?_O=L\ZD(ZGT8F4W9K-8>5>8%6TT/+M>]\]ZF9SF9CT%!C
MK>$E1_OY>-H9>"F[1XL6]PC3DMH!C?5 ,D0**O<3(K<EC"#1'!VA6F0>!"P?
M\:NCB:+'X<^6EG:[,SNB><M__2T'L:J^F6<K3V>3;61<LVYSIPKT&3>XRWOC
M+DB2(?'WO#MNQ^6[&._)K"S4K^Q%R#]$]?]8,'-INK.CR'XQ_$T:SA=Q ):8
MT#_6>TSA+)1)Y(I?(RDHQ]-HB2 5M_/A=O\0SPF4[MO; ?*Y"9(T3$'(01AS
M?!>*>5 -@1'?AXF=9,N$3A4?"B[Q*<;[ZF^P'G5[4'F]V1HM,WA4IJ#:,I]>
M]]/A"@"/*?VE'?:)Z_<%&^G%JSF(X4G"-Q!E#16-!2.V<&%9\/5XS59@_M"Z
MWF6]Z2U8Z$U2MB)V\D/7< 6A406ZRR$/K.M)5'5S&'*4<17=\T&\[[MWP<(3
M.@"-,H%E*E>9KY2LEL#)_KO+N]B Y:QPMH3E>0D!F6$W$ULA?DN6S/B'"^LE
MN.O@LBP4JT#=B)Z,J=$(<E7-SN;S[E3&+J^^^24U2)G/?,ZT/O;M:(&6@('<
M584'T]?:I 3UMI]O&920DAY/A$<%CI@(5;?UG[4EJIC&5?-:<WR*";VE2+>-
M+02]7ZPAW8VY&\S@4(*!+?_F_XR[MZ*&:WF!)+A(&44S$@P%J^V,8U4NR:71
M'3O:S)+Q\./*]ZW<YO=&FTW>HK^Z+-L 2MA0M:U!0TD3V<W-;7V>8^LF\L#2
MG>O).9/7CV6YL,4Q8!MNE!LK-/8O"SACNEDOM]+1@?'G:Q;&6->5ME"<Y0W-
M'$C=TPDN-T:6N\I,D'-^FWKP3.J2.>SB>2!O=H=,1*L8 X/VPHS#M_<)\,*8
M/X]T.]E#.XMW4$I, 3)9EX,JAV0.->)0!S!)41=P>G1%(G35O6EHK];].@;3
MB&Q"]_/INX-_L#U@$\!_;&4Q8U@4:,URRM_@%A.1@^ ^&5JN@&,7*8.9(0;\
M(,; 9T/4[ @31UC;&,=AQ:,0HS1Q[L2Y1,"^A01$ZZ05[0H3 V$?MUFWA3,/
MQG71]+X)D#42$(OD]ID;Y#[ 3?WDR0AZ#.<@&T@*-7,-#G7F"<AV@"1US6B%
MU<C.VYJ..==D\@V("B#7_N1*Y>K,?T;SKSA#D0K\5X#0:,<#K&T'R16@H^T[
MZM.R=SR-G#/58.2TEL3)T@'G:F(P?%I++2^X5T$.>U%IC$T]2<0\]T?$-N<&
M@&&M; FY(\Y37H?ITLEMM)<84OKC]?B\*2Q4 S'JU2<EAE>8$(^@,+'K<N]Z
M]YJO>(E@DT\O'!2^8!%Z!9!@'@RBUFA?  XW$RS'2G:V@D:71XZ<9>CK$#5U
MIMQVL@%)/[D/U+@/'&VB^9.;MOMO1//F_VURZ9@)7MBKE&8E"[A= 5@4^+?
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M=7,6QL^U[NQ!_[!A4,):K!A8[,0S>:9;BC@E,&>K)1C]X@H0+D$CB_5?12X
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MN2MS-T9V_QVOO;F)K.ML=ARPOV<S:R.._N PQ?;_;P( 4$L#!!0    ( (B
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MGN\/W/MGPEJ2A0_3#]6AU37Q ^GWLX=BR@5RD/REO.72-&;536_VOQ*">DK
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ME 8;G W3N'TAVW^^@,V8H:5F9(<8A06L$OJ06OF\GLA6&HP/D_SC[GOEF<O
M+E@G#*6?]=)%<+6+] 54MQCWNBP,T0OX6298\F]%*;\UH?A-S4VSH^)PYGCU
M"6?"0S(,:4>R9-B1;Y60'#!CM[7$4CVP_1)IXR1@/JI;.<597E8&9:ROKP''
M]= $64;G$/6VVM_Y>?%)),'_W&@F7XAFU.T+LE?H,=OFL9BQY +Y-B/6D+OL
M81-'8N:K9#ZB5O1D"(&Z8$@5Y_!F.$=F4KDN26VGPI4V9B'6YB3FH73I7'EQ
MHTE3@!4AU6^]$WJ3=_;Z=@:>TPNHQ$YCBF,O*42X+.+NZ#=%$?ST^-3:K?5
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MT&U$CWB<]C5YR25+?7ME31AC\B>ES0Z9[\W;L"N\RYX']#^Z==A  W")Z1:
MAW1TSG/GQ(=Y3R6^KFYB+_NVR*JH8LY&0U"D&YXG#\2"*\8'XU V57Y_/6[D
M\*23@@KKQZ+0"!MFZ[^W'X6_J-E<D_!\]R ZSWVILIJWVH9[0#'FQ"C1P"ZL
MM#D<P1OQIDLRY.".O3B@].JC%0>GR;@,^=(7<I,36[KWU1/DM*8./=K9X8#<
MB7^>L-'U#&G9-T_^K?R0P[*TAK?=[(IX/-@.?S%4)KY9K,=&$1&M[HF':+K3
M-D*%.VRO#(&1<!^=N "@U-+-;'CD\"L3_0#OO8NC?>^7AC&S?3):*9L%R^=(
M0Y6='@@U+$KV#QSY\F+MMLW2Y!3S4'06YV5H,2KAX,AC^3"J[V? 9O07$;Q3
M.PJWD3.5&5L;IR3E^):F*[,I8M[W(K&0S/+$!\&;_=S:F,20X/5QU'HPZUU<
M&)R'W^%WH:?>G\9[S3LK[Y?$-(EK5B*4EO-'(Y<0B> "'4L7/4OZ#W@T-T>#
M/LX>#78HW7MJ-" S%1*3<_\<$M2VRPK<M![4\2BQE*P_-XO(8755\][=CP_[
M*<40%:!=<BN$RAQ @#RZ&S0"@[8:H\TE9UI]T(# C'7H-6[?%35.-QI B(D&
M,#X@/Y,AF=:+@(8<BDM:M\2 'NG8W-F5:HD5+)(GF]1Z5S?KLT>2ZVS\DZ:E
M!PZ]8[XODGZ()H[=A!T\"/G\>QK(V* =&N!5A]*>FDRL#HLO]2*T\AFPI6AI
MS)DJA'*@ 4$I*# :(,W1=G>ZNFZ(!@2+R16@JN3JIIU* ILJZZFBS':[\BR_
M@F8D0V\9L]TF5:P)715KIL$T][K+'VB)[3W\CX7+PN"KS[RTI\1X;F0Y(ST+
MPR%X4NM7SC0A802/56$C?*A/.-DHXW4?_W6Z1V#J7JK<R=36O]"7?+\U@]DB
MKACE3-+9DR'S;1U@^)47/<=QSJ1IHV#%DHS$XF]SCB8/>1PLH-5VL^"-P:X1
MT_0;F]FNY*/D_5"F/0H*[N+\W,_/:B53&%+M:<C71%R/E!&\HQU&+(B/"<DU
M*W??=/5#2]=OR,-PN4W_?NGY>^7^=YA;HAUE#8^31FD7K$KEBF\-#]^V.J]D
M%:KN+(V@VM]L$JQY:OE4PMF[&ON"#Y&]&>HUR1/[2G,U2OH9G AS2.N].;<2
M$3$=H(QF-$3=<A4O.H++R7J#^>VC4[# ^_ HWXH.H5&?FI$EG_%TFJ"33@2S
M(%]/^=X?JTZWB\.:6IE!L=1[6HOD=R[WI'#9N+4, JE,4$7=A9=51\!1RQ;'
M95+_3??F=O/VXH4J7*"VC+P=;*3\E@9:VY.EX-.G&F5S3/"B#RIN5> /L082
MH=JZ/222%]Y"<^</5,;W]/*0KVLO US4<9DDUK0XVHX*,H=!G)E>+##^<?#)
MHDKCM%? VXM3G 5\;ENI7K=A@,?#?/M06S[(>)\FF#Y9D@"')4/CTI5JW/&1
M@8/!93?7_$V7\5,O#3N8^/L=K8H9<%EDJ:"'X5Z=VU3J)HD(&I"JG;8'J8YJ
M8.VSH[34%B'<@_?&YY;=ZINHO0B,:(A/<5VVES">^2,F=:.SX';07BO2&H@3
MVLQEZ:ST!%*=,$#Q+,DP/I-F$43KU>VT095)K#;99@[!VO,!CE>'?&GFWO/P
MG69*.Q94%NAU;-5BVKY[#0V5-,O 1B7J3SGCLLR\89C:.CLGY%-ML[0Y 3;$
M<@N/"'>0:_>TU1"%KRM#-"8RQYS;2%Y&A"S47"39,H<-NDB@ <*LZ>_]#9!M
MU0P3$KQNL8;2FNQK#_=R<;^R;XO #[7ID!K[K@?@FLYSEW;["G8PB#^WJ X_
MNHNOJ(HZD6IZ^X<21W[.]WM;D%5ZW@T7BOJF4T3B!W;+<4+RQR-'BT(=0\H3
MIOC6FZMZ88[5%UDHAQLERU42,0UPIG*VU0IM6TNM8 +FYU!-NQ=TNGAQ5[34
M_K#+;K!QIR15Z_/=BSK8I.QT01-UA$UFL/PZ)Z\J$Y9%&&#OGO*6!+[3:7UG
M="GC>55^KA[I*G[7G[9E-CJD0-7?/VS0B)++-')KTT<PASK<%92"T(#YQ ]*
MIY0N1U>R0D(G1I[9][,KE#,"RR*+-TPZ->/.[),%\]9GG24@L?D%,L?Z;W!<
ML@?K<3_C01QTJ\R9X;Q^Y'C#R2'EU#?3C<?Q8<@>T+\D5T^&L<C:08P'Z:R(
M;N?3[7=<GYNTDGN3%",OZH]#V84Y-L,:_#!]N):\5H[#CJ76B7777HVZS3-<
MD=UCB_)Y>D*A +8.9&[K7:Z89-Z<V_WVQ<#%]"W]?AVWQ/#E$]3IBH2'A#U?
M6#>"]<@B&^5S?K@!7VDH-IR?ZX$4RY@]%;RPL6T*3G;]\I-7W@#)CS&G=_L8
M7I-J]#A*Z-@/)0BYT#+?:WF?=NNUQ(8L:WOL]7:\&:<(%84&*.HF>/O<G;.O
MOE5N'UIVB; 7+QGU4K[1<K-3R'A?-U[=HM'CZM&:*F )1A9._=&WH%ETH-VI
MTT../G(;&87A!-H('%#:<AR53\603YD+?_*3TM(8\WN22?0?[Y_^6SQ6?CKZ
MK'?C=;L?^\@)1_+(OHY^,:T/^>[Y@%OKX+=Q@\+UWIGKJ/C)]UKQ34F?M;6%
M!]BRFT;LB^X7':HL,EZ.C]D*%;+EV%,(7_]#HF3S9O),(&;G#T9*/.WD/S94
M:710+WM>-BV=*66\)*-MH(,0>\!'R5"C!HB\ENFA$;!3(7EJ9S#^CX.[#2-9
M/MZ\0)]AS\G#-J.^,;-Y#B\G[^H,%H&+C-W&!RFV&ODVV;,E/QQX$;FZ?":Y
ME9QQ8.3N;%*&:CTXTIM>#-ROS%B_YI(R(FKEF\YL%GQ^";9MWWJ/T0[5AT-Z
MRB1.Y%2/4G)K6Z5KZM?[3(TE(PLBRAN*FZ!;AI)#US9U5(DFN7OK.2 (?YGK
MWMPA$@T@GMO+=/\4Y'!KUU_&&3^ !G2.PF?OL#9N(X'PJEL!-$#J']XS4NR:
MTI>ZZX.^ 5.)#F1#^)VE_8V2X <PKV2G&%!C:9#2U_=]HK2_[Z(+H;C_ WE*
MKEN@K._]'.YEZW(KR<R&G[35;W8KX8;Z!RI 6X"V.6_"J.1?NV/1/RG0'LD@
ME 1!\4 7P2K3YX43;+TF23^$@,L"2VA E_+M6S0@*V'U_LH.#BW*DP21L^N@
MJ)$MD7+X!=O1ZMG-G5P+^NM#I[D@F)*+ZY?BMW7,]^1[/P>JNF,9EZ*R?EW[
M3]1P XW('6YX5B+?7VRHHF)@'"]IDI)-P>8OY*<J1P%XEWI7.9UH0'4*2@\2
MFFC$T9BAYJ^,> KR4(XO533S_OLD\EVO^[$E9A4">%BW#B%?EO.$%%D[6/'J
MY>7=30?N^>ZSM6"M83;!>XP1=H>S:R?D"Y9CF5/\%!-@Y<B6WG G\-:-\,$S
M6MHB)%0$Y7^C)Y:!WVSAD+FK5QL'6Z9F/K.!9JGR#AOX5E7T8TLD[9 /NE%<
M!"/N,S:(@^GIII!E=NKAVK6@\F.[HQ<*Y:ZTP=&F7UX0-9O_!BK-W_*.\[<!
MN/R=D"FJXUK JJ.ZN*=DH\,)#)MU#.E7 C]@J_-GG:U<;74-J:MSK_7[+,1;
M,QPW>UP?T98Z<A)MT<^504(A9#8^%'W9RD6Z2Z.@HM6^@KMLPB:.9=3[*R8_
MMPV!?E3*11I\-)#K5A=[J^Q >GV/L386QJ*EGY+D<TCJ^UU_'Y"+DX/R[Z26
M"Q/C<5P_4AD0+:.'8=BQ5#FQX6 N4E)>:V.N/6!A2:</\2S#=,*.SHP=QU?+
M-U&5/K;/ARF_A/S M*.UB--IA!P99X[FH-)A:,#[&7ZPJE2U_AXR94HF74?'
ME^H)N !:)I5U/Y-L7E4,TE)^N"+I7&V5S=D>L:-M<>,/38ZMOC-O&$:O/1OF
ME ^=E^B$!(4;R(F#T%P?.UW?E]7[J%&.<VG-]64]\;/[@0?#K-)4MG]J=-#H
MO5WS\@8-.#SZT%F'V<C[PZ]U92?Y+#H86$N^E=$I.DKAMO&AS0TV@P94/=47
M4M/TY\/PU8_]8;]RQUY4BSH6DT*P=I2?'K123=H=<G$R3T!+83I;\DG!:4S/
M5YH)?'%4JC%V/;3;,YY8MC)43I>]H7[U!ADT!JM;_>TSX!#/'J709S KG',_
MX/-DO":%O=O;:'^@<^-(RT-@^D;!!,SYG>I%'Q9]$BNY?N=JC58@S-M5J<80
MT_#/A+-U4.UDS6"*C9ZA?,O[G]\E<O$V6FGO)V,M,XCM:HPIE)S+]EWI&>HG
MD(OL; ]KS-JK,.='>Q_KC*_H*,G]P#T>@KZF<%6!L](47#1\$2FM6/' WU"@
M\$OY]ATAJ@YRSP=K4^4:(&9<IK/?,%6M-*BO]E5?IOEMMK7#Q"MN80.'7G:E
M=<%>;W;8P/Z8OJ[1[G5M/'?0C=+4IS?P9W]9L?R("P5V7-  ^CQX=(]J!!#^
MR^J#FW[7VYFGB^\K_?Y.!"T]?JQ3V0/P&.T"!HFP=DKBR_WS[F/N7D$NE)OB
MJ7MTPUSE#F9#N>W!A0/<>2?8^>ZI_(E$5]G^ZJ+V%]4SFBAAC2B*+5HM;7\(
MZ Z_^SKM(J70LK$MJ ;?6[Q&OJR&3?8FQ9FVV42A_^+@\RWKC19(@@W!3,V$
M,C:<.+$K8VF>E#F4S[Y24S+A[L/ZT7OX"<<!\6QM-?C^I70>&@"B610]>A-G
M5@2J>XQ?XA7!K8V9A?E3QA'N,R2!&]XY81E-=]>I7-A7O+1J8$C%66[+-#(3
M^U[X8/)15L5=/C^A1I<$WO01_\W>:H^(/VAF1JEJ.' LAEWAS!2W>@=KYD$6
M!J_KIUE1SBI,]P7G3TE6,2$8 V7B5%.Q1UQ-Q2PH8;_I R4[3H@-W'*Z16[R
M^BZ"F@H(.>&A/AH Y0RV/ARZ ^OV%?Q)'WHW#17XQ4]F0Y%.24Y2OF,;"[%4
M@G/HZUF(M3B./$*K,G?1#6(P?8CTK#0KM$K@9N^PXWS'$'$LQ$J+:;2*->A
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MJ%*5>ZX;]PSCP.ZCG0MWU45E[!Q9JD,Y,1]K,0DAA=8F,/_:2I#?JL)9(\5
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M%6.Y,_HJ#^\#F?^!H;>4WRSG&X9= 1XMX!.T_6=[U=YH]MU8)OUVA/*]3 H
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MBRK0N:6?3PGI'JY3"L1]S."'2QO@_:L.]NJ4/_JT+^WEY:H>VB/1)U9KO%>
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M.Y</3BKQ,OQTIGJU=8Y94JNPIE^N[9<)9G<79IZG%<Y!&DGM..U2OF!5XT5
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M9XU(&NO)&DMMM^)O7NL3J0'KE[6+\;'1]"R_AA^MW6'%A&&^YU> .#@"VW]
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M8I28YMQT$&V_QD%;^N,@82)-%_:83K,3D;)5:DU7MCAW!>C9A?;5^#1%:6-
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MGY:B9UNBM,,?I.GG]0R'1!.,2JO^-50X_'M8 7"P3_T=_.BMFO(?UI7Z5F
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MN'TD?IWO).5J%T][2V2(Z$X.8X$-!J&!!IBP,KA_=RA:V6T[]=EY'MM3?>%
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ME;O8Z!J_XS_]T]PNTN2_ 5!+ P04    " "(@$E8SU;CD0<K  "'+@  &
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M;(^$Q7-SS=_DF)/B,]\_Y:O6C.Q+AAD*2/&W#I A9#?U[DP]<B%W%F9(2WA
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M />F OYG]^7_48#0T_\+4$L#!!0    ( (B 25C"!&)(P3H  *\\   8
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MYWB^U#N<!2W:,C2NN%>8J74Z),I[7R="0'@1?[+BQZ:%[EC\U<S,F+[,24Z
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M[-^4\.(ZM&+*;8YQ^-_7&(K?O-ZLK//8L2T.8EQ;+(+RPXK"$$L"@20//>9
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M%M'K%USL_ED];]&F.^Q"R[<:=?ZK4/"-XLUG'U:O31RX5ZD2+U=3WRIOLF7
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M<ZJZ/D[6["O, ]\?Q">+?"%'VGTO:\, WF(3*L]48+T%4JI[<(-9Y(TK8%%
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M,]=RQC $C4%M1L>K/U,!71 GHB_W>#3?H3E'+ABGZUH?!JDB&(/@*>6 NWD
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MU7#E=]]\%@CWKC(<UVWQ+\*I?#24#!D\^+7GQ[DC#Q.[\,6H[A$H$^I9JX_
MGU<_">!"XE'WDPA5=M<).,NFD_ ";T2K_3HK]XL!MZ<J_*A%)%?Z8+S/C [N
M"LJ:K,^>,HYOG_A2/"?2I65KGKVPX%<:['Y=>A 1A G03(-Z>C=L);;(9<M3
M5J2M+FE0PRZ<7>C;CZ!(3>EJXV@:62$UAZ^-:Y765GV5+.FM@C"18L4XE'/]
M"?]Y]>I?VV/_#D9=72:DE@D[M%\N&4SZ$M*K4E_RS7(3@*T"P&/EZ_F^&ZH
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M!,Q7F*C6XEQ\!40JJ '.-5^*9!STMYYB3SCQW^\&Z''A?P!02P,$%     @
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M1^OS^8,WI)>0&?JR/K8D(00.@R^;I-0.SI@_QY6O%7=5RJWWISC>!U^-.:@
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MUC0FL@NIAMQGY91(.?GVF=87T-5]T<MCV3Y;+_9->J:W6M4R+J9-"+.U\+!
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MW:E!0+AF[4>5H@6*@51&\7=MD0PM>GFPS(%,\ZPZ'INL*,Z")_^VV8"!W^?
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MT7N\UINW@@9K,\+UKY@44E/1=GNFTL_O '3OO-5^6=JI.C\=Z99&2IWR&YY
M^ V1ROJ+2]*)"55)G<G[P$H._/]!8;EI>D_E:2Y+8UWD2(_KO-VAR)2?+(G9
M8*R!SRK7-"?R#-99UQ0U0Q<%0E8*[W_\'N7N(NX=,9W[41NBDV; C*G*]PY=
MR;S3'.4QYSW0?Y46#NTA!]2(+_P_$>*:JJ-U%;\U/JLW]T0+XV@35RU3D8ZK
M^T7E=346=F8U$]?L% NKXMUZTTUYW'A6Y=4O^Q@A]F'K^[?OT_VY(@MJK7LD
M)#E9>O&&/%0R:\92Q.U"63WIBIS&QZ/K$RT89G)V=P#9^9&3MFBSY>^2ZV?.
MK:)E[79)Q:Z_3TSBFDK!*W1(*S\O@CE%7;U7--,4ZOP_Q3?C4O3Y?#^*$>'\
M=$.:OP[SQ'GT74; 3!+Y:0/54C;L")/.@PTQ639Q!K5H H/&LS^I&'FCE=6>
M7=6^-Q?C'8Q153%;1BA]V&FH'#YF"HDW?6R5&/G2A_54AKO+W2F*ME?RU&"1
M;;N-UK#E>99A06(C*^%*W6[V@_/K,5)OT6&=#M;E]J,?+HVNWAO16*/;BJ=B
MODBC34AP*S&"^"+H&WPNM+C1C-P$)/4Z;?+%A%&O+.)M%O7<0A8;0G#7\-D<
M/Z/9L7(X,O.,8N<.( C$VFVG1BCG;KZO(4%FZQDO/R^.\00\<XB%PB\ N.&A
M6\7^KX&11*Y^R$E9DM8\3I>0YJ1:V?XDI=070QV,P+IS3GER/+!B<J.YF(52
M9R]<Z^.A],/U:QDZ]?CAZMH8%6H.#HS99CR[J@G-?[A'](?VH9$LV88)?#/
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MFPYG[78-1VR-^$;@#C#055LFG-AMZ/-_BGNM2FA)G2V5?5Y7*"T(Z59_)"M
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M\X)IM\GT<8C<B&=_F!V/XD"&5H8?OVE2*!0ZN"?N,_W@S7TTV/[K)]HEBU_
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M7P0B6W26]H_^&_/ ?VZ]CKS4IBZ/N_R=H?+([/B&8>[KOEER@<>IM%,0P<-
M92+(UL"5*R=QV8M@&EM*"K"ES8(E5HOH]T 9"/. IL"/QFHQX^"B/JJ@Q!?)
M1@"D 1Q'.B.:*X1(X=]C#.'?1ER$Z3=+K,K+Q(372JR.40H#Q-6> 2)Q_<X=
MB3633.(^;1AVX*8^L0]"0( +9\:4'(RSQA@#D<);P5/7[?MJU,6(Y,4FU7>L
MD4)6JW8'>@O^)&;*1_$V^$L0K'%(UG6Q_^;36!NOTZ2<#@+@NNO('0WZ92!.
MTK,-+EUOW?T@E;*8;_3MQUZY$+%T=ZH7L1O@HNHD!%G%?:ST!U>;.WANY8"?
MD5Z,UQ?DS+* LL5WD!#@'/H"]Y-(-IR%TCVB>LR#O)2]KCO,)ZOAY4R#:].W
M^ +ZEYC](2PDG5/9Y2:ULI<5+,+CF3ZHL8#4 ,HNN;POB8S(&%G0(IC6PWY.
MFUEEV*5E^=Z.O45HY5*JH5$)U::\(,:6EM;VP):IN(!I/#6_(Y"J!/5!QH$#
MIWA2Q/^0J%89S?9S:8RFOA/7"P)=T.Z8G!6_0BV^_H0UC_^.U;8"DI>8F(0(
MWWX0#:WC[@0!,+')W^J?_+1^ZH:Q0VR9$TG5H"#T(3&_6G;W$X@;U?-#Z+,/
ML+$T5?S>I:<?#K:)FGQ^*#@_V;A8%UW3%?X+TJ;Y8S'FBLA%L![M4(F$'"2,
M+_7*_Y1%1U-(K",8Y>4\E!<9OY3 O+Y8[KZHF6AJSN+F5/_+X%U\I?$QV'H>
MPZ]:N81VS?1X51C\XV/(SN'-3XA*7AK>03?4F)_\$6;RTHQ8+T8C^U-RE'-M
M15;8/=Y?>3P]N+)"BN_J\39<,]RE(RZZ*VA$NXUEZ? >I%7K@=)=?B-<12=6
M#9?=_YOQZ--X,A\F?XGR]F='B4+-Q5/%ZTX)3^32(Q&IJ!)Y(A0V2SDX]#64
MHB4W=]X^=DHC8B3M[H/ NX_P?U8NPX!SL28P-=85/=^V:_/+9KRF[_@3:Q'+
MBBHM6H,;GM/X\ICQ@N(2C&B6QO(?8!7S/59_H9]7B!" -PHJ$4+X,5\;Y#CU
M#FR+E@(CHXA!_%).]W#6+!\LZVK8K2]XHPB>LQA-FHF%O>M1H#=1H_E99W"*
MYF%"\ZDO?59*X]M@5 .\J:)[]*^7#0L!)D<V6;9Y[[/.RTCL>K2/;'_%1_<H
M,/6.ML,M#_:Q]Z%4V)<9 OOQWM?8[LSW*M8_PN2 (EVO0FR^ZLR1)%3)4>[Q
MD:+=E^3+/PC?*0E3#0,]4%^\04T_P+;$^)W]8ZV@5X B=GL,88.ZFD*.?3%Z
M?)"AYN@N3J7C,ML QCJU>PHY<H9*V,,-<Z8BB]"SO&<.;XW!+_NW(70>*.T?
M)-Z+EX9R4S-?P D$P+RZP#)1E7]21'JTYL!G?KZBK@2\$]ODF_63 %#N!^VK
M"ITT/D@>]L<I%,E'6!7J"'#^K6]@578.+A_9Y:7(UMFP+2  U.7J)1:'\[AN
M=;Q+CWAI36FIBHGUDOJ?6;%%'M7U,_^:Y F.J(D"=0FMZ=>R^=W+!,!-%326
M';OHK.1(!HMO(@#I?]4N>23TXM1'"S7FR7J0^TJ(3+/ #LAH@^36K=^<*338
M=FC(DGPI\[SU?=!N.W)5C9OZQ["&*RMNQ;83EZIVE"9S_L;5B4Z-XDXZG.Y8
M8E9[F1-"'K@[=84Q62)>TF-2.=UGC)7LI@U[FV0II-O5=='@4MR!.]95YZO1
M,=G"ZQ^O#HMG^@<;1#PZ6WNSM8E"WJ6E+A"6T_L-FUQ/JHPKQXMB$*#WF.\H
M#K?Z+Z8$8&/4=B')Z.!KYRT;PYLIK\ +H_1(BKZS=XV!&QD$X)&:('6*DC7B
MX*5PY-1;U5A,DO:H&^C<9_AMCX^F/4IM +%0"*7;S8#N0JD]K/1"K]/9KT]7
MRU?/+1^CPGB'9247OIT8=Y;%3Q;D%X*?1^"7CK7V7K_+M&0&*\H2E1>Y%I1M
MXX.Q+936?,BZR,!1LO_5#4JJ5A;K9KSP4.XFN!(9L"8@+%YHVY6<H<*1ZJN=
M,M1 43($.57D+)]YT__4LZ[$-RE?"4KI$3QAM5/Y #Q)M7R<G4=#.R0G?-J+
M,<EM97!$];Q;>!U>^^0%;2>9H=4ON!?&N6!7<DY\,$DNHX8.A$4PGLL(5:"L
M=9+L!0A (RE5D2OKP.*BDEHU@S-5YRZB0_@FEAN#/E#3PWAZHME;)=TK#739
MO4-&B%Q*I>:9K,Y9[6-6TA^W9,:[&TO6=^.\+Q_8&A)%GCS/9(]3ZK2IF(IG
MMD@54]1,:8?B] -:XG+D[^*)OO%!G@()C:6/X0C'+X^K+?0SVXJ9WRMAKK?A
MH"WIK69W[NY_3>$5BYS$R9Q>8FARGT:EW+1+>R!6X>V9SKW]I7!;>)I[H?"<
MR[ MDLP*[V5&20".;PL>)9PZ8HP/D$M6[>&.%![3FDZ>A4_76KS9.RO??R6Q
MSU3K"7DQ\?CO*Z_Q<:GY TU40.7K<S&/Q('D9(.T$-#9B*J?O%\I+AW/"/5[
MC8E<M.K'J2R ^O(_]BPU!I0_\$&VUW".>7E*1PAC$QN>UA$+@SK\$1P7UX;G
M]2, P\:WHQ$;Q492!.! G0!0F73R=*.97Y8&2#SHE_OT@.&&!N^')3]YS._1
MG?)7PE;NY$-1A=?#EH\E/C:RXUFLI<\"?<%3&-H%Y.=]K!I<@F\E >*!_?;6
MG_*(^C:/I\?LCW5N4M;'J FT O5_^\F[%6SNSC#\499VCNWX@,VI[O6ZLUMD
MNIAD_"@Z89>6N" Y!K#T'!?NGXKEUBA-JE\ZIW@LR5%<ZOCO6)-NIW# 50_V
M6W^*S,,N?DC2O=Y1?1+[<B/TB<4QRA_Q3U'Q_S2SR45E4-'QHH^=],E%HR!H
MX'U].UP*;74:@79LES-8\E'3K9)WIV'[ S'DBL"%_&XZS<:RX+[#G=%3Z.=Q
MV4GVG"9V-3_'+,J1XVL=Q-U9DCI (;B,##/GQL3E:-W_Y2DT_FTU@K*S9\:[
MF/>ASU]M;_<FQPF9#BBC=D7ADAR>Z>!H<0Q6190R]Z$7[Z^M@W;E*;)@.XW^
MT.)*_X;K]^J/*[:7=.A2*2Y5\2)Z3 0@Z]%'9MQR_!GC?K#><XWN$W&25OA=
M#-T"*D#Z=<5!1VSTK.ANBE[*+;-^_/'/D$M!_UWS@'=Y'1";>#\A5ILL<Z]1
M"R&IOE1J5:B78Y+^L[)@"%#V_BSKNVWNOPH%?-Y+6;A>GUA$_NN\SU9Q?-+:
M $4SXN!%/X5/0GO\Q8S-I\:R*#TU[''HN2.1J7^10 ?YIN*GDNF@]' ^K8.D
MC.&'BLX$X%DFEXFO]N_Q-;*8,E%9.Y$NS9@]0:,=+785!OU0&Y:,[&'U=N >
M@Z["M8K8LC+QRH07=#,=)2&J1H,S>=\?'0:H/4L&TST;*WCY?-3!/CJVN&&P
M-F>! ^3TPY?1[*&.Z-KJ0VNV3WIS:;:)GXJGE!UO?](LE'T3$/NY5);?5MNY
MS>J5/M.VLV6<:O I_<=^CJ,K&M'""D\VI\O?QH0):-Z*:=#G';#\J0*X7J""
M=N&B#POQT^_S;&]21IQ^?(K^/4?"]=(%[L#:.6(9"6MVA\CMXB+_?LEWMK$6
M-M[=T[CZD$0PYNCUCYO2-WT$@K*C3L*U/-[0*XL[>;YY=KJQI\\B^@ON($#)
M854A<!J#%M0;MA3M8S-7ARR<%^S$"O3WAA5(T\R+'#\YR<QA.!&^:MYYK]=M
MRNSLNX-"HJ0@[]?+^G5/:.WA47^CDQX&W'&T$=?IZ+(KF=Q)X=0=/N/M_>IL
MGNY==4/C=Y=:QX?X.1GOK]\G5[Z_NJGUN+.W+<"$\Y7W^I?:*JWORAETTWYY
MF=Q_KY&RKE=GPPH5+F[P/XU9-?DH0G;3X_:89&K%D<ZJ["-U[V %)V-YIK&Y
MZ28E-%'XC16KIW)=ZH"&JB.9._J$M@K&2K3%(\=$:8\*C/H=ZP^D0ER%)P/;
M$] ;%Q\QL?,&E5%_]]]F7!JGS>5Y=$T9Q?2SHNX'P&BOV*A;!$N-9"!MWO.*
M_HBK6CFXZM0AYC]7 $OF9:K( :U1]@XHXP<!^G.^_J%J>QF=E#;F2'>WMO9D
MG;/&2:Z C/1Y\&L4, _7P>7">7/,ZI!7O\O8'JE?(SLG_>BR4=MK,?S#</?#
M9A^<@BC4RC$N]H58Z/(3^UZGJG"-TN@B$M*SV 4<_!?&<+X,^+1@V4C4U/8I
M4]FOT*C0.QBI@]*^40E[I3<P5XF8[J_=G5\R$)1[7AQ<K<F5ISNXWTE-;B5P
MV8.GA9Y+?<HXKB4MZ/>%V<XOW]8]_]Z0MN+4X>3=D;@D*K>6V$&3#GGASPX-
M=[;0>U^ZCQ!63V?.-1$-B BBK%-C[:)PNKSKVP.![DPN0 6@PB_0P5GY#U%Y
M)+%]X]T1R4]M$?OIW3L4#?^M%R7,==&5IZ$'1(8:_CY@13*]L ?T_48*-:!$
M 'Q5\>0+%W$3+RAR34W;K4C[9'.OJU/+1C7KJ^7R9L);T<NGAP>.+=M/%@;W
M[HP)=[PR%0.5YB-*D8DO=^J\QYM3RL"[^TNHS^/,!I()2O/::K=56/@=JO:8
M"T)PV<L#AG_V70L]EB%/_1W*[557 ^Y,#:FO'+_2[5\@![P=.\'3H XPDRLK
M3XI>,CL\AM4B6'>3C?8K^'J*UR&4#"Y'!-C^FS12K5-F<[G>_#-K(D9^B# U
MV=MG%M 76&IBK?+:@C0'&F'"G>['V$XX94S_EOI(J\$><_.4U3'3IW^AD12#
M6!P+X8I9K+\_K3X\C#<VR:).V9=Q=3M[JPW .P]X\=>.%HEDLK A=WDR'7TU
M2V19RR_&BJ@$[*M$4[I]RT]6?Y8W)%G19&;00:9:?MT-(*.,R=E@5 5 FF_B
M$]^E4IO;B_?HUTW]%W9"\M?T6*VO=!/Q\!\0[26"*!%6\UE]-K,T@=*U(=;_
M@Z'$ ?F>7XAD'"(Z#)\J^!<93UK^22+[9F$7]C3Z'12B<66]E/%<9Z&)#1N
MKDB\@(;N+<=(BDDN-40.AJS1^':R.@T<01-3*L !B$4FS*\\#09OH;W[EZ9&
M'';?'#H7%MM?N=/+(]+"!-\J10\-*EQ/^Q)A$)14E&+W\$_(SV\%=X*5EO-C
MYCG)KT:'R!RJA!O1*[^JJWTQ;C3K:#U7_Q,';%$@,I^.Q]ABS:O"]LLG.<!E
MWPC 0,BR\<[0[%\-H0=_/^H86#SCIA@8;E1F591RT7*U$?K18-JE7QPS(W)"
M4766(SDZ;:_0SAPC2AUNNMYC$9 ]JG.0,I3D;EFL6MJT9F+U^+HJJ\Z9D1OX
M;[C;K;CG0_Q+8:[B$7K_O*4 J&YJ\S+0:^M[9A@MZ_WM!*B 8RBY>H(\Q<CK
MF);(P_LZ562^Y9%6U[DX2X] MTP?=W+VIY[F['0-E+7$JD.='2=HR8NCP!W5
MLR\AEC^-1WH>1##2(;Z^/GG/G38L/HE5]!AG)@LE.4\:Q\5 =?!_B&7Y-/=2
M 5-X1]]'J@7BS3_BRFCZVO5F9_+U"/!^3/<.;;@'V]3\"Q.)QEAVK1<]:VID
M@;Z]1Q'H6M;MN<87\M2^HRE4<.9%&K%6R,.0W TOUPQOM6Z.Z23,STF3![V>
MO*#HI>C^[+H[BYS<3;[LOP=<!%G*=@4Z'C$PH:^3DU:?\!QJK,1JH)(:[5'3
M5WL6P"'W!L0%/Z5TN!<O*G'@/K-\6,>58KDKY^1*_V+U<86ND<IM/!B#HTOF
M5@.Z?5AUVDNAY9A8]==N=X])\SGB_".PVY?"'H:*N%]@6/98.4[ZS+2D-,Q>
MV;4WV"BCVH#\W3>I@]CGS+_NJ#WG(YU$O)Z?9#N=.@5'(&Z]\4ZAAQ* #!LF
M*0LAV\BNJ@^(U72K58K4)UNJ\N@,4M(K\?^M'TAO'DM@3B[UX%XPQRGJ3H.+
ML:0/:)5<+6N_!>EVT-X(HURH*?*MX"E;HRAB(1\,& P;#37PV53,5S5.9V\U
M&%V6YN!Z0W KY#HUM!  4[37N9@2NM?7LN45%2G(<?ZQLT;BX@/BI\_[2S#V
M!09\4-%\=Z L]&_:'R9[H]E.N9&&NHJA0-Q7P >VT&I9_RWL38G=RDV=>L"W
M83,%5,>:2]0);=V[UW:=J/FP'2JN$/=(%SE3RQZCXNKN)KJ_&7AC5(>)T$N#
MH2[)A'$## %(?BD"BH>E%F/*E_H>(S'?RQ9<+I]I$H BL8L!BAW$#Y9W'$A=
MC;6U1OXZ\.4KCTIE/M)H9KQ/T;OPXVY0II=5" %PP#D,V\YVNRELKZMQ+!\M
M#%!L&!/1 7K; W%Z..S@)K0T4;U?VUMI<1X@.%0F/-79DOBG:&-52>W^G-$:
MZ!?%<2JML^@0*\QO&"_AH:S;,?M&:(( T/P11^2R%,5WMD$<<FH+3JAAJ8CU
MB#_S70-7F_\W+(D3 2BB;%C(0'3X61F)=8^VZ%H^*W^#/6!,G$V@.#;Q?2JU
M_#^P%E$6K F4O$?%$WV%DB/L/&!:8TM(8:Y+?B-::#(Q3XHAR]!GY^5=<..#
M)C2JM=Y90W]6-G[-2"Y3YR=8%]GA![YO70BF(WIEM2WUR%Z@8'J$J^D(N28H
M6OF4G$'W&9G$>_^J8J2CT%5E/OSF$XKST;=B6AQ(ZA!5@=9?#&Q*II4ZEO)#
M6R:"WXKNV,=V-'^MIW&#D ?'+/E8/:L=8=S=A2#NG]"UQ#_^4Y*\/-X@&&NF
M0)]04?FU7I/N?"%,JU[5I#V2_=V'SMB8I[7Z&EM.V_L:B=XQX8;5,YB>EN(M
MR/"4#??S\JJ*7HMG1E-3;JQ=X"=WE3>4/\H8WK.QDOL]*E3T*Y:4X_J[*'T!
MW6;VC[3**>O:26WNXP85IV=Z]U8,%D*#_E"\X_*O61ZP"INL1'O!*EJ?C?\5
M4J=FW!&\G/XH[;!_URNP:U?;^F.?LR!W;(9M8\'&&1OCY=1,T /@7<P-O:>R
M^;E[&2X2R<^M^?@+;#3:100UE\3_ ;P;QX _Q)B13DN& Q!,+2D+5Z\\XCE?
M<WR.;PD7Y#NN@G?+VR0%J!TR2@3_E*]V1]8$[H/?<P7.E7Q!%6O0&=DD<-VM
MO_=9/6&_\9^S]<B%[)WJ/#@<?1(?GJJ\HD+%7-O@>E_&Z!#LL7Y$XE4,AE0>
MP!;6RM%6[6-<# ?M6>>K,IG?FP]WERG6XE5W*-:> RMAN$ ,YX&. H9^(1Q!
MN^%$$;VD-7UFJN4N^<3MF#/@F!1]_ZJO#XRH0OM!F[5)FNC[(7FW+_/OQ/*"
M$Q=\7=<OQG>HT8VM#W:9@R-WK,76;"H'J\$J-"E#C6_Y1>3X2-&.SW I>-&9
MK4$/MZ,67_ZK&$^G5MGGQ59@S^_!5Z(RXJ"YH%+#G9,,WW[?*X&:Y49[$DE?
MC26$%(3%-) UM&;A7:1;WN-%;_][ /4O6Y$7@HL/X47@TN/P.P77C6WCU^AO
MOX P;\4*U_PV &EN;Z32=D!#B7)8>SX"?WW$ 5'JH@[7S\J/89R+^Q#TPZWW
MF7+@=C/76AUW.Y@"[KQ@]1Y-\<FU$&3#[;H:$9-[<4L$087_1$E1R-U1PLV=
M\_Y-0&'773_P#ZG(=/N"3).!DZSEL<946B;?_GF:NH\1$O.DUM*!OV__.:4K
MJ#MIS;D.)C7G7R( F/L)S<+TYX56&5OF'#'HP$QH!3.>E,^I#_ 5_Z9;DX/-
M#1X2&Z [EK@P6YK'\.BGQR.N8Q7B9>,J: R:1$@KS"4)P"2L7=:8R(GK,=V+
M1]PV@QMSW)$?%8L;Z(I)<=^5CG;$%$"<[,*JV':QG8^J3;^ B]QFE!D:L=.,
M-FGRM8"9DXS;OU:@-BU,TJ(D !6?O^)@?7L%10\RK/=NQUYC6(Q5$5 \N^K'
M;K%D[TT$1J3]\].;,M<T0#%]+FR(#AT&FQUJ,Q4GY/DN)<61J:&X(F>. 'L.
MQ;8"5V.J[Y@Y_^!IP)E .FIR'T2!OS+)N,E&L=N7TU[N>._+!2YKU-376A$G
MN&KAR(Z@Q/(']]$JJ0 ^JZGX:6D5M'ZU%C,O*D%&:3X.N6T>E(X?FF,:9=0*
M3X(3@%M!7]66LB\,UY2-DWLIS])XJBKL!V4ZYHJ+7UZ\H-B^D8*V:$E,)H/,
MECS"7_M,Y.;+388JL+RI^=LPV+<BAN-'ZNS@&%2WC Z;1^!S0"7/C!S4RNT(
MBK.LX11;-@P]7J=I8%7'W\Z2Q(Z$ 3A=&QO9*>SF  & "=^R\=<O$DXGC5!S
M7A->6:JG?HJK0#%;U\;SRQ454A&_J,N:=)=;Z$Y\@P.QOYW970)@G3PTV[UO
M[T9" !I,2<TZDBY5/32QM)(F^;)G\9P]Y[GB)%MX(E 'IFBNE,U_;F >$Q%R
MW6:V:%+]P@UJ_@WS9>\JHG?1R\B?C FD'?(#RR!L$:1$+0)"L^L:I4_:#;/^
M:EK^D[ .[=H#!7E4P/;ZI\'-W)"#L93"MN^QG&/.(L>.B:*^$<3T^ANVD-U4
MEZ4;,2A^5WR>T2<9]NO&_7)9B=04NBW+B9E[&71M9_0SCWG4V*Z7OG;=>;1O
M+%&^*&? *6@ MKUG1X31H<4O[PH<JAY0%#=C^4BS!LHH3Z"T)J;<$R7\,48S
M)LY!']+7:&)^-IU>SGKD.-8QWHY75_U.]Q[(J$BP@L6J3Y&>@ 4YK(@"T%"S
M;F O\>_;:=.KJI&?HUSQS.:]-**4KM2O(?2R3\@_1+V*]HJP2C1QO3HT,U]S
M\#:SE2]0+T <*&5A<M!Y9B<GPGY8A-#['=:=T%UCDF'12CE)N<"E[*.S"O%R
MCRRO?[QGDO!-\&IO?E4NU1]YA_1@6?<<8:R.9*%E166,*K=20:&#OXE YBO7
M#GF+"Z\7Y+L2_9]EQ=RSNH_F-F/*9^.XLFX[/X JGG5FL57K.9E)M1IP=T)$
M$==+64R]\KFO@F**+-614VPL_C&!7UY(_^!XR3+ 9OA*P7AB@62NAIJ=\C@'
MWOUA6(H5U/5R1WRC+/1ZZ9LLV5O@Z&S(5'^!69!NO_,DN16_J0UY9,3%Z(1N
M$\BS]C8*@C$[:#7$A"S9R[3,L13#^I0V3_.BKB"78J9+_+OE@O0.F/U.0(PP
M+T2(K)S%PU]YYG_NAK%T]NYXQ7H#3W@. -2XSJ3WJ?40P@I%&8IF/ L3CGF>
MGANT/?\'*1LZ0@#FU>(F*%GS+Z7Q_1#0SN5"V]#Q0:57>1<1?+43:)UO[\C1
M>5(U?EY)//F??/+SC\45"C$ WT ZF<X-/!CG11W6I^CM.;8AB0R'-'P'?R-'
M2>(&$9*398TO2;"T:,LUQ%6US-[)WBFSWHH5*UQT.T(3#68F*M][=:Q>/(XT
M'IU&0R:.78F?'LT6[7^LO2&X+\U'>HAL)P*ZILYG:47W@?)=:O-P\%UQI#W_
M1;!>.OX"Q8!VW-%"ES;73ATUL?V<L=79%Q^H#/>?/WL7+9_6Z+0IPD=Z/C,&
M%RKP<%O>N2A*\,S6'N^I\5\"QY$8)^ED<Y7C&+9JF'X63=579+ZQSS&IFAJ8
M;2E)IU5BN:GB"0YOM$ %FDN*2J8?7*I'J:UTOV$M>W-\&#9 L>C&?]UV]A6H
MI1%2]P].HS#&!?$^["_'7:ZQX$9_/N2&IM6L$P N%#W:'7M+IZWBS7RK^>-A
M"0F2;VHYTQIVZX.*9LOHQZFT_<OVK+O(3/&I&[T(M@NK]OD#'9TH+H:Y[47%
M@NF<_J2,V<XGX*=="*Q;G44[F INM1#R?APK5&"]^GSX=)J?F_4B)@Q82ARM
M3\P(6-KK76/-"D6>KZT@!'X/ECPRT*/<HH5H K6.R]JV,Q:[_;>/ORL3@$<F
MB=#V66>MUX,:JS&#J5^7P+^*#%FSOGTAJNU4VE=5N#2)>@O5%(V1?<>B![R
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ML/QJ[.<M_QEV=WV]-0B":!33%?/_OPD 4$L#!!0    ( (B 25A2?#"IY(D
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M-ZW*]D&QY^#0?ABM/_1U*O SLF#?F'8Z+Y%Y?QN]9\'I'P/X=9-E0,Q[;E2
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M+]*;-$&J=*4D(-*E2V]*$0(&I <(A"*]"0@H'>G2I/<:JHAT4'H"4@42:H0
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M9A(MP-1<:L/MP^^7J'DX>I\._&0@^XZ_62+"F=XOFR?ABJ_"?:A7$Z;V;25
M])OS0 ?%Y5@Q:J/W"L#H*.6G\^.(C)'3F<SP^X;NS>C63R<*7Q3DT3I/GZ6#
M$" J!#I""VLJ]'7.J[XS/'=RN<\H*?]SEJ&MXP3=[^HZ:@9,+'E]%]09.1#?
M08A3P/!&VS4#>=$X)LG"L)2XPG=T(YZ#WN7/.5YJ!6W(OG;$G^T PG33D$0(
MYU&J^<+DA0*T>:\D(Y/LZPDU&N'A00 UG/@KUA_SS@E$=@QG@":;H_O6/Q3O
M^[2@^WJ3>S^%ID!POS^L.FZKT4[ U%SO6$#%F*M(MXQD4JM8/B^H%VSS>(\R
MK*NES!/7P+TR8N/=,F>CP=;7&3SZDL,"&FHQO08B,S><K? *&[,Q]T<O.[SA
M)(DKZ.]MHJ8L5S$4T^;#'[\"O%R.]6OL7[[I=/:M'HE!QIRSNI]J0"2&U^4T
M28(^*DT&DC.SV+$8^21<WL6IHH4;"YY <$(!SF7;0\4_S(KG;D[FB_Z.^K;P
MZ<9 [&MGKA7Z8" 'C'NR[7GZ5_Q>#V<KR;;V.,/=W;;61X7#5K!RCZ87;94,
MM@R5/: ;VTL<V(-+_IF5 T\M(IWS>V%4*2::<LL[>\2A*1S/[BZ(A[_2)6Q$
M=+(N8F/,,,#@,M4[9OT1GEP>  Z>L/[-3/S)>(JFRNTV5R0D<08HA5/#/"$U
MUWIKMO6VZ;Q&3N/IFX#;??X\__%B_I\2_%\OR_[QE!C 9^I_7?GVNB4GOHH'
M6U6$!6G&TYF4?\O_I,7'7?#D71PE/D+\AKN_2+N'=5U$/YP21X-.=FY1?6-L
M_3ET6#JMD;Z,P*A[/9Z'^;7E]P]X , #<A//3])SI**78W,71>7WM*3[LMG#
M;[T,\15:$R%YD"21*F5L--==4TXAQQ2Q&M'-N'=MC45X5S91?7MG:U/2G"94
M4M[*N=FD8DV_PT7XY\LN0QM\T"ORGB 9Z^AL( 8>7F_R"B?]$7Q@IFPK=+%7
M7?$5_:.?,NBS !_WX$(V%$ SJK&(%NFE6@6%M3C$,@V5WUS/.9FI?[OQ@EB=
M<8 KGOP1@V0O+F"L31-%%Z.C$W%FW#MZ:W&NS0-L+&;>Y^;LD[.X0)@5<@?P
MUANW[<NX999#*B'"!)5&7@$B8%PE\WUP'^?\&JU*=7?N:($@-Q8><C9E8H7E
M!5ZY=,#:%<"A<X[(!#OZJ4RK!"O^2XL@62JC<$GS7B%@P5 Z']:TFFE<"ZVZ
MI,8KR,&J=-9VUIW&PIUND\H^&EVXNU$(V[V7B+G=9IL/';9 DU6&+Y%,5N%+
M9?B27 %<-#F#JKL2]QQ7N1VH 8KR9/Z7%>7.[M ;._H3GJ$BD59=(\Y%FOQ5
M9XI/RU_]>IR0 4B.!JP!*6&*?^WZU5O5$K!J&)];1IP^^"%T&6]_\+-)=#]5
M[I%<KF,W5S-7O<=I9UU6YC*+,.RV0P!RASE & JIOUWO?,CZ=5(MN-<(P]?-
M8>IN$6\"H'BX!63%BAA@)=$1FA-'BQ+8Y-X;SYJF?"P*1+R\W![ZMX9R8;J3
M5 =>YZDZ'<"9<4R8S+F-!+E'A5C] =UQF$-9]Z>$.Y(+HJS2MZE;AA@YC>T/
M:L+PV*5YW!38?JSDL"YN=XAA0&'UCL@$_0E+WG U11+Y\@_?O\O?NEN*$VBI
M8D2S!D__]0<'##LG!XR>YZSW9I7%$EJYO_0M$TU#B7:L1O[77H*_G?;RF>["
M(BXU!A#+IU[L%]1U>,M_O4Z.[;Y3_1!@EX[1M([)EL (A?7G(>$49MO>LW.U
MX!;3G*\FN=&<1N89:;J!^EUANK)>&PD.K9&CSA+/5UIHB;8%UH5H3#"7H6AR
M:S(H!6*_#-JJ/;4G,?]]M:DQW/QANH.KO)$OEY%-+#$.D;RKP 3DNBCQRB&%
MB<S4!RAICI?C% NQX2"*P8-%T(ESZP,VQV3FD. DQ36J>.>I#A+LLCXV& GV
M@BCIHV<^5;P>NCD0ML>=OI +H.S[3<[LP_:^2@[=D+-J282$U(<'H_LMA7<T
MVM0+)]JTX/9N4I7%]TRI'5\F4NL/<!3<M;,-'M%!._0$2J"]6U$)U,M0#2')
M-ONJ 0^I"/*\VY>#C>9>L2-<]^]SU:K<-ADZ7\TF UA@9GM!41VW,2+A@L ^
M)$3+Z\))7F9N@J*NHBLH:?*I.@_<A[@U^U$7?DG5BYEC?U>*S=.6K-5?];5A
M&RGMM(J\OXVS3;":%C.7\DZ! C._PHK"<K?*BK"^3TMV/;B_)^VM?4HRV.NC
M#N_^S;)**I[GZA: B4!J5Y,MI?%&%$U-''SA$\[P_<ZZJJZ#'T',S+ YA?<%
M1WF1>UTCN9EMIYT<.(KU<YQKQ2<4.;$%YOT\K/MZZU9ATPHUH:]D*=H5==**
MH>AC$QN74T2^;Q/WS=4AM5D4N3DL-L3PVC*(F)GHK9C\B)OU+2 K=$@.@I0=
M@?<8!5+7H5,3[R4)"U4BWSG%=O%YF@S=9Z/WYL:K\?.I[.RV(L?0AP7RPHPQ
MS%LV_A#3W:*),0N5HLT!ESM5ULGK#,-X.PHDYUHX7W9 !].RLY'9BUG<DW&-
M,^^W%8W?#L:&!..7$2QN9>+2G_6&\<S,X'T"[SON0AV4IN^&,X/N@.\=:J;+
MK5GTAZCGNEHG-I8>J58]Q!ZCN?I!=V"/4!5P]1GN23GE3U!]"),(V8BKJXR*
M)4.;^NNO-^C=\W**O[2':4J'23KO1[/C2PBT+N^RZO1(-9HU5'M7E[^@K6";
MX^9PSZT=#@X=C(L#!##^Q^5!?S^BU\[6MKHBC8N:&[V(L^*X DSV+0)$(JX
M:RLXCRN S5+8%:!0IL)/$MJ^F!8EW.EHS2@5]ND'N+HXO$Y'=M?[TF7_*,N
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M1ZRP$P*INUA#UJ;3E[?B#Q\..#F0N^T2PB9Q4M%8$9#MA,K&,3VH5-8K]\F
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M0YI/5@MO:#FG2M/%(AK$,PD7G_^6H",Y]?4FT:2C92_::SU>*MUXM*C9:*B
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M'S,?RHWP'U>Y/5_29HAESE#<<3#KKC[,%5&E%1GC53IO&2ATQ4"9.>Q%^K?
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MQQVZTV[SQA#=L-)1@F 6A!G!F,#Z%2S@A^1127M4>/JUF"K=<'EJC5T$$V&
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ME?0BOQ4A^<X,WZ!$L$5EE-R/'MU]Y1YKDN8L*2USX0J]D=WG+4D_&'5Z?IT
M'%WY$PO;[F'4D,\N?H0MS5N-E_GK^ CG%Z']>AM,!H)>%%GUY5EV'/!JF)O;
MO9VUTA']OE- 2:&'M(FO%8G*8:V#0:5+.DNW&>3#O$U^K;VI,C4BOUW]G?]9
ML"H>)5'Y())B-N=9QJIP533#DR;V^S-*L JUCOE=4X)]N,4L ,?D/EOV[2:2
MVF +)J4;3_8_MV>R^UW>&.&!=HS8C1C9/;[!LG;I6.EHD&/0;^D;O]OF3- Y
M]T*'SI?NG[,&?F#4T*TK[>$/Y@80AS3.<.+6M!=U$0?/[S9Z/<_38AQJYZ%X
MS^J8M8S"=2G)MV(CEY<%/V_?VBZ6+\"O5KKD%"00'V-&<L"[=:&-5YE_O  W
M>R5SQ-@U3=JF!$B_+6%F \Z3L*;PM]W>YWGNF=/JA#NCQ.WOA 1U>5<E]EQT
M5C6VD<^<S9S5+(YLA8KPI=V6#[.,'U$QS-&N*'HX<W(-H-XZ ]:G^9!__FJC
MED$/\SI@E\U_?KOY^PX1)RS1_Q6*/,T9X5/[2;HG2RO8/P#\15>H/5IR4=;Q
MG2Z=YT8GBT15_& O:]Q'G)0R.>DS6Y123'M-;K"@;72M7PE4R5WHQ+O)7.1N
MA'+:9K0^TW2L0 1)W*-/8OB M^RWKKX&LOOKH5B!?!%UKE>/+D#20T%[\NCR
MW*$1C*7.K1ZMP=?>QPGBUODV3/[,TV_;;Z%W5^H3D:,(\H8UCAL=!+\0>JHR
M(_RET4T.+N"8QB?:%WMFJM.E-@BYJU9 O]$V_$_6_VOZL5*E4AFYC$D_9 N:
MY=:Z!HP=%@/^Y+0T#X%N;]4#%_MJ0/FSJJ4+P@-U1.7)[KPVFDED/7XTEKG=
ME;\YE/B#9KWF;R3)1'*+%@>XJ5?3VEB7@Y@AWJRS/3L:8G0(C^)\SV.O@Q>7
MT%>:2+;-Q1OE[*4FV20=D^OXF'A T!Z7(XCGT^(;SZSQ+\%B[@J\GQ=WO^]Z
M;L']X3\%JH4T=<W@",D3<Z(%PK&I&K2W3E-#4T/VXYITDI*'QSUG6T,2H8S>
M>"^RUZT-%"@>_;$%",/]V:6AQMIZJQF\OC 6D*X;O6_GP\X:<307-6 9[)4C
MQC\[4191#!9U=)?D)JJ7SC'ZW<?9&^:'^M02+>\9]W&Z^1XNMPTR(A11Y2[9
M2J,_HU$#BKQ4FY#%?#VU6EE!RM)Y7_(/[7^W#DA8WG_]<$S=8UTDD_75LVH!
MNSLZQOVL;/D3Y88JC-Z!!,BEST6J18N0(-VF[^^>*IC4F&NBM.[J+'TSQ:G6
MZ6<:*#6Q9IZ0V(TJJITH*W>,?FFV'K%(E:3=60 (26(*=OAAA"-9J 'P*>KE
M"#.U%AN3N!+OSOJ:L5HL=#?%I+H5>=56^$(V\,W9WI-($]ZT-%BZ?*A#.1IW
MI3YT9322$J*&O0<U=)G4\_&3*G>EB1W*M'>V3\N?KWIST'./$1>WSA>?%@<_
M/KX^TY&L\!/4)/U[L?9*R"VN>UMT6@"_VSDQ_TG;_B4[MY.V'E2=@<G:[%R^
MI'D+NKH3$:QH] >CY36WUU<YX0_WF&SXX(D26XI\V.3AWRR142"'E.QV9YG>
M!,3.RO0N#.FI+MLK011S;'R/@TOL/" P,H5O96J_PX76XLV2@RU?NLL"SK9Y
MM35?@E5W?M JC/=]_C3][)SO5IL?NJD(+=WCZY:8B.6"V &;4F:8)-P$.IJ;
M&M+EAYH*C.)9B<P4NU_!RRS#]39)!BH<'Z&YW8HPLDB"4,3L<]1Y D;QBY4!
M"(D]!D8!^U,6[FYGVAL=766:<^H8#.*R2XNMX.YTJ#(1<IY_FX$'I!4N3IV=
MC:F#WQA7\"9(FKX/"1?6$@KI&'5!+<_.. ;-;7:_-O 1FE[_V."58?A81\J3
M=^K;V>=HWG1JA;RYW^]P^U[++H?ED$YB*"Z!&,WJR8+6=%FH:*'E$._IKP8Q
MA7@/[Z98[9Z$T)!@T8X\BL )C&+AENN;9O=LQZ+RG^42B!F\*%UNUIKZ,6E1
MGE\Y>D;M2.4(,!G]O';KC7_K66!!]<O,TOPA\J&67E4:O#VX-)!KNFCLQ"]V
MWDWXT#R+\_:<V=YQX2:CU5[IX0#=<>Z^1AX<G=W11H.J.\@M<[J84N(>6XDU
M:(7:TP_""^[-?T[0C*JYKRS-AT<: [BPE5GY7J^=;[9?OO8D*N;6EY QG+';
M66V&Z,O5=GJ,]=47(0QW85'$X5L]BFY<4S>!7AV%,V]I<4N%%UE$!8D_[]C"
MF3Z4^0W >^+\#+HX8L;]3=!,>>B37H)WDD(B^RD%DP+J3CM$_@-C7ZJK%L>*
MAP'>ILQU\1^I#137H90]A3DZO,;/<$MX<O"!> _P6$/'8M!!9X%H*X:.(&K,
M@QL'S%\<>=YS%B@R4?'J%=1XM466;"&%MRI+LS%M+ATABUCRSE.1P:-4K?2[
M2JL3R$#2M^89>$A.*=&AI$I7=V4K&&OC74&ON_ =%*K,YFCX*@8!9RY_]*8?
M*U,&#0RB*;"]'%1!VPZQUIG6C@B*W[(V.#<"D(\0N1(<=\*=_*-N^1^URU"&
M,YBT-#URH5?P[!?Q%RW\+SPO"7"3D_M'76*!4^2I^<O+>,=DM=1Z-9?SSSX&
MIJW:U,RT!*V.OE/"@RFOLD[[FY:A9V:4*7>9TS_]8FM@>%1#<S_EH;SQ2Z+/
MGG6VN-_S*(*H/R?E@85EYW."^$V3;8U&.FG!@J\%5M*_-R,U2U9_2U(0N<X$
M,<PC1"T2Z70<N>:7YRQMAJKH=P_T:(!B]T)T[M?PFKIK37+4*;\K0*<B^Y:[
MQEP".28/)/4<.NUB>\H"AWQM/SE>*G6H:_^\H\R5I&VRR91'\:@>N1$FV00>
M"A#1Q\XF*Y1(WBM?NU07.7\<[,X]+S'43@ )O 9H9>@TC=7.?^(W9W86M*^-
MS_-ABA5_S^ULVU,E,\"3=20R!R:,6$?]>.<.%5VM)-]58I^RM6B"\CJ=S3 ,
M20@(&I7I_^Q?U9\Q&A[\Q4IE'8^X!C",%BS'BY[H63HW4(HVHNC*TE'SSCNJ
MB]RU*016H1LC?;A+P7)^)'[R+$Y[>_GOEHAHN2SFBXWCM51H7Q/6F3D0$=L"
MV(;]O5<3\;?:28.<*L,HM^@%\B'N%R-8$A!M9V!&#630M(9:!)X)V*O6YWD5
M88_C%6H=>_D:(F* HM@[7U,$'NDNUVY=Z/6<E>#_^MZ[\?S%)ZIW_9HR"T2L
M8X30J^;Y_7:[RX<VKD>8Y9I#=H>?:UY+C:-,VT]A8=AQ/(AC9PXA:CK3"9Q+
MX>K[V'" @TRR=?&G5&H'MGA(:2_(5T)1I=+K/\PSA>+5IVO KV4L4]!LU=>@
M;1[C+>/-]IIV3/:-V1:YI)<8O>*):;T=_$=+J(#5CE0ZA7N#Z9-YR9]?&$V<
M;V6^Y$R*S87.XJUX=I:2=A*8A;-_A>IOK-<%P9_V,#!XB;FL=;$SUS5.[''!
M+0W /%C7/%M:;2,\E9ZX6]TR=I89^U:%JBB*L]<HZ>@Z-Q9+)#:_ -X"W#YO
MR#&!+>5"(2MI^4%N/6MC3P@GCAXE"V^"-4[M0IZX,+OEU#C,-,Q\MP%J&V>Q
M1,UHS[YCTL&C?*W"O8!K(X8=RWJ5PX?.1=9H-B"G."CGWF9?#N42V2P(M9:$
M"=X3,5^@%4S89C0BOD)QL[@V7R7P.5[E^,N"A!8:I$U,&<Z\J?0:ZSY6+8V4
M.Y%0FS_G'C 9_5EU_U"%O;028J>.LC2TV 7JYY9ID43;Q6#G^*@:'' Z.\]+
M[1Y5,[RV(I'W .-I,A8=9?A[?+2GJTHJ<D'*K/B:CK;?AM(501C.ZE&GZ5GG
MU5K*X1(M)2_;H.D[6FD5E3BV$Z+<P3*,N&P"2U"-4H//6PVF,W"KI1H)3KJJ
MJKE-W10"!C]^U,>C[F"G6RP4I) @E:F#4Q8A/KU),,D:-MD;O]9#]W70_&L<
M4$_6;&5LFTQW (H/X?5] 'D*M0*#5G)EH<J55KWN<-)RA2[Y,,[FVI0P4*/W
MO6@?EM(%P?QIJ,$E+YPO0E(^_BFP#>EO9S!E]N%K8^8^P8"8OO&')!\%&A7V
M*L\2\SF@ ?CFAO1C]YT=TE5*&-ET165P=TUP\&Z1JQX(K"6&2@%QT&MY:%#W
M$NXTYOZ7'25BJ 'U]L5,)F^*U>-4"ZX:G@_B,F*/OCXA>CX<\<ICCZ-:*^JP
M;CE,R+[8@'<!RSY39T#!.]4>Z.0F8A]!;[?P6X>1K\G(;XRP]A\#9'+1(*RN
M=T+['E7^-6#+>WJ+;A/+<@U(65RKO,1SN@9<L)T"_ORFG6<:NV5-.0U518D@
M GHCXT\/27NRAK^Q6 F3*:YY88>JY0<:Z](:WA"2$M!Z?$R=O 9TU: XKN@J
M&:\!*W?CKP&#%X 39H'1]E5S="(V!A87A*2Y">37 SB099@;#U;#M4\939P?
M=-06K$@0<WR(-@GDO@9\J5OCP."-M_^VT<((*%-= \:!J$3L+:=E3&4>A>H7
MZ"66+C?JY@[ED!_7 !P)$-9T_!IP>[0GZ,0$:G<-",ZZB6L$MG#'G"IO8J%P
M1X3RA8"UZ#6@0^_FNFDG0?__!A%:>69T$U-;HF^"/EOWF\4%#V9R_PQCI<35
MAS9VU_/V&ILNUZA /G1%%Q.4MZ _/?T,KI- )^5!&67=^_%; L&&7<@ 7Q;@
M0NQOWKQ2H1U)D%_D[U2-ZHN5L'&8DEC-WYVA_M3VRJ-%Q]6#"8MY=7SGZ7GZ
MFS>W 2-_[^9*=S!DR-&>0VJGK+/JBUK@U[B4PCBX5ZF'TYWC!VSO^E;<.>V\
MQ./B5K)*OV%'K:EG]M^&0]T<7*\$1NA]V\]Z!Y?[4M9^)N[C](2SN*SK_!B4
M093_]1CE/^,68(/<[#(@@V@JDW7G T>_SD,"A*D'X21-)G>/KP$SM24M-*+*
M4MO2E#J<O[+:.8)/6@P8798$:Z(Z$4*/NH24+!H<WAY]<6:^L_Z+G-E$X?G'
M-<G0?\$"_P('.%7(EHYE9+D2.R2H:].D#9:K6ZOK/75Z_W$&@[[224)/:HJ.
MS, /W#H@JC+D)"A*[J&<0X,[S.3UDH7-%\%X)AI5_F$:>VT%N?L_U./8!3[]
M/31G(S@ZE6_[&TR]JF-SF=E1U)\@%N)NFZS\6O.Q\P[^JF/T^]I7*KSZFIJN
M6IIH^]5E"KVB:X##G.*GPHC4JVA0D89\K$3M8%*;IA?];Y4ES;V7CG@S?^&0
M_+^(Q1B!5N0UP+&2&"/6:.79Y<N]L.MK_[Z^6;*^L&24MRY&ABD&L#=TB^T;
M>>]E/IM,1>S*9G<ZVF;%PHUKX_SRJ4F6SRG;4T/B[U9+"]J3EMH,?"X97O F
MF2?Y?$S?<O\L'HE_9F$5]E -G_._ 25A'BP3'8K5-^T(.KN'CKT&Z$H &_Y*
MSMV1NN5(WPOL&)8X&/,$93&(I8=]<L^":1]SDWCGOXO!3U@L;Z1)X[O7R.E.
MBG,B2;>Y_'\0Q@!!'0D0:PP;*YW]BR35'8$0-.\*R0WUK:F"B'3%K)RRC'\F
M;Z4>_/S2^P'ZI%_T_,N"+5[ NH8"M<9?%,E?H6"FQO B%V&):ZBTQ;+SBU_*
MJ!V8M]$06?ZK66M&\QC-WC<D_._>^/R: L(ZETG1L=W-$=$EJMX^]GXE4A5
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M5/K!7,>Q ;_J;=+:E ?&ACLZVT;@//S_7:-^S,8.BTQ< XT6GDJPM>;M)C[
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M)D72CY?IY*S[9ZC]S^^[]J_^Y]26,9E4B15DXCO6HI^ ^]98 EIPMH+3Z7P
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M=T>>9/9\P@8T+"E1"DWJ%H;K7#K9!1\+XVBL$0/16EQCQO(7V*6#(A66$_]
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M9/6PVS31Y;7_H=QE"6)BH2XC@49DH$*NYE:<3\4;FA4QA"HNYE-6JI%8X@4
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M6U1W@?F)  "/<_S!]B2:O1<E_ZKZY_%Z=*<59MM#-NX(?75NAR_I*$%$(T<
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M[OHPBME.8"D\QO@F)+C'ZL@,FFMR1(IMMSB#E^,!1S]%OX,9(Q9^*SV'^ 1
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M6.T%0!3 73P0JOI7<L\^%3W+@T-)PQXTXGT;L%X^3_<5Y9;KZ<CIKPP?)PW
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M,Y?C8TM69RK2PB1ZF;']YM=&)!S'W(3$MG6]SM<&5O%$K-$XF^-5#Y[P4!J
M61=:M@ZB:9ILVYQG$.W0+,68"\]VF*+BMZRY;'O$WEF4RJ8*+(C\J6G*7]M]
M$8W,KGI[N4MJ8/(X]( <-1*?Y5DU+Q7OXYO*.>2K.3<1(4=UGPY3=YF"Y-H5
MBHNS;IN!$*M5<Z&!QK,.,-+>"%\GFYUFY+I1A=9CD\0)9SE-@L@"\%=UQ!-M
M4\.EF=89)O3,'.2%H0FRS$'V3A:W7?WWPK$E]OR7UXE &LGSVE$8/Y2'28P!
MZM%Q:ID?QT/6Q222-CO9*Q]8"<<,%8QU\N1V!;R/C*J[.J1*]CN;01'''FTB
M ;60D.W&*[G/ZB'9Z$HA&QR@,P*U-FRL)')]26\:Z3?@..!_WM<1;88Z '':
M'T,C]V(H*&"<X^M]/?EQ])!F1EWN>D]2GC=OL!?A$O!/DN!CDFG8##X8D(-_
M.\E5C4L42ULD?ZHQ C:5=RFR!S$U,OMZ#LF++IS**0\4U9MDO?&]]3A5X G]
M0.^37997L=G^]89=X'+2S5"?.6T$-V34G\W!77I5(20YUW3]KHE7E-N!-412
M/P93%O^:=*LU_ BNA4J+WHL)32H.+ 3IA+8@L@?,IU9;)C<2K"<J8M@^(^#Q
M3^&_A8G6%8GT&8DXB(C(#MD=;2N^FOS&NH\S#B)$4KT><M\LJLQ*.NZ'(0+B
M@MF:V%;O.?S[2(#])1)XX2.!:MJZ%49 ^X>08MDOR9QJ?<ZOW[I#*; 4K!%V
M+WBT'IXER5(4[#"&=*]L/(>RB2F0]<JS]&!JO73X[)/,Z96J?T/-8$W/VT6D
MWK2XY!#<(4+ERXR>0+D8H.N*,$:5I<C"@R1AB/(@[_C'T^R'B OZ5M:$3]:#
M.CEWY-*>I[%C*!&P9C!3;EN$".7W5-)^Z](1>0'Y;W%3&@1$'S5W/D.*M O]
MH3C@3WV[;57/6==E8K!O6$-]NO-[U7.PO<C9B75P&>%]=-'$]?Y'POL348Y:
MT9NQ KP)<\;$*6H@M^3'+M.9D'!%0A1IL*_0DN>*:DE<*YBYHT$ANVWIG ]?
M'2"OS&I-<)BFE#L EX/]*8S,.Q+5L68S1S&I9C%]!1"$^'64="<807BK!ATN
M,>:K:<&;&%*OXNR^Z>C8%Z]&*EK@^F6^UB0F!DY3WG!NHL7#7'K0;=/Q)MK6
M+7/*\_GM'L[-B<T)\EN3-;.[D*0_#RC4P2P'.$!$:271<@T\)M*.>)QBC_)H
M*7-4:SD>#:N_=N G;29:HJFJQGM8&YDNEYB:QG]0G%<!8Y[ T%0C/Z%(HRRP
M(S&STX76MH4-K2$U#?;*UY?J,.UAA(^]CAQW87.]D;YNR&1S/]N66 =9U71D
M15TW4\V%A8=DJL2WN,]S@*ZKHU@ZN.30)<4ICNTN#M[?,C^I\J8R'^FXZ@,/
M:"Q4-)[DZ7:_O8\#6HFL%MB-3J1G(1U4ESK@I(ILB!E?DXAF!%X*^7O'C76G
MA1Y7>O*:C*ZV/K7F59T4+4HT0<.1@PN]S^I5<N^C>V\A@\8QMZ%T;4G-=L'M
MJ1>/%@".6/WJXF^0/XU\R9GJC=;@S]>6'(U.-5$A!3F8VV@G%-0 >=AF)M>"
M4.EM]_'Y4'$D/,UZ*>K1 B]AKNG">2XR[6Q?PQ-KC'%?O<^)SEKC%62=R5JM
M6UYEU&/K&%&(.GG -S64 %VT=Z#Y?9JP>D<H\GBAF0X'V(D$;TD2#_,.8K]-
MG%O2>Q"7XU(5OHP#?HL25_O!G*U%> 'L9?8E7D?.[0X(@J$=QHEHT6:J2&GO
MB8PK9Z&]OE3;SKU-:PM>6^@Z"W[N'&=N:_CC+C\ ;RTR3\58R*@G3^%^HAN^
M'!R$5</B-0U$RK54!01"_117Z2QM;.R, -&N2TS@'WQ5_5ZHW&%"]SY(H/*O
M2@##S0N8SZF&8\=Z;5Q\0Q_AUL5!YD+(KSO*7K.G#EMDT^?9G+8H/I;(Q1R$
M<NPW%SN@AT^T[=21XFVR[GGY:*F33G_I^K+JQN1F9F$B=3;*7=.ZDEU>'&#U
MP JD!Z&V-X9'[$&HUQ!4;X8L^O?-TAZ5T=9$WPV]<JM3QV?DT@^<F$:G7);L
MX<V$KQ\EF6M:^;_P7%]0C/-"0N?O>G8O" >CY-2&,6!&+HZ!N#O1".R$#O#H
M94?ZD8]HUZ1+<Y'A+'A3X/TZA*S(EVX!QM@^;P;1&5BQFT/=+&9^^ZA_D_D@
M6L_^0;,'O<D[_F\"<VE_BJQLW<SNQ]#/O@,-&SY+\!A?,J3+P6@IRO#YP#5?
MFBQ'4>USB%C4<]% D003G@\V?C4;Q!XPQD8F#*>3[3RTC5-OOJ>R!)I??M@(
M&I"7DQ*Q2KTOG3]9\+[E@\QYC^UVWU=_6A 9%-Y8S=NK7+_[^ 24H>>9JXR.
M/S'R[T4DADH6F&EJ(XM#9AM&'A=F?;FO!F60:+3 <CRYMJ6T#;F\/E/A$<9P
M!Q43O!?A=TW^0M',S&27O621L;;BPU5NCA5O2F*%FG5SQ[E3VW8LT\!^(5C]
M7%1P4=F9"<C'JZ5OYZFJ+\A\F]SG/!D!_6 0O;-W(T;4<0 $J3J9IMQ?@0,0
MFNVIW&@31^3!CI TEB[BUOGP$82<62%AQ]?;7\9Q@-')A ^HH9.#?"?_SPL_
MPYO6&G(2RG=]7@NDHSUP "]I"QZA3/CM^[ONS_PV!$)]P?UNK+X^<XFQ+:MT
M;IIW[[]_ .PF(G*R;ST%>SV2:9^R@ZD?@% +^-1A.GJDJ_*;4^)VKII63ZX#
M3FEC=+*'R_GP:2H[3<'0C/PQXU@8<$6$P+]OAD:1;YTLVQ/:]FEF3>SF8#N4
MAT%I4+5ZLO_H0^,#-C:!=U;>(Z:^JZ!S\/4MV*F4R>C7-$+,?5YL,=)IL,/
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M-,E0@AO+?^+R*8RID0ZMIH7V*30SL2MI=Z;40%4G*)>'FG(9!R@\;<7*.^&
M]20<<(7_$PZ(88<=+\._A ,+BIRPS[TH%FQK%P[(DHJ?,J1 KF-582_@!US:
MIQ?*B]9^?7A#40-M/XL#B-&#S5S\J*JV:\R#[0G35X;F:D:2;B0F.8<<+52%
M\"UFO!@YSTAY]='NNR%9VX@*JC.];<?N$?G3]QV\>V.@0G/,4JM"/2V"7)97
MV*Z^>!*0\+@ITFJT+RFM&7QF75$0!SQ/.FQE9I%=WG\]56\KN 886G\;L0A\
M=EV>W+T.[ZQ<O(-;@FY@JG&S"5,(I\9-M_/)L5>MB3A"N".?R<BDTZ26]T:
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MQTP9KUR4R['B#F@?*]JJ9DVG?N'+A*QAH_!7.WW^J[7 <[<]C8HV()O[>#Y
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M/W]-01RZ !G16FO;NFFS1=3(H$Q?"X6_#5$NUC$A:<CXNQ_=V;86'[%A+^*
M,2_P7LA 73YJFQI-,M$V+84.]9 J+AK[-#( %M :MJV,B6 WU^ F2/4^%?C%
M!:Y;X@!E4 0,^;X6S\QWPOJ,:C#Z'C-X3Q2-KT;)V8NQPC$_S0,NK\'+1@/W
MB^DGUSUDG9J3UI:@PD[<#6\%MRZQMI6:A-#58?+5!;Z1V!_/--$0KX^4MBJF
M.5,TYAPW59<W))$MU+KR;\5RDYCF75&2:5XU@,WI&.$=OG-^!L/_&(ZNO8X,
M;RZ+H4=_6@B*H9V"H5P)7J>5:0?,]C^2Z#:AF#C[T2I5TR="06->X+DXQQ?Y
MI2=+1CO797(=8&60UM.[HW<J96]6NA\8:.9\=&>),_E8F?_T0J(EC:28>NM*
MWKYD'EZ*9YW8$# SWA#*;O@0W?^[5_I(>L/\07:*0OWEFP)W2^F-[ ^E#MW[
M.C99HV^Q2MQTX@ZXYSR0C<Q])@$C%LZI52FI/!>_D13\S<IV1CY4>#(N\IA:
M@!3+1!QS2NDOA ^,(>OX@)/Y\POIU#OAOZ#A1^G!/\V!;?XBFO^;]ZH&1<%W
M^%9G#L30,!R@S>RZ_1.>JJ&1:>2"A;[<N;7HH'8QAGDA,E'AAJ<+R\.%+#(B
M0[;G#\[3?4ZG<?L;R)3[(A#T>U#_ <R5#= 6<Z>VD&')FLT5+<.[@R2OG-V@
M+CQWG((2R;.-G"Z\26DEG<Y L;1 J="EAZK5(T)%DD0#-TZ31GQJC"=+7^HO
M1KB/L]*>%2;+3T-^$(1]MT1!L8S2$(P9Z,<IX(0N:Y*EB=J "KFER,J5UP68
MJ/-I='V2<2-?(+[UA)7VZ5G2"A4+Y+KRH"^;UYRGT.2JX:NOB6?LC=7YQ%:^
MVKKSE(D^5)>,^QU(!T#/I0B+P^2-P%L6_Q"*]#::QKH0;7A]$&-N73-<SFHU
M6"CI)WS@J)Y3/G=/3O6+O]6]Z>>OJNGE# WG1((5.9&*^54(A0+C-^7?RPM\
MGC2U0Q]']U:0B$F+6X==XA')UOM;NG2'G?D^RG6M$N6;D+4^,B*2J^:R+$5$
M.3?NO@+R)'QG4[,)GE5[MM?+W#W/+U'%,F"JZ;%8\37*(:X;6WHOH"JA:/S:
M@YIKBA67,%<H0,>L&!,\#:I1',"B]O,+2HP2L$!%-J36PAJ68S#K7,-'!K6<
M3B\?B<H#FSM&RNRB1H$RW_ID%K*A&!&D&+YO=LMYR<O"(K=87?N.TJOL<_LB
MM"WN/@[X]P;S>&U(BM=V2*<,#G@>UXYO(DK^%-P_')GM6_Z\HH@47P^2/UI"
M%Z/(&>9I&/E?V(]9CSY6EK*PW.4\4AQ?5>+:5WD"^PM^XGO0*W-;82@6[:KR
MD?3X]O*6^6D?^VFRV9=GI'E>*%]NY@Z:+OEKAZV8ZWV>RH9,24BTS1[O<7+,
M/4W/@CB\2K!)>VO^P.3P:UOL_9VGZOGXEIA]=CL4,;&&D$H1-$S5G&BQK4VP
MJ@@;$^\DEZ.CCR6XH/2--%ONKWV?S&TF2)$>Q;2<XNR1O2DE>$XF_>U\&(K_
M#1G=+6JB $56+E5[.+T\H?-\E'*K\73\DX3:K4"?@V2/N"U-ALOJ&8]<*9_O
MC@7>_D,4*EN\@[6HSW\]AK7\(V83C_LSH;W7.WKF3R+LBR11=.%D*S5>=WOY
MZ2+I2BXST%Z]KW3IW;YDYFP,B3T60 X7A>5X%3H2N.\*LTK$RI78>#RBC#5*
MC0_Z._F!.$R1&GT'2KIFSA*G26^'"%X\?HXL+Z[;I/]JX\6T6V/R]6%3'JN"
MZ/V7_KV-9$$MA]ZT@[F>PL6&=Y-V-,>34%NO^=4;^TR^3K]G)*P+ )B@?R.0
M^IBA"7.FOANS/"]O.V%YGCF\,%+A%FN;M(PULF;HB-Y0?S#(\VA#G8=O&N.]
M^3.F2.>(7[ I\J >@S<L?DCTE[ VVO\V$X)_?\I5G *WQUL@P1NV,8AR6,6O
M8_C:YZEF^%K-N6BRBSV^[/7<ZT:V.]=(GPD,_IS<_Z]/9W]K+X$(=#<.X.EL
M ^TWP;X[ZO_NED7L%8Q@V6 CR%%:H!B=:A/.Z\S94>/"XQ1JSJ8Y&V.IQ-7Z
MQ]_9 IS3?C[@*PA&XTW #6Z#G-!<PKY$&+K]^B092-Q7K,\-'I7*,2+O)AWA
MID6#-^3S4)W*DNC++RI*JRKJ/>F9@\Y+&0B6R,<NY]F#F21%0I-(HQ\O#$G@
M@,K>!9]D5L@]S8C &!%G(Z=9*L&>G7>J*23:2HY#DN#QJA9$:@G,%2H982:M
M4R\;O!7LY%6F75,MR)9E=[ BV"0.-#'$JO&E%/A_4V09RK0)V388V"8I$:ZB
M.DASY4ZE".,6K58N#P@F8[^E8$?X51CL2.6_/9<;4J]IGSVV^@EB9H98DVW,
MM/ ^D-(B0^3<5*%OX[G6'$?PQ,,@,1H'V&O3>UK[<CMSYH:ZGHH;#'(WQ!DU
M)GGM=>78$&Z@S&_*5^]0ZR_.+CYP*YKO/GC<)Q%UIE=S8'^&WAYBG31O75\Q
MY"P?XO*6,#;;B*%7X-78(+Z2MH&03]G)ND<XPHKL9;5R4FOUQHT@K\/7QNC=
M-3Z>O=;53<FE+4&@>1"#$L[.]B1M2:SUFQC3=IO7XKI\;L0T)%KS36O.W/ M
M'I_P'85+G?X7XCI2F0+W(RI#H.&'QX]>6,OX6)?56+_  :5L]Q;&# >P0FB+
M#,_N5L2=,.^X=HOL*<3T!&]]LD9#74$;V?E%:U4U[^:JTS1? <=\^\/OT/H3
M$)W6O&>93.<$3_BM9&[HY4K5EN.%)&"O]K?_#<%OQ^^.W4;]3&DZ9HX87+=/
MV'SQ36!NA"RP_2$C'#A:.7B%DDP-78"33Z#+S(=])6?M]TX&1,H7!.WY<BC-
M;][M8N6Q$1=5D:%LY7A'OAO%AN7SA:)MD65M4E<GUT:>C*]QZU3)MMJ+3\OV
M+$W4T6:M/+)ZJ704(U.<7^\V^Z'>)Y/OK7/^6I(^/(GGU5YR(%&<\(@>NQ39
MF(=58-#+:T6V$#3I7,-#3JI'MD/UXHI1-@B_[&^A+HL:E3U1_?3Z@40!7FR]
MYY<#N-&:\Q3@\!D">7 >VN'P;K]3A8+,66%A(RTOAZ;7;C:/0MRLK7E67ID[
M(T<ZVZ?YT"SS#<+=I@W#;@7:C!"$FI>/6ZE]X5Q#J]IRX$[<N=*@:''SGEE(
MR#EP:X265.?UV)U!]<'RQ4&G\M9KCJXJ3M,V V)6EZX]].HQ1L(")(J)[)-2
M0E)6DOU4CU=TT[[%.>_:/MUY$'!5[ ZI X"*"4QCR8YKAR'#'8^'GG2S^6A2
MB''-Y<:YP'N?L#RX0!?/](9E;(/@3%T,BYDI.G3!-J1>RC:!2NQ;A]E#J[ O
M1P,A9*R/W,C59;Y[%O1CB)&%\/"]37>$7(%AJ9V5"7_.&83Z14.C+#=NWM=R
M#Q:]WPW',*)E3QMYT-!VQ-VL4A,5OA0_PLJID1W:YJ'C L!YD@'?MK?:56R2
M+HRV:9W9;4/$O,B(N#Y8/"L;\<$H.T&SXD%X.K&I:E",QN[V\^YY6$BC:+\\
M>,%1<PEE&R8QI5[>H(,.+!82?GP1(KK@^>(,=TG09396@^7&N)BYZ1A09$4O
M@YBF\/N/JTC[1.?/1V'O7WRY1]Q)>M@;E^I9)-<*+P,_QQM*V7W'(:G>(,'P
MG%MP:I['RG4+J")1'OFLY1."I^HRK-_X";]@@1D'&)GO=<MTC'K(<2<DN74[
M3[%8L7[T()&">O#)URP"=LJ0!6[.M>THFO"*M'&(&:H8P^/=&2HI,"9<K\)!
M>U7=,D3)>'JJ5"S0<F>'A-K%['5:J4<P#BCC*SU75.8:>Y_O=1I"&F+'?.SI
M9B_TD)5==_@&_5/GZ0:U#D7JP7KH')5>J_&SSTDVF8]&XH3JB"S8*6ES23E\
M=$@#,7=1(I$5V6C=.6T:9875X;VN?3/=S"'_MIU.(ITYRKK[ ;9O&,JM%C@H
MAQ1%AT4P7LC&SHXD5_]+U>7E \O!\M(9D_FFS>[!K=J"P4.?&7, (&Z(,.F
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MQCCMHSS-$!E=RCN5)W);'A<5O]3H6,%_]DK/MAAIKKP@C\1^A2<:L:'N@N/
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M6]78PCV8Q]OK);<YYS[S=R[[O=;OGO@^VYXV='6G#$$7/#@G"A)&%SLQ&^D
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M8^Z:0FP3RF4_O&;P3%&Q>V:C?03<ONZ=.SB#>.(Z1@2%IYV$U/?2CT"5/_,
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MI4SZU#26X,VV [L#>Q4H@^IOX>CA(2>(C)1-)4?L3$\?&>3*:T4\]3L3<0R
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M" U1W@)?U]5H&%T&?J)[:K=%0!>D_6Q&) ]##A[OL-FL9]"8W%$9U\08;5
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M]U1&BN OTB03D/9!)&0E'=]!/#$[5H1L38+(D2\QUBH!N+5WXNO[QE>D[U)
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MO=PB&WMBW*2%N10[Y+*Z7CTRBQ=R>>UHK:9U*H3SR1F",,6>PX3T$=F>)]Z
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M@<T)]USK'2SV'VG"NZ!T5:9TXF'4#LP3N,1!D8F[>4*[? GG +/'@(A,S6-
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M/^3:4"@#_XB>>@35"I12Z3'YMD.6553-M=R77[_)M!2(UMX^/15L67\A^=Z
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M& 4*P"9.Y?YIT-ZKRVA/\3R3/%0O>((_]'PTOY/.[&3^T<9B<;;>X=Y@WNR
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M4 UX[IG!/0*R47;__;UGX:5C'2OG*-VL8\(>/UZ($,_[H6#=SU;QT)^4PX4
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MV? L(1<K IO+?2UF[]]5_O=Q-V)*KMC!@55Q ^#SW?/N)J%GRB4]=U'NE5(
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M0 [0'SR520!'J5\#\!:GM5"" <//JM#\@N4Q;B6T]762]BC>FTR3\#[+6L1
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M4>RVLJ>K75,U ODY3MVI1B((\3Q[M!IGP,M/S^;5&#K;DG0-"$_,N_'E^M>
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MFMUE,-WC+1RXAP30;A)Y&[&@OK.V/Y5'2:9Z-?'+QKG]SJGVVQR=^S<LZ?B
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M1F>51K=;8M1'HY:4FCJ8Y+YTLY9" WRBFA2#7?EM6<9I5?*<K<]D!2!0HGB
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M<B&</#)(S"A\9GINOWN?&I_=_VQ)8AI^K61Y^_M/16'"&)6$\XW$O'UOC:J
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MX2*SF_*MW<G=#6E4=P_?KK;]N,?_X+[X%,_YV!_#[FI]/#14(0;A5'GYUT"
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M&;_NA&25807[QO !JY"!4!+ AZ^_C:,Y:DQ.T<I?5:?,N&FG<N;&;J/D+9;
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M=D]"K8(8GCWX@[)97I[YP%G5!$,2?G*IT U_B5E.+IO;_JV;7;449]3SX14
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M6-VZ>9S4$\S0'\O+IA?.KR9_:V9;SSV[!F"/* 1_,OU-T.9+P !(:LWQ3)B
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MY+["CN[EK\ZV3]=LSLC84&CP3G-N#\^G/9/8^-NRTB&@6/?M3R:@ECKZ8/]
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M&"7NAK(S7XTO<S0E7 -TFS!45:MS)R<3NG5L7Y91CR4/^KZR!W<NU,6WP9P
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M&*/1/,>19*<YA!([K:0VEY329 $W]!6@FC5]SSCF\Z(D*B.9T9X6LY@$5 U
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M0MO8Z?!D<J'8WJ/QO02+->$*5Y);!6#X5BF&<7NW<: W&:F2@&).57SP\WU
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MPVDSB_PYD8(#[T[3"G_&U(B@[)X/C"V:ML);WN:9>*7K+FRN;OU9POV3R3P
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ME@BU]SNI+2,/]YX0N=]SW)7]^D:V\ ;3T IB_X%TSTKBFA4_/>/+_[7ZQ[A
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M1?+<WB?2A=)GY1D"+N>*4F*Z54:Y21]<#8J6RWP/\[04M5V1/?W*EXR4O"2
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MJ=A;/4;W/9D'*<TJ.0_+T02FGANT1UT1G=Y$S2';;A#G*FGL\%92MF%[LYN
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MF[ .C/*]VQ0>%;O(!@?\+]7^IMG_FF(A_UN:_9-B_UTO"(  '>UA\]!) 3*
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M/RE<1NL7ZGVM*?B]JS55;F7S8M5KM]&%QQEOR=SBMDJUI*UW7;;T.R@YRP^
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M;1QK9P7:&8(D?IP_9!RHC"9+R]4D/,3K56$RR#"J\\J0-'Q>CQ:#*2_^RR#
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M!-B;[:OV'Z.=F?1_PXT,(5&CNPEIK:@)OZ/J@#-TL>3V^[Z"'#7M3*MKJ-%
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M=$FW2>S4E8%D8BI$;C)=2-)QIN )TRS:N4).+DQW0W# .4(_D+9Y.O Q<G+
ME%6=LO'8;"#"8(XOJ:J:0QSO3+*RY>REA1?Q*I&2/ (OJU3J><U/03SP86]N
MW3U@. [8/YP"-NL7M/-CC:DRWAA*2Q?$.]'F[T2D/GY6BVDL_/(+9O">ZS6H
MY( *4O296B]EV-U1$L2G^VHI:>HCSZB2EAP&\TON1^/_H"63Z\;DE:#I\WO
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M<LT)L)$&Y I5$,0_8HUP<'+^!<+'#Q";I_>SM6P.83> 1K/C1.8!*-^X
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M]8,1\[_2$FN_;J]=@P]3\LN[;(M!<VS1UR>#[VCAV!'==@'R2EUPPJK5@GL
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M6(2[89+:00&./C)]N5B2B/EQ&R))3:%*ESJ:40PZ\#N'#W)#+VO1 1E%%?[
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M7H)P E\BS&%R<2E]*;XQ$Q%Z,F/@G<Q64K,8Y%XGPNYW!6^DG(/.1T>7&-(
M5XK_@P^6Y^IPI%U"OJVIII8\YE*M=64I-9E&7+*@PF_EE:OWJJ]'M3@<!_8%
M9#[IL3(W77G9[%[YR9_.A\VQ?Z=P]"<+20)9PRN/Y]?X0\6N;[=-LZ47>&_
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M^2OX*C5._#S2?/K&KH&F#1,4O^B#.N:3N9>ZQK'\;(20VR8& Y_3PT.VLG&
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M3:*M=OB(X6[-?_^@T/4._ID54DT%0H:#2T#2</I2&<@27RGH-78(1SYTIJ+
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M1+31E*X>L@=RAGLI5CAX*K&E[UF:\/C0$9)@$G.3EJBA('WS7W\5O45:'1]
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M)%=N3*',;22N!%QZUFECC5OZK8%;,#C D#(#5_:M?Q121->X_V%_IY6R5W\
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ML$= UUOO5NFZCMJ9W98FL"Z82";=G9O07)H'$Y];:-^GWULB(M#4^ZH::[#
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M;36G,>=YY]ZL-2*ZN(MV^MTA)14R5@K#LO?&&PM2 E9NQ3#5HRM(-A'(8BJ
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M8Z])0]8U8D[_&#X==)8OW^Q9WD5M]A\/'T:=4\&'OWT36+82&A[[(S_X^_2
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MH8VMB 3WW YFY?E^?NU>F/(#8?'ZS4VS(Z5=,#KH-I3)D3:&XM 7>8LEJ+V
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MXD>?:#IA*HVZONRK::^8GJ#@-YKOV%;4V=-!41KF59L76K!=C*PV!6%!$K<
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M_I-;E<??^);QG_]F.;/K5<#&"$OO#9-.OV!37'_;],3XL)5Z?(')FT3J$<O
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M\,A1YA;$QF],CKV2I&=A(38K-FR'RO,"YXGA1?9A1)JMB6C);T!/3SI09>^
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MI=4=ZJ@]M,UU4O[FPOLZ?5>..#PFB_V<J?/C"_8+NC]E\TTD11/!>>&0WUF
M-\JW3:A5T/"E*PWSC;^9+I7^6_I3\+=\Z>_/TX;_$CI*3JTMDKVVS<NR\1ZI
MDYO:[L_6>^*5KR2*J\4^:+4SS$AC6KI<][(H*]S>=9_R=41N8DY^99:7-BH6
MC%TS)E'PA;$U+3 3<BVZPB(")9=I[BM:=SLPEO_5H>D^T:GU==?SO[&!S_3'
MK'^1>]OT\HW&^_,<$ D@TVK\Y%@YPJ!DRD?@C+D&*^R.1;Q-2MQC38*VI-5M
MUV'*2>20#-Z^9T+7AOC%Z/JX+J38:U=,OV&QR<52[W7EW)GI!Q>#4XAZ1_QQ
MOY'R6)__^MS9^6FK)W].J-E^A^E!HRY3&.4>?(!PM*EPEM'J3$0!'70;0%VO
MJS%M'A*RU>Q/U[_H9H2QKN=^5H'I@M;Q?)@JY7GT-!U>VC5S%M.>?\X2>GVT
MAB)'L?Q2EWW.0_RJ*D=)27 /\CSPU[3VK[A:""*5%_97#P<O>7VQJ=Q^>5"A
MSTTU&D;J ?+=NTBY=Z3XU&:3G)EG15Z:">/L)>1Z.Y/^X4:Y_L!V/?F2>@:Q
M2Z'JD7JZ,8>\:1)UXW[-XK"Y2KR+[<E4MY;:XZ/$IZK<DL.W#J<P-U1._GG0
M_3]2^>SW'UH6@8JQ/X'N>U".\L1Q((R R-MX'#O5'$@GQF=:4^[.4N4V+]46
M\[]D318[+=?!:Q0N/' ?D>Z:]1OK'S2<QQXPGS(^D_*C\%0(>HP'D#6EYMS'
M[:BX,I:.=] 12KJ,Y?*1XCUXAJU.C3!O_;KM ^-S25S3D/>HK4\.NJ:ZD=IV
M]],[&9G'!AO&B#<A>0XUWVD>A3RQ4G30"SJHMQM8I'59\=!!R_>J7--=87_]
M[::PH/U'.J@.%[L](+2"8R&0NCJ<X*^LQK#!D7+M;3ZE3J)^,BETT/L%987%
MJIQ-]-0  0$!ZQ_UTD2"\XA#<U]?DFLK$L)2K_0>*>/Y>=<K$;S5]I5E*5*(
M'+_^G6C%"61WN4H"T#+X9$\[C#LWF("I_>[*$9D=<!1MN8C;-UEFW8J?*:%"
MR9RS->!V]+<-^Z_;#4&23J[CM_.YKG8]U PE3SIKFI:4D>>PP8=#7_#4>F(?
M-ZN1_6").)%6WM;2P^&HE&K!\: !7B]OJWV-M1"R7W>82GW'RY]E>BN8#N6H
M?$&@BZ+713[5&9Z\C.$+SM5)=:()?*O K%^0;7I]QW.B,0$?S[P;9GOVM=3K
MKRS?U.T_M&J0%F,0EA3[E5G2,P0$0U3.GM/C*V@>#OI881.0OQ&$=[S(=V<N
M17@_OV:;#HJJM@1WS/*HKTJR="Q^:+P2\N;%X*10;+E![VEK<_8'5R^>C+K0
M*(]7GB#B-SI\+=HA7!MO 7$XXG*IY!#PR44*+.TL4_5F(&_!#_^$=RKPN7TQ
MW(:(3:Y9;N;#GU>Z!3W&(^PM9I]P5[@/73D1K9 B4+!7V>OUZ$+87!)HWR\)
MR.V UJ#3FLW+E_)EWM.^CJA'FG;ZO#7'ZT!9OU?[>WUY<(MR;>10EI>@F]W2
M'Y]VOELV'[S05_2D@[@T9I/L7>6&Y+X&*8M9%("Y35]Q[3ZU*$IV<R5^/G*'
MG0XZ8]OSD<-/P9]IY[O0)CJJV8* 84..H"1_4LV)ODY.I-I8]X(K.8JM?PS'
MBL@'O#,2C'AVV5<\2>G.'.Z[T$.*P8HK%U!.QLS5T"I)%%LR+58SG7 B1WU2
MC2,V.*,=T7&8YG#M7)A>@DST1?"]0>C)57NQNH=8I !P:NYGM@<IT(H<^;-0
M[J#BS<L>A<?'7MC-2/,?F0E)D9SH9F,Y5@$E\*P;D+FY8 1VP'M_OI"DUSZL
M&.2#8OGNS4&0+[IM?DK5^1+[5*+HSHDSGTB?_8U!D37&" \B'32)Z7:D@](0
MUJ\!1\+N!Q5XJ,7[?/D04MY8Y<E7J #8#OI$2"IJD&CL^97<_-1]\"+$!J%&
MMEU,TY>"!W:*I65K)A9YV_%^=UX>9^V5JRYCQ/F;1X^=EXCR9'Z5?6!SP.6/
MJ6+0P,>H.#IH1]$+MV\A&?J #BI!O:P0V$'101D\I%E:5[D6'63N_H)[/^GT
MBT-_*_+S7TS;'\.-=N9)1SK%\K%%YJ5+8NLCJ\7>_,XF,>:^-6XF.NZVW&U'
MF+'G7_ 4+6%CD1#$<8;SBYTE*Q.4DUL/.R+L2#&.D0_KFNM'B7&$_K')&9-Z
MBEX#RY<'_3U>*HMNFX$V\&Q3AC-ME?$.[TE!@ E6@@"++:DV@P[BR36MJL\7
M/[P)[;])K:J=7 Q(2)3 ,B%O"7YEF7YB_YCVL55AK#F0HH;0&F\V5L\6&]U)
MY<Q6^_Q@L_:<)/I!VR&KEO#MO[\/RXC2;=B]4^?HH FK&W30<&Q7^)'_ZK?_
M?(G6OF]6HEGH:#+%',%//N2=T_)EK)C@0,@86[R6M7[<>'CAN%NTCD#6X<>J
MD3[Y!X6M[#XX7I2G#IAO&B$Q3%,$;*Q([]['#=N,N;\S\\M9_Y'U5;5U<7/L
MW%%!"<P?UU@F;MA_S*#>(H6B]440N@",M!]$THM/NL]9]W3H<VV59_@EO^OS
M#YQ^9#U79XL>:>)I<-E8$XB A5&DJ4J\5H(+DB>T?_#5^Z:P?7H>I)O&!8K8
M_H_WWQAF?5#>SM>F@RIS&!'7(*WE4#,C/139'Y! 37QAW'W1<U'JH;'@-::_
M%80U>:,C7'V6O_74#-685)B(,#H_1,AN#W^:[1.@J\G^3NO9#W/1J?]5S96&
M0_F^[4>1L@W*6AFA^&=+0MF7*"3U"Q,SR!::IDE24VCLVV!"*&*0J.Q;MF%4
M]F)0S61D&4MV9K)-C)EWWO_[?GG['<=?'WY?W@_WM^>YK_NZK_.\SO,ZCN=X
M$*>?WE*;NJ.]$@)/2AD')1KJ@4)9 LVT3]FZB5O4[X_42'=C:[ +10BK^\E*
M'H&OPS0T0G_HI+TQTW^=%/J8:Y/?_ &Q!7QH-EN7 ??<= EA'<">2W/F"^;I
MQBW,EASL0HFE3WDY/W4X))*82D?,<%#TX*7/9N]+*E*DC3ZG?G#HPVM4:O&T
M\+")8;[\<37L$F5P+,G>@WL"^T2DA7>F38RNV#8$$F:*,"(#)Y +/;KDJ_6D
MY=)%O*/?0ZG2A?RJ)(^J9)YM:MSW\>N\4[N^(_1P8JL;[P@2OJPCM#>^)$IB
MR:LYW>,=WNACC3=)&SWJ:9*6*IX"2.X3+1WZ=W.$UO^7%R CFB+SR6@L;FV+
M(Z#YER$Y$!QC/\L*V4K<W*Y@ P-*17U*0%[<?Z]?T/4X&BFS* C5[\W 4A'P
M=K @*'HRZOWGBU79ZR3!*T2>;!^WKA%WBGQ2E(1@Y[$0P]=YS:H,,ZJDH0:+
MJ"M4.($!'V 4F=%*RXH&AQ@FP]XI5R+57 ZZW2OVUVS!A/!/R*;4A;ID;HG!
M\D< ^EGMOF%?:2]"K+I[.>WK5D5]W^([Y[3*L(OO#1G&CG:G@21CL&F_*XC5
MA]OGR?% 6#QZG!BJ;72 J8@L')1<7JJ)&<L>H.S-]V41N1Q6H"J6W 7W$FUL
MZ?RV*=;-GPV/H]#&-5]/!1O/9$1'UG"D6F6_D^.#?0G:IXF]W-OK4QKRFA/>
MLN";_2[F6V>"+E33.R+&:G"P!A+SK&K>5Z2:VLW)FD3/>K79HV_JN(<\3[8_
MT+/S_-%T[W\^X5K95F=9+\<2%AP'"*M%E\N,RXP&V,!D,R.3U9:ES :L:J2!
MU7\_J=S%!GQPB=-C.I$+ :=H4TL$U;6.P60[Y+'V3Q.&B*EV4)+$%A2:K0%U
MY5[#BJ*P+32XC")97Z=TQ+6^+LJ63SQPK[LL(N'H]6,P__0C_K@&I=W-><V[
MR$S% D;*V$8'*%YG?0470P%A:B(' FJ?I<W;1G5O=-?6QH='QLNY/;X]E'FF
MYUZS+,,OAPFGERUR%:$:VIVM_Z*5--5DAP<H%)<4@!8ZEX*&$(4;M[P>)T]P
M+^[.R0%5*I7%LK1G(6!ACI<E\ 29D+2:O-8(#/-5O?HC;[\HA)$>_-C2M%2I
M.+++XNC0LB?(:LOJ,\N 8Q#]T*F #8>NO#BF.AM(PHVCM^,_LH&"CWQ*#%<V
M(&_4R@:VI-+9@$W:@4L\P;RLBSH=1NN<>K$!:ZV,U;B5K5%!5(H5XV4)JO!<
MS4"-LO,5B\_5[6&;+"@D=K&P^7'Y$'=N.'^+GH?;?,87U@"=O,V?S7%N[Y@<
MY8@TWC=.C!8W5*>CPX/,_/W]!,F12Z5JBWF86UU.T/NAX9/[0RI%3YR3A3S!
M?BM\=X)Q</Q^%*(L0 ^E'_A0;?E6^ MK7^E.!6O4R7P5*Y8'C^R*\B:YB WX
MHN99D400>HR%9IF^V++N<%U50P6R 5Y.U_HI!MC1D.^S]-Z-Z-)K,<E+\Y=(
M0?9^W.FBPV)R(Y)R(FU(8<!=Z]?0\^3>UHRI:N)@H=E 0""T,1CZ%Q1N)$8<
M'X**>OS,J<L03SP/F>J,J<(_[;VO,<TK1D'O$/=.0_3"*-6:2.&W8;S;F_VQ
M39P2E!'P'IHJ["HO^&9%[:2SQ'%)X=NW[P =.N@M^=ETIULEU(]H*4:Z+4VH
M1+_*!65!\3%_45SLXN-@)I4J=P>J5+I',C3$SR5K^^5$V::$O@$;"/_%!G[Q
M81?5#Z/[ZJG+3#"1#73:<7V LX&J%%B0!:Y=1HK>7#56]'HUT$;4VD!MA'3>
MD'CK9_55T=9)D1_E8Q, Y"7#P[2I7__,GLS7<(B+;*.Y5\IE?.*I-%CR Y$W
MKUI.CPFE9NX8<1HG1/ ^#*>FI>;Y4&S;D*)9NRV5RF=3G*X^\4FME7R&3_BF
M'S]]V@!>T,?:Q0@T9@R/@V/7?\*RX$X5B;UP![=UG^X(2*J$%$BNC:^"*'=T
MHV3TMQC_]\)SA)0_@*OR&)H0VP6C0ZCT"S3\0\P-7^K38S%.Q0E'4E^ IG[E
MR4VFR&S7*=P]_>9AX4(A=1@ZQFJD_;1QO6*C#B$KD+T:KH"?)S>--2@1U(8;
MVT<L_$;UR3D[(LIK%L=;O.H:OSG::BWHPJ+,P\K?5GY9S9VJ*>FJ'9%],G6_
M2"FI0X"+*%>]AHO6UB6W$@08)&AF!*'O)K+X6JU-LUWLW6MJT/C)X"R_,-WG
MTW&N_SG5O4'VM/<?VIH-:-YQ2[=*W9IHC<,&U1J(GU.:K?*(7]RT/19[?]1M
M>Z_[Q2'%4)BKM.4$O.589Y#ER>_STH\P*M9BGZCBFB?3$S+^)25BXM.IZ&-@
M7#KT>UY@BHLN&\CU_S#*,,*Q@<>O=B?0P0N+@AL):T9B#/]V:<X\NA;L3N*W
M<5Y-CR0Q35^Z)[56- _:7RU=>]>N.=!D??YS%/:EXS<,!E.!X#-54YL\:7.L
M;\^TQT>-=LLE..[W?G!N/3V1, .C;;! TYP.?1R8\V(#' =E!E-<8 -L0 %,
M)6QCG)"LY XGU5>,V2=8QKD@_9.<B?;(OT%8_@CL*Z-+4P_!ZU"K7J >KLYL
M>KW-6L<MUD^LX%^E&6P]:K\W?<LO)7[M%-?L78CBCB F78;A?CN3434^@ V8
M3D<3:&@C3N!+O(XPARI:E2VI684![Q@8_E[P,M=W(^.N>%=M5Y*:M-S"=V_Y
M;MBUT*[>&\0=]]H]@1V,^]A&P<5-E=.C8_#J!:@:O[)9IPOEQ1*MK4?N\TQ<
MCQW1LKMNP1VB%S<3Y$VS&FHS%.W'*Q8R,(ZTPLB;JD(X[<S<[L>9C8@8S'XK
MN\Y0^_/=)U/PDZL[T4=PF->TG-8<Z_9BUJ'BVVR:\-&:FFJS?0=\<NW/E0-\
MA#^Y"?,[Z-\Q\[>>?]A+K&MG1C$Y@UFR/V@[8LUV^S2,8X:>,?9;T,EA^-,9
ME_OQ!@_>SLU-]["&LHS(,$MMC77-SY^&GJ_$TY]#3'XO:HANMW+*CDB;5RJU
MW1'_NPB)AAQ?IT^W#0L8^MB8&8CCNR%Z0[OB7:UG+TW_J&>GHN3C[!-W>/Q9
M.@R!; 5ZTRCF+EA\/GL?&;G@_KE&:M5C'_2;N[<&TM'C]F']P5T-8R'?2O^6
M_-]I][B?X+D<H>L:M>HLO4P=C6*:R*3XO+WM F^P:5KK-[8.&NB.;TV[[D%T
MT*JE*8^E1QMYCT8U0,*8FK=BO=R?)L^\.^3O8MG7HY%@IQ\!\(L\YYIUPOTS
MA0IX\B<T@N"8<FS <0*[)55FM"HY?^7W??Q'A/OQ 50',FA=)[J44+UVI@;\
M2[ WV_7I@9ML *OY'#'?X?*$:[;Z'R+M'M<V9$3T> _>";$1IY6E_&'@;-\-
M:8MTA=L%N0<#+!4HGGP6=A%>G0K21#JAQ4"]-:,V6BN+WYY ,VS*<31,]WHU
MXR[KT+5^??!%DI2T?GO$+L._<N(AECL>+F$,'2X^*K2:P'^Q/V#;14FE;"E
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ML]^1DM]FBH=C/H&M%4##;*>[W<(/U44T29"@+UKLDTP2H168 -O;6UOP/<!
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M<G UG+(BEO!0?I#BO;7$BC<Z'Q?G(/%R$A 3ZI;IC7X'P"B,V  *B:L4 TZ
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M"0W*@K9O![GQ)^2VT&MB+0A['[!>%,"Z)_"%?ZA1PKY- 'N1$1R_Q5*Q\-I
M &L9XD=>=7R$CXS9ETC;IWD6X?Q4RB4+)(^FWC70;!EP4HU7%4_=7FPJOCP
M]WM-Q9>FXLMBPMY-Q9>[$ATGO[\TNJ%?OS,M,EUPTY"!@P$%(@%Y]3B3>0Z,
MDKL6$4YBW2AP#&?$%<<);*!E2EE:SCM247A-[H#)%H,<L'7M3*U34[^37.'X
M-UYUQXJ?VG3?F9CW%^TY6GO#'NW8N5W0D?Q &)0P(I6=0+$HD>L)TQMFNE7
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M=M1SNT?OAXDV',UV?//K";(9,^NY=?P'4$L#!!0    ( (B 25CS2M<4PP@
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M$R&X486#$S<@$TE\8@G7\1JQX)#DH<RD79$.NFU8XJ\#M\.MI]X5T\81P67
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M7HQE)@R[$'-VJ3*>OVCZ$GP:H>7DQ9&3-O(O@:XQ/2NN;8NG<HK.2=<C/_\
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M".V,Y&%&$CTK(SF;\;1T3I< )"83L'4YP]:;6UCWBG7=(XCXQ]N)N#,)-$0
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M[B%H3S,U!VD&YY",QO UNYI.92048+4N\E7@/.R-7F%@(Q3&78F+HDR6 VG
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M;5"<"9=(71>#5)SNE,QZRHGHE\'03FVU07V3*H(V]^ /D?M(S.6<*S;\0%M
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M$9=, '!FM@;-[Y007H6S,I-3A6R8W47'N1SG/=2@Z[E:S#I"ZX[T"K.""2-
M #HYDS4H\9%E)V02# KBS[RT+_YTI*JSL6X5/!/MT4WL"42BJ=3NXF>+1B42
MK22S0C>]^?4RF]-<;=!C)<U5?HJ\OOR@D<Z7Q?<'!^77"W$UX:G0W:N'1"S]
M-PN-!H,1<-X2!C)?BI4CNPWN+73[+I)I(Z1_VA?BA,QU3^MZ%B6UF^US#X&,
MUKZ")^AG=>D(7X<&SR&6[OM] D<_WM X^P/$?8_8\)E1_*:(T$_+U-: NS5L
M]U]H@PAFR[K"=AFX;!8.6TE[:>\G2@5SI&(J(YN)ZS"\!K\$#<WPSR"9@%]5
M5C\;@IT_]KPI)?9=(/:C"/58$6I_>T6HKZ\XW6<R?JS@U+??4DI?>WKR7U!+
M 0(4 Q0    ( (B 25@BD\CV<P\  -V4   1              "  0    !C
M=G)X+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( (B 25@5Y-[,"1    OK   5
M              "  :(/  !C=G)X+3(P,C,Q,C,Q7V-A;"YX;6Q02P$"% ,4
M    " "(@$E8[STQQ3XB  "S$@( %0              @ '>'P  8W9R>"TR
M,#(S,3(S,5]D968N>&UL4$L! A0#%     @ B(!)6&0W O1:6@  5MX% !4
M             ( !3T(  &-V<G@M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( (B 25A18K24^CL  (55!  5              "  =R<  !C=G)X+3(P
M,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " "(@$E8% @C/Q 1 P#*-1P %0
M            @ $)V0  8W9R>"TR,#(S,3(S,7@Q,&LN:'1M4$L! A0#%
M  @ B(!)6$CQV$@%0@  IT8  !@              ( !3.H# &-V<G@M,C R
M,S$R,S%X,3!K,# V+FIP9U!+ 0(4 Q0    ( (B 25AR_J%: Z8  ."O   8
M              "  8<L! !C=G)X+3(P,C,Q,C,Q>#$P:S P-RYJ<&=02P$"
M% ,4    " "(@$E8SU;CD0<K  "'+@  &               @ ' T@0 8W9R
M>"TR,#(S,3(S,7@Q,&LP,#@N:G!G4$L! A0#%     @ B(!)6,($8DC!.@
MKSP  !@              ( !_?T$ &-V<G@M,C R,S$R,S%X,3!K,# Y+FIP
M9U!+ 0(4 Q0    ( (B 25C'-4:*WU8  ,I@   8              "  ?0X
M!0!C=G)X+3(P,C,Q,C,Q>#$P:S Q,"YJ<&=02P$"% ,4    " "(@$E8V"V%
M_K1#  #^3   &               @ $)D 4 8W9R>"TR,#(S,3(S,7@Q,&LP
M,3$N:G!G4$L! A0#%     @ B(!)6%)\,*GDB0  'J8  !@
M ( !\],% &-V<G@M,C R,S$R,S%X,3!K,#$R+FIP9U!+ 0(4 Q0    ( (B
M25@06L(1A<,  ,_F   8              "  0U>!@!C=G)X+3(P,C,Q,C,Q
M>#$P:S Q,RYJ<&=02P$"% ,4    " "(@$E8:D@U-AFK   XW   &
M        @ '((0< 8W9R>"TR,#(S,3(S,7@Q,&LP,30N:G!G4$L! A0#%
M  @ B(!)6,R&MA+9X   J^P  !@              ( !%\T' &-V<G@M,C R
M,S$R,S%X,3!K,#$U+FIP9U!+ 0(4 Q0    ( (B 25CQEY>10H,  !R4   8
M              "  2:N" !C=G)X+3(P,C,Q,C,Q>#$P:S Q-BYJ<&=02P$"
M% ,4    " "(@$E8Y>.#R7!/  !A80  &               @ &>,0D 8W9R
M>"TR,#(S,3(S,7@Q,&LP,3<N:G!G4$L! A0#%     @ B(!)6$J/ ^_[(P
MB$4! !@              ( !1($) &-V<G@M,C R,S$R,S%X97@Q,&0W+FAT
M;5!+ 0(4 Q0    ( (B 25AP(]18JP,  (L/   8              "  76E
M"0!C=G)X+3(P,C,Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4    " "(@$E8\TK7
M%,,(  "N-   &               @ %6J0D 8W9R>"TR,#(S,3(S,7AE>#,Q
M9#$N:'1M4$L! A0#%     @ B(!)6##IA*B\"   ^30  !@
M ( !3[() &-V<G@M,C R,S$R,S%X97@S,60R+FAT;5!+ 0(4 Q0    ( (B
M25A#I/%U<@4  %P?   8              "  4&["0!C=G)X+3(P,C,Q,C,Q
M>&5X,S)D,2YH=&U02P$"% ,4    " "(@$E8M7-/UF\%   ^'P  &
M        @ 'IP D 8W9R>"TR,#(S,3(S,7AE>#,R9#(N:'1M4$L! A0#%
M  @ B(!)6)$%*_#N$0  RE4  !@              ( !CL8) &-V<G@M,C R
F,S$R,S%X97@Y-V0Q+FAT;5!+!08     &0 9 , &  "RV D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>cvrx-20231231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:cvrx="http://www.cvrx.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cvrx-20231231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b8RRVB7Uq0ilxq9okISsEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cchEQDekhUyFexTD45-WZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R8cE_HFzF0aFvnYTtQwY3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hwN6aAp_7UWY8-X1PMow3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TYjt-cOP6EmP8oe6WXLi1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_oxQlkGA_EEi6G6wAtaoTqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wy3kn6snkkWPv53PI5w4dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zbMLgVLwskWIMhYab9L2qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3dLk7Sy_E0KsftAeppu0Vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qCtrCvgNa0C-1eQGTvWtGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_z5thRTHU6UqLA7ga0nCfkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_DDdMMm9gRkiqyIWxmaA5XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvrx:ShareBasedPaymentArrangementOtherOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PemZyTerfEyhpKp4nuNIIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_naG0zLCR-EKkwa1gEwsa0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zEoL8JtTB0KWcZl84O9JzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VXKHvG6viUyua5uD_4yltw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EBpawY17Z0eCyg95O44tGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VckApq6WlEaWJ9cemmQc9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_57PyY8_YEUuCWQnZ9zZCBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMTCyrrsukCaWB_FFt4-Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hd2dVLfWykWfyk-CsotRYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:OfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9XD2uHnOhUWYk_34nMOzkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvrx:NonOfficerEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2008_To_12_31_2008_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_PajlFFmwTkWsKigwduPhHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">cvrx:EmployersOfCertainNonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2008-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2001_To_6_30_2001_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_7rx5_d8IikeJHLuprsGqsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2001-06-01</startDate>
            <endDate>2001-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2001_To_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_PYd31BxNC0604nl8MDpilQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2001-06-01</startDate>
            <endDate>2001-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_z-s50K3S1kivNIA3YmG5FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_MEKc9Q4xt0S15FUWcDf8Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_DE_li7LfrlDcE-yU9xxp6rxsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_UW_cLJGP9UCo_5BtyGIPrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cvrx:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_DeT00G4a6EO7jrVDjnnWKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_Nr4zMiPicku7JB9fF5v_mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_R1Bqa2cBBEeteyh9zoNgFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_Qx_lM9M1-U2I_9bBopvULQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tmU2-D_zdkyR5NTA7xTdTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JMLg2X07bEuHweDOuklZhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_RDgZV8eKn0q48yeiBOKJrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_BAuUOTojQESzFVAzqd4DhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_MpXjFm5HkU2XNvuqY4WPsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_FSq9BY_du0er2CE9ESvvpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_amp52TUrr0uPXJ9VAkjlow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_-1zVdT_0tkOxZQEUVJnt6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_sgJuXpn0yUa8L7xiptpJRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_dqIej4ejsE2n1BDRzJlgJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cvrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_15_2023_To_12_15_2023_srt_StatementScenarioAxis_cvrx_TrancheTwoMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_6qk8DRW53E2gnuQbDupIdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="Duration_3_10_2023_To_3_10_2023_srt_StatementScenarioAxis_cvrx_TrancheOneMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_MsUf-wRe3UOCGdw87WJNbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-10</startDate>
            <endDate>2023-03-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XBqz8Ajq30SHLvU8-PjfiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_pdlrV4rnDEG1xPe8LI1SMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_7Lza9lQnP0GeHg-QJ6eaQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3sIcs8CI8UW6e5DtAQYNdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jWno4e5JIkauZQOY8SolYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_21_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_RM2963Hq80uyOziblZLLAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_SKjkOlcWxkeaJnFxtqthxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember__P6VIstV9ke4AlgA3xarog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_DKj1YSlDwU2ZlmMFDIgwbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_YUEJZcskw0GxQzI269v8CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_LGXJ91kYF0WAsdsON9A6IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandOneStockIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2001-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M3MwyXey0USuIVtewS_fUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_UrSmq1MvHUGq4lKnkUhBMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eeym4sX_ZE-eYRj-nhAxtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_kyjAoWWjHEOiI5UhzjPamg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fkJEZGVxqUusT4haccsrQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__6BtJaAInUut6oE3yTHB_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GPUIUQBt3ECv70XnSLRrTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8_aaeerAjEej9OSFdIalGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TGtZmK623E2xW1C_jsdOhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LHxLWQFoVk6j4n7SU0LYMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_r0JJqTzes0K61mq122BZFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_2_2024_uYC7wagxU0yxRMgfubU3Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2024-02-02</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_dc9hk3dVYkCOZVwQkXY8cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_up0KPm3ldUy5PK6Gt_PEvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvrx:TwoThousandTwentyOneEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_ilFiREhHNkW7Pr6DPc2vbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cvrx:LineOfCreditDrawDownPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvrx:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_IO8dwnoe_0GELVflzKHRYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_CzzcDrZpiEu6QYTiVCHdNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-07</instant>
        </period>
    </context>
    <context id="Duration_11_7_2023_To_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_L3R5rGyJ60OsNpQkqtgCzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">cvrx:OfficeSpaceInMinneapolisMinnesotaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-07</startDate>
            <endDate>2023-11-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cvrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001235912</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_sqft_GqVn26Et2UKhRhM1bZ7Trg">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_item_rCbhtU9w5EOG859qhsdnSg">
        <measure>cvrx:item</measure>
    </unit>
    <unit id="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment__laEB6QyrUy_CRagT_GFBw">
        <measure>cvrx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      id="Hidden_ePKRbe4dB0aPeXYbdjXkNA"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      id="Hidden_OOfVHfY4c0-blkkbbWepfQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="2"
      id="Hidden_yFT6SI8hckSwZ0Z0oJRWgA"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="2"
      id="Hidden_RJz8J98SB06oqS-Wx5ZSrA"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-2.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="0"
      id="Hidden_IwFJrxEx2EaTygBMU1MB9w"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20754375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="0"
      id="Hidden_FT04qFxYGEur9rK_xfNhLg"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20532838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      id="Hidden_KRGdCIu5gUe_MTcgpv6-bQ">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      id="Hidden_oldANodHgkOeQhYQiaVPUA">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="0"
      id="Hidden_K2osPffarkeK2nJPdvZI1Q"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20754375</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="0"
      id="Hidden_PnlFT0u0ZUmD1AeGlYRhLA"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20532838</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="2"
      id="Hidden_1-VKvzFxtkGYxn2bxA0KOQ"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="2"
      id="Hidden_9k-u6oSvH0SUWtDFYknU1A"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-2.02</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_NDyxVP6zzEewboTm__TJTQ_2_1">0001235912</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_yjK_fswgv0acOywcWRf3xA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_wdojtOixu0SPsDJNew40jg_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_3vVqzWHuOUGplLU9Sp9EVA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_NVJ3uWUzQ0SvNNGNMSb_xQ">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      id="Hidden_YDnHhonymkmLROCgApvJbw">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="INF"
      id="Hidden_OpBAXBMwEk6NYw4JEdrq0g"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20879199</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="INF"
      id="Hidden_q21DJISsyEqTNoQ9KQzmfA"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20663736</us-gaap:CommonStockSharesIssued>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_IO8dwnoe_0GELVflzKHRYA"
      id="Hidden_R84I04otGUuPgFKJgT8KOA">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MinimumMember_R1Bqa2cBBEeteyh9zoNgFw"
      id="Hidden_zQ9v7lRugkaZk4A4ENmecQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2023_srt_RangeAxis_srt_MaximumMember_Qx_lM9M1-U2I_9bBopvULQ"
      id="Hidden_4ZtIQYWjMEy5zwZJd8Tmlg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_guZglyooB0WmXzjYe5WtZQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_xKPCkhkV30GMy3SGBYzN3Q">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_zLRS8ugNuEu9UGzHfjYf3A">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_mumhLtlDG0a5KfnQT2PRXA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_vS34CnFDW0OkHGPL79j5Jg">001-40545</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_81TUXIh2sEWKdBZ8kq5ntQ">CVRx,&#160;Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_A0GL2Tu3vUa6xyIcsMrykg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_YShSGwBlN0CTOXByWkBnmw_1_1">41-1983744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_zCWXRtdvnkKW1aRRGthh1g">9201 West Broadway Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_MA4gwwly4E64R2NAxYkmyg">Suite&#160;650</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_VMuYyC8Z1UCPOUGf1DlC5A">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_S1kyHNLH5Uy5oJBPXq_-HA">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_KgBWeJeGOkqs57beFs1r6g">55445</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_yFa7e1uWXE2FE716JeE49Q">763</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_TCYBL78wz0ma9nNQItDZkQ">416-2840</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_HI3VsvyHeUi2eH7HwxRlwg_2_0">Common stock,</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_2EgrLfowsE6tdbKiHw1VYg_2_2">CVRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_KmIG6ea2KkO-WIhJnX0nqQ_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_If_PoHo-gEaRi1NvRYVLuQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_-KJywlOB7E2MGOgmFX0q4A">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_qkhSqLWKqEi2iBqrytOzMA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_pTyLZsZzXkOWJtveXZSVIA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_8hywR7pFw0uBne07oFc8HA_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tc_QEdGq8NPm0uATmhsT36u5A_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_YXUbQcEr1Em1AK1wjjfoPg">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_EnWyth76hE-n12yI-7az1w">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_0Ad0mcgS6U2v4WXsyHLWaw">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_cgcRpmqGT0KfzXmxzidYZw">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_n05hRLFmm0CPLbOYoYKOXw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2023_r0JJqTzes0K61mq122BZFw"
      decimals="-5"
      id="Narr_Hy4GF9-kKE6GpGruw38NEg"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">190000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_2_2024_uYC7wagxU0yxRMgfubU3Mg"
      decimals="INF"
      id="Narr_dQto2ygQbkiFWAGRkVo0LQ"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20927729</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_jdYvAK8oS0W6GFiLKqpq7w">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_Jkven45CVEiQMEj9UWgBcQ">Minneapolis, Minnesota</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_LzNvCaLZHkK_71AbctLdwg_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">90569000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_y8-LQuKdSU2Wjtnw-Vab9Q_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">106194000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Narr_6zjtccf1QkCvr5XQDMgErA"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">508000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Narr_PHPryfE8I0agf3rPgJrEmw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">679000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_SfcDMXCGzUu-mVKMS0nARQ_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7551000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_M1ScxOsAk0W9VVnytzWzpQ_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5504000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_p7kqH38ZFE-HTPFruPaHxA_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">10983000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_OcGLenrbNUScmu79B_N1tA_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6957000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_fiLcsXhE60Og1xdqSeNvww_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2987000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_3IsdG-FM3kyENSdxD2NPHQ_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4223000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_JJAqpTqgQE-84wQRIFaP6Q_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">112090000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_rE4BNfIVtECdaz9ZMTaDeQ_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">122878000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_wDJjkDVjdUKA6md7ZSnnbA_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1763000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_ajSyAF8clkiGL-5KD6mg5g_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1698000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_sNUZeLp580SjHsNQEoVaQA_11_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1349000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_pEs2atZs9ka7UCUMInNG5A_11_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">334000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_vFE2VnGVh0at2t6d9EQ-Pw_12_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">27000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_3CC3HuU4nE2zyou0osUO2A_12_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">27000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_xXWprTAd_k-Pzf3fO081kA_13_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">115229000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_1meMNhWAJEKxDPoaygTF0w_13_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">124937000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_Uf0O5tIBVk67i-NrBbCiZA_16_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1884000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_41rTQJ4zA06GoXx7PYg25A_16_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1719000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_5F52MHYx1Uix1LogfdCmxg_17_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5980000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_TSQzI7TtREeZ8HaEZ-DmqA_17_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6369000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_w2GRfU84AUOGdd4OyV9hYQ_18_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7864000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_SiziKAKlbkWjBFYvp4PGpA_18_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">8088000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_0_PHEjJcPk6hvLSazPaCcw_19_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">29222000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_EofeAGeBZ0e34-EqfmFv4Q_19_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6747000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_ZIDQkJpH6U2OWU2iMdfS6g_20_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1160000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_ldPR3t1WMEy14r0mE6kXdQ_20_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">117000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_F8i9bBltEk6WQ9jaQVOZ9A_21_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1036000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_uwaz2O4HeUGC81ynuhaODQ_21_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">805000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_Hbg7oBuPf0GLRMwS5V-Nfw_22_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">39282000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_7TkXTJj5iEao-hgRMXsVKA_22_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">15757000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="INF"
      id="Narr_0OjycGWTKUqai0GtyK5leA"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="INF"
      id="Narr_hJfdqvljQEKWrKfV-mRwug"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="INF"
      id="Narr_JaxzQX74g0OME_vRoXqITg"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="INF"
      id="Narr_fvAAWWgeAEmvi5e2n_4AoQ"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="INF"
      id="Narr_eQgGNiZirEWj5ZujRN_sfQ"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20879199</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="INF"
      id="Narr__c9B3EO8PES2nAk_JhV4Sw"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20663736</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_WxLsmixnpE-v8pjxLMsw7g_25_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">209000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_PMdPTAtmd0yrGt5RxxkP4A_25_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">207000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_FyDhBr_NM0aedgqZAlvVbw_26_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">553326000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_SYdVKlVeW0OzpiP9pR5ykA_26_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">545362000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_iilMjx0L502KaH6gIgzHPQ_27_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-477381000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_-pbLq2CObUKuZqKtzjC5sg_27_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-436182000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_JYZdptL3kkSlBZpmPEGj2g_28_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-207000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_ktQbUY62NEmeS5NUEkgo1A_28_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-207000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_jF5N8QsbVEqF8BuDGxxPJQ_29_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">75947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_YGWDMRi0XkC-mQtjj1yx2A_29_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">109180000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_brMZsG3rjU2mZIy-5vYv3g_30_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">115229000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_K9ncy6C2v0C8djGOrDpCAg_30_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">124937000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_yFv_QR1-dUiJA6FhnZxxFA_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">39295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_99t4lMrK0kq4x4BNTRAeWg_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">22469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_cs8SrOhS80GJJ2ZCe6Nmdw_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6256000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_MqkyAV_t1Emt9iq3PjrYCg_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4999000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_vXX5WOyaG0GT0N6bRSQNMA_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">33039000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_IGp2q3uhQkijpxeFug6Eog_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">17470000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_Ju0sHZLp0UKKixxUXGL64w_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">11633000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_-UAxBaOfpkOJwf1Yx4zFhw_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">9952000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_9LOFJq3CD0O1S1RVQMiy8Q_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">64509000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_V2gTLcCUcUGI-AXeR3iNlw_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">50045000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_Jq4jc1fVkUeym8S1bln_UA_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">76142000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_O5zQaBLjvESSFE2ky-YRjw_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">59997000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_S74QEmYkBU-W-9vuA3w7FQ_11_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-43103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_4DszrbNF-EmiVe7jG45W0g_11_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-42527000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_iOZehtDDGEyYOKnj9rW-uQ_12_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1799000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_h9iFFzrHqUCMyoH2TFj2XQ_12_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">165000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_gcQRMT5luUe31TNfRTO01Q_13_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3850000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_voSYtGsxoEezBcQpiYPtHg_13_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1373000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_q1XEVG2cUUagqMkGHD38EA_14_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41052000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_HqT2oY414U6BsOeNK8GAaA_14_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41319000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_6mTa21kqAkiuKuf7PUkGwQ_15_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_MrLcMFqoh0W6jJDuGHpttg_15_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">109000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_nW0RPcdM6Ea9rWBITEPykg_16_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_0pIEMAMSsECLyrlqfms94A_16_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_TAKYC--ftEKSN4zbPFuPSA_17_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_dzDrdnhol0yUUIx51b_nlQ_18_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41199000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_wi8-g5Tmh0--UheY1f0SJQ_18_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41437000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="2"
      id="Tc_0mK8p8c0KUacFJ5OeSy2Qw_19_3"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="2"
      id="Tc_yaXitwVM-UehuJJEzJN2eA_19_6"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="0"
      id="Tc_7XWY7J1LgkG6WC-ktMhGnw_20_3"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20754375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="0"
      id="Tc_3te3EkcuHEGdpCAf6gVY9A_20_6"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20532838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg"
      decimals="INF"
      id="Tc_gN_P46pkKUe8iGRdgH7_IA_5_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20399337</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vpOordAebkqPwlbzNyvUfg"
      decimals="-3"
      id="Tc_Fh1G7dO-SU61kuKdKvxoOg_5_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">204000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zbMLgVLwskWIMhYab9L2qw"
      decimals="-3"
      id="Tc_-GQ_SDzPL0uesk1Ajo7Bmg_5_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">540707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Wy3kn6snkkWPv53PI5w4dA"
      decimals="-3"
      id="Tc_ukzDojS7cUKgjwQSuj6frw_5_11"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-394754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3dLk7Sy_E0KsftAeppu0Vg"
      decimals="-3"
      id="Tc_KcFOpEwJqkigCyUCSiJ6vw_5_14"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg"
      decimals="-3"
      id="Tc__hIElquNMEiHhnFOL0IGLw_5_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">145959000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA"
      decimals="INF"
      id="Tc_ZxFCNbq9FEmCP1GRZQYfyQ_6_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">150509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA"
      decimals="-3"
      id="Tc_kdbLx_Iq7U6MGyMwA7LRxg_6_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA"
      decimals="-3"
      id="Tc_fz5NzSugzU63DWN5hvLYbQ_6_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">182000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_6tlxkH7mrEGlE8qgLzLAlw_6_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">184000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA"
      decimals="INF"
      id="Tc_ZSwEUiDRQU6VjeSv8Ms4lA_7_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">113890</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jZwr4dDFWE-Z-Kq-K-pWlA"
      decimals="-3"
      id="Tc_zFTZL7rInkG33wo3JuZsSg_7_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA"
      decimals="-3"
      id="Tc_vG03xDeTlE2SgZ09nP5hHA_7_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">586000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_3SYUS26JXkisgZiLthuXXg_7_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">587000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pLcvviFgQ0q6sMbH3dtaYA"
      decimals="-3"
      id="Tc_yv0ZFrs5SUSVmWCUoE743A_8_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_MmLU8Bk7HkKXrQx-2FwU6g_8_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jWno4e5JIkauZQOY8SolYQ"
      decimals="-3"
      id="Tc_Z-I40aTwZE6Qjvp_suHXQg_9_11"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_fG-uwixYrkybGV-CreiWNQ_9_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XBqz8Ajq30SHLvU8-PjfiA"
      decimals="-3"
      id="Tc_adiWEsHOl0eKoJAKDwyfXg_10_14"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-9000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_SNxFUmNZ6EetVWANoiaQqg_10_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-9000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_z5thRTHU6UqLA7ga0nCfkA"
      decimals="INF"
      id="Tc_UTfS6T2rX0i0mFX0HVTpxQ_11_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20663736</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_z5thRTHU6UqLA7ga0nCfkA"
      decimals="-3"
      id="Tc_EAb75GRUG0SYVzsVEs4EVw_11_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TYjt-cOP6EmP8oe6WXLi1g"
      decimals="-3"
      id="Tc_OsCPPokjJEKqXtB4msJpwA_11_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">545362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hwN6aAp_7UWY8-X1PMow3w"
      decimals="-3"
      id="Tc_LmfvW1MM9Ua27chhVIDXUg_11_11"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-436182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_oxQlkGA_EEi6G6wAtaoTqA"
      decimals="-3"
      id="Tc_l98bLgEX4k6FJRVJjKHjeA_11_14"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_CSBHrpnZxUaqydoHiMzKmQ_11_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">109180000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw"
      decimals="INF"
      id="Tc_c_iCpf_h0UuRM2xHXLXnSQ_12_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">144187</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw"
      decimals="-3"
      id="Tc_60oVhXlHPkyrQ_UGDlwm3g_12_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA"
      decimals="-3"
      id="Tc_Qt-BRuB8F0u4edAmAZEoKw_12_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">727000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_thU03FM6KUud5QeswWnd4A_12_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">728000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw"
      decimals="INF"
      id="Tc_aSkhPMx4CU28h-yQwwQbZg_13_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">71276</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q8tCS1SM50msuH0kYRiIJw"
      decimals="-3"
      id="Tc_-PDF4DR0tU6tIpgK1Ua0og_13_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA"
      decimals="-3"
      id="Tc_-7RYMc7OsE2NkIgkDLbvfg_13_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">934000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc__NivF5NMukGFKf8REi6tbg_13_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">935000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WmivlzFwGkWPmHihDpEOEA"
      decimals="-3"
      id="Tc_Vrjgdykd7kufUtaf8kdUkg_14_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6303000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc__Qxzr8nbDEWB8-BBV1EMzg_14_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6303000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3sIcs8CI8UW6e5DtAQYNdA"
      decimals="-3"
      id="Tc_fAxcI_Z1BkSaeY7PqzpD4w_15_11"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_zP_3M6nhzECPCntOVVfn9Q_15_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41199000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qCtrCvgNa0C-1eQGTvWtGw"
      decimals="INF"
      id="Tc_HDqaZlhtuUuGVDAoFkiobQ_16_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20879199</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qCtrCvgNa0C-1eQGTvWtGw"
      decimals="-3"
      id="Tc_8E7wrmFHA0umC2b89DkpnA_16_5"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cchEQDekhUyFexTD45-WZA"
      decimals="-3"
      id="Tc_W29SY9n_cEiWmlyH3fjycg_16_8"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">553326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b8RRVB7Uq0ilxq9okISsEw"
      decimals="-3"
      id="Tc_DV6Tf3om4UGbpJDePFKodQ_16_11"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-477381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_R8cE_HFzF0aFvnYTtQwY3A"
      decimals="-3"
      id="Tc_8jwWuUsy8UyUL6TXQBnfAA_16_14"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_En8H4ZIWNEGV_J9xN4JpBg_16_17"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">75947000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_elifCtOvr0-Hc-xw3UO6Mw_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41199000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_mTuP9X4dBkSxAVk_wC3_0Q_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41428000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_y35BgnHAc0SpC3LwQpDWPQ_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6303000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_H_meNd7MnkyuegPr1oE0mQ_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3887000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_6n8iyP57PkC1NQyWRGKkzA_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">522000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_UZITZISu3UqsGl-mYxNy5Q_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">412000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_WS4F4UT5yUWZfcdQni_uCQ_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_0Ad76IS93ESjI7jBRqN3tQ_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_dEbrylCahE61ACsastyj9w_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">154000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_cNgh41iyL0qDkel8JqJvCw_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">25000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_OB5JM1UvJ0asGKMaYSxKGg_12_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2047000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_lz2DwLLLpE6WGQkW3pKIPw_12_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2944000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_ZUgzbFqStUSQqCne5lEx7Q_13_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4026000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_9QyFFcOoR0Kro_j5oYNSTw_13_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3077000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_xEN8sOcM4EuPw4FSUMfSNg_14_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-1273000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_O02AuJfwZkqMDRLB-2rAQA_14_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1634000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_yVT3rcux10ehWYCPPFC5xA_15_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">165000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_QUSBJv-0NEudpylUr8gExA_15_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1209000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_AnyjpyP6iEWkZ0IZxCJtZg_16_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-170000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_Kcp55-pZsUanEfygTlsHZg_16_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">873000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_avg6R68ncU-9Epl7g2A1BA_17_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-39021000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_8P2hv2WnrEOy2-QMKdE0Kw_17_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-42677000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_l5AWIMfQNE60zmECEk52zQ_19_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">591000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_y9IdeHZqjUqhcU3a6cgO8Q_19_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">685000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_U0Yc4trGJUaW7-fC8mgFBw_20_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-591000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_OFUvS-4ccU6CrKXGdo5hgA_20_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-685000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_tSaSTzXvAU64aq99FrQeog_22_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">728000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_DCl9wc2Ya0eoF8v1AA5WyQ_22_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">184000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_4afF07bNYkm8yYWp4w1bhw_23_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">935000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_J5IyCY-3rU6HDM-SyLnb7A_23_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">587000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_A5penc1PoE258Q7hJlYneg_24_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">22500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_qrlp0BUMJEGKIFhnXET9Ug_24_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_X1gDG82ESkSOo9lCAAjeQA_25_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">179000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_RQ8bJeVxgEaNQAr8AyVDAQ_25_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">778000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_akUlqrVU3kKr8NVO89Bm6A_26_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">23984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_IhkUjefWkkO0ITfva9w4wQ_26_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7493000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_wgi4iDwMlECbNG1dIQLQVA_27_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_TLF6qfeiek-AARQHajA3Hg_27_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_dj6-D8I7HE--EdwdcECHPA_28_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-15625000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_B8EZVPbNXUW-2TcJvkeWYw_28_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-35878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_BFET9EOVX0GnHk0oEul0WA_29_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">106194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg"
      decimals="-3"
      id="Tc_FU-lsmrzNkOdOFsiTgTAgg_29_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">142072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_Ma3c2K5jTEW9btt_a4gZPg_30_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">90569000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_gjijIbn2XUm-5JarJLgABA_30_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">106194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_pcnF8f1bqU-6EY-ZLmlBgA_32_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1396000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_E4jGLD-QwkOiKZDYxAkoRA_32_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">59000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_XGgqiIiIL0uVYqi2cN23sw_33_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc__W3Ab23yFUWObW7kcNawUg_33_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_HEvfjK1xAU-asHxkhJMpow">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;1.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Business organization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;CVRx,&#160;Inc. (the &#x201c;Company&#x201d;) was incorporated in Delaware and is headquartered in Minneapolis, Minnesota. We have developed and is marketing a medical device, Barostim, for heart failure (&#x201c;HF&#x201d;) and resistant hypertension. We are focused on the sale of our product in the U.S. and Europe.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management expects that operating losses and negative cash flows from operations could continue in the foreseeable future. There is no assurance that we will generate sufficient product sales to produce positive earnings or cash flows.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_HrVqg9vxq0eQwUdl3qyZGA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;2.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement presentation and basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy, which was closed during 2023. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;JOBS Act accounting election&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As a result, we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2023 and 2022, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value. Additionally, as of December 31, 2023 and 2022, a majority of our cash and cash equivalents were maintained with two financial institutions in the U.S., and our current deposits are likely in excess of insured limits.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. &lt;span style="background:#ffffff;"&gt;We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023. We have determined that the adoption of ASU 2016-13 did not have a material impact on our results of operations, cash flows, or financial position as we do not have a history of credit losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We regularly review inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) asset, accrued expenses and operating lease liability &#x2013; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We sell our products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. Our revenue consists primarily of the sale of our Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services it transfers to the customer. We recognize net revenue on product sales, adjusted for any applicable estimates of variable consideration, when the customer obtains control of our product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract. All our contracts have a single performance obligation and our payment terms with customers are generally between 30 and 90 days. Variable consideration related to certain customer rebates is estimated based on the amounts expected to be paid based on the agreement with the customer.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i style="font-style:italic;"&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2023-07&#x201d;), which requires public companies to disclose for each reportable segment the significant expense categories and amounts for such expenses. ASU 2023-07 is effective for annual periods beginning December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU will be effective for our annual period ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures &lt;/i&gt;(&#x201c;ASU 2023-09&#x201d;), which requires public business entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2023. This ASU will be effective for our annual period ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_Bb6DPZRoIEuaAfn9pl6HlQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Statement presentation and basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and with the applicable rules&#160;and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CVRx,&#160;Inc., its wholly owned subsidiary, CVRx Switzerland LLC, and its sales branch in Italy, which was closed during 2023. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</cvrx:BasisOfPresentationAndConsolidationPolicyPolicyTextBlock>
    <cvrx:JobsActAccountingElectionPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_lpZqqhVcYEyQnpwatNcMpg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;JOBS Act accounting election&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). As a result, we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies.&lt;/p&gt;</cvrx:JobsActAccountingElectionPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_rQSGBqDOnEmnlFp0yr87Pw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_0-QlA8a6nEajwRNHriu14g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents include highly liquid investments with an original maturity of three&#160;months or less. As of December 31, 2023 and 2022, cash equivalents consisted of money market funds, which are stated at cost and approximate fair value. Additionally, as of December 31, 2023 and 2022, a majority of our cash and cash equivalents were maintained with two financial institutions in the U.S., and our current deposits are likely in excess of insured limits.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_nyo9K7ILRkWNxoc3sKip5g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the standard generally being net 30 days. &lt;span style="background:#ffffff;"&gt;We evaluate the collectability of our accounts receivable based on known collection risks and historical experience. In circumstances where we are aware of a specific customer's inability to meet its financial obligations to us, we record a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount we reasonably believe will be collected. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;ASU 2016-13 became effective for us for interim and annual periods beginning January 1, 2023. We have determined that the adoption of ASU 2016-13 did not have a material impact on our results of operations, cash flows, or financial position as we do not have a history of credit losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_TfxT24rZkUSMBRF3McfUYQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. We regularly review inventory quantities in consideration of actual loss experiences, projected future demand and remaining shelf life to record a provision for excess and obsolete inventory when appropriate.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_RlMf-rofSEa6GTOoQAT_RA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) asset, accrued expenses and operating lease liability &#x2013; non-current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. We used the incremental borrowing rate based on information readily available at the time of recognition to determine the present value of the lease payments. The determination of our incremental borrowing rate requires management judgement based on information available at lease commencement.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_W5q3XjvPBkGXe4oN6YHKKg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We sell our products primarily through a direct sales force and to a lesser extent through a combination of sales agents and independent distributors. Our revenue consists primarily of the sale of our Barostim, which consists of two implantable components: a pulse generator and a stimulation lead.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;), revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services it transfers to the customer. We recognize net revenue on product sales, adjusted for any applicable estimates of variable consideration, when the customer obtains control of our product, which generally occurs at a point in time upon delivery based on the contractual shipping terms of a contract. All our contracts have a single performance obligation and our payment terms with customers are generally between 30 and 90 days. Variable consideration related to certain customer rebates is estimated based on the amounts expected to be paid based on the agreement with the customer.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_UiYUQQjmG0-Bj0lBFmr79g">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize equity-based compensation expense for awards of equity instruments to employees and non-employees based on the grant date fair value of those awards in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all equity-based compensation awards to employees and non-employee directors, including grants of restricted shares and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the grant date fair value of stock options using the Black-Scholes option pricing model. We account for forfeitures as they occur. We expense the fair value of our equity-based compensation awards granted to employees on a straight-line basis over the associated service period, which is generally the period in which the related services are received.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_pZtIw4MqmUy0GL8KqZEOcw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recent accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i style="font-style:italic;"&gt;Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2023-07&#x201d;), which requires public companies to disclose for each reportable segment the significant expense categories and amounts for such expenses. ASU 2023-07 is effective for annual periods beginning December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. This ASU will be effective for our annual period ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;i style="font-style:italic;"&gt;Improvements to Income Tax Disclosures &lt;/i&gt;(&#x201c;ASU 2023-09&#x201d;), which requires public business entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 is effective for annual periods beginning after December 15, 2023. This ASU will be effective for our annual period ended December 31, 2024.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_o5DdFHTu4kykK96UwCkjlw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;3.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Selected balance sheet information&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw material&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital equipment in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,978&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="display:inline-block;visibility:hidden;width:0pt;"&gt;&#x200b;&lt;/span&gt;&lt;br/&gt;Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally&#160;&lt;span style="-sec-ix-hidden:Hidden_zQ9v7lRugkaZk4A4ENmecQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&#160;to&#160;&lt;span style="-sec-ix-hidden:Hidden_4ZtIQYWjMEy5zwZJd8Tmlg;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;/span&gt;. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation expense was $0.5 million and $0.4 million for the&#160;years ended December 31, 2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical trial and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Paid time off&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KRGdCIu5gUe_MTcgpv6-bQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Operating lease liability, current portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_7DEnhg82NkecqaQtCtYUSw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Inventory consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw material&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work-in-process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,615&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,957&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_MXn7JApc9kGjQ8eLFtOmYw_3_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4714000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_d7q8ywcM4kSLC6BXzjR1_Q_3_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2390000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_kY8nDSzQfUaa4MWZajE70A_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">654000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_X4eLdYqT2UyY3urIonE25g_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1033000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_VDAKXeKx0EG7vH-RS-jUMg_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5615000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_OtCOB57DW0Ga0O57EBqt5A_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3534000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_7b2pWnAkgk2zSonlBNo9Kg_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">10983000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_shYepnAFmkW5pwo1w5cb8w_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6957000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_ILnY_osKA0m5Tu3wIFpUyg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Property and equipment, net consists of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital equipment in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,551&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,978&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_tmU2-D_zdkyR5NTA7xTdTA"
      decimals="-3"
      id="Tc_nLboCbPAXkqVokiZfLTOOQ_3_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_FSq9BY_du0er2CE9ESvvpw"
      decimals="-3"
      id="Tc_-rlwu_bMkUqGLVhZx1UI-A_3_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">350000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_BAuUOTojQESzFVAzqd4DhA"
      decimals="-3"
      id="Tc_FjiqDHd2E0GxJGGHkNqasQ_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2721000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_LabEquipmentMember_sgJuXpn0yUa8L7xiptpJRQ"
      decimals="-3"
      id="Tc_8X3Md1jSAkqXJwhnlMM2Yg_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2684000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_MpXjFm5HkU2XNvuqY4WPsA"
      decimals="-3"
      id="Tc_Z31YjbkCskWpDPi5jwRtOA_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cvrx_ComputerEquipmentAndSoftwareMember_dqIej4ejsE2n1BDRzJlgJg"
      decimals="-3"
      id="Tc_F62kkk1p2E6eVv0HIVJ1gg_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_JMLg2X07bEuHweDOuklZhw"
      decimals="-3"
      id="Tc_KUNQy1Po9UydM7Max9xnzA_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">98000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_amp52TUrr0uPXJ9VAkjlow"
      decimals="-3"
      id="Tc_JW2Bjnno_UWz9ojh5CCZTQ_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">95000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_RDgZV8eKn0q48yeiBOKJrw"
      decimals="-3"
      id="Tc_cHU_qUDPgEC1g8sQOas_qw_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">554000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetUnderConstructionMember_-1zVdT_0tkOxZQEUVJnt6A"
      decimals="-3"
      id="Tc_R8RYiGxC60mQ_R6EhfojRw_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">231000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_6ERV1aoGg0WbHqMsRXx3zQ_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4551000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_8FqEuese5kGpjqSmWbLxcg_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3978000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_NOtd_d6CrUiyplGTcPwKhg_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2788000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_tQL8D7XKz0uTnXjWjrM8Zg_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2280000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_Tejrgy6fkUi3JCD_n3ck2A_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1763000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_r5TXwNxkk0yPgfIVZfgqfA_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1698000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-5"
      id="Narr_2090__YHZ0qnqdpcmWYdaQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-5"
      id="Narr_qhnfL4fkv0CvsSnvtGsKqw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">400000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_OFlPDXFWkEWktxGP7vhGdA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Accrued expenses consist of the following at:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Clinical trial and other professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Bonuses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Paid time off&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KRGdCIu5gUe_MTcgpv6-bQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Operating lease liability, current portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cvrx:ClinicalTrialAndOtherProfessionalFees
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_snset307002iwjafRYI_hw_3_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">277000</cvrx:ClinicalTrialAndOtherProfessionalFees>
    <cvrx:ClinicalTrialAndOtherProfessionalFees
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_T52sNKEo8EKfZnZMTttpTQ_3_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1733000</cvrx:ClinicalTrialAndOtherProfessionalFees>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_n_4gcXMTzkCLvmz-uADGHA_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3335000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_u1nMyTzSYUeluY1VxTwBpg_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2303000</us-gaap:AccruedBonusesCurrent>
    <cvrx:AccruedPaidTimeOff
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_KRaSufnFE0GO5kV_aP7YJA_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">770000</cvrx:AccruedPaidTimeOff>
    <cvrx:AccruedPaidTimeOff
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_9cLWhZI6sUeh2SGFIwK-6g_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">960000</cvrx:AccruedPaidTimeOff>
    <cvrx:AccruedLiabilitiesCustomerRebateCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_5uek8hf_Ik2DeIxjRdIPiw_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">411000</cvrx:AccruedLiabilitiesCustomerRebateCurrent>
    <cvrx:AccruedLiabilitiesCustomerRebateCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_Bc22SGMreU684tLK-eg1CA_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">256000</cvrx:AccruedLiabilitiesCustomerRebateCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_qzWYVOCpG02lijmRXH6bAA_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">231000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_wrv7cHuIokmvykgzZCORyw_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">222000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_-gJkaPzESUGeTj7c_1hlFQ_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">125000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_DMaNRVKa1E-gAxoSGukbCg_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">120000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_rWfb5bR8y0OF17OTROubHw_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">831000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_Hsy1mgkzP02qPU4WpgsG3Q_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">775000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_O0CCh4pyVUuvLXXeXouoew_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5980000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_QGDP8m_Pe0GaLPimdrEReQ_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6369000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_56PbfSrp9kyK4bSI-uXLaA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;4. Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Innovatus Loan Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;On October 31, 2022, we entered into a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, under which we may borrow, subject to our achievement of certain milestones, up to a total of $50.0 million in a series of term loans. On the closing date, we borrowed the minimum amount of $7.5 million under the Loan Agreement. On March 10, 2023, we borrowed the $7.5 million remaining under the first tranche of the Loan Agreement. On December 15, 2023, we borrowed an additional $15.0 million under the second tranche of the Loan Agreement. The Loan Agreement initially requires interest only payments through November 2027, followed by three monthly principal and interest payments. A final payment of $1.4 million, equal to 4.5% of the original borrowed principal, is due in January 2028. The term loans advanced pursuant to the Loan Agreement (collectively, the &#x201c;Term Loans&#x201d;) bear interest at a floating rate per annum equal to the sum of (a)&#160;the greater of (i) the prime rate and (ii) 5.50% plus (b)&#160;2.65%. The Term Loans are secured by substantially all of our personal property. We have the option to draw down&#160;up to $20.0 million between September&#160;1, 2024 and December&#160;15, 2024 if we achieve trailing three months revenue of $9.0 million prior to June&#160;30, 2024. A performance covenant takes effect at the earlier of September&#160;30, 2025 or the third tranche funding, requiring that we achieve 50% of the trailing twelve months revenue target set in the Board-approved revenue plan in effect for such period. The Loan Agreement requires the payment of certain penalties if the Term Loans are paid off prior to maturity for any reason, including pursuant to an acceleration clause, and includes various restrictive covenants, including a restriction on the payment of dividends or making other distributions or payments on our capital stock, subject to limited exceptions. We were in compliance with these covenants as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In connection with the Loan Agreement, we recorded $1.0 million of debt issuance costs and discounts as a reduction of long-term debt. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The annual principal maturities of debt under the Loan Agreement are as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Less: Unamortized debt costs and discounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (778)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA"
      decimals="-5"
      id="Narr_1ojXi2B_EEmTAewOK1a2tQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A"
      decimals="-5"
      id="Narr_ui9LLsbTL0CzBRCKzCsebQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_3_10_2023_To_3_10_2023_srt_StatementScenarioAxis_cvrx_TrancheOneMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_MsUf-wRe3UOCGdw87WJNbQ"
      decimals="-5"
      id="Narr_pbJyA63-8EiHsRQ48RXy9g"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7500000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_12_15_2023_To_12_15_2023_srt_StatementScenarioAxis_cvrx_TrancheTwoMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_6qk8DRW53E2gnuQbDupIdw"
      decimals="-5"
      id="Narr_f8o-hJAftUicBqvP1xFfMw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">15000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <cvrx:NumberOfDebtPaymentsConsistingOfPrincipalAndInterest
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A"
      decimals="INF"
      id="Narr_XOkdDZdXKE-4417aniVg6A"
      unitRef="Unit_Standard_item_rCbhtU9w5EOG859qhsdnSg">3</cvrx:NumberOfDebtPaymentsConsistingOfPrincipalAndInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA"
      decimals="-5"
      id="Narr_DEzbRMrn-k6BzTOebR2FfQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1400000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA"
      decimals="3"
      id="Narr_m8kvzW2Rv0SkE2-_2IGTzA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.045</cvrx:DebtInstrumentPercentageOfFinalPaymentOnOriginalPrincipal>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A"
      decimals="4"
      id="Narr_X5E_nBjGO0GtwGqhO6ilig"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A"
      decimals="4"
      id="Narr_44fIG9nxU0G90Uw_aploRw"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0265</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_ilFiREhHNkW7Pr6DPc2vbQ"
      decimals="-5"
      id="Narr_MUBXn6Iw8UeqEFO4hGMwpg"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">20000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <cvrx:RevenueTreeMonthsTrailing
      contextRef="Duration_10_31_2022_To_10_31_2022_srt_StatementScenarioAxis_cvrx_LineOfCreditDrawDownPeriodThreeMember_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_ilFiREhHNkW7Pr6DPc2vbQ"
      decimals="-5"
      id="Narr_K7qSJMjVP0K6Hy5g70GXLg"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">9000000.0</cvrx:RevenueTreeMonthsTrailing>
    <cvrx:PercentOfRevenueTarget
      contextRef="Duration_10_31_2022_To_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_b_kniJy_kkqxuU5kOv_2-A"
      decimals="2"
      id="Narr_PAXOCj6SUkSDSoJTJp5aMQ"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.50</cvrx:PercentOfRevenueTarget>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_10_31_2022_us-gaap_DebtInstrumentAxis_cvrx_LoanAndSecurityAgreementMember_u7tgCMNv7Uaa5PtLyPJthA"
      decimals="-5"
      id="Narr_-ikuADde6U2WzNZk0Lh4aA"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1000000.0</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_8B9ns1w950acCUrE_RSyIw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The annual principal maturities of debt under the Loan Agreement are as follows:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Less: Unamortized debt costs and discounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (778)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:83.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 29,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_WY4D4kMtKkuODxfCsAtcCQ_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">20000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_GbMw96EWAEa4nmbg3vXTdQ_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">10000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_QYhhvKwKFEOGmR8S0GrdhA_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_iTESwVeVQEGnxqnKzsB87g_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">778000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_YnkCaZUc1U2ot5lYxFGh2A_11_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">29222000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_OjSgZy1i-E6BL4J2JBzCfg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;5. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We lease &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;31,505&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; square feet of office space in Minneapolis, Minnesota, which houses our principal executive offices and our manufacturing facility. We lease this space under an operating lease agreement that commenced December 1, 2008 and was scheduled to expire August 31, 2024. On April 21, 2023, we extended the operating lease for our office space in Minneapolis, Minnesota for an additional&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;49&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;consecutive months through August 31, 2028. On November 7, 2023, we expanded our existing office space with the addition of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;7,615&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; square feet of property adjacent to our principal executive offices and our manufacturing facility. The term on this expanded property is for &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;57&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; consecutive months that will run concurrently with the term on the existing lease. We intend to add new facilities as we grow, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. Our operating lease agreement includes an option to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;renew&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; for one additional period of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_R84I04otGUuPgFKJgT8KOA;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; years. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability, as it is not reasonably certain of exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to base rent, we also pay our proportionate share of operating expenses, as defined in the lease. These payments are made monthly and are adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the lease balances within the consolidated balance sheets:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,349&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YDnHhonymkmLROCgApvJbw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease liability, non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Maturities of our lease liability for our operating lease are as follows as of December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 362&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,624&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (233)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, the remaining lease term was 4.7 years, and the weighted average discount rate was 6.7%. The operating cash outflows from our operating lease were $0.4 million for each of the years ended December 31, 2023 and 2022.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cvrx:LesseeOperatingLeaseAreaOfLandLeased
      contextRef="As_Of_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_IO8dwnoe_0GELVflzKHRYA"
      decimals="INF"
      id="Narr_xCL9nzInPU6c0pBeck6a-Q"
      unitRef="Unit_Standard_sqft_GqVn26Et2UKhRhM1bZ7Trg">31505</cvrx:LesseeOperatingLeaseAreaOfLandLeased>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_4_21_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_RM2963Hq80uyOziblZLLAA"
      id="Narr_hlAh4Oe1TEm-xMH9geVtQA">P49Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cvrx:LesseeOperatingLeaseAreaOfAdditionalLandLeased
      contextRef="As_Of_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_CzzcDrZpiEu6QYTiVCHdNQ"
      decimals="INF"
      id="Narr_vY2_iLwWQE6c_aH-C4chlA"
      unitRef="Unit_Standard_sqft_GqVn26Et2UKhRhM1bZ7Trg">7615</cvrx:LesseeOperatingLeaseAreaOfAdditionalLandLeased>
    <cvrx:LesseeOperatingLeaseAdditionalRenewalTerm
      contextRef="Duration_11_7_2023_To_11_7_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_L3R5rGyJ60OsNpQkqtgCzA"
      id="Narr_vLRBcL084UCSCzKYRLAPEA">P57Y</cvrx:LesseeOperatingLeaseAdditionalRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cvrx_OfficeSpaceInMinneapolisMinnesotaMember_SKjkOlcWxkeaJnFxtqthxg"
      id="Narr_UzBV2LndVECYJ3iqDpwDYQ">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_A8ctzUjLeUO0qiAqRSikdg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the lease balances within the consolidated balance sheets:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,349&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YDnHhonymkmLROCgApvJbw;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating lease liability, non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Total operating lease liabilities &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvrx:ScheduleOfLeaseBalancesWithinBalanceSheetsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_PvS55w4pZU2ZB9CKUQPJ-Q_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1349000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_BdCxKe8PiUqmEuPQjb8QUw_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">231000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_zntDlKTxakiepwkZduE_Pw_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1160000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_hjyEmy9nP0ymI6Nn-py0rA_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1391000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_lzn8BNphVUi-0bdRSh2lFw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Maturities of our lease liability for our operating lease are as follows as of December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 350&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 362&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,624&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (233)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,391&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_khaLLIhEYUaC9aq6E9nf-Q_3_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">315000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_yqFpsBlBbkyPFNx17gYlug_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">350000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_kTkeOlNM_k60-QnjYum8tg_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">362000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc__cVlGKCPYka54sB2oAMW-Q_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">374000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_w3sJil-3rUG5wcocsMUm4g_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">223000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_aqV_mmlzZ0e2p-r3CKiQ2g_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1624000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_0Utq9yA9h02y_gkSigY7Ww_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">233000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_Gvdc0vg9o0SGAEijSgxpVg_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1391000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      id="Narr_PufI4pmeREmXn0NDiBfNSQ">P4Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="3"
      id="Narr_5ykjKLjXOkOtzPqruaDyGw"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.067</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-5"
      id="Narr_Lv-BjIU-t0C7Li0ZY7_uNQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-5"
      id="Narr_rhh-9FVceE21Qu1Y7pjw0g"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_DyyFiJ58d0u6g3L9MVAXBw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;6.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Stockholders&#x2019; equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We have common stock warrants exercisable for 716,131 shares of common stock upon conversion at a weighted average exercise price of $2.39 per share. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA"
      decimals="INF"
      id="Narr_YA4379anT0KAvjUb1iNbZQ"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">716131</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOffering>
    <cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_cvrx_WarrantsToPurchaseCommonStockMember_th-rNP0i00ic5JR9rAhMiA"
      decimals="2"
      id="Narr_zZ8T0Akh7EyP3gJ7xm1DIA"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">2.39</cvrx:PreferredStockWarrantsConvertedToCommonStockWarrantsAtInitialPublicOfferingWeightedAverageExercisePrice>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_UaBBzSh0I0K6s8bobm7gaw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Summary of plans and activity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2001, our Board of Directors and stockholders established the 2001 Stock Incentive Award Plan (&#x201c;2001 Plan&#x201d;). Under the 2001 Plan, as amended, 2,674,749 shares of common stock had been reserved for the issuance of incentive stock options granted to employees, non-employee directors, consultants or independent contractors. Options granted under the 2001 Plan have vesting terms that range from the date of grant to four&#160;years and expire within a maximum term of 10 years from the grant date. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2021, our Board of Directors and stockholders established the 2021 Equity Incentive Plan (&#x201c;2021 Plan&#x201d;). The number of shares of common stock initially reserved for issuance under the 2021 Plan was 1,854,490 newly reserved shares in addition to the 600,737 shares that remained available for issuance under the 2001 Plan. The shares available for issuance under the 2021 Plan automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 1,033,186 shares being reserved for issuance under the 2021 Plan as of January 1, 2023. The 2021 Plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, stock unit awards and other stock-based awards and cash incentive awards to employees, consultants and non-employee directors of the Company and its subsidiaries. Awards granted under the 2021 Plan will have such vesting schedules and other terms as determined by the Compensation Committee and stock options and stock appreciation rights have a maximum term of 10 years from the grant date. No further awards can be made under the 2001 Plan following the adoption of the 2021 Plan. As of December 31, 2023, there were 1,671,202 shares available for future issuance under the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Options are granted at exercise prices not less than the fair market value (as determined by the Board of Directors) of our common stock on the date of grant. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years 2008 through the IPO, the Board of Directors authorized the grant of stock options for the purchase of shares of common stock to the employers of certain non-employee directors. The options were not granted under the 2001 Plan or the 2021 Plan, but terms are substantially the same as our standard form of option agreement for non-employee directors as they have an exercise price not less than the fair market value on the grant date and vest over 48&#160;months from the date of grant.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of stock option activity:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 16,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,486,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (328,902)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (150,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 36,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,161,926 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;14.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;(285,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;10.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;(144,187)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;5.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 4,488,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;9.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 97,266&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2,450,327 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 59,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2023, stock options outstanding included 8,559 options that were not granted under the 2001 Plan or the 2021 Plan. For options outstanding as of December 31, 2023, the weighted average &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;remaining contractual life was 7.3&#160;years. For options exercisable as of December 31, 2023, the weighted average remaining contractual life was 6.3 years.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Our Board of Directors and stockholders also established an Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The number of shares of common stock initially reserved for issuance under the ESPP was 278,170. The shares available for issuance under the ESPP automatically increase on the first day of each year, commencing January 1, 2022, and ending on (and including) January 1, 2031, in an amount equal to 1% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or such lesser number of shares as determined by the Board of Directors. The annual increase resulted in an additional 206,637 shares being reserved for issuance under the ESPP as of January 1, 2023. The ESPP permits certain of our U.S. employees to purchase shares of our common stock at a price per share not less than 85% of the l&lt;span style="letter-spacing:0.25pt;"&gt;ower of (i)&#160;the closing market price per share of our common stock on the first day of the applicable purchase period or (ii)&#160;the closing market price per share of our common stock on the purchase date at the end of the applicable six-month purchase period. The first purchase date under the ESPP was June 30, 2022. &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;For the year ended December 31, 2023,&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;71,276&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;shares of common stock were purchased under the ESPP for&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million of employee contributions. &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;As of December 31, 2023, there were &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;503,634&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; shares available for issuance under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We use the Black-Scholes option pricing model to determine the fair value of stock options and ESPP purchase rights on the grant date. We measure stock-based compensation expense based on the grant date fair value of the award and recognizes compensation expense over the requisite service period, which is generally the vesting period for stock options and the offering period for ESPP purchase rights. The amount of stock-based compensation expense recognized for stock option awards during a period is based on the portion of the awards that are ultimately expected to vest. The amount of stock-based compensation expense recognized for ESPP purchase rights during a period is based on the estimated purchase rights as of the grant date. We account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;10.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;non-officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.5 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.3 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.5 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.2 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;77.2% to 79.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.3% to 60.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.40% to 4.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1.75% to 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:31.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per ESPP purchase right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&#x2009;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;76.2% to 84.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;51.3% to 62.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;4.77% to 5.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.22% to 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We review these assumptions on a periodic basis and adjust them, as necessary. We utilize the simplified method to develop the estimate of the expected term for stock option awards and ESPP purchase rights. The expected volatility is based upon observed volatility of comparable public companies. The expected dividend yield is assumed to be zero, as we have never paid dividends and have no current plans to do so. The risk-free interest rate is based on the yield on U.S. Treasury securities for a period approximating the expected term of the options being valued.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components and classification of stock-based compensation expense for the periods indicated: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general &amp;amp; administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,073&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,304&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023, unrecognized compensation expense related to unvested stock-based compensation arrangements was $13.4 million. As of December 31, 2023, the related weighted average period over which the expense is expected to be recognized is approximately 2.4&#160;years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_LGXJ91kYF0WAsdsON9A6IA"
      decimals="INF"
      id="Narr_OTMBJYY5Fk2c9Oc7jc_D7g"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">2674749</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2001_To_6_30_2001_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_PYd31BxNC0604nl8MDpilQ"
      id="Narr_kJ3fPAyI4EukuE1_RhQeEA">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_6_1_2001_To_6_30_2001_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_7rx5_d8IikeJHLuprsGqsw"
      id="Narr_b_GIxLdRZUmO9VwwS0ufZw">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_dc9hk3dVYkCOZVwQkXY8cQ"
      decimals="INF"
      id="Narr_HPTMPvNKzUqq5o2lUR6z9w"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">1854490</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandOneStockIncentiveAwardPlanMember_naG0zLCR-EKkwa1gEwsa0w"
      decimals="INF"
      id="Narr_NOZ_wGz7ZEeQmYY0l3C_1A"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">600737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_dc9hk3dVYkCOZVwQkXY8cQ"
      decimals="2"
      id="Narr_CFdWv0wPCUOrb9dc6f0nQg"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.05</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_DKj1YSlDwU2ZlmMFDIgwbg"
      decimals="INF"
      id="Narr_SLV8nDKihEmW_8fuvr3z2g"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">1033186</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember_up0KPm3ldUy5PK6Gt_PEvg"
      id="Narr_7AlqTaOy20mhWa4j1y0MiA">P10Y</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTerm>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_TwoThousandTwentyOneEquityPlanMember__P6VIstV9ke4AlgA3xarog"
      decimals="INF"
      id="Narr_w5XJawD_3UOaMS7O5BuRZQ"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">1671202</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2008_To_12_31_2008_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_PajlFFmwTkWsKigwduPhHg"
      id="Narr_IzHbOGg45kmvyTDuUBDmjw">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_qfVzhM8FZ06gl2vFflJEyQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a summary of stock option activity:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 2,749,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 16,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,486,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (328,902)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (150,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;8.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 36,616&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;1,161,926 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;14.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Cancelled / Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;(285,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;10.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;(144,187)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;5.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Balance as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 4,488,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;9.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 97,266&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Options exercisable as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;2,450,327 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt;7.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.4pt 0pt 0pt;"&gt; 59,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw"
      decimals="INF"
      id="Tc_EK8EYGz-qUCA3y9ueCTfOA_6_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">2749441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw"
      decimals="2"
      id="Tc_irspkEBjGEGC__0PHev8_Q_6_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">7.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_KuDUKBFAUU-4wF6s1mNnFw"
      decimals="-3"
      id="Tc_-O0myfJdI0qHnp8Vzzf-eA_6_9"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">16262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"
      decimals="INF"
      id="Tc_Nsl3SRDa70q9FR99je9cqg_7_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">1486805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"
      decimals="2"
      id="Tc_gZrHJup3Okq2Py6W3_epmw_7_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">8.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"
      decimals="INF"
      id="Tc_huHMtXS2okKyt68DbEOdLQ_8_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">328902</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"
      decimals="2"
      id="Tc_81VhxnfkDUWDhiE59ZaEbg_8_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">7.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"
      decimals="INF"
      id="Tc_57Cr3CkN70iJ0sHLbBtNKw_9_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">150509</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_fGCUnnU8JESergySOSOTWg"
      decimals="2"
      id="Tc_9eYrzjw8RU2Sey4qBbtPMQ_9_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">1.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA"
      decimals="INF"
      id="Tc_kM1TTHWyZU6CCRB3v_t2oA_10_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">3756835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA"
      decimals="2"
      id="Tc_BYpceHyUNka4aBypsMorgQ_10_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_FNxdYjiS8k2yw63_h03HnA"
      decimals="-3"
      id="Tc_bsIhE1Z5N0-IkwCtI66hfw_10_9"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">36616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"
      decimals="INF"
      id="Tc_0aVkmQwaPUS680210Tx52g_11_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">1161926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"
      decimals="2"
      id="Tc_rMhq3ai4HkiAOEPmKsYdmQ_11_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">14.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"
      decimals="INF"
      id="Tc_9J7-0vcWWEWzld_G0c54AQ_12_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">285729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"
      decimals="2"
      id="Tc_-BCUIlR7kUqAqFSaoMnZqg_12_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">10.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"
      decimals="INF"
      id="Tc__NFQNaqg7EmZKiJxWDYTJA_13_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">144187</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_g_oysEXpvkOw-4MyY-jw2g"
      decimals="2"
      id="Tc_SL2-kzfoEE2AHGbsuPqlAg_13_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">5.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"
      decimals="INF"
      id="Tc_C4YCf0PI4U-gnzFRV-rymQ_14_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">4488845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"
      decimals="2"
      id="Tc_TsazrhR1IUGU4WtyGC0qZQ_14_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">9.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"
      decimals="-3"
      id="Tc_tX7-A9G5tUGXcqNv14Z8og_14_9"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">97266000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"
      decimals="INF"
      id="Tc_g55N46jzpk2qDxIACZyKzQ_15_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">2450327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"
      decimals="2"
      id="Tc_ITLwl8htqUO2qudfd2Jz9Q_15_5"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_cvrx_EmployersOfCertainNonEmployeeDirectorsMember_UIGG9IeGkUSY3X2c1Zxvbg"
      decimals="-3"
      id="Tc_WJusDfmxXEaRdZOjbhPwmA_15_9"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">59295000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_cvrx_ShareBasedPaymentArrangementOtherOptionsMember_DDdMMm9gRkiqyIWxmaA5XQ"
      decimals="INF"
      id="Narr_KKYxQyC5ZkGDHIV1zqPTcw"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">8559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      id="Narr_ANcL7QrjhUOTkkpkRoJKkA">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      id="Narr_r2Qi-WURfES_ZEis9ILdMg">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA"
      decimals="INF"
      id="Narr_EDngguvYp0KbciIlorf-_w"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">278170</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage
      contextRef="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA"
      decimals="2"
      id="Narr_LbLmq9i4eU2n-0c9XyAY7Q"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.01</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesReservedForIssuanceAutomaticIncrementalAnnualPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_YUEJZcskw0GxQzI269v8CA"
      decimals="INF"
      id="Narr_qJg37c_GeEyGttm6jcMfZA"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">206637</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage
      contextRef="As_Of_7_2_2021_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_okfOu4ghVEmzOMT8WtseHA"
      decimals="2"
      id="Narr_y7DG8HcS_kedjHABl9rFHA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.85</cvrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePricePermittedToBePurchasedMinimumPercentagePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="INF"
      id="Narr_lKnqzJJVv0eSxXML82FxRA"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">71276</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="-5"
      id="Narr_BemTuqbPQEyYgRDMyO_vuA"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">900000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_PemZyTerfEyhpKp4nuNIIQ"
      decimals="INF"
      id="Narr_s9JD_M3dAkiTL_fz0U_hTA"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">503634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      id="Tb_NJU5tpJiYUyDaZufA5IECQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:39.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Weighted average fair value of options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;10.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;4.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;non-officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.5 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;5.3 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected term (in years)&#x2009;&#x2014;&#x2009;officer employees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;2.5 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.2 to 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;77.2% to 79.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;56.3% to 60.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;3.40% to 4.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;1.75% to 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="2"
      id="Tc_l5f4qMq4vEmPxbfN45BsTw_3_3"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">10.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="2"
      id="Tc_6orxADIeeEuTw1N2vxPjlw_3_7"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">4.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VXKHvG6viUyua5uD_4yltw"
      id="Narr_BN6pSpec2UOZj0Z6ZM-Bcg">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VckApq6WlEaWJ9cemmQc9A"
      id="Narr_sLFwIa8ZZUapXMofL4yQ4w">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_pMTCyrrsukCaWB_FFt4-Jg"
      id="Narr_h_rxyKtCUU-6B1ZMpjAg1Q">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_NonOfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9XD2uHnOhUWYk_34nMOzkg"
      id="Narr_8p8YuHgOnUW3AEimIop1Wg">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zEoL8JtTB0KWcZl84O9JzA"
      id="Narr__Ix7a4iUj0yAXcigPjUYNA">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_EBpawY17Z0eCyg95O44tGg"
      id="Narr_B_SNFFRNt0eFiKEwRlNWCw">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_57PyY8_YEUuCWQnZ9zZCBg"
      id="Narr_I4TVMw6uSEW0KNs51qsYJg">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_cvrx_OfficerEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hd2dVLfWykWfyk-CsotRYA"
      id="Narr_tA37H4kUUUq-7P86F68t5g">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="3"
      id="Narr_hG4ToHrgyUCsjRmVle_TFA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="3"
      id="Narr_YdflUVXhrkmNUNGqQRcZaA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="3"
      id="Narr_G8LCugGpIk6sHEOimOOjiw"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="3"
      id="Narr_dhmx_79RR0mhw_7uYah1Ow"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="4"
      id="Tc_httBTbdRPEyFu7QIc8cksw_7_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="4"
      id="Tc_joMfFfFtb0qPG3BABGnF-Q_7_7"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="4"
      id="Narr_SCf5JyDUnUqknutjW1XvRw"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="4"
      id="Narr_c5Jrfn3xiUy8gx47xdfL6w"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="4"
      id="Narr_qrUE0FQ2B0inl0JRKMhREQ"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="4"
      id="Narr_IC6SjC4nQ0qXyL-8Gn0w-w"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      id="Tb_-3tod4s2nE6bZCq4F6jdLQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides the weighted average fair value of ESPP purchase rights and the related assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2023 and 2022.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:31.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average fair value per ESPP purchase right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&#x2009;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;76.2% to 84.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;51.3% to 62.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;4.77% to 5.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.22% to 2.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="2"
      id="Tc_FxcmODofWkmEJZsFB3sBWQ_3_3"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="2"
      id="Tc__dFZTijdzEacQvm-0s8rLQ_3_7"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      id="Tc_okv8Y4ytQUqgTRIkYyFQHA_4_3">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      id="Tc_oJdn65-2SE-LuaB92KTG8w_4_7">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="3"
      id="Narr_6CMeAQUPwUKxE7pf4vkJZQ"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="3"
      id="Narr_Gu5M6W-AWkW-lc30E5lsiA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw"
      decimals="3"
      id="Narr_R6ANK4f5EUy6oQaER8pKkA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw"
      decimals="3"
      id="Narr_KtvoPtnx-UGMMTOoJZIfOg"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="4"
      id="Narr_0gIPzdw5M02FCzWVJ9KpQA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="4"
      id="Narr_I--XO-NmRkW-wFVvZyjsig"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw"
      decimals="4"
      id="Narr_E2UzAs6Nw0ydZu8U5_IzXA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw"
      decimals="4"
      id="Narr_JSGxuImZWEGaJVeuGC9B8g"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.0252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="2"
      id="Narr_HpFFC8JyhkK0EwZTkPuRjA"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_-HON-094-UKJZlGPvFVOVA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the components and classification of stock-based compensation expense for the periods indicated: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general &amp;amp; administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 5,073&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,304&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research &amp;amp; development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,152&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 519&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,887&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_X6IIKK9MkkiBaKXsovbvIg"
      decimals="-3"
      id="Tc_DMx2Q-pIhEONVzCgF2k4wA_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_34mR8jbTvkSSpW69cXXAPQ"
      decimals="-3"
      id="Tc_nkD-u4WiQ0mrjniXFapG0w_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3664000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_w7VHLtkyR0Seh5wrPagRZg"
      decimals="-3"
      id="Tc_hLGfoJfI2EyE0jj5VWT_Og_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">402000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_cvrx_EmployeeStockPurchasePlanMember_HmeVoqINoEq1BHY3AyzEfw"
      decimals="-3"
      id="Tc_NZ6ualOdQUG6CqFYITkLmg_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">223000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_3_nrVofSwUaJkkVv2eEKog_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_HocpfTsmDk2Sl1PdfrOFcg_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fkJEZGVxqUusT4haccsrQg"
      decimals="-3"
      id="Tc_Ng3JO9uzsEWzy_q7b5i1JA_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">5073000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8_aaeerAjEej9OSFdIalGA"
      decimals="-3"
      id="Tc_cx2EMHKyo0C7T-jjNVKPjg_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3304000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember__6BtJaAInUut6oE3yTHB_g"
      decimals="-3"
      id="Tc_X3sPPXVQ5kmYH2dxh1SUDA_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_TGtZmK623E2xW1C_jsdOhg"
      decimals="-3"
      id="Tc_Lr3yl4WjkEeke1_ppg_4Iw_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GPUIUQBt3ECv70XnSLRrTA"
      decimals="-3"
      id="Tc_IJ79Wulcpkq3dlArUZvjKQ_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">78000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_LHxLWQFoVk6j4n7SU0LYMw"
      decimals="-3"
      id="Tc_5qdgiXubm0iEASJz44TUJw_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">64000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_pdKQSMw23UGH2sfAqxsPkw_11_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">6303000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_m9qZ1NE-f0ClLZSUgJEusA_11_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-5"
      id="Narr_ty-PpDV-e0S5qeObcNYdfw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">13400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_eJ7hXHjl4EOiEmS6FMj_RA">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_0Tv-MvIzDUi9XUgMtesNUA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2023 and 2022, a valuation allowance was recorded against all deferred tax assets due to our cumulative net loss position. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of our provision for income taxes are as follows for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The reconciliation of taxes at the federal statutory rate to our provision for income taxes are as follows for the periods indicated:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant components of net deferred tax assets were as follows for the periods indicated:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;89,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;82,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;R&amp;amp;D tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;9,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;9,072&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-qualified stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;752&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 110,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 101,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,552)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (101,836)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2023, we had federal and state net operating loss carryforwards (&#x201c;NOLs&#x201d;) of approximately $389.9 million and $7.3 million, respectively. The federal NOLs began expiring in 2021 and the state NOLs began expiring in 2020. As of December 31, 2023, we had federal and state tax credit carryforwards of approximately $9.8 million and $2.0 million, respectively. The federal tax credit carryforwards began expiring in 2021 and the state tax credits will begin expiring in 2028. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Utilization of NOLs may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit our utilization of the NOLs and could be triggered by subsequent sales of securities by us or our stockholders.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The changes to our gross unrecognized tax benefits were as follows for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross increases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross decreases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;All of these unrecognized tax benefits, if recognized, would impact the effective tax rate before taking consideration of the valuation allowance. The amount of unrecognized tax benefits subjected to the valuation allowance was $1.7 million and $1.6 million for the&#160;years ended December 31, 2023 and 2022, respectively. We recognized approximately $0.1 million of interest or penalties for each of the&#160;years ended December 31, 2023 and 2022. As of December 31, 2023 and 2022, total accrued interest and penalties were $0.5 million and $0.4&#160;million, respectively. We recognize accrued interest and penalties related to unrecognized tax positions as a component of income tax expense. We do not expect a significant change in the amount of unrecognized tax benefits in the next year.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. Tax&#160;years from 2004 through present remain open for audit under the applicable statute of limitations due to the carryover of the unused NOLs and tax credit carryforwards. We do not have any tax audits or other proceedings pending.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_1giAcaiuDU6R3D4D4NaNYQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The components of our provision for income taxes are as follows for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_Z5nVHSRV8UytDOymJEGKxg_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_85E4tKMQ1ESB8G-CAkzgXg_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_YvvKVC4XaUaSm1aBh0oaxQ_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">147000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_3rADFbiBTUmZUNqhDcdBvg_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">109000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_hGjnzcCHFkGTnyfkPWsQ0A_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">147000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_GRdBu-wn6kSEJKq7tmPRAg_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">109000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_mbHavD_77E2H_HKyAntgFQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development ("R&amp;amp;D") tax credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Uncertain tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_bwLWz7Rc0ki-BCsdx9jaBA_4_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc__R3Tr3O6NEOaHOCirrPIFA_4_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_YO9H-xHQek6pGFdcUwuUZQ_5_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.043</cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_xYl33uTA9kiVVnRknmq7QQ_5_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.021</cvrx:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_GGvuyQAKT0-PW5dtsxShdw_6_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_15_s-Je-rUyZ6ZvnRX3ocg_6_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_hAfgSUty3kWopqHZXEoNsg_7_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.003</cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_u9v3KmOVMEetT8U6o72a9g_7_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.003</cvrx:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_wONjMgmV1UK5jkfQSKRZWQ_8_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_EssoK77eZUOHOtpejDTUmQ_8_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_bmO3SfkEX0uRO5tD7RtdPQ_9_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_iJ8N9cpZgEulyvBQY6Retw_9_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_8XGMYvn5SEuIAlDerjhL8A_10_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.212</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_IwlR2W0nWEGb7r2S6izzPw_10_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.195</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="3"
      id="Tc_1LAZIn8rtEuwKGYL8K0bsg_11_3"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="3"
      id="Tc_jDjH_uPpCEmuTZnYYEL4Vg_11_6"
      unitRef="Unit_Standard_pure_1bLnH04Qy0qmIB3frezIWg">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_mT7QbQmt_0ykTAnyanp2aQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;89,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;82,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;R&amp;amp;D tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;9,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;9,072&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,963&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;8,412&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-qualified stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;1,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;752&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Start-up costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Accrued vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;212&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 110,552&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 101,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (110,552)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (101,836)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_qZghomTcVkmd0Ots9UjWUw_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">89173000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_I1UYr2gXwEi4wt860GWyZA_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">82050000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_bABffPOhMECQ5cBbV4Q3AQ_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">9664000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_PQV9e4eGZEWdqbzYGiukBA_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">9072000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <cvrx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_eZQSnEuqpEO88VpSJr3Ymg_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">8963000</cvrx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <cvrx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_1DUgIGadKkeHJ9Z1aUS-bA_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">8412000</cvrx:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_p1hLjxrrWket62o_vY5qvQ_8_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1473000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_VY-7gszDK06bH_FU3cXdww_8_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">752000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cvrx:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_dtcXex9lb06veswx62YR8g_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">680000</cvrx:DeferredTaxAssetsStartUpCosts>
    <cvrx:DeferredTaxAssetsStartUpCosts
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_48zord1AkkmBn6TeVlBDJA_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">894000</cvrx:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_uLMWVjQShEGnAOHqQIycjA_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">179000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_HJ6MX-uAJ0uD1jBMJ3GO8g_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">212000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_TjygEyDegUCs52nRAmjMag_11_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">59000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_3lyLw3pe80OdfPxRTcpBHA_11_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">144000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_ptGKXLGnRkuY1dT6VrDFtA_12_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">361000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_lamefEVQN0Sw6TQXhU3Pkw_12_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">300000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_GxA26gAquEST9rO37Lvj3Q_13_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">110552000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_LH0uiF9qKEq42JCB4BPE8w_13_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">101836000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc__6sBaYs-xkGpznaIroE0wQ_14_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">110552000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_YrW_ktuuIUqaeOjiuuItEg_14_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">101836000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_8729aqw9hEGFcc1MpLDYTg_15_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_fknw6Nd5GkmPosVAZw9a-A_15_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_7Lza9lQnP0GeHg-QJ6eaQg"
      decimals="-5"
      id="Narr_BrnnSg4n1kCXef9WkS5lhg"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">389900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_pdlrV4rnDEG1xPe8LI1SMA"
      decimals="-5"
      id="Narr_hJHjznAnfUeAZ4UiCt0HPg"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">7300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_7Lza9lQnP0GeHg-QJ6eaQg"
      decimals="-5"
      id="Narr_ZapPGW8oBUaeu1I2tz_UWw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">9800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_pdlrV4rnDEG1xPe8LI1SMA"
      decimals="-5"
      id="Narr_keD6PwIUAEWnvtqwlgMvCA"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_Fuyla09NXk220WEykXE6kQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The changes to our gross unrecognized tax benefits were as follows for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross increases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Current year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross decreases:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prior year tax positions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross unrecognized tax benefits at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,046&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_Kf8ZWcGzVUOz6RdGfe9OEQ_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2046000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_OAsARdQZM0ud86arPIzOVg"
      decimals="-3"
      id="Tc_z9DPw28jv0Kt0soc1yre_A_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1939000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_wQHXUvKjoUq7s7l20jcRCQ_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">12000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_lrd2DJg57U-Jow-fNnzBxw_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">4000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_ByZWT1eGoUWkuh632SsaVQ_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">185000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_Ypg7YPqk302h9YAkArpEDg_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">113000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_PCNbdBTMxkOam3Ht6tjcNg_9_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">22000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_ASx4WhAdgEOI0U40m1v1hA_9_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">10000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Tc_JUlHS_Y6oE25_9IvNVpUng_10_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2221000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Tc_hILw-fDEBUSc6h21VB_CdA_10_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">2046000</us-gaap:UnrecognizedTaxBenefits>
    <cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-5"
      id="Narr__2CvsZuts0K92CsciyVlZw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1700000</cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance>
    <cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-5"
      id="Narr_1hMIEoAQ20K0i-EMxa2Cig"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">1600000</cvrx:UnrecognizedTaxBenefitsSubjectedToValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-5"
      id="Narr_rreyNCr1gEucl7jSLGGsCQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-5"
      id="Narr_Pr3GW3TeeUOEYrH40VicEw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">500000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-5"
      id="Narr_mR2dCCIA7kS-YISjbXcoVw"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">400000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_2j4a6zQV2Um89PNXHaX70w">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;9. Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,428)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,754,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,532,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1-VKvzFxtkGYxn2bxA0KOQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.99)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9k-u6oSvH0SUWtDFYknU1A;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.02)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Our potentially dilutive securities, which include stock options and warrants to purchase shares of common stock, have been excluded from the computation of diluted net loss per share attributable to common stockholders, as the effect would be to reduce the net loss per share attributable to common stockholders. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. We excluded the following potential common shares, presented based on amounts outstanding at each period end, from the &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,488,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,204,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,472,966&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_6Ojm5wg51kOSAIJ8W-ZzQg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated for the periods indicated (in thousands, except share and per share data):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,199)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (41,428)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted average common shares outstanding&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,754,375&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,532,838&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders&#x2009;&#x2014;&#x2009;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1-VKvzFxtkGYxn2bxA0KOQ;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.99)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9k-u6oSvH0SUWtDFYknU1A;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.02)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_Bl8JKkCmKk2s6i0NgZ7JhQ_5_4"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_pPbFGW5y4US8ZboCT-jqMQ_5_7"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">-41428000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="0"
      id="Tc_nP2TRmoKckGCfT3oxiR1Nw_7_4"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20754375</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="0"
      id="Tc_phj-TtmCZ0CSh72iwUzJzw_7_7"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">20532838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="2"
      id="Tc_aQobqL87lUCxdrVnX_LnOw_8_4"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="2"
      id="Tc_hVvVwDwgxEil6uvxYHg92A_8_7"
      unitRef="Unit_Divide_USD_shares_sZ8CCB-Y2UiY4iOpeAz1Mw">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_9Z824_9G0E6A8V_UMSGVwg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,488,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,756,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 716,131&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,204,976&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,472,966&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_M3MwyXey0USuIVtewS_fUw"
      decimals="INF"
      id="Tc_OL3i2SBZokWuwmazBnD7PQ_4_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">4488845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eeym4sX_ZE-eYRj-nhAxtA"
      decimals="INF"
      id="Tc_e22pD9YxYEeCidF_x7Nc1Q_4_4"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">3756835</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_UrSmq1MvHUGq4lKnkUhBMQ"
      decimals="INF"
      id="Tc_wOas_bpCNUiMOb36_bKlzw_5_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">716131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cvrx_WarrantsToPurchaseCommonStockMember_kyjAoWWjHEOiI5UhzjPamg"
      decimals="INF"
      id="Tc_KgN_zTfg1EiT-iOyQrVCxg_5_4"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">716131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="INF"
      id="Tc_vXXfTj_KAEGQXNFywuUqsg_6_2"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">5204976</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="INF"
      id="Tc_6AyAjprz-Eykgwv3WVpmIw_6_4"
      unitRef="Unit_Standard_shares__1HGFGFdsUS2GjH3EDTnVg">4472966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_v6P-OBMMdUC-XIr6GgJlTQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, we may have certain contingent liabilities that arise in the ordinary course of business. We accrue a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There have been no contingent liabilities requiring accrual or disclosure as of December 31, 2023 or December 31, 2022.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2022_J6HNql9R6kiHR3C_folJIw"
      decimals="-3"
      id="Narr_7TbO-0EF4k2BYmcZp4TaPQ"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2023_byi0Igy3dkCawZX9aUILHQ"
      decimals="-3"
      id="Narr_Xi85bmxgbUO0tIP2PwHASg"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">0</us-gaap:ContractualObligation>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_29BCHxQQ40m55Vf0RbOONQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Employee benefit plans&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We sponsor a voluntary defined-contribution employee retirement plan (the &#x201c;401(k)&#160;plan&#x201d;) for its U.S. employees. The 401(k)&#160;plan provides that each participant may contribute pre-tax or post-tax compensation up to the statutory limit allowable. Under the 401(k)&#160;plan, each participant is fully vested in his or her deferred salary contributions when contributed. We do not provide matching contributions to employees.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_R_uCxYkfHUiAPTdWRnQcvw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;12.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;Segment, geographic information and revenue disaggregation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Our chief operating decision maker is our Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. We have one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, we have determined that we have a single reportable and operating segment structure. We and our Chief Executive Officer evaluate performance based primarily on revenue in the geographic locations in which the Company operates.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We derive all our revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 39,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2023 and 2022, long-lived assets were located primarily in the U.S.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="0"
      id="Narr_PqU_t4U_L06RlRcyZEXO3g"
      unitRef="Unit_Standard_segment__laEB6QyrUy_CRagT_GFBw">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_L4JIyeT_pUmxDvSEk4rJNg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We derive all our revenues from sales to customers in Europe and the U.S. The following table provides revenue by country for each location accounting for more than 10% of the total revenue for the periods indicated:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 35,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,690&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,477&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 39,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 22,469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_US_MEKc9Q4xt0S15FUWcDf8Vw"
      decimals="-3"
      id="Tc_GsBZOSo0-EOqY5EveItrzA_4_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">35111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_DeT00G4a6EO7jrVDjnnWKg"
      decimals="-3"
      id="Tc_HUOMvmrFa0unkXuO5jWCgQ_4_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">18021000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_country_DE_li7LfrlDcE-yU9xxp6rxsg"
      decimals="-3"
      id="Tc_0o0k7TSIHkq-sgleHQLilQ_5_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_DE_Nr4zMiPicku7JB9fF5v_mw"
      decimals="-3"
      id="Tc_CLVvS8-fF06_OBeISuAUzQ_5_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">3477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_z-s50K3S1kivNIA3YmG5FQ"
      decimals="-3"
      id="Tc_XyBs8AKQ6kub4IeNOUm4KQ_6_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_cvrx_OtherCountriesMember_UW_cLJGP9UCo_5BtyGIPrQ"
      decimals="-3"
      id="Tc_uoPhoOJgiken4ZLQ8oBRMg_6_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      decimals="-3"
      id="Tc_9aqEqdaq3EKczEK19souPw_7_3"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">39295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_lMEE2WqXZ0G0EKm-GCHw5A"
      decimals="-3"
      id="Tc_FSAWmRqzEU6FpVA3LtUYiw_7_6"
      unitRef="Unit_Standard_USD_rY84WIBhpEicvjNqgdzgOg">22469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Tb_x8WfqCeT_EysrCwE3wkDDg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-size:12pt;font-weight:bold;"&gt;13. Subsequent events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;On January&#160;31, 2024, we announced that our Board of Directors appointed Kevin Hykes as President and Chief Executive Officer, effective February&#160;12, 2024 to succeed Nadim Yared, who previously announced his plans to retire upon the appointment of his successor. In connection with a transition and consulting agreement we entered into with Mr. Yared, we also modified certain terms and conditions of Mr. Yared&#x2019;s stock options granted under the 2001 Plan and 2021 Plan, however, the impact of this modification on the amount of stock-based compensation expense cannot yet be quantified.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg"
      id="Narr__4Sc6R5W7kecb84uvMh4yQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg"
      id="Narr_ndVbYL8T0UC9xQw-5q7QaA">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg"
      id="Narr_3fv9CQ7noEeqhsFn56qUzQ">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2023_To_12_31_2023_xWnbq5qwv0axKfk_ehGEbg"
      id="Narr_bb0oUhvipEOz-KRQO1YqkQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2023_To_12_31_2023_YFl7KBo39kaBmxtgcK7plA"
      id="Narr_zcq4-MoB8EGkg4B-EkVM9Q">248</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
